Clustering O 0 0.00015699343930464238
of O 0 2.6797729333338793e-06
missense O 0 0.026615461334586143
mutations O 0 0.0008181303855963051
in O 0 1.7207067912750063e-06
the O 0 0.00033177484874613583
ataxia B-Disease 1 1.0
- I-Disease 1 0.9999967813491821
telangiectasia I-Disease 1 0.999996542930603
gene O 0 1.1291855116724037e-05
in O 0 5.6065729836518585e-08
a O 0 1.1221327440580353e-06
sporadic B-Disease 0 0.0025096985045820475
T I-Disease 1 0.7213835716247559
- I-Disease 0 0.12006647884845734
cell I-Disease 1 0.545275866985321
leukaemia I-Disease 1 0.546545147895813
. O 0 1.6622817611278151e-06

Ataxia B-Disease 1 0.9999990463256836
- I-Disease 1 0.9999892711639404
telangiectasia I-Disease 1 0.9999974966049194
( O 0 0.051297035068273544
A B-Disease 1 0.9999914169311523
- I-Disease 1 0.9999861717224121
T I-Disease 1 0.9999973773956299
) O 0 1.2078385225322563e-07
is O 0 2.7519394762975935e-08
a O 0 3.9320147493526747e-07
recessive B-Disease 0 0.0023840887006372213
multi I-Disease 0 0.004639711696654558
- I-Disease 1 0.9660788774490356
system I-Disease 0 0.49979570508003235
disorder I-Disease 1 0.9666866660118103
caused O 0 6.052218850527424e-06
by O 0 1.7702342347547528e-07
mutations O 0 2.1008370367781026e-06
in O 0 2.2436870139586063e-08
the O 0 3.1000432443306636e-08
ATM O 0 8.208111808016838e-07
gene O 0 3.1690950663687545e-07
at O 0 3.6630137145721164e-08
11q22 O 0 3.974536866735434e-06
- O 0 1.4366642062668689e-05
q23 O 0 2.2546777472598478e-05
( O 0 8.448597554888693e-08
ref O 0 2.3667898858548142e-05
. O 0 5.04180022176115e-08
3 O 0 8.478122737187732e-08
) O 0 1.1847964742628392e-07
. O 0 5.705626335839042e-07

The O 0 2.6396239718451397e-06
risk O 0 3.1295453482016455e-06
of O 0 1.6274167080609914e-07
cancer B-Disease 0 0.005541506689041853
, O 0 3.1020249480206985e-07
especially O 0 3.856624459785962e-07
lymphoid B-Disease 0 1.9562547095119953e-05
neoplasias I-Disease 0 0.0029496147762984037
, O 0 1.2099262391984666e-07
is O 0 1.5158288135808107e-07
substantially O 0 1.2099983905500267e-05
elevated O 0 0.00021033463417552412
in O 0 2.0746456357301213e-06
A B-Disease 1 0.9999970197677612
- I-Disease 1 0.9999994039535522
T I-Disease 1 1.0
patients O 1 0.9988211989402771
and O 0 8.952970347309019e-07
has O 0 4.265908501110971e-06
long O 0 1.023865252136602e-06
been O 0 1.8277494291396579e-06
associated O 0 2.185367549145667e-07
with O 0 1.059562691807514e-06
chromosomal O 1 0.9999847412109375
instability O 1 0.999356210231781
. O 0 3.2963995181489736e-05

By O 0 1.3634101378556807e-05
analysing O 0 0.00014064228162169456
tumour B-Disease 1 0.9999650716781616
DNA O 0 9.006386972032487e-05
from O 0 5.463257934934518e-07
patients O 0 9.303756087319925e-06
with O 0 2.748861049894913e-07
sporadic B-Disease 0 0.0026466776616871357
T I-Disease 0 0.4999569356441498
- I-Disease 0 0.03252319619059563
cell I-Disease 0 0.31598976254463196
prolymphocytic I-Disease 1 0.6294693350791931
leukaemia I-Disease 1 0.8624398112297058
( O 0 3.2058338206297776e-07
T B-Disease 0 0.0003836227988358587
- I-Disease 0 0.0008274141582660377
PLL I-Disease 0 0.011109486222267151
) O 0 1.0466407474041262e-07
, O 0 1.991052123173631e-08
a O 0 1.3020711264744023e-07
rare O 0 2.2448548406828195e-06
clonal B-Disease 0 4.702036312664859e-05
malignancy I-Disease 0 0.0010825460776686668
with O 0 4.225650940270498e-08
similarities O 0 3.756458397674578e-07
to O 0 9.560066871472372e-08
a O 0 1.634724685573019e-05
mature B-Disease 0 4.161439574090764e-05
T I-Disease 0 0.007948090322315693
- I-Disease 0 0.002423191210255027
cell I-Disease 0 0.09068078547716141
leukaemia I-Disease 0 0.049382541328668594
seen O 0 9.594058383299853e-07
in O 0 5.346554488028232e-08
A B-Disease 1 0.9990265369415283
- I-Disease 1 0.9998284578323364
T I-Disease 1 0.9999953508377075
, O 0 1.990851359323642e-07
we O 0 1.0323749854990183e-08
demonstrate O 0 5.698340288518011e-08
a O 0 6.297353394302263e-08
high O 0 5.6439429130250574e-08
frequency O 0 8.294372833006491e-08
of O 0 1.7415083819471988e-09
ATM O 0 2.2580018139706226e-06
mutations O 0 3.192499661963666e-06
in O 0 1.901550632510407e-07
T B-Disease 0 0.004590177908539772
- I-Disease 0 0.0025121301878243685
PLL I-Disease 0 0.01333034597337246
. O 0 3.300012167528621e-06

In O 0 5.759323357779067e-06
marked O 0 6.255267180677038e-06
contrast O 0 1.908615786305745e-06
to O 0 4.2278195167000376e-08
the O 0 2.55336463084177e-08
ATM O 0 4.054179953527637e-06
mutation O 0 3.1975150704965927e-06
pattern O 0 1.7023930922732688e-06
in O 0 4.6544974452444876e-07
A B-Disease 1 0.9999828338623047
- I-Disease 1 0.9999856948852539
T I-Disease 1 0.9999986886978149
, O 0 1.768233062193758e-07
the O 0 8.117822858366708e-09
most O 0 1.381146397250177e-08
frequent O 0 1.6165178351457143e-07
nucleotide O 0 7.705502014232479e-08
changes O 0 3.2835792751484405e-08
in O 0 1.3421400879565226e-08
this O 0 1.6681131853601983e-07
leukaemia B-Disease 0 0.2759777307510376
were O 0 2.7125274755235296e-06
missense O 0 0.0007982038077898324
mutations O 0 4.1369625250808895e-05
. O 0 1.3726945553571568e-06

These O 0 1.357183691652608e-06
clustered O 0 2.6034779239125783e-06
in O 0 7.342732999404689e-08
the O 0 1.6892940379875654e-08
region O 0 3.921334013057276e-08
corresponding O 0 3.2290486728925316e-08
to O 0 1.220304213234158e-08
the O 0 8.246163751834956e-09
kinase O 0 8.492929168824048e-07
domain O 0 3.6055357810482747e-08
, O 0 1.2822336081796948e-08
which O 0 1.944335892289928e-08
is O 0 8.034456655536815e-09
highly O 0 1.0348353285394296e-08
conserved O 0 3.795920378024675e-08
in O 0 9.381522225737626e-09
ATM O 0 5.732138106395723e-07
- O 0 3.2196780921367463e-06
related O 0 4.73256775990194e-08
proteins O 0 1.2095682677681907e-08
in O 0 6.992010082029765e-09
mouse O 0 1.1990292705377215e-06
, O 0 3.0361483993601723e-08
yeast O 0 1.008181357065041e-06
and O 0 1.8346180752359942e-07
Drosophila O 0 1.437843138774042e-06
. O 0 5.827995437357458e-07

The O 0 2.694382146728458e-06
resulting O 0 3.806229869951494e-06
amino O 0 4.624979510481353e-07
- O 0 2.7409969334257767e-06
acid O 0 8.059944889282633e-07
substitutions O 0 1.1096705065938295e-07
are O 0 5.621679122214118e-09
predicted O 0 2.1381767112416128e-07
to O 0 3.200182163709542e-08
interfere O 0 2.8948187491550925e-07
with O 0 1.651001468871982e-07
ATP O 0 4.096916745766066e-05
binding O 0 1.4666477909486275e-05
or O 0 2.0108066678403702e-07
substrate O 0 1.8232740330859087e-05
recognition O 0 2.352194769628113e-06
. O 0 2.155897391276085e-06

Two O 0 1.8525190625950927e-06
of O 0 1.6356321452803968e-07
seventeen O 0 7.11573238731944e-06
mutated O 0 9.636321192374453e-05
T B-Disease 0 0.00036798909422941506
- I-Disease 0 0.00016943625814747065
PLL I-Disease 0 0.0013900381745770574
samples O 0 1.4515560451400233e-06
had O 0 4.5501980139306397e-07
a O 0 2.2587502712667629e-07
previously O 0 5.584593054663856e-06
reported O 0 1.3325804502528626e-05
A B-Disease 1 0.9987427592277527
- I-Disease 1 0.9998738765716553
T I-Disease 1 0.9999953508377075
allele O 0 0.0014867597492411733
. O 0 2.552328624005895e-06

In O 0 1.767610592651181e-05
contrast O 0 5.338059781934135e-05
, O 0 2.5057227048819186e-07
no O 0 3.7203960800979985e-07
mutations O 0 1.3187825516070006e-06
were O 0 1.5589846213970304e-07
detected O 0 5.272808039080701e-07
in O 0 1.546925609829941e-08
the O 0 2.0122332244909558e-08
p53 O 0 1.162201215265668e-06
gene O 0 1.6881675435342913e-07
, O 0 1.452908282573162e-08
suggesting O 0 1.338287063390453e-07
that O 0 2.7657417689397334e-08
this O 0 1.461154539583731e-07
tumour B-Disease 1 0.9999957084655762
suppressor O 0 0.015145444311201572
is O 0 1.821775583721319e-07
not O 0 3.719817343039722e-08
frequently O 0 2.838608565980394e-07
altered O 0 1.9976002931798575e-06
in O 0 1.3925594544161868e-07
this O 0 1.4441881148741231e-06
leukaemia B-Disease 0 0.49663791060447693
. O 0 2.543651362429955e-06

Occasional O 0 0.002325203502550721
missense O 0 0.15781879425048828
mutations O 0 0.0010766315972432494
in O 0 2.0208898376949946e-07
ATM O 0 2.1845601168024587e-06
were O 0 2.2265292045631213e-06
also O 0 8.301271918753628e-07
found O 0 3.650790461051656e-07
in O 0 9.759744443726959e-07
tumour B-Disease 1 0.9999994039535522
DNA O 0 0.00013281023711897433
from O 0 7.990462336238124e-08
patients O 0 7.179219664976699e-06
with O 0 9.051340299492949e-08
B B-Disease 0 7.308427484531421e-06
- I-Disease 0 3.607031248975545e-05
cell I-Disease 0 0.000142629723995924
non I-Disease 0 2.0964196210115915e-06
- I-Disease 0 0.4522712230682373
Hodgkins I-Disease 1 0.9982557892799377
lymphomas I-Disease 1 0.9799519181251526
( O 0 1.7949997754840297e-07
B B-Disease 0 1.4171331486068084e-06
- I-Disease 0 4.9037571443477646e-06
NHL I-Disease 0 8.69818109094922e-07
) O 0 1.2478094113532734e-08
and O 0 1.2637107360546906e-08
a O 0 4.54423968676565e-07
B B-Disease 0 4.6620725697721355e-06
- I-Disease 0 3.8590562326135114e-05
NHL I-Disease 0 1.088312183128437e-05
cell O 0 4.1942526877392083e-05
line O 0 4.607234586728737e-06
. O 0 6.334263389362604e-07

The O 0 1.5472642189706676e-06
evidence O 0 2.974291533064388e-07
of O 0 1.4659468305922019e-08
a O 0 3.582674139579467e-07
significant O 0 2.3029400608720607e-07
proportion O 0 1.3696370615434716e-07
of O 0 4.65016469775037e-09
loss O 0 7.853335773688741e-06
- O 0 3.672714001368149e-06
of O 0 1.1937060229172403e-08
- O 0 0.00016505346866324544
function O 0 4.0808612311593606e-07
mutations O 0 5.216867862145591e-07
and O 0 7.692106507306562e-09
a O 0 1.0009237172425856e-07
complete O 0 2.4336699766536185e-07
absence O 0 9.080304153030738e-08
of O 0 2.4062558612314433e-09
the O 0 1.0395654115313846e-08
normal O 0 2.5332816733225627e-08
copy O 0 4.668135744623214e-08
of O 0 1.8247579003372039e-09
ATM O 0 1.8046289085305034e-07
in O 0 1.0441319808762728e-08
the O 0 1.168839336429528e-08
majority O 0 5.971359655632114e-07
of O 0 4.81924935513689e-08
mutated O 0 0.23172816634178162
tumours B-Disease 1 0.999982476234436
establishes O 0 1.0175798706768546e-05
somatic O 0 5.751748631155351e-06
inactivation O 0 3.364610893186182e-05
of O 0 8.502360593354297e-09
this O 0 1.1523544785063677e-08
gene O 0 5.3914284592337935e-08
in O 0 8.210897739502343e-09
the O 0 1.6641099165326523e-08
pathogenesis O 0 1.1671684205794008e-06
of O 0 2.5871514708342147e-08
sporadic B-Disease 0 0.00033834308851510286
T I-Disease 0 0.13074705004692078
- I-Disease 0 0.0003452048113103956
PLL I-Disease 0 0.0017375918105244637
and O 0 1.6592423435213277e-07
suggests O 0 3.599118514330257e-08
that O 0 3.621227095962354e-09
ATM O 0 1.1000001620686817e-07
acts O 0 4.6494484706727235e-08
as O 0 7.888984754345074e-08
a O 0 1.8708307834458537e-05
tumour B-Disease 1 0.9999912977218628
suppressor O 0 0.028486056253314018
. O 0 5.444453108793823e-06

As O 0 6.30123759037815e-06
constitutional O 0 7.940831892483402e-06
DNA O 0 7.1929812293092255e-06
was O 0 2.4065566321951337e-06
not O 0 1.712133901321522e-08
available O 0 1.0509172199135719e-08
, O 0 7.886063357886997e-09
a O 0 3.648138431344705e-07
putative O 0 0.0005030285683460534
hereditary O 1 0.9887070655822754
predisposition O 0 0.08716513216495514
to O 0 1.3838466657034587e-05
T B-Disease 0 0.1658419519662857
- I-Disease 0 0.0038337891455739737
PLL I-Disease 0 0.003907779231667519
will O 0 3.192157009834773e-07
require O 0 1.0943477946057101e-07
further O 0 9.286829794064033e-08
investigation O 0 5.220919092607801e-07
. O 0 2.850362648132432e-07
. O 0 9.604613069313928e-07

Myotonic B-Disease 1 0.9999986886978149
dystrophy I-Disease 1 0.9999996423721313
protein O 0 0.006683632265776396
kinase O 0 0.0004300020809751004
is O 0 2.9690997394027363e-07
involved O 0 4.596078539975679e-08
in O 0 5.951225734435184e-09
the O 0 7.577734884023357e-09
modulation O 0 1.408215894116438e-06
of O 0 9.846689685844012e-09
the O 0 9.060426009455114e-08
Ca2 O 0 0.0002153933746740222
+ O 0 7.981633643794339e-06
homeostasis O 0 1.6004869394237176e-05
in O 0 3.091251983278198e-07
skeletal O 0 0.05067211762070656
muscle O 0 0.05554617568850517
cells O 0 4.042405998916365e-05
. O 0 1.6046157043092535e-06

Myotonic B-Disease 1 0.9999994039535522
dystrophy I-Disease 1 1.0
( O 1 0.9970672726631165
DM B-Disease 1 0.9999998807907104
) O 0 8.438203622063156e-06
, O 0 1.2723538134196133e-07
the O 0 9.2730196854518e-09
most O 0 1.2513348224274523e-07
prevalent O 0 5.9215941291768104e-05
muscular B-Disease 1 0.9999873638153076
disorder I-Disease 1 0.9998409748077393
in O 0 1.0344956535845995e-05
adults O 0 0.0023483389522880316
, O 0 1.6316002415805997e-07
is O 0 9.79314108917606e-07
caused O 0 2.045836481556762e-05
by O 0 1.6018209691992524e-07
( O 0 2.389996467400124e-08
CTG O 0 5.364867774915183e-06
) O 0 2.3324467690599704e-08
n O 0 1.590529024042553e-07
- O 0 5.259308863969636e-07
repeat O 0 1.6670189495471277e-07
expansion O 0 2.9382769994867886e-08
in O 0 4.809578069142617e-09
a O 0 3.5121527020010035e-08
gene O 0 3.692404959565465e-08
encoding O 0 3.940287385262309e-08
a O 0 1.6174894312825927e-07
protein O 0 1.1862633755299612e-06
kinase O 0 2.5932142307283357e-05
( O 0 1.784622014611159e-07
DM B-Disease 1 0.999997615814209
protein O 0 2.2209491362445988e-05
kinase O 0 1.0467327228980139e-05
; O 0 7.31149825128341e-08
DMPK O 0 2.5792156520765275e-05
) O 0 1.0244836090578247e-08
and O 0 6.371654759362855e-09
involves O 0 1.3461677994541787e-08
changes O 0 6.30858210115548e-08
in O 0 4.9840025440062163e-08
cytoarchitecture O 0 6.352273339871317e-05
and O 0 7.142044751162757e-07
ion O 0 0.00039980647852644324
homeostasis O 0 0.000893699296284467
. O 0 4.0472800719726365e-06

To O 0 6.2493522818840574e-06
obtain O 0 3.5859532090398716e-06
clues O 0 5.141886958881514e-06
to O 0 1.5699208688602084e-07
the O 0 2.997955661498963e-08
normal O 0 5.702526451045742e-08
biological O 0 1.4002871751017665e-08
role O 0 8.352665226141198e-09
of O 0 3.4501699275324427e-09
DMPK O 0 9.94701695162803e-05
in O 0 7.199955831538318e-08
cellular O 0 2.096439857268706e-06
ion O 0 1.622724266781006e-05
homeostasis O 0 1.4676508726552129e-05
, O 0 1.2365624968424527e-08
we O 0 2.4656170438674962e-09
have O 0 7.833444115590282e-09
compared O 0 3.41088686184321e-08
the O 0 5.151270077163872e-09
resting O 0 4.440430984686827e-06
[ O 0 1.201784414206486e-07
Ca2 O 0 1.2702930689556524e-06
+ O 0 1.2884156319614704e-07
] O 0 2.1848668652069136e-08
i O 0 1.720251852077581e-08
, O 0 2.1591559651312764e-09
the O 0 1.6315488959861568e-09
amplitude O 0 2.419082818505558e-07
and O 0 2.8548154062946196e-08
shape O 0 1.8981985761001852e-07
of O 0 1.1869357052773921e-08
depolarization O 0 9.898597454593983e-06
- O 0 0.0014311844715848565
induced O 0 0.007475679274648428
Ca2 O 0 3.6269790143705904e-05
+ O 0 1.2834909739467548e-06
transients O 0 5.098307156004012e-06
, O 0 1.6866218643940556e-08
and O 0 4.5023340611294316e-09
the O 0 3.0803202211160396e-09
content O 0 1.8429823001042678e-08
of O 0 3.376996904336238e-09
ATP O 0 3.7396728203020757e-07
- O 0 1.0467001629876904e-06
driven O 0 1.4830311556579545e-06
ion O 0 1.3536315464079962e-06
pumps O 0 1.6609649264864856e-06
in O 0 2.14623163685701e-08
cultured O 0 2.5769970761757577e-06
skeletal O 0 0.013641761615872383
muscle O 0 6.158566975500435e-05
cells O 0 1.4099465772687836e-07
of O 0 3.0698565911535525e-09
wild O 0 6.177671707519039e-08
- O 0 2.75413112831302e-05
type O 0 6.491607109637698e-06
and O 0 2.65554092493403e-07
DMPK O 0 0.0005222820909693837
[ O 0 4.106694859729032e-07
- O 0 7.115135758795077e-06
/ O 0 1.7519339507998666e-06
- O 0 2.1883925001020543e-05
] O 0 3.3405806334485533e-06
knockout O 0 0.0003725097922142595
mice O 0 0.008806346915662289
. O 0 1.2351326859061373e-06

In O 0 8.072514901868999e-06
vitro O 0 6.399716949090362e-05
- O 0 0.00015086474013514817
differentiated O 0 4.847957461606711e-05
DMPK O 0 7.455175364157185e-05
[ O 0 6.122452873569273e-07
- O 0 4.602728949976154e-06
/ O 0 2.4737828425713815e-06
- O 0 1.9568406059988774e-05
] O 0 5.814121664116101e-07
myotubes O 0 3.3971143693634076e-06
exhibit O 0 3.812035060946073e-07
a O 0 2.1342549416658585e-07
higher O 0 1.3104225615734322e-07
resting O 0 9.61142450250918e-06
[ O 0 5.084567646918003e-07
Ca2 O 0 3.8252615013334434e-06
+ O 0 3.5981858559352986e-07
] O 0 5.861187446498661e-08
i O 0 2.8195220380666797e-08
than O 0 8.489153380253356e-09
do O 0 1.3585567337770499e-08
wild O 0 4.253086416383667e-08
- O 0 7.64308151701698e-06
type O 0 4.429729870025767e-06
myotubes O 0 1.6398804291384295e-05
because O 0 3.3516389663645896e-08
of O 0 9.902679787288093e-10
an O 0 3.157654759888828e-08
altered O 0 1.2682207852776628e-06
open O 0 5.5039340196572084e-08
probability O 0 7.555653880331192e-09
of O 0 2.268315757447681e-09
voltage O 0 5.4797746997792274e-05
- O 0 4.411942063597962e-05
dependent O 0 2.012277263929718e-06
l O 0 5.868777407158632e-06
- O 0 3.668621729957522e-06
type O 0 1.7451056919526309e-06
Ca2 O 0 6.127007509348914e-06
+ O 0 4.369731811948441e-07
and O 0 3.5141226817358984e-08
Na O 0 1.3434435004455736e-06
+ O 0 6.926044875399384e-07
channels O 0 5.928387736275909e-07
. O 0 4.083909743712866e-07

The O 0 2.904720986407483e-06
mutant O 0 1.235486979567213e-05
myotubes O 0 2.563320958870463e-05
exhibit O 0 9.822886113397544e-07
smaller O 0 7.664912970994919e-08
and O 0 3.1965157631930197e-08
slower O 0 3.5023604141315445e-06
Ca2 O 0 8.310038538184017e-05
+ O 0 1.4039289908396313e-06
responses O 0 1.213217046824866e-07
upon O 0 2.5550844995336774e-08
triggering O 0 1.9100166070984415e-07
by O 0 3.8427611315228205e-08
acetylcholine O 0 3.3231328870897414e-06
or O 0 7.555138381576398e-08
high O 0 3.243910668970784e-07
external O 0 1.0086399925057776e-05
K O 0 1.153937500930624e-05
+ O 0 3.678925622807583e-06
. O 0 5.166386927157873e-07

In O 0 4.914628789265407e-06
addition O 0 2.730498636083212e-07
, O 0 5.9208741021166134e-08
we O 0 1.1311398928626204e-08
observed O 0 4.420511245939451e-08
that O 0 1.0636863834179167e-08
these O 0 1.4259294189855609e-08
Ca2 O 0 2.603572102088947e-05
+ O 0 4.471929059945978e-06
transients O 0 3.900613955920562e-05
partially O 0 7.636203918082174e-06
result O 0 3.712587570703363e-08
from O 0 1.6579597694743597e-09
an O 0 6.1305889254015256e-09
influx O 0 5.330283414650694e-08
of O 0 6.554931708535605e-09
extracellular O 0 3.7344338466027693e-07
Ca2 O 0 4.134862138016615e-06
+ O 0 1.5044027179555997e-07
through O 0 5.127938962345979e-09
the O 0 9.621252239355726e-09
l O 0 3.0136100122035714e-06
- O 0 5.29223189005279e-06
type O 0 7.3579963100200985e-06
Ca2 O 0 3.602496872190386e-05
+ O 0 3.0492983569274656e-06
channel O 0 4.711052497441415e-06
. O 0 7.003350788181706e-07

Neither O 0 1.5487077689613216e-05
the O 0 8.962967967818258e-08
content O 0 8.692262554177432e-08
nor O 0 5.7862767022243133e-08
the O 0 2.493577344608866e-09
activity O 0 4.22715595860268e-09
of O 0 4.8180064382563614e-09
Na O 0 2.428236712148646e-06
+ O 0 1.005717194857425e-06
/ O 0 3.8943301206018077e-07
K O 0 2.7930067858505936e-07
+ O 0 1.8783200061989191e-07
ATPase O 0 8.415167940256651e-07
and O 0 9.371617437636814e-08
sarcoplasmic O 0 2.7197776944376528e-05
reticulum O 0 0.00021755688067059964
Ca2 O 0 7.215051300590858e-05
+ O 0 2.4027133349591168e-06
- O 0 1.8624481299411855e-06
ATPase O 0 5.673889972968027e-06
are O 0 2.667093212949112e-08
affected O 0 6.238891359089394e-08
by O 0 1.0919521287178213e-07
DMPK O 0 0.0023875501938164234
absence O 0 1.767836329236161e-05
. O 0 3.3610833725106204e-06

In O 0 4.398653800308239e-06
conclusion O 0 1.042575718201988e-06
, O 0 3.984073870810789e-08
our O 0 4.9088928477658555e-09
data O 0 1.9284325247781453e-08
suggest O 0 5.42224292132687e-08
that O 0 2.7545757674829474e-08
DMPK O 0 7.211763295345008e-05
is O 0 4.799664665711134e-08
involved O 0 1.830011342462967e-08
in O 0 7.617876995880124e-09
modulating O 0 6.075832743590581e-07
the O 0 5.888143750354402e-09
initial O 0 6.516527406574824e-08
events O 0 5.2170241460203215e-09
of O 0 4.2860821558576845e-09
excitation O 0 1.3504416074283654e-06
- O 0 3.721185930771753e-05
contraction O 0 2.2064794393372722e-05
coupling O 0 5.310502274369355e-06
in O 0 3.3431288670726644e-07
skeletal O 0 0.076133131980896
muscle O 0 0.0023004538379609585
. O 0 9.17980571557564e-07
. O 0 1.5530844166278257e-06

Constitutional O 0 0.0034522993955761194
RB1 O 1 0.9654099345207214
- O 0 0.012995585799217224
gene O 0 0.0001254544622497633
mutations O 0 0.00011289594112895429
in O 0 1.913992946356302e-06
patients O 0 0.00019854884885717183
with O 0 6.488101007562364e-07
isolated O 0 5.808805508422665e-05
unilateral B-Disease 0 0.0008882262045517564
retinoblastoma I-Disease 0 0.39210671186447144
. O 0 8.662355867272709e-06

In O 0 1.285877988266293e-05
most O 0 2.4231312636402436e-06
patients O 0 4.0487866499461234e-05
with O 0 2.6303962386009516e-07
isolated O 0 1.5600387996528298e-05
unilateral B-Disease 0 0.000608891888987273
retinoblastoma I-Disease 1 0.6122524738311768
, O 0 1.349091235169908e-06
tumor B-Disease 0 1.1754259503504727e-05
development O 0 9.408508638841795e-09
is O 0 1.5870904590542523e-08
initiated O 0 7.058972784079742e-08
by O 0 1.9418454400010887e-08
somatic O 0 9.918848036249983e-07
inactivation O 0 3.6526438634609804e-05
of O 0 8.219343428095272e-09
both O 0 2.1686830109501898e-08
alleles O 0 1.264444193793679e-07
of O 0 8.066057155531325e-09
the O 0 3.8414790992646886e-07
RB1 O 0 0.002742614597082138
gene O 0 4.6966260924818926e-06
. O 0 1.0260009730700403e-06

However O 0 4.543918839772232e-05
, O 0 1.7528988394133194e-07
some O 0 1.1633523477883045e-08
of O 0 5.900702149119752e-09
these O 0 1.4251128277464886e-07
patients O 0 0.00030875400989316404
can O 0 5.524874495677068e-07
transmit O 0 0.0017714855493977666
retinoblastoma B-Disease 0 0.16796834766864777
predisposition O 0 0.0008780821808613837
to O 0 5.048315188105335e-07
their O 0 6.251052582229022e-07
offspring O 0 4.000726039521396e-05
. O 0 2.23782467401179e-06

To O 0 3.869614829454804e-06
determine O 0 6.996161232564191e-07
the O 0 6.442142819196306e-08
frequency O 0 1.5067242884470033e-06
and O 0 3.5870158399120555e-08
nature O 0 1.8469130225184927e-08
of O 0 6.530871399235139e-09
constitutional O 0 0.00010979780199704692
RB1 O 0 0.15666769444942474
- O 0 4.071444709552452e-05
gene O 0 2.2298015665001003e-06
mutations O 0 2.750019575614715e-06
in O 0 1.3723892777761648e-07
patients O 0 1.1654816262307577e-05
with O 0 1.0318419185750827e-07
isolated O 0 8.10763503977796e-06
unilateral B-Disease 0 0.0001035869718180038
retinoblastoma I-Disease 0 0.03286568447947502
, O 0 1.1188751614099601e-07
we O 0 1.0987478482604729e-08
analyzed O 0 9.888475460684276e-08
DNA O 0 9.548221413524516e-08
from O 0 1.3622361016984996e-08
peripheral O 0 4.954614269081503e-06
blood O 0 2.1106991425767774e-06
and O 0 1.6085181187008857e-07
from O 0 3.431399875353236e-07
tumor B-Disease 0 0.026964249089360237
tissue O 0 0.00014060770627111197
. O 0 2.879940439015627e-06

The O 0 1.5781031379447086e-06
analysis O 0 3.0477877999146585e-07
of O 0 1.2130399795751146e-07
tumors B-Disease 1 0.9999196529388428
from O 0 2.858733978428063e-07
54 O 0 1.123380206990987e-05
( O 0 4.7313491791101114e-08
71 O 0 2.655158368725097e-06
% O 0 2.4109890972567882e-08
) O 0 3.1247311405024902e-09
of O 0 4.454677959842002e-09
76 O 0 4.11755136155989e-05
informative O 0 3.278048461652361e-05
patients O 0 0.10503456741571426
showed O 0 6.88666186761111e-05
loss O 0 1.5913284414637019e-06
of O 0 3.6544300030527666e-08
constitutional O 0 0.00020914494234602898
heterozygosity O 1 0.8535877466201782
( O 0 6.64477647660533e-06
LOH O 1 0.9996356964111328
) O 0 1.942433129897836e-07
at O 0 1.41614009407931e-07
intragenic O 0 4.193600398139097e-05
loci O 0 1.2263062671991065e-05
. O 0 1.8103256707036053e-06

Three O 0 2.9921573059255024e-06
of O 0 2.715610492032283e-07
13 O 0 2.6838929443329107e-06
uninformative O 0 0.13804757595062256
patients O 0 0.11158401519060135
had O 0 4.055100362165831e-06
constitutional O 0 7.1173885771713685e-06
deletions O 0 0.0002817903005052358
. O 0 7.507227110181702e-06

For O 0 2.6039224394480698e-06
39 O 0 5.734490059694508e-06
randomly O 0 2.759956259978935e-06
selected O 0 3.491468760330463e-06
tumors B-Disease 1 0.999496579170227
, O 0 2.301166119877962e-07
SSCP O 0 0.00010429743269924074
, O 0 2.991290557474713e-07
hetero O 0 7.68644895288162e-05
- O 0 2.8710373953799717e-05
duplex O 0 0.0004978126380592585
analysis O 0 1.7665290386048582e-07
, O 0 8.021503461463908e-09
sequencing O 0 1.993472764638682e-08
, O 0 4.800293496032282e-09
and O 0 6.109239336637984e-09
Southern O 0 4.2410086109612166e-08
blot O 0 8.57553823152557e-05
analysis O 0 7.817327229986404e-08
were O 0 3.0890880964307144e-08
used O 0 5.285061632775978e-08
to O 0 9.965594216509999e-08
identify O 0 6.491879503300879e-06
mutations O 0 1.5870466086198576e-05
. O 0 9.61672071753128e-07

Mutations O 0 0.020039625465869904
were O 0 1.028769929689588e-05
detected O 0 5.295331447996432e-06
in O 0 1.325613965263983e-07
21 O 0 1.2637776762858266e-06
( O 0 4.4832095369429226e-08
91 O 0 5.779653292847797e-06
% O 0 4.480234849779663e-08
) O 0 2.995622194745806e-09
of O 0 9.372937093132805e-09
23 O 0 0.0782909244298935
tumors B-Disease 1 0.999998927116394
with O 0 0.0015582889318466187
LOH O 1 0.9999865293502808
. O 0 1.57182748807827e-05

In O 0 6.150611170596676e-06
6 O 0 3.2684849884390133e-06
( O 0 1.222803547307194e-07
38 O 0 9.042899478117761e-07
% O 0 2.290227385515209e-08
) O 0 4.204031345267367e-09
of O 0 2.5253747537590243e-08
16 O 0 0.012806599028408527
tumors B-Disease 1 0.9999997615814209
without O 0 0.00022059856564737856
LOH O 1 0.9999641180038452
, O 0 6.154785126000206e-08
one O 0 2.1504192204702122e-08
mutation O 0 1.7403046115305187e-07
was O 0 4.849581500820932e-07
detected O 0 4.10103552894725e-07
, O 0 1.5470257963556833e-08
and O 0 2.4989779134898527e-08
in O 0 3.4293609729729724e-08
9 O 0 3.347215624671662e-07
( O 0 1.3252443586964091e-08
56 O 0 9.697350833448581e-07
% O 0 1.43546934339156e-08
) O 0 1.7237817839799163e-09
of O 0 7.1983468075131896e-09
the O 0 1.1014673873432912e-05
tumors B-Disease 1 0.9999998807907104
without O 0 0.00029858291964046657
LOH O 1 0.9999610185623169
, O 0 1.4970763118071773e-07
both O 0 4.8416655573646494e-08
mutations O 0 6.260777922761918e-07
were O 0 1.0909923986446302e-07
found O 0 4.761691343446728e-07
. O 0 6.218433554749936e-07

Thus O 0 1.6960610082605854e-05
, O 0 8.94182861088666e-08
a O 0 4.7640032363460705e-08
total O 0 1.5921962415177404e-08
of O 0 8.132871265331687e-09
45 O 0 9.077876939045382e-07
mutations O 0 1.5761870599817485e-06
were O 0 2.254291331382774e-07
identified O 0 1.9377923763386207e-06
in O 0 5.262594982013979e-07
tumors B-Disease 1 0.9999825954437256
of O 0 1.8119027345164795e-07
36 O 0 0.00032797461608424783
patients O 0 0.0006145820370875299
. O 0 1.2194524288133834e-06

Thirty O 0 8.274257561424747e-05
- O 0 2.467791455273982e-05
nine O 0 3.7249157003316213e-07
of O 0 9.678603696272603e-09
the O 0 3.6087143939766975e-08
mutations O 0 2.737324166446342e-06
- O 0 5.174165380594786e-06
including O 0 8.524025219003306e-08
34 O 0 3.6991301044508873e-07
small O 0 7.178291383524993e-08
mutations O 0 1.2263917597010732e-06
, O 0 1.4938482451043456e-08
2 O 0 2.8156366127518595e-08
large O 0 3.1884717088814796e-08
structural O 0 3.4030563256237656e-05
alterations O 0 0.0001544623082736507
, O 0 2.528913398691657e-07
and O 0 3.2974563168863824e-07
hypermethylation O 0 0.0017730715917423368
in O 0 1.506175522081321e-06
3 O 0 0.00012946987408213317
tumors O 1 0.9999974966049194
- O 0 0.0046766214072704315
were O 0 3.7094846447871532e-06
not O 0 8.878405566292713e-08
detected O 0 2.7980667027804884e-07
in O 0 7.0273338259596585e-09
the O 0 9.787034294106434e-09
corresponding O 0 4.1798153915806324e-07
peripheral O 0 4.473603257793002e-05
blood O 0 1.3540391591959633e-05
DNA O 0 6.453361493186094e-06
. O 0 1.0306465583198587e-06

In O 0 9.141452210315038e-06
6 O 0 4.364040250948165e-06
( O 0 9.945485146545252e-08
17 O 0 3.3498437801426917e-07
% O 0 1.446010600147929e-08
) O 0 1.0763350211107081e-09
of O 0 1.3528620446123796e-09
the O 0 9.534717548831395e-08
36 O 0 0.0006210964638739824
patients O 0 0.0006019744323566556
, O 0 1.859067388920721e-08
a O 0 1.7618518199924438e-07
mutation O 0 1.0708558875194285e-06
was O 0 3.737373504009156e-07
detected O 0 1.309735324639405e-07
in O 0 6.532864471608946e-09
constitutional O 0 1.0062659612231073e-06
DNA O 0 7.89952446211828e-06
, O 0 4.086331983899072e-08
and O 0 2.122004261195798e-08
1 O 0 5.295886396083915e-09
of O 0 1.1824385914849245e-09
these O 0 1.499975432750489e-08
mutations O 0 4.612052180164028e-07
is O 0 1.5769094474649137e-08
known O 0 2.059790915609483e-08
to O 0 5.0016868868851816e-08
be O 0 2.2773301111556066e-07
associated O 0 1.4152691107938153e-07
with O 0 1.5928256402730767e-07
reduced O 0 4.846575393457897e-05
expressivity O 0 0.017106013372540474
. O 0 2.999288199134753e-06

The O 0 7.351069939431909e-07
presence O 0 2.2209869143807737e-07
of O 0 7.185054773373167e-09
a O 0 1.291652580448499e-07
constitutional O 0 1.1308428838674445e-05
mutation O 0 1.9214041458326392e-05
was O 0 4.3569875742832664e-06
not O 0 9.237223963509678e-08
associated O 0 2.1136827399459435e-08
with O 0 8.951671404133776e-09
an O 0 6.464212276569015e-08
early O 0 9.900880968416459e-07
age O 0 4.6472675307995814e-07
at O 0 7.223835751801744e-08
treatment O 0 4.3367937905713916e-05
. O 0 2.5140577690763166e-06

In O 0 8.200059710361529e-06
1 O 0 3.1886170290817972e-06
patient O 0 2.838087675627321e-05
, O 0 8.916385496604562e-08
somatic O 0 7.909565283625852e-06
mosaicism O 0 0.008119883947074413
was O 0 0.00013241785927675664
demonstrated O 0 1.069041672963067e-06
by O 0 1.8730549555812104e-08
molecular O 0 1.7059183221590501e-07
analysis O 0 1.732540511056868e-08
of O 0 3.238421975026995e-09
DNA O 0 4.006753329122148e-07
and O 0 3.153586192183866e-08
RNA O 0 2.1063205224436388e-07
from O 0 4.318826896110295e-08
peripheral O 0 2.1309744624886662e-05
blood O 0 1.382274513161974e-05
. O 0 1.8116659248335054e-06

In O 0 3.1508097890764475e-05
2 O 0 5.2423562010517344e-05
patients O 0 0.00017468967416789383
without O 0 1.1723351889258993e-07
a O 0 1.0411062021375983e-06
detectable O 0 4.152021574554965e-05
mutation O 0 1.3408681525106658e-06
in O 0 5.68480302831631e-08
peripheral O 0 0.00014460044621955603
blood O 0 6.339371611829847e-05
, O 0 7.249889222293859e-07
mosaicism O 0 0.0007458426989614964
was O 0 7.171711331466213e-05
suggested O 0 8.816169270176033e-07
because O 0 3.3480226591109385e-08
1 O 0 1.2592042075709742e-08
of O 0 3.923366964642128e-09
the O 0 1.035971763485577e-06
patients O 0 0.09209524095058441
showed O 1 0.5564196109771729
multifocal O 1 0.9999903440475464
tumors B-Disease 1 0.9999998807907104
and O 0 1.8815238433944614e-07
the O 0 1.5251549356776195e-08
other O 0 6.930971796492713e-09
later O 0 3.373644972270995e-07
developed O 0 3.7823483012289216e-07
bilateral B-Disease 0 1.2386442449496826e-06
retinoblastoma I-Disease 0 0.06293457746505737
. O 0 7.520297458540881e-06

In O 0 1.5167296396612073e-06
conclusion O 0 3.3374331565028115e-07
, O 0 1.5578187628761953e-08
our O 0 7.476249841431581e-09
results O 0 2.3679893601524782e-08
emphasize O 0 8.315043942275224e-08
that O 0 3.03873797236065e-08
the O 0 1.3857825997831696e-08
manifestation O 0 1.136667606260744e-06
and O 0 1.300986411933991e-07
transmissibility O 0 3.001766344823409e-06
of O 0 2.055105419174197e-08
retinoblastoma B-Disease 0 9.038709322339855e-06
depend O 0 4.253597651882046e-08
on O 0 4.301751133084508e-08
the O 0 5.099876965175554e-09
nature O 0 5.451150197899324e-09
of O 0 4.770872585879715e-10
the O 0 6.791886608681352e-09
first O 0 1.4849344154299615e-07
mutation O 0 3.8506672694893496e-07
, O 0 4.4779260299776524e-09
its O 0 7.03748748165367e-09
time O 0 2.2701261315205556e-08
in O 0 1.2568023954884211e-08
development O 0 4.620696714141559e-09
, O 0 1.2679454819419789e-08
and O 0 5.954234438831918e-09
the O 0 6.30523544487005e-09
number O 0 1.1704657687516828e-08
and O 0 8.325371503303813e-09
types O 0 1.3023488953933793e-08
of O 0 3.064135389863054e-09
cells O 0 1.0353905821602893e-07
that O 0 3.633343226283614e-08
are O 0 1.900462187620633e-08
affected O 0 8.648141403000409e-08
. O 0 3.97697483833781e-08
. O 0 3.1371902764476545e-07

Hereditary B-Disease 1 0.9999961853027344
deficiency I-Disease 1 0.9992803931236267
of I-Disease 0 1.5855070500947477e-07
the I-Disease 0 3.219835775780666e-08
fifth I-Disease 0 5.152226094651269e-07
component I-Disease 0 8.287146613383811e-08
of I-Disease 0 4.886537841031213e-09
complement I-Disease 0 1.3575832724654902e-07
in O 0 1.182188213988411e-07
man O 0 0.00012912933016195893
. O 0 7.257436323016009e-07

I O 0 0.0010060406057164073
. O 0 4.862463174504228e-05

Clinical O 0 0.04903286695480347
, O 0 5.945350494585e-06
immunochemical O 0 0.00011764964438043535
, O 0 3.583528780382039e-07
and O 0 1.5165777256243018e-07
family O 0 7.554819489996589e-07
studies O 0 2.467938600148045e-07
. O 0 6.196341360009683e-07

The O 0 1.1067045306845102e-06
first O 0 4.247395679612964e-07
recognized O 0 3.163994506394374e-07
human O 0 2.1511254999495577e-07
kindred O 0 0.0003960559261031449
with O 0 0.00088473194045946
hereditary B-Disease 1 0.9999986886978149
deficiency I-Disease 1 0.975140392780304
of I-Disease 0 6.430661780854052e-09
the I-Disease 0 2.4393624897811605e-08
fifth I-Disease 0 3.7828530707884056e-07
component I-Disease 0 8.368647286260966e-08
of I-Disease 0 4.5443151464041875e-09
complement I-Disease 0 4.833254934055731e-07
( O 0 9.18535931759834e-08
C5 O 0 2.0529625544440933e-05
) O 0 2.6943403952373046e-08
is O 0 1.2253846648491162e-07
described O 0 1.5287134374375455e-05
. O 0 9.754412531037815e-07

The O 0 4.5997535380593035e-06
proband O 0 4.1374914871994406e-05
, O 0 1.575599384295856e-07
a O 0 1.5779993134401593e-07
20 O 0 7.548023006620497e-08
- O 0 2.088051360260579e-06
year O 0 1.903956814430785e-07
- O 0 4.581952453008853e-06
old O 0 1.4923090020602103e-05
black O 0 1.272859844902996e-05
female O 0 9.47423541219905e-05
with O 0 0.001450967974960804
systemic B-Disease 1 1.0
lupus I-Disease 1 0.9999998807907104
erythematosus I-Disease 1 0.9999998807907104
since O 0 0.007484061643481255
age O 0 2.2269284727371996e-06
11 O 0 1.8036205062799127e-07
, O 0 9.594774752486046e-08
lacked O 0 4.3691266910173e-05
serum O 0 6.767182640032843e-05
hemolytic O 0 3.142311834380962e-05
complement O 0 7.440759475230152e-08
activity O 0 1.919778824799323e-08
, O 0 8.62313509486512e-09
even O 0 7.431710002947511e-08
during O 0 9.533623597235419e-07
remission O 0 2.3599564883625135e-05
. O 0 6.377396175594185e-07

C5 O 0 0.18679064512252808
was O 0 0.00017041913815774024
undetectable O 0 2.4155857317964546e-05
in O 0 2.325619590237693e-07
her O 0 1.9000076463271398e-06
serum O 0 2.9255322715471266e-06
by O 0 6.065214819273024e-08
both O 0 7.15757835223485e-08
immunodiffusion O 0 3.368906254763715e-05
and O 0 2.4780520107015036e-06
hemolytic O 0 0.0378534235060215
assays O 0 0.00023857034102547914
. O 0 5.9296316976542585e-06

Other O 0 1.4669685697299428e-06
complement O 0 1.1032533393517951e-06
components O 0 3.83979397611256e-07
were O 0 7.538843505017212e-08
normal O 0 6.781378658615722e-08
during O 0 2.9504701615223894e-07
remission O 0 8.6481413745787e-06
of O 0 1.1698635660195578e-07
lupus O 1 0.6678802967071533
, O 0 2.5577571705071023e-07
but O 0 4.117055141250603e-07
C1 O 0 5.251442053122446e-05
, O 0 4.888843463390913e-08
C4 O 0 4.4504954530566465e-06
, O 0 2.684958246845781e-07
C2 O 0 2.27824566536583e-05
, O 0 5.637702926719612e-08
and O 0 6.615373848717354e-08
C3 O 0 7.666808232897893e-05
levels O 0 3.2724972243158845e-07
fell O 0 9.655955182097387e-06
during O 0 2.4882774596335366e-06
exacerbations O 0 0.15932254493236542
. O 0 7.223398370115319e-06

A O 0 6.441862205974758e-05
younger O 0 3.973699131165631e-05
half O 0 4.231982586588856e-07
- O 0 6.877508894831408e-06
sister O 0 7.34923014533706e-06
, O 0 6.367757521275053e-08
who O 0 7.61726880682545e-07
had O 0 1.9347251054568915e-06
no O 0 2.017979113588808e-06
underlying O 0 0.022982841357588768
disease O 0 0.0005411247257143259
, O 0 1.119880863598155e-07
was O 0 7.767669558234047e-06
also O 0 2.112969923473429e-07
found O 0 2.8264356188856254e-08
to O 0 6.666825669299214e-08
lack O 0 1.1682107015076326e-06
immunochemically O 0 0.12121602147817612
detectable O 0 0.00026846263790503144
C5 O 0 6.672518065897748e-05
. O 0 1.1413787888159277e-06

By O 0 5.669103120453656e-05
hemolytic O 0 0.22017915546894073
assay O 0 0.00029797552269883454
, O 0 1.1063774536523852e-06
she O 0 2.4082971776806517e-06
exhibited O 0 2.1691046185878804e-06
1 O 0 6.621407777629429e-08
- O 0 5.166739811102161e-06
2 O 0 1.3618469552056922e-07
% O 0 5.836474414877557e-09
of O 0 6.4899641216698e-10
the O 0 1.7429911736144277e-08
normal O 0 2.9517480015783804e-07
serum O 0 5.558377324632602e-06
C5 O 0 3.373282652319176e-06
level O 0 1.7482285841197154e-08
and O 0 1.1426368295985867e-08
normal O 0 4.8676756847498837e-08
concentrations O 0 5.096125832437792e-08
of O 0 1.442670982676475e-09
other O 0 4.406534692691366e-09
complement O 0 2.0892495911084552e-07
components O 0 1.6629064703010954e-06
. O 0 7.351715112235979e-07

C5 O 0 0.03740439563989639
levels O 0 3.8692273847118486e-06
of O 0 3.4838969042993995e-08
other O 0 2.311220903550293e-08
family O 0 8.869299961133947e-08
members O 0 2.0315539472903765e-08
were O 0 1.4134320736047812e-07
either O 0 2.629587747549067e-08
normal O 0 4.386629370856099e-08
or O 0 1.2678003535881999e-08
approximately O 0 1.5398869734895015e-08
half O 0 7.875964769255006e-08
- O 0 5.1898014135076664e-06
normal O 0 2.9927085165581957e-07
, O 0 4.615193560653097e-08
consistent O 0 5.359378860703146e-07
with O 0 7.660541996301617e-07
autosomal O 0 0.047052543610334396
codominant O 0 0.0006147000822238624
inheritance O 0 4.93990000904887e-07
of O 0 2.7839628380377235e-09
the O 0 3.535501846840816e-08
gene O 0 8.5505198512692e-06
determining O 0 0.00011521857231855392
C5 B-Disease 1 0.999998927116394
deficiency I-Disease 1 0.9999974966049194
. O 0 1.1682948752422817e-05

Normal O 0 0.0024792097974568605
hemolytic O 1 0.9609068036079407
titers O 0 0.03745820373296738
were O 0 1.2183912076579873e-05
restored O 0 3.710100145326578e-06
to O 0 2.800298659622058e-07
both O 0 1.4348720469570253e-06
homozygous O 0 0.1423785239458084
C5 B-Disease 1 0.9999849796295166
- I-Disease 1 0.9999788999557495
deficient I-Disease 1 0.9999994039535522
( O 0 7.670055310882162e-06
C5D B-Disease 1 0.9999836683273315
) O 0 3.4578607710500364e-07
sera O 0 3.5461666811897885e-06
by O 0 1.1675604483230018e-08
addition O 0 7.934131573961167e-09
of O 0 3.4599298981419224e-09
highly O 0 3.1576129799759656e-07
purified O 0 3.0631022127636243e-06
human O 0 7.410442321997834e-07
C5 O 0 5.921469710301608e-05
. O 0 1.8523124936109525e-06

In O 0 7.66692483011866e-06
specific O 0 8.788467198428407e-07
C5 O 0 0.00021674687741324306
titrations O 0 0.0054231248795986176
, O 0 5.613923690361844e-07
however O 0 2.832038035194273e-07
, O 0 4.051648616609782e-08
it O 0 3.336534959430537e-08
was O 0 3.2590819500910584e-06
noted O 0 1.4264114156503638e-07
that O 0 1.4385006963379965e-08
when O 0 2.3050136022106926e-08
limited O 0 1.4476940535246285e-08
amounts O 0 7.71867814108873e-09
of O 0 2.0559118851792846e-09
C5 O 0 2.3016320938040735e-06
were O 0 6.252734152667472e-08
assayed O 0 4.0442066051582515e-07
in O 0 1.1875652461412756e-08
the O 0 3.0071629630867847e-09
presence O 0 1.3606728188619854e-08
of O 0 2.272698473859691e-09
low O 0 4.920876222058723e-07
dilutions O 0 1.1124461707368027e-05
of O 0 4.9215515218747896e-08
either O 0 4.164650363236433e-06
C5D B-Disease 1 0.9999945163726807
serum O 0 6.088673399062827e-05
, O 0 2.7340467667613666e-08
curving O 0 3.0386601679310843e-07
rather O 0 3.915862833991923e-08
than O 0 2.0378331910819725e-08
linear O 0 2.6390347329652286e-07
dose O 0 1.1351618013577536e-05
- O 0 3.255202045693295e-06
response O 0 2.9450839633682335e-07
plots O 0 1.7436903476664156e-07
were O 0 4.3110168235216406e-07
consistently O 0 2.547404392316821e-06
obtained O 0 1.2953643135915627e-07
, O 0 1.3589818159687184e-08
suggesting O 0 1.3418360822470277e-07
some O 0 2.8649720817952584e-08
inhibitory O 0 3.1157751436694525e-06
effect O 0 4.3892464418604504e-06
. O 0 8.614201760792639e-07

Further O 0 2.9244025427033193e-05
studies O 0 1.9727106064237887e-06
suggested O 0 9.049154527929204e-07
that O 0 7.88326914857862e-08
low O 0 7.514466346947302e-07
dilutions O 0 2.5229410312022083e-05
of O 0 4.3382866010688304e-07
C5D B-Disease 1 0.9999967813491821
serum O 0 5.433250771602616e-05
contain O 0 1.5207285741780652e-07
a O 0 1.4677534920792823e-07
factor O 0 9.692721647525104e-08
( O 0 9.223505514910357e-09
or O 0 9.691866864613985e-09
factors O 0 1.7477450597880306e-08
) O 0 5.637022404414438e-09
interfering O 0 4.792913088635942e-08
at O 0 8.735637990753276e-09
some O 0 3.40930439435283e-09
step O 0 2.5201490672088767e-08
in O 0 6.953229991779608e-09
the O 0 3.719994978723662e-08
hemolytic O 0 0.00020166454487480223
assay O 0 2.0195366232655942e-06
of O 0 1.871969246280969e-08
C5 O 0 3.921866664313711e-05
, O 0 1.7611034408560045e-08
rather O 0 9.177807847038366e-09
than O 0 1.0594303212485556e-08
a O 0 1.633979564985566e-07
true O 0 8.015799721761141e-07
C5 O 0 2.178377144446131e-05
inhibitor O 0 1.2450545909814537e-05
or O 0 3.184874231010326e-07
inactivator O 0 0.0001123673064284958
. O 0 3.136764462396968e-06

Of O 0 4.610166342899902e-06
clinical O 0 0.00012938692816533148
interest O 0 4.1955107121793844e-07
are O 0 4.788682517187226e-08
( O 0 1.7512521210960585e-08
a O 0 3.3433138924010564e-07
) O 0 2.289340983452348e-08
the O 0 1.001883997986397e-08
documentation O 0 2.496706201782217e-07
of O 0 1.6300201366448164e-07
membranous O 1 0.9997499585151672
glomerulonephritis B-Disease 1 1.0
, O 0 0.17619378864765167
vasculitis B-Disease 1 0.9999995231628418
, O 0 0.00040310880285687745
and O 0 0.11464061588048935
arthritis B-Disease 1 1.0
in O 0 1.3669388181369868e-06
an O 0 4.230122385706636e-07
individual O 0 9.027289138430206e-08
lacking O 0 4.104938852833584e-06
C5 O 0 9.812120697461069e-05
( O 0 2.3412050964566333e-08
and O 0 1.4750312971045787e-08
its O 0 2.3405085869399045e-08
biologic O 0 3.1701547413831577e-06
functions O 0 1.405030491952175e-08
) O 0 1.4296385408840706e-08
, O 0 1.6451711104537026e-08
and O 0 3.618432842245056e-08
( O 0 9.527224342775753e-09
b O 0 4.3810857164316985e-08
) O 0 2.2007926592237936e-09
a O 0 4.41409966356332e-08
remarkable O 0 2.8115857730881544e-07
propensity O 0 8.50118522066623e-05
to O 0 0.0005779810016974807
bacterial B-Disease 1 0.9999998807907104
infections I-Disease 1 0.9999998807907104
in O 0 7.626245519531949e-07
the O 0 8.609465140807515e-08
proband O 0 9.841102291829884e-05
, O 0 3.168000972664231e-08
even O 0 1.7742932456599192e-08
during O 0 1.8315793326451058e-08
periods O 0 2.792761044645431e-08
of O 0 4.803709874323658e-09
low O 0 3.4035826956824167e-07
- O 0 3.7242552934912965e-06
dose O 0 8.16445390228182e-06
or O 0 9.103399811749568e-09
alternate O 0 8.274984253375806e-08
- O 0 7.480748081434285e-06
day O 0 1.9399371922190767e-06
corticosteroid O 1 0.5734166502952576
therapy O 0 0.0005526409368030727
. O 0 1.192253989756864e-06

Other O 0 3.5794203085970366e-06
observations O 0 9.475491424382199e-06
indicate O 0 2.926238266809378e-06
that O 0 9.002940970503914e-08
the O 0 8.125587669383094e-08
C5D B-Disease 1 0.9999871253967285
state O 0 1.010306718285392e-07
is O 0 2.05918979645503e-08
compatible O 0 6.11456911769892e-08
with O 0 2.1689436024985298e-08
normal O 0 1.1307800917847999e-07
coagulation O 0 5.766103754467622e-07
function O 0 2.213338312628821e-08
and O 0 6.187150791703289e-09
the O 0 3.958137817505758e-09
capacity O 0 8.368967030492058e-08
to O 0 4.651515084219682e-08
mount O 0 1.5570990399282891e-06
a O 0 2.253880120406393e-05
neutrophilic O 1 0.8036606907844543
leukocytosis O 0 0.05767112970352173
during O 0 2.5873598133330233e-05
pyogenic B-Disease 1 0.9480798840522766
infection I-Disease 0 0.022275693714618683
. O 0 4.663899346724065e-07
. O 0 8.611031603322772e-07

Susceptibility O 1 0.9988094568252563
to O 1 0.9159840941429138
ankylosing B-Disease 1 0.9999998807907104
spondylitis I-Disease 1 1.0
in O 0 0.08671677112579346
twins O 0 0.014742763713002205
: O 0 2.278645894193687e-08
the O 0 4.698405664527172e-09
role O 0 2.199870330343856e-08
of O 0 4.954230359288658e-09
genes O 0 2.0711256354388752e-07
, O 0 3.0252928695517767e-07
HLA O 0 0.000254278042120859
, O 0 8.277209673224206e-08
and O 0 1.711787689373523e-08
the O 0 3.2109490177845146e-08
environment O 0 1.479180696151161e-06
. O 0 4.871818077845091e-07

OBJECTIVE O 0 2.3624017558177002e-05
To O 0 8.251860208474682e-07
determine O 0 2.1632551749917184e-07
the O 0 3.4382878766336944e-08
relative O 0 6.754385708518384e-07
effects O 0 7.907165695542062e-07
of O 0 1.1365854923894858e-08
genetic O 0 1.7689292235445464e-06
and O 0 1.1784521092295108e-07
environmental O 0 3.4897368550446117e-07
factors O 0 8.700522613480643e-08
in O 0 6.809477781644091e-07
susceptibility O 1 0.9986053109169006
to O 1 0.997900128364563
ankylosing B-Disease 1 1.0
spondylitis I-Disease 1 1.0
( O 0 0.00019136321498081088
AS B-Disease 1 0.9927809834480286
) O 0 1.285192183786421e-06
. O 0 1.706669991108356e-06

METHODS O 0 0.0003599232586566359
Twins O 0 0.0015478911809623241
with O 0 2.113194568664767e-06
AS B-Disease 1 0.9703235030174255
were O 0 2.572746552687022e-06
identified O 0 2.53038024311536e-07
from O 0 4.481377491316607e-09
the O 0 1.725243059524928e-08
Royal O 0 1.5013891243143007e-05
National O 0 1.313873667641019e-07
Hospital O 0 0.00027774268528446555
for O 0 6.659570772171719e-06
Rheumatic B-Disease 1 0.9999761581420898
Diseases I-Disease 0 0.04121486470103264
database O 0 5.195307949179551e-06
. O 0 2.7694929940480506e-06

Clinical O 0 0.007006378844380379
and O 0 1.1629480468400288e-05
radiographic O 0 0.04280382767319679
examinations O 0 5.1641832214954775e-06
were O 0 6.469991262747499e-07
performed O 0 3.6321657148619124e-07
to O 0 5.229689747920929e-08
establish O 0 2.490518909326056e-06
diagnoses O 1 0.996406614780426
, O 0 5.234757281868951e-06
and O 0 0.001386928604915738
disease O 0 0.08479444682598114
severity O 0 0.1369742602109909
was O 0 0.0026556546799838543
assessed O 0 2.4712687718420057e-07
using O 0 1.6692183635313995e-08
a O 0 7.959356196352019e-08
combination O 0 1.7706545918372285e-07
of O 0 7.696039361348994e-09
validated O 0 7.214533752630814e-07
scoring O 0 3.2505749913980253e-07
systems O 0 1.9288133898953674e-06
. O 0 8.720615483071015e-07

HLA O 0 0.013460877351462841
typing O 0 0.0001548755681142211
for O 0 4.493175310926745e-06
HLA O 0 0.00026135821826756
- O 0 8.829239231999964e-05
B27 O 0 2.8423672119970433e-05
, O 0 1.6938521696374664e-07
HLA O 0 2.0506477085291408e-05
- O 0 1.9794670151895843e-05
B60 O 0 7.031236691545928e-06
, O 0 4.132033026849058e-08
and O 0 9.25632477333238e-08
HLA O 0 0.0007464499794878066
- O 0 0.26795387268066406
DR1 O 1 0.999901533126831
was O 0 1.8316392015549354e-05
performed O 0 1.3504424600796483e-07
by O 0 5.203389275010295e-09
polymerase O 0 2.1462915356096346e-07
chain O 0 3.9138325291787623e-07
reaction O 0 7.399927426376962e-08
with O 0 5.232610345018429e-09
sequence O 0 1.1550302936313983e-08
- O 0 3.303896676243312e-07
specific O 0 1.1911494901539754e-08
primers O 0 1.5425670198965236e-06
, O 0 4.4074788263515075e-08
and O 0 3.581997276569382e-08
zygosity O 0 2.251686601084657e-05
was O 0 8.691050084053131e-07
assessed O 0 1.6875414132755395e-07
using O 0 3.3058884696401947e-07
microsatellite O 0 0.00015589686518069357
markers O 0 3.69555018551182e-05
. O 0 2.786955974443117e-06

Genetic O 0 0.002167789964005351
and O 0 2.391963334957836e-06
environmental O 0 1.7015960338540026e-06
variance O 0 2.875324867090967e-07
components O 0 8.900895522856445e-07
were O 0 9.5687926204846e-07
assessed O 0 4.357891896233923e-07
with O 0 2.4312523549951948e-08
the O 0 2.464903836596477e-08
program O 0 2.9382601240968143e-08
Mx O 0 1.766070340636361e-06
, O 0 6.284368136988405e-09
using O 0 1.1211733763616394e-08
data O 0 9.325983540975358e-09
from O 0 1.4900740641365928e-09
this O 0 5.664430702267964e-09
and O 0 4.130803787916193e-08
previous O 0 2.448324210035935e-07
studies O 0 2.1137070760346433e-08
of O 0 6.072180092075996e-09
twins O 0 1.5772571714478545e-05
with O 0 1.0142493778175776e-07
AS B-Disease 1 0.9237631559371948
. O 0 3.337275302328635e-06

RESULTS O 0 0.00010035459854407236
Six O 0 5.367649009713205e-07
of O 0 4.951455423451989e-08
8 O 0 3.2598402412986616e-06
monozygotic O 0 0.00488891638815403
( O 0 1.4250139201976708e-06
MZ O 1 0.9968935251235962
) O 0 8.137496365634433e-07
twin O 0 0.023973669856786728
pairs O 0 3.901336640410591e-06
were O 0 1.587767110322602e-05
disease O 0 1.9625555069069378e-05
concordant O 0 0.0003152141289319843
, O 0 6.353484423016198e-07
compared O 0 4.6377309104173037e-07
with O 0 1.935274873687831e-08
4 O 0 4.574336998075523e-08
of O 0 6.957807219265533e-09
15 O 0 1.318597213639805e-07
B27 O 0 4.719258868135512e-06
- O 0 3.7254998460412025e-05
positive O 0 1.5008043874331634e-06
dizygotic O 0 4.605346020980505e-06
( O 0 5.3664365395889035e-08
DZ O 0 2.266348928969819e-05
) O 0 8.373070414791073e-08
twin O 0 0.00014764038496650755
pairs O 0 2.4380187824135646e-07
( O 0 1.5972819511489433e-08
27 O 0 4.6195751224331616e-07
% O 0 1.2343308597451141e-08
) O 0 3.922993041527434e-09
and O 0 9.692126212712537e-09
4 O 0 1.6254276147265045e-08
of O 0 7.680876379367874e-09
32 O 0 1.585854874974757e-06
DZ O 0 0.006717972457408905
twin O 0 0.008203580975532532
pairs O 0 4.07732500207203e-07
overall O 0 3.342698562391888e-07
( O 0 2.7799529789263033e-08
12 O 0 1.4156552197164274e-07
. O 0 4.940050857271672e-08
5 O 0 2.0552373314330907e-07
% O 0 9.852422522271809e-08
) O 0 1.0905387881621209e-07
. O 0 1.0782321169244824e-06

Nonsignificant O 0 0.001736353151500225
increases O 0 2.983092053909786e-05
in O 0 8.59822435472779e-08
similarity O 0 4.23388001991043e-07
with O 0 7.455249573240508e-08
regard O 0 1.9790657290741365e-07
to O 0 9.94062816062069e-07
age O 0 9.655936992203351e-06
at O 0 6.424694447559887e-07
disease O 0 2.6916573915514164e-05
onset O 0 2.241092261101585e-06
and O 0 4.6229818195797634e-08
all O 0 1.9648505045211095e-09
of O 0 3.6103375844476204e-09
the O 0 8.263350537163205e-07
disease O 0 0.0042588915675878525
severity O 0 0.013539586216211319
scores O 0 4.990037268726155e-06
assessed O 0 1.5876435099926312e-06
were O 0 4.3009066530430573e-07
noted O 0 1.4026416010892717e-06
in O 0 5.7228367040806916e-06
disease O 0 0.0031413082033395767
- O 1 0.5304970741271973
concordant O 1 0.9983239769935608
MZ O 1 0.9999473094940186
twins O 0 0.05881033092737198
compared O 0 2.6764221274788724e-06
with O 0 3.5208393001084914e-07
concordant O 0 0.013069899752736092
DZ O 1 0.8462024331092834
twins O 0 0.0014265431091189384
. O 0 2.3641096049686894e-06

HLA O 0 0.2854998707771301
- O 0 0.0012890740763396025
B27 O 0 8.962744323071092e-05
and O 0 6.75898604640679e-07
B60 O 0 6.610910531890113e-06
were O 0 3.141070124001999e-07
associated O 0 5.833661731458051e-08
with O 0 5.5126122333604144e-08
the O 0 3.062170435441658e-06
disease O 0 0.00022014114074409008
in O 0 1.7646532057824516e-07
probands O 0 0.0008730989648029208
, O 0 4.266215825055042e-08
and O 0 6.274857966559466e-09
the O 0 8.731207756795811e-09
rate O 0 8.758900094107958e-08
of O 0 1.5895684768452156e-08
disease O 0 3.2250097774522146e-06
concordance O 0 1.3142014722689055e-05
was O 0 0.00010697536345105618
significantly O 0 7.3947730925283395e-06
increased O 0 8.952629286795855e-07
among O 0 1.5322963520247868e-07
DZ O 0 0.020663002505898476
twin O 0 0.11586938798427582
pairs O 0 2.3466598975119268e-07
in O 0 1.4183451746418996e-08
which O 0 5.120024937355083e-08
the O 0 3.824349548153805e-08
co O 0 7.028730760794133e-05
- O 0 0.0015345176216214895
twin O 0 0.05925067886710167
was O 0 6.353493972710567e-06
positive O 0 4.427582567245736e-08
for O 0 7.896072240498597e-09
both O 0 3.074188370533193e-08
B27 O 0 9.8711097962223e-06
and O 0 1.8178010350311524e-06
DR1 O 1 0.9974969029426575
. O 0 3.992349320469657e-06

Additive O 0 0.00023002283705864102
genetic O 0 0.0001440911873942241
effects O 0 2.864599446184002e-05
were O 0 6.684103937004693e-07
estimated O 0 1.0009084405737667e-07
to O 0 5.31118438118483e-08
contribute O 0 1.4905714351698407e-07
97 O 0 4.059388345467596e-07
% O 0 1.5950959664223774e-08
of O 0 1.4780299206762493e-09
the O 0 2.8700039678142275e-08
population O 0 1.570892749214181e-07
variance O 0 6.724441732330888e-07
. O 0 1.5863948874539346e-06

CONCLUSION O 0 0.0002958369441330433
Susceptibility O 0 0.30277737975120544
to O 0 1.3937175936007407e-05
AS B-Disease 1 0.9602601528167725
is O 0 8.48881597903528e-07
largely O 0 9.979172546081827e-07
genetically O 0 9.028715339809423e-07
determined O 0 1.9931608221668284e-06
, O 0 2.225220363527569e-08
and O 0 1.0122700011550023e-08
the O 0 1.232352531133074e-08
environmental O 0 2.1222071211468574e-07
trigger O 0 3.490080644041882e-06
for O 0 7.636268151145487e-08
the O 0 1.1418175063226954e-06
disease O 0 0.00016269279876723886
is O 0 3.3692015222186456e-07
probably O 0 1.4692914191982709e-06
ubiquitous O 0 6.261533599172253e-06
. O 0 1.2834150311391568e-06

HLA O 0 0.3064629137516022
- O 0 0.0014962998684495687
B27 O 0 7.177917723311111e-05
accounts O 0 2.752554451035394e-07
for O 0 2.0863538452431385e-08
a O 0 2.5973199058171303e-07
minority O 0 3.3954907507904863e-07
of O 0 1.9392536465545618e-09
the O 0 3.628633749030996e-08
overall O 0 1.682592846918851e-05
genetic O 0 5.1068298489553854e-05
susceptibility O 0 0.01397781353443861
to O 0 6.252398634387646e-06
AS B-Disease 1 0.9982472658157349
. O 0 1.7100774130085483e-05

Cell O 0 0.0002653170668054372
cycle O 0 1.297704511671327e-05
- O 0 1.8551198081695475e-05
dependent O 0 1.4319957699626684e-06
colocalization O 0 3.1322981612902367e-06
of O 0 2.8360586767917084e-08
BARD1 O 0 0.00020873636822216213
and O 0 5.382057679526042e-07
BRCA1 O 0 6.283960374275921e-06
proteins O 0 5.407092373843625e-08
in O 0 1.3618073779753104e-08
discrete O 0 4.244982108048134e-07
nuclear O 0 2.250934585390496e-06
domains O 0 2.2435278879129328e-06
. O 0 1.2934883670823183e-06

Germ O 0 0.0007734450045973063
- O 0 0.0038418318144977093
line O 0 2.5780449504964054e-05
mutations O 0 2.1645626020472264e-06
of O 0 8.40931768664177e-09
the O 0 7.313004601883222e-08
BRCA1 O 0 0.00013416376896202564
gene O 0 4.609915777109563e-06
predispose O 0 1.953136052179616e-05
women O 0 3.3431513202231145e-07
to O 0 1.3124423503541038e-07
early O 0 8.320108463522047e-06
- O 1 0.982887864112854
onset O 1 0.9869532585144043
breast B-Disease 1 0.9999916553497314
and I-Disease 1 0.9999294281005859
ovarian I-Disease 1 1.0
cancer I-Disease 1 0.9999978542327881
by O 0 2.2211543182493187e-07
compromising O 0 1.7171101944768452e-06
the O 0 2.8101267091074078e-08
genes O 0 3.666197869733878e-07
presumptive O 0 0.0021227621473371983
function O 0 1.210646445315433e-07
as O 0 6.724987144934857e-08
a O 0 2.09692166208697e-06
tumor B-Disease 0 0.0005271090194582939
suppressor O 0 0.0008806817349977791
. O 0 6.7938590291305445e-06

Although O 0 7.647893653484061e-06
the O 0 1.2151346595601353e-07
biochemical O 0 3.327928197904839e-06
properties O 0 3.0048371968405263e-07
of O 0 2.3250159131293913e-08
BRCA1 O 0 6.293678598012775e-05
polypeptides O 0 5.008148946217261e-06
are O 0 7.51618642880203e-08
not O 0 1.135087828174619e-07
understood O 0 2.6373689365755126e-07
, O 0 9.066974726579247e-09
their O 0 4.903530914646126e-09
expression O 0 1.0471479328089117e-07
pattern O 0 2.388688926657778e-07
and O 0 3.4837572826518226e-08
subcellular O 0 1.274994929190143e-06
localization O 0 5.407142680269317e-07
suggest O 0 4.911039752641955e-08
a O 0 3.210893950722493e-08
role O 0 8.79061516911861e-08
in O 0 4.540003573083595e-08
cell O 0 9.233987839252222e-06
- O 0 2.3065296772983856e-05
cycle O 0 2.086878794216318e-06
regulation O 0 1.9328772395965643e-06
. O 0 1.058030875356053e-06

When O 0 2.5828163416008465e-05
resting O 0 5.060246985522099e-05
cells O 0 2.434083853586344e-06
are O 0 7.107934862915499e-08
induced O 0 1.8633312720339745e-05
to O 0 6.446518909797305e-07
proliferate O 0 5.126898486196296e-06
, O 0 2.953526490045988e-08
the O 0 7.1741546037173975e-09
steady O 0 4.3207012367929565e-07
- O 0 8.757928071645438e-07
state O 0 2.5838819084356146e-08
levels O 0 5.3097028995807705e-09
of O 0 1.1327369042746227e-09
BRCA1 O 0 1.1143637266286532e-06
increase O 0 8.448952115713837e-08
in O 0 1.8440793780882814e-08
late O 0 5.690020543624996e-07
G1 O 0 6.011881123413332e-05
and O 0 3.927576841533664e-08
reach O 0 3.0194811984074477e-08
a O 0 1.811453529398932e-07
maximum O 0 7.829419814697758e-07
during O 0 6.204566034284653e-07
S O 0 7.817996083758771e-05
phase O 0 6.837473392806714e-06
. O 0 1.3742559303864255e-06

Moreover O 0 0.00015403197903651744
, O 0 1.6729178469176986e-06
in O 0 2.0974266590201296e-07
S O 0 7.5806092354469e-05
phase O 0 2.9303519113454968e-06
cells O 0 1.6942688034760067e-06
, O 0 8.856098077103525e-08
BRCA1 O 0 5.137877451488748e-06
polypeptides O 0 8.238462214649189e-07
are O 0 1.2767499946164662e-08
hyperphosphorylated O 0 2.4883297555788886e-06
and O 0 4.878299364463601e-08
accumulate O 0 1.9811579932138557e-07
into O 0 1.4111512847136964e-08
discrete O 0 4.897709686702001e-07
subnuclear O 0 1.7449294318794273e-05
foci O 0 1.7544789443491027e-05
termed O 0 6.839840807515429e-06
" O 0 1.6530306083950563e-06
BRCA1 O 0 3.0823943234281614e-05
nuclear O 0 4.4976941353525035e-06
dots O 0 3.840849967673421e-05
. O 0 2.592009877844248e-06

" O 0 0.00014511539484374225
BRCA1 O 0 0.08440327644348145
associates O 0 6.656604091404006e-05
in O 0 1.2993371001357445e-07
vivo O 0 1.936654734890908e-05
with O 0 9.206319617760528e-08
a O 0 5.71409464100725e-06
structurally O 0 0.015027707442641258
related O 0 3.3519401654302783e-07
protein O 0 1.9911449271603487e-06
termed O 0 9.72729867498856e-06
BARD1 O 0 0.001510259578935802
. O 0 2.97916199087922e-06

Here O 0 2.421872068225639e-06
we O 0 6.576586741857682e-08
show O 0 4.2880547113099965e-08
that O 0 2.307660507128162e-09
the O 0 2.736335380504329e-09
steady O 0 3.398869807824667e-07
- O 0 1.3503358786692843e-06
state O 0 4.3710777219985175e-08
levels O 0 1.1808794830869829e-08
of O 0 2.733805404275813e-09
BARD1 O 0 0.00015590726980008185
, O 0 5.762861121638707e-08
unlike O 0 2.7189241080805004e-08
those O 0 1.0603556921395807e-09
of O 0 2.2604682570204204e-09
BRCA1 O 0 1.5752939361846074e-05
, O 0 8.646640736742484e-08
remain O 0 1.5350929061241914e-07
relatively O 0 4.03974205198665e-08
constant O 0 1.822858166633523e-07
during O 0 1.637506557017332e-07
cell O 0 6.346251666400349e-06
cycle O 0 1.8563445109975873e-06
progression O 0 8.499755494995043e-06
. O 0 1.0709763955674134e-06

However O 0 3.160150663461536e-05
, O 0 1.0626055200191331e-06
immunostaining O 0 5.551861977437511e-05
revealed O 0 7.764596375636756e-06
that O 0 1.4301353701284825e-07
BARD1 O 0 0.00018605643708724529
resides O 0 2.2843109945824835e-06
within O 0 1.7635976234942063e-08
BRCA1 O 0 1.6337532997567905e-06
nuclear O 0 2.2043063552246167e-07
dots O 0 1.5897827552180388e-06
during O 0 1.4435833861625724e-07
S O 0 1.2009865713480394e-05
phase O 0 4.421658417186336e-08
of O 0 1.2185917830365156e-09
the O 0 5.637033062555474e-09
cell O 0 1.50005757859617e-06
cycle O 0 1.7030899357450835e-07
, O 0 7.488794473431426e-09
but O 0 9.140493695269925e-09
not O 0 8.70882033154885e-09
during O 0 1.9984712551490702e-08
the O 0 3.192329955936657e-08
G1 O 0 8.018038352020085e-05
phase O 0 3.2978066428768216e-06
. O 0 5.373523777052469e-07

Nevertheless O 0 0.0007003215723671019
, O 0 3.2482989809068386e-06
BARD1 O 0 0.00012800928379874676
polypeptides O 0 9.235722245648503e-06
are O 0 7.276328517491493e-08
found O 0 4.460249058979571e-08
exclusively O 0 3.23873869945146e-08
in O 0 7.392221945679012e-09
the O 0 4.8855506307177166e-09
nuclear O 0 6.079913106304957e-08
fractions O 0 2.943431987034728e-08
of O 0 2.827313050346447e-09
both O 0 2.8919510342007015e-08
G1 O 0 2.7275282263872214e-05
- O 0 8.433522452833131e-06
and O 0 2.151613642809025e-07
S O 0 0.00011047245789086446
- O 0 2.7528391001396812e-05
phase O 0 1.060453723766841e-05
cells O 0 4.9564432629267685e-06
. O 0 9.721619562697015e-07

Therefore O 0 1.8648403056431562e-05
, O 0 2.714973561523948e-07
progression O 0 1.2751834219670855e-06
to O 0 1.7143109687367541e-07
S O 0 0.0003002594457939267
phase O 0 8.520219125784934e-07
is O 0 6.96928523780116e-08
accompanied O 0 1.9340799894962402e-07
by O 0 4.237545425667122e-09
the O 0 3.798127146126262e-09
aggregation O 0 6.012255937548616e-08
of O 0 4.674762354994755e-09
nuclear O 0 2.260530322928389e-07
BARD1 O 0 1.1443943549238611e-05
polypeptides O 0 9.343023066321621e-07
into O 0 1.522139001508549e-07
BRCA1 O 0 1.6388361473218538e-05
nuclear O 0 2.453555907777627e-06
dots O 0 4.4331856770440936e-05
. O 0 4.607586106430972e-06

This O 0 2.1922655832895543e-06
cell O 0 8.967223948275205e-06
cycle O 0 1.326372967014322e-06
- O 0 6.489985480584437e-06
dependent O 0 6.165307127048436e-07
colocalization O 0 3.046182655452867e-06
of O 0 2.602593518474805e-08
BARD1 O 0 0.00019246518786530942
and O 0 6.295960588431626e-07
BRCA1 O 0 1.8498907593311742e-05
indicates O 0 1.2159867424088588e-07
a O 0 1.2231056700784393e-07
role O 0 1.952587069808942e-07
for O 0 8.64858691329573e-08
BARD1 O 0 0.0007633090135641396
in O 0 6.712191407132195e-07
BRCA1 O 0 0.00021476995607372373
- O 0 0.0001732072269078344
mediated O 0 0.008186186663806438
tumor B-Disease 0 0.02452237904071808
suppression O 0 1.7403592210030183e-05
. O 0 3.341918954902212e-06

Ethnic O 0 5.242575934971683e-05
differences O 0 1.3047829270362854e-05
in O 0 2.3531566739620757e-07
the O 0 1.154517619283979e-07
HFE O 0 0.0002034539356827736
codon O 0 6.272016435104888e-06
282 O 0 8.8914530351758e-06
( O 0 8.019331971809152e-07
Cys O 0 0.07232403010129929
/ O 0 0.00015243962116073817
Tyr O 0 0.00037297263043001294
) O 0 6.945656423340552e-07
polymorphism O 0 0.00011225731577724218
. O 0 3.848563665087568e-06

Recent O 0 2.830508674378507e-05
studies O 0 2.139132448064629e-06
have O 0 3.3844079894151946e-07
shown O 0 7.9267747423728e-06
that O 0 0.026462053880095482
hereditary B-Disease 1 1.0
hemochromatosis I-Disease 1 1.0
( O 0 0.0026456560008227825
HH B-Disease 1 0.9985010623931885
) O 0 1.3800553233522805e-07
is O 0 2.5912140699801967e-07
likely O 0 8.829564421830582e-07
to O 0 1.0121507187932366e-07
be O 0 1.261680040443025e-06
caused O 0 3.3983974390139338e-06
by O 0 4.670076947377311e-08
homozygosity O 0 1.0632446901581716e-05
for O 0 2.2457291137811808e-08
a O 0 8.195730174520577e-07
Cys282Tyr O 0 0.00021524738986045122
mutation O 0 1.921715011121705e-06
in O 0 4.2903618435730095e-08
the O 0 1.033792216276197e-07
HFE O 0 0.0003395751991774887
gene O 0 1.8206445702162455e-06
located O 0 3.760767128824227e-07
4 O 0 1.3196884083299665e-06
. O 0 9.562069180901744e-07

5 O 0 8.196097041945904e-05
Mb O 0 0.0004293656093068421
telomeric O 0 0.0010656786616891623
to O 0 6.014835889800452e-06
HLA O 0 0.000980239361524582
- O 0 9.877506090560928e-05
A O 0 3.302944605820812e-05
. O 0 3.3630906273174332e-06

Population O 0 1.9458910173852928e-05
studies O 0 1.4559245187228953e-07
of O 0 5.774499101107722e-09
this O 0 2.6635550653963946e-08
polymorphism O 0 0.0001249650667887181
are O 0 3.8295393522957966e-08
facilitated O 0 1.0451286414081551e-07
by O 0 2.261745812859317e-08
the O 0 6.709839794893924e-09
fact O 0 1.7757082915181854e-08
that O 0 2.0188146265809337e-08
the O 0 2.4826967148783297e-08
Cys282Tyr O 0 6.113435665611178e-05
mutation O 0 1.7189551044793916e-06
creates O 0 2.9307972226888523e-07
a O 0 2.852540887943178e-07
Rsal O 0 7.678003385080956e-06
restriction O 0 1.3675216905539855e-06
site O 0 9.992580771722714e-07
. O 0 5.23666642493481e-07

We O 0 2.023137767537264e-06
have O 0 1.734019150489985e-07
studied O 0 5.164859118167442e-08
the O 0 1.061608934094238e-08
codon O 0 6.10614335982973e-07
282 O 0 2.4428206870652502e-06
( O 0 3.63328155117415e-07
Cys O 0 0.019012534990906715
/ O 0 5.851649621035904e-05
Tyr O 0 0.00014766149979550391
) O 0 5.515767398378557e-08
polymorphism O 0 3.5448717881081393e-06
in O 0 1.8602449358695594e-08
different O 0 9.935963163343331e-09
ethnic O 0 1.0927855242925943e-07
groups O 0 3.517986044698773e-07
. O 0 7.828262482689752e-07

In O 0 6.328289600787684e-06
agreement O 0 2.9725222816523456e-07
with O 0 2.8016655662099765e-08
previous O 0 8.625013236951418e-08
observations O 0 1.9765306547014916e-07
the O 0 4.309914913847024e-08
Tyr O 0 0.00013455789303407073
allele O 0 7.99328881839756e-06
appeared O 0 2.693051555979764e-06
to O 0 2.024343892514935e-08
be O 0 3.853653751662023e-08
rare O 0 4.473642718494375e-07
or O 0 1.6453695650398004e-07
absent O 0 2.2427386738854693e-06
in O 0 2.3385166514344746e-07
Asiatic O 0 3.0401142794289626e-06
( O 0 1.227400581171878e-08
Indian O 0 1.27983668107845e-08
, O 0 1.871269716957613e-08
Chinese O 0 4.626368976801132e-08
) O 0 1.0670355976571955e-07
populations O 0 2.3100602675185655e-07
. O 0 3.417471248212678e-07

The O 0 5.333809440344339e-06
highest O 0 3.232920789741911e-06
allele O 0 1.294450066779973e-05
frequency O 0 2.9072764391457895e-06
( O 0 3.177107998908468e-08
7 O 0 1.2782075486938993e-07
. O 0 3.1360947616576595e-08
5 O 0 1.0991822563255482e-07
% O 0 2.0575409820366986e-08
) O 0 5.387879475904356e-09
was O 0 9.117979402617493e-07
found O 0 1.0821553786399818e-07
in O 0 8.034783149923896e-08
Swedes O 0 0.010852782055735588
. O 0 4.51029654868762e-06

Saamis O 0 0.0023589804768562317
( O 0 5.7647685025585815e-06
2 O 0 2.0197101093799574e-06
% O 0 8.901788817183842e-08
) O 0 1.1703988000988375e-08
and O 0 3.9518631922419445e-08
Mordvinians O 0 1.7342623323202133e-05
( O 0 1.2600979815147184e-08
1 O 0 2.282064670566797e-08
. O 0 1.1214257966685182e-08
8 O 0 7.822995229389562e-08
% O 0 1.6634656319070018e-08
) O 0 5.959290394486061e-09
had O 0 2.5195108719344717e-06
significantly O 0 2.1631653908116277e-06
lower O 0 2.521895225982007e-07
frequencies O 0 9.154542368605689e-08
of O 0 4.397231911923427e-09
the O 0 8.623829472753641e-08
Tyr O 0 0.0004549969744402915
allele O 0 2.6725818315753713e-05
. O 0 7.726406465735636e-07

Comparisons O 0 8.563624578528106e-05
with O 0 1.462433033339039e-06
allele O 0 2.7542257157620043e-05
frequencies O 0 1.8457635633239988e-06
based O 0 2.2831362400665967e-07
on O 0 3.0157054879964562e-06
prevalence O 0 5.4669239034410566e-05
estimates O 0 2.570430979176308e-07
of O 0 2.6077810133529056e-08
HH B-Disease 1 0.9992641806602478
showed O 0 0.004663597792387009
some O 0 2.7290450788086673e-08
disagreements O 0 9.914421070789103e-07
with O 0 7.866326967587156e-08
the O 0 7.925709155642835e-08
RFLP O 0 0.00044891666038893163
data O 0 3.1266915812011575e-07
, O 0 2.4315072622016487e-08
particularly O 0 3.667935288831359e-08
in O 0 8.51364276854838e-08
Finns O 0 0.0005230428068898618
. O 0 2.130406528522144e-06

The O 0 4.342212832852965e-06
newly O 0 7.70861061027972e-06
described O 0 1.0183769518334884e-05
HFE O 0 0.00038317139842547476
marker O 0 2.1124122213223018e-05
provides O 0 9.510270615464833e-08
a O 0 3.7279786369026624e-08
new O 0 1.7036965616057387e-08
approach O 0 7.890805875376827e-08
to O 0 3.141045823440436e-08
the O 0 1.3154329181475077e-08
screening O 0 2.7061199148192827e-07
of O 0 3.499767942116705e-08
HH B-Disease 1 0.9623224139213562
as O 0 1.3784508610115154e-06
well O 0 4.0497788234006293e-08
as O 0 3.4561324468995736e-08
studies O 0 3.075811383368432e-09
of O 0 9.32702914901995e-10
the O 0 3.879863097466796e-09
relationship O 0 4.0794557065737536e-08
between O 0 1.755593181940185e-08
the O 0 9.931419242548145e-08
HFE O 0 0.012779504992067814
Tyr O 0 0.0007183097186498344
allele O 0 9.171036253974307e-06
and O 0 1.6546314896004333e-07
different O 0 2.8462147838581586e-07
disorders O 0 0.018137658014893532
including O 0 8.827234705677256e-05
cancer B-Disease 1 0.8474538922309875

Autosomal B-Disease 1 0.9997139573097229
dominant I-Disease 1 0.9990110397338867
neurohypophyseal I-Disease 1 0.9999579191207886
diabetes I-Disease 1 0.9999982118606567
insipidus I-Disease 1 0.9995661377906799
associated O 0 2.286213384650182e-05
with O 0 1.6420055715116177e-07
a O 0 3.900231604347937e-06
missense O 0 0.00234392867423594
mutation O 0 4.615388206730131e-06
encoding O 0 6.598663162549201e-07
Gly23 O 0 8.916909791878425e-06
- O 0 2.5769975763978437e-05
- O 0 0.00031973718432709575
> O 0 5.257546035863925e-06
Val O 0 7.284058665391058e-05
in O 0 4.044414652071282e-07
neurophysin O 0 0.00019183346012141556
II O 0 0.0006344406865537167
. O 0 1.460654516449722e-06

Autosomal B-Disease 1 0.9996438026428223
dominant I-Disease 1 0.9981223940849304
neurohypophyseal I-Disease 1 0.9998881816864014
diabetes I-Disease 1 0.9999970197677612
insipidus I-Disease 1 0.9998255372047424
( O 0 3.795174052356742e-05
ADNDI B-Disease 0 0.12780575454235077
) O 0 5.57584769467212e-07
is O 0 6.89130956743611e-07
an O 0 0.0015489422949030995
inherited B-Disease 1 1.0
disease I-Disease 1 0.9999986886978149
caused O 0 0.0032028136774897575
by O 0 3.114361106781871e-06
progressive O 1 0.6604641675949097
degeneration O 1 0.6353612542152405
of O 0 5.984225737165616e-08
the O 0 1.1277097655693069e-07
magnocellular O 0 4.1171744669554755e-05
neurons O 0 8.819398544801516e-07
of O 0 2.821715527900892e-09
the O 0 1.4802960635051932e-08
hypothalamus O 0 4.751312189910095e-06
leading O 0 6.816318887103989e-07
to O 0 3.41650661539461e-07
decreased O 0 6.5706708483048715e-06
ability O 0 6.815130149107063e-08
to O 0 2.8998496048870948e-08
produce O 0 1.1357115425880693e-07
the O 0 7.528367973463901e-08
hormone O 0 7.366000318143051e-06
arginine O 0 2.5057468064915156e-06
vasopressin O 0 1.2423432963259984e-05
( O 0 1.9710154219865217e-07
AVP O 0 2.8563174055307172e-05
) O 0 1.0771960887723253e-06
. O 0 2.359653990424704e-06

Affected O 0 0.0001933303865371272
individuals O 0 1.7922745882970048e-06
are O 0 9.710374371252328e-08
not O 0 3.517771745009668e-07
symptomatic O 0 0.0006993968272581697
at O 0 6.628489472859656e-07
birth O 0 1.0220799595117569e-05
, O 0 6.408074426644816e-08
but O 0 3.6163564232083445e-07
usually O 0 4.202232048555743e-06
develop O 0 0.000110411383502651
diabetes B-Disease 1 0.9934493899345398
insipidus I-Disease 0 0.0012574393767863512
at O 0 4.42706742376231e-08
1 O 0 9.66056958873196e-08
- O 0 1.6741016224841587e-05
6 O 0 1.2552077350846957e-06
yr O 0 2.2610638552578166e-05
of O 0 1.5695908572865847e-08
age O 0 6.717333462802344e-07
. O 0 4.351388440682058e-07

The O 0 1.598263906998909e-06
genetic O 0 4.542403985396959e-06
locus O 0 2.7369169401936233e-06
of O 0 5.81153898338016e-08
the O 0 1.5342207007051911e-06
disease O 0 4.6798784751445055e-05
is O 0 8.714773258589048e-08
the O 0 4.867796121743595e-08
AVP O 0 0.0002224924974143505
- O 0 0.015377992764115334
neurophysin O 0 0.033280905336141586
II O 0 0.005706191062927246
( O 0 7.940401758332882e-08
NPII O 0 3.522090264596045e-05
) O 0 1.2259032011741056e-08
gene O 0 5.3678284928082576e-08
, O 0 1.355561973781505e-08
and O 0 5.3978080671868156e-08
mutations O 0 7.953693170748011e-07
that O 0 2.0373168752030324e-07
cause O 0 3.702712547237752e-06
ADNDI B-Disease 0 0.011747034266591072
have O 0 2.513971367079648e-06
been O 0 4.3651041892189824e-07
found O 0 4.0075629925695466e-08
in O 0 3.747053334279826e-09
both O 0 4.675315246061018e-09
the O 0 2.7376250155697335e-09
signal O 0 1.7874408797524666e-07
peptide O 0 2.081631578221277e-08
of O 0 1.1543647149281355e-09
the O 0 8.218528080305987e-09
prepro O 0 9.095849236473441e-06
- O 0 7.2106804509530775e-06
AVP O 0 2.5680677936179563e-05
- O 0 4.136134157306515e-05
NPII O 0 4.705808169092052e-05
precursor O 0 2.315006781827833e-07
and O 0 4.443419499011725e-08
within O 0 2.88225905364925e-08
NPII O 0 3.702125104609877e-05
itself O 0 3.2742568691901397e-06
. O 0 9.460839578423474e-07

An O 0 1.5569294191664085e-05
affected O 0 6.468259925895836e-06
girl O 0 1.2438049452612177e-05
who O 0 4.667940061153786e-07
presented O 0 1.1175016823017359e-07
at O 0 1.137396576922356e-08
9 O 0 6.409956654351845e-08
months O 0 7.91397241073355e-08
of O 0 3.3515479280765703e-09
age O 0 2.0561645897032577e-07
and O 0 3.0536760675659025e-08
her O 0 2.3719185264781117e-06
similarly O 0 1.2542165677587036e-05
affected O 0 2.892884367611259e-07
younger O 0 1.902272060760879e-06
brother O 0 1.7753548036125721e-06
and O 0 3.992776598238379e-08
father O 0 1.1348425914547988e-06
were O 0 3.2534867244748966e-08
all O 0 2.0156434299423154e-09
found O 0 1.4038706197538886e-08
to O 0 1.518956871393584e-08
have O 0 3.9309345112314986e-08
a O 0 4.813655323232524e-07
novel O 0 7.2253478720085695e-06
missense O 0 2.9951241231174208e-05
mutation O 0 1.0090758451042348e-06
( O 0 1.9971679421360022e-08
G1758 O 0 4.229499609209597e-06
- O 0 6.00545754423365e-05
- O 0 0.00507214292883873
> O 0 7.640640433237422e-06
T O 0 8.808397069515195e-06
) O 0 6.548146469498306e-09
encoding O 0 1.254684978135856e-08
the O 0 3.099663192784874e-09
amino O 0 2.3248206915127412e-08
acid O 0 5.8151538695483396e-08
substitution O 0 3.362934819506336e-08
Gly23 O 0 3.700580464283121e-06
- O 0 8.208783583540935e-06
- O 0 0.00011384978279238567
> O 0 6.794843557145214e-06
Val O 0 0.000127948762383312
within O 0 4.942392592965916e-07
NPII O 0 0.0001476028119213879
. O 0 2.507106955818017e-06

The O 0 8.369065653823782e-06
mutation O 0 7.711874786764383e-05
was O 0 4.508645361056551e-06
confirmed O 0 6.430504981835838e-07
by O 0 6.711250932767143e-08
restriction O 0 1.0986618690367322e-06
endonuclease O 0 0.00018745374109130353
analysis O 0 2.9737516342720482e-06
. O 0 1.0125993412657408e-06

A O 0 4.341842213761993e-05
T1 O 0 0.0006797524401918054
- O 0 1.532835631223861e-05
weighted O 0 6.718364602420479e-07
magnetic O 0 3.7002841963840183e-06
resonance O 0 5.806968147226144e-06
imaging O 0 8.773897206992842e-06
of O 0 9.075417750636916e-09
the O 0 8.792225258957842e-08
fathers O 0 1.0923558875219896e-05
pituitary O 0 7.618866948178038e-05
gland O 0 3.133657810394652e-05
demonstrates O 0 2.5457457013544627e-06
an O 0 4.227771057685459e-07
attenuated O 0 0.0009645213722251356
posterior O 0 0.0002610917144920677
pituitary O 0 0.0004122298851143569
bright O 0 0.00013718291302211583
spot O 0 1.830720793805085e-05
. O 0 3.356605247972766e-06

This O 0 5.2434807003010064e-06
mutation O 0 0.00010439902689540759
may O 0 9.377496894558135e-07
be O 0 1.5107193718222334e-08
valuable O 0 2.2932610477255366e-08
for O 0 1.1927546061940575e-08
developing O 0 3.7690174536919585e-08
models O 0 6.104961016717425e-07
of O 0 5.1057387651098907e-08
dominantly B-Disease 1 0.9184210300445557
inherited I-Disease 1 0.9990190267562866
neurodegeneration I-Disease 1 0.9999997615814209
, O 0 3.4490344091864245e-07
as O 0 1.0977361242225925e-08
the O 0 4.274627762868022e-09
early O 0 2.2347077788253955e-07
age O 0 8.828034481211944e-08
of O 0 3.815255222860969e-09
onset O 0 1.8721762899076566e-05
of O 0 2.8766519335476914e-06
symptoms O 1 0.9867896437644958
suggests O 0 9.450253060094838e-07
that O 0 4.1565527908460354e-08
this O 0 4.0666840561698336e-08
mutation O 0 2.32828779189731e-06
may O 0 2.251700124134004e-07
be O 0 1.788543357861272e-08
particularly O 0 6.756718562428432e-08
deleterious O 0 4.785642431670567e-06
to O 0 1.0816869888685687e-07
the O 0 6.999525936635109e-08
magnocellular O 0 0.00017883347754832357
neuron O 0 0.0003667828568723053
. O 0 2.403964174391149e-07
. O 0 3.95414474496647e-07

Frequent O 0 0.000520215486176312
inactivation O 0 0.0005550928181037307
of O 0 9.374001592732384e-07
PTEN O 0 0.23065856099128723
/ O 0 8.680438622832298e-05
MMAC1 O 0 0.0009003643062897027
in O 0 8.882325346348807e-06
primary O 1 0.9299237728118896
prostate B-Disease 1 1.0
cancer I-Disease 1 0.9999986886978149
. O 0 1.420509215677157e-05

Sporadic B-Disease 1 0.9994507431983948
prostate I-Disease 1 0.9999986886978149
carcinoma I-Disease 1 1.0
is O 0 1.150509160652291e-05
the O 0 1.2647481639760372e-07
most O 0 3.011650733242277e-07
common O 0 3.475645144135342e-06
male B-Disease 1 0.6633605360984802
cancer I-Disease 0 0.000813580583781004
in O 0 2.7378090905472163e-08
the O 0 2.2620564976705282e-08
Western O 0 1.3358287276332703e-07
world O 0 5.9021456166874486e-08
, O 0 2.4844920787359115e-08
yet O 0 4.138895093319661e-08
many O 0 1.0749543477572843e-09
of O 0 5.584634421573753e-10
the O 0 3.813392712714858e-09
major O 0 3.429334682891749e-08
genetic O 0 1.8298688075901737e-07
events O 0 1.2179301123182995e-08
involved O 0 1.587284081949747e-08
in O 0 1.5327955793509318e-08
the O 0 2.9734568585126908e-08
progression O 0 4.6831314648443367e-07
of O 0 7.0684142983168385e-09
this O 0 1.6776776590177178e-07
often O 0 0.00021808106976095587
fatal O 1 0.9996213912963867
cancer B-Disease 1 0.7083966732025146
remain O 0 8.366523047698138e-07
to O 0 1.2872108356987155e-07
be O 0 9.482355949330667e-07
elucidated O 0 0.0006304669077508152
. O 0 3.0651829092676053e-06

Numerous O 0 0.00011168619676027447
cytogenetic O 0 0.0665261521935463
and O 0 1.0420139005873352e-05
allelotype O 0 0.0009332804474979639
studies O 0 1.4238198673410807e-06
have O 0 5.390507453739701e-07
reported O 0 1.9345923192304326e-06
frequent O 0 2.602341055535362e-06
loss O 0 5.651220362778986e-06
of O 0 2.1125059035398408e-08
heterozygosity O 0 3.565454971976578e-05
on O 0 9.379733683090308e-07
chromosomal O 0 0.00017020688392221928
arm O 0 7.811334216967225e-05
10q O 0 3.9013026253087446e-05
in O 0 2.457267328281887e-06
sporadic B-Disease 1 0.9967406392097473
prostate I-Disease 1 1.0
cancer I-Disease 1 0.9999977350234985
. O 0 1.7863832908915356e-05

Deletion O 0 0.004961194936186075
mapping O 0 6.894711987115443e-05
studies O 0 3.888284027198097e-06
have O 0 5.946258738731558e-07
unambiguously O 0 8.889728633221239e-05
identified O 0 9.938277116816607e-07
a O 0 1.666565907498807e-07
region O 0 5.278442927192373e-08
of O 0 1.0297790176139188e-08
chromosome O 0 7.613356501678936e-06
10q23 O 0 1.1137241244796314e-06
to O 0 2.4015573529823087e-08
be O 0 8.30545054952836e-09
the O 0 1.0573066866470526e-08
minimal O 0 1.3593572703030077e-06
area O 0 1.219581093891975e-07
of O 0 3.617942567757382e-08
loss O 0 6.71010056976229e-05
. O 0 1.7299470300713438e-06

A O 0 3.684641342260875e-05
new O 0 3.830843525065575e-06
tumor B-Disease 0 0.00010246561578242108
suppressor O 0 4.857541716773994e-05
gene O 0 3.4111451441276586e-06
, O 0 4.6901533323762123e-07
PTEN O 0 0.001317480462603271
/ O 0 1.2010564205411356e-05
MMAC1 O 0 0.0010962532833218575
, O 0 5.370695248529955e-07
was O 0 4.1471917029412e-06
isolated O 0 5.286947271088138e-07
recently O 0 5.602707346952229e-07
at O 0 3.8666394530650905e-09
this O 0 4.445841916833615e-09
region O 0 1.1939951249928527e-08
of O 0 5.535198521755547e-09
chromosome O 0 1.2536485883174464e-05
10q23 O 0 7.856212505430449e-06
and O 0 4.7138744463381954e-08
found O 0 2.9266542966865927e-08
to O 0 2.5901437439301844e-08
be O 0 4.6397303776757326e-08
inactivated O 0 2.6439017801749287e-06
by O 0 2.659427877915732e-08
mutation O 0 4.458276237073733e-07
in O 0 2.7701508997779456e-07
three O 0 0.005619053263217211
prostate B-Disease 1 1.0
cancer I-Disease 1 0.9999984502792358
cell O 0 0.0017566676251590252
lines O 0 2.8816335543524474e-05
. O 0 3.18713341584953e-06

We O 0 2.0599263734766282e-05
screened O 0 0.001261828700080514
80 O 0 0.00044283331953920424
prostate B-Disease 1 0.9998822212219238
tumors I-Disease 1 0.999996542930603
by O 0 9.71160375229374e-07
microsatellite O 0 0.00016641411639284343
analysis O 0 4.475477908272296e-07
and O 0 9.919114773992987e-08
found O 0 1.1622439899383608e-07
chromosome O 0 1.373112240798946e-06
10q23 O 0 6.392668296939519e-07
to O 0 2.6009754350297953e-08
be O 0 1.1576262615164978e-08
deleted O 0 7.629118954355363e-07
in O 0 1.1730195836889834e-07
23 O 0 2.0700231289083604e-06
cases O 0 1.0880430636461824e-06
. O 0 2.8310164452705067e-06

We O 0 3.594032932596747e-06
then O 0 3.4005620364041533e-07
proceeded O 0 5.408468268797151e-07
with O 0 9.251731825088427e-09
sequence O 0 8.348428615079229e-09
analysis O 0 3.918244395606507e-09
of O 0 9.633898123695417e-10
the O 0 1.8303778048789354e-08
entire O 0 4.798246209247736e-07
PTEN O 0 0.00474507873877883
/ O 0 8.486617844027933e-06
MMAC1 O 0 0.00024163519265130162
coding O 0 4.901559805148281e-06
region O 0 2.1126373894730932e-07
and O 0 1.614644276060062e-07
tested O 0 9.817604222916998e-07
for O 0 2.8417876052344582e-08
homozygous O 0 3.000106289618998e-06
deletion O 0 1.0303664339517127e-06
with O 0 1.9018694175088058e-08
new O 0 4.018431809527101e-08
intragenic O 0 3.6713510780828074e-05
markers O 0 2.014957999563194e-06
in O 0 2.4541515486475873e-08
these O 0 1.8388460532037243e-08
23 O 0 8.544402589905076e-07
cases O 0 1.199283872210799e-07
with O 0 1.2981159613900672e-07
10q23 O 0 0.00020275039423722774
loss O 0 3.5316104458615882e-06
of O 0 7.295449933053533e-08
heterozygosity O 0 0.0005545045132748783
. O 0 4.018243544123834e-06

The O 0 5.884575671188941e-07
identification O 0 1.5142509823817818e-07
of O 0 5.242770217961379e-09
the O 0 1.0838054897988059e-08
second O 0 4.1353058577442425e-07
mutational O 0 0.00014339311746880412
event O 0 1.7489847436991113e-07
in O 0 4.0364145803550855e-08
10 O 0 6.123941176383596e-08
( O 0 1.6124216628554677e-08
43 O 0 2.921623490692582e-06
% O 0 2.758822574833175e-07
) O 0 1.4414457609746023e-06
tumors B-Disease 1 0.9999948740005493
establishes O 0 0.0032452724408358335
PTEN O 0 0.483919233083725
/ O 0 7.788426046317909e-06
MMAC1 O 0 2.490041333658155e-05
as O 0 3.681490667872822e-08
a O 0 3.0556392971448076e-08
main O 0 3.88900787129387e-08
inactivation O 0 1.2161147424194496e-05
target O 0 5.4152767603454777e-08
of O 0 3.0505307169192974e-09
10q O 0 4.159779564361088e-06
loss O 0 1.6487417724420084e-06
in O 0 1.0947441069220076e-06
sporadic B-Disease 1 0.9998476505279541
prostate I-Disease 1 1.0
cancer I-Disease 1 0.9999997615814209
. O 0 1.0013167184297345e-06
. O 0 8.366171755369578e-07

Risk O 0 0.00027566071366891265
reversals O 0 0.00011903969425475225
in O 0 1.4396420056073111e-06
predictive O 0 2.128671076206956e-05
testing O 0 8.499204341205768e-06
for O 0 1.8155460566049442e-05
Huntington B-Disease 1 0.9999926090240479
disease I-Disease 1 0.9998958110809326
. O 0 9.776906154002063e-06

The O 0 2.039436822087737e-06
first O 0 4.7438464889637544e-07
predictive O 0 4.264106792106759e-06
testing O 0 2.427162598905852e-06
for O 0 3.418157575652003e-05
Huntington B-Disease 1 0.9999988079071045
disease I-Disease 1 0.9999772310256958
( O 0 3.0560858021999593e-07
HD B-Disease 0 0.0007286910549737513
) O 0 4.3953562567367044e-08
was O 0 1.050093601406843e-06
based O 0 2.491486839062418e-08
on O 0 2.376640928503093e-08
analysis O 0 8.397281092697995e-09
of O 0 1.488188128284662e-09
linked O 0 5.976920078865078e-07
polymorphic O 0 2.186231540690642e-05
DNA O 0 3.0430644528678386e-06
markers O 0 4.82128143630689e-07
to O 0 3.778915314001097e-08
estimate O 0 8.544780172314859e-08
the O 0 6.082613079883004e-09
likelihood O 0 8.888724778444157e-08
of O 0 6.526911455750906e-09
inheriting O 0 6.629759923271195e-07
the O 0 5.579316919579469e-08
mutation O 0 1.1377782129784464e-06
for O 0 2.3028873386010673e-07
HD B-Disease 0 0.0007160514942370355
. O 0 2.995869181177113e-06

Limits O 0 9.366751328343526e-06
to O 0 4.5555299266197835e-07
accuracy O 0 9.011752126752981e-07
included O 0 8.798733830417405e-08
recombination O 0 1.397736610897482e-07
between O 0 2.8747319191779752e-08
the O 0 3.1826694169012626e-08
DNA O 0 1.4430357850869768e-06
markers O 0 1.7400618617102737e-06
and O 0 2.940452326072318e-08
the O 0 3.455657804352086e-08
mutation O 0 1.4887162933518994e-06
, O 0 4.9848107863681435e-08
pedigree O 0 2.5225665467587532e-06
structure O 0 1.1452020487467962e-07
, O 0 7.165279480858544e-09
and O 0 7.487765962821413e-09
whether O 0 3.7017834131347627e-08
DNA O 0 2.578897522198531e-07
samples O 0 1.2856919795467547e-07
were O 0 7.57887974600635e-08
available O 0 1.575463492997642e-08
from O 0 6.349066605793041e-09
family O 0 7.363335186028053e-08
members O 0 4.4330750625931614e-08
. O 0 6.287727956078015e-07

With O 0 2.359064637857955e-06
direct O 0 9.520176718069706e-07
tests O 0 5.481639391291537e-07
for O 0 1.2245851443992706e-08
the O 0 3.124535652432314e-08
HD B-Disease 0 0.0026126112788915634
mutation O 0 5.545693966269027e-07
, O 0 8.933660033960678e-09
we O 0 4.757680471811909e-09
have O 0 8.541467977352113e-09
assessed O 0 3.5418597832403975e-08
the O 0 2.7618343168001047e-09
accuracy O 0 1.0587721988031262e-07
of O 0 1.0633049996044974e-08
results O 0 1.7869257362690405e-06
obtained O 0 9.239003162520021e-08
by O 0 8.271193507880525e-09
linkage O 0 1.7239116800737975e-07
approaches O 0 8.062230705263573e-08
when O 0 2.8172268073944906e-08
requested O 0 6.349819869910789e-08
to O 0 2.0799689082195982e-08
do O 0 1.4475199705543673e-08
so O 0 1.8950110813875654e-08
by O 0 7.465705387232902e-09
the O 0 8.39768077298686e-09
test O 0 3.856484909192659e-07
individuals O 0 6.235072902427419e-08
. O 0 2.395219951267791e-07

For O 0 1.927149469338474e-06
six O 0 4.775739057549799e-07
such O 0 3.044098306759224e-08
individuals O 0 2.7492376375448657e-08
, O 0 3.4912272184328685e-08
there O 0 4.511422346809013e-08
was O 0 1.3324853398444247e-06
significant O 0 1.1091816531916265e-07
disparity O 0 4.1514908843964804e-07
between O 0 3.1859126892186396e-08
the O 0 1.1924753096081986e-07
tests O 0 2.8074271085642977e-06
. O 0 1.5963672694851994e-06

Three O 0 4.652331881516147e-06
went O 0 1.5015174312793533e-06
from O 0 3.4336938625756375e-08
a O 0 7.630937943758909e-07
decreased O 0 4.474879096960649e-05
risk O 0 1.7194012968957395e-07
to O 0 3.066247700189706e-08
an O 0 3.768018927985395e-07
increased O 0 2.9260821975185536e-05
risk O 0 7.963734560689772e-07
, O 0 1.9420268060343915e-08
while O 0 1.4518722224465819e-08
in O 0 6.072088165609557e-09
another O 0 2.6862227997526134e-08
three O 0 1.1180491199525022e-08
the O 0 1.2745868360752866e-08
risk O 0 5.40076257493638e-07
was O 0 1.06393645182834e-05
decreased O 0 1.088449153030524e-05
. O 0 1.0326191386411665e-06

Knowledge O 0 4.04645061280462e-06
of O 0 9.183783333810425e-08
the O 0 2.7085100384738325e-08
potential O 0 8.922152261447991e-08
reasons O 0 5.357967935992747e-08
for O 0 5.39935962606819e-09
these O 0 4.4196490911474484e-09
changes O 0 5.5221047290388015e-08
in O 0 5.119634494121783e-08
results O 0 3.674293793665129e-07
and O 0 3.7147266596093687e-08
impact O 0 2.6310928546990908e-08
of O 0 1.6993924045749509e-09
these O 0 1.5969316535802136e-08
risk O 0 8.160362341413929e-08
reversals O 0 7.012466539890738e-06
on O 0 8.656302270537708e-06
both O 0 6.373058113240404e-06
patients O 0 0.00016860387404449284
and O 0 3.115508206974482e-08
the O 0 2.211439564803186e-08
counseling O 0 1.696333669087835e-07
team O 0 1.6159468430032575e-08
can O 0 5.012648518487595e-09
assist O 0 6.5572578478168e-09
in O 0 4.355089178176286e-09
the O 0 3.846168716847842e-09
development O 0 1.7797322504620183e-09
of O 0 1.6355712340043738e-09
strategies O 0 3.32635536892667e-08
for O 0 9.804971057292278e-09
the O 0 5.298556615684902e-08
prevention O 0 2.6996602286999405e-07
and O 0 1.1438311986466942e-07
, O 0 2.9518426813979204e-08
where O 0 4.1912233683660816e-08
necessary O 0 4.578125256671228e-08
, O 0 2.1849835718512622e-08
management O 0 1.2427288531569047e-08
of O 0 1.2516416791896745e-09
a O 0 3.8786336631346785e-07
risk O 0 2.233925897598965e-07
reversal O 0 1.1537728141775005e-06
in O 0 1.8329595619093197e-08
any O 0 1.9466886769237135e-08
predictive O 0 4.6155898303368303e-07
testing O 0 1.8227765963274578e-07
program O 0 5.3374048292198495e-08
. O 0 3.73736206427111e-08
. O 0 3.216291588614695e-07

A O 0 7.85687516327016e-05
novel O 0 1.749593320710119e-05
common O 0 9.221386676472321e-07
missense O 0 7.388660014839843e-05
mutation O 0 8.310354132845532e-06
G301C O 0 3.890587322530337e-06
in O 0 4.6767087980015276e-08
the O 0 3.082578459157048e-08
N O 0 1.359761427011108e-05
- O 0 0.00016065285308286548
acetylgalactosamine O 0 0.0006424062303267419
- O 0 0.00014388345880433917
6 O 0 3.3268238439632114e-06
- O 0 0.0003620933275669813
sulfate O 0 0.0014786665560677648
sulfatase O 0 5.016548675484955e-05
gene O 0 2.1647174435202032e-06
in O 0 4.20283896573892e-07
mucopolysaccharidosis B-Disease 0 0.00034753428190015256
IVA I-Disease 0 0.0054029906168580055
. O 0 8.776491085882299e-06

Mucopolysaccharidosis B-Disease 1 0.9509921073913574
IVA I-Disease 1 0.9981653094291687
( O 0 0.026012398302555084
MPS B-Disease 1 0.9999977350234985
IVA I-Disease 1 0.9999896287918091
) O 0 2.3675886495766463e-06
is O 0 7.462162443516718e-07
an O 0 1.0935671525658108e-05
autosomal B-Disease 1 0.9991059899330139
recessive I-Disease 1 0.9998413324356079
lysosomal I-Disease 1 0.9988685846328735
storage I-Disease 1 0.9970171451568604
disorder I-Disease 1 0.9994797110557556
caused O 0 7.346667553065345e-05
by O 0 4.834781179852143e-07
a O 0 0.016403187066316605
genetic B-Disease 1 0.9999762773513794
defect I-Disease 1 0.9999825954437256
in O 0 2.0634322481782874e-06
N O 0 3.5137298254994676e-05
- O 0 5.5035554396454245e-05
acetylgalactosamine O 0 0.0007271067006513476
- O 0 0.0005334492307156324
6 O 0 6.449276497733081e-06
- O 0 0.020449789240956306
sulfate O 1 0.605547308921814
sulfatase O 0 0.0009213053854182363
( O 0 2.053524923439909e-07
GALNS O 0 2.8714097425108775e-05
) O 0 2.168944064351308e-07
. O 0 5.068069413027843e-07

In O 0 5.345726094674319e-06
previous O 0 2.7109290385851637e-06
studies O 0 8.102789905706231e-08
, O 0 2.1828926222156042e-08
we O 0 8.645828941666878e-09
have O 0 1.6349639864188248e-08
found O 0 1.5844831224853806e-08
two O 0 1.2855616127183112e-08
common O 0 7.472076646308778e-08
mutations O 0 5.467235268952209e-07
in O 0 2.1087620538651208e-08
Caucasians O 0 1.002021804197284e-06
and O 0 5.285384574449381e-08
Japanese O 0 1.9956644337071339e-07
, O 0 8.753055169563595e-08
respectively O 0 4.840381961912499e-07
. O 0 5.691246656169824e-07

To O 0 2.5859187644527992e-06
characterize O 0 6.994006071181502e-06
the O 0 1.6674896130552952e-07
mutational O 0 0.0011673900298774242
spectrum O 0 2.7760490411310457e-05
in O 0 3.8297731208558616e-08
various O 0 7.142724189890259e-09
ethnic O 0 1.1881050454576325e-07
groups O 0 5.089404098157502e-08
, O 0 1.1164853930267782e-07
mutations O 0 4.2388575138829765e-07
in O 0 1.2982219743662426e-08
the O 0 3.830131234394685e-08
GALNS O 0 0.00010615296923788264
gene O 0 5.020161779611954e-07
in O 0 1.1722613635356538e-07
Colombian O 0 6.053069591871463e-05
MPS B-Disease 1 0.999998927116394
IVA I-Disease 1 0.9999997615814209
patients O 1 0.998508632183075
were O 0 3.3373360110999784e-06
investigated O 0 5.66327253181953e-06
, O 0 9.437017212121646e-08
and O 0 9.579450477303908e-08
genetic O 0 1.13128430712095e-06
backgrounds O 0 9.027495906366312e-08
were O 0 1.423153008772715e-07
extensively O 0 3.4558462402856094e-07
analyzed O 0 3.2587351483925886e-07
to O 0 3.421507699385984e-08
identify O 0 1.1885038730952147e-07
racial O 0 9.179773030609795e-08
origin O 0 5.904544053692007e-08
, O 0 1.6748568754110238e-08
based O 0 3.182736207918424e-08
on O 0 2.1856259024843894e-07
mitochondrial O 0 5.054267239756882e-05
DNA O 0 3.957562057621544e-06
( O 0 3.331053832766884e-08
mtDNA O 0 3.8560804682674643e-07
) O 0 3.4211357302638135e-08
lineages O 0 2.7947811531703337e-07
. O 0 4.3400908111834724e-07

Three O 0 3.214723983546719e-05
novel O 0 4.458590046851896e-05
missense O 0 0.001427900162525475
mutations O 0 0.00021203854703344405
never O 0 7.409315458062338e-06
identified O 0 1.3897247299610171e-06
previously O 0 2.355916421947768e-07
in O 0 2.2527734344635064e-08
other O 0 1.7871860436002862e-08
populations O 0 4.363339556334722e-08
and O 0 6.491529802588047e-08
found O 0 9.1387541090171e-08
in O 0 1.730875887062666e-08
16 O 0 2.662011056031588e-08
out O 0 8.787795380271746e-09
of O 0 5.2238746661714686e-09
19 O 0 7.764913334540324e-07
Colombian O 0 4.718012496596202e-05
MPS B-Disease 1 0.9999892711639404
IVA I-Disease 1 0.9999513626098633
unrelated O 0 4.7723224270157516e-05
alleles O 0 2.0856555238424335e-06
account O 0 3.167605484577507e-07
for O 0 9.108734388973971e-08
84 O 0 5.487745966092916e-06
. O 0 1.0371264806963154e-06

2 O 0 1.772442919900641e-05
% O 0 2.716926417178911e-07
of O 0 5.8234976840765285e-09
the O 0 2.1443208098048672e-08
alleles O 0 8.495999850310909e-07
in O 0 7.546381652900891e-08
this O 0 1.1234300245632767e-07
study O 0 8.605005632489338e-07
. O 0 1.331250700786768e-06

The O 0 2.8024032872053795e-06
G301C O 0 3.4482225601095706e-05
and O 0 5.685848805114802e-07
S162F O 0 1.7075577488867566e-05
mutations O 0 3.76333923668426e-06
account O 0 4.4260121967454324e-07
for O 0 9.402018719129046e-08
68 O 0 1.8985525457537733e-05
. O 0 3.240693558836938e-06

4 O 0 4.889758929493837e-05
% O 0 2.2671288206765894e-06
and O 0 1.8153428982259356e-07
10 O 0 6.551472324645147e-07
. O 0 1.3783366057396051e-06

5 O 0 2.6979332687915303e-05
% O 0 6.974045163588016e-07
of O 0 2.1448320453032466e-08
mutations O 0 3.964474672102369e-06
, O 0 1.1293768409359473e-07
respectively O 0 4.425606903168955e-07
, O 0 2.7784897937976893e-08
whereas O 0 2.5550844995336774e-08
the O 0 4.573933232165928e-09
remaining O 0 7.804752755191657e-08
F69V O 0 8.071216871030629e-05
is O 0 3.3694579570919814e-08
limited O 0 1.522870185510783e-08
to O 0 1.5008740916755414e-08
a O 0 1.9863985301071807e-07
single O 0 4.035498022858519e-06
allele O 0 1.2928981959703378e-05
. O 0 4.894030780633329e-07

The O 0 4.407442702358821e-06
skewed O 0 7.68039099057205e-05
prevalence O 0 1.6402575056417845e-05
of O 0 4.760097382927597e-08
G301C O 0 9.347601917397697e-06
in O 0 9.581351179122066e-08
only O 0 1.817236210399642e-07
Colombian O 0 5.5017553677316755e-05
patients O 0 0.021664375439286232
and O 0 6.654515232185076e-07
haplotype O 0 0.0019640882965177298
analysis O 0 1.056528944332058e-07
by O 0 1.931863558013447e-08
restriction O 0 4.977885055268416e-07
fragment O 0 2.0501140170381404e-05
length O 0 4.052625627082307e-06
polymorphisms O 0 1.104237639992789e-06
in O 0 1.3878140414647078e-08
the O 0 9.33424093574331e-09
GALNS O 0 7.396302680717781e-05
gene O 0 2.633724704992346e-07
suggest O 0 6.198776247856586e-08
that O 0 2.3696745898860172e-08
G301C O 0 1.9725582660612417e-06
originated O 0 5.366006305962401e-08
from O 0 6.363614524218519e-09
a O 0 2.392521594174468e-07
common O 0 4.4078237237954454e-07
ancestor O 0 4.236790118739009e-06
. O 0 2.8643821678997483e-06

Investigation O 0 1.1976298083027359e-05
of O 0 6.393131002369046e-08
the O 0 9.974532133583125e-08
genetic O 0 1.8172272575611714e-06
background O 0 8.701500178176502e-07
by O 0 5.388734791722527e-08
means O 0 2.1645423231575478e-08
of O 0 6.508736216659372e-09
mtDNA O 0 5.062084369455988e-07
lineages O 0 6.151968534595653e-08
indicate O 0 1.0129193128705083e-07
that O 0 9.957515700875774e-09
all O 0 2.522061670617859e-09
our O 0 1.813004857353917e-08
patients O 0 1.327789277638658e-06
are O 0 3.7125291729722676e-09
probably O 0 4.056396107898763e-08
of O 0 4.156384569853344e-09
native O 0 6.522532913777468e-08
American O 0 4.4861263859274914e-07
descent O 0 0.0002172310050809756

Low O 0 0.00019863103807438165
frequency O 0 1.5058458302519284e-05
of O 0 2.740046056715073e-07
BRCA1 O 0 0.0002686454390641302
germline O 0 9.043021418619901e-05
mutations O 0 1.7613387171877548e-05
in O 0 2.9098595177856623e-07
45 O 0 9.51433594309492e-06
German O 1 0.9997087121009827
breast B-Disease 1 0.9999979734420776
/ I-Disease 1 0.9999980926513672
ovarian I-Disease 1 1.0
cancer I-Disease 1 0.9999991655349731
families O 0 1.1708692909451202e-05
. O 0 3.0830838113615755e-06

In O 0 1.9300830444990424e-06
this O 0 7.611620134184705e-08
study O 0 5.8443308859068566e-08
we O 0 1.3374584995062833e-08
investigated O 0 4.3981279418403574e-07
45 O 0 1.445632165086863e-06
German O 1 0.9942415952682495
breast B-Disease 1 0.9999970197677612
/ I-Disease 1 0.9999990463256836
ovarian I-Disease 1 1.0
cancer I-Disease 1 0.9999998807907104
families O 0 9.739270581121673e-07
for O 0 1.1962637813667243e-07
germline O 0 0.0002214148989878595
mutations O 0 5.848295131727355e-06
in O 0 2.5549576676553443e-08
the O 0 1.6401743607730168e-07
BRCA1 O 0 0.0003106196818407625
gene O 0 1.0561482667981181e-05
. O 0 1.045188923853857e-06

We O 0 4.484219516598387e-06
identified O 0 1.8205577134722262e-06
four O 0 1.326728238382202e-07
germline O 0 1.650429840083234e-05
mutations O 0 1.0281764843966812e-05
in O 0 2.0274512735340977e-07
three O 0 6.78534124745056e-05
breast B-Disease 1 0.9999566078186035
cancer I-Disease 1 0.904747486114502
families O 0 1.892079097842725e-07
and O 0 6.032368560227042e-08
in O 0 5.356782821763773e-07
one O 0 0.034199461340904236
breast B-Disease 1 0.9999943971633911
- I-Disease 1 0.9999998807907104
ovarian I-Disease 1 1.0
cancer I-Disease 1 0.9999997615814209
family O 0 5.464641617436428e-06
. O 0 1.0988756571350677e-08
among O 0 6.159903254143728e-09
these O 0 1.4612394627633307e-09
were O 0 2.9947440083333277e-08
one O 0 2.6882378278969554e-07
frameshift O 0 0.05965518206357956
mutation O 0 1.7648362700128928e-06
, O 0 2.527499809445999e-08
one O 0 5.042415907041686e-08
nonsense O 0 1.2660875654546544e-05
mutation O 0 2.1059017853986006e-06
, O 0 2.1595319310563355e-08
one O 0 2.0415212631519353e-08
novel O 0 2.3302108331790805e-07
splice O 0 4.953584266331745e-06
site O 0 2.142605353583349e-06
mutation O 0 6.83579003180057e-07
, O 0 1.4671803327814814e-08
and O 0 6.045810607702151e-08
one O 0 9.125338920057402e-07
missense O 0 0.000668731692712754
mutation O 0 2.9664170142496005e-05
. O 0 1.5274364386641537e-06

The O 0 4.935981905873632e-06
missense O 0 0.0014633084647357464
mutation O 0 0.00032761768670752645
was O 0 1.5627041648258455e-05
also O 0 6.410678565771377e-07
found O 0 1.8027779447038483e-07
in O 0 9.105781373364152e-08
2 O 0 2.91625656245742e-06
. O 0 2.438191359033226e-06

8 O 0 2.5933772121788934e-05
% O 0 5.402364422479877e-07
of O 0 5.698044258650725e-09
the O 0 1.2090215939508653e-08
general O 0 2.865142221253336e-07
population O 0 7.212435804149209e-08
, O 0 1.8643440569121594e-08
suggesting O 0 1.1876382899345117e-07
that O 0 2.4177445823170274e-08
it O 0 1.0623588053704225e-07
is O 0 7.190911333054828e-07
not O 0 1.889022132672835e-05
disease O 0 5.0272374210180715e-05
associated O 0 1.5746620647405507e-06
. O 0 1.113379994421848e-06

The O 0 3.04899026559724e-06
average O 0 5.228301233728416e-06
age O 0 5.18492072387744e-07
of O 0 8.479286606188907e-08
disease O 0 0.00016744200547691435
onset O 0 0.00010697761172195897
in O 0 1.1391526868465007e-06
those O 0 2.021666887230822e-07
families O 0 1.6468389674173523e-07
harbouring O 0 7.350668602157384e-05
causative O 0 0.00024108334037009627
mutations O 0 3.308461600681767e-05
was O 0 2.611983063616208e-06
between O 0 1.688802058197325e-07
32 O 0 4.365139375295257e-06
. O 0 2.484786818968132e-06

3 O 0 4.419311153469607e-05
and O 0 2.087575467157876e-06
37 O 0 8.046366929193027e-06
. O 0 2.159010364266578e-06

4 O 0 5.0410922995069996e-05
years O 0 4.010215434391284e-06
, O 0 9.90669306588643e-08
whereas O 0 9.120713428956151e-08
the O 0 1.9399204020942307e-08
family O 0 2.1298508556810702e-07
harbouring O 0 3.5134537483827444e-06
the O 0 7.115422562264939e-08
missense O 0 7.135107443900779e-05
mutation O 0 2.7198555017093895e-06
had O 0 1.85967607535531e-07
an O 0 2.3699051610037714e-08
average O 0 2.015815994127479e-07
age O 0 2.8292403086993545e-08
of O 0 3.7046774536975136e-09
onset O 0 2.1655100681527983e-06
of O 0 2.443871096602379e-07
51 O 0 7.092458690749481e-05
. O 0 2.306921714989585e-06

2 O 0 0.00014244108751881868
years O 0 3.5783377825282514e-05
. O 0 1.0184876373386942e-05

These O 0 3.5475095501169562e-06
findings O 0 3.2993295917549403e-06
show O 0 8.481435429530393e-07
that O 0 2.1063807764676312e-07
BRCA1 O 0 6.071447933209129e-05
is O 0 3.5813249610328057e-07
implicated O 0 7.980742680047115e-07
in O 0 1.1081915829436184e-08
a O 0 4.9393349854653934e-08
small O 0 2.0856218085896217e-08
fraction O 0 2.2057110982132144e-07
of O 0 3.6940713243893697e-07
breast B-Disease 1 0.9999880790710449
/ I-Disease 1 0.999998927116394
ovarian I-Disease 1 1.0
cancer I-Disease 1 0.9999998807907104
families O 0 9.901183375404798e-07
suggesting O 0 2.4309562718372035e-07
the O 0 1.1970165303409885e-08
involvement O 0 1.356066832158831e-07
of O 0 1.1678789491043062e-08
another O 0 8.36144681670703e-06
susceptibility O 0 0.08640511333942413
gene O 0 1.0830689461727161e-05
( O 0 3.704764992562559e-07
s O 0 0.00014304433716461062
) O 0 3.5955413295596372e-06

Paternal O 1 0.8544276356697083
transmission O 0 0.32916438579559326
of O 0 0.0002479542454238981
congenital B-Disease 1 0.9999991655349731
myotonic I-Disease 1 1.0
dystrophy I-Disease 1 1.0
. O 0 0.021775055676698685

We O 0 5.970760412310483e-06
report O 0 1.107273533307307e-06
a O 0 2.845194444489607e-07
rare O 0 4.652535778859601e-07
case O 0 9.425213534086652e-07
of O 0 1.8484871588952956e-07
paternally O 1 0.9962604641914368
transmitted O 1 0.9999518394470215
congenital B-Disease 1 0.9999998807907104
myotonic I-Disease 1 1.0
dystrophy I-Disease 1 1.0
( O 0 0.49080583453178406
DM B-Disease 1 0.9999998807907104
) O 0 2.276964187331032e-05
. O 0 4.147986601310549e-06

The O 0 1.8367765051152674e-06
proband O 0 3.4050815884256735e-05
is O 0 1.3616053706755338e-07
a O 0 1.613987024029484e-07
23 O 0 2.2961373247198935e-07
year O 0 9.677998491497419e-08
old O 0 2.1461642973008566e-05
, O 0 9.095433597394731e-06
mentally B-Disease 1 0.9999974966049194
retarded I-Disease 1 0.9999988079071045
male O 0 0.11328568309545517
who O 0 0.0023839205969125032
suffers O 1 0.9999120235443115
severe O 1 0.9993855953216553
muscular B-Disease 1 0.9999275207519531
weakness I-Disease 1 0.9949946403503418
. O 0 4.1229573980672285e-05

He O 0 4.4001269998261705e-05
presented O 0 1.0716991710069124e-05
with O 0 2.9251781597849913e-05
respiratory O 1 0.9971195459365845
and O 0 9.996365406550467e-06
feeding O 0 0.00010963072418235242
difficulties O 0 2.0188866983517073e-05
at O 0 4.985838018001232e-07
birth O 0 1.615500877960585e-05
. O 0 2.167826551158214e-06

His O 0 4.598754458129406e-05
two O 0 1.5912490198388696e-05
sibs O 1 0.9249637126922607
suffer O 0 0.36661380529403687
from O 0 1.5243136886056163e-06
childhood O 0 0.0004971156595274806
onset O 0 0.39514997601509094
DM B-Disease 1 0.9999991655349731
. O 0 0.0003778851532842964

Their O 0 3.0667147257190663e-06
late O 0 2.4049370495049516e-06
father O 0 1.6631951211820706e-06
had O 0 1.135449494427121e-07
the O 0 6.0761773390538565e-09
adult O 0 3.3113187214439677e-07
type O 0 3.6257250712878886e-07
of O 0 8.202746215602019e-08
DM B-Disease 1 1.0
, O 0 3.699924036482116e-06
with O 0 1.7849946232217917e-07
onset O 0 8.255243301391602e-06
around O 0 1.9454641631000413e-07
30 O 0 2.4366613615711685e-07
years O 0 4.217727678224037e-07
. O 0 6.291326712926093e-07

Only O 0 4.103142600797582e-06
six O 0 3.147108884604677e-07
other O 0 1.936740900987388e-08
cases O 0 2.6984958267917136e-08
of O 0 1.577065944502465e-08
paternal O 0 0.22243282198905945
transmission O 0 0.04518388211727142
of O 0 1.7756659872247837e-05
congenital B-Disease 1 0.9999998807907104
DM I-Disease 1 1.0
have O 0 0.07905013859272003
been O 0 7.639091927558184e-05
reported O 0 1.5496711057494394e-05
recently O 0 5.721276011172449e-06
. O 0 1.3651580275109154e-06

We O 0 3.35033087139891e-06
review O 0 1.2438384828783455e-06
the O 0 6.3697136454266e-08
sex O 0 4.573970500132418e-07
related O 0 1.0578315112752534e-07
effects O 0 1.627882170396333e-06
on O 0 4.031095886602998e-05
transmission O 0 0.020363546907901764
of O 0 1.6859110473887995e-05
congenital B-Disease 1 0.999998927116394
DM I-Disease 1 0.9999998807907104
. O 0 0.001533260103315115

Decreased O 0 0.0019378582946956158
fertility O 0 1.718442581477575e-05
of O 0 1.1641852637467309e-07
males O 0 1.3399286444837344e-06
with O 0 2.3785210601090512e-07
adult O 0 0.0010834468994289637
onset O 0 0.06204316020011902
DM B-Disease 1 0.9999998807907104
and O 0 6.306985142146004e-06
contraction O 0 2.027634536716505e-06
of O 0 5.987797369044756e-09
the O 0 1.5036132339218966e-08
repeat O 0 1.021188381855609e-06
upon O 0 1.4446135310208774e-07
male O 0 1.598499329702463e-05
transmission O 0 1.1939367823288194e-06
contribute O 0 1.883947220449045e-08
to O 0 1.5365364092190248e-08
the O 0 1.0878398626346097e-08
almost O 0 8.487053548833501e-08
absent O 0 3.1687082469034067e-07
occurrence O 0 8.542335905303844e-08
of O 0 7.896328035883471e-09
paternal O 0 0.0003909695369657129
transmission O 0 0.0005781669751740992
of O 0 6.1461551013053395e-06
congenital B-Disease 1 0.9999986886978149
DM I-Disease 1 1.0
. O 0 0.0049580722115933895

Also O 0 3.4996462545677787e-06
the O 0 9.951499890803461e-08
fathers O 0 1.6860244045346917e-07
of O 0 4.1587235877216244e-09
the O 0 1.3297949408297427e-07
reported O 0 0.00011065295984735712
congenitally O 0 0.32254159450531006
affected O 0 3.2865634693735046e-06
children O 0 2.9991022074682405e-06
showed O 0 1.2576875633385498e-05
, O 0 2.131618259682e-08
on O 0 3.542242268395057e-07
average O 0 7.648096129742044e-07
, O 0 6.504345151370217e-08
shorter O 0 2.464589897499536e-06
CTG O 0 1.2875370885012671e-05
repeat O 0 1.8575503872853005e-06
lengths O 0 6.4304340412491e-06
and O 0 9.770027986633067e-08
hence O 0 3.2697769825063006e-07
less O 0 2.2466260816145223e-06
severe O 1 0.9890041947364807
clinical O 1 0.9992207288742065
symptoms O 1 0.9996023774147034
than O 0 2.487010419827129e-07
the O 0 5.589147988871446e-08
mothers O 0 1.9355684344191104e-06
of O 0 1.785557657285608e-08
children O 0 9.512993528915104e-06
with O 0 0.0008437269134446979
congenital B-Disease 1 0.9999996423721313
DM I-Disease 1 1.0
. O 0 0.005630142521113157

We O 0 2.6097272893821355e-06
conclude O 0 2.7945677629759302e-06
that O 0 2.440377500079194e-07
paternal O 0 0.00017066336295101792
transmission O 0 0.0007326538325287402
of O 0 7.773494871798903e-06
congenital B-Disease 1 0.9999998807907104
DM I-Disease 1 1.0
is O 0 0.03498075529932976
rare O 0 4.7057183110155165e-05
and O 0 1.6720596249797381e-06
preferentially O 0 0.0001288135099457577
occurs O 0 7.596058537728823e-08
with O 0 2.169858070999453e-08
onset O 0 1.5013426946097752e-06
of O 0 1.5019627142009995e-07
DM B-Disease 1 0.9999995231628418
past O 0 1.2233113920956384e-05
30 O 0 1.765587569479976e-07
years O 0 2.2697797419368726e-08
in O 0 3.7870666602657366e-09
the O 0 1.3527235331878273e-08
father O 0 5.764889465353917e-06
. O 0 8.961959707676215e-08
. O 0 3.938574764106306e-07

The O 0 3.5237157135270536e-05
RB1 O 0 0.011823038570582867
gene O 0 2.8120517526986077e-05
mutation O 0 1.7025964552885853e-05
in O 0 7.557487435860821e-08
a O 0 6.23832022483839e-07
child O 0 2.9432405426632613e-05
with O 0 7.968243153300136e-05
ectopic B-Disease 1 0.9999738931655884
intracranial I-Disease 1 0.999982476234436
retinoblastoma I-Disease 1 0.9720696210861206
. O 0 2.3919901650515385e-05

The O 0 3.797186218434945e-05
RB1 O 0 0.01831711456179619
gene O 0 2.896293153753504e-05
mutation O 0 6.387906614691019e-05
was O 0 2.3025718292046804e-06
investigated O 0 1.0565003094598069e-06
in O 0 2.5542707504655482e-08
a O 0 2.355579908908112e-06
child O 0 0.00013748108176514506
with O 0 0.0001111582459998317
ectopic B-Disease 1 0.9999843835830688
intracranial I-Disease 1 0.9999712705612183
retinoblastoma I-Disease 0 0.01684073731303215
using O 0 1.0446019587107003e-06
DNA O 0 1.1456558013378526e-06
obtained O 0 4.4767496376607596e-08
from O 0 3.324901687307147e-09
both O 0 5.9067488678010704e-09
the O 0 2.072713378709068e-08
pineal B-Disease 0 0.00022777492995373905
and I-Disease 0 0.0009050557855516672
retinal I-Disease 1 0.9997792840003967
tumours I-Disease 1 0.9999960660934448
of O 0 1.879378999092296e-07
the O 0 1.3615200487038237e-06
patient O 0 0.003433576552197337
. O 0 4.316942522564204e-06

A O 0 4.112206443096511e-05
nonsense O 0 0.00020043326367158443
mutation O 0 3.627020487328991e-05
in O 0 1.9283540098058438e-07
exon O 0 8.056993465288542e-06
17 O 0 3.2374018132941274e-07
( O 0 6.1081206759183715e-09
codon O 0 1.0741415934489851e-07
556 O 0 2.5370346179443004e-07
) O 0 8.077265079009521e-09
of O 0 2.0502142206169083e-09
the O 0 4.8316838530126915e-08
RB1 O 0 0.00016272631182800978
gene O 0 2.544623782796407e-07
was O 0 7.382748776763037e-07
found O 0 1.96085689907477e-08
to O 0 1.3530124576277558e-08
be O 0 4.103413431266745e-08
present O 0 7.683326685992142e-08
homozygously O 0 2.6927460567094386e-05
in O 0 2.2211029460095233e-08
both O 0 1.0795100813254521e-08
the O 0 4.444903112243992e-08
retinal B-Disease 0 0.002530040219426155
and I-Disease 0 5.742681992160215e-07
the I-Disease 0 7.182084118539933e-07
pineal I-Disease 0 0.4560452699661255
tumours I-Disease 1 0.9999923706054688
. O 0 1.3305043466971256e-05

The O 0 1.8624978110892698e-06
same O 0 4.998911435905029e-07
mutation O 0 2.5365220608364325e-06
was O 0 5.645831606670981e-07
present O 0 6.44806803506981e-08
heterozygously O 0 1.2346742551017087e-05
in O 0 2.0470892536650354e-08
the O 0 1.1772677943611143e-08
DNA O 0 1.6420041504261462e-07
from O 0 3.231277245774322e-09
the O 0 4.305985346064745e-09
constitutional O 0 4.098791066553531e-07
cells O 0 5.334504393772477e-08
of O 0 2.2145238975923576e-09
the O 0 6.001233998631506e-08
patient O 0 0.00013541615044232458
, O 0 7.114241640238106e-08
proving O 0 6.246249881769472e-07
it O 0 2.4542405441252413e-08
to O 0 1.3383873564976057e-08
be O 0 2.141398347532686e-08
of O 0 1.5511476547658276e-08
germline O 0 2.2721204004483297e-05
origin O 0 7.73201577430882e-07
. O 0 1.2599654155565077e-06

The O 0 1.7142500610134448e-06
initial O 0 4.650442406273214e-06
mutation O 0 6.3867905737424735e-06
was O 0 1.1596481499509537e-06
shown O 0 3.183881176482828e-07
to O 0 3.808873216826214e-08
have O 0 1.4373136991707725e-07
occurred O 0 1.1190032012109441e-07
in O 0 1.0951470841291666e-08
the O 0 8.577797672160159e-08
paternally O 0 7.956413901410997e-05
derived O 0 4.457703653315548e-06
RB1 O 0 0.00023250075173564255
allele O 0 1.7239412045455538e-05
. O 0 1.858165205703699e-06

The O 0 3.0657442948722746e-06
mutation O 0 1.983620495593641e-05
is O 0 7.636807453081929e-08
in O 0 1.6094871213567785e-08
an O 0 2.8805445140278607e-08
area O 0 2.616440042402246e-08
of O 0 1.3852983204998282e-09
the O 0 1.2998448539747187e-08
gene O 0 6.889956694067223e-08
that O 0 9.005548307072786e-09
encodes O 0 4.068437320370322e-08
the O 0 3.7248069073569923e-09
protein O 0 6.44900310931007e-08
- O 0 5.81554729706113e-07
binding O 0 4.3830291929225496e-07
region O 0 2.2766519336414603e-08
known O 0 3.6389607771525334e-08
as O 0 1.6395075519426427e-08
the O 0 1.2804983740011266e-08
pocket O 0 0.006578764878213406
region O 0 1.6705904215541523e-07
and O 0 1.1689313339502405e-07
has O 0 8.479899520352774e-07
been O 0 3.4568682849567267e-07
detected O 0 2.658475182215625e-07
in O 0 5.9336686675237615e-09
other O 0 3.5156628719335004e-09
cases O 0 4.7326309982054227e-08
of O 0 2.2798067433882352e-08
retinoblastoma B-Disease 0 0.016073783859610558
. O 0 7.291756674021599e-07
. O 0 5.442508950181946e-07

Low O 0 0.00014936509251128882
levels O 0 4.7188490270855254e-07
of O 0 1.9808362949902403e-08
beta O 0 1.4592104946586915e-07
hexosaminidase O 0 6.8970562097092625e-06
A O 0 1.6167997500815545e-06
in O 0 2.6923942186840577e-07
healthy O 0 2.162416649298393e-06
individuals O 0 3.6909824530084734e-08
with O 0 9.175656714432989e-07
apparent O 1 0.9992963075637817
deficiency O 1 0.5364061594009399
of O 0 1.9421195318614082e-08
this O 0 9.293633951301672e-08
enzyme O 0 2.012354116232018e-06
. O 0 7.464340114893275e-07

Appreciable O 0 0.0011001176899299026
beta O 0 3.7640249502146617e-05
hexosaminidase O 0 0.00015752816398162395
A O 0 5.031031378166517e-06
( O 0 1.2674358629283233e-07
hex O 0 4.017059382022126e-06
A O 0 1.2014720596198458e-06
) O 0 1.7252331119266273e-08
activity O 0 1.852610864716553e-08
has O 0 9.982259285834516e-08
been O 0 2.0093364128115354e-07
detected O 0 6.01506599196e-07
in O 0 4.786792118238736e-08
cultured O 0 0.00037782712024636567
skin O 1 0.9917935729026794
fibroblasts O 0 0.0006149347173050046
and O 0 0.003505173372104764
melanoma B-Disease 1 0.9998397827148438
tissue O 0 0.00025202592951245606
from O 0 1.7379477412760025e-07
healthy O 0 1.7663129483480589e-06
individuals O 0 3.476190713058713e-08
previously O 0 1.2649678637899342e-06
reported O 0 3.660765287349932e-06
as O 0 8.068974466368672e-07
having O 0 0.0001245844323420897
deficiency B-Disease 0 0.00013876032608095556
of I-Disease 0 2.707883473007655e-09
hex I-Disease 0 6.239674803509843e-06
A I-Disease 0 4.2968889601979754e-07
activity O 0 2.8416144104426166e-08
indistinguishable O 0 1.225617154432257e-07
from O 0 2.1661477056511558e-09
that O 0 5.922192070073606e-09
of O 0 3.107899715359963e-08
patients O 0 0.007452717050909996
with O 0 0.16443105041980743
Tay B-Disease 1 1.0
- I-Disease 1 0.9999991655349731
Sachs I-Disease 1 0.9999996423721313
disease I-Disease 0 0.44033506512641907
( O 0 1.4500466249955934e-06
TSD B-Disease 0 0.0009124476346187294
) O 0 1.184879465654376e-06
. O 0 1.3691802678295062e-06

Identification O 0 3.7282792618498206e-05
and O 0 1.1581449825825985e-06
quantitation O 0 2.180455339839682e-05
of O 0 5.5873037752007804e-08
hex O 0 7.63338539400138e-06
A O 0 1.116834141612344e-06
, O 0 4.725054481014013e-08
amounting O 0 2.574113295850111e-07
to O 0 1.659802677522748e-07
3 O 0 1.6446305153294816e-06
. O 0 1.9941037407988915e-06

5 O 0 8.713861461728811e-05
% O 0 8.882808288035449e-06
- O 0 8.263818017439917e-05
6 O 0 1.0864341675187461e-05
. O 0 1.8874072793551022e-06

9 O 0 5.5338536185445264e-05
% O 0 5.895136041544902e-07
of O 0 8.440910193030504e-09
total O 0 2.9141768109752775e-08
beta O 0 8.133961415524027e-08
hexosaminidase O 0 2.6241350497002713e-06
activity O 0 2.863060188929012e-08
, O 0 2.4348953076014368e-08
has O 0 1.240381379830069e-07
been O 0 1.118250096965312e-07
obtained O 0 3.9408512009231345e-08
by O 0 4.5066403941973476e-08
cellulose O 0 3.9728995034238324e-05
acetate O 0 0.002397914184257388
gel O 0 0.013340151868760586
electrophoresis O 0 1.0227849088551011e-05
, O 0 5.6490694788635665e-08
DEAE O 0 5.299888471199665e-06
- O 0 1.4279972901931615e-06
cellulose O 0 6.936727459105896e-06
ion O 0 6.715983090543887e-06
- O 0 3.843696049443679e-06
exchange O 0 1.2350284350759466e-07
chromatography O 0 1.144204702541174e-06
, O 0 7.656569778191624e-08
radial O 0 2.367620254517533e-06
immunodiffusion O 0 1.076216904039029e-05
, O 0 5.8161074178997296e-08
and O 0 1.4193715003329999e-07
radioimmunoassay O 0 0.0001776858262019232
. O 0 9.564914762449916e-07

Previous O 0 0.00017068877059500664
family O 0 8.429356967099011e-06
studies O 0 1.6703083360880555e-07
suggested O 0 2.1337443456559413e-07
that O 0 1.3743717275360723e-08
these O 0 7.469664886627925e-09
individuals O 0 7.807667401493745e-09
may O 0 6.657867288595298e-07
be O 0 9.4562601304915e-08
compound O 0 2.7872931696037995e-06
heterozygotes O 0 3.719346750585828e-06
for O 0 1.2240363389537379e-08
the O 0 2.187468872705267e-08
common O 0 1.7926149098457245e-07
mutant O 0 1.9423183402977884e-05
TSD B-Disease 0 5.555665120482445e-05
gene O 0 3.7208326375548495e-07
and O 0 5.563207139402948e-08
a O 0 1.2219472864671843e-06
rare O 0 2.2780110157327726e-05
( O 0 3.8348392195075576e-07
allelic O 0 1.6235693692578934e-05
) O 0 2.7885673148375645e-07
mutant O 0 9.299312296207063e-06
gene O 0 3.123733904430992e-06
. O 0 5.934944624641503e-07

Thus O 0 1.2043643437209539e-05
, O 0 1.9161613806772948e-07
the O 0 2.240462393388043e-08
postulated O 0 5.713157861464424e-06
rate O 0 1.6054178786362172e-07
mutant O 0 5.569598329202563e-07
gene O 0 8.02586868076105e-08
appears O 0 1.4574636963970988e-07
to O 0 5.664365865243326e-09
code O 0 1.121971315853898e-08
for O 0 1.1364727825480259e-08
the O 0 5.472767572456405e-09
expression O 0 4.906086914502339e-08
of O 0 5.3958801871090145e-09
low O 0 3.4815326444004313e-07
amounts O 0 2.700514301068324e-08
of O 0 7.073822416714393e-09
hex O 0 8.069374416663777e-06
A O 0 1.8651514892553678e-06
. O 0 1.0398846370662795e-06

Heterozygotes O 0 0.011837877333164215
for O 0 2.6118834739463637e-06
the O 0 2.611345450986846e-07
rare O 0 2.881429281842429e-06
mutant O 0 0.00014974799705669284
may O 0 4.215590706735384e-06
be O 0 6.685621656288276e-08
indistinguishable O 0 4.2254657728335587e-07
from O 0 2.328384063332578e-08
heterozygotes O 0 1.9593746856116923e-06
for O 0 1.9817242957742565e-08
the O 0 4.257883290392783e-08
common O 0 3.712163731961482e-07
TSD B-Disease 0 0.0006752621848136187
mutant O 0 9.661863441579044e-05
. O 0 1.57396402755694e-06

However O 0 1.3852819392923266e-05
, O 0 1.704240162325732e-07
direct O 0 1.1558153545365712e-07
visualization O 0 9.234094591192843e-07
and O 0 6.885436931725053e-08
quantitation O 0 6.0379275055311155e-06
of O 0 6.372748995175925e-09
hex O 0 3.1526833481620997e-06
A O 0 1.6423925330855127e-07
by O 0 7.788688805021593e-09
the O 0 7.777065214042977e-09
methods O 0 1.5829100163955445e-07
described O 0 2.9484686820069328e-05
may O 0 1.8336891116632614e-06
prevent O 0 2.504069414044352e-07
false O 0 1.0069589961858583e-06
- O 0 0.00015351262118201703
positive O 0 1.798744597181212e-05
prenatal O 0 0.04436159506440163
diagnosis O 0 0.007938798516988754
of O 0 8.126269079866688e-08
TSD B-Disease 0 0.00787703413516283
in O 0 3.7401011923066108e-06
fetuses O 0 0.0009742664988152683
having O 0 1.1928040066777612e-07
the O 0 2.636417661960877e-08
incomplete O 0 2.8848746751464205e-06
hex B-Disease 0 0.004664071369916201
A I-Disease 0 0.032009538263082504
deficiency I-Disease 0 0.0005501483683474362
of O 0 1.6998915608468224e-09
the O 0 1.8335295948190833e-08
type O 0 7.4927788773493376e-06
described O 0 2.9218908821349032e-06
in O 0 1.8605003759830652e-08
the O 0 2.213456795630009e-08
four O 0 5.477333502312831e-07
healthy O 0 3.7721356420661323e-06
individuals O 0 5.993227318867866e-07

The O 0 1.3523409506888129e-05
tumor B-Disease 0 0.00020030087034683675
suppressor O 0 5.544280429603532e-05
gene O 0 7.42714291845914e-06
Smad4 O 0 4.325183545006439e-05
/ O 0 5.029150543123251e-06
Dpc4 O 0 8.48124545882456e-06
is O 0 6.6179737245875e-08
required O 0 2.4366606510284328e-08
for O 0 1.035358554446475e-08
gastrulation O 0 1.7403656329406658e-06
and O 0 1.1518418574496536e-07
later O 0 1.9297411313345947e-07
for O 0 1.4539146775405243e-08
anterior O 0 2.0005725218652515e-06
development O 0 7.647430244617226e-09
of O 0 2.113701880190888e-09
the O 0 3.970176720713425e-08
mouse O 0 1.020464060275117e-05
embryo O 0 8.90373939910205e-06
. O 0 1.496636627962289e-06

Mutations O 0 0.02456226386129856
in O 0 4.238649125909433e-06
the O 0 1.2276824463697267e-06
SMAD4 O 0 0.10912071168422699
/ O 0 0.00035389693221077323
DPC4 O 0 0.04538802057504654
tumor B-Disease 0 0.0008312278077937663
suppressor O 0 6.429697532439604e-05
gene O 0 7.344146979448851e-07
, O 0 1.2582102471014878e-08
a O 0 2.035844026693212e-08
key O 0 2.4906791296075426e-08
signal O 0 5.979981665404921e-07
transducer O 0 1.8451248251949437e-05
in O 0 6.529105434083249e-08
most O 0 6.280272657477326e-08
TGFbeta O 0 2.4264554667752236e-05
- O 0 5.1962717407150194e-05
related O 0 4.4142345245745673e-07
pathways O 0 2.5420285965083167e-07
, O 0 1.5088705396237856e-08
are O 0 2.0192449934341994e-09
involved O 0 1.4347166121808641e-08
in O 0 1.3054650693788972e-08
50 O 0 7.998895057426125e-08
% O 0 4.1533354533385136e-08
of O 0 6.595429624667304e-08
pancreatic B-Disease 1 0.9998928308486938
cancers I-Disease 1 0.9738267660140991
. O 0 4.0994773371494375e-06

Homozygous O 0 0.012924705632030964
Smad4 O 0 0.002791603794321418
mutant O 0 0.0028251209296286106
mice O 0 0.05638349801301956
die O 0 7.27200967958197e-05
before O 0 5.313696860298478e-08
day O 0 1.394362811879546e-07
7 O 0 1.1123210015284712e-06
. O 0 7.172548635026033e-07

5 O 0 1.629900543775875e-05
of O 0 6.746377039235085e-07
embryogenesis O 0 0.00016669869364704937
. O 0 1.3756086445937399e-05

Mutant O 0 0.00014582266157958657
embryos O 0 4.3298514356138185e-05
have O 0 1.507234514974698e-06
reduced O 0 9.517517582935398e-07
size O 0 3.47252012034005e-07
, O 0 1.464987207100421e-07
fail O 0 1.629166604288912e-06
to O 0 1.2905481128200336e-07
gastrulate O 0 6.995350122451782e-05
or O 0 2.73842015729997e-08
express O 0 2.295469414548279e-07
a O 0 1.5984194590146217e-07
mesodermal O 0 1.0842253686860204e-05
marker O 0 1.9474857253953815e-05
, O 0 6.525196027951097e-08
and O 0 3.205533616323919e-08
show O 0 7.701724484832084e-07
abnormal O 0 2.31619151236373e-06
visceral O 0 9.581125050317496e-05
endoderm O 0 3.1378804123960435e-05
development O 0 4.151874861690885e-07
. O 0 1.0086256452268572e-06

Growth B-Disease 1 0.9992825388908386
retardation I-Disease 1 0.9999473094940186
of O 0 2.9531841505558987e-07
the O 0 2.4037348111960455e-07
Smad4 O 0 0.0021893407683819532
- O 0 0.13849972188472748
deficient O 0 0.0012288520811125636
embryos O 0 3.6289631566432945e-07
results O 0 5.826322535540385e-08
from O 0 8.167162945937889e-09
reduced O 0 1.2165330076641112e-07
cell O 0 3.1989134186005685e-07
proliferation O 0 3.287665251150429e-08
rather O 0 1.9569935005847583e-08
than O 0 4.203416281711725e-08
increased O 0 7.84911094342533e-07
apoptosis O 0 2.948201472463552e-05
. O 0 2.2319634354062146e-06

Aggregation O 0 4.1596576920710504e-05
of O 0 8.086623211056576e-07
mutant O 0 6.101065446273424e-05
Smad4 O 0 0.00020567805040627718
ES O 0 1.2006074939563405e-05
cells O 0 9.649471621742123e-07
with O 0 7.051490769072188e-08
wild O 0 3.053198724956019e-07
- O 0 6.973624840611592e-05
type O 0 7.00565487932181e-06
tetraploid O 0 2.9125685614417307e-05
morulae O 0 6.922486500116065e-05
rescues O 0 1.5692421584390104e-05
the O 0 2.2470881333447323e-07
gastrulation B-Disease 0 0.00010566809942247346
defect I-Disease 0 0.0003674159524962306
. O 0 5.372127816372085e-06

These O 0 5.0863359319919255e-06
results O 0 2.3196334950625896e-06
indicate O 0 4.0785579358271207e-07
that O 0 9.670100808989446e-08
Smad4 O 0 1.4127493159321602e-05
is O 0 1.0105746639510471e-07
initially O 0 4.5631392708855856e-07
required O 0 9.023377600669846e-09
for O 0 1.3808822973970791e-09
the O 0 1.83390636010472e-09
differentiation O 0 1.063096188858026e-08
of O 0 2.3960839978798276e-09
the O 0 9.535278344685594e-09
visceral O 0 4.6497716539306566e-05
endoderm O 0 2.5878978703985922e-05
and O 0 6.869997548619722e-08
that O 0 1.4020563376959672e-08
the O 0 2.07258317175274e-08
gastrulation B-Disease 0 6.0270367612247355e-06
defect I-Disease 0 8.04257706477074e-06
in O 0 2.987407299315237e-08
the O 0 3.4846344476591185e-08
epiblast O 0 3.989631659351289e-05
is O 0 1.948498180581737e-07
secondary O 0 2.648771690871854e-08
and O 0 2.56990357883069e-08
non O 0 1.3942178611614509e-07
- O 0 2.2981859729043208e-05
cell O 0 8.139092096826062e-05
autonomous O 0 2.470630761308712e-06
. O 0 1.5458689404113102e-06

Rescued O 0 0.0034434276167303324
embryos O 0 0.00014407331764232367
show O 0 0.00016188595327548683
severe O 0 0.1783747673034668
anterior O 0 0.0010449980618432164
truncations O 0 0.0006994887953624129
, O 0 1.2257263506398886e-06
indicating O 0 7.465151838914608e-07
a O 0 1.1052789972154642e-07
second O 0 9.376964271723409e-08
important O 0 6.83045753291367e-09
role O 0 5.6679780868762464e-08
for O 0 9.842092651979328e-08
Smad4 O 0 5.277210948406719e-05
in O 0 3.441700471285003e-07
anterior O 0 3.7250771129038185e-05
patterning O 0 0.0002767058031167835
during O 0 3.7892075397394365e-06
embryogenesis O 0 5.956617678748444e-05
. O 0 6.473172106780112e-06

Prevalence O 0 0.007712415885180235
of O 0 1.3879908919989248e-06
p16 O 0 8.006561984075233e-05
and O 0 1.7070166222765693e-06
CDK4 O 0 0.00456664664670825
germline O 0 0.0004947680281475186
mutations O 0 4.623189306585118e-05
in O 0 4.736522782877728e-07
48 O 0 0.00014155420649331063
melanoma B-Disease 1 0.9912978410720825
- O 0 0.0880819782614708
prone O 0 0.06825125217437744
families O 0 2.469735591148492e-06
in O 0 9.273338150705968e-07
France O 0 7.703385199420154e-05
. O 0 4.477997663343558e-06

The O 0 3.619680865085684e-05
French O 0 0.0015696028713136911
Familial B-Disease 1 0.9887767434120178
Melanoma I-Disease 1 0.9999179840087891
Study O 0 2.0665811462095007e-05
Group O 0 3.341539695611573e-06
. O 0 1.5079347122082254e-06

Germline O 0 0.34494832158088684
mutations O 0 0.07129018008708954
in O 0 1.1680090210575145e-06
the O 0 1.6229220989316673e-07
p16 O 0 7.690965503570624e-06
and O 0 2.0622975682726974e-07
CDK4 O 0 0.00011588232155190781
genes O 0 1.0778276049450142e-07
have O 0 2.6740256231505555e-08
been O 0 1.2310562169659534e-07
reported O 0 2.0684451840224938e-07
in O 0 1.966031337730101e-09
a O 0 2.5591328167706706e-08
subset O 0 7.943947366584325e-08
of O 0 6.565669963265464e-08
melanoma B-Disease 1 0.9897353649139404
pedigrees O 0 1.0642246706993319e-05
, O 0 4.3511391822903533e-08
but O 0 6.280512110379277e-08
their O 0 6.473170088838742e-08
prevalence O 0 1.0605872375890613e-05
is O 0 5.033133732013084e-08
not O 0 2.7804089697269774e-08
well O 0 3.746405141669129e-08
known O 0 7.093199201335665e-07
. O 0 8.365198596038681e-07

We O 0 2.2613330656895414e-06
searched O 0 1.5803803989911103e-06
for O 0 1.8567815729397807e-08
such O 0 1.9473013423976226e-08
germline O 0 1.912171319418121e-05
mutations O 0 6.115179985499708e-06
in O 0 8.693572084439438e-08
48 O 0 6.609687716263579e-06
French O 0 0.005915713496506214
melanoma B-Disease 1 0.9997424483299255
- O 1 0.5008306503295898
prone O 0 0.12720182538032532
families O 0 4.6894777483430516e-07
selected O 0 4.381946183684704e-08
according O 0 8.089969583124912e-09
to O 0 1.514828085191766e-08
two O 0 1.7977228594645567e-08
major O 0 4.930740971076375e-08
criteria O 0 3.343855894399894e-07
families O 0 1.5982145384896285e-08
with O 0 5.906388267362672e-09
at O 0 2.2662757004354717e-08
least O 0 8.533053375003874e-08
three O 0 3.591650354906051e-08
affected O 0 6.821008469160006e-08
members O 0 1.726954934611058e-08
( O 0 1.7836512711255637e-08
n O 0 5.230138526712835e-07
= O 0 3.620635595780186e-07
20 O 0 3.831848260915649e-08
) O 0 5.404428904398628e-09
or O 0 6.341005942545053e-09
families O 0 1.0692884799823332e-08
with O 0 1.1571560598611086e-08
two O 0 1.3301068690907414e-07
affected O 0 8.304520093815881e-08
members O 0 1.1058099325111925e-08
, O 0 5.300868632929223e-09
one O 0 4.0449443794443596e-09
of O 0 8.678520679872292e-10
them O 0 6.223687787354493e-09
affected O 0 7.613867758493598e-09
before O 0 7.527474643609366e-09
the O 0 7.852442251987668e-09
age O 0 2.2047640158007198e-08
of O 0 1.8495242004590295e-09
50 O 0 3.542738369333165e-08
( O 0 9.695379610263899e-09
n O 0 4.971873863723886e-07
= O 0 3.523183522702311e-07
28 O 0 1.4347308763262845e-07
) O 0 5.447824413806757e-09
, O 0 8.174410481842642e-09
and O 0 6.533849017387183e-09
one O 0 2.0912503728709453e-08
additional O 0 7.311525962450105e-08
minor O 0 6.161392889225681e-07
criterion O 0 1.9879076717188582e-05
. O 0 2.1025948626629543e-06

Sixteen O 0 4.116907075513154e-05
different O 0 1.3248180721348035e-06
p16 O 0 3.182579530403018e-05
germline O 0 0.00014459092926699668
mutations O 0 0.00018137329607270658
were O 0 1.321350737271132e-06
found O 0 2.8170393306936603e-07
in O 0 6.169052824134269e-08
21 O 0 2.317572580068372e-06
families O 0 3.0613914958621535e-08
, O 0 8.021120656565017e-09
while O 0 1.636870372578869e-08
one O 0 2.41376820753203e-08
germline O 0 2.6612806323100813e-06
mutation O 0 1.0352675872127293e-06
, O 0 2.4201021631142794e-08
Arg24His O 0 3.263706958023249e-06
, O 0 5.5775291940562965e-08
was O 0 4.91256685108965e-07
detected O 0 1.8774406385091424e-07
in O 0 8.048276711747349e-09
the O 0 5.5412439081692355e-08
CDK4 O 0 0.007163897156715393
gene O 0 8.054542377067264e-06
. O 0 1.3375411072047427e-06

The O 0 1.2624840337593923e-06
frequency O 0 2.300385858688969e-06
of O 0 4.286018651100676e-08
p16 O 0 3.880778422171716e-06
gene O 0 1.5183780988081708e-06
mutation O 0 8.184505304598133e-07
in O 0 8.78067485388101e-09
our O 0 8.493591607816597e-09
sample O 0 5.7175672196763117e-08
( O 0 8.082998270708686e-09
44 O 0 2.4944833398876654e-07
% O 0 1.3532860165810234e-08
) O 0 3.1356388596748275e-09
is O 0 1.210396760598087e-08
among O 0 3.926900582484905e-09
the O 0 6.027190746493716e-09
highest O 0 2.8685161623798194e-07
rates O 0 3.2168560437639826e-07
yet O 0 4.009115457392909e-07
reported O 0 8.289096626867831e-07
and O 0 2.085769068571608e-08
the O 0 3.1325200211540505e-08
CDK4 O 0 0.02094544842839241
mutation O 0 7.900396781224117e-07
is O 0 3.5784175622666226e-09
the O 0 1.8491431719169782e-09
second O 0 7.184372066149081e-07
mutation O 0 1.0822602689586347e-06
detected O 0 1.2931364778978605e-07
in O 0 3.2580866893283655e-09
this O 0 7.3731984961966646e-09
gene O 0 3.404663857509149e-07
worldwide O 0 4.580317636282416e-07
. O 0 4.2060946725541726e-07

In O 0 4.416324372868985e-06
summary O 0 3.7834518025192665e-06
, O 0 6.279984887669343e-08
our O 0 1.2526644610488802e-08
results O 0 3.993720909534204e-08
show O 0 1.290133440079444e-07
frequent O 0 2.505792053852929e-07
involvement O 0 5.6227328570912505e-08
of O 0 2.320115211063012e-09
the O 0 1.165308916029062e-08
p16 O 0 3.1470658541365992e-06
gene O 0 2.602733104595245e-07
in O 0 1.0021519614156205e-07
familial B-Disease 0 0.2884400188922882
melanoma I-Disease 1 0.9999681711196899
and O 0 1.792291641322663e-06
confirm O 0 1.939411959028803e-06
the O 0 6.002410568584082e-09
role O 0 1.33769324506261e-08
of O 0 1.6263788094050824e-09
the O 0 1.820691153398002e-08
CDK4 O 0 6.397855759132653e-05
gene O 0 1.5380443585399917e-07
as O 0 2.3176482955022948e-08
a O 0 1.4505717444990296e-05
melanoma B-Disease 1 0.9986338019371033
- O 0 0.008330647833645344
predisposing O 0 0.00043610422289930284
gene O 0 3.0714593322045403e-06
. O 0 1.7800802254441805e-07
. O 0 4.798731083610619e-07

Progression O 0 0.00043200975051149726
of O 0 1.7196535964103532e-06
somatic O 0 9.659201896283776e-05
CTG O 0 0.0008870240417309105
repeat O 0 5.950542981736362e-05
length O 0 1.4385549548023846e-05
heterogeneity O 0 9.382370080857072e-06
in O 0 1.288726565462639e-07
the O 0 8.108634830250594e-08
blood O 0 4.787450052390341e-06
cells O 0 2.1904995719523868e-06
of O 0 2.715467644520686e-06
myotonic B-Disease 1 1.0
dystrophy I-Disease 1 1.0
patients O 1 0.9999327659606934
. O 0 1.6324016542057507e-05

The O 0 2.221892600573483e-06
genetic O 0 6.728753760398831e-06
basis O 0 5.769360313934158e-07
of O 0 6.761063104931964e-06
myotonic B-Disease 1 1.0
dystrophy I-Disease 1 1.0
( O 0 0.2904081642627716
DM B-Disease 1 0.9999998807907104
) O 0 1.1895034504050273e-06
is O 0 6.182835221579808e-08
the O 0 3.810280979621439e-09
expansion O 0 3.776933610311062e-08
of O 0 7.273037283539452e-09
an O 0 2.3806384774616163e-07
unstable O 0 0.00020837286137975752
CTG O 0 0.0001278353447560221
repeat O 0 2.077019189528073e-06
in O 0 2.423580625077193e-08
the O 0 1.9678482843232814e-08
34 O 0 3.4958625860781467e-07
UTR O 0 4.070365321240388e-06
of O 0 1.3589661840285316e-08
the O 0 5.371617248783878e-07
DM B-Disease 1 0.9999996423721313
protein O 0 2.0730334654217586e-05
kinase O 0 3.086008064201451e-06
gene O 0 1.2253251213678595e-07
on O 0 2.0608840145541762e-07
chromosome O 0 4.3612588342512026e-05
19 O 0 1.9090582554781577e-06
. O 0 7.154055765568046e-07

One O 0 1.468121809011791e-06
of O 0 2.1233200087067416e-08
the O 0 1.2829209694587007e-08
principal O 0 5.567304484088709e-08
features O 0 9.810399603793485e-08
of O 0 1.075014388618456e-08
the O 0 4.7022058424772695e-06
DM B-Disease 1 1.0
mutation O 0 0.00884009525179863
is O 0 2.081199710346482e-07
an O 0 4.863898439566583e-08
extraordinarily O 0 9.933796718541998e-06
high O 0 2.1900534363794577e-07
level O 0 8.87352591405488e-09
of O 0 6.196929636104187e-09
somatic O 0 9.765472896106075e-06
mosaicism O 0 0.013820076361298561
, O 0 1.17797462451108e-07
due O 0 7.103909638317418e-08
to O 0 4.5601112219628703e-08
an O 0 3.956709804242564e-07
extremely O 0 7.514587923651561e-05
high O 0 1.3979474715597462e-06
degree O 0 8.031457809920539e-08
of O 0 6.376481564984715e-09
somatic O 0 4.876898856309708e-06
instability O 0 1.616605572962726e-06
both O 0 2.093265649705245e-08
within O 0 2.704750201587558e-09
and O 0 1.387943804331826e-08
between O 0 2.3522428449496147e-08
different O 0 6.324726342654685e-08
tissues O 0 1.4066041330806911e-05
. O 0 1.3286455669003772e-06

This O 0 1.1166615877300501e-05
instability O 0 2.13560870179208e-05
appears O 0 5.130503268446773e-06
to O 0 1.91668405591372e-07
be O 0 6.801326435379451e-08
biased O 0 6.501684879367531e-07
towards O 0 4.185463353678642e-08
further O 0 2.137313792616169e-08
expansion O 0 4.302711431591888e-08
and O 0 1.8267785506509426e-08
continuous O 0 1.0727186605663519e-07
throughout O 0 6.459045742701619e-09
the O 0 5.830399718576018e-09
life O 0 1.1732486093762873e-08
of O 0 7.869290774564774e-10
an O 0 2.3604766141716027e-08
individual O 0 1.430511264999268e-08
, O 0 2.749127681056507e-08
features O 0 2.7639762834041903e-07
that O 0 6.171371325081054e-08
could O 0 3.6782310530725226e-07
be O 0 1.0029111052745066e-07
associated O 0 3.151950167534778e-08
with O 0 9.920245958028318e-09
the O 0 4.748001103394017e-08
progressive O 0 2.9916331186541356e-05
nature O 0 4.919374063661053e-08
of O 0 1.1341882100168732e-08
the O 0 8.755072258281871e-07
disease O 0 0.0016307723708450794
. O 0 2.171076857848675e-06

Although O 0 1.2404467270243913e-05
increasing O 0 1.1363902103767032e-06
measured O 0 5.901919848838588e-06
allele O 0 5.143790076544974e-06
size O 0 4.209537962651666e-07
between O 0 5.35662479705934e-07
patients O 0 0.004217532463371754
clearly O 0 7.007953627180541e-06
correlates O 0 3.4491699807404075e-06
with O 0 2.8963340170662377e-08
an O 0 1.688331821014799e-07
increased O 0 1.1708022611855995e-05
severity O 0 0.0003852944646496326
of O 0 1.844584716081954e-07
symptoms O 1 0.9239576458930969
and O 0 2.0546453072256554e-07
an O 0 1.9270522955139313e-07
earlier O 0 4.748920218844432e-06
age O 0 4.586856761079616e-08
of O 0 5.465017327566102e-09
onset O 0 3.944772743125213e-06
, O 0 2.4936262832397915e-08
this O 0 3.379058588492967e-09
correlation O 0 3.164274531286537e-08
is O 0 2.065802817696749e-08
not O 0 2.9788722599732864e-08
precise O 0 3.291850987352518e-07
and O 0 1.0978119036053613e-07
measured O 0 1.6101825167424977e-05
allele O 0 1.4546880038324161e-06
length O 0 6.439686330850236e-07
cannot O 0 1.8270509372086963e-07
be O 0 4.691286470404066e-09
used O 0 1.6308122852137785e-08
as O 0 8.336622059346155e-09
an O 0 1.3494970474425827e-08
accurate O 0 4.717949195764959e-07
predictor O 0 1.8629953046911396e-06
of O 0 1.0088832880228438e-08
age O 0 1.4119649449639837e-07
of O 0 3.084990041202218e-08
onset O 0 6.994269642746076e-05
. O 0 5.820785190735478e-06

In O 0 1.2642719866562402e-06
order O 0 1.198739738583754e-07
to O 0 3.0255979055482385e-08
further O 0 2.7999506713172195e-08
characterize O 0 6.568952244379034e-07
the O 0 4.5528196324085e-08
dynamics O 0 2.2835506570118014e-06
of O 0 8.363159054169955e-08
DM B-Disease 1 0.9999990463256836
CTG O 0 0.009439687244594097
repeat O 0 1.0869637662835885e-05
somatic O 0 1.1092469321738463e-05
instability O 0 2.196402647314244e-06
, O 0 3.514055535447369e-08
we O 0 8.771836590426574e-09
have O 0 1.54763384330181e-08
studied O 0 4.189281099797881e-08
repeat O 0 3.977085611950315e-07
length O 0 1.1756014828279149e-06
changes O 0 3.285026295429816e-08
over O 0 1.9318195043638298e-08
time O 0 4.4790215980583525e-08
in O 0 2.4786095309536904e-07
111 O 0 0.30205416679382324
myotonic B-Disease 1 1.0
dystrophy I-Disease 1 1.0
patients O 1 0.9999039173126221
with O 0 3.974893388658529e-06
varying O 0 7.44745775591582e-05
clinical O 0 0.0018237195909023285
severity O 0 0.020230161026120186
and O 0 8.560747914998501e-07
CTG O 0 6.08775662840344e-05
repeat O 0 1.6834164853207767e-06
size O 0 6.219548964736532e-08
over O 0 2.3665489123914085e-08
time O 0 1.5316265589149225e-08
intervals O 0 2.0823900825917008e-08
of O 0 1.867813459455192e-09
1 O 0 4.899662542356964e-08
- O 0 2.0791019778698683e-05
7 O 0 2.337489377168822e-06
years O 0 5.910312665946549e-07
. O 0 5.695416689377453e-07

We O 0 5.9470066844369285e-06
have O 0 5.423680136118492e-07
found O 0 5.870843367006273e-08
a O 0 6.77301486007309e-08
direct O 0 1.1444193148690829e-07
progression O 0 3.1221952667692676e-07
of O 0 3.5261793485119597e-09
the O 0 5.575899297838305e-09
size O 0 1.1244440401014799e-07
heterogeneity O 0 9.207774951391912e-07
over O 0 1.3102375362450402e-07
time O 0 5.495122934462415e-08
related O 0 2.5872502362744854e-08
to O 0 4.135454645393111e-08
initial O 0 5.054770895185356e-07
CTG O 0 8.057154445850756e-06
repeat O 0 5.726826657337369e-07
size O 0 4.156283495149182e-08
and O 0 5.285865523063649e-09
the O 0 2.332761539491912e-09
time O 0 5.766024546716153e-09
interval O 0 2.0930778887873203e-08
and O 0 4.9121893219705726e-09
always O 0 1.8744882979149224e-08
biased O 0 1.0830557073404634e-07
towards O 0 1.0403985228890633e-08
further O 0 5.415648729467648e-08
expansion O 0 1.1798481409641681e-06
. O 0 1.5274961242539575e-06

Attempts O 0 4.812879706150852e-05
to O 0 4.265770712663652e-06
mathematically O 0 2.7992304239887744e-05
model O 0 3.1568533813697286e-06
the O 0 5.658774782091314e-08
dynamics O 0 6.182232482387917e-06
have O 0 3.948424591726507e-07
proved O 0 5.114401574246585e-06
only O 0 6.216963299721101e-08
partially O 0 1.67854477695073e-06
successful O 0 2.1172463959828747e-07
suggesting O 0 1.6970942340321926e-07
that O 0 1.1401963817547767e-08
individual O 0 3.4590388331423583e-09
specific O 0 6.426946530524447e-09
genetic O 0 4.373922024569765e-07
and O 0 6.267815138016886e-07
/ O 0 1.7602977095521055e-05
or O 0 1.8788109912293294e-07
environmental O 0 1.052859147421259e-06
factors O 0 3.3649108388544846e-08
also O 0 1.0263694605328055e-07
play O 0 1.1446807945958426e-08
a O 0 4.8414996456358494e-08
role O 0 1.1478963557465249e-07
in O 0 1.4159550687509181e-07
somatic O 0 6.532388943014666e-05
mosaicism O 0 0.011484208516776562
. O 0 8.74624333846441e-07
. O 0 1.1795376622103504e-06

Aspartylglucosaminuria B-Disease 1 0.9962983727455139
among O 0 2.2588399588130414e-05
Palestinian O 0 2.5553108571330085e-05
Arabs O 0 3.3254003938054666e-05
. O 0 3.477621248748619e-06

Aspartylglucosaminuria B-Disease 1 0.9999812841415405
( O 0 0.08198100328445435
AGU B-Disease 1 0.9999904632568359
) O 0 2.847826863217051e-06
is O 0 6.773220206923725e-07
a O 0 1.0901685527642258e-05
rare O 0 0.015231475234031677
disorder B-Disease 0 0.327686071395874
of I-Disease 0 3.5002017284568865e-08
glycoprotein I-Disease 0 0.00889089796692133
metabolism I-Disease 0 9.690448496257886e-05
caused O 0 9.358518582303077e-06
by O 0 1.8888950137352367e-07
the O 0 2.51857886723883e-06
deficiency B-Disease 0 0.00359540618956089
of I-Disease 0 1.7831956355962575e-08
the I-Disease 0 2.4292529587910394e-07
lysosomal I-Disease 0 0.001369274570606649
enzyme I-Disease 0 7.034341706457781e-06
aspartylglucosaminidase I-Disease 0 6.596389721380547e-05
( O 0 1.7065806900973257e-07
AGA O 0 7.408428791677579e-05
) O 0 4.973480827175081e-07
. O 0 9.4684577334192e-07

AGU B-Disease 1 0.999994158744812
is O 0 0.0016707017784938216
inherited O 0 0.0012347649317234755
as O 0 7.246619588840986e-07
an O 0 4.082977739017224e-06
autosomal O 1 0.9988988637924194
recessive O 1 0.9995205402374268
trait O 0 0.33582553267478943
and O 0 1.747187184264476e-06
occurs O 0 3.6655855240042e-08
with O 0 1.2025979323482261e-08
a O 0 1.2465151257856633e-06
high O 0 2.277335170219885e-06
frequency O 0 5.701846930605825e-06
in O 0 9.003181133948601e-08
Finland O 0 0.00011232028919039294
because O 0 2.908213403429727e-08
of O 0 2.2542208100162497e-09
a O 0 5.035774961470452e-07
founder O 0 1.9036322555621155e-05
effect O 0 3.15081365442893e-06
. O 0 1.8643459043232724e-06

While O 0 5.571230758505408e-06
very O 0 1.241876816493459e-06
few O 0 3.997290605184389e-06
patients O 0 0.0004579548258334398
with O 0 1.1404645192669705e-05
AGU B-Disease 1 0.9999996423721313
have O 0 4.7291025111917406e-05
been O 0 1.3694728977498016e-06
reported O 0 2.2530319654379127e-07
from O 0 2.9111977273288403e-09
non O 0 4.224409622111125e-08
- O 0 1.2350028555374593e-05
Finnish O 0 0.030071740970015526
origin O 0 2.343005860439007e-07
, O 0 6.058647272766393e-08
we O 0 1.7811534291922726e-07
diagnosed O 0 0.01365377102047205
the O 0 5.198690473662282e-07
disorder O 0 0.11718019843101501
in O 0 7.139361741792527e-07
8 O 0 1.965539195225574e-05
patients O 0 4.0545131923863664e-05
originating O 0 4.315870683058165e-08
from O 0 1.7373222860328497e-08
3 O 0 9.890248264809998e-08
unrelated O 0 1.3872339650333743e-06
families O 0 6.995787771302275e-08
, O 0 1.019785145217611e-08
all O 0 3.986701635483314e-09
Palestinian O 0 6.022218030921067e-07
Arabs O 0 5.107744982524309e-07
from O 0 3.5274709819788086e-09
the O 0 1.1168832969588038e-08
region O 0 4.999235869718177e-08
of O 0 1.2148327677152793e-08
Jerusalem O 0 1.7530941477161832e-05
. O 0 1.5579307728330605e-06

The O 0 1.3563085303758271e-05
clinical O 0 0.00986423622816801
diagnosis O 1 0.8914830684661865
of O 0 3.1663867048337124e-06
AGU B-Disease 1 0.9999995231628418
is O 0 9.349637548439205e-05
often O 0 1.1556967365322635e-06
difficult O 0 6.939969239283528e-07
, O 0 2.0573839520920956e-08
in O 0 4.4373873464564895e-09
particular O 0 8.20361822917448e-09
early O 0 4.130252051481875e-08
in O 0 8.432477827113871e-09
the O 0 6.327439017184133e-09
course O 0 2.5938613035236813e-08
of O 0 3.875647358597689e-09
the O 0 5.263784714770736e-07
disease O 0 0.00011595449177548289
, O 0 1.8486645103621413e-08
and O 0 1.5232537009524094e-08
most O 0 5.631670241257325e-09
of O 0 1.6477894604349785e-09
the O 0 7.098444143593952e-07
patients O 0 0.06731915473937988
are O 0 1.4402846773009514e-06
diagnosed O 0 0.10484306514263153
after O 0 1.1055023918515872e-07
the O 0 2.1829590579613978e-08
age O 0 7.396597112574455e-08
of O 0 4.044967472083272e-09
5 O 0 2.9972187576277065e-07
years O 0 6.439759658860567e-07
. O 0 1.046566353579692e-06

However O 0 4.037243706989102e-05
, O 0 4.6767269168412895e-07
since O 0 3.295441217687767e-07
these O 0 1.0443873321719366e-07
patients O 0 3.428678837735788e-06
excrete O 0 5.369250857256702e-07
early O 0 4.49854233863789e-08
large O 0 1.6756844800625004e-08
amounts O 0 1.1083606921147293e-08
of O 0 4.70252992101905e-09
aspartylglucosamine O 0 9.25065342016751e-06
in O 0 1.0947736228672511e-07
urine O 0 3.78612617168983e-06
, O 0 2.3039454788431613e-08
biochemical O 0 2.7337111419001303e-07
screening O 0 1.6242692879586684e-07
is O 0 2.396144616056972e-08
easy O 0 1.5196167169051478e-07
by O 0 3.114207629550947e-07
urine O 0 2.7344090995029546e-05
chromatography O 0 4.789459126186557e-06
. O 0 2.115181700901303e-07
. O 0 5.879796844965313e-07

Detection O 0 3.506419307086617e-05
of O 0 2.690310054731526e-07
heterozygous O 0 1.6881795090739615e-05
carriers O 0 9.247057164429862e-07
of O 0 3.956478877853442e-08
the O 0 2.5474029826000333e-05
ataxia B-Disease 1 1.0
- I-Disease 1 0.9999977350234985
telangiectasia I-Disease 1 0.9999985694885254
( O 0 9.26525956401747e-07
ATM O 0 1.4704575050927815e-06
) O 0 2.9188496952770038e-08
gene O 0 7.891573261531448e-08
by O 0 1.7268595442487822e-08
G2 O 0 3.324439603602514e-05
phase O 0 1.629813027648197e-06
chromosomal O 0 3.983617352787405e-05
radiosensitivity O 0 1.147049533756217e-05
of O 0 1.0366868963274101e-07
peripheral O 0 0.00034798900014720857
blood O 0 0.0002868097508326173
lymphocytes O 0 7.491227734135464e-05
. O 0 1.816826852518716e-06

In O 0 0.051462672650814056
ataxia B-Disease 1 0.9999996423721313
- I-Disease 1 0.9999948740005493
telangiectasia I-Disease 1 0.9999990463256836
( O 0 0.00042609675438143313
A B-Disease 1 0.9999963045120239
- I-Disease 1 0.9999970197677612
T I-Disease 1 0.9999998807907104
) O 0 6.037010098225437e-05
patients O 0 0.007665497250854969
, O 0 1.3080801863907254e-07
mutations O 0 5.308885420163278e-07
in O 0 8.423990394135217e-09
a O 0 1.7444820343825995e-07
single O 0 4.5464071263268124e-07
gene O 0 1.146626047443533e-07
, O 0 1.0049290288804968e-08
ATM O 0 1.7873932733891706e-07
, O 0 2.4788402441799917e-08
result O 0 4.3986943865093053e-08
in O 0 1.5782461559865624e-07
an O 0 0.3104472756385803
autosomal B-Disease 1 1.0
recessive I-Disease 1 1.0
syndrome I-Disease 1 1.0
that O 0 3.2433244996354915e-06
embraces O 0 1.2582110002767877e-06
a O 0 3.1904252750791784e-07
variety O 0 3.529505221422369e-08
of O 0 1.708665919863961e-08
clinical O 0 8.489969332003966e-06
features O 0 1.8014383385889232e-05
and O 0 7.449434633599594e-07
manifests O 0 5.711330959456973e-05
extreme O 0 0.000493253639433533
radiosensitivity O 0 0.00011304018698865548
and O 0 2.30981953563969e-08
a O 0 1.0504525960186584e-07
strong O 0 2.8610276103790966e-07
pre O 0 5.045681064075325e-06
- O 0 0.00019133841851726174
disposition O 0 4.8883273848332465e-05
to O 0 5.135486389917787e-06
malignancy B-Disease 0 0.0012182153295725584
. O 0 3.833412847598083e-06

Heterozygotes O 0 0.003655771492049098
for O 0 7.272803941305028e-07
the O 0 5.701047456341257e-08
ATM O 0 8.199443186640565e-07
gene O 0 4.195918847926805e-07
have O 0 8.998924272418662e-08
no O 0 1.3479822769113525e-07
clinical O 0 1.6145347672136268e-06
expression O 0 3.870419789109292e-07
of O 0 1.8345895469451534e-08
A B-Disease 1 0.9999794960021973
- I-Disease 1 0.9999891519546509
T I-Disease 1 0.9999996423721313
but O 0 0.00028419450973160565
may O 0 8.131450886139646e-05
be O 0 1.7429354556952603e-05
cancer B-Disease 0 0.002809944562613964
prone O 0 1.3431330444291234e-05
with O 0 9.813768286903723e-08
a O 0 4.9030045374820475e-06
moderate O 0 0.012496976181864738
increase O 0 1.7356815078528598e-06
in O 0 6.656788542613867e-08
in O 0 1.0933108995914154e-07
vitro O 0 5.968700133962557e-05
radiosensitivity O 0 0.0003676888591144234
. O 0 1.0484565109436517e-06

We O 0 5.229318048804998e-06
performed O 0 4.346903097030008e-06
a O 0 1.0969009736072621e-06
blind O 0 2.578143175924197e-05
chromosomal O 0 2.1829000615980476e-05
analysis O 0 2.400182097517245e-07
on O 0 3.963814094731788e-07
G2 O 0 0.0004905166570097208
- O 0 0.00015060014266055077
phase O 0 4.9970090003625955e-06
lymphocytes O 0 3.044411187147489e-06
from O 0 3.6945603909543934e-08
7 O 0 3.310302076897642e-07
unrelated O 0 4.996989900973858e-06
A B-Disease 1 0.9999880790710449
- I-Disease 1 0.9999984502792358
T I-Disease 1 1.0
patients O 1 0.9262238144874573
, O 0 5.928558266532491e-08
13 O 0 7.236702970203623e-08
obligate O 0 1.3927165127824992e-06
A B-Disease 1 0.9999035596847534
- I-Disease 1 0.9999581575393677
T I-Disease 1 0.999998927116394
heterozygotes O 0 0.0094505799934268
( O 0 3.769945067233493e-08
parents O 0 3.316283070375903e-08
of O 0 2.7015383263773174e-09
the O 0 6.79054153351899e-07
patients O 0 0.0033345224801450968
) O 0 2.8604400625908966e-08
, O 0 4.33966853563561e-08
and O 0 4.4520895414734696e-08
14 O 0 6.295695698099735e-08
normal O 0 3.536864312536636e-08
controls O 0 2.598581204438233e-06
following O 0 1.1042843084396736e-07
X O 0 1.9986897314083762e-05
- O 0 3.443618652454461e-06
irradiation O 0 3.695653731483617e-06
with O 0 1.069048209956236e-07
1 O 0 1.1595138005304761e-07
Gy O 0 7.867353815527167e-06
in O 0 1.3382138952522382e-08
order O 0 9.050785010344953e-09
to O 0 1.9340978596460445e-08
evaluate O 0 1.254853003729295e-07
this O 0 2.704524781904638e-08
cytogenetic O 0 3.21268271363806e-05
method O 0 1.9922075011891138e-07
as O 0 2.6832834620904578e-08
a O 0 2.151527134230946e-08
tool O 0 6.354787274176488e-08
for O 0 1.0891166191129287e-08
detection O 0 8.010498220301088e-08
of O 0 2.2825522805192122e-08
ATM O 0 1.7472806575824507e-05
carriers O 0 4.499521764955716e-06
. O 0 1.5309686887121643e-06

Both O 0 4.764741606777534e-05
A B-Disease 1 0.9948006868362427
- I-Disease 1 0.9996795654296875
T I-Disease 1 0.9999896287918091
homozygotes O 0 0.01017263438552618
and O 0 6.382866217791161e-07
heterozygotes O 0 3.8768503145547584e-05
showed O 0 4.140558303333819e-05
significantly O 0 7.89086413988116e-07
increased O 0 2.053446621630428e-07
levels O 0 1.700887963806963e-08
of O 0 1.0960456542363772e-08
radiation O 1 0.5328694581985474
- O 0 0.05041372776031494
induced O 1 0.9031370878219604
chromatid O 1 0.8361895084381104
damage O 0 0.00011746334348572418
relative O 0 3.0291093366940913e-07
to O 0 3.7955292242486394e-08
that O 0 2.6721954426989214e-08
of O 0 1.6988195739031653e-08
normal O 0 5.801814495498547e-07
controls O 0 6.669972935924307e-05
. O 0 2.3005634375294903e-06

These O 0 1.8975375724039623e-06
results O 0 5.871206667507067e-07
show O 0 1.0995680099767924e-07
that O 0 1.0019127749671952e-08
the O 0 1.5547612974842195e-08
G2 O 0 0.00014867082063574344
- O 0 1.703715679468587e-05
phase O 0 1.7783947896532482e-06
chromosomal O 0 3.5489476431393996e-05
radiosensitivity O 0 3.076010398217477e-05
assay O 0 2.2177473510964774e-06
can O 0 3.897591938084588e-08
be O 0 5.203548703036631e-09
used O 0 1.3960894662545797e-08
for O 0 2.702440049517918e-09
the O 0 3.580356455756828e-09
detection O 0 1.0940681249849149e-07
of O 0 3.048647911896296e-08
A B-Disease 1 0.9999428987503052
- I-Disease 1 0.9999758005142212
T I-Disease 1 0.9999967813491821
heterozygotes O 0 0.007125786505639553
. O 0 2.8747019769070903e-06

In O 0 3.826666670647683e-06
combination O 0 7.273709798027994e-06
with O 0 4.337492498507345e-07
molecular O 0 5.647093530569691e-06
genetic O 0 1.600043674443441e-06
analyses O 0 5.26428152625158e-07
, O 0 1.5376212303408465e-08
this O 0 1.288023288026352e-08
test O 0 5.665178264280257e-07
may O 0 4.5623735900335305e-07
be O 0 4.678919029998951e-09
of O 0 8.547966778849059e-10
value O 0 2.4363435713326e-09
in O 0 5.635570676787438e-09
studies O 0 1.4197255815417975e-08
of O 0 5.1494231101401056e-09
familial B-Disease 0 7.623455985594774e-06
and I-Disease 0 9.532769240649941e-07
sporadic I-Disease 0 0.015210138633847237
cancers I-Disease 0 0.013633357360959053
aimed O 0 4.984007659913914e-07
at O 0 4.621324123377235e-08
determination O 0 3.5843078194375266e-07
of O 0 4.669183706340618e-09
the O 0 8.37487146299054e-09
potential O 0 2.972946688828415e-08
involvement O 0 4.1984563381447515e-08
of O 0 1.004289007511261e-08
ATM O 0 1.6573190805502236e-05
mutations O 0 1.2313688785070553e-05
in O 0 2.834080419233942e-07
tumor B-Disease 0 0.004235720261931419
risk O 0 8.655367196297448e-07
or O 0 2.8671752971831665e-08
development O 0 4.195614522473079e-08
. O 0 2.894559258947993e-07
. O 0 1.210899881698424e-06

Ataxia B-Disease 1 0.9999985694885254
- I-Disease 1 0.9999674558639526
telangiectasia I-Disease 1 0.999984622001648
: O 0 1.102566602639854e-05
identification O 0 8.812588703221991e-07
and O 0 6.681006681219515e-08
detection O 0 1.11091992494039e-07
of O 0 1.0875555567224637e-08
founder O 0 8.524108125129715e-06
- O 0 0.00032751812250353396
effect O 0 5.549780780711444e-06
mutations O 0 3.2472939892613795e-07
in O 0 2.0604615791341985e-09
the O 0 2.1709996023133726e-09
ATM O 0 3.7888031556576607e-07
gene O 0 1.1719293979695067e-07
in O 0 3.099381018500935e-08
ethnic O 0 7.565245709884039e-07
populations O 0 1.2341459978415514e-06
. O 0 6.832812005086453e-07

To O 0 1.6778453755250666e-06
facilitate O 0 2.402483403329825e-07
the O 0 1.888519918225029e-08
evaluation O 0 3.012181792882984e-08
of O 0 4.657958463383238e-09
ATM O 0 1.5205531553874607e-06
heterozygotes O 0 2.633186522871256e-05
for O 0 6.735924529266413e-08
susceptibility O 0 0.000843637331854552
to O 0 2.6459142645762768e-06
other O 0 1.7422304381398135e-06
diseases O 0 2.853529622370843e-05
, O 0 2.7528635371254495e-08
such O 0 2.5413443793809165e-08
as O 0 0.017109517008066177
breast B-Disease 1 0.9999810457229614
cancer I-Disease 1 0.6551820635795593
, O 0 2.642065766167434e-08
we O 0 4.810623455142604e-09
have O 0 5.083008236539399e-09
attempted O 0 2.2095092333529465e-07
to O 0 1.4718444241168527e-08
define O 0 6.474416380797265e-08
the O 0 1.0285443607926936e-08
most O 0 5.578082351576086e-08
common O 0 6.982816813660975e-08
mutations O 0 2.5447937446188007e-07
and O 0 1.2617284994576039e-08
their O 0 1.9042687426917837e-08
frequencies O 0 9.477767889620736e-06
in O 0 8.644266927149147e-05
ataxia B-Disease 1 1.0
- I-Disease 1 0.9999988079071045
telangiectasia I-Disease 1 0.9999995231628418
( O 0 5.0110920710721985e-06
A B-Disease 1 0.9999749660491943
- I-Disease 1 0.9999470710754395
T I-Disease 1 0.999996542930603
) O 0 3.8272253277682466e-07
homozygotes O 0 5.194099230720894e-06
from O 0 1.0649186421574086e-08
10 O 0 2.134946797127668e-08
ethnic O 0 2.2115708020464808e-07
populations O 0 6.288063332249294e-07
. O 0 1.3581807252194267e-06

Both O 0 1.0269573067489546e-05
genomic O 0 1.9798104403889738e-05
mutations O 0 7.821038161637262e-05
and O 0 2.805757048918167e-07
their O 0 4.701608702362137e-08
effects O 0 8.221101097660721e-07
on O 0 4.3630859636323294e-07
cDNA O 0 2.4445778308290755e-06
were O 0 1.1219563020858914e-06
characterized O 0 5.05589741806034e-06
. O 0 1.4031018054083688e-06

Protein O 0 3.969722456531599e-05
- O 0 2.597089951450471e-05
truncation O 0 9.091427273233421e-06
testing O 0 3.541151158970024e-07
of O 0 3.4179314933879823e-09
the O 0 4.472300751956482e-09
entire O 0 1.9145204532833304e-08
ATM O 0 2.7987073281110497e-07
cDNA O 0 8.920695222514041e-07
detected O 0 1.3148180642019724e-06
92 O 0 3.7715099665547314e-07
( O 0 2.3959664474659803e-08
66 O 0 1.6260341908491682e-06
% O 0 4.413552545656785e-08
) O 0 1.7938045715482076e-08
truncating O 0 2.387291488048504e-06
mutations O 0 1.3464858739098418e-06
in O 0 2.7966255089495462e-08
140 O 0 5.947755994384352e-07
mutant O 0 4.8832811444299296e-05
alleles O 0 8.719612196728121e-06
screened O 0 5.22406080563087e-05
. O 0 3.694437964441022e-06

The O 0 3.00567080557812e-06
haplotyping O 0 7.871844718465582e-05
of O 0 5.804681109111698e-07
patients O 0 0.0005201718304306269
with O 0 3.051257522201922e-07
identical O 0 0.0019794292747974396
mutations O 0 1.6921801943681203e-05
indicates O 0 1.8361112097409205e-07
that O 0 1.555959805443763e-08
almost O 0 1.0612222212103006e-08
all O 0 6.762798099302358e-10
of O 0 6.123515028377824e-10
these O 0 4.736836256569177e-09
represent O 0 3.7210096337503273e-08
common O 0 8.567578646534457e-08
ancestry O 0 9.700412419988425e-07
and O 0 5.3182802162154985e-08
that O 0 5.314224083008412e-08
very O 0 6.797046836481968e-08
few O 0 1.8912834320872207e-07
spontaneously O 0 1.524008325759496e-06
recurring O 0 6.271017809922341e-06
ATM O 0 1.4597031622543e-05
mutations O 0 1.742039603414014e-05
exist O 0 4.6835555167490384e-07
. O 0 5.857633027517295e-07

Assays O 0 0.0007025957456789911
requiring O 0 3.6224020732333884e-05
minimal O 0 4.312009423301788e-06
amounts O 0 1.3926843678291334e-07
of O 0 5.806251479612001e-09
genomic O 0 1.7727683143675677e-07
DNA O 0 6.548199280587141e-07
were O 0 9.124401856297482e-08
designed O 0 1.1537827049323823e-06
to O 0 5.2688470475459326e-08
allow O 0 1.040220425352345e-07
rapid O 0 8.102031188172987e-07
screening O 0 1.1311785783618689e-06
for O 0 6.081594250417766e-08
common O 0 1.746169857597124e-07
ethnic O 0 1.6747775362091488e-06
mutations O 0 6.548225064761937e-05
. O 0 1.925332526298007e-06

These O 0 1.4828868870608858e-06
rapid O 0 4.469703981158091e-06
assays O 0 1.490541035309434e-05
detected O 0 5.433725618786411e-06
mutations O 0 1.6690486290826811e-06
in O 0 6.384260586855817e-08
76 O 0 7.4778595262614544e-06
% O 0 3.884500188178208e-08
of O 0 5.906997113669377e-09
Costa O 0 3.5049470170633867e-06
Rican O 0 0.00871929433196783
patients O 0 0.12369375675916672
( O 0 1.5547970022566915e-08
3 O 0 2.0620040785956917e-08
) O 0 4.0093195430301876e-09
, O 0 6.874909974641241e-09
50 O 0 1.053082154811591e-08
% O 0 3.711778884252226e-09
of O 0 3.5228451267244054e-09
Norwegian O 1 0.9751672148704529
patients O 0 0.0496724396944046
( O 0 9.126313038620992e-09
1 O 0 3.175599161409082e-08
) O 0 5.585787832274036e-09
, O 0 1.581460828958825e-08
25 O 0 3.5106925366790165e-08
% O 0 6.017668141566901e-09
of O 0 9.558822178235005e-09
Polish O 1 0.9966802597045898
patients O 1 0.6062682867050171
( O 0 3.07269907295904e-08
4 O 0 5.11391533564165e-08
) O 0 3.9144048002981435e-09
, O 0 5.552931892083279e-09
and O 0 1.5303182721027042e-08
14 O 0 6.732802404485483e-08
% O 0 5.6751692234513484e-09
of O 0 3.2059108701076866e-09
Italian O 0 0.1525522619485855
patients O 1 0.5179942846298218
( O 0 1.9092693648303793e-08
1 O 0 3.67495189834699e-08
) O 0 8.15804046538915e-09
, O 0 9.072786966157764e-09
as O 0 1.6642337286043585e-08
well O 0 1.5226611083107855e-08
as O 0 4.8467750701775e-08
in O 0 1.2070542254605243e-07
patients O 0 2.8068300252925837e-06
of O 0 1.4402193215801162e-08
Amish O 0 2.7549374863156117e-05
/ O 0 2.0992206373193767e-06
Mennonite O 0 4.225999873597175e-06
and O 0 5.458550162984466e-07
Irish O 0 2.4194207526306855e-06
English O 0 4.580099073336896e-07
backgrounds O 0 6.950016882001364e-07
. O 0 9.288987712352537e-07

Additional O 0 3.687048956635408e-05
mutations O 0 8.940311090555042e-05
were O 0 7.681113061153155e-07
observed O 0 3.3800407095441187e-07
in O 0 2.680623367723456e-08
Japanese O 0 1.849441133572327e-07
, O 0 2.3820595274059997e-08
Utah O 0 1.7971680676964752e-07
Mormon O 0 8.939561269016849e-08
, O 0 8.773374915449494e-09
and O 0 1.7632174831305747e-08
African O 0 3.7177038336722035e-08
American O 0 1.4980873856984545e-06
patients O 0 6.725457205902785e-05
. O 0 2.2885128601046745e-06

These O 0 1.6374455071854754e-06
assays O 0 6.948307145648869e-06
should O 0 1.3626537054278742e-07
facilitate O 0 4.6250015373061615e-08
screening O 0 7.72124280956632e-07
for O 0 3.564020403246104e-07
A B-Disease 1 0.9999493360519409
- I-Disease 1 0.9999556541442871
T I-Disease 1 0.9999979734420776
heterozygotes O 0 0.0004644334549084306
in O 0 7.079521679997924e-08
the O 0 3.6964706850994844e-08
populations O 0 2.075180702831858e-07
studied O 0 4.5499723455577623e-07
. O 0 1.1726023529945451e-07
. O 0 7.420760539389448e-07

The O 0 1.225545202032663e-05
von B-Disease 1 0.9186801314353943
Hippel I-Disease 1 0.9950844645500183
- I-Disease 1 0.9672101736068726
Lindau I-Disease 1 0.9974591135978699
tumor I-Disease 0 0.007255585864186287
suppressor O 0 6.619484338443726e-05
gene O 0 1.4197682958183577e-06
is O 0 4.208735049360257e-08
required O 0 2.4407075471799544e-08
for O 0 7.740306173786848e-09
cell O 0 8.685747161507607e-07
cycle O 0 2.0951914336819755e-07
exit O 0 8.058077582973056e-07
upon O 0 2.430186611945828e-07
serum O 0 4.448119398148265e-06
withdrawal O 0 5.183238044992322e-06
. O 0 8.500659873789118e-07

The O 0 2.1688460947189014e-06
inactivation O 0 3.333836866659112e-05
of O 0 7.751316388748819e-08
the O 0 3.640485033429286e-07
von B-Disease 1 0.9966297745704651
Hippel I-Disease 1 0.9997581839561462
- I-Disease 1 0.9992400407791138
Lindau I-Disease 1 0.9992361068725586
( I-Disease 0 1.8031612398772268e-06
VHL I-Disease 0 0.00036070862552151084
) I-Disease 0 4.5714151042375306e-07
tumor I-Disease 0 6.194407615112141e-05
suppressor O 0 0.00017442056559957564
gene O 0 5.61728302272968e-06
predisposes O 0 0.00044839747715741396
affected O 0 7.747206041130994e-07
individuals O 0 1.5972757339000054e-08
to O 0 4.832882183336551e-08
the O 0 8.397266242354817e-07
human O 0 0.012427189387381077
VHL B-Disease 1 0.9999995231628418
cancer I-Disease 1 0.9999998807907104
syndrome I-Disease 1 0.9999990463256836
and O 0 1.5851865100557916e-06
is O 0 4.997696123609785e-07
associated O 0 1.6923618773034832e-07
with O 0 6.44822819140245e-07
sporadic B-Disease 1 0.9982227683067322
renal I-Disease 1 0.9999997615814209
cell I-Disease 1 0.9999970197677612
carcinomas I-Disease 1 1.0
( O 0 3.906245910911821e-05
RCC B-Disease 1 0.6391933560371399
) O 0 3.3893596196321596e-07
and O 0 2.3606310151080834e-06
brain B-Disease 0 0.0016558856004849076
hemangioblastomas I-Disease 0 0.00027868329198099673
. O 0 1.755467906150443e-06

VHL O 0 0.13322214782238007
- O 0 0.01284345518797636
negative O 0 0.0001580440584803
786 O 0 0.0002860088716261089
- O 0 0.028000082820653915
0 O 0 0.00014756016025785357
RCC B-Disease 0 0.02849518321454525
cells O 0 2.6393092866783263e-06
are O 0 3.8568593652144045e-08
tumorigenic O 0 2.204563315899577e-05
in O 0 7.929048706500907e-07
nude O 1 0.7387514114379883
mice O 0 0.06235598400235176
which O 0 2.78677021015028e-07
is O 0 6.917200323641737e-08
suppressed O 0 2.50173030735823e-07
by O 0 7.541715696390838e-09
the O 0 9.49420897455866e-09
reintroduction O 0 1.1422129091442912e-06
of O 0 9.132410383472234e-08
VHL B-Disease 0 0.0008236932917498052
. O 0 4.924837867292808e-06

Remarkably O 0 0.02133764699101448
, O 0 1.1243350854783785e-06
this O 0 1.6925621082464204e-07
occurs O 0 5.439811445739906e-08
without O 0 2.3269855375929183e-08
affecting O 0 2.1457690735360302e-08
the O 0 1.0157725327530898e-08
growth O 0 8.771103665594637e-08
rate O 0 5.651860490729632e-08
and O 0 1.2488427181267525e-08
cell O 0 9.797644224818214e-07
cycle O 0 1.7717863443067472e-07
profile O 0 2.2580481129352847e-07
of O 0 3.607136811467626e-09
these O 0 1.0567018371432368e-08
cells O 0 6.842090982672744e-08
in O 0 3.841735107812383e-08
culture O 0 2.6851529355553794e-07
. O 0 1.2060789913448389e-06

The O 0 7.42023303246242e-06
786 O 0 0.00010576811473583803
- O 0 0.00016917103494051844
0 O 0 3.1541719636152266e-06
cell O 0 5.3152039072301704e-06
line O 0 6.943451467122941e-07
, O 0 9.794336008894788e-09
like O 0 6.895465531897571e-08
many O 0 5.419408921625291e-07
cancer B-Disease 0 0.00038031177246011794
cells O 0 2.1297675800724392e-07
, O 0 2.3646945734867586e-08
fails O 0 8.909838129511627e-07
to O 0 2.1201755018296353e-08
exit O 0 3.7934452734589286e-07
the O 0 2.4744190696424084e-08
cell O 0 1.010478968055395e-06
cycle O 0 2.621345913667028e-07
upon O 0 1.8075742502787762e-07
serum O 0 7.33770320948679e-06
withdrawal O 0 7.781097338011023e-06
. O 0 1.7671992509349366e-06

Here O 0 9.993600542657077e-06
, O 0 2.2305346192297293e-07
it O 0 2.69200839397854e-08
is O 0 2.1859507981503157e-08
shown O 0 1.0392763982736142e-07
that O 0 6.3438854169817205e-09
reintroduction O 0 1.1533576582678506e-07
of O 0 4.308745360503963e-09
the O 0 7.043503558179509e-09
wild O 0 8.482715685431685e-08
- O 0 0.00012663206143770367
type O 0 6.742216646671295e-05
VHL B-Disease 0 8.531923231203109e-05
gene O 0 4.638181962945964e-07
restores O 0 1.3795608992950292e-06
the O 0 1.419362671839508e-08
ability O 0 8.27602590902643e-08
of O 0 2.0092189245701775e-08
VHL O 0 0.006412804592400789
- O 1 0.7749592661857605
negative O 0 0.10922694951295853
RCC B-Disease 1 0.999346911907196
cancer I-Disease 0 0.0458587221801281
cells O 0 1.3983192559408053e-07
to O 0 1.4759375055461987e-08
exit O 0 1.2942356875100813e-07
the O 0 7.785807554228086e-09
cell O 0 4.78634035516734e-07
cycle O 0 7.108124577825947e-08
and O 0 1.9522810035255134e-08
enter O 0 9.358702612871639e-08
G0 O 0 1.679085471550934e-05
/ O 0 1.6548981420783093e-06
quiescence O 0 1.0789689440571237e-05
in O 0 3.522135614275612e-07
low O 0 8.683761734573636e-06
serum O 0 6.823027069913223e-05
. O 0 1.4162617389956722e-06

Both O 0 3.553706483216956e-05
VHL O 0 0.0028015344869345427
- O 0 0.00023622115259058774
positive O 0 1.6963366533673252e-06
and O 0 1.8985771532697981e-07
VHL O 0 0.000262774177826941
- O 0 0.008956855162978172
negative O 0 0.00010851648403331637
RCC B-Disease 0 0.0037575052119791508
cells O 0 1.1658846688078484e-06
exit O 0 3.8324481010931777e-07
the O 0 1.6570689709283215e-08
cell O 0 1.8195787561126053e-06
cycle O 0 2.6640714168024715e-07
by O 0 4.0405200962823073e-08
contact O 0 2.243713197458419e-07
inhibition O 0 4.101522790733725e-06
. O 0 1.4159470538288588e-06

The O 0 3.6187891510053305e-06
cyclin O 0 0.0001391448313370347
- O 0 1.706293005554471e-05
dependent O 0 3.8527018659806345e-06
kinase O 0 8.288856406579725e-06
inhibitor O 0 2.7343783131072996e-06
, O 0 6.775844241246887e-08
p27 O 0 4.432180503499694e-06
, O 0 4.9891671238810886e-08
accumulates O 0 9.213115959028073e-07
upon O 0 5.393856028490518e-08
serum O 0 9.023335678648436e-07
withdrawal O 0 4.4928142983735597e-07
, O 0 1.20397274372408e-08
only O 0 5.078763631871652e-09
in O 0 2.0432615599474957e-09
the O 0 3.3982550107225507e-09
presence O 0 1.7353285031163068e-08
of O 0 6.374803351860692e-09
VHL B-Disease 0 7.592032488901168e-05
, O 0 3.418409377786702e-08
as O 0 1.0261890004414909e-08
a O 0 7.969929072260129e-08
result O 0 1.2598215803905077e-08
of O 0 4.727032099083317e-10
the O 0 1.9475121515455385e-09
stabilization O 0 3.1984736637014066e-08
of O 0 2.308928603866889e-09
the O 0 3.46854776012151e-08
protein O 0 1.5018611065897858e-06
. O 0 6.359176154546731e-07

We O 0 1.1109311799373245e-06
propose O 0 1.731359930090548e-06
that O 0 7.733668638820745e-08
the O 0 1.4266094083836833e-08
loss O 0 1.8271222756993666e-07
of O 0 4.673630371598847e-09
wild O 0 4.098939712093852e-07
- O 0 0.018474295735359192
type O 0 0.0012264467077329755
VHL B-Disease 0 0.0006108870729804039
gene O 0 1.6152555417647818e-06
results O 0 9.173996318168065e-08
in O 0 6.641187155764783e-09
a O 0 1.8315344618713425e-07
specific O 0 4.2398600186288604e-08
cellular O 0 8.163199709088076e-06
defect O 0 2.669209243322257e-05
in O 0 9.202264550367545e-08
serum O 0 8.502844139002264e-06
- O 0 1.0677296813810244e-05
dependent O 0 5.931498208155972e-07
growth O 0 6.642405026013876e-08
control O 0 5.50899585505249e-07
, O 0 4.4873502247355646e-08
which O 0 8.175349108796581e-08
may O 0 8.50070819069515e-07
initiate O 0 3.5831706099997973e-06
tumor B-Disease 0 0.0015606929082423449
formation O 0 7.507346708734985e-07
. O 0 6.389273607965151e-07

This O 0 6.203706561791478e-06
is O 0 1.323172909906134e-06
corrected O 0 4.9635768846201245e-06
by O 0 1.8013372127256844e-08
the O 0 1.4172364615205879e-08
reintroduction O 0 6.677611281702411e-07
of O 0 1.8275661872735327e-08
wild O 0 3.4852337194024585e-07
- O 0 0.0033218562602996826
type O 0 0.0027733449824154377
VHL B-Disease 0 0.01446437370032072
, O 0 9.959852604879416e-07
implicating O 0 3.946742072002962e-05
VHL B-Disease 0 4.6521574404323474e-05
as O 0 1.1837032332095987e-07
the O 0 1.3511788132802849e-08
first O 0 1.353250382862825e-07
tumor B-Disease 0 6.7902383307227865e-06
suppressor O 0 4.970886038790923e-06
involved O 0 2.5129011760327558e-08
in O 0 4.176896162277899e-09
the O 0 3.8118219691796185e-09
regulation O 0 1.856778020226102e-08
of O 0 3.104964951816669e-09
cell O 0 1.936539774760604e-06
cycle O 0 2.8758159942299244e-07
exit O 0 1.3545264891945408e-06
, O 0 1.669995519648637e-08
which O 0 2.076139971052271e-08
is O 0 1.8480829311329217e-08
consistent O 0 1.0876265577053346e-07
with O 0 1.013396211391182e-08
its O 0 4.613442072809448e-08
gatekeeper O 0 1.4285992619988974e-05
function O 0 6.673161578873987e-08
in O 0 2.1099005209634925e-08
the O 0 1.4290827721197275e-07
kidney O 0 0.0011492136400192976
. O 0 2.1867373334316653e-07
. O 0 5.726942049477657e-07

Piebaldism B-Disease 1 0.9999595880508423
with O 1 0.7981983423233032
deafness B-Disease 1 0.9999998807907104
: O 0 5.241711278358707e-06
molecular O 0 5.450718163046986e-06
evidence O 0 3.450363124102296e-07
for O 0 6.433572252717568e-08
an O 0 1.0666622074495535e-05
expanded O 1 0.6305558085441589
syndrome O 1 0.9999605417251587
. O 0 3.2356599604099756e-06

In O 0 3.4470194805180654e-06
a O 0 9.116927799368568e-07
South O 0 1.8476605134765123e-07
African O 0 7.616194608317528e-08
girl O 0 1.7560707874508807e-06
of O 0 3.096816314496209e-08
Xhosa O 0 5.6625336583238095e-05
stock O 0 7.207800649666751e-07
with O 0 2.2293755819191574e-07
severe O 0 0.12238291651010513
piebaldism B-Disease 1 0.5634984970092773
and O 0 7.909812120487913e-05
profound O 1 0.9827196598052979
congenital O 1 0.9999998807907104
sensorineural B-Disease 1 0.9999998807907104
deafness I-Disease 1 1.0
we O 0 0.00025167607236653566
identified O 0 3.3433725548093207e-06
a O 0 1.716912407800919e-07
novel O 0 4.2302031033614185e-07
missense O 0 8.537064104530145e-07
substitution O 0 4.552081733777413e-08
at O 0 1.232124535732737e-08
a O 0 7.524980105699797e-08
highly O 0 1.4021196648172918e-07
conserved O 0 7.804842283576363e-08
residue O 0 1.678103274116438e-07
in O 0 4.747229276347298e-09
the O 0 4.182907797911639e-09
intracellular O 0 1.3928013231634395e-07
kinase O 0 2.2173149716309126e-07
domain O 0 1.0598042443632494e-08
of O 0 1.0730962785032716e-09
the O 0 1.4083977539769421e-08
KIT O 0 6.779319664929062e-05
proto O 0 0.03197154402732849
- O 0 0.0004461526405066252
oncogene O 0 0.00017698510782793164
, O 0 7.296020498870348e-07
R796G O 0 2.0059384041815065e-05
. O 0 2.411149125691736e-06

Though O 0 0.0002141867153113708
auditory B-Disease 0 0.0006610403070226312
anomalies I-Disease 0 0.033222854137420654
have O 0 8.497806334162306e-07
been O 0 7.15651253813121e-07
observed O 0 5.009382562093379e-07
in O 0 2.165504895401682e-07
mice O 0 0.0026869054418057203
with O 0 2.2716491798746574e-07
dominant O 0 3.2176954846363515e-05
white O 0 1.9622579202405177e-05
spotting O 0 0.00012998755846638232
( O 0 7.86233442795492e-07
W O 0 0.1411340981721878
) O 0 7.27180591297838e-08
due O 0 3.2582752851340047e-07
to O 0 2.625391744004446e-06
KIT O 1 0.9897162318229675
mutations O 0 0.13839943706989288
, O 0 0.00022341976000461727
deafness B-Disease 1 0.9999998807907104
is O 0 5.849728495377349e-06
not O 0 3.51368100837135e-07
typical O 0 9.54190113588993e-07
in O 0 2.472367270911491e-07
human O 0 7.871788056945661e-07
piebaldism B-Disease 0 0.0004586245340760797
. O 0 2.667287162694265e-06

Thus O 0 7.106435077730566e-06
, O 0 5.096271848969991e-08
the O 0 2.3366188983686698e-08
occurrence O 0 5.920744001741696e-07
of O 0 5.629551651509246e-07
sensorineural B-Disease 1 0.9999971389770508
deafness I-Disease 1 1.0
in O 0 0.0002294496080139652
this O 0 4.1170965232595336e-06
patient O 0 0.0035042259842157364
extends O 0 6.1368668866634835e-06
considerably O 0 3.3021813123923494e-06
the O 0 3.125036229789657e-08
phenotypic O 0 5.649280410580104e-06
range O 0 3.764979439324634e-08
of O 0 3.787875790806083e-09
piebaldism B-Disease 0 3.668877252493985e-05
due O 0 2.605551685519458e-07
to O 0 1.1490561746541061e-07
KIT O 0 0.00041804718784987926
gene O 0 1.8051467804980348e-06
mutation O 0 6.201667588356941e-07
in O 0 2.787210462429357e-08
humans O 0 3.3589667935984835e-08
and O 0 5.007930070632938e-08
tightens O 0 0.36610740423202515
the O 0 7.885733452894783e-07
clinical O 0 9.740768291521817e-06
similarity O 0 1.0513762163100182e-06
between O 0 4.795784391831148e-08
piebaldism B-Disease 0 1.7739124814397655e-05
and O 0 1.2292630913179892e-08
the O 0 2.1528641092061207e-09
various O 0 9.757844310342989e-09
forms O 0 2.95054348953272e-07
of O 0 1.4520223885483574e-05
Waardenburg B-Disease 1 0.9999995231628418
syndrome I-Disease 1 0.999996542930603
. O 0 1.3266879932416487e-06
. O 0 9.914780321196304e-07

Cycloheximide O 0 0.00026354670990258455
facilitates O 0 6.242526069399901e-06
the O 0 1.672099898542001e-07
identification O 0 3.0878871370987326e-07
of O 0 3.8866346585564315e-08
aberrant O 0 1.120551041822182e-05
transcripts O 0 1.3049547305854503e-05
resulting O 0 1.4143842008706997e-06
from O 0 2.3276514937720094e-08
a O 0 3.6978710227231204e-07
novel O 0 8.360070751223247e-07
splice O 0 6.745541668351507e-06
- O 0 7.599883974762633e-05
site O 0 2.7121884613734437e-06
mutation O 0 6.780899184377631e-07
in O 0 1.6849242001626408e-08
COL17A1 O 0 3.6301411455497146e-05
in O 0 8.59047020185244e-08
a O 0 5.9121161939401645e-06
patient O 0 0.0007857927703298628
with O 0 6.816222594352439e-06
generalized O 0 0.43907874822616577
atrophic B-Disease 1 0.999860405921936
benign I-Disease 1 0.9974871873855591
epidermolysis I-Disease 1 0.9977222084999084
bullosa I-Disease 1 0.9908056855201721
. O 0 0.0001444038061890751

Patients O 1 0.9947447776794434
with O 0 5.690330362995155e-05
generalized O 0 0.15999573469161987
atrophic B-Disease 1 0.9997984766960144
benign I-Disease 1 0.998685896396637
epidermolysis I-Disease 1 0.9987682700157166
bullosa I-Disease 1 0.9944708347320557
often O 0 6.39390418655239e-05
show O 0 7.487935363315046e-06
decreased O 0 2.0543313894449966e-06
expression O 0 1.3129218245921948e-07
of O 0 3.343510712738862e-08
type O 0 9.704560943646356e-05
XVII O 1 0.7852137684822083
collagen O 0 0.004519646521657705
, O 0 1.0982538611870041e-07
a O 0 3.968186206293467e-07
transmembrane O 0 2.241907532152254e-05
hemidesmosomal O 0 1.0171045687457081e-05
protein O 0 1.5817524001704442e-07
encoded O 0 1.1152169321348993e-07
by O 0 9.505700404588424e-08
COL17A1 O 0 0.00013890342961531132
. O 0 2.152661636500852e-06

This O 0 5.05904699821258e-06
report O 0 1.0656083304638742e-06
documents O 0 2.030148351650496e-07
a O 0 2.881787111164158e-07
novel O 0 1.2197129990454414e-06
splice O 0 9.919653166434728e-06
- O 0 8.801130024949089e-05
site O 0 2.7313265036355006e-06
mutation O 0 9.165773917629849e-07
in O 0 2.8031941212702804e-08
COL17A1 O 0 4.630235707736574e-05
in O 0 4.2702129832150604e-08
a O 0 4.5339343159866985e-06
patient O 0 0.0006472819368354976
with O 0 3.354317414050456e-06
generalized O 0 0.09137873351573944
atrophic B-Disease 1 0.9999417066574097
benign I-Disease 1 0.9977051615715027
epidermolysis I-Disease 1 0.9982413053512573
bullosa I-Disease 1 0.9939219951629639
, O 0 1.1059606777052977e-06
and O 0 1.2298757212647615e-07
applies O 0 2.1180258613640035e-07
a O 0 1.448298121431435e-07
new O 0 6.991572831793746e-08
methodology O 0 1.3531678177969297e-07
to O 0 3.5378224794158086e-08
define O 0 2.0946202994309715e-07
and O 0 6.322326129293288e-08
characterize O 0 8.373650643989095e-07
the O 0 4.119583962847173e-08
resulting O 0 4.331866136908502e-07
mRNA O 0 1.0372717724749236e-06
splice O 0 1.3967833183414768e-05
variants O 0 9.866647815215401e-06
. O 0 2.2006674953445327e-06

Mutational O 0 0.0706799253821373
analysis O 0 2.4015860617510043e-05
of O 0 1.4764240177100874e-06
COL17A1 O 0 0.00252881390042603
identified O 0 1.0121366358362138e-05
a O 0 1.148538444795122e-06
maternally O 0 0.0003450006479397416
inherited O 0 0.00015088114014361054
G O 0 0.0004549261066131294
- O 0 2.375908115936909e-05
to O 0 3.8466811247417354e-07
- O 0 0.00036452856147661805
T O 0 9.402244177181274e-05
transversion O 0 2.1167063550819876e-06
at O 0 4.6896051486555734e-09
the O 0 3.486999800017543e-09
- O 0 1.1139269417981268e-06
1 O 0 3.988285612877007e-08
position O 0 6.245487327305455e-08
of O 0 1.1402899069423711e-08
exon O 0 7.204872417787556e-06
32 O 0 2.4172386474674568e-06
. O 0 7.901542176114162e-07

This O 0 6.787705046917836e-07
acceptor O 0 8.752609801376821e-07
splice O 0 6.906343514856417e-06
- O 0 3.798867328441702e-05
site O 0 1.147659190792183e-06
mutation O 0 5.398342182161286e-07
led O 0 6.825484888395295e-08
to O 0 3.630648492958244e-08
the O 0 1.0103911485259687e-08
formation O 0 2.4617651916969407e-08
of O 0 2.5672077796912163e-09
aberrant O 0 1.1267986792518059e-06
transcripts O 0 9.061754440153891e-07
present O 0 6.469701219202761e-08
at O 0 2.2466331017767516e-08
extremely O 0 1.6561264146730537e-06
low O 0 1.0680882041924633e-05
levels O 0 5.185356144465914e-07
. O 0 5.271038503451564e-07

Based O 0 6.863631369924406e-06
on O 0 2.645505787768343e-07
our O 0 2.924556063987893e-08
recent O 0 5.602051089681481e-08
finding O 0 7.889932618354578e-08
that O 0 1.1557756351976423e-07
cycloheximide O 0 4.030742638860829e-05
stabilized O 0 5.555330790230073e-05
mutant O 0 3.2495818231836893e-06
COL17A1 O 0 7.176646249718033e-06
transcripts O 0 3.8654985701214173e-07
in O 0 1.8281170355294307e-08
keratinocytes O 0 1.0863057468668558e-05
homozygous O 0 3.2776902116893325e-06
for O 0 1.7790373618709054e-08
a O 0 3.474067625575117e-06
frameshift O 1 0.9493808746337891
mutation O 0 1.646585951675661e-05
, O 0 1.8598335316255543e-08
the O 0 2.6268291986042414e-09
effects O 0 6.575069022574098e-08
of O 0 1.3850287583494492e-09
the O 0 7.414108882386472e-09
splice O 0 5.024126949138008e-06
- O 0 3.845771789201535e-05
site O 0 8.801182502793381e-07
mutation O 0 1.3641633245242701e-07
on O 0 1.5308293299653997e-08
splicing O 0 2.214871841488275e-07
of O 0 1.2409784311273597e-08
COL17A1 O 0 3.991024277638644e-05
transcripts O 0 6.980772013776004e-07
were O 0 3.733407893946605e-08
determined O 0 3.6635167788290346e-08
using O 0 1.4001348525027879e-08
reverse O 0 7.029829589555447e-07
transcriptase O 0 1.666397452027013e-06
polymerase O 0 7.094376428540272e-07
chain O 0 4.479756228192855e-07
reaction O 0 5.5723404557284084e-08
of O 0 2.326642656313993e-09
total O 0 9.44992883944451e-09
RNA O 0 9.299308345589452e-08
from O 0 2.4846436019743123e-08
keratinocytes O 0 6.9919583438604604e-06
incubated O 0 9.109174243349116e-06
for O 0 1.4966495598400797e-07
2 O 0 1.0413295967737213e-06
. O 0 8.829463808979199e-07

5 O 0 1.839121978264302e-05
h O 0 1.5765097487019375e-05
in O 0 6.814064335003422e-08
the O 0 1.2930867043792205e-08
presence O 0 4.414133059071901e-08
or O 0 1.2801174342769173e-08
absence O 0 3.749192600821516e-08
of O 0 1.0084369783669445e-08
10 O 0 7.074298480347352e-08
microg O 0 6.2380449890042655e-06
cycloheximide O 0 1.930517828441225e-05
per O 0 5.016582349526288e-07
ml O 0 1.5420202544191852e-05
. O 0 1.3815937336403294e-06

Using O 0 2.2583506051887525e-06
this O 0 1.3976753621136595e-07
approach O 0 6.714547566843976e-07
, O 0 1.4745369014690368e-07
an O 0 2.398701610673015e-07
abnormally O 0 6.890977965667844e-05
spliced O 0 0.01777615211904049
transcript O 0 0.00035236417897976935
was O 0 3.924970314983511e-06
identified O 0 4.624075344850098e-08
that O 0 1.5856643775791213e-09
contains O 0 2.938286947085089e-09
an O 0 4.766954830870418e-09
extra O 0 4.477825754634068e-08
264 O 0 3.469709781711572e-07
bases O 0 5.343812503610934e-08
upstream O 0 9.608142903516637e-08
from O 0 8.629749359556627e-09
exon O 0 8.722619782020047e-07
32 O 0 2.444013205149531e-07
, O 0 2.0205096262770894e-08
resulting O 0 1.1607408367808603e-07
in O 0 2.5052584007312362e-08
a O 0 1.2695119266936672e-06
premature O 0 0.00016171099559869617
termination O 0 3.986840965808369e-06
codon O 0 1.3519235153580667e-06
27 O 0 9.385800581185322e-07
bp O 0 4.166025064478163e-06
downstream O 0 2.373522534071526e-07
from O 0 6.087475856730862e-09
the O 0 2.3573587526470874e-08
cryptic O 0 1.0198074051004369e-05
splice O 0 3.431901859585196e-05
site O 0 1.2169570254627615e-05
. O 0 1.3321676988198305e-06

Three O 0 1.6791786947578657e-06
other O 0 8.540820317648468e-08
splice O 0 8.037056431930978e-06
variants O 0 5.509576112672221e-06
, O 0 1.0102874625772529e-07
including O 0 1.6093920862658706e-08
one O 0 2.2232050866932695e-08
derived O 0 9.74824576616129e-09
from O 0 1.0223066837511396e-09
the O 0 2.411925992262809e-09
skipping O 0 4.4693273082430096e-08
of O 0 2.617446925867739e-09
exon O 0 7.367015655290743e-07
32 O 0 1.8276364244229626e-07
, O 0 1.2172659324960478e-08
were O 0 3.495851785828563e-08
also O 0 5.082972620584769e-07
identified O 0 1.8483439134797663e-06
. O 0 3.4021289252450515e-07

These O 0 3.208447651559254e-06
results O 0 1.3300286809680983e-06
indicate O 0 1.8866877837808715e-07
the O 0 1.8847092775331475e-08
usefulness O 0 1.7755432679678051e-07
of O 0 1.6075819786465217e-08
cycloheximide O 0 0.023869730532169342
treatment O 0 0.000363271712558344
in O 0 2.7686077430644218e-08
evaluating O 0 5.491633814358465e-08
the O 0 1.2276229810481709e-08
abnormal O 0 1.739932855571169e-07
processing O 0 9.469341755163896e-09
of O 0 1.5021504040646505e-09
mRNA O 0 2.626249617776466e-08
due O 0 2.657561815055942e-08
to O 0 1.487956069468055e-08
splice O 0 4.414581326273037e-06
- O 0 0.00046968829701654613
site O 0 7.496295438613743e-06
mutations O 0 1.5932115502437227e-06
, O 0 4.739351311400242e-08
because O 0 6.624932780141535e-08
( O 0 7.861628681382626e-09
i O 0 6.87289372081068e-08
) O 0 5.758572729774869e-09
aberrant O 0 2.0425929392331454e-07
splicing O 0 7.602970981679391e-07
often O 0 1.1234450170150012e-07
generates O 0 2.814987851706974e-07
a O 0 2.9756137109870906e-07
premature O 0 2.756953654170502e-05
termination O 0 1.7344437992505846e-06
codon O 0 3.7940134234304423e-07
, O 0 8.340729351630216e-08
( O 0 1.0550624374161544e-08
ii O 0 4.163006451562978e-06
) O 0 1.9737647960482718e-08
transcripts O 0 4.849017045671644e-07
with O 0 2.399667096142366e-07
premature O 0 0.00014075470971874893
termination O 0 3.408329121157294e-06
codons O 0 3.9466590351366904e-07
can O 0 4.4113559027891824e-08
occur O 0 1.0483765855440197e-08
at O 0 1.1482977235743874e-08
low O 0 7.563254484921345e-07
or O 0 1.668991558290145e-07
undetectable O 0 4.6464083425235e-06
levels O 0 4.435731071339433e-08
due O 0 3.436950279933626e-08
to O 0 3.897636347005573e-08
nonsense O 0 2.5825522698141867e-06
- O 0 2.3166069240687648e-06
mediated O 0 1.8547696072346298e-06
mRNA O 0 1.2294090367959143e-07
decay O 0 1.9010610685654683e-07
, O 0 1.8433970794262677e-08
and O 0 3.2177972286717704e-08
( O 0 9.391082578247278e-09
iii O 0 4.8798297029861715e-06
) O 0 2.4754560623563293e-09
the O 0 2.5396034164515413e-09
levels O 0 2.1887613943505357e-09
of O 0 3.090528943872073e-10
these O 0 1.570386487514952e-09
transcripts O 0 7.302982396595326e-08
can O 0 1.1456965154366117e-08
be O 0 1.1291114709877093e-08
increased O 0 8.479221946799953e-08
by O 0 6.822855880272982e-08
cycloheximide O 0 0.00017703793128021061
. O 0 1.197239953398821e-06

A O 0 8.681067993165925e-05
deletion O 0 0.0008271106635220349
mutation O 0 6.494512490462512e-05
in O 0 2.1858615184555674e-07
COL17A1 O 0 0.0002142100129276514
in O 0 1.9839183096337365e-07
five O 0 2.7230714749748586e-07
Austrian O 0 0.024434195831418037
families O 0 1.5060132909638924e-06
with O 0 1.7502607079222798e-06
generalized O 0 0.2676997780799866
atrophic B-Disease 1 0.9999566078186035
benign I-Disease 1 0.9995718598365784
epidermolysis I-Disease 1 0.9993882179260254
bullosa I-Disease 1 0.9940898418426514
represents O 0 7.719380846538115e-06
propagation O 0 5.895883532502921e-07
of O 0 2.099523399579084e-08
an O 0 3.660534559912776e-07
ancestral O 0 2.2788106434745714e-05
allele O 0 0.00010745136387413368
. O 0 1.9635911030491116e-06

Patients O 1 0.97254478931427
with O 0 1.591992622707039e-05
generalized O 0 0.13468840718269348
atrophic B-Disease 1 0.9998798370361328
benign I-Disease 1 0.9994829893112183
epidermolysis I-Disease 1 0.9993237257003784
bullosa I-Disease 1 0.9975774884223938
, O 0 4.216217803332256e-06
a O 0 4.7447784368159773e-07
usually O 0 1.8420567471366667e-07
nonlethal O 0 2.304001782249543e-06
form O 0 3.6745635156876233e-07
of O 0 2.7553437575988937e-07
junctional B-Disease 1 0.9769510626792908
epidermolysis I-Disease 1 0.9987232089042664
bullosa I-Disease 1 0.9880642294883728
, O 0 1.3750792504652054e-06
have O 0 1.4735823583578167e-07
generalized O 0 6.571291123691481e-06
blistering B-Disease 0 0.33783361315727234
, O 0 1.6225045328610577e-05
nail B-Disease 1 0.9999494552612305
dystrophy I-Disease 1 0.9999880790710449
, O 0 0.0002541300200391561
patchy B-Disease 1 0.9980364441871643
alopecia I-Disease 1 0.9999951124191284
, O 0 6.1709638430329505e-06
and O 0 2.829019103955943e-05
dental B-Disease 1 0.9948069453239441
abnormalities I-Disease 1 0.9994788765907288
. O 0 7.358557922998443e-06

Skin B-Disease 1 0.9995974898338318
fragility I-Disease 0 0.16211481392383575
in O 0 2.2032063498045318e-06
most O 0 6.557266374329629e-07
cases O 0 1.1041596508221119e-06
is O 0 6.406461352526094e-07
due O 0 1.3181802387407515e-06
to O 0 6.78453432101378e-07
mutations O 0 1.8526762914916617e-06
in O 0 7.987243755280815e-09
the O 0 1.0143940798457152e-08
gene O 0 3.645213269010128e-07
encoding O 0 8.142511660480523e-07
type O 0 2.3769754989189096e-05
XVII O 0 0.015593722462654114
collagen O 0 0.0022261454723775387
( O 0 4.2115857468161266e-07
COL17A1 O 0 6.035616752342321e-05
) O 0 3.567808732896083e-07
. O 0 9.036675123752502e-07

Recently O 0 0.00011263776832493022
, O 0 2.095649023203805e-07
we O 0 3.417574845343552e-08
reported O 0 1.4429116390601848e-07
five O 0 2.7937732127725212e-08
Austrian O 0 0.0014564034063369036
families O 0 2.6125135832444357e-07
with O 0 6.696622563140409e-07
generalized O 0 0.07484912127256393
atrophic B-Disease 1 0.9999467134475708
benign I-Disease 1 0.9982972741127014
epidermolysis I-Disease 1 0.998030960559845
bullosa I-Disease 1 0.9915603995323181
who O 0 3.274979826528579e-05
share O 0 3.012736726759613e-07
the O 0 4.0798916245421424e-08
same O 0 7.332809559557063e-07
COL17A1 O 0 0.06025037541985512
mutation O 0 8.213756518671289e-05
. O 0 1.354336518488708e-06

Affected O 0 0.00015724032709840685
individuals O 0 8.377349445254367e-07
in O 0 5.0159986386688615e-08
three O 0 9.537664169556592e-08
families O 0 6.941240826563444e-08
are O 0 1.2556162332089116e-08
homozygous O 0 2.001433131226804e-06
for O 0 4.1064826206138605e-08
4003delTC O 0 2.3790003979229368e-05
, O 0 6.970216048785005e-08
whereas O 0 3.074182330919939e-08
those O 0 2.918970620768846e-09
in O 0 3.899560674369695e-09
two O 0 3.596874620370727e-08
others O 0 1.6304818473145133e-07
are O 0 4.04806428377924e-08
compound O 0 9.270657756133005e-06
heterozygotes O 0 0.0001230840862262994
. O 0 2.9515326787077356e-06

To O 0 6.799692528147716e-06
determine O 0 1.0666351499821758e-06
if O 0 7.436786830794517e-08
the O 0 1.2578191821432938e-08
occurrence O 0 1.082721112766194e-07
of O 0 9.662132427479264e-09
4003delTC O 0 6.018020030751359e-06
in O 0 3.417705229935564e-08
these O 0 9.279513157878228e-09
unrelated O 0 4.532890613972995e-07
families O 0 1.1994349335964216e-07
signifies O 0 1.5717080259491922e-07
propagation O 0 1.5941172648581414e-07
of O 0 8.175907062479837e-09
an O 0 6.034359500972641e-08
ancestral O 0 1.2788162848664797e-06
allele O 0 1.5333722558352747e-06
or O 0 1.1029578139698515e-08
a O 0 1.1682759293307754e-07
mutational O 0 0.0001596218644408509
hot O 0 3.7236884963931516e-05
spot O 0 4.15370686823735e-06
, O 0 1.4419927651942999e-07
haplotypes O 0 1.4204903891368303e-05
were O 0 5.336804633770953e-07
determined O 0 8.597270948484947e-07
for O 0 4.2578022885209066e-08
polymorphisms O 0 2.9459729375957977e-06
both O 0 5.953715387363445e-08
within O 0 1.443013086799283e-08
and O 0 1.9783486493452074e-07
flanking O 0 0.0007673026411794126
COL17A1 O 0 0.14801213145256042
. O 0 4.132008143642452e-06

Five O 0 2.073061295959633e-05
intragenic O 0 0.00018020006245933473
polymorphisms O 0 0.00014501951227430254
were O 0 1.732213831928675e-06
chosen O 0 2.128395095724045e-07
based O 0 1.2461663345675333e-07
on O 0 1.5734387659449567e-07
their O 0 1.2657592662890238e-07
informativeness O 0 0.0004689416382461786
. O 0 2.3627255814062664e-06

One O 0 2.3148688796936767e-06
of O 0 4.696947897286918e-08
these O 0 2.412364530357536e-08
, O 0 5.00749059995087e-08
not O 0 1.957729409696185e-07
previously O 0 6.0651154853985645e-06
reported O 0 2.104223540300154e-06
, O 0 2.3208864163848375e-08
was O 0 8.444430363852007e-07
2988 O 0 1.3846381534676766e-06
A O 0 3.12046768158325e-06
or O 0 1.1911887298765578e-07
C O 0 4.2008551304206776e-07
that O 0 2.5825467986351214e-08
introduces O 0 3.9014267372294853e-07
a O 0 9.033937686808713e-08
new O 0 3.509079249397473e-08
restriction O 0 9.551281721087435e-08
site O 0 8.819720420660815e-08
for O 0 1.593988940840063e-08
Eco0109 O 0 7.3522446655260865e-06
I O 0 3.203155074515962e-06
. O 0 5.126773316987965e-07

All O 0 2.529055507238809e-07
the O 0 5.706160521867787e-08
4003delTC O 0 4.274403636372881e-06
alleles O 0 1.7892313053380349e-06
showed O 0 9.76233309302188e-07
the O 0 1.0630049729343227e-08
same O 0 1.661704800426378e-07
haplotype O 0 6.418291013687849e-05
for O 0 9.235336051460763e-09
these O 0 1.0441598696786514e-08
five O 0 1.1011294986928988e-07
polymorphic O 0 9.132375998888165e-05
markers O 0 6.663901876891032e-05
. O 0 3.3722533316904446e-06

Fourteen O 0 0.00015784151037223637
microsatellite O 0 0.0007041129283607006
polymorphisms O 0 0.0004889723495580256
were O 0 2.588514462331659e-06
selected O 0 1.069827462174544e-07
based O 0 4.346544102418193e-08
on O 0 8.707561960363819e-08
their O 0 4.206495773928509e-08
high O 0 1.2638307680390426e-06
heterozygosity O 0 1.3245604350231588e-05
and O 0 3.595701159042619e-08
their O 0 6.429521359763157e-09
location O 0 7.34686551595587e-08
within O 0 9.382183918660303e-09
10q23 O 0 2.3651648461964214e-06
- O 0 8.77222373674158e-06
q25 O 0 2.196643254137598e-05
near O 0 2.5286626623710617e-06
COL17A1 O 0 0.00024540573940612376
. O 0 2.9517664188460913e-06

Three O 0 1.1718208952515852e-05
families O 0 3.930083039449528e-06
shared O 0 5.220764478508499e-07
microsatellite O 0 9.654735185904428e-05
polymorphisms O 0 3.199187995051034e-05
covering O 0 1.5316492181227659e-06
at O 0 1.1756032591847543e-07
most O 0 2.371122036493034e-07
19 O 0 1.7436184407415567e-06
cM O 0 9.067640348803252e-05
, O 0 1.4232101364086702e-07
whereas O 0 5.3959244183943156e-08
the O 0 1.0088966995169812e-08
others O 0 6.835529831050735e-08
shared O 0 1.681322281399389e-08
smaller O 0 4.253905672157998e-08
regions O 0 2.513984576069106e-08
consistent O 0 2.8673235874521197e-07
with O 0 2.5297762107356903e-08
cross O 0 6.370345317918691e-08
- O 0 1.571674511069432e-05
over O 0 3.116079199116939e-07
events O 0 2.3099781643054484e-08
during O 0 2.6441782097208488e-08
passage O 0 3.265504133764807e-08
of O 0 1.4006977799851938e-09
this O 0 1.0846946452147677e-08
mutation O 0 1.8556829672888853e-07
through O 0 1.239523594875891e-08
several O 0 6.572562227802337e-08
generations O 0 6.203862312759156e-07
. O 0 9.536578886581992e-07

These O 0 7.2959896897373255e-06
results O 0 4.153349891566904e-06
indicate O 0 4.780405333804083e-07
that O 0 6.05686807375605e-08
4003delTC O 0 1.1351510693202727e-05
occurs O 0 4.271011277978687e-08
on O 0 2.3624133760336008e-08
a O 0 1.6718495032819192e-07
single O 0 7.47105616483168e-07
ancestral O 0 2.7203434456168907e-06
allele O 0 6.1938226281199604e-06
. O 0 1.2293608619984298e-07
. O 0 9.21464447856124e-07

The O 0 8.799757779343054e-06
haptoglobin O 0 0.0001466085814172402
- O 0 2.3011380108073354e-05
gene O 0 3.052434976780205e-06
deletion O 0 7.929638741188683e-06
responsible O 0 7.202029905784002e-07
for O 0 3.735780467195582e-07
anhaptoglobinemia B-Disease 0 0.0006949145463295281
. O 0 4.335476205596933e-06

We O 0 4.648659796657739e-06
have O 0 2.771170954929403e-07
found O 0 7.355782827289659e-08
an O 0 3.592041153410719e-08
allelic O 0 3.3687690574879525e-06
deletion O 0 4.163470748608233e-06
of O 0 1.4846194495987675e-08
the O 0 7.990386308165398e-08
haptoglobin O 0 6.339830724755302e-05
( O 0 2.780525498735642e-08
Hp O 0 4.6072690906839853e-07
) O 0 9.3336183226711e-09
gene O 0 2.3478593291770267e-08
from O 0 2.221186568007738e-09
an O 0 1.4241517298785311e-08
individual O 0 2.2411891009710416e-08
with O 0 2.264604006541049e-07
anhaptoglobinemia B-Disease 0 0.005354255437850952
. O 0 2.501625658624107e-06

The O 0 3.367972567502875e-06
Hp O 0 9.437451808480546e-06
gene O 0 1.0571129678282887e-06
cluster O 0 4.0861343109099835e-07
consists O 0 4.937695763373995e-08
of O 0 5.597273755597598e-09
coding O 0 5.438617449726735e-07
regions O 0 1.7100026283856096e-08
of O 0 1.2954286532362858e-09
the O 0 6.440260769124961e-09
alpha O 0 7.925664391450482e-08
chain O 0 9.132480727203074e-08
and O 0 4.1219552215920885e-09
beta O 0 1.663808468777006e-08
chain O 0 3.521772029557724e-08
of O 0 2.0459640648340383e-09
the O 0 1.467673005350889e-08
haptoglobin O 0 7.794586053933017e-06
gene O 0 2.633734652590647e-07
( O 0 7.289507664154371e-09
Hp O 0 1.2960167339315376e-07
) O 0 6.953760234296169e-09
and O 0 2.0883714757502503e-09
of O 0 5.292975502335651e-10
the O 0 2.1832742280736284e-09
alpha O 0 6.315685396884874e-08
chain O 0 7.154888947979998e-08
and O 0 3.1224134389162828e-09
beta O 0 9.32710442214102e-09
chain O 0 2.685044719896723e-08
of O 0 1.7937559215752685e-09
the O 0 3.624123934287127e-08
haptoglobin O 0 3.7362951843533665e-05
- O 0 3.8581805711146444e-05
related O 0 4.997329483558133e-07
gene O 0 5.930502879891719e-07
( O 0 7.916840871757813e-08
Hpr O 0 1.9739396520890296e-05
) O 0 2.5321126528865534e-08
, O 0 1.6191153306976958e-08
in O 0 1.3250446961876605e-08
tandem O 0 4.408859240356833e-06
from O 0 1.291346585219344e-08
the O 0 1.5127954000604404e-08
5 O 0 3.0118118843347474e-07
side O 0 5.253837116470095e-06
. O 0 9.749883247422986e-07

Southern O 0 6.26973487669602e-05
blot O 0 0.0008128958288580179
and O 0 5.02252760270494e-07
PCR O 0 2.581917397037614e-05
analyses O 0 1.6466299257444916e-06
have O 0 1.3142847876679298e-07
indicated O 0 5.63034632250492e-07
that O 0 7.765074805377026e-09
the O 0 7.72107799917876e-09
individual O 0 6.122794271590237e-09
with O 0 2.2103767705061728e-08
anhaptoglobinemia B-Disease 0 7.96891181380488e-05
was O 0 2.5911474494932918e-06
homozygous O 0 3.672213040317729e-07
for O 0 3.629406997163187e-09
the O 0 3.39725048092987e-09
gene O 0 8.302366438783793e-08
deletion O 0 9.011313863993564e-07
and O 0 1.1751678741234173e-08
that O 0 8.350212077345986e-09
the O 0 8.126932904417572e-09
gene O 0 1.3655768782427913e-07
deletion O 0 1.7551800510773319e-06
was O 0 8.18151704606862e-07
included O 0 1.4503443779290137e-08
at O 0 9.546997858933537e-09
least O 0 1.0502158254155347e-08
from O 0 3.6716711893092224e-09
the O 0 1.0796315841332671e-08
promoter O 0 3.234691121178912e-06
region O 0 8.07110822620416e-08
of O 0 6.91324064661103e-09
Hp O 0 1.5133674651224283e-06
to O 0 2.0899031483168073e-07
Hpr O 0 7.060102689138148e-06
alpha O 0 1.5090179772414558e-07
but O 0 2.972617707541758e-08
not O 0 1.3855024683095962e-08
to O 0 7.337329321899233e-08
Hpr O 0 5.2520630561048165e-05
beta O 0 4.884304303232057e-07
( O 0 5.967857674704646e-08
Hpdel O 0 5.178450464882189e-06
) O 0 1.749188243138633e-07
. O 0 4.4332233528621146e-07

In O 0 4.567063115246128e-06
addition O 0 2.1552446582973062e-07
, O 0 2.9101665077746475e-08
we O 0 8.605455015242569e-09
found O 0 2.2935759957931623e-08
seven O 0 2.2829874879448653e-08
individuals O 0 2.6458668589413037e-09
with O 0 1.5359328031649966e-08
hypohaptoglobinemia B-Disease 0 0.00010170944005949423
in O 0 5.101348321545629e-08
three O 0 2.977406943216465e-08
families O 0 1.6487648579754932e-08
, O 0 6.822072684542491e-09
and O 0 1.605982191676958e-08
the O 0 1.76914323191113e-08
genotypes O 0 9.478043807575887e-07
of O 0 3.2680447237254384e-09
six O 0 1.4597387298920239e-08
of O 0 8.808196394483048e-10
the O 0 5.984269080272497e-09
seven O 0 6.069682001452747e-08
individuals O 0 6.840770172544808e-09
were O 0 2.3796708603640582e-08
found O 0 2.0236875286627765e-08
to O 0 5.261957269908635e-08
be O 0 4.3491110091053997e-07
Hp2 O 0 0.00044716510456055403
/ O 0 1.8979477317770943e-05
Hpdel O 0 6.752189801773056e-05
. O 0 1.5733276086393744e-06

The O 0 9.604781553207431e-06
phenotypes O 0 0.0006931868265382946
and O 0 7.093449880812841e-07
genotypes O 0 3.373162689968012e-05
in O 0 8.282863461772649e-08
one O 0 2.91347674874487e-08
of O 0 1.9777020021649605e-09
these O 0 2.825959910524034e-09
three O 0 1.5824745958070707e-08
families O 0 1.9350240521021078e-08
showed O 0 5.442301471703104e-07
the O 0 4.073427817274933e-09
father O 0 5.008570269637858e-07
to O 0 5.8249224110795694e-08
be O 0 1.6051806994710205e-07
hypohaptoglobinemic B-Disease 0 2.8623384423553944e-05
( O 0 4.315080204264632e-08
Hp2 O 0 1.2139443015257712e-06
) O 0 9.404633516396643e-09
and O 0 4.5741973764279464e-08
Hp2 O 0 1.6241718185483478e-05
/ O 0 6.484971208919887e-07
Hpdel O 0 5.304591013555182e-06
, O 0 2.202767568348918e-08
the O 0 7.45152206604871e-09
mother O 0 4.0935566403277335e-07
to O 0 1.4813072546360218e-08
be O 0 2.2344877947944042e-08
Hp2 O 0 1.2788028698196285e-06
- O 0 8.711014629625424e-07
1 O 0 4.0568451709077635e-08
and O 0 3.669222792268556e-08
Hp1 O 0 7.822912266419735e-06
/ O 0 4.526920633907139e-07
Hp2 O 0 3.4211336696898798e-06
, O 0 8.745173474267176e-09
one O 0 2.041711022471304e-09
of O 0 4.720617230447033e-10
the O 0 4.774716622080177e-09
two O 0 6.184698975175706e-08
children O 0 8.807297291468785e-08
to O 0 1.2565171125800134e-08
be O 0 1.0285447871183351e-07
hypohaptoglobinemic B-Disease 0 3.6368674045661464e-05
( O 0 1.858220066708327e-08
Hp2 O 0 1.3389999367063865e-06
) O 0 8.301824117040724e-09
and O 0 4.8304492850093084e-08
Hp2 O 0 9.854516974883154e-06
/ O 0 6.798135245844605e-07
Hpdel O 0 7.27178894521785e-06
, O 0 2.0807346956530637e-08
and O 0 3.6946783410485295e-09
the O 0 2.329426651570543e-09
other O 0 2.7712057093509657e-09
child O 0 9.549204804670808e-08
to O 0 1.5839271227946483e-08
be O 0 6.814727271375887e-08
Hp1 O 0 8.501360753143672e-06
and O 0 3.9043820265760587e-07
Hp1 O 0 5.475924626807682e-05
/ O 0 1.8748352204056573e-06
Hpdel O 0 7.835037649783771e-06
, O 0 4.154127708488886e-08
showing O 0 1.907642825926814e-07
an O 0 3.440255724740382e-08
anomalous O 0 4.946395620208932e-06
inheritance O 0 8.899393151295953e-07
of O 0 2.083121231066798e-08
Hp O 0 5.298637188388966e-05
phenotypes O 0 7.330879452638328e-05
in O 0 4.190064473164057e-08
the O 0 7.585547479038723e-08
child O 0 5.92654441788909e-06
with O 0 9.487674219599285e-07
Hp1 O 0 0.0015756799839437008
. O 0 2.7421212962508434e-06

The O 0 1.1982625437667593e-05
Hp2 O 0 0.00046448750072158873
/ O 0 3.9934078813530505e-05
Hpdel O 0 0.00012334823259152472
individuals O 0 1.5816966936199606e-07
had O 0 1.8759533304546494e-07
an O 0 3.118260849532817e-08
extremely O 0 2.415247763565276e-06
low O 0 5.858180429640925e-07
level O 0 1.0618782297910911e-08
of O 0 4.449090873492878e-09
Hp O 0 1.1968438684561988e-06
( O 0 2.0004543799245766e-08
mean O 0 1.4144690396733495e-07
+ O 0 3.431822221955372e-07
/ O 0 3.449665939569968e-07
- O 0 4.652247753256233e-06
SD O 0 0.00018848000036086887
= O 0 6.272204018387129e-07
0 O 0 5.755874710189346e-08
. O 0 1.2929115555948556e-08
049 O 0 3.0535936730302637e-06
+ O 0 2.54837345892156e-07
/ O 0 9.016206803380555e-08
- O 0 9.868067536444869e-07
0 O 0 3.7426556787067966e-07
. O 0 3.138021753557041e-08
043 O 0 2.782889851005166e-06
mg O 0 4.61996351077687e-05
/ O 0 2.065158696495928e-06
ml O 0 6.427705557143781e-06
; O 0 1.65717395361753e-07
n O 0 6.124969331722241e-07
= O 0 2.9384403887888766e-07
6 O 0 5.169097150314883e-08
) O 0 9.661635047564232e-09
, O 0 1.726513687572151e-08
compared O 0 5.4300357987813186e-08
with O 0 3.1194431482362006e-09
the O 0 5.646943801451698e-09
level O 0 1.842184538247693e-08
( O 0 4.520309015987323e-09
1 O 0 1.563417839633985e-08
. O 0 8.91377993639253e-09
64 O 0 1.2245949676525925e-07
+ O 0 1.4076410081997892e-07
/ O 0 8.810506813006214e-08
- O 0 5.765053288087074e-07
1 O 0 8.109933702371563e-08
. O 0 1.9534505568685745e-08
07 O 0 7.62462377679185e-07
mg O 0 3.8770391256548464e-05
/ O 0 7.885612944846798e-07
ml O 0 2.3407060325553175e-06
) O 0 1.3163139023220083e-08
obtained O 0 4.075660342550691e-08
from O 0 1.0381447701490742e-08
52 O 0 1.4578572518075816e-06
healthy O 0 4.48554914100896e-07
volunteers O 0 3.03066371998284e-07
having O 0 7.579544103464286e-07
phenotype O 0 8.50673095555976e-05
Hp2 O 0 8.243709999078419e-06
, O 0 4.011929988223528e-08
whereas O 0 4.709847800654643e-08
the O 0 1.9306590104406496e-08
serum O 0 1.690935505394009e-06
Hp O 0 4.2696350988080667e-07
level O 0 6.161336774113124e-09
of O 0 1.479259603698324e-09
an O 0 2.8623393433235833e-08
individual O 0 1.1139175803975832e-08
with O 0 8.836760656549814e-08
Hp1 O 0 0.00040131498826667666
/ O 0 3.6287976854509907e-06
Hpdel O 0 1.561536373628769e-05
was O 0 8.122664439724758e-06
0 O 0 1.188486294267932e-06
. O 0 5.112993903821916e-07

50 O 0 5.402514943853021e-05
mg O 0 0.0007771893288008869
/ O 0 1.4192121852829587e-05
ml O 0 1.5704892575740814e-05
, O 0 9.401122014196517e-08
which O 0 3.7277086306630736e-08
was O 0 2.1629745106110931e-07
approximately O 0 5.084133114507949e-09
half O 0 3.3490366035948682e-09
the O 0 8.073872126423964e-10
level O 0 2.138107690896618e-09
of O 0 1.3521630481960756e-09
Hp O 0 5.187933425077063e-07
in O 0 4.980932999387733e-08
control O 0 5.826894721394638e-06
sera O 0 9.931390195561107e-06
from O 0 1.0431207897454442e-08
the O 0 1.8071634855232332e-08
Hp1 O 0 0.0003890076477546245
phenotype O 0 0.000369955669157207
( O 0 4.8955501874559104e-09
1 O 0 1.2245711111802393e-08
. O 0 9.677828316512205e-09
26 O 0 8.407461393744597e-08
+ O 0 9.212854479301313e-08
/ O 0 1.1125676024903441e-07
- O 0 1.932160330397892e-06
0 O 0 1.8417247815705196e-07
. O 0 1.4334037068408634e-08
33 O 0 3.1656634291721275e-07
mg O 0 1.7494514395366423e-05
/ O 0 1.4023660241946345e-06
ml O 0 1.3774384569842368e-05
; O 0 1.0965709407173563e-07
n O 0 5.439493975245568e-07
= O 0 4.3363303348087356e-07
9 O 0 5.513138034984877e-08
) O 0 5.031087102480569e-09
, O 0 4.7616750542545105e-09
showing O 0 7.157782988542749e-08
a O 0 2.195970125740132e-07
gene O 0 9.830907856667181e-07
- O 0 4.0738956158747897e-05
dosage O 0 0.00012175890879007056
effect O 0 2.903048198277247e-06
. O 0 1.1068311778217321e-06

The O 0 1.0546881412665243e-06
other O 0 2.8679966135314316e-07
allele O 0 3.7674080886063166e-06
( O 0 4.091346639256699e-08
Hp2 O 0 1.922428054967895e-06
) O 0 9.911016896069214e-09
of O 0 3.2196005861351296e-09
individuals O 0 5.6460720543327625e-09
with O 0 2.5861400132498602e-08
Hp2 O 0 0.0004909067647531629
/ O 0 3.3188950965268305e-06
Hpdel O 0 1.0399072380096186e-05
was O 0 1.4559218470822088e-06
found O 0 3.742662357808513e-08
to O 0 2.7633953791905697e-08
have O 0 1.1544162958898596e-07
, O 0 1.3433950840635589e-08
in O 0 5.7315179269323835e-09
all O 0 4.798746733314374e-09
exons O 0 5.604754278465407e-07
, O 0 1.5688634391608502e-08
no O 0 5.9253249418134146e-08
mutation O 0 2.466512682985922e-07
, O 0 1.0583800502672602e-08
by O 0 1.2902214407972679e-08
DNA O 0 3.1204805850393313e-07
sequencing O 0 9.875353725874447e-07
. O 0 5.178007995709777e-07

On O 0 1.2810525049644639e-06
the O 0 3.0345216117666496e-08
basis O 0 5.961029447831834e-09
of O 0 1.213956712931008e-09
the O 0 1.543739358567109e-08
present O 0 1.6583534545588918e-07
study O 0 5.1870326700509395e-08
, O 0 2.2550119549435976e-09
the O 0 1.779820513192476e-09
mechanism O 0 7.6841146778861e-09
of O 0 2.6981343825838167e-09
anhaptoglobinemia B-Disease 0 1.0445260159031022e-05
and O 0 7.032281423846598e-09
the O 0 1.85015225362406e-09
mechanism O 0 1.8797836176531746e-08
of O 0 7.997137174697855e-09
anomalous O 0 1.3937109542894177e-05
inheritance O 0 3.190472398273414e-06
of O 0 3.5053933089557177e-08
Hp O 0 6.446163024520501e-05
phenotypes O 0 0.00014280338655225933
were O 0 2.826716922754713e-07
well O 0 1.4484942312265048e-07
explained O 0 3.114171249762876e-06
. O 0 1.2633114465643303e-06

However O 0 1.3412232874543406e-05
, O 0 1.1793539300697375e-07
the O 0 9.46376310650976e-09
mechanism O 0 8.135031492884082e-08
of O 0 4.5424371819535736e-08
hypohaptoglobinemia B-Disease 0 0.000355056778062135
remains O 0 3.243200990254991e-05
unknown O 0 1.924815478560049e-05

ATM O 0 0.001002113800495863
mutations O 0 0.01612895168364048
and O 0 2.2269869077717885e-05
phenotypes O 0 0.25534316897392273
in O 0 0.0007152804173529148
ataxia B-Disease 1 1.0
- I-Disease 1 0.9999955892562866
telangiectasia I-Disease 1 0.9999991655349731
families O 0 7.435138832079247e-05
in O 0 7.929610745804894e-08
the O 0 5.987662632378488e-08
British O 0 2.9082997571094893e-05
Isles O 0 1.4479280707746511e-06
: O 0 1.5122759933205998e-08
expression O 0 2.1241586267706225e-08
of O 0 1.5239735029481949e-09
mutant O 0 2.2539452970704588e-07
ATM O 0 1.426890321454266e-07
and O 0 7.331604212623688e-09
the O 0 1.094817125846248e-08
risk O 0 1.2332935739323148e-07
of O 0 9.255018795784054e-08
leukemia B-Disease 1 0.9997009038925171
, O 0 0.0070154014974832535
lymphoma B-Disease 1 0.9999998807907104
, O 0 2.6679408620111644e-06
and O 0 0.0008120759739540517
breast B-Disease 1 0.9999046325683594
cancer I-Disease 1 0.7630397081375122
. O 0 7.057450602587778e-06

We O 0 4.855111455981387e-06
report O 0 6.612376637349371e-07
the O 0 1.3628078221472606e-08
spectrum O 0 2.059874191218114e-07
of O 0 8.556388486624655e-09
59 O 0 1.4291362049334566e-06
ATM O 0 1.4456390999839641e-05
mutations O 0 1.4107783499639481e-05
observed O 0 1.1930660548387095e-06
in O 0 9.757141015143134e-06
ataxia B-Disease 1 1.0
- I-Disease 1 0.9999995231628418
telangiectasia I-Disease 1 0.9999998807907104
( O 0 4.2849915189435706e-05
A B-Disease 1 0.9999942779541016
- I-Disease 1 0.9999953508377075
T I-Disease 1 0.9999995231628418
) O 0 4.5065257836540695e-06
patients O 0 2.1348067093640566e-05
in O 0 2.251995923074901e-08
the O 0 7.202015694929287e-08
British O 0 4.028905459563248e-05
Isles O 0 1.8482734958524816e-05
. O 0 1.8744793806035887e-06

Of O 0 4.431588877196191e-06
51 O 0 3.2671472581569105e-05
ATM O 0 1.6375426639569923e-05
mutations O 0 2.959471930807922e-05
identified O 0 9.517997909824771e-07
in O 0 3.699567230341927e-08
families O 0 5.535855862603967e-08
native O 0 1.552639439239556e-08
to O 0 4.848180523708834e-08
the O 0 9.659095923097993e-08
British O 0 0.00018658462795428932
Isles O 0 2.133462430720101e-06
, O 0 4.731421299197791e-08
11 O 0 2.47697364841315e-08
were O 0 2.16961808519045e-08
founder O 0 2.156117488993914e-06
mutations O 0 1.0274972055412945e-06
, O 0 1.2455432241154085e-08
and O 0 1.9978919851837418e-08
2 O 0 1.4354912813985266e-08
of O 0 1.0954014362241082e-09
these O 0 5.400503155783554e-09
11 O 0 5.2124715210766226e-08
conferred O 0 5.917763701290824e-07
a O 0 1.273522684641648e-05
milder O 1 0.9995237588882446
clinical O 1 0.9699538350105286
phenotype O 1 0.9249836206436157
with O 0 1.0623283230870584e-07
respect O 0 2.7386446888044702e-08
to O 0 1.0899358215965549e-07
both O 0 1.5373535688922857e-06
cerebellar B-Disease 1 0.835162878036499
degeneration I-Disease 1 0.9966778755187988
and O 0 1.9895867353625363e-06
cellular O 0 1.573174085933715e-05
features O 0 8.50415017339401e-06
. O 0 1.2863399661000585e-06

We O 0 1.5940770026645623e-05
report O 0 1.3184543377064983e-06
, O 0 2.2265872701154876e-08
in O 0 1.1972083768796438e-08
two O 0 3.4307225860175095e-07
A B-Disease 1 0.9999856948852539
- I-Disease 1 0.999987006187439
T I-Disease 1 0.9999994039535522
families O 0 5.720222588934121e-07
, O 0 5.845576467322644e-09
an O 0 6.256620554978554e-09
ATM O 0 1.020394051920448e-06
mutation O 0 5.628886015074386e-07
( O 0 7.556835157629394e-09
7271T O 0 1.1068734693253646e-06
- O 0 1.3284872693475336e-05
- O 0 0.0015767246950417757
> O 0 6.7670753196580335e-06
G O 0 0.0008817018242552876
) O 0 2.153740119581471e-08
that O 0 1.4588349017685687e-07
may O 0 2.757643642326002e-06
be O 0 1.0432484742750603e-07
associated O 0 1.619319256462859e-08
with O 0 8.562804687528569e-09
an O 0 1.3738218740400043e-07
increased O 0 5.542254712054273e-06
risk O 0 5.469123038892576e-07
of O 0 2.8308875243965304e-07
breast B-Disease 1 0.9999537467956543
cancer I-Disease 0 0.4661576449871063
in O 0 9.101874098860208e-08
both O 0 2.396085960754135e-07
homozygotes O 0 8.03692382760346e-05
and O 0 8.801367243904679e-07
heterozygotes O 0 2.3444827093044296e-05
( O 0 2.124219200538846e-08
relative O 0 4.972400233782537e-07
risk O 0 3.4527531056482985e-07
12 O 0 7.004907587315756e-08
. O 0 2.5862632924145146e-08
7 O 0 3.285471734670864e-07
; O 0 3.0903913739166455e-07
P O 0 2.5903993446263485e-05
= O 0 1.1557673360584886e-06
. O 0 2.891961869977422e-08
0025 O 0 2.0240602225385373e-06
) O 0 2.3938834914360996e-08
, O 0 1.675745231466408e-08
although O 0 1.8326973716398243e-08
there O 0 6.69797417529594e-09
is O 0 9.5251886378378e-09
a O 0 1.8387851241641329e-07
less O 0 2.7738440167013323e-06
severe O 1 0.9480089545249939
A B-Disease 1 0.9999990463256836
- I-Disease 1 0.9999988079071045
T I-Disease 1 0.9999998807907104
phenotype O 1 0.9713170528411865
in O 0 4.8970282051641334e-08
terms O 0 1.4279271098871504e-08
of O 0 1.3845744550877725e-09
the O 0 7.650814204396283e-09
degree O 0 1.292786322437678e-07
of O 0 2.759703932042612e-07
cerebellar B-Disease 1 0.9837477803230286
degeneration I-Disease 1 0.9992802739143372
. O 0 2.7178666641702875e-05

This O 0 8.843360774335451e-06
mutation O 0 2.86289541691076e-05
( O 0 2.5605737619116553e-07
7271T O 0 5.21529864272452e-06
- O 0 4.750500011141412e-05
- O 0 0.0015158887254074216
> O 0 7.629099400219275e-06
G O 0 0.00010777378338389099
) O 0 2.2355706619237026e-08
also O 0 2.4180813795737777e-08
allows O 0 2.6349095350042262e-08
expression O 0 3.5096348938168376e-08
of O 0 1.4307535156632412e-09
full O 0 5.283257564769883e-08
- O 0 3.343203388794791e-06
length O 0 2.976808559651545e-07
ATM O 0 1.0022991148161964e-07
protein O 0 2.667739451567286e-08
at O 0 2.5839050898923688e-09
a O 0 4.1777031611900384e-08
level O 0 1.7665669815869478e-08
comparable O 0 6.241938166340333e-08
with O 0 2.0849379112064526e-08
that O 0 1.0271489259139344e-07
in O 0 2.9836323278686905e-07
unaffected O 0 0.000418533687479794
individuals O 0 2.2013315970070835e-07
. O 0 6.545576525240904e-07

In O 0 2.0924428554280894e-06
addition O 0 3.6173634043734637e-07
, O 0 3.623999589308369e-08
we O 0 1.3997262904297259e-08
have O 0 2.8113007033425674e-08
studied O 0 2.8239037419552915e-07
18 O 0 2.1909738734393613e-06
A B-Disease 1 0.9999440908432007
- I-Disease 1 0.9999982118606567
T I-Disease 1 1.0
patients O 1 0.9975799322128296
, O 0 6.504010485741674e-08
in O 0 3.005014548307372e-08
15 O 0 1.0281387829991218e-07
families O 0 2.5864409280984546e-08
, O 0 2.7512992772926737e-08
who O 0 1.3439056601782795e-05
developed O 0 0.004990401212126017
leukemia B-Disease 1 0.999860405921936
, O 0 0.03523349389433861
lymphoma B-Disease 1 0.9999998807907104
, O 0 1.5688148096160148e-06
preleukemic O 0 0.0008163187303580344
T O 0 0.00020279677119106054
- O 0 9.634174602979328e-06
cell O 0 4.877210812992416e-06
proliferation O 0 2.399808920472424e-07
, O 0 3.156640389079257e-07
or O 0 0.0002757758484221995
Hodgkin B-Disease 1 0.9999998807907104
lymphoma I-Disease 1 1.0
, O 0 9.593911727279192e-07
mostly O 0 1.6447137340946938e-07
in O 0 1.3066599535704881e-07
childhood O 0 1.0089430361404084e-05
. O 0 1.2713062460534275e-06

A O 0 3.638847920228727e-05
wide O 0 3.317540631542215e-06
variety O 0 1.4320761465569376e-07
of O 0 1.565760499033786e-08
ATM O 0 9.83067639026558e-06
mutation O 0 1.210188838740578e-05
types O 0 1.5935853525661514e-07
, O 0 2.8729177259378957e-08
including O 0 5.279439818650644e-08
missense O 0 0.0011753669241443276
mutations O 0 4.239223471813602e-06
and O 0 4.939607833875925e-08
in O 0 2.9486070474149528e-08
- O 0 9.895078983390704e-05
frame O 0 0.1366264671087265
deletions O 0 7.107987130439142e-06
, O 0 6.22811953121527e-08
were O 0 3.5454490898700897e-08
seen O 0 2.1369190505993174e-07
in O 0 2.4415687249756957e-08
these O 0 1.808805336622754e-07
patients O 0 5.607630737358704e-05
. O 0 1.1903874792551505e-06

We O 0 2.485564436938148e-06
also O 0 1.255280324130581e-07
show O 0 6.777473515739985e-08
that O 0 1.263727611444665e-08
25 O 0 6.064150426254855e-08
% O 0 3.7639291683433385e-09
of O 0 3.5327479830371544e-10
all O 0 2.8309353083955102e-08
A B-Disease 1 0.9999916553497314
- I-Disease 1 0.9999991655349731
T I-Disease 1 1.0
patients O 1 0.9355878829956055
carried O 0 2.4803925953165162e-06
in O 0 3.299298967363029e-08
- O 0 2.1971041860524565e-05
frame O 0 0.006382191088050604
deletions O 0 4.474522484088084e-06
or O 0 2.593003785023029e-07
missense O 0 0.00011984288721578196
mutations O 0 9.96849121293053e-06
, O 0 3.0718613430735786e-08
many O 0 3.888990907086054e-09
of O 0 2.977757374011958e-09
which O 0 1.0064358093586634e-06
were O 0 4.779161372425733e-06
also O 0 6.4570676840958185e-06
associated O 0 6.123730855733811e-08
with O 0 1.4392445457644953e-08
expression O 0 9.806939260670333e-08
of O 0 5.292786209309952e-09
mutant O 0 1.7519372477181605e-06
ATM O 0 1.2878202824140317e-06
protein O 0 1.1188703865627758e-06
. O 0 3.6255005397833884e-07

The O 0 8.824026735965163e-06
DMPK O 0 0.00035465791006572545
gene O 0 8.497502676618751e-06
of O 0 1.290856062041712e-06
severely O 1 0.7560923099517822
affected O 0 0.17421391606330872
myotonic B-Disease 1 1.0
dystrophy I-Disease 1 1.0
patients O 1 0.9999865293502808
is O 0 4.539186647889437e-06
hypermethylated O 0 0.00023841756046749651
proximal O 0 0.00040898050065152347
to O 0 3.560398909030482e-07
the O 0 5.3592660975709805e-08
largely O 0 8.352181453119556e-07
expanded O 0 1.6901793742363225e-06
CTG O 0 7.125710544642061e-05
repeat O 0 1.8037624613498338e-05
. O 0 2.4566627416788833e-06

Using O 0 6.687408586003585e-06
methylation O 0 1.5552202967228368e-05
- O 0 1.9446664737188257e-05
sensitive O 0 9.253029134015378e-07
restriction O 0 1.0183874792346614e-06
enzymes O 0 2.0920208498864667e-07
, O 0 1.5598317304466036e-08
we O 0 6.404552888028547e-09
characterized O 0 8.146863450519959e-08
the O 0 5.8865490260018305e-09
methylation O 0 3.8038206184864976e-07
pattern O 0 2.819834890033235e-07
on O 0 7.379433952792169e-08
the O 0 1.2083806844032097e-08
5 O 0 3.6813499804111416e-08
side O 0 7.513234123734946e-08
of O 0 1.5536577580022026e-09
the O 0 1.4686895255522359e-08
CTG O 0 2.1237903638393618e-05
repeat O 0 9.09050868358463e-07
in O 0 1.1519150078243001e-08
the O 0 1.0814184214780198e-08
DMPK O 0 1.6530208085896447e-05
gene O 0 7.389137834934445e-08
of O 0 2.0994903593418712e-09
normal O 0 3.573072149265499e-08
individuals O 0 4.983686352488803e-09
and O 0 2.649736963178384e-08
of O 0 8.468231271763216e-08
patients O 0 0.0033365851268172264
affected O 0 2.902458618336823e-06
with O 0 0.01243288442492485
myotonic B-Disease 1 1.0
dystrophy I-Disease 1 1.0
, O 0 7.548333996965084e-06
showing O 0 1.212528104588273e-06
expansions O 0 1.847922987963102e-07
of O 0 6.450476597308352e-09
the O 0 3.126121583818531e-08
repetitive O 0 2.8742646463797428e-05
sequence O 0 3.100722778981435e-06
. O 0 1.102335318137193e-06

The O 0 1.9973488178948173e-06
gene O 0 2.9679549697902985e-06
segment O 0 1.535088586024358e-06
analyzed O 0 5.574231636273907e-07
corresponds O 0 1.249715353424108e-07
to O 0 1.334861554624922e-08
the O 0 2.0379188114816316e-08
genomic O 0 8.763392997934716e-07
SacI O 0 1.7345531887258403e-05
- O 0 3.457788579908083e-06
HindIII O 0 6.3366960603161715e-06
fragment O 0 2.0338375179562718e-06
carrying O 0 3.948857454361132e-07
exons O 0 1.6777636346887448e-06
11 O 0 1.9233583259392617e-07
- O 0 3.4941167541546747e-06
15 O 0 8.979837957667769e-07
. O 0 6.115835162745498e-07

There O 0 5.480371783050941e-06
is O 0 1.468964683226659e-07
constitutive O 0 1.103308136407577e-06
methylation O 0 1.7899070599014522e-06
in O 0 1.3812338295338122e-07
intron O 0 3.39621547027491e-05
12 O 0 2.4687270183676446e-07
at O 0 6.605309632590206e-09
restriction O 0 3.7479914283267135e-08
sites O 0 3.830245898228668e-09
of O 0 2.539124022149508e-09
SacII O 0 2.523743205529172e-06
and O 0 5.3615256234706976e-08
HhaI O 0 1.570817858009832e-06
, O 0 1.412713235282581e-08
localized O 0 1.370028996916517e-07
1 O 0 3.377139989879652e-08
, O 0 2.9279943802862363e-08
159 O 0 8.591106848143681e-07
- O 0 1.3454086911224294e-05
1 O 0 1.226274264354288e-07
, O 0 3.386945479633141e-08
232 O 0 3.997204203187721e-07
bp O 0 2.7670141662383685e-06
upstream O 0 2.989482084103656e-08
of O 0 1.6462029517327892e-09
the O 0 2.0292263869237104e-08
CTG O 0 1.636897650314495e-05
repeat O 0 2.528954610170331e-06
, O 0 3.8524554213381634e-08
whereas O 0 4.700299527371499e-08
most O 0 7.641160593152563e-09
, O 0 4.88503770768034e-09
if O 0 4.481668369749059e-09
not O 0 2.182033886910517e-09
all O 0 6.823513420961547e-10
, O 0 1.1030287794255855e-09
of O 0 2.069452664787974e-10
the O 0 1.1203349359334425e-09
other O 0 5.495703891966741e-10
sites O 0 1.2818172079320789e-09
of O 0 1.7208874325547185e-09
SacII O 0 3.879002633766504e-06
, O 0 3.1972778202771224e-08
HhaI O 0 2.406168960078503e-06
, O 0 1.3095625028824998e-08
and O 0 7.914240818251983e-09
HpaII O 0 1.0879663250307203e-06
in O 0 5.675569791918633e-09
this O 0 7.166878646103214e-09
region O 0 5.800653468668315e-08
are O 0 1.7546526009937224e-08
unmethylated O 0 7.975120752234943e-06
, O 0 4.2364000307770766e-08
in O 0 7.022630921227346e-09
normal O 0 2.2484378803255822e-08
individuals O 0 1.480097822081916e-09
and O 0 6.7388516988842184e-09
most O 0 7.527087397818377e-09
of O 0 2.9519819921830504e-09
the O 0 6.76273884891998e-07
patients O 0 0.00192910002078861
. O 0 1.2918955007990007e-06

In O 0 3.387331844351138e-06
a O 0 4.967579343428952e-07
number O 0 4.6137852649508204e-08
of O 0 1.3153952593825124e-08
young O 0 1.6587408708801377e-06
and O 0 3.4104166388715385e-06
severely O 1 0.9367925524711609
affected O 0 0.0001697058032732457
patients O 0 0.0053565059788525105
, O 0 9.625347985320332e-08
however O 0 1.339106745490426e-07
, O 0 6.604326863168808e-09
complete O 0 1.0360222901795169e-08
methylation O 0 2.6542437581156264e-08
of O 0 7.006865643255367e-10
these O 0 1.2943222049699443e-09
restriction O 0 3.5216508820212766e-08
sites O 0 1.1876241323705017e-08
was O 0 1.9090478531325061e-07
found O 0 2.0334224970497417e-08
in O 0 3.51908435725079e-09
the O 0 2.628610040744661e-08
mutated O 0 6.77578427712433e-05
allele O 0 2.441284595988691e-05
. O 0 1.0586546750346315e-06

In O 0 2.78410266218998e-06
most O 0 1.2436754559530527e-07
of O 0 1.4345032717244521e-08
these O 0 1.3989300384764647e-07
patients O 0 2.330554707441479e-05
, O 0 2.2066698690537123e-08
the O 0 1.4352750099533296e-08
onset O 0 6.290078999882098e-07
of O 0 2.3355140044145628e-08
the O 0 9.514490557194222e-06
disease O 0 0.07139928638935089
was O 0 0.4446818232536316
congenital O 1 0.9999616146087646
. O 0 3.179970008204691e-05

Preliminary O 0 0.0001570590102346614
in O 0 3.632983862189576e-06
vivo O 0 0.0003398167609702796
footprinting O 0 0.0015539866872131824
data O 0 4.550428229777026e-07
gave O 0 4.523062671069056e-07
evidence O 0 4.690269506113509e-08
for O 0 1.0286738572062859e-08
protein O 0 2.408838497558463e-07
- O 0 6.484553068730747e-06
DNA O 0 8.400157298638078e-07
contact O 0 3.129390790945763e-08
in O 0 7.670174717588907e-09
normal O 0 3.6855091423149133e-08
genes O 0 2.4619435379236165e-08
at O 0 4.575067436007885e-09
an O 0 2.448652836051224e-08
Sp1 O 0 1.6357161030100542e-06
consensus O 0 5.154014814934271e-08
binding O 0 1.4375673629274388e-07
site O 0 5.117799162235315e-08
upstream O 0 1.2994705755886571e-08
of O 0 1.0654117588160261e-09
the O 0 1.3258764752777097e-08
CTG O 0 1.805127067200374e-05
repeat O 0 1.9721107946679695e-06
and O 0 1.556880135922256e-08
for O 0 4.2211292239358045e-09
a O 0 1.0522413873559344e-07
significant O 0 5.7181448909204846e-08
reduction O 0 6.577528210982564e-08
of O 0 1.3378330665503313e-09
this O 0 5.900251842660964e-09
interaction O 0 1.2449993036511842e-08
in O 0 3.374236356989968e-08
cells O 0 8.836794052058394e-08
with O 0 3.2361516133505575e-08
a O 0 1.6787672620921512e-06
hypermethylated O 0 0.00031277586822398007
DMPK O 0 0.0001463747612433508
gene O 0 9.899983979266835e-07
. O 0 1.2370158231078676e-07
. O 0 4.728728413283534e-07

The O 0 4.652038114727475e-05
hemochromatosis B-Disease 1 0.9999371767044067
gene O 0 1.4128638213151135e-05
product O 0 5.386637553783657e-07
complexes O 0 2.6879069991991855e-07
with O 0 1.6506621847156566e-08
the O 0 1.7864840273773552e-08
transferrin O 0 2.4782675609458238e-05
receptor O 0 1.3609566167360754e-06
and O 0 8.601914203154593e-08
lowers O 0 1.0498279152670875e-05
its O 0 1.7123037210353687e-08
affinity O 0 4.764775596299842e-08
for O 0 2.6524370255742724e-08
ligand O 0 8.059513675107155e-06
binding O 0 1.0768369975266978e-05
. O 0 1.4512597772409208e-06

We O 0 4.8367273848271e-06
recently O 0 4.229749720252585e-06
reported O 0 2.840710067175678e-07
the O 0 1.1616318573715034e-08
positional O 0 2.3886259441496804e-06
cloning O 0 4.050567383728776e-07
of O 0 5.686166648644075e-09
a O 0 2.6794535301633005e-07
candidate O 0 5.149503067514161e-06
gene O 0 9.843114639807027e-06
for O 0 5.4998152336338535e-05
hereditary B-Disease 1 1.0
hemochromatosis I-Disease 1 1.0
called O 0 0.33204808831214905
HFE O 1 0.7251462340354919
. O 0 1.2395337762427516e-05

The O 0 2.888673634515726e-06
gene O 0 2.6681952931539854e-06
product O 0 1.767769362004401e-07
, O 0 1.3156085110210824e-08
a O 0 4.7277499248821186e-08
member O 0 8.342125212834617e-09
of O 0 8.027728481962981e-10
the O 0 8.204088075558502e-09
major O 0 6.57371472811974e-08
histocompatibility O 0 2.3796994355507195e-05
complex O 0 6.802986263210187e-07
class O 0 2.580563034371153e-07
I O 0 4.3455287368487916e-07
- O 0 8.146845402734471e-07
like O 0 9.315675697507686e-08
family O 0 1.3429550449473027e-07
, O 0 1.1345148820396389e-08
was O 0 1.1801542996181524e-06
found O 0 5.5679628019333904e-08
to O 0 2.0623264873620428e-08
have O 0 2.4865116188266256e-08
a O 0 5.453648554976098e-07
mutation O 0 1.8086448108078912e-06
, O 0 5.373954792275981e-08
Cys O 0 1.4685665519209579e-05
- O 0 1.0968154128931928e-05
282 O 0 1.8354141957388492e-06
- O 0 4.6256856876425445e-05
- O 0 0.0002852265315596014
> O 0 1.498874894423352e-06
Tyr O 0 8.501223419443704e-06
( O 0 1.5622402926851464e-08
C282Y O 0 3.176577934027591e-07
) O 0 4.642888296046976e-09
, O 0 3.4657221537059968e-09
in O 0 9.277601797919033e-09
85 O 0 3.7997307344994624e-07
% O 0 2.2240914887561303e-08
of O 0 1.569459051609101e-08
patient O 0 0.00013688918261323124
chromosomes O 0 2.0978894099243917e-05
. O 0 1.9434019122854806e-06

This O 0 4.353415533842053e-06
mutation O 0 1.9894649085472338e-05
eliminates O 0 2.579079364295467e-06
the O 0 9.418494784085851e-08
ability O 0 2.173812561068189e-07
of O 0 3.117250102491198e-08
HFE O 0 0.0004158604715485126
to O 0 1.0440681990075973e-06
associate O 0 2.7475240926833067e-07
with O 0 1.6178965722701832e-07
beta2 O 0 0.0004263462615199387
- O 0 0.0011930355103686452
microglobulin O 0 0.00185322854667902
( O 0 8.776861193382501e-08
beta2m O 0 7.88780289440183e-06
) O 0 1.7362721038693962e-08
and O 0 2.4998932701691956e-08
prevents O 0 3.182818488767225e-07
cell O 0 1.4178890523908194e-05
- O 0 4.083685780642554e-05
surface O 0 6.807636236771941e-05
expression O 0 3.6595297387975734e-06
. O 0 1.018935336105642e-06

A O 0 3.362416464369744e-05
second O 0 9.14173051569378e-06
mutation O 0 9.169671102426946e-06
that O 0 8.814137686385948e-08
has O 0 2.0370954700865695e-07
no O 0 8.440044751978348e-08
effect O 0 1.3424414646578953e-07
on O 0 8.22611241346749e-07
beta2m O 0 0.002183738397434354
association O 0 8.527586459194936e-08
, O 0 2.8889738601378667e-08
H63D O 0 6.586954259546474e-05
, O 0 4.5069931786656525e-08
was O 0 6.093542879170855e-07
found O 0 2.114311747902775e-08
in O 0 3.3414564448719375e-09
eight O 0 1.5729742841585903e-08
out O 0 1.3698990386501464e-08
of O 0 5.634421373912346e-09
nine O 0 6.282438789639855e-06
patients O 0 9.531032992526889e-05
heterozygous O 0 1.428129394298594e-06
for O 0 8.55960369250397e-09
the O 0 3.004034709874759e-08
C282Y O 0 1.8549180822446942e-05
mutant O 0 1.8584843928692862e-05
. O 0 9.681946266937302e-07

In O 0 3.5906039101973874e-06
this O 0 2.6998557700608217e-07
report O 0 1.506352163005431e-07
, O 0 7.094577370025945e-09
we O 0 7.055671602529401e-09
demonstrate O 0 1.287474873379324e-07
in O 0 4.103421247236838e-08
cultured O 0 5.464933110488346e-06
293 O 0 4.869142685492989e-06
cells O 0 1.6444531638626358e-06
overexpressing O 0 8.465164683002513e-06
wild O 0 1.2750311384479573e-07
- O 0 5.290076842356939e-06
type O 0 2.206850240327185e-06
or O 0 6.180312084325124e-08
mutant O 0 7.246837867569411e-06
HFE O 0 5.843129110871814e-05
proteins O 0 3.749865129520913e-08
that O 0 1.608505151295958e-08
both O 0 5.379161116536579e-09
the O 0 6.573424027322972e-09
wild O 0 1.3846668878159107e-07
- O 0 0.0002109047636622563
type O 0 2.266316550958436e-05
and O 0 5.327412395672582e-07
H63D O 0 0.016135241836309433
HFE O 0 0.00043034570990130305
proteins O 0 1.5108899731330894e-07
form O 0 1.5319136537073064e-07
stable O 0 1.3541622365664807e-06
complexes O 0 2.759235542271199e-07
with O 0 5.7078040072156e-08
the O 0 2.2192614324012538e-07
transferrin O 0 0.002730539534240961
receptor O 0 4.072466254001483e-05
( O 0 7.900698051344079e-07
TfR O 0 0.0001312102103838697
) O 0 3.1332166372521897e-07
. O 0 5.702210046365508e-07

The O 0 6.948114787519444e-06
C282Y O 0 0.00010610237950459123
mutation O 0 4.277120024198666e-05
nearly O 0 6.314534743978584e-07
completely O 0 7.472074798897665e-07
prevents O 0 1.798731830149336e-07
the O 0 2.144504840373429e-08
association O 0 1.3369636953086683e-08
of O 0 1.5578209833222445e-09
the O 0 2.680510924335522e-08
mutant O 0 1.3370806300372351e-05
HFE O 0 2.0630897779483348e-05
protein O 0 2.4430929101981746e-07
with O 0 6.680701147843138e-08
the O 0 5.044686304245261e-07
TfR O 0 0.006886206101626158
. O 0 2.6916086426354013e-06

Studies O 0 7.564851330243982e-06
on O 0 9.724207075123559e-07
cell O 0 7.030378128547454e-06
- O 0 3.336333611514419e-05
associated O 0 5.020995104132453e-07
transferrin O 0 7.280170848389389e-06
at O 0 3.1721970827902624e-08
37 O 0 2.6826981525118754e-07
degrees O 0 3.99645728066389e-07
C O 0 9.704798458187724e-07
suggest O 0 7.908479915386124e-08
that O 0 1.0485185164554878e-08
the O 0 2.0279960821767418e-08
overexpressed O 0 9.347405466542114e-06
wild O 0 2.4221898797804897e-07
- O 0 1.4995330275269225e-05
type O 0 1.2251385669515003e-05
HFE O 0 6.330491305561736e-05
protein O 0 4.995404196961317e-07
decreases O 0 3.0950334917179134e-07
the O 0 5.708204131593675e-09
affinity O 0 3.064417697373756e-08
of O 0 5.465538244209256e-09
the O 0 8.638119197712513e-08
TfR O 0 0.0003287459257990122
for O 0 8.886170803634741e-07
transferrin O 0 0.00041562961996532977
. O 0 2.9294747037056368e-06

The O 0 6.343915629258845e-06
overexpressed O 0 0.0002580657310318202
H63D O 0 0.00023041004897095263
protein O 0 1.2076892517143278e-06
does O 0 1.501296793549045e-07
not O 0 1.5170718015156126e-08
have O 0 1.1813256151071982e-08
this O 0 8.323275402233321e-09
effect O 0 4.6168929657142144e-07
, O 0 4.5118266456256606e-08
providing O 0 7.113058586583065e-09
the O 0 2.8495585890908615e-09
first O 0 1.2797658932584e-08
direct O 0 4.2856996174123196e-08
evidence O 0 1.196903838263097e-07
for O 0 1.2445933172955392e-08
a O 0 4.953401457896689e-07
functional O 0 5.90472950534604e-07
consequence O 0 9.708911363759398e-08
of O 0 2.846636260045443e-09
the O 0 1.4336777098833409e-07
H63D O 0 0.020499425008893013
mutation O 0 3.388748882571235e-05
. O 0 7.471319918295194e-07

Addition O 0 2.774762151602772e-06
of O 0 1.4929999281321216e-07
soluble O 0 7.054314210108714e-06
wild O 0 4.029323292797926e-07
- O 0 0.0001799648453015834
type O 0 0.0001904974051285535
HFE O 0 0.055327147245407104
/ O 0 1.9568313291529194e-05
beta2m O 0 4.3659987568389624e-05
heterodimers O 0 2.9513770641642623e-05
to O 0 3.0544396167897503e-07
cultured O 0 7.297799129446503e-06
cells O 0 2.205232704000082e-06
also O 0 5.409866048466938e-07
decreased O 0 2.3993672471078753e-07
the O 0 6.6551737454290105e-09
apparent O 0 1.1531876680237474e-06
affinity O 0 7.729613571427763e-08
of O 0 7.0352594860878526e-09
the O 0 5.574530348440021e-08
TfR O 0 2.8164506147732027e-05
for O 0 1.2115817682456509e-08
its O 0 4.2052924698054994e-08
ligand O 0 1.7181831708512618e-06
under O 0 5.288243301038165e-07
steady O 0 4.647698006010614e-06
- O 0 7.315226412174525e-06
state O 0 2.1342651734812534e-07
conditions O 0 3.8153043533384334e-06
, O 0 2.649236741092409e-08
both O 0 1.068750155042153e-08
in O 0 2.7589610596123748e-08
293 O 0 1.3222621646491461e-06
cells O 0 8.160352535924176e-07
and O 0 7.054100592540635e-08
in O 0 1.8639480003912468e-07
HeLa O 0 0.00032575769000686705
cells O 0 1.114035512728151e-05
. O 0 1.1054482911276864e-06

Furthermore O 0 3.401446883799508e-05
, O 0 2.9511397769965697e-07
at O 0 3.832367312384122e-08
4 O 0 1.6178812245470908e-07
degrees O 0 1.9428052837611176e-06
C O 0 3.743044771908899e-06
, O 0 2.1608379086046625e-08
the O 0 1.3564309675473396e-08
added O 0 2.71671638074622e-07
soluble O 0 4.860031594944303e-07
complex O 0 6.279769593220408e-08
of O 0 3.234176659816512e-08
HFE O 0 0.003961344249546528
/ O 0 6.365636181726586e-06
beta2m O 0 1.871187487267889e-05
inhibited O 0 1.3060075616522226e-06
binding O 0 2.6114224738194025e-07
of O 0 1.3754469563309613e-08
transferrin O 0 1.0018067769124173e-05
to O 0 5.226489179221971e-07
HeLa O 0 3.8683378079440445e-05
cell O 0 8.578890992794186e-05
TfR O 0 3.780486440518871e-05
in O 0 2.7002309721524398e-08
a O 0 7.927974934318627e-07
concentration O 0 2.5159351935144514e-05
- O 0 2.232737278973218e-05
dependent O 0 4.018404069938697e-06
manner O 0 4.632423042494338e-06
. O 0 9.824046856010682e-07

Scatchard O 0 0.0005857280921190977
plots O 0 1.0418191777716856e-05
of O 0 1.1051314174892468e-07
these O 0 2.2575564528892755e-08
data O 0 5.3243699227323305e-08
indicate O 0 7.956548131460295e-08
that O 0 6.374377914397655e-09
the O 0 6.642111749499691e-09
added O 0 1.3314839009126445e-07
heterodimer O 0 6.637289334321395e-05
substantially O 0 1.2992919437238015e-05
reduced O 0 9.356400454407776e-08
the O 0 5.717029960550235e-09
affinity O 0 9.468045192306818e-08
of O 0 4.263620567712678e-08
TfR O 0 0.00010546294652158394
for O 0 4.6164572609086463e-07
transferrin O 0 0.0008915093494579196
. O 0 2.680859324755147e-06

These O 0 4.246445769240381e-06
results O 0 9.765758477442432e-07
establish O 0 3.014366143361258e-07
a O 0 1.0863343504752265e-06
molecular O 0 4.540515874396078e-06
link O 0 4.215325134282466e-06
between O 0 1.446485669021058e-07
HFE O 0 0.004208216443657875
and O 0 1.01121671036708e-07
a O 0 9.260668321076082e-08
key O 0 4.0057596351061875e-08
protein O 0 6.673136709878236e-08
involved O 0 1.3936471532360883e-08
in O 0 2.352902583879768e-08
iron O 0 0.004686352796852589
transport O 0 8.153126032084401e-07
, O 0 3.381613566943997e-08
the O 0 5.1542802026460777e-08
TfR O 0 0.00019815207633655518
, O 0 3.467952325308943e-08
and O 0 1.166612051406446e-08
raise O 0 3.066522324957077e-08
the O 0 2.9634563691871563e-09
possibility O 0 2.8652564765252464e-08
that O 0 1.8983719485277106e-08
alterations O 0 1.623384719096066e-06
in O 0 1.659235415729654e-08
this O 0 8.99250363062265e-09
regulatory O 0 2.979759869958798e-07
mechanism O 0 1.871673447340072e-07
may O 0 5.357809982342587e-07
play O 0 1.3362168260755425e-08
a O 0 3.626101374720747e-08
role O 0 3.817076787981932e-08
in O 0 1.520409043109794e-08
the O 0 6.317263512300997e-08
pathogenesis O 0 6.92847024765797e-05
of O 0 7.500485935452161e-06
hereditary B-Disease 1 1.0
hemochromatosis I-Disease 1 1.0
. O 0 7.283704326255247e-05
. O 0 1.6882735280887573e-06

Genomic O 0 8.494652865920216e-05
organization O 0 1.3207296660766588e-06
of O 0 5.0960483832795944e-08
the O 0 2.7824864901049295e-07
UBE3A O 0 0.02815423347055912
/ O 0 0.00014477303193416446
E6 O 0 0.006954584736377001
- O 0 0.058080751448869705
AP O 0 9.702968964120373e-05
gene O 0 7.208344072751061e-07
and O 0 9.61531156917772e-08
related O 0 5.932652697993035e-07
pseudogenes O 0 6.588254473172128e-05
. O 0 3.5229991226515267e-06

The O 0 6.397061497409595e-06
UBE3A O 0 0.00026378402253612876
gene O 0 7.009899036347633e-06
encodes O 0 1.787537712516496e-06
the O 0 2.0795748412183457e-07
E6 O 0 8.856729255057871e-05
- O 0 0.0004537519998848438
AP O 0 2.0241670426912606e-05
ubiquitin O 0 3.3163578336825594e-06
- O 0 3.677007043734193e-06
protein O 0 2.405454608833679e-07
ligase O 0 1.9560984299005213e-07
and O 0 5.243862943871136e-08
has O 0 3.4817620075955347e-07
recently O 0 8.817951879791508e-07
been O 0 1.1818172396260707e-07
shown O 0 7.032404880646936e-08
to O 0 4.471526793281555e-08
be O 0 4.504346406974946e-07
mutated O 0 0.1079520434141159
in O 1 0.9806368947029114
Angelman B-Disease 1 1.0
syndrome I-Disease 1 1.0
patients O 1 0.9998156428337097
who O 0 2.1769857994513586e-05
lack O 0 1.1695841521941475e-06
15q11 O 0 5.90159252169542e-05
- O 0 4.323253597249277e-05
q13 O 0 2.9977105441503227e-05
deletions O 0 1.1083226127084345e-05
or O 0 4.2428209212630463e-07
chromosome O 0 0.00012143796629970893
15 O 0 2.3605859951203456e-06
paternal O 0 0.0004475843452382833
uniparental B-Disease 0 0.09035488218069077
disomy I-Disease 0 0.005820505786687136
. O 0 6.928515631443588e-06

Previous O 0 4.3809170165332034e-05
UBE3A O 0 0.00041786706424318254
cDNA O 0 1.9681878256960772e-05
analysis O 0 2.442708819216932e-06
has O 0 4.836999778490281e-07
shown O 0 9.040660131631739e-08
a O 0 5.116100965096848e-08
coding O 0 6.040284574737598e-07
region O 0 4.8172186239980874e-08
of O 0 6.315731049255646e-09
approximately O 0 1.2011267358502664e-07
2 O 0 7.621388817824482e-07
. O 0 7.405066071441979e-07

6 O 0 3.426800321904011e-05
kb O 0 4.744786929222755e-05
and O 0 1.582277633360718e-07
a O 0 8.501746719957737e-07
3 O 0 1.1231959433644079e-06
- O 0 0.0007164883427321911
untranslated O 0 0.010587234050035477
region O 0 1.5942587197059765e-06
( O 0 7.65113910006221e-08
UTR O 0 6.439639491873095e-06
) O 0 1.173172492485719e-08
of O 0 2.765793150061313e-09
< O 0 1.8212125496575027e-07
50 O 0 7.380616295904474e-08
bp O 0 7.235947123263031e-06
, O 0 3.280361582369551e-08
whereas O 0 6.327067580969015e-08
Northern O 0 3.663349090743395e-08
analysis O 0 2.6955072840451066e-08
has O 0 5.419471804657405e-08
indicated O 0 7.780170108162565e-08
mRNA O 0 9.893697416885061e-09
sizes O 0 1.67646128090837e-08
of O 0 1.926446335787091e-09
5 O 0 8.320580491272267e-08
- O 0 1.4769655535928905e-05
8 O 0 1.722264869385981e-06
kb O 0 0.00029361320775933564
. O 0 2.093327111651888e-06

We O 0 2.708386318772682e-06
have O 0 2.0859408778051147e-07
analyzed O 0 3.30680933302574e-07
additional O 0 5.443277828476312e-08
cDNA O 0 3.975883373641409e-07
clones O 0 1.1806992006313521e-06
and O 0 5.9508085570314506e-08
provide O 0 3.3560912271468624e-08
evidence O 0 3.047397711952726e-08
for O 0 5.714762441044741e-09
an O 0 6.16951183474157e-08
additional O 0 3.6641390011027397e-07
0 O 0 2.3731674900773214e-06
. O 0 1.1634166412477498e-06

5 O 0 1.2680257896136027e-05
kb O 0 3.0896371754352e-05
of O 0 2.3236286494920932e-07
5 O 0 5.678538741449302e-07
- O 0 2.464428143866826e-05
UTR O 0 0.00020322456839494407
and O 0 5.921517640672391e-07
> O 0 3.211543742054346e-07
2 O 0 6.362549243021931e-08
kb O 0 1.2466149428291828e-06
of O 0 1.5702166678011054e-08
3 O 0 8.032627647480695e-07
- O 0 0.000417383766034618
UTR O 0 0.012419292703270912
. O 0 4.3768659452325664e-06

We O 0 1.7584185343366698e-06
have O 0 1.7917277261858544e-07
established O 0 1.3721400904387338e-08
the O 0 4.184551372077294e-09
genomic O 0 8.621115910045773e-08
organization O 0 8.574980725484238e-09
of O 0 4.290621635760772e-09
UBE3A O 0 1.1860331142088398e-05
and O 0 3.6341472053891266e-08
the O 0 5.670819369640867e-09
sequence O 0 2.995166781261105e-08
of O 0 1.010387329358764e-08
intron O 0 3.9370021113427356e-05
- O 0 6.721020326949656e-05
exon O 0 2.078794568660669e-05
borders O 0 2.1080800252093468e-06
. O 0 1.21692676202656e-06

We O 0 6.392238447006093e-06
have O 0 5.536472826861427e-07
also O 0 3.0845760079500906e-07
mapped O 0 2.321388137715985e-06
two O 0 2.9550649927045924e-08
highly O 0 6.723935541685933e-08
homologous O 0 1.9528401651314198e-07
processed O 0 4.5653985125682084e-07
pseudogenes O 0 4.404274477565195e-06
, O 0 8.902468096039229e-08
UBE3AP1 O 0 1.6472440620418638e-05
and O 0 6.457003820514728e-08
UBE3AP2 O 0 2.388370739936363e-05
, O 0 9.921343746555067e-09
to O 0 9.293878555638457e-09
chromosomes O 0 9.953911472848631e-08
2 O 0 6.162984789170878e-08
and O 0 6.326850154891872e-08
21 O 0 2.824149021307676e-07
, O 0 2.773941076839037e-08
respectively O 0 2.186130387826779e-07
, O 0 1.3059755943345408e-08
and O 0 1.6532016644532632e-08
determined O 0 2.987988807490183e-07
their O 0 2.653560571275193e-08
genomic O 0 9.1921225475744e-07
organization O 0 3.1683333645560197e-07
. O 0 5.878775937162573e-07

These O 0 6.935767942195525e-06
results O 0 1.6352092870874912e-06
will O 0 4.8123879992090224e-08
form O 0 1.610700195442405e-08
the O 0 6.3631904190231126e-09
basis O 0 1.1983505743273781e-08
for O 0 1.0496150615324495e-08
studies O 0 1.8245396304905626e-08
of O 0 5.785059986607166e-09
mutation O 0 3.032965310012514e-07
and O 0 1.3998571191109477e-08
imprinting O 0 1.215103793583694e-06
of O 0 9.074383200413649e-08
UBE3A O 0 0.0006244467804208398
. O 0 2.521352143958211e-06

Mutation O 0 0.07296210527420044
spectrum O 0 0.0006115168798714876
and O 0 4.737498784379568e-06
genotype O 0 0.048479847609996796
- O 0 0.23047927021980286
phenotype O 1 0.9453020095825195
analyses O 0 7.814821401552763e-06
in O 0 1.6250312455667881e-06
Cowden B-Disease 1 0.9992175102233887
disease I-Disease 0 0.04342838004231453
and O 0 4.735579295811476e-06
Bannayan B-Disease 1 0.9825752973556519
- I-Disease 1 0.9999545812606812
Zonana I-Disease 1 0.9999904632568359
syndrome I-Disease 1 0.9999926090240479
, O 0 7.374887900368776e-07
two O 0 4.878811068920186e-06
hamartoma B-Disease 1 0.9997264742851257
syndromes I-Disease 1 0.9934966564178467
with O 0 1.3189750461606309e-05
germline O 0 0.06305721402168274
PTEN O 1 0.8711934685707092
mutation O 0 0.0003605209640227258
. O 0 3.5989789921586635e-06

The O 0 3.794591611949727e-05
tumour B-Disease 1 0.9998258948326111
suppressor O 0 0.005524704698473215
gene O 0 3.244865365559235e-05
PTEN O 0 0.0009610041161067784
, O 0 1.1264349808470797e-07
which O 0 2.674734744800844e-08
maps O 0 3.4945591664836684e-07
to O 0 5.023974267714948e-07
10q23 O 0 8.169246575562283e-05
. O 0 1.9323924789205194e-06

3 O 0 1.6048257748479955e-05
and O 0 3.0960461572249187e-07
encodes O 0 5.916493819313473e-07
a O 0 2.0426163871434255e-07
403 O 0 3.7298423194442876e-07
amino O 0 1.8799059375851357e-07
acid O 0 9.986836175812641e-07
dual O 0 2.2787646685173968e-06
specificity O 0 5.774562851001974e-06
phosphatase O 0 0.012144755572080612
( O 0 3.1367349606625794e-08
protein O 0 1.5105888451216742e-07
tyrosine O 0 2.361964106967207e-06
phosphatase O 0 9.060259617399424e-05
; O 0 9.577897941426272e-08
PTPase O 0 1.4832630768069066e-06
) O 0 1.266529192633925e-08
, O 0 1.3297386303179337e-08
was O 0 1.479931370340637e-06
shown O 0 2.466481987539737e-07
recently O 0 9.878974793764428e-08
to O 0 5.4635371782296716e-09
play O 0 1.4045133944762256e-08
a O 0 6.795167450945883e-08
broad O 0 1.7666486940015602e-07
role O 0 2.048425784551e-07
in O 0 1.5798997310412233e-07
human O 0 1.2473166179916007e-06
malignancy B-Disease 0 0.0013941783690825105
. O 0 5.036426955484785e-06

Somatic O 0 0.005372753832489252
PTEN O 0 0.4098935127258301
deletions O 0 0.002180788666009903
and O 0 3.2690448279026896e-05
mutations O 0 7.880729390308261e-05
were O 0 4.1517088789078116e-07
observed O 0 5.48500736385904e-07
in O 0 2.788216306726099e-07
sporadic B-Disease 0 0.28402018547058105
breast I-Disease 1 0.9997076392173767
, I-Disease 0 2.3490641979151405e-05
brain I-Disease 0 0.006921239197254181
, I-Disease 0 1.6732910808059387e-06
prostate I-Disease 1 0.8572502732276917
and I-Disease 0 0.010972247458994389
kidney I-Disease 1 0.9997640252113342
cancer I-Disease 0 0.29232385754585266
cell O 0 2.176748967031017e-05
lines O 0 1.5464719353985856e-06
and O 0 4.8601890512145474e-08
in O 0 5.385754775488749e-08
several O 0 2.8369927917992754e-07
primary O 0 0.00023812994186300784
tumours B-Disease 1 0.9999772310256958
such O 0 2.545084782923368e-07
as O 0 0.00029729248490184546
endometrial B-Disease 1 0.9999514818191528
carcinomas I-Disease 1 0.9999998807907104
, O 1 0.8791923522949219
malignant B-Disease 1 1.0
melanoma I-Disease 1 1.0
and O 1 0.9793282151222229
thyroid B-Disease 1 0.9999774694442749
tumours I-Disease 1 0.9999967813491821
. O 0 2.5909699616022408e-05

In O 0 4.353652457211865e-06
addition O 0 9.57809561441536e-07
, O 0 2.404147494416975e-07
PTEN O 0 0.0010661615524441004
was O 0 6.799913080612896e-06
identified O 0 1.113291432375263e-07
as O 0 5.889873477826768e-09
the O 0 2.2190405957189796e-08
susceptibility O 0 0.00010611300240270793
gene O 0 5.528912083718751e-07
for O 0 8.86803093180788e-08
two O 0 4.234074367559515e-05
hamartoma B-Disease 1 0.9999908208847046
syndromes I-Disease 1 0.9999959468841553
Cowden B-Disease 1 0.9999933242797852
disease I-Disease 1 0.9963655471801758
( O 0 3.7376582895376487e-07
CD B-Disease 0 0.00033971769153140485
; O 0 2.743332288446254e-06
MIM O 0 7.444482616847381e-05
158350 O 0 5.278581738821231e-06
) O 0 5.773070554937476e-08
and O 0 1.7964980258966534e-07
Bannayan B-Disease 0 0.00025403525796718895
- I-Disease 0 0.006650581490248442
Zonana I-Disease 0 0.012832696549594402
( I-Disease 0 2.7288533033242857e-07
BZS I-Disease 0 1.2234233508934267e-05
) I-Disease 0 1.4276008641900262e-07
or I-Disease 0 1.747892639514248e-07
Ruvalcaba I-Disease 0 0.00021426635794341564
- I-Disease 0 0.00013370771193876863
Riley I-Disease 0 0.00015521944442298263
- I-Disease 0 0.4857262074947357
Smith I-Disease 1 0.945773184299469
syndrome I-Disease 1 0.9997599720954895
( O 0 4.517570744155819e-07
MIM O 0 0.00012527561921160668
153480 O 0 2.0056895664311014e-05
) O 0 2.659405424765282e-07
. O 0 4.944868123857304e-07

Constitutive O 0 0.00024558574659749866
DNA O 0 3.8961603422649205e-05
from O 0 5.109196763442014e-07
37 O 0 9.40666154747305e-07
CD B-Disease 0 5.381665687309578e-06
families O 0 2.005409953653725e-07
and O 0 6.287464060505954e-08
seven O 0 1.6902455968192953e-07
BZS B-Disease 0 7.798175647621974e-05
families O 0 4.2714921733022493e-07
was O 0 6.676293082819029e-07
screened O 0 6.6153379520983435e-06
for O 0 6.30700583315047e-07
germline O 0 0.0006917484570294619
PTEN O 1 0.7119625210762024
mutations O 0 0.00016386107017751783
. O 0 3.425642489673919e-06

PTEN O 1 0.9859484434127808
mutations O 0 0.2354278415441513
were O 0 1.0192173249379266e-05
identified O 0 1.4750194168300368e-06
in O 0 2.5285075366809906e-08
30 O 0 5.0439165732996116e-08
of O 0 1.1920087139571933e-08
37 O 0 2.605238933028886e-06
( O 0 8.709887566737962e-08
81 O 0 5.9238529502181336e-05
% O 0 8.278314567178313e-08
) O 0 6.2335128170332155e-09
CD B-Disease 0 8.330286618729588e-06
families O 0 5.461195939915342e-08
, O 0 8.571186427275279e-09
including O 0 1.8908735910372343e-08
missense O 0 4.314115358283743e-06
and O 0 7.872060336922004e-08
nonsense O 0 5.094681455375394e-06
point O 0 3.519066638091317e-07
mutations O 0 1.2624526561921812e-06
, O 0 2.4806471543570296e-08
deletions O 0 6.309532523118833e-07
, O 0 7.526515588551774e-08
insertions O 0 2.255128720207722e-06
, O 0 6.176988875949974e-08
a O 0 5.557765803132497e-07
deletion O 0 7.127967546693981e-05
/ O 0 2.51362598646665e-06
insertion O 0 2.476856479916023e-06
and O 0 2.4362546469092194e-07
splice O 0 4.389850437291898e-05
site O 0 1.694686579867266e-05
mutations O 0 1.493716990808025e-05
. O 0 9.967664027499268e-07

These O 0 3.367034878465347e-06
mutations O 0 1.6903817595448345e-05
were O 0 2.2045124126179871e-07
scattered O 0 1.204488881967336e-07
over O 0 1.264843376702629e-07
the O 0 4.3176488162544047e-08
entire O 0 7.14536980694902e-08
length O 0 2.5082235310947e-07
of O 0 6.283445319610337e-09
PTEN O 0 0.004421988036483526
, O 0 2.502211593480297e-08
with O 0 6.624651494036016e-09
the O 0 7.970442972293768e-09
exception O 0 3.428124983884118e-08
of O 0 1.2087350009792885e-09
the O 0 4.160992883583958e-09
first O 0 1.623990328880609e-07
, O 0 2.5911120360433415e-08
fourth O 0 1.8887763530983648e-07
and O 0 6.542855146562943e-08
last O 0 1.8917158968179137e-06
exons O 0 2.0087829398107715e-05
. O 0 1.7249934671781375e-06

A O 0 3.0904975574230775e-05
hot O 0 2.7661919375532307e-05
spot O 0 2.72890497399203e-06
for O 0 3.161822803576797e-07
PTEN O 0 0.010837043635547161
mutation O 0 7.778649887768552e-06
in O 0 5.479005338315801e-08
CD B-Disease 0 4.548201832221821e-05
was O 0 5.325282472767867e-05
identified O 0 3.0166381748131244e-07
in O 0 1.3466481263435526e-08
exon O 0 1.3641247278428636e-06
5 O 0 5.164938343682479e-08
that O 0 7.67114016753112e-09
contains O 0 1.1540503663809432e-08
the O 0 6.035980160135068e-09
PTPase O 0 8.813630643089709e-07
core O 0 1.6295194882331998e-07
motif O 0 1.832862324135931e-07
, O 0 3.9295455778187716e-09
with O 0 2.3469086674055006e-09
13 O 0 1.257759141282122e-08
of O 0 1.5633723204899752e-09
30 O 0 5.250829104852528e-08
( O 0 6.236866578746003e-09
43 O 0 1.289071065002645e-06
% O 0 2.7265945945487147e-08
) O 0 1.081432809968419e-08
CD B-Disease 0 0.00019021498155780137
mutations O 0 6.727425898134243e-06
identified O 0 1.40406527293635e-07
in O 0 1.061781063071976e-08
this O 0 5.638197464463701e-08
exon O 0 1.052325933414977e-05
. O 0 1.3893815093979356e-06

Seven O 0 6.527525783894816e-06
of O 0 1.8617610919591243e-07
30 O 0 4.6933476482990955e-07
( O 0 4.570865996811335e-08
23 O 0 1.199238568005967e-06
% O 0 2.569545820563235e-08
) O 0 4.819826315838327e-09
were O 0 2.177212365950254e-08
within O 0 1.5286373278300402e-09
the O 0 3.795809888629265e-09
core O 0 2.8968099741177866e-07
motif O 0 3.815985394339805e-07
, O 0 2.0918808019132484e-08
the O 0 1.1863088289487678e-08
majority O 0 3.1795377708476735e-06
( O 0 5.630778954213156e-09
five O 0 5.666051183794707e-09
of O 0 1.5221666149756174e-09
seven O 0 3.343377130704539e-08
) O 0 3.270376858210966e-09
of O 0 1.5729735292069336e-09
which O 0 1.3603646209503495e-07
were O 0 1.0333362752135145e-06
missense O 0 0.0002128520281985402
mutations O 0 2.016907501456444e-06
, O 0 1.993765508245815e-08
possibly O 0 2.595494486001826e-08
pointing O 0 1.616856906139219e-07
to O 0 2.9720563787805077e-08
the O 0 1.6839024397086177e-08
functional O 0 1.566394445262631e-07
significance O 0 2.4230258688362483e-08
of O 0 4.540728237856229e-09
this O 0 6.213407033328622e-08
region O 0 1.107156322177616e-06
. O 0 1.5356624771811767e-06

Germline O 1 0.7046951055526733
PTEN O 1 0.9937067627906799
mutations O 1 0.8547729253768921
were O 0 5.40796245331876e-05
identified O 0 3.2380273751186905e-06
in O 0 2.528266485057884e-08
four O 0 1.8292261927399522e-08
of O 0 6.872956426207111e-09
seven O 0 3.4091053180418385e-07
( O 0 8.227440417840626e-08
57 O 0 1.6855043213581666e-05
% O 0 1.754343799120761e-07
) O 0 8.670306783642445e-08
BZS B-Disease 0 6.191325519466773e-05
families O 0 4.536065034699277e-07
studied O 0 1.5719928114776849e-06
. O 0 1.068794972525211e-06

Interestingly O 0 0.003458591876551509
, O 0 2.65924586528854e-06
none O 0 2.0415880896962335e-07
of O 0 4.400504405310812e-09
these O 0 1.512408687176503e-08
mutations O 0 7.124480134734767e-07
was O 0 8.931241950449476e-07
observed O 0 5.301923167166933e-08
in O 0 4.702969569336801e-09
the O 0 2.5656962776565706e-08
PTPase O 0 1.784860978659708e-05
core O 0 2.033614464380662e-06
motif O 0 4.186400474281982e-06
. O 0 7.89090904618206e-07

It O 0 3.680153895402327e-06
is O 0 2.528110485400248e-07
also O 0 1.0079854462219373e-07
worthy O 0 8.720825661612253e-08
of O 0 5.4284279293881355e-09
note O 0 1.4125978964329988e-07
that O 0 1.3264962461789764e-08
a O 0 5.338575803648382e-08
single O 0 1.8252397637752438e-07
nonsense O 0 7.938635917525971e-07
point O 0 1.2136892735270521e-07
mutation O 0 5.149843218532624e-07
, O 0 2.757903416750196e-08
R233X O 0 1.6053750186983962e-06
, O 0 1.969383944810943e-08
was O 0 8.087857850114233e-07
observed O 0 4.282055598991974e-08
in O 0 3.7133649488652054e-09
the O 0 1.4223791033884936e-08
germline O 0 2.476433792253374e-06
DNA O 0 3.967883515088033e-07
from O 0 7.847829941454165e-09
two O 0 1.7067831592498806e-08
unrelated O 0 4.29757733400038e-07
CD B-Disease 0 4.170398096903227e-05
families O 0 1.8718306193932222e-07
and O 0 8.664355277687719e-08
one O 0 3.4970796036759566e-07
BZS B-Disease 0 0.00030571655952371657
family O 0 4.173166416876484e-06
. O 0 7.858901085455727e-07

Genotype O 1 0.9928948283195496
- O 1 0.9901431798934937
phenotype O 1 0.9968895316123962
studies O 0 1.1913913340322324e-06
were O 0 3.120022142866219e-07
not O 0 8.507166171511926e-08
performed O 0 1.039531639435154e-06
on O 0 8.752270730383316e-08
this O 0 9.374188536526162e-09
small O 0 3.405101622888651e-08
group O 0 1.0651323378851885e-07
of O 0 3.3038709545962774e-08
BZS B-Disease 0 0.00017676872084848583
families O 0 1.3051783298578812e-06
. O 0 7.478633961000014e-07

However O 0 2.855467755580321e-05
, O 0 1.1019957355529186e-06
genotype O 0 0.00021446873142849654
- O 0 0.0017490581376478076
phenotype O 0 0.04223386198282242
analysis O 0 9.187269256472064e-08
inthe O 0 1.1525015679580974e-06
group O 0 3.5528479713775596e-08
of O 0 3.246560797975917e-09
CD B-Disease 0 5.127442273078486e-05
families O 0 6.521351281207899e-08
revealed O 0 1.0890526169760051e-07
two O 0 3.990673125287003e-09
possible O 0 8.266540341139716e-09
associations O 0 3.075547150288571e-09
worthy O 0 3.123606617805308e-08
of O 0 2.8971722798587507e-09
follow O 0 6.642202521334184e-08
- O 0 1.034191996041045e-06
up O 0 7.702681159571512e-08
in O 0 2.252519948342524e-08
independent O 0 2.668269303285342e-07
analyses O 0 1.37817619361158e-06
. O 0 3.689455638777872e-07

The O 0 5.825177709084528e-07
first O 0 4.371886745957454e-07
was O 0 9.466119763601455e-07
an O 0 1.0564422581182953e-07
association O 0 5.587154561226271e-08
noted O 0 1.579547159735739e-07
in O 0 1.1982934644549914e-08
the O 0 7.370104526671639e-09
group O 0 1.8800202283841827e-08
of O 0 2.0541166545484657e-09
CD B-Disease 0 9.789764590095729e-05
families O 0 6.160922794151702e-07
with O 0 2.36530522670364e-05
breast B-Disease 1 0.9999316930770874
disease I-Disease 0 0.05819284915924072
. O 0 4.7418425310752355e-06

A O 0 2.6701183742261492e-05
correlation O 0 1.6280377167277038e-05
was O 0 7.255412583617726e-06
observed O 0 4.833430580220011e-07
between O 0 1.7178418687535668e-08
the O 0 2.1884162038077193e-08
presence O 0 4.921129175272654e-07
/ O 0 1.8822322545020143e-06
absence O 0 1.071013642217622e-07
of O 0 2.5435444861443557e-09
a O 0 4.628347141988343e-06
PTEN O 0 0.4970337152481079
mutation O 0 2.6528373382461723e-06
and O 0 8.440459886571716e-09
the O 0 7.3395791666541754e-09
type O 0 4.157188300268899e-07
of O 0 5.406349501413388e-08
breast O 0 0.4786109924316406
involvement O 0 8.257708032033406e-06
( O 0 2.8107976390856493e-07
unaffected O 0 0.0005003492115065455
versus O 0 0.00036822963738813996
benign O 0 0.07051078975200653
versus O 0 0.003926393110305071
malignant O 1 0.78119295835495
) O 0 4.857988074036257e-07
. O 0 1.6398082607338438e-06

Specifically O 0 4.3947507947450504e-05
and O 0 6.361044597724685e-07
more O 0 7.506158539172247e-08
directly O 0 9.230936370840936e-08
, O 0 2.6701929556338655e-08
an O 0 5.710374040290844e-08
association O 0 7.650350397625516e-08
was O 0 4.038554834551178e-06
also O 0 4.724297753000428e-07
observed O 0 4.447489487802159e-08
between O 0 4.792032992639861e-09
the O 0 6.547459907579878e-09
presence O 0 3.483279087390656e-08
of O 0 5.1349369201147965e-09
a O 0 2.427639174129581e-06
PTEN O 1 0.5836071372032166
mutation O 0 0.00010009119432652369
and O 0 5.2111590775894e-05
malignant B-Disease 1 0.9999812841415405
breast I-Disease 1 0.999984860420227
disease I-Disease 0 0.1418829709291458
. O 0 6.628226401517168e-06

Secondly O 0 0.0008504652068950236
, O 0 8.961000048657297e-07
there O 0 1.209430280368906e-07
appeared O 0 1.1642884601315018e-05
to O 0 6.416305353695861e-08
be O 0 3.585927998983607e-08
an O 0 1.3946129229225335e-07
interdependent O 0 1.902035546663683e-05
association O 0 8.66260378984407e-08
between O 0 2.091609374588188e-08
mutations O 0 3.34523377887308e-07
upstream O 0 2.8149440112201773e-08
and O 0 6.933986274049175e-09
within O 0 1.4009916560198121e-09
the O 0 5.920487211596992e-09
PTPase O 0 2.0321351712482283e-06
core O 0 1.7872619650916022e-07
motif O 0 1.584172366619896e-07
, O 0 9.931283351249931e-09
the O 0 4.128800856761927e-09
core O 0 1.2014314165753603e-07
motif O 0 1.7534104301830666e-07
containing O 0 1.546872496760443e-08
the O 0 4.946402842875841e-09
majority O 0 1.5371293216048798e-07
of O 0 6.031112498305902e-09
missense O 0 0.0002012768673012033
mutations O 0 5.126873929839348e-06
, O 0 2.489282913131774e-08
and O 0 1.1012298628543249e-08
the O 0 5.852928808280922e-09
involvement O 0 4.01114199632957e-08
of O 0 1.8700450077346886e-09
all O 0 5.176069350909529e-09
major O 0 4.5969290596303836e-08
organ O 0 9.088547085411847e-05
systems O 0 7.427879609167576e-06
( O 0 2.101398344223071e-08
central O 0 4.3889226475357646e-08
nervous O 0 4.431432898854837e-06
system O 0 9.686564226285554e-07
, O 0 1.457256757930736e-06
thyroid O 0 0.09603811055421829
, O 0 7.820025530236308e-06
breast O 1 0.73282790184021
, O 0 4.5380424126051366e-05
skin O 1 0.9996498823165894
and O 1 0.8183335661888123
gastrointestinal O 1 0.999998927116394
tract O 1 0.9992110729217529
) O 0 1.552073172206292e-06
. O 0 1.3466425343722221e-06

However O 0 3.579989788704552e-05
, O 0 9.848421456126744e-08
these O 0 6.919559147888776e-09
observations O 0 2.1519831250316201e-07
would O 0 7.07915717157448e-08
need O 0 2.5804885339653083e-08
to O 0 8.98098804213987e-08
be O 0 3.6290529692450946e-07
confirmed O 0 2.0472709820751334e-06
by O 0 9.518996257895651e-09
studying O 0 1.3101845830476577e-08
a O 0 5.0500773340900196e-08
larger O 0 3.057761688296523e-08
number O 0 1.0683018025758884e-08
of O 0 9.757174623814535e-09
CD B-Disease 0 0.00011678673763526604
families O 0 1.500890334682481e-06
. O 0 8.556128250347683e-07

Molecular O 0 0.3263297975063324
defects O 1 0.9987388253211975
leading O 0 9.90299758996116e-06
to O 0 3.8632580867670185e-07
human O 0 5.279792389956128e-07
complement B-Disease 0 4.188372986391187e-05
component I-Disease 1 0.819273054599762
C6 I-Disease 1 1.0
deficiency I-Disease 1 0.9999995231628418
in O 0 2.7468013286124915e-07
an O 0 1.524851711565134e-07
African O 0 1.4438339235312014e-07
- O 0 2.9599319532280788e-05
American O 0 7.819465395186853e-07
family O 0 6.056417873878672e-07
. O 0 4.424294672844553e-07

Complement B-Disease 0 0.0039019070100039244
component I-Disease 1 0.9559261798858643
C6 I-Disease 1 0.9999998807907104
deficiency I-Disease 1 0.9999997615814209
( O 0 3.4976640108652646e-06
C6D B-Disease 0 0.013440566137433052
) O 0 9.252447057406243e-07
was O 0 0.050208814442157745
diagnosed O 1 0.8106229305267334
in O 0 2.7676257730036014e-08
a O 0 4.1719547994034656e-07
16 O 0 1.6802619029476773e-07
- O 0 5.960286671324866e-06
year O 0 3.5926720443058e-07
- O 0 5.461135060613742e-06
old O 0 5.356790097721387e-06
African O 0 3.675008031223115e-08
- O 0 2.2608371637033997e-06
American O 0 6.791603937017499e-07
male O 0 4.256389001966454e-05
with O 0 0.00012947159120813012
meningococcal B-Disease 1 0.999998927116394
meningitis I-Disease 1 0.9999973773956299
. O 0 3.256319178035483e-05

The O 0 6.55800467939116e-05
patients O 0 0.058244019746780396
father O 0 1.4374016245710663e-05
and O 0 8.887538172075438e-08
two O 0 1.4652206914433918e-07
brothers O 0 1.7639831639826298e-06
also O 0 1.095231141334807e-07
had O 0 9.06657760424423e-07
C6D B-Disease 0 0.00019045273074880242
, O 0 5.697047100738928e-08
but O 0 3.142070426065402e-08
gave O 0 1.0883528744898285e-07
no O 0 1.7575933597413496e-08
history O 0 1.7135844743165762e-08
of O 0 8.419304009521511e-08
meningitis B-Disease 1 0.9999542236328125
or O 0 3.713884666467493e-07
other O 0 1.389435482224144e-07
neisserial B-Disease 1 0.7982630729675293
infection I-Disease 0 0.05285343900322914
. O 0 2.476653207850177e-06

By O 0 3.7369031815615017e-06
using O 0 4.656859289298154e-07
exon O 0 3.511534487188328e-06
- O 0 8.377205631404649e-07
specific O 0 2.768396534236217e-08
polymerase O 0 1.2133482414355967e-06
chain O 0 3.690902076414204e-06
reaction O 0 4.870396423939383e-07
( O 0 4.998136571288114e-09
PCR O 0 1.8810605979524553e-06
) O 0 2.3887658073817875e-08
/ O 0 8.103717163976398e-08
single O 0 8.255672412360582e-08
- O 0 2.3677671379118692e-06
strand O 0 2.488201744199614e-06
conformation O 0 5.829418228131544e-07
polymorphism O 0 1.924058778968174e-06
as O 0 2.1058239596527528e-08
a O 0 4.034544431874565e-08
screening O 0 1.7789669470857916e-07
step O 0 1.4320679042612028e-07
and O 0 7.9919679762952e-09
nucleotide O 0 1.1655223453033159e-08
sequencing O 0 8.461253031555316e-09
of O 0 1.2436719432074028e-09
target O 0 2.5721496044184278e-08
exons O 0 2.406083581263374e-07
, O 0 8.499166703757055e-09
we O 0 2.8377347138786035e-09
determined O 0 3.937387660357672e-08
that O 0 6.934727458940415e-09
the O 0 5.966239058352585e-09
proband O 0 4.896397058473667e-06
was O 0 2.835286352365074e-07
a O 0 2.629046136348734e-08
compound O 0 5.243998089099478e-07
heterozygote O 0 4.509453447099077e-06
for O 0 2.9241100207855197e-08
two O 0 2.893090993438818e-07
C6 O 0 0.11115802824497223
gene O 0 5.680364483851008e-05
mutations O 0 3.773649950744584e-05
. O 0 3.2934569844655925e-06

The O 0 2.3782245079928543e-06
first O 0 7.411339879581647e-07
, O 0 9.319212068703564e-08
1195delC O 0 1.0812419759531622e-06
located O 0 7.197786544566043e-08
in O 0 2.0160749514275267e-08
exon O 0 1.8280353515365277e-06
7 O 0 2.64610122258091e-07
, O 0 1.3966968026579707e-08
is O 0 1.4636976963799953e-08
a O 0 1.7622366499381314e-07
novel O 0 2.4122045942931436e-06
mutation O 0 3.63219328392006e-07
, O 0 2.999201109687988e-09
while O 0 3.7220160287176896e-09
the O 0 1.171595376270318e-09
second O 0 5.517030032820003e-08
, O 0 1.9213466373457777e-08
1936delG O 0 3.566005659649818e-07
in O 0 1.4380947988001935e-08
exon O 0 6.865477644169005e-07
12 O 0 1.0940827621652716e-07
, O 0 1.7997678014580742e-08
has O 0 2.417408495603013e-07
been O 0 1.2689585560110572e-07
described O 0 1.9910203263862059e-07
before O 0 1.1421509960030107e-08
to O 0 1.0858502008659343e-07
cause O 0 2.302264419995481e-06
C6D B-Disease 0 0.0008781845681369305
in O 0 9.007664658611247e-08
an O 0 9.467395045703597e-08
unrelated O 0 4.4796325937568326e-07
African O 0 5.493896892971861e-08
- O 0 5.899697043787455e-06
American O 0 6.162608769955114e-07
individual O 0 1.2129694937357272e-07
. O 0 5.430993610389123e-07

Both O 0 2.692134876269847e-05
mutations O 0 0.00030703385709784925
result O 0 2.4786004360066727e-06
in O 0 9.303616366196366e-07
premature O 0 0.003199645783752203
termination O 0 6.52745075058192e-05
codons O 0 7.611353339598281e-06
and O 0 2.737940121733118e-06
C6 O 0 0.029386671259999275
null O 0 0.004476604983210564
alleles O 0 4.1799095924943686e-05
. O 0 6.665391083515715e-06

Allele O 0 0.004302289802581072
- O 0 0.00017170557111967355
specific O 0 1.0245910289086169e-06
PCR O 0 9.348343883175403e-05
indicated O 0 9.023430720844772e-06
that O 0 2.4861842362611242e-08
the O 0 1.5035386269346418e-08
probands O 0 4.5344473619479686e-05
two O 0 2.8245719363440003e-07
brothers O 0 2.7115290777146583e-06
also O 0 2.2453571091318736e-07
inherited O 0 6.101195708652085e-07
the O 0 1.2438671426195924e-08
1195delC O 0 7.880058547016233e-06
mutation O 0 4.068799057677097e-07
from O 0 3.493823674816099e-09
their O 0 1.687790174287329e-08
heterozygous O 0 2.6777604944072664e-05
mother O 0 4.207794518151786e-06
and O 0 1.7911652605562267e-08
the O 0 1.4861408992317138e-08
1936delG O 0 1.4604966054321267e-05
mutation O 0 6.891217481097556e-07
from O 0 6.7164216410731115e-09
their O 0 2.2943197564018192e-08
homozygous O 0 6.909274816280231e-06
father O 0 6.835106887592701e-06
. O 0 2.337199020985281e-07
. O 0 8.254088470494025e-07

PAX6 O 1 0.9709787964820862
mutations O 1 0.8575977683067322
reviewed O 0 0.0010274754604324698
. O 0 4.174779314780608e-05

Mutations O 0 0.18137216567993164
in O 0 5.092952051199973e-06
PAX6 O 0 0.0016532879089936614
are O 0 2.592029773040849e-07
responsible O 0 3.6698111216537654e-07
for O 0 1.430638718602495e-07
human O 0 6.518186523862823e-07
aniridia B-Disease 1 0.9999953508377075
and O 0 4.083966814505402e-06
have O 0 2.9426104219965055e-07
also O 0 2.3535091031590127e-07
been O 0 5.140261123415257e-07
found O 0 3.640870431809162e-07
in O 0 8.698471560819598e-07
patients O 0 0.0016913433792069554
with O 0 2.4678454792592674e-05
Peters B-Disease 1 0.9999988079071045
anomaly I-Disease 1 0.9999995231628418
, O 0 7.458900654455647e-05
with O 0 0.1733703911304474
congenital B-Disease 1 1.0
cataracts I-Disease 1 0.9999980926513672
, O 0 1.4480231584457215e-05
with O 0 1.1561405699467286e-05
autosomal B-Disease 1 0.9850432872772217
dominant I-Disease 1 0.5507778525352478
keratitis I-Disease 1 0.9987432360649109
, O 0 9.827515441429568e-07
and O 0 1.5041344170185766e-07
with O 0 3.50729055753618e-06
isolated B-Disease 0 0.022857578471302986
foveal I-Disease 1 0.9999953508377075
hypoplasia I-Disease 1 0.9999935626983643
. O 0 6.073966869735159e-05

No O 0 8.755291673878673e-06
locus O 0 8.689121386851184e-06
other O 0 6.025963017464164e-08
than O 0 1.2813515581910906e-07
chromosome O 0 1.1717940651578829e-05
11p13 O 0 1.2831193089368753e-05
has O 0 5.306976618157933e-07
been O 0 2.610200056096801e-07
implicated O 0 1.6498696595590445e-06
in O 0 3.869264446620946e-07
aniridia B-Disease 1 0.9999892711639404
, O 0 3.481725627807464e-07
and O 0 1.574346697452711e-07
PAX6 O 0 0.0003482780302874744
is O 0 3.4891047562268795e-07
clearly O 0 1.493148147346801e-07
the O 0 3.803107606614731e-09
major O 0 1.4468492182118098e-08
, O 0 2.4398415732207468e-08
if O 0 7.4475998701473145e-09
not O 0 1.03275512586265e-08
only O 0 1.8605359031198532e-08
, O 0 2.9208379714873445e-08
gene O 0 1.677853589399092e-07
responsible O 0 4.589495574691682e-07
. O 0 4.893522032034525e-07

Twenty O 0 2.0814406525460072e-05
- O 0 2.6346431695856154e-05
eight O 0 9.632967703510076e-07
percent O 0 2.531263589844457e-07
of O 0 1.8795791589809596e-08
identified O 0 4.9402578952140175e-06
PAX6 O 0 0.04054609686136246
mutations O 0 3.49700239894446e-05
are O 0 1.1324139848056802e-07
C O 0 6.239073627511971e-06
- O 0 0.0004959219950251281
T O 0 0.00032195114181376994
changes O 0 9.061220396233693e-08
at O 0 1.895817369756969e-08
CpG O 0 1.244469672201376e-06
dinucleotides O 0 1.294331559620332e-05
, O 0 3.8867977281142885e-08
20 O 0 1.698657570159412e-08
% O 0 3.865673114944457e-09
are O 0 9.509500964455242e-10
splicing O 0 4.076500772498548e-07
errors O 0 3.5997504710394423e-07
, O 0 1.7887344938571914e-08
and O 0 1.7921220063499277e-08
more O 0 1.451537201546671e-08
than O 0 5.275986936226218e-08
30 O 0 6.21260127786627e-08
% O 0 1.3444743096613365e-08
are O 0 3.2146243444941547e-09
deletion O 0 1.4035005051482585e-06
or O 0 3.402536918883925e-08
insertion O 0 2.326782805539551e-06
events O 0 7.547705536126159e-07
. O 0 1.9648966826935066e-06

There O 0 4.2136171032325365e-06
is O 0 2.577508269041573e-07
a O 0 6.237475531634118e-07
noticeably O 0 0.0023425540421158075
elevated O 0 0.00021885574096813798
level O 0 2.2776641017685506e-08
of O 0 2.7327315965663956e-09
mutation O 0 4.886499027634272e-07
in O 0 1.3602109660837414e-08
the O 0 2.4227762907003125e-08
paired O 0 2.6903817342827097e-06
domain O 0 1.6278357861665427e-07
compared O 0 1.4703830686357833e-07
with O 0 4.82956208358587e-09
the O 0 1.1142915923301189e-08
rest O 0 2.5073044085388574e-08
of O 0 3.627372624492864e-09
the O 0 2.8530298123996545e-08
gene O 0 1.8369446479482576e-06
. O 0 5.467798018798931e-07

Increased O 0 0.00011501472909003496
mutation O 0 4.706643085228279e-05
in O 0 1.8322087669275788e-07
the O 0 2.0342416462426627e-07
homeodomain O 0 6.060624946258031e-05
is O 0 3.7758681514787895e-07
accounted O 0 1.9275908869076375e-07
for O 0 4.351485838327562e-09
by O 0 7.432727766598646e-09
the O 0 3.150507765781185e-08
hypermutable O 0 9.803890861803666e-05
CpG O 0 8.782470104051754e-06
dinucleotide O 0 8.611453267803881e-06
in O 0 1.3476841331794276e-07
codon O 0 1.2127339914513868e-06
240 O 0 2.457403297739802e-06
. O 0 2.14031797440839e-06

Very O 0 1.1847195310110692e-05
nearly O 0 6.934967586857965e-07
all O 0 2.9165347470438974e-08
mutations O 0 1.7457981584811932e-06
appear O 0 1.4051612424736959e-06
to O 0 1.732709620227979e-06
cause O 0 0.0005084886215627193
loss O 0 1.3731811122852378e-05
of O 0 8.378417959420403e-09
function O 0 9.061199790494356e-09
of O 0 9.789381527625096e-10
the O 0 7.832203330337961e-09
mutant O 0 2.494983391443384e-06
allele O 0 4.327010572069412e-07
, O 0 5.043759632172851e-09
and O 0 6.088880954990827e-09
more O 0 1.737978472249324e-08
than O 0 3.157763117656032e-08
80 O 0 6.306464683802915e-08
% O 0 4.077796766921438e-09
of O 0 9.53550904903011e-10
exonic O 0 3.1910901725495933e-06
substitutions O 0 3.1919165621729917e-07
result O 0 7.448313255054018e-08
in O 0 4.184433777254526e-08
nonsense O 0 1.064451953425305e-05
codons O 0 6.219363058335148e-06
. O 0 9.479769573772501e-07

In O 0 4.310320036893245e-06
a O 0 1.2279670045245439e-06
gene O 0 3.7381113315859693e-07
with O 0 3.869917009069468e-08
such O 0 2.9414845670316936e-08
extraordinarily O 0 3.827908949460834e-05
high O 0 2.7470002805785043e-07
sequence O 0 3.4976459062363574e-08
conservation O 0 7.855378569843197e-09
throughout O 0 3.5418175059476198e-09
evolution O 0 9.746869977789174e-09
, O 0 8.943838558650441e-09
there O 0 1.1240425479286387e-08
are O 0 1.9222778036009913e-08
presumed O 0 0.00012823408178519458
undiscovered O 0 8.510772022418678e-05
missense O 0 0.00023186785983853042
mutations O 0 4.780282324645668e-06
, O 0 1.899907786651056e-08
these O 0 7.324740813885455e-09
are O 0 1.1497200524956952e-08
hypothesized O 0 1.8106881043422618e-06
to O 0 1.0291020657859917e-07
exist O 0 1.2105792812633354e-08
in O 0 7.656902667463328e-09
as O 0 8.16149849924841e-08
- O 0 2.0842177036684006e-05
yet O 0 1.2351159057288896e-05
unidentified O 0 1.0483701771590859e-05
phenotypes O 0 1.1517465281940531e-05
. O 0 1.138577800929852e-07
. O 0 3.7232854310786934e-07

Genetic O 0 0.005149705335497856
heterogeneity O 0 0.0038310782983899117
and O 0 1.2849634913436603e-05
penetrance O 0 0.0002030808391282335
analysis O 0 4.234110235756816e-07
of O 0 1.031564078601832e-08
the O 0 1.1471018979136716e-07
BRCA1 O 0 0.0002230107202194631
and O 0 1.316564521403052e-06
BRCA2 O 0 0.00020543797290883958
genes O 0 1.4055364090381772e-06
in O 0 2.4117694920278154e-05
breast B-Disease 1 0.9999810457229614
cancer I-Disease 1 0.997467041015625
families O 0 3.5032192045036936e-06
. O 0 2.5620372525736457e-06

The O 0 0.005928488913923502
Breast B-Disease 1 0.9999979734420776
Cancer I-Disease 1 0.9999657869338989
Linkage O 0 0.0005610976368188858
Consortium O 0 7.987474964465946e-05
. O 0 6.305361239355989e-06

The O 0 2.381558715569554e-06
contribution O 0 3.587348089695297e-07
of O 0 4.86991353909616e-08
BRCA1 O 0 0.00012913733371533453
and O 0 8.489548235957045e-06
BRCA2 O 0 0.39023974537849426
to O 0 0.2245287448167801
inherited B-Disease 1 1.0
breast I-Disease 1 0.9999998807907104
cancer I-Disease 1 0.9999998807907104
was O 0 0.023548992350697517
assessed O 0 2.4586295239714673e-06
by O 0 5.835219596406205e-08
linkage O 0 5.37447976967087e-06
and O 0 1.393635898239154e-06
mutation O 0 1.8422357470626594e-06
analysis O 0 3.96681585357328e-08
in O 0 1.947045191741381e-08
237 O 0 1.7464475376982591e-06
families O 0 2.3201390320082282e-07
, O 0 1.3053032432708278e-08
each O 0 1.5579665335607729e-09
with O 0 3.5158371769483665e-09
at O 0 8.652757621518958e-09
least O 0 2.580060431967013e-08
four O 0 2.5258659164251185e-08
cases O 0 7.072598151580678e-08
of O 0 4.505196784521104e-07
breast B-Disease 1 0.9999785423278809
cancer I-Disease 0 0.3605698347091675
, O 0 2.452967429178443e-08
collected O 0 3.8185184791927895e-08
by O 0 7.275717450738739e-08
the O 0 2.5285800802521408e-05
Breast B-Disease 1 0.9999998807907104
Cancer I-Disease 1 0.9999909400939941
Linkage O 0 9.046566992765293e-05
Consortium O 0 1.4697827282361686e-05
. O 0 7.279881515387387e-07

Families O 0 0.00018359979731030762
were O 0 1.623688149265945e-06
included O 0 1.429358178484108e-07
without O 0 3.978067297794041e-08
regard O 0 3.1139816059067016e-08
to O 0 4.239779016756984e-08
the O 0 2.6331312241723026e-08
occurrence O 0 3.0933398420529556e-07
of O 0 1.9424572883508517e-07
ovarian B-Disease 1 0.5000289082527161
or I-Disease 0 4.6093481387288193e-07
other I-Disease 0 7.436594842147315e-07
cancers I-Disease 0 0.013227283954620361
. O 0 5.073855845694197e-06

Overall O 0 0.006585721392184496
, O 0 0.00032069272128865123
disease O 0 0.0007888336549513042
was O 0 2.9287875804584473e-06
linked O 0 1.2238866702318774e-06
to O 0 1.827399387366313e-07
BRCA1 O 0 5.2029314247192815e-05
in O 0 5.269932401574806e-08
an O 0 1.1491975726585224e-07
estimated O 0 4.3177894326618116e-07
52 O 0 1.7006681218845188e-06
% O 0 5.972307981494396e-09
of O 0 1.6881820386061008e-09
families O 0 5.2367468583724985e-08
, O 0 1.815551975425933e-08
to O 0 3.0229622893784835e-07
BRCA2 O 0 8.182891178876162e-05
in O 0 5.891022425430492e-08
32 O 0 3.297830630799581e-07
% O 0 7.796194800846479e-09
of O 0 2.358328865526005e-09
families O 0 5.8463715646439596e-08
, O 0 1.984368047658336e-08
and O 0 2.5079980758846432e-08
to O 0 6.366737181906501e-08
neither O 0 1.0816705042770991e-07
gene O 0 1.9543151097423106e-08
in O 0 1.0065710931428384e-08
16 O 0 4.682787491105955e-08
% O 0 8.249923411085547e-09
( O 0 1.6559212889788455e-09
95 O 0 7.637637366997296e-08
% O 0 1.900799517784435e-08
confidence O 0 1.3081849203899765e-07
interval O 0 1.2426356477135414e-07
[ O 0 9.361541231101e-08
CI O 0 1.937186198119889e-06
] O 0 1.6979845440801e-07
6 O 0 1.2466644250253012e-07
% O 0 3.403244619448742e-08
- O 0 8.682238330948167e-06
28 O 0 2.7529547878657468e-05
% O 0 3.8442273364580615e-08
) O 0 5.758429733049297e-09
, O 0 2.2812638889035952e-08
suggesting O 0 9.517290209259954e-07
other O 0 8.403773676946003e-08
predisposition O 0 0.00018601793271955103
genes O 0 2.7474350190459518e-06
. O 0 1.4480317531706532e-06

The O 0 5.613662779069273e-06
majority O 0 4.6171619032975286e-05
( O 0 2.7201022589906643e-07
81 O 0 1.0770732842502184e-05
% O 0 4.088133209734224e-08
) O 0 4.222039606815997e-09
of O 0 4.9376081001639704e-09
the O 0 1.3409651728579774e-05
breast B-Disease 1 0.9999940395355225
- I-Disease 1 0.9999998807907104
ovarian I-Disease 1 1.0
cancer I-Disease 1 0.9999997615814209
families O 0 7.702128073105996e-07
were O 0 1.0468683342423901e-07
due O 0 1.8838471760318498e-07
to O 0 8.680778478264983e-07
BRCA1 O 0 0.0015220389468595386
, O 0 3.476031551485903e-08
with O 0 1.7097875115723582e-08
most O 0 3.0510332749145164e-07
others O 0 7.002255415500258e-07
( O 0 1.1862409721175027e-08
14 O 0 1.5275239206857805e-07
% O 0 3.603157239240318e-08
) O 0 1.5456366853072723e-08
due O 0 4.945679279444448e-07
to O 0 1.748811155266594e-05
BRCA2 O 0 0.13481014966964722
. O 0 2.626142759254435e-06

Conversely O 0 0.0009012535447254777
, O 0 8.178435564332176e-07
the O 0 3.395107839310185e-08
majority O 0 3.273486868238251e-07
of O 0 8.47110381840821e-09
families O 0 1.2388126435780578e-07
with O 0 1.4017238925134734e-07
male B-Disease 0 0.0002620826126076281
and I-Disease 0 4.553218968794681e-05
female I-Disease 1 0.997651994228363
breast I-Disease 1 0.9999771118164062
cancer I-Disease 1 0.7172238826751709
were O 0 7.7500948236775e-07
due O 0 6.348506076392368e-07
to O 0 6.229703558346955e-06
BRCA2 O 0 0.14837266504764557
( O 0 1.4495817879378592e-07
76 O 0 5.15076972078532e-05
% O 0 2.3612854249677184e-07
) O 0 1.0480031420456726e-07
. O 0 8.69191239871725e-07

The O 0 2.0301981749071274e-06
largest O 0 2.332893018319737e-06
proportion O 0 1.2982847010789555e-06
( O 0 1.0919166726353069e-07
67 O 0 8.7753114712541e-06
% O 0 6.334517621553459e-08
) O 0 6.253447537574175e-09
of O 0 8.077696733721496e-09
families O 0 1.226046322244656e-07
due O 0 3.44887297387686e-07
to O 0 1.1914521991229776e-07
other O 0 1.516250414113074e-08
genes O 0 4.948529053194761e-08
was O 0 3.248243274356355e-06
found O 0 7.718062988715246e-08
in O 0 1.496817247925719e-08
families O 0 1.9647165672154188e-08
with O 0 1.822574446919134e-08
four O 0 5.478880638065675e-08
or O 0 5.949670534022289e-09
five O 0 1.3266125087341152e-08
cases O 0 5.96127094354415e-08
of O 0 7.155448855655777e-08
female O 1 0.998683750629425
breast B-Disease 1 0.9999691247940063
cancer I-Disease 0 0.28739234805107117
only O 0 7.080777209012012e-07
. O 0 9.591459502189537e-07

These O 0 4.212897692923434e-06
estimates O 0 2.862426981664612e-06
were O 0 1.2196950649467908e-07
not O 0 8.316391841844961e-08
substantially O 0 9.245520232070703e-06
affected O 0 1.0911588788076187e-07
either O 0 2.005000077076602e-08
by O 0 1.9093130632086286e-08
changing O 0 4.678457443674233e-08
the O 0 2.4313589364055588e-08
assumed O 0 4.20750939156278e-06
penetrance O 0 2.8900929009978427e-06
model O 0 5.421828745966195e-07
for O 0 2.0185606075528995e-08
BRCA1 O 0 1.6373754988308065e-05
or O 0 2.5912800794003488e-08
by O 0 1.9232311743166974e-08
including O 0 6.811712438548057e-08
or O 0 1.0567586627985293e-07
excluding O 0 7.97243592387531e-06
BRCA1 O 0 0.0010469930712133646
mutation O 0 6.4700493567215744e-06
data O 0 3.608942051869235e-07
. O 0 4.915885369882744e-07

Among O 0 1.956329469976481e-05
those O 0 6.352709078782937e-07
families O 0 9.074604463421565e-07
with O 0 4.820780304726213e-06
disease O 0 0.0007032863795757294
due O 0 4.023473593406379e-06
to O 0 1.1209327567485161e-05
BRCA1 O 0 0.003951914142817259
that O 0 6.987813208070293e-07
were O 0 1.5478130990231875e-06
tested O 0 5.730050247620966e-07
by O 0 9.795998678896467e-09
one O 0 4.952737331365142e-09
of O 0 4.6563305988733816e-10
the O 0 4.712487733371518e-09
standard O 0 1.5485262849779247e-07
screening O 0 6.788522455281054e-08
methods O 0 9.969263459197464e-08
, O 0 3.763249267763058e-08
mutations O 0 1.532185223140914e-07
were O 0 3.231235723433201e-08
detected O 0 1.9517062810336938e-07
in O 0 6.1930420791611596e-09
the O 0 4.750607462966627e-09
coding O 0 1.1556566192894024e-07
sequence O 0 8.508102666837658e-09
or O 0 1.6474123176735134e-09
splice O 0 9.83464332193762e-08
sites O 0 8.988541466692368e-09
in O 0 4.427867406064934e-09
an O 0 2.900651630000084e-08
estimated O 0 3.512046191644913e-07
63 O 0 2.0990603388781892e-06
% O 0 2.709021451607896e-08
( O 0 3.7704892541512436e-09
95 O 0 4.4717660330206854e-07
% O 0 2.1163498331588926e-07
CI O 0 1.2055732440785505e-05
51 O 0 2.3485286874347366e-05
% O 0 9.763265751416839e-08
- O 0 1.61981770361308e-05
77 O 0 7.100944640114903e-05
% O 0 2.3424405526384362e-07
) O 0 9.038212311907046e-08
. O 0 4.3085836409773037e-07

The O 0 2.1515409116545925e-06
estimated O 0 2.649681846378371e-06
sensitivity O 0 9.251765732187778e-06
was O 0 4.427964540809626e-06
identical O 0 6.325570325316221e-07
for O 0 3.834821793446963e-09
direct O 0 3.172971574372241e-08
sequencing O 0 1.0423853069596589e-07
and O 0 1.555835282829321e-08
other O 0 5.055413865306946e-09
techniques O 0 5.695101776836964e-07
. O 0 1.5784041806909954e-06

The O 0 3.3568583148735343e-06
penetrance O 0 0.00010492118599358946
of O 0 4.935699280395056e-07
BRCA2 O 0 0.0018022980075329542
was O 0 1.2544654055091087e-05
estimated O 0 2.5809714543356677e-07
by O 0 1.9864243583356256e-08
maximizing O 0 1.680667338632702e-07
the O 0 4.4998465398293774e-08
LOD O 0 0.007984182797372341
score O 0 1.1205190730834147e-06
in O 0 2.7340422548149945e-07
BRCA2 O 0 0.0026832190342247486
- O 0 0.0005722500500269234
mutation O 0 3.205625034752302e-05
families O 0 6.999151480613364e-08
, O 0 1.121109161061895e-08
over O 0 1.663230975168517e-08
all O 0 8.910277848883652e-09
possible O 0 2.1784840953387175e-07
penetrance O 0 1.3206868970883079e-05
functions O 0 2.1246412984510243e-07
. O 0 5.860035798832541e-07

The O 0 1.6993046756397234e-06
estimated O 0 9.096457347368414e-07
cumulative O 0 9.759613703863579e-07
risk O 0 5.768584401266708e-07
of O 0 9.386268828848188e-08
breast B-Disease 1 0.9990397095680237
cancer I-Disease 0 0.14429019391536713
reached O 0 5.093176582704473e-07
28 O 0 1.0768868605737225e-06
% O 0 3.6405715775345016e-08
( O 0 7.902777099388913e-09
95 O 0 2.940565480002988e-07
% O 0 1.1139648137259428e-07
CI O 0 6.2104486460157204e-06
9 O 0 6.598525033041369e-07
% O 0 3.1295162017386247e-08
- O 0 3.978822405770188e-06
44 O 0 3.547871529008262e-06
% O 0 1.423396778221786e-08
) O 0 1.4050109964358626e-09
by O 0 8.303232768014368e-09
age O 0 3.9056736511611234e-08
50 O 0 8.814536656132077e-09
years O 0 2.9173913063118562e-08
and O 0 6.027526211482837e-08
84 O 0 1.1345666734996485e-06
% O 0 1.9821627006422204e-08
( O 0 2.77449530017293e-09
95 O 0 8.028241893498489e-08
% O 0 6.292814447306228e-08
CI O 0 5.962543582427315e-06
43 O 0 3.24465486301051e-06
% O 0 3.7574540812101986e-08
- O 0 2.8876352189399768e-06
95 O 0 2.553862486820435e-06
% O 0 4.7957662729913864e-08
) O 0 4.155742416855901e-09
by O 0 2.122919262603773e-08
age O 0 2.3090667866654258e-07
70 O 0 1.3440337909287337e-07
years O 0 4.791030505657545e-07
. O 0 5.884575671188941e-07

The O 0 4.208259269944392e-05
corresponding O 0 0.45286911725997925
ovarian B-Disease 1 0.9999998807907104
cancer I-Disease 1 0.999998927116394
risks O 0 0.0005710179102607071
were O 0 4.62548314317246e-06
0 O 0 6.612487140955636e-06
. O 0 1.454097173336777e-06

4 O 0 4.070808790856972e-05
% O 0 8.895998462321586e-07
( O 0 4.3107782232709724e-08
95 O 0 2.9990741268193233e-07
% O 0 1.0296282226818221e-07
CI O 0 5.392319962993497e-06
0 O 0 1.3860042145097395e-06
% O 0 4.063846148483208e-08
- O 0 2.1741079763160087e-06
1 O 0 4.16630513200289e-07
% O 0 2.017036493384694e-08
) O 0 2.1771613401000423e-09
by O 0 1.0541473471903373e-08
age O 0 1.0456689381044271e-07
50 O 0 9.023154667886502e-09
years O 0 1.8048348593424635e-08
and O 0 2.936741871906179e-08
27 O 0 7.851020313864865e-07
% O 0 1.1512407027680638e-08
( O 0 1.8328574213910542e-09
95 O 0 9.784798038481313e-08
% O 0 6.451734435586332e-08
CI O 0 3.556069259502692e-06
0 O 0 1.1242675554967718e-06
% O 0 2.566308232587744e-08
- O 0 7.425145668094046e-06
47 O 0 9.931587555911392e-05
% O 0 3.443866702923515e-08
) O 0 3.551179572625074e-09
by O 0 2.670422283301832e-08
age O 0 2.8833815690632036e-07
70 O 0 4.429575639619543e-08
years O 0 1.3580584834471665e-07
. O 0 4.77869150472543e-07

The O 0 5.337850325304316e-06
lifetime O 0 3.070541424676776e-05
risk O 0 4.4713874558510724e-06
of O 0 8.938885684983688e-07
breast B-Disease 1 0.9999059438705444
cancer I-Disease 1 0.9379705190658569
appears O 0 1.3158141882740892e-05
similar O 0 1.3908646678828518e-07
to O 0 3.3426118761781254e-08
the O 0 4.8298414156988656e-08
risk O 0 3.6668620850832667e-07
in O 0 7.491055242780931e-08
BRCA1 O 0 0.00010655824007699266
carriers O 0 6.845053803772316e-07
, O 0 3.106921653284189e-08
but O 0 4.805151121445306e-08
there O 0 1.0714259701671836e-08
was O 0 1.1636569752226933e-07
some O 0 3.6367802103143276e-09
suggestion O 0 5.841433647901795e-08
of O 0 1.448889452859703e-09
a O 0 4.979736445420713e-07
lower O 0 1.2376108315947931e-05
risk O 0 2.8453490585889085e-07
in O 0 1.2096678858597443e-07
BRCA2 O 0 0.00030523890745826066
carriers O 0 1.0227244047200656e-06
< O 0 3.184506738307391e-07
50 O 0 3.658140101947538e-08
years O 0 1.973885233041983e-08
of O 0 1.5692705801484408e-08
age O 0 2.2121203073766083e-06
. O 0 1.0483504411240574e-06

Eye B-Disease 1 0.9966657757759094
movement I-Disease 0 0.012463655322790146
abnormalities I-Disease 1 0.9986670017242432
correlate O 0 8.709175745025277e-05
with O 0 6.1572895901917946e-06
genotype O 0 0.375907301902771
in O 0 1.1486094081192277e-05
autosomal O 1 0.9976499676704407
dominant O 1 0.9416458606719971
cerebellar B-Disease 1 0.9996565580368042
ataxia I-Disease 1 0.9999567270278931
type I-Disease 0 0.031286295503377914
I I-Disease 0 0.00014228660438675433
. O 0 2.577090526756365e-06

We O 0 7.555997399322223e-06
compared O 0 8.081403393589426e-06
horizontal O 0 0.00023035204503685236
eye O 0 0.09917588531970978
movements O 0 6.2638150666316506e-06
( O 0 2.2310366887268174e-07
visually O 0 5.9460930970089976e-06
guided O 0 3.2986120004352415e-06
saccades O 0 0.00019473642169032246
, O 0 1.7163475263259897e-07
antisaccades O 0 3.90044351661345e-06
, O 0 1.5288042831684834e-08
and O 0 1.3467841952774506e-08
smooth O 0 6.033042154740542e-07
pursuit O 0 4.079962252490077e-07
) O 0 2.0182525872769475e-08
in O 0 2.2080888228970252e-08
control O 0 4.239785084791947e-06
subjects O 0 1.6247848861894454e-06
( O 0 4.13241139085585e-08
n O 0 1.4854786059004255e-06
= O 0 8.499006298734457e-07
14 O 0 4.468167702498249e-08
) O 0 1.9473496593036543e-08
and O 0 1.828628228395246e-06
patients O 0 0.00023963245621416718
with O 0 2.650115860092228e-08
three O 0 3.795536329675997e-08
forms O 0 3.6399256941876956e-08
of O 0 4.064218117605378e-08
autosomal O 0 0.2099539041519165
dominant O 0 0.0011052184272557497
cerebellar B-Disease 0 0.006516529247164726
ataxias I-Disease 0 0.0020775897428393364
type I-Disease 0 1.54057088366244e-05
I I-Disease 0 1.2985859029868152e-05
spinocerebellar B-Disease 0 0.008074603974819183
ataxias I-Disease 0 0.00015073591202963144
1 I-Disease 0 2.574128075139015e-07
and I-Disease 0 8.064107248628716e-08
2 I-Disease 0 2.414026596397889e-07
( O 0 3.210538679354613e-08
SCA1 B-Disease 0 4.66080782643985e-05
, O 0 8.087782532584242e-08
n O 0 6.644406767009059e-07
= O 0 4.700066540408443e-07
11 O 0 9.428237746078594e-08
; O 0 5.0612822377615885e-08
SCA2 B-Disease 0 2.5589391952962615e-05
, O 0 9.039643344976867e-08
n O 0 3.419942231630557e-07
= O 0 1.7588551770586491e-07
10 O 0 1.3144748400861772e-08
) O 0 9.747019191763684e-09
and O 0 2.0723862803606607e-07
SCA3 B-Disease 1 0.99998939037323
/ O 0 4.940620419802144e-05
Machado B-Disease 0 2.1138956071808934e-05
- I-Disease 0 0.0395137257874012
Joseph I-Disease 0 0.3739868104457855
disease I-Disease 0 0.0020042427349835634
( O 0 2.3989073838492914e-07
MJD B-Disease 1 0.9999877214431763
) O 0 2.31434029274169e-07
( O 0 4.447370827165287e-08
n O 0 2.0548798147501657e-06
= O 0 1.7355059753754176e-06
16 O 0 2.4242723384304554e-07
) O 0 1.029753917691778e-07
. O 0 7.839229283490567e-07

In O 0 1.5176995475485455e-05
SCA1 B-Disease 0 0.00015667371917515993
, O 0 3.6565847949532326e-07
saccade O 0 8.086884918157011e-06
amplitude O 0 3.328379079903243e-06
was O 0 2.0859974938503e-06
significantly O 0 9.626915016269777e-07
increased O 0 2.3226007783705427e-07
, O 0 4.6609375914385964e-08
resulting O 0 6.877993996567966e-07
in O 0 3.91058279092249e-07
hypermetria B-Disease 0 0.0007748599746264517
. O 0 1.7939332792593632e-06

The O 0 6.334756562864641e-06
smooth O 0 3.3875563531182706e-05
pursuit O 0 1.64413340826286e-05
gain O 0 1.96675810002489e-05
was O 0 6.167260289657861e-05
decreased O 0 3.482439205981791e-05
. O 0 1.7292840084337513e-06

In O 0 1.2026852346025407e-05
SCA2 B-Disease 0 0.00012254212924744934
, O 0 2.2373968988631532e-07
saccade O 0 1.0911106983257923e-05
velocity O 0 5.966872322460404e-06
was O 0 1.0279313755745534e-05
markedly O 0 0.0003140308253932744
decreased O 0 2.2589261789107695e-05
. O 0 2.082884520859807e-06

The O 0 2.2684221221425105e-06
percentage O 0 8.584211173001677e-07
of O 0 1.6718695761142044e-08
errors O 0 7.792197607159324e-07
in O 0 1.3869373560737586e-07
antisaccades O 0 0.001681783702224493
was O 0 0.00010215012298431247
greatly O 0 8.84826931724092e-07
increased O 0 1.80508664016088e-07
and O 0 2.17500844001961e-08
was O 0 7.3061833063547965e-06
significantly O 0 2.166251761082094e-06
correlated O 0 3.5465248515720305e-07
with O 0 1.6721077145120944e-07
age O 0 2.8354666028462816e-06
at O 0 6.57043642604549e-07
disease O 0 0.00015361687110271305
onset O 0 8.841953240334988e-05
. O 0 7.099559297785163e-06

In O 0 2.375192025283468e-06
addition O 0 3.28554676798376e-07
, O 0 2.7798627399988618e-08
a O 0 1.1414055478553564e-07
correlation O 0 2.4108055640681414e-07
between O 0 2.489653283532789e-08
smooth O 0 5.121376489114482e-06
pursuit O 0 2.64225059254386e-06
gain O 0 2.3451348170056008e-06
and O 0 2.007211818977339e-08
the O 0 4.412927356867158e-09
number O 0 1.5594004310059972e-08
of O 0 1.9665836958893124e-08
trinucleotide O 0 6.31600123597309e-05
repeats O 0 4.598148734658025e-06
was O 0 3.115513663942693e-06
found O 0 6.030718395777512e-07
. O 0 5.021627202950185e-07

In O 0 6.052682510926388e-05
SCA3 B-Disease 1 0.9992141723632812
, O 0 4.8814358706295025e-06
gaze B-Disease 0 0.00020447239512577653
- I-Disease 0 0.003510832553729415
evoked I-Disease 0 0.06238260492682457
nystagmus I-Disease 0 0.11456035822629929
was O 0 2.11924434552202e-05
often O 0 3.425948875701579e-07
present O 0 4.514409113198781e-08
as O 0 5.746726117195067e-08
was O 0 4.599866940679931e-07
saccade O 0 4.567045834846795e-06
hypometria O 0 5.983329174341634e-06
and O 0 4.074463788583671e-08
smooth O 0 6.787472557334695e-07
pursuit O 0 1.3278196320243296e-06
gain O 0 8.039010936045088e-06
was O 0 8.051744953263551e-05
markedly O 0 0.001917614950798452
decreased O 0 6.559568282682449e-05
. O 0 2.669918785613845e-06

Three O 0 4.297681698517408e-06
major O 0 6.906718681420898e-07
criteria O 0 3.587666128623823e-07
, O 0 5.89664352901309e-08
saccade O 0 3.226880380680086e-06
amplitude O 0 1.0917132158283493e-06
, O 0 1.6933297430909988e-08
saccade O 0 1.3742703686148161e-06
velocity O 0 8.121270411720616e-07
, O 0 9.158362956895871e-09
and O 0 6.005720365465095e-09
presence O 0 1.878973421298724e-08
of O 0 7.567941828767744e-09
gaze B-Disease 0 0.0003056926070712507
- I-Disease 0 0.0060401116497814655
evoked I-Disease 0 0.03381062299013138
nystagmus I-Disease 0 0.0004157167859375477
, O 0 4.888824989279783e-08
permitted O 0 1.566381691020524e-08
the O 0 3.193680431223811e-09
correct O 0 1.0106999326353616e-07
assignment O 0 4.532812880597703e-08
of O 0 4.3977017583074485e-09
90 O 0 3.866139763886167e-08
% O 0 3.882276278233121e-09
of O 0 5.818920345568301e-10
the O 0 1.3517819752451032e-08
SCA1 B-Disease 0 0.0002793784369714558
, O 0 4.4496786699710356e-08
90 O 0 1.3667619924717656e-08
% O 0 3.448913599157777e-09
of O 0 4.104066808618967e-10
the O 0 1.9348210145153644e-08
SCA2 B-Disease 0 0.0006581511697731912
, O 0 2.83548526880395e-08
and O 0 1.8763875786476092e-08
93 O 0 2.1496407498489134e-07
% O 0 4.17653778228555e-09
of O 0 9.398729572396292e-10
the O 0 7.145042104639288e-07
patients O 0 0.007150993682444096
with O 0 1.24808059354109e-06
SCA3 B-Disease 1 0.9999974966049194
to O 0 9.550076356390491e-07
their O 0 3.8185479667163236e-08
genetically O 0 2.2094129690231057e-06
confirmed O 0 3.3740379876689985e-05
patient O 0 3.612590808188543e-05
group O 0 4.0651721633366833e-07
and O 0 9.631720843117364e-08
, O 0 8.370244586330955e-08
therefore O 0 1.5506454076330556e-07
, O 0 5.686115045477891e-08
may O 0 2.3666127901833534e-07
help O 0 7.836615623091348e-08
orient O 0 1.4798728443565778e-05
diagnoses O 0 0.0009045401820912957
of O 0 1.8521021161177487e-08
SCA1 B-Disease 0 0.0025991820730268955
, O 0 3.2612254585728806e-07
SCA2 B-Disease 0 4.023214933113195e-05
, O 0 6.366118299183654e-08
and O 0 6.77252387504268e-08
SCA3 B-Disease 1 0.9999427795410156
at O 0 4.121006469404165e-08
early O 0 1.6335992825133872e-07
clinical O 0 7.978155167620571e-07
stages O 0 1.0801078076383419e-07
of O 0 7.714910488232363e-09
the O 0 1.0286089491273742e-06
diseases O 0 0.0002192383399233222
. O 0 2.4595740910626773e-07
. O 0 7.93950619026873e-07

Genetic O 0 0.0007326541817747056
basis O 0 3.411184252399835e-06
and O 0 5.792604156340531e-07
molecular O 0 5.2297823458502535e-06
mechanism O 0 2.9547773010563105e-06
for O 0 0.00017952403868548572
idiopathic B-Disease 1 1.0
ventricular I-Disease 1 0.9999996423721313
fibrillation I-Disease 1 0.9999998807907104
. O 0 0.0004013128636870533

Ventricular B-Disease 1 0.9997815489768982
fibrillation I-Disease 1 0.9999548196792603
causes O 0 0.0019015315920114517
more O 0 5.641348366225429e-07
than O 0 1.3828959311013023e-07
300 O 0 9.248048371546247e-08
, O 0 7.850243832763226e-08
000 O 0 1.9162600040090183e-07
sudden O 0 1.9998204152216204e-05
deaths O 0 8.14804843685124e-06
each O 0 7.988432138006374e-09
year O 0 2.5225777022797047e-08
in O 0 1.2666233395464133e-08
the O 0 7.231583509792472e-08
USA O 0 9.90150510915555e-06
alone O 0 3.6471647035796195e-06
. O 0 6.758747872481763e-07

In O 0 2.7383764518162934e-06
approximately O 0 6.996588126639836e-07
5 O 0 1.2462423626402597e-07
- O 0 3.148188625345938e-06
12 O 0 3.4226965794914577e-07
% O 0 7.814491276292301e-09
of O 0 6.931629714657106e-10
these O 0 1.1235473884596558e-08
cases O 0 1.4457091879194195e-07
, O 0 2.7503968880182583e-08
there O 0 1.5471645298248404e-08
are O 0 7.2709562815020945e-09
no O 0 3.807798805155471e-07
demonstrable O 0 0.43227657675743103
cardiac O 1 0.9947624802589417
or O 0 4.956199290973018e-07
non O 0 8.35049320357939e-07
- O 1 0.8410399556159973
cardiac O 1 0.9999126195907593
causes O 0 2.4132996259140782e-05
to O 0 1.7218282266640017e-07
account O 0 6.454934720068195e-08
for O 0 7.863173223654485e-09
the O 0 1.3010280852654432e-08
episode O 0 1.664199044171255e-05
, O 0 3.953114457999618e-08
which O 0 4.078483328839866e-08
is O 0 5.290335991503525e-08
therefore O 0 1.6574489336562692e-07
classified O 0 1.9926571894757217e-06
as O 0 0.0003391791833564639
idiopathic B-Disease 1 1.0
ventricular I-Disease 1 0.9999998807907104
fibrillation I-Disease 1 1.0
( O 0 0.003211985109373927
IVF B-Disease 1 0.9999858140945435
) O 0 6.146377472759923e-06
. O 0 1.7357625665681553e-06

A O 0 4.011155397165567e-05
distinct O 0 4.204681772534968e-06
group O 0 1.6607668840151746e-06
of O 0 3.3524580089761e-07
IVF B-Disease 1 0.9999997615814209
patients O 1 0.999340832233429
has O 0 1.2088059520465322e-05
been O 0 4.907669222120603e-07
found O 0 4.356130034466332e-08
to O 0 1.4287661720402411e-08
present O 0 7.370090759906134e-09
with O 0 1.0516229664858656e-08
a O 0 2.4720402507227845e-06
characteristic O 0 1.3364533515414223e-05
electrocardiographic O 0 0.0008195750997401774
pattern O 0 2.6621703000273556e-05
. O 0 1.8713965346250916e-06

Because O 0 4.168774921708973e-06
of O 0 2.2005670174962688e-08
the O 0 1.143580963258728e-08
small O 0 1.3649253283176677e-08
size O 0 3.4671916893103116e-08
of O 0 3.3608684724129034e-09
most O 0 4.584363821891202e-08
pedigrees O 0 1.8573697389001609e-06
and O 0 6.424902210255823e-08
the O 0 1.5507925610336315e-08
high O 0 1.9625015283963876e-06
incidence O 0 2.9546552468673326e-05
of O 0 1.4881945453737444e-08
sudden B-Disease 0 0.09070189297199249
death I-Disease 0 0.4547004699707031
, O 0 1.5806789122052578e-07
however O 0 1.631033939020199e-07
, O 0 2.5023929595135996e-08
molecular O 0 5.273411716189003e-07
genetic O 0 2.3890285660854715e-07
studies O 0 1.9523925587350277e-08
of O 0 2.3331097054324346e-08
IVF B-Disease 1 0.9999786615371704
have O 0 9.319847777078394e-06
not O 0 5.6477546195310424e-08
yet O 0 1.352211853600238e-07
been O 0 1.572189205489849e-07
done O 0 3.5517373930815666e-07
. O 0 3.9953445707396895e-07

Because O 0 0.003937430214136839
IVF B-Disease 1 0.999937891960144
causes O 1 0.5291488170623779
cardiac O 1 0.997755229473114
rhythm O 0 0.26472359895706177
disturbance O 0 0.0001717707491479814
, O 0 1.643494016434488e-07
we O 0 9.807533452033113e-09
investigated O 0 1.405800276188529e-07
whether O 0 5.7541402753713555e-08
malfunction O 0 4.9434758693678305e-05
of O 0 4.901997030515304e-09
ion O 0 7.960364200698677e-06
channels O 0 1.184252596431179e-06
could O 0 1.0757527206806117e-06
cause O 0 1.4060217381484108e-06
the O 0 8.268072519967973e-07
disorder O 0 0.034307435154914856
by O 0 3.815970117670986e-08
studying O 0 9.933579292464856e-08
mutations O 0 1.160677129519172e-06
in O 0 4.4226872830677166e-08
the O 0 3.099130196915212e-07
cardiac O 1 0.8375675678253174
sodium O 0 0.034038130193948746
channel O 0 7.941412332002074e-05
gene O 0 4.260420155333122e-06
SCN5A O 0 0.00010642013512551785
. O 0 1.6985674164970987e-06

We O 0 5.6383005357929505e-06
have O 0 4.2611739559106354e-07
now O 0 7.335845708666966e-08
identified O 0 1.2405305938045785e-07
a O 0 2.458614858369401e-07
missense O 0 0.0003423616290092468
mutation O 0 2.6958598482451634e-06
, O 0 1.336958632691676e-08
a O 0 1.1113078102198415e-07
splice O 0 9.601750207366422e-06
- O 0 0.00014018612273503095
donor O 0 2.3409204459312605e-06
mutation O 0 1.970151970454026e-06
, O 0 1.3339530369194108e-08
and O 0 2.113900521294454e-08
a O 0 3.818438926828094e-06
frameshift O 1 0.609034538269043
mutation O 0 2.9532784537877887e-06
in O 0 2.60685606434663e-08
the O 0 1.9330355982560832e-08
coding O 0 1.151113224295841e-06
region O 0 5.000151404033204e-08
of O 0 7.007777913514701e-09
SCN5A O 0 0.00017103529535233974
in O 0 2.0444288395538024e-07
three O 0 8.973939316092583e-07
IVF B-Disease 1 0.9998682737350464
families O 0 2.6257496301695937e-06
. O 0 9.69430857367115e-07

We O 0 1.1807577493527788e-06
show O 0 3.131896164632053e-07
that O 0 2.6997932778272116e-08
sodium O 0 1.5106594446478994e-06
channels O 0 1.0151570961625112e-07
with O 0 9.654321786456421e-09
the O 0 2.364009077382434e-08
missense O 0 0.00010087538248626515
mutation O 0 3.849844688375015e-06
recover O 0 1.280815581594652e-06
from O 0 9.848455384542376e-09
inactivation O 0 4.463341974769719e-05
more O 0 5.0299284737320704e-08
rapidly O 0 5.1878735973787116e-08
than O 0 9.149790258788926e-09
normal O 0 1.1849000003394394e-08
and O 0 9.7571009050057e-09
that O 0 1.9728766176285717e-08
the O 0 4.875304071561004e-08
frameshift O 1 0.6718198657035828
mutation O 0 4.820380581804784e-06
causes O 0 1.0341904754795905e-07
the O 0 7.3241683828939586e-09
sodium O 0 1.222820264956681e-05
channel O 0 1.1241089623581502e-06
to O 0 2.1958669549348997e-08
be O 0 3.50491191625224e-08
non O 0 1.0533859295946968e-07
- O 0 1.6578092981944792e-05
functional O 0 2.7145793865201995e-05
. O 0 1.772155997059599e-06

Our O 0 6.949466751393629e-06
results O 0 2.351037437620107e-06
indicate O 0 3.4280211025361496e-07
that O 0 6.283939768536584e-08
mutations O 0 8.720108439774776e-07
in O 0 8.18166725480296e-08
cardiac O 0 0.002063184278085828
ion O 0 5.533235889743082e-05
- O 0 7.352049578912556e-05
channel O 0 5.222370873525506e-06
genes O 0 4.348675020082737e-08
contribute O 0 1.0389311633218767e-08
to O 0 1.2551230277324521e-08
the O 0 2.7714079919860524e-08
risk O 0 1.3657410136147519e-07
of O 0 1.5981290957256533e-08
developing O 0 1.4252611890697153e-06
IVF B-Disease 1 0.9998979568481445
. O 0 2.481457386238617e-06
. O 0 1.260371618627687e-06

Molecular O 0 0.0002099419361911714
heterogeneity O 0 0.00022684170107822865
in O 0 4.446532784641022e-06
mucopolysaccharidosis B-Disease 0 0.0006666139233857393
IVA I-Disease 0 0.00180045363958925
in O 0 1.7540957060191431e-06
Australia O 0 2.788817425880552e-07
and O 0 1.2802289006685896e-07
Northern O 0 4.7272314418478345e-07
Ireland O 0 3.870150067086797e-07
: O 0 1.5712112499954856e-08
nine O 0 9.112714138836964e-08
novel O 0 1.212070287692768e-06
mutations O 0 8.165841336449375e-07
including O 0 2.7028228544168087e-08
T312S O 0 6.261665021156659e-06
, O 0 2.672699928041311e-08
a O 0 9.586487692558876e-08
common O 0 1.0785657877931953e-07
allele O 0 2.0402655991347274e-06
that O 0 8.782387084238508e-08
confers O 0 4.747448110720143e-05
a O 0 0.0002669432433322072
mild O 1 0.9996098875999451
phenotype O 1 0.9985571503639221
. O 0 7.977265340741724e-06

Mucopolysaccharidosis B-Disease 1 0.9511711001396179
IVA I-Disease 1 0.9980721473693848
( O 0 0.04707494378089905
MPS B-Disease 1 0.999997615814209
IVA I-Disease 1 0.999994158744812
) O 0 4.011114015156636e-06
is O 0 7.882636055001058e-07
an O 0 8.54751851875335e-06
autosomal B-Disease 1 0.9991950392723083
recessive I-Disease 1 0.9998346567153931
lysosomal I-Disease 1 0.999377965927124
storage I-Disease 1 0.9986441731452942
disorder I-Disease 1 0.999703586101532
caused O 0 5.912430424359627e-05
by O 0 5.681306447513634e-07
a O 0 0.012281919829547405
genetic B-Disease 1 0.999956488609314
defect I-Disease 1 0.9999527931213379
in O 0 2.0502679944911506e-06
N O 0 3.7895610148552805e-05
- O 0 7.28892264305614e-05
acetylgalactosamine O 0 0.00027493605739437044
- O 0 0.00022014429850969464
6 O 0 6.741560810041847e-06
- O 0 0.02022928185760975
sulfate O 0 0.21078646183013916
sulfatase O 0 0.0006396743701770902
( O 0 4.41514401927634e-07
GALNS O 0 5.65315640415065e-05
) O 0 3.6770700262422906e-07
. O 0 7.570297384518199e-07

Previous O 0 7.721808651695028e-05
studies O 0 1.6216811218328075e-06
of O 0 1.4821570459844224e-07
patients O 0 2.7975114790024236e-05
from O 0 1.623515899495942e-08
a O 0 1.0675552175598568e-06
British O 0 0.0001795245480025187
- O 0 0.001271342160180211
Irish O 0 3.851372457575053e-05
population O 0 4.4932768616945395e-08
showed O 0 3.5225249916948087e-07
that O 0 5.857697438216292e-09
the O 0 1.7377729477630055e-08
I113F O 0 4.3674022890627384e-05
mutation O 0 9.227712212123151e-07
is O 0 1.041486630271038e-08
the O 0 2.848591584836413e-09
most O 0 1.3826277012185528e-08
common O 0 2.281638167289657e-08
single O 0 2.4020878299779724e-06
mutation O 0 1.7664813640294597e-05
among O 0 3.6748790535057196e-06
MPS B-Disease 1 0.9999997615814209
IVA I-Disease 1 1.0
patients O 1 0.9996680021286011
and O 0 5.446901809591509e-07
produces O 0 2.9437685498123756e-06
a O 0 4.062803782289848e-05
severe O 1 0.9985935091972351
clinical O 1 0.9621801376342773
phenotype O 1 0.9865550994873047
. O 0 4.507905487116659e-06

We O 0 3.700665274664061e-06
studied O 0 1.3853699556420906e-06
mutations O 0 2.254511628052569e-06
in O 0 1.545565986305064e-08
the O 0 3.592260355844701e-08
GALNS O 0 0.00018583003839012235
gene O 0 4.921983531858132e-07
from O 0 2.343045579777936e-08
23 O 0 6.71153202347341e-07
additional O 0 5.721783963963389e-06
MPS B-Disease 1 0.9999988079071045
IVA I-Disease 1 0.9999996423721313
patients O 1 0.999675989151001
( O 0 6.723922751916689e-08
15 O 0 5.159276739163943e-08
from O 0 1.4385145519213438e-08
Australia O 0 5.8773078848162186e-08
, O 0 1.760465373479292e-08
8 O 0 3.061245479329955e-08
from O 0 6.9279582071146706e-09
Northern O 0 8.167774012690643e-08
Ireland O 0 7.823860670441718e-08
) O 0 4.222184379898408e-09
, O 0 4.652044971464875e-09
with O 0 1.0465045718888177e-08
various O 0 2.3717500852171725e-08
clinical O 0 0.0012005376629531384
phenotypes O 0 0.20208419859409332
( O 0 1.9958416430654324e-07
severe O 0 0.4172075688838959
, O 0 2.404418637524941e-06
16 O 0 1.9572119072108762e-06
cases O 0 1.787079099813127e-06
; O 0 2.0234315911693557e-07
intermediate O 0 7.600636990900966e-07
, O 0 5.658839796751636e-08
4 O 0 4.22222683482687e-07
cases O 0 1.3809166148348595e-06
; O 0 4.500753220781917e-06
mild O 1 0.952522337436676
, O 0 2.8596684842341347e-06
3 O 0 1.8624444919623784e-06
cases O 0 1.3933035916124936e-06
) O 0 5.54776761418907e-07
. O 0 9.42821600347088e-07

We O 0 2.522513568692375e-06
found O 0 2.7935556090596947e-07
two O 0 2.7054120721459185e-08
common O 0 6.906231675429808e-08
mutations O 0 5.680163326360343e-07
that O 0 1.7794786089098125e-08
together O 0 3.8298683335824535e-08
accounted O 0 8.883063884468356e-08
for O 0 1.0655016424720998e-08
32 O 0 1.3012817134949728e-07
% O 0 4.165987999016352e-09
of O 0 8.733900824786645e-10
the O 0 2.4987109270568908e-08
44 O 0 5.831937528455455e-07
unrelated O 0 4.5141510440771526e-07
alleles O 0 3.874519052260439e-07
in O 0 9.293172809066164e-08
these O 0 2.3670460791436199e-07
patients O 0 0.0002995032409671694
. O 0 3.967167685914319e-06

One O 0 7.152513262553839e-06
is O 0 2.4875274107216683e-07
the O 0 5.6062201991835536e-08
T312S O 0 2.4599812604719773e-05
mutation O 0 3.1257393402484013e-06
, O 0 1.6757260468125423e-08
a O 0 2.47538963549232e-07
novel O 0 3.645390961537487e-06
mutation O 0 7.174156735345605e-07
found O 0 4.290140864782188e-08
exclusively O 0 1.3390977926519554e-07
in O 0 2.3925011305436783e-07
milder O 1 0.9895925521850586
patients O 1 0.7723464965820312
. O 0 2.4863797989382874e-06

The O 0 1.1891607982761343e-06
other O 0 7.253866129985909e-08
is O 0 2.6699078503611418e-08
the O 0 1.0249057602607081e-08
previously O 0 6.041223628017178e-07
described O 0 1.25350550206349e-06
I113F O 0 2.8385752557369415e-06
that O 0 6.475355007751205e-08
produces O 0 1.463250555389095e-06
a O 0 1.4975395060901064e-05
severe O 1 0.9953012466430664
phenotype O 1 0.9976134300231934
. O 0 9.308495464210864e-06

The O 0 3.1995982681110036e-06
I113F O 0 3.823596489382908e-05
and O 0 4.5530805437010713e-07
T312S O 0 1.3432573723548558e-05
mutations O 0 3.804168727583601e-06
accounted O 0 2.883046192891925e-07
for O 0 1.653797809808566e-08
8 O 0 7.943734203763597e-08
( O 0 1.4924470548294266e-08
18 O 0 2.0574788095473195e-07
% O 0 2.0221714081003483e-08
) O 0 6.5907865831604795e-09
and O 0 7.120038247876437e-08
6 O 0 3.3337875038341735e-07
( O 0 6.758416493113373e-09
14 O 0 1.1020077295142983e-07
% O 0 4.583128987434293e-09
) O 0 1.4591311492395675e-09
of O 0 1.582392328280946e-09
44 O 0 3.9149489339251886e-07
unrelated O 0 1.867246396614064e-06
alleles O 0 1.4823638139205286e-06
, O 0 2.2678914035623166e-07
respectively O 0 1.4196152733347844e-06
. O 0 1.101831799132924e-06

The O 0 5.433415026345756e-06
relatively O 0 6.093512638472021e-06
high O 0 9.090820185519988e-07
residual O 0 1.1856044693558943e-05
GALNS O 0 0.00010253130312776193
activity O 0 1.0413718598556443e-07
seen O 0 1.559363767000832e-07
when O 0 1.6177446937604145e-08
the O 0 1.1761769336260386e-08
T312S O 0 1.0392421927463147e-06
mutant O 0 5.921585284340836e-07
cDNA O 0 4.6436611000899575e-07
is O 0 5.4399670545990375e-08
overexpressed O 0 1.7097764839490992e-06
in O 0 4.140221676607325e-08
mutant O 0 1.0547662895987742e-05
cells O 0 3.5144518051311024e-07
provides O 0 2.4242925888984246e-08
an O 0 1.2878415667216814e-08
explanation O 0 1.9080211188793328e-07
for O 0 2.7484563958068975e-08
the O 0 1.4387196642928757e-06
mild O 1 0.9999393224716187
phenotype O 1 0.9999494552612305
in O 0 2.4819408281473443e-05
patients O 0 0.0012135549914091825
with O 0 4.628716965271451e-08
this O 0 4.4246027641747787e-07
mutation O 0 1.4391038348549046e-05
. O 0 7.905914003458747e-07

The O 0 7.069070306897629e-07
distribution O 0 1.3573192347848817e-07
and O 0 3.865121911417191e-08
relative O 0 1.0201863176462211e-07
frequencies O 0 7.94320413888272e-08
of O 0 2.15483608734246e-09
the O 0 1.3491752604011253e-08
I113F O 0 2.8055105758539867e-06
and O 0 6.300957977600774e-08
T312S O 0 4.278894266462885e-06
mutations O 0 3.684269245241012e-07
in O 0 1.9517113258871177e-08
Australia O 0 3.4493560008286295e-08
corresponded O 0 2.326624581883152e-07
to O 0 3.978166063234312e-08
those O 0 1.4472687936972761e-08
observed O 0 4.4432159285179296e-08
in O 0 8.695674402758868e-09
Northern O 0 2.103367648942367e-07
Ireland O 0 3.7687161125177226e-07
and O 0 4.4541454968793914e-08
are O 0 3.6799023828137933e-09
unique O 0 7.1811090407436495e-09
to O 0 1.6481358500186616e-08
these O 0 4.251656360310108e-09
two O 0 1.987895004162965e-08
populations O 0 4.021943666998595e-08
, O 0 7.431224968712513e-09
suggesting O 0 8.523976902097274e-08
that O 0 1.2230866097695525e-08
both O 0 2.1488284929205292e-08
mutations O 0 3.1238153042068006e-07
were O 0 3.3855695136253416e-08
probably O 0 1.2518134440142603e-07
introduced O 0 8.725101707796057e-08
to O 0 8.061200418296721e-08
Australia O 0 5.01428623067568e-08
by O 0 2.1604300570743362e-08
Irish O 0 1.7694848963856202e-07
migrants O 0 3.342828591712532e-08
during O 0 1.6905994826288406e-08
the O 0 1.7953928121983154e-08
19th O 0 3.085444006956095e-07
century O 0 7.808250188645616e-07
. O 0 2.659925712578115e-06

Haplotype O 1 0.9837513566017151
analysis O 0 1.8922404706245288e-05
using O 0 1.3626099644170608e-06
6 O 0 1.2809304053007509e-06
RFLPs O 0 1.602761221874971e-05
provides O 0 1.4172884732488455e-07
additional O 0 3.4389895375852575e-08
data O 0 1.5236894412851143e-08
that O 0 2.963999046201593e-09
the O 0 9.341864171119596e-09
I113F O 0 4.52043313998729e-05
mutation O 0 9.37562845138018e-07
originated O 0 3.1059972371849653e-08
from O 0 4.3731271937019756e-09
a O 0 1.2380580471926805e-07
common O 0 2.755995467396133e-07
ancestor O 0 3.4091710858774604e-06
. O 0 1.4363835134645342e-06

The O 0 3.531287120495108e-06
other O 0 2.523685225241934e-07
9 O 0 9.660806199462968e-07
novel O 0 2.683529828573228e-06
mutations O 0 3.795131306105759e-06
identified O 0 3.2180497555600596e-07
in O 0 1.9068929546506297e-08
these O 0 3.5306701562376475e-08
23 O 0 0.0001310550287598744
patients O 0 9.642350778449327e-05
were O 0 8.450756894262668e-08
each O 0 6.923084328036566e-09
limited O 0 2.9346701069243863e-08
to O 0 3.919569380173016e-08
a O 0 3.9535487417197146e-07
single O 0 3.1251699965650914e-06
family O 0 2.204265229011071e-06
. O 0 1.0755290986708133e-06

These O 0 3.5880091218132293e-06
data O 0 6.576348710041202e-07
provide O 0 1.9310832044538984e-07
further O 0 7.075849595139516e-08
evidence O 0 1.459037974882449e-07
for O 0 4.788573093605919e-08
extensive O 0 2.1945957087154966e-06
allelic O 0 5.8424331655260175e-05
heterogeneity O 0 0.00021241653303150088
in O 0 3.9680795453023165e-05
MPS B-Disease 1 0.999990701675415
IVA I-Disease 1 0.9999349117279053
in O 0 1.2581890587171074e-05
British O 0 0.0006475466070696712
- O 0 0.07310252636671066
Irish O 0 0.02887698821723461
patients O 0 0.001237374497577548
and O 0 6.470207125630623e-08
provide O 0 5.5508696306105776e-08
evidence O 0 3.846941254437297e-08
for O 0 9.123371391694945e-09
their O 0 2.8534435259075508e-08
transmission O 0 1.1775168786698487e-06
to O 0 4.6005162346318684e-08
Australia O 0 2.759108497230045e-08
by O 0 2.231153217735482e-08
British O 0 1.5496491414523916e-06
- O 0 1.1037195690732915e-05
Irish O 0 1.4159173815642134e-06
migrants O 0 2.919168196058308e-07
. O 0 6.722242318346616e-08
. O 0 3.655758575860091e-07

Identification O 0 2.0488276277319528e-05
of O 0 4.97790381359664e-07
constitutional O 0 7.12052860762924e-05
WT1 O 1 0.9799973964691162
mutations O 0 0.0008902936824597418
, O 0 3.135745600957307e-07
in O 0 4.626907355032017e-07
patients O 0 8.850996528053656e-05
with O 0 2.326405592611991e-06
isolated O 0 0.0850759893655777
diffuse B-Disease 1 0.9999862909317017
mesangial I-Disease 1 1.0
sclerosis I-Disease 1 0.9999998807907104
, O 0 8.614094895165181e-07
and O 0 4.346187409964841e-08
analysis O 0 9.271273171407302e-08
of O 0 5.7110927542680656e-08
genotype O 1 0.6282851099967957
/ O 0 0.008263610303401947
phenotype O 0 0.12793020904064178
correlations O 0 1.8345584749113186e-06
by O 0 6.506340799461441e-09
use O 0 7.187769046623771e-09
of O 0 4.3732604204649306e-09
a O 0 4.95306608172541e-07
computerized O 0 0.0004538198991212994
mutation O 0 2.117603798978962e-05
database O 0 1.451133925911563e-06
. O 0 8.226434147218242e-07

Constitutional O 0 0.0001444932131562382
mutations O 0 9.067994687939063e-05
of O 0 5.012966397544005e-08
the O 0 1.0054220922484092e-07
WT1 O 0 0.0003167057875543833
gene O 0 8.588141326981713e-07
, O 0 1.4146222859778845e-08
encoding O 0 9.226271657780671e-08
a O 0 9.522265713712841e-07
zinc O 0 0.00025953954900614917
- O 0 2.2572610305360286e-06
finger O 0 1.9040091956412653e-06
transcription O 0 1.8905315357642394e-07
factor O 0 4.2767666741383437e-08
involved O 0 5.078049625240055e-08
in O 0 6.660788471890555e-07
renal O 1 0.9997609257698059
and O 0 1.5792920748936012e-05
gonadal O 0 3.196686884621158e-05
development O 0 2.806409327149595e-08
, O 0 1.3632341477887167e-08
are O 0 3.0215194790628175e-09
found O 0 1.9891199798394155e-08
in O 0 3.200243270384817e-08
most O 0 3.021393922608695e-06
patients O 0 0.0013768956996500492
with O 0 3.5407130781095475e-05
Denys B-Disease 1 0.9999268054962158
- I-Disease 1 0.999997615814209
Drash I-Disease 1 0.9999992847442627
syndrome I-Disease 1 0.9999996423721313
( O 0 1.5037156799735385e-06
DDS B-Disease 1 0.999997615814209
) O 0 3.149841347749316e-07
, O 0 2.6043741740977566e-07
or O 0 5.441862867883174e-06
diffuse B-Disease 1 0.999976396560669
mesangial I-Disease 1 1.0
sclerosis I-Disease 1 1.0
( O 0 3.38602221745532e-05
DMS B-Disease 1 0.8920685648918152
) O 0 2.8206227398186456e-07
associated O 0 1.3042634350313165e-07
with O 0 1.4184026042585174e-07
pseudohermaphroditism B-Disease 1 0.9999949932098389
and O 0 2.784368916763924e-05
/ O 0 0.00020646420307457447
or O 0 8.991596587293316e-06
Wilms B-Disease 1 0.9979750514030457
tumor I-Disease 1 0.8728930950164795
( O 0 2.8398778795235557e-06
WT B-Disease 1 0.9995812773704529
) O 0 1.345009877695702e-06
. O 0 2.2275403352978174e-06

Most O 0 3.261502934037708e-05
mutations O 0 0.00180275016464293
in O 0 7.708293560426682e-05
DDS B-Disease 1 1.0
patients O 1 0.9999252557754517
lie O 0 8.112459909170866e-05
in O 0 2.1147681650290906e-07
exon O 0 2.846724328264827e-06
8 O 0 1.536595846118871e-07
or O 0 2.590227587973004e-08
exon O 0 1.3827589100401383e-06
9 O 0 2.3201367582714738e-07
, O 0 2.8921824934968754e-08
encoding O 0 2.3559432804631797e-07
zinc O 0 4.981799065717496e-05
finger O 0 4.724071914097294e-06
2 O 0 2.1668807903552079e-07
or O 0 8.63146496499212e-08
zinc O 0 0.0010570212034508586
finger O 0 0.0001732025993987918
3 O 0 3.558823777893849e-07
, O 0 4.553966093112649e-08
respectively O 0 1.53981432049477e-07
, O 0 3.5656495533942234e-09
with O 0 4.14964373973703e-09
a O 0 2.296351908626093e-07
hot O 0 2.365713589824736e-05
spot O 0 3.179598479619017e-06
( O 0 4.5033409890038456e-08
R394W O 0 1.4503259535558755e-06
) O 0 1.913980085532785e-08
in O 0 5.113310663773518e-08
exon O 0 6.542227765748976e-06
9 O 0 1.922213641591952e-06
. O 0 4.676169282902265e-07

We O 0 3.963551989727421e-06
analyzed O 0 1.821759610720619e-06
a O 0 1.4216148258583416e-07
series O 0 8.971776566113476e-08
of O 0 2.9175916793633405e-08
24 O 0 0.000130628832266666
patients O 0 0.00017665886844042689
, O 0 4.0110347043764705e-08
10 O 0 4.737688286127195e-08
with O 0 6.358042696774646e-07
isolated B-Disease 0 0.0022702550049871206
DMS I-Disease 1 0.9986910223960876
( O 0 4.392171888412122e-07
IDMS B-Disease 0 0.0032299640588462353
) O 0 6.864718216093024e-08
, O 0 5.310799267022048e-08
10 O 0 2.8015586295282446e-08
with O 0 6.634732017118949e-07
DDS B-Disease 1 0.9999998807907104
, O 0 9.473278623772785e-06
and O 0 1.4185636132424406e-07
4 O 0 1.9921657212762511e-07
with O 0 1.1168469882250065e-06
urogenital B-Disease 1 0.9990546107292175
abnormalities I-Disease 1 0.9999535083770752
and O 0 2.0528999812086113e-05
/ O 0 0.0011044649872928858
or O 0 2.6697362045524642e-05
WT B-Disease 1 0.9999905824661255
. O 0 2.995458635268733e-05

We O 0 8.698980309418403e-06
report O 0 3.714476406457834e-06
WT1 O 0 0.00043510101386345923
heterozygous O 0 0.00021097276476211846
mutations O 0 1.2857481124228798e-05
in O 0 2.956912510398979e-07
16 O 0 3.285195998614654e-05
patients O 0 0.0064118304289877415
, O 0 1.2821264760987106e-07
4 O 0 1.3010843247229786e-07
of O 0 1.2627492829153653e-08
whom O 0 2.184920504078036e-06
presented O 0 1.0619612567097647e-06
with O 0 1.3835384606863954e-06
IDMS B-Disease 0 0.4113715589046478
. O 0 4.409716893860605e-06

One O 0 1.2337950465735048e-05
male O 0 2.306925307493657e-05
and O 0 1.542021408340588e-07
two O 0 5.196063170842535e-07
female O 0 0.09891845285892487
IDMS B-Disease 1 0.9997633099555969
patients O 1 0.7405363321304321
with O 0 7.1361132540914696e-06
WT1 O 1 0.9761330485343933
mutations O 0 0.0020313437562435865
underwent O 0 0.00437882449477911
normal O 0 2.654160653037252e-06
puberty O 0 1.316429097641958e-05
. O 0 2.2413573788071517e-06

Two O 0 2.7087533453595825e-05
mutations O 0 0.0007261061109602451
associated O 0 2.6510974748816807e-06
with O 0 5.627259724860778e-07
IDMS B-Disease 0 0.4079478085041046
are O 0 1.0082219148443983e-07
different O 0 5.627772470262471e-09
from O 0 8.62431903669858e-09
those O 0 2.839371227025822e-08
described O 0 2.1876036043977365e-05
in O 0 2.9249047656776384e-05
DDS B-Disease 1 1.0
patients O 1 0.9995821118354797
. O 0 1.1299795005470514e-05

No O 0 8.139442070387304e-05
WT1 O 0 0.0629519671201706
mutations O 0 0.0012083366746082902
were O 0 1.3730035561820841e-06
detected O 0 1.3423868949757889e-06
in O 0 2.4687997424166497e-08
the O 0 3.066955400754523e-08
six O 0 5.623429615297937e-07
other O 0 4.0367461906498647e-07
IDMS B-Disease 1 0.9997531771659851
patients O 1 0.9613341093063354
, O 0 1.936242881583894e-07
suggesting O 0 3.1185218176688068e-06
genetic O 0 9.599897339285235e-07
heterogeneity O 0 1.7243487491214182e-06
of O 0 3.940339965424755e-08
this O 0 5.166310984350275e-06
disease O 0 0.0006431636866182089
. O 0 2.913360276579624e-06

We O 0 9.296474672737531e-06
analyzed O 0 3.03771721519297e-05
genotype O 0 0.006010306533426046
/ O 0 0.0003373378422111273
phenotype O 0 0.1315605193376541
correlations O 0 1.6801041056169197e-05
, O 0 5.878384357060895e-08
on O 0 6.060242441208175e-08
the O 0 4.9128736634429515e-09
basis O 0 2.4683319832519146e-09
of O 0 4.489759952708283e-10
the O 0 1.0380338366644537e-08
constitution O 0 1.5278180853783851e-07
of O 0 3.2291824769714594e-09
a O 0 1.3086531680528424e-06
WT1 O 0 0.004288069438189268
mutation O 0 6.467394086939748e-07
database O 0 1.215032163770502e-08
of O 0 3.337080833887285e-09
84 O 0 4.6247015461631236e-07
germ O 0 3.0040689580346225e-06
- O 0 9.675555338617414e-05
line O 0 8.294323197333142e-05
mutations O 0 1.6447967254862306e-06
, O 0 1.084862244482565e-08
to O 0 1.1794793586261676e-08
compare O 0 2.137693044801381e-08
the O 0 1.654150372232266e-09
distribution O 0 4.27267954350441e-09
and O 0 1.0033891051364208e-08
type O 0 2.1368455804804398e-07
of O 0 8.221679337339083e-09
mutations O 0 2.22063431465358e-06
, O 0 1.3788090669208941e-08
according O 0 5.439206862689616e-09
to O 0 1.2542758831557421e-08
the O 0 4.032474620885296e-08
different O 0 5.864676495548338e-07
symptoms O 0 0.029920484870672226
. O 0 2.574005520727951e-06

This O 0 1.626925222808495e-05
demonstrated O 0 3.570391709217802e-05
( O 0 1.9617439761532296e-07
1 O 0 5.2366168290518544e-08
) O 0 7.715822647469395e-09
the O 0 1.1884399242489962e-08
association O 0 2.874759452708986e-08
between O 0 1.6125445867487542e-08
mutations O 0 8.528966759513423e-07
in O 0 3.726151476257655e-08
exons O 0 1.708602894723299e-06
8 O 0 1.1352177864409896e-07
and O 0 5.439438055532264e-08
9 O 0 5.315313842402247e-07
and O 0 3.399175284357625e-06
DMS B-Disease 1 0.9897854924201965
; O 0 1.4311192444438348e-06
( O 0 1.2793680781442163e-08
2 O 0 1.3899642681280966e-07
) O 0 8.38611242670595e-08
among O 0 1.4095850247031194e-06
patients O 0 0.00397607684135437
with O 0 6.742292839589936e-07
DMS B-Disease 1 0.9710155129432678
, O 0 9.031818848370676e-08
a O 0 1.0356077950746112e-07
higher O 0 3.0176330767517356e-08
frequency O 0 1.1348831918667202e-07
of O 0 6.017484288634023e-09
exon O 0 2.82720156974392e-06
8 O 0 2.3436675178345467e-07
mutations O 0 4.7459687380069226e-07
among O 0 2.1976896746878083e-08
46 O 0 9.741760322867776e-07
, O 0 7.13033955435094e-07
XY O 1 0.9980980753898621
patients O 0 0.1871027797460556
with O 0 3.6625982602345175e-07
female O 0 0.018571343272924423
phenotype O 0 0.04897688701748848
than O 0 1.5194819980024477e-07
among O 0 4.692112653970071e-08
46 O 0 1.8759654949462856e-06
, O 0 1.3975568435853347e-06
XY O 1 0.9985625147819519
patients O 0 0.1924174427986145
with O 0 7.037516525087995e-08
sexual O 0 1.560088236374213e-07
ambiguity O 0 5.48500736385904e-07
or O 0 1.0977403235301608e-06
male O 0 0.22025084495544434
phenotype O 1 0.9345853328704834
; O 0 6.193304784574138e-07
and O 0 5.02816362768499e-07
( O 0 2.4765295592033e-08
3 O 0 3.7887229353827934e-08
) O 0 5.23151255649168e-09
statistically O 0 4.7374534517530265e-08
significant O 0 1.0942555306314716e-08
evidence O 0 4.560903121841875e-08
that O 0 7.510225685791738e-08
mutations O 0 6.062109605409205e-07
in O 0 3.3604212745785844e-08
exons O 0 1.8400410226604436e-06
8 O 0 7.438602267484384e-08
and O 0 3.051573926882156e-08
9 O 0 1.2902096102607175e-07
preferentially O 0 4.004742550023366e-06
affect O 0 8.464146361575331e-08
amino O 0 3.36051755311928e-08
acids O 0 1.3359287898140337e-08
with O 0 2.8866753432055248e-09
different O 0 1.8437408266791522e-09
functions O 0 9.598541517163994e-09
. O 0 3.3209605732054115e-08
. O 0 2.9800867196172476e-07

The O 0 8.156095645972528e-06
185delAG O 0 0.00030873663490638137
BRCA1 O 0 0.0008503278950229287
mutation O 0 1.402282123308396e-05
originated O 0 1.743716921964733e-07
before O 0 1.8665215151258963e-08
the O 0 3.2686306994378356e-09
dispersion O 0 5.40298799478478e-07
of O 0 1.6143172132387917e-08
Jews O 0 3.0992720212452696e-07
in O 0 3.374989532289874e-08
the O 0 1.93273699267138e-08
diaspora O 0 1.1281927925210766e-07
and O 0 7.012540947926027e-08
is O 0 7.040913629907664e-08
not O 0 5.517409107369531e-08
limited O 0 1.0434197150743785e-07
to O 0 7.094092211445968e-07
Ashkenazim O 0 3.1061925255926326e-05
. O 0 1.119594003284874e-06

The O 0 6.3818038142926525e-06
185delAG O 0 0.00010592090984573588
mutation O 0 3.554944123607129e-05
in O 0 2.488737607109215e-07
BRCA1 O 0 7.21876640454866e-05
is O 0 4.121977781323949e-07
detected O 0 1.5242205790855223e-06
in O 0 7.09311862578943e-08
Ashkenazi O 0 1.2607980352186132e-05
Jews O 0 1.3522802078114182e-07
both O 0 1.6627234700195004e-08
in O 0 1.638898652345233e-07
familial B-Disease 1 0.9300159215927124
breast I-Disease 1 0.9999936819076538
and I-Disease 1 0.999956488609314
ovarian I-Disease 1 1.0
cancer I-Disease 1 0.9999994039535522
and O 0 2.7250354150964995e-07
in O 0 1.6486012555105845e-08
the O 0 1.840298580191302e-08
general O 0 4.510531823598285e-07
population O 0 5.674294811797154e-07
. O 0 9.546643013891298e-07

All O 0 7.764618203509599e-06
tested O 0 2.8003732950310223e-05
Ashkenazi O 0 4.775786510435864e-05
mutation O 0 3.838391876342939e-06
carriers O 0 1.5680444676036132e-07
share O 0 2.6868375968547298e-08
the O 0 5.265107017038417e-09
same O 0 4.514529550192492e-08
allelic O 0 2.6943100692733424e-06
pattern O 0 1.8804919363901718e-06
at O 0 6.280919961909603e-08
the O 0 1.4192644925969944e-07
BRCA1 O 0 0.0001244945451617241
locus O 0 3.329843457322568e-05
. O 0 5.463109573611291e-06

Our O 0 3.138284455417306e-06
previous O 0 1.1717946790668066e-06
study O 0 2.58765567195951e-07
showed O 0 5.281444259708223e-07
that O 0 1.0584245480060872e-08
this O 0 3.3352307582390495e-08
Ashkenazi O 0 0.0001272751105716452
mutation O 0 2.473575250405702e-06
also O 0 3.7480634773601196e-07
occurs O 0 1.413397754390644e-08
in O 0 1.061505638944027e-08
Iraqi O 0 5.078098297417455e-07
Jews O 0 3.0776789117226144e-08
with O 0 1.9585392863064044e-08
a O 0 8.229549166571815e-07
similar O 0 1.3799214002574445e-06
allelic O 0 5.003667320124805e-05
pattern O 0 3.667656346806325e-05
. O 0 1.6559732785026426e-06

We O 0 3.0328519642353058e-06
extended O 0 8.323690394718142e-07
our O 0 2.6222252813568048e-08
analysis O 0 2.487730732525506e-08
to O 0 8.771969817189529e-09
other O 0 3.20644932827463e-09
non O 0 1.7839983712519825e-08
- O 0 2.2585356873605633e-06
Ashkenazi O 0 1.7380600638716714e-06
subsets O 0 9.187584737446741e-08
354 O 0 2.451826901506138e-07
of O 0 1.2650708036687774e-08
Moroccan O 0 8.027970579860266e-06
origin O 0 1.0031981645397536e-07
, O 0 2.3299433493662036e-08
200 O 0 4.117949714554925e-08
Yemenites O 0 1.83835015832301e-06
and O 0 4.936725872539682e-08
150 O 0 1.241755569481029e-07
Iranian O 0 1.7154308125100215e-06
Jews O 0 1.4017053899806342e-06
. O 0 6.245451800168667e-07

Heteroduplex O 0 0.0009689595317468047
analysis O 0 4.605925369105535e-06
complemented O 0 1.6743334754210082e-06
by O 0 3.2379112724356673e-08
direct O 0 3.28395479698429e-08
DNA O 0 1.156468130147914e-07
sequencing O 0 4.955981225407413e-08
of O 0 1.3880231186647052e-08
abnormally O 0 2.210905449828715e-06
migrating O 0 1.147787926925048e-07
bands O 0 2.0358989161195495e-07
were O 0 8.780460802881862e-08
employed O 0 1.5406706097564893e-06
. O 0 9.499934208179184e-07

Four O 0 3.397367436264176e-06
of O 0 2.268274243988344e-07
Moroccan O 0 4.151118628215045e-05
origin O 0 4.912988629257597e-07
( O 0 3.312275254074848e-08
1 O 0 7.006605073911487e-08
. O 0 2.2794894860567183e-08
1 O 0 5.17891649565172e-08
% O 0 1.3095625028824998e-08
) O 0 4.4172052682256435e-09
and O 0 2.0297180824968564e-08
none O 0 1.7908782012909796e-08
of O 0 6.030246857413601e-10
the O 0 2.2703080304609102e-08
Yemenites O 0 4.428416104929056e-06
or O 0 1.9428975761570655e-08
Iranians O 0 7.79683730911529e-08
was O 0 8.513172389257306e-08
a O 0 5.0888896652168114e-08
carrier O 0 2.19396682155093e-07
of O 0 2.4347222016274372e-09
the O 0 4.393478647557458e-08
185delAG O 0 0.00017508957535028458
mutation O 0 1.182823962153634e-05
. O 0 9.925244057740201e-07

BRCA1 O 0 0.4710008203983307
allelic O 0 0.005460372660309076
patterns O 0 0.0002481304691173136
were O 0 1.122808225773042e-05
determined O 0 2.175607505705557e-06
for O 0 2.3489388212283302e-08
four O 0 3.0462473432635306e-08
of O 0 2.331618231821153e-09
these O 0 5.491201271468071e-09
individuals O 0 2.5314641494134094e-09
and O 0 1.8526177925082266e-08
for O 0 1.8629187081842247e-08
12 O 0 6.050251499800652e-08
additional O 0 5.532784186357276e-08
non O 0 9.257949074026328e-08
- O 0 1.9192468244000338e-05
Ashkenazi O 0 9.20403272175463e-06
185delAG O 0 2.9711040951951873e-06
mutation O 0 1.9171936855855165e-06
carriers O 0 4.802068360731937e-07
who O 0 2.1596138140012044e-06
had O 0 0.014028125442564487
breast B-Disease 1 0.9999775886535645
/ I-Disease 1 0.9999947547912598
ovarian I-Disease 1 1.0
cancer I-Disease 1 0.9999988079071045
. O 0 5.283668542688247e-06

Six O 0 1.2244107892911416e-05
non O 0 1.9208996491215657e-06
- O 0 0.0001370398822473362
Ashkenazi O 0 0.0002689419488888234
individuals O 0 4.319898039284453e-08
shared O 0 1.820771089455775e-08
the O 0 1.504278657193936e-08
common O 0 5.403761065281287e-07
Ashkenazi O 0 0.01494272705167532
haplotype O 0 0.046206504106521606
, O 0 5.216768172999764e-08
four O 0 1.9174878573835485e-08
had O 0 9.528082500764867e-08
a O 0 8.132037265795589e-08
closely O 0 1.9570201459373493e-07
related O 0 1.2714174602024286e-07
pattern O 0 1.390640818499378e-06
, O 0 4.918914342511016e-08
and O 0 1.485562695080489e-08
the O 0 1.6693075366447374e-08
rest O 0 5.969269523120602e-08
( O 0 1.131653437624891e-08
n O 0 8.546211915927415e-07
= O 0 5.426504685601685e-07
6 O 0 6.98175171010007e-08
) O 0 5.3098241359350595e-09
displayed O 0 1.695518534461371e-07
a O 0 3.3045898817363195e-07
distinct O 0 1.59183400683105e-06
BRCA1 O 0 0.00012746776337735355
allelic O 0 2.669275454536546e-05
pattern O 0 2.8357691917335615e-05
. O 0 3.101009497186169e-06

We O 0 1.0651338016032241e-06
conclude O 0 7.257630159074324e-07
that O 0 3.721619989960345e-08
the O 0 4.543156606473531e-08
185delAG O 0 0.0001390948164043948
BRCA1 O 0 0.0009254104224964976
mutation O 0 3.898465365637094e-06
occurs O 0 1.990459885803375e-08
in O 0 3.5386640284684745e-09
some O 0 1.729869225641778e-08
non O 0 1.0210487033646132e-07
- O 0 0.00047125614946708083
Ashkenazi O 0 0.0005529013578779995
populations O 0 1.149001391809179e-07
at O 0 1.1629575524807478e-08
rates O 0 1.0483209678113781e-07
comparable O 0 2.8664588924698364e-08
with O 0 4.744133086376223e-09
that O 0 3.72042769924974e-08
of O 0 4.158170696655361e-08
Ashkenazim O 0 2.25908552238252e-05
. O 0 2.2356061890604906e-06

The O 0 4.88823707200936e-06
majority O 0 2.375330041104462e-06
of O 0 4.393814023728737e-08
Jewish O 0 6.179004117257136e-07
185delAG O 0 1.9985202015959658e-05
mutation O 0 3.004040081577841e-06
carriers O 0 2.99058314112699e-07
have O 0 2.0010000767456404e-08
a O 0 1.9728018685327697e-07
common O 0 2.7383947553971666e-07
allelic O 0 2.9421515137073584e-05
pattern O 0 3.006144288519863e-05
, O 0 7.767492604671133e-08
supporting O 0 6.882758896153973e-08
the O 0 2.4956342770110496e-08
founder O 0 1.089465627046593e-06
effect O 0 1.8180422500790883e-07
notion O 0 8.549214669528737e-08
, O 0 2.225997164373439e-08
but O 0 1.7852476830171327e-08
dating O 0 3.0109010396017766e-08
the O 0 8.621523051033364e-09
mutations O 0 1.573410060018432e-07
origin O 0 6.185286505200338e-09
to O 0 1.3965235190482872e-08
an O 0 6.444650324510803e-08
earlier O 0 1.464730530642555e-06
date O 0 9.344487494900022e-08
than O 0 3.140710091997789e-08
currently O 0 1.6637092414839572e-07
estimated O 0 2.063472237523456e-07
. O 0 3.655978275673988e-07

However O 0 1.3987080819788389e-05
, O 0 5.388909585235524e-08
the O 0 3.744788479309591e-09
different O 0 7.527416912012086e-09
allelic O 0 1.524586991763499e-06
pattern O 0 1.3279083077577525e-06
at O 0 2.0867599204166254e-08
the O 0 3.0280919105507564e-08
BRCA1 O 0 2.1542269678320736e-05
locus O 0 8.740373118598654e-07
even O 0 3.397290981865808e-08
in O 0 5.815106174367202e-09
some O 0 1.2587431541533078e-08
Jewish O 0 1.3419716538010107e-07
mutation O 0 7.149841394493706e-07
carriers O 0 2.2470707961019798e-07
, O 0 1.64435540739305e-08
might O 0 7.905011045750143e-08
suggest O 0 4.715178292258315e-08
that O 0 9.682942447852838e-09
the O 0 2.5139128112527942e-08
mutation O 0 1.0072030818264466e-06
arose O 0 1.7897383486342733e-07
independently O 0 2.6596265456646506e-07
. O 0 6.60420340636847e-08
. O 0 2.6617576054377423e-07

Crystal O 0 0.0013292762450873852
structure O 0 3.4475585835025413e-06
of O 0 8.110969673680302e-08
the O 0 2.193957698182203e-06
hemochromatosis B-Disease 1 0.999998927116394
protein O 0 9.360181138617918e-05
HFE O 0 0.00047435841406695545
and O 0 1.1022642354419077e-07
characterization O 0 3.6656595625572663e-07
of O 0 1.7376561300963544e-09
its O 0 1.1419745149510163e-08
interaction O 0 4.531680630748269e-08
with O 0 3.2693935736460844e-07
transferrin O 0 0.0006614196463488042
receptor O 0 3.703325637616217e-05
. O 0 1.680942773418792e-06

HFE O 1 0.668947696685791
is O 0 1.4794184608035721e-05
an O 0 1.3252060853119474e-06
MHC O 0 0.0074953725561499596
- O 0 0.0007922181976027787
related O 0 2.8817100883316016e-07
protein O 0 1.1241802155836922e-07
that O 0 1.6912833800120097e-08
is O 0 1.3261724163271538e-08
mutated O 0 6.145536417534458e-07
in O 0 1.9181866761641686e-08
the O 0 9.244291732102283e-08
iron B-Disease 1 0.9963498115539551
- I-Disease 1 0.999911904335022
overload I-Disease 1 0.999968409538269
disease I-Disease 1 0.9998940229415894
hereditary B-Disease 1 0.9999998807907104
hemochromatosis I-Disease 1 1.0
. O 0 0.0007942636730149388

HFE O 0 0.0038729580119252205
binds O 0 3.87581494578626e-05
to O 0 1.908870672195917e-06
transferrin O 0 8.591335063101724e-05
receptor O 0 1.5560655810986646e-05
( O 0 2.4786376684460265e-07
TfR O 0 2.966569627460558e-05
) O 0 2.7836350113830122e-08
and O 0 6.95189328325796e-08
reduces O 0 1.752291495904501e-06
its O 0 6.923998085994754e-08
affinity O 0 1.997625815874926e-07
for O 0 8.061692824412603e-08
iron O 0 0.0014934941427782178
- O 0 1.3428667443804443e-05
loaded O 0 5.5905293265823275e-06
transferrin O 0 4.0173301385948434e-05
, O 0 1.3154986788777023e-07
implicating O 0 1.709315984044224e-05
HFE O 0 0.00044920342043042183
in O 0 8.320627102875733e-07
iron O 0 0.03816781938076019
metabolism O 0 2.684469654923305e-05
. O 0 1.8531411569711054e-06

The O 0 9.350365871796384e-06
2 O 0 1.3920412129664328e-05
. O 0 4.569132215692662e-06

6 O 0 7.501929940190166e-05
A O 0 3.3902873838087544e-05
crystal O 0 0.00015196041204035282
structure O 0 5.684092343472003e-07
of O 0 2.6022657806379357e-08
HFE O 0 0.00023322411288972944
reveals O 0 3.2370332974096527e-06
the O 0 1.8537665624762667e-08
locations O 0 1.0671088546132523e-07
of O 0 1.5806533326667704e-07
hemochromatosis B-Disease 1 0.9999998807907104
mutations O 0 0.011630848981440067
and O 0 3.156896468681225e-07
a O 0 2.2876204184285598e-06
patch O 0 0.00984769407659769
of O 0 3.4213314847875154e-08
histidines O 0 3.312240369268693e-05
that O 0 3.900909106846484e-08
could O 0 4.124772701175061e-08
be O 0 8.314961164046508e-09
involved O 0 2.1188981236264226e-08
in O 0 1.0046571929933634e-07
pH O 0 0.0002694190479815006
- O 0 7.252425712067634e-05
dependent O 0 2.3239288111653877e-06
interactions O 0 5.001763270229276e-07
. O 0 4.5064473397360416e-07

We O 0 2.683655111468397e-06
also O 0 4.812021074940276e-07
demonstrate O 0 6.230698090803344e-07
that O 0 4.545566127944767e-07
soluble O 0 0.00011545512825250626
TfR O 0 0.0003115613362751901
and O 0 1.7888099534957291e-07
HFE O 0 7.173394260462373e-05
bind O 0 2.1501728042494506e-06
tightly O 0 2.6108075417141663e-06
at O 0 2.0274583789614553e-08
the O 0 5.100187827622449e-09
basic O 0 1.0780516390695993e-07
pH O 0 3.3401778409825056e-07
of O 0 2.7359128296211566e-09
the O 0 1.3622517336386863e-08
cell O 0 3.337074758746894e-06
surface O 0 1.024069388222415e-05
, O 0 2.383672814687543e-08
but O 0 1.7685561459757082e-08
not O 0 3.509052248773514e-08
at O 0 1.2072058019896303e-08
the O 0 5.373985345613619e-08
acidic O 0 0.00027761777164414525
pH O 0 4.240225734974956e-06
of O 0 1.8739699569891854e-08
intracellular O 0 2.2639699182036566e-06
vesicles O 0 2.6084853743668646e-05
. O 0 1.1458492963356548e-06

TfR O 1 0.9737973809242249
HFE O 1 0.669560968875885
stoichiometry O 0 0.004567394498735666
( O 0 7.554160220024642e-06
2 O 0 1.1945815003855387e-06
1 O 0 3.0565317388209223e-07
) O 0 4.710854284439847e-08
differs O 0 7.784412900946336e-07
from O 0 1.2829852380491502e-07
TfR O 0 0.00011394622561056167
transferrin O 0 3.7004243495175615e-05
stoichiometry O 0 2.796839225993608e-06
( O 0 2.587570868683997e-08
2 O 0 6.114976969229247e-08
2 O 0 4.55951969513535e-08
) O 0 8.803279882840798e-09
, O 0 8.547416996407264e-09
implying O 0 5.2112785198232814e-08
a O 0 2.1184980880661897e-08
different O 0 8.79646133711276e-10
mode O 0 1.0299303632166357e-08
of O 0 2.4662378805828666e-09
binding O 0 1.7086016157463746e-07
for O 0 7.28421554185843e-08
HFE O 0 0.0001178904203698039
and O 0 7.278840143953857e-07
transferrin O 0 4.3993211875204e-05
to O 0 1.8435082438372774e-06
TfR O 0 0.00030419277027249336
, O 0 3.436589679495228e-08
consistent O 0 6.13937842786072e-08
with O 0 6.5579959240835706e-09
our O 0 6.4389098497485975e-09
demonstration O 0 1.1831547652718655e-07
that O 0 5.078242892864182e-08
HFE O 0 3.950018071918748e-05
, O 0 1.322788847346601e-07
transferrin O 0 2.206908720836509e-05
, O 0 1.0524099280928567e-07
and O 0 1.4335149955968518e-07
TfR O 0 0.00018366998119745404
form O 0 8.721440991621421e-08
a O 0 5.826711344525393e-07
ternary O 0 1.0382881555415224e-05
complex O 0 6.026887604093645e-06
. O 0 2.3689754016231745e-06

Identification O 0 1.542031895951368e-05
of O 0 1.412778374287882e-07
three O 0 1.3030202694608306e-07
novel O 0 1.3282021882332629e-06
mutations O 0 9.669784049037844e-07
and O 0 3.145584059893736e-08
a O 0 3.3897737239385606e-07
high O 0 3.389502012396406e-07
frequency O 0 3.664589769414306e-07
of O 0 4.379203222271144e-09
the O 0 4.1847130205496796e-08
Arg778Leu O 0 0.00010201227996731177
mutation O 0 1.7917891454999335e-06
in O 0 4.508454765073111e-08
Korean O 0 7.442877176799811e-06
patients O 0 0.0008611968369223177
with O 0 3.5867092265107203e-06
Wilson B-Disease 0 0.022908100858330727
disease I-Disease 0 0.000597166595980525
. O 0 1.976880412257742e-06

Four O 0 2.1647339963237755e-05
mutations O 0 5.218175283516757e-05
- O 0 2.9157587050576694e-05
- O 0 5.031952241552062e-05
R778L O 0 8.47876253828872e-06
, O 0 5.853869922134436e-08
A874V O 0 5.970915140096622e-07
, O 0 3.4908744339645637e-08
L1083F O 0 6.202347435646516e-07
, O 0 1.0834003028037387e-08
and O 0 8.391404904273259e-09
2304delC O 0 7.842713785066735e-07
- O 0 7.1134595600597095e-06
- O 0 1.0796956303238403e-05
in O 0 2.5205672216088715e-08
the O 0 4.78602268927375e-09
copper O 0 4.850187451665988e-07
- O 0 1.8332049478431145e-07
transporting O 0 2.610613307751919e-07
enzyme O 0 1.1653560250124428e-07
, O 0 1.9163543640843272e-08
P O 0 4.686777401730069e-07
- O 0 2.2239828467718326e-06
type O 0 6.958784979360644e-06
ATPase O 0 1.1245752830291167e-05
( O 0 1.7151899456280262e-08
ATP7B O 0 8.800008799880743e-06
) O 0 1.0079408419017e-08
, O 0 9.84868009368256e-09
were O 0 4.750084414695266e-08
identified O 0 1.4045299678855372e-07
in O 0 2.0790684729377062e-08
Korean O 0 1.272299141419353e-05
Patients O 0 0.0007788782240822911
with O 0 1.4446977729676291e-06
Wilson B-Disease 0 0.0036512305960059166
disease I-Disease 0 0.00016992796736303717
. O 0 1.4399166730072466e-06

Arg778Leu O 0 0.0015222389483824372
, O 0 1.0618761052683112e-06
the O 0 2.0632194619452093e-08
most O 0 5.616901788130235e-08
frequently O 0 7.860040227569698e-07
reported O 0 6.789867939005489e-07
mutation O 0 6.635719529413109e-08
of O 0 1.4153475058620302e-09
this O 0 9.092536501498216e-09
enzyme O 0 1.3016564537338127e-07
, O 0 1.7290380682766227e-08
was O 0 7.631098242200096e-07
found O 0 1.3180498470433122e-08
in O 0 3.07910430485947e-09
six O 0 1.2074177213605708e-08
of O 0 3.591525521429162e-09
eight O 0 7.844479341656552e-07
unrelated O 0 0.0005430598394013941
patients O 0 0.013186014257371426
studied O 0 2.1316188281161885e-07
, O 0 9.517743038145454e-09
an O 0 1.986405528953128e-08
allele O 0 5.30272245669039e-07
frequency O 0 1.9813525398149068e-07
of O 0 1.5660171825970792e-08
37 O 0 2.6142558908759383e-06
. O 0 5.715876341128023e-07

5 O 0 7.220419502118602e-05
% O 0 1.8484408883523429e-06
, O 0 4.676646270240781e-08
which O 0 5.079754217263144e-08
is O 0 4.37481446624588e-08
considerably O 0 4.09447693527909e-06
higher O 0 2.829380640889667e-08
than O 0 1.1391443344166419e-08
those O 0 2.8499500537293443e-09
in O 0 6.754576897805009e-09
other O 0 1.3864514869510458e-08
Asian O 0 1.4698110817334964e-07
populations O 0 8.474102628497349e-07
. O 0 9.911320830724435e-07

The O 0 1.9029108671020367e-06
novel O 0 2.3735885861242423e-06
single O 0 7.589771939819911e-07
nucleotide O 0 1.4733099078512168e-06
deletion O 0 3.4406216400384437e-06
, O 0 1.0146034412628069e-07
2304delC O 0 5.805949058412807e-06
, O 0 8.829432118773184e-08
was O 0 5.973859629193612e-07
found O 0 2.483587202561921e-08
in O 0 1.4266094083836833e-08
one O 0 4.469267764761753e-07
patient O 0 0.00017792894504964352
. O 0 2.435737087580492e-06

Since O 0 3.677519089251291e-06
a O 0 4.418513981363503e-07
mutation O 0 8.315835202665767e-07
at O 0 2.8652452854771582e-08
cDNA O 0 7.428541834997304e-07
nucleotide O 0 1.2172146170996712e-06
2302 O 0 9.359134310216177e-06
( O 0 6.196317769990856e-08
2302insC O 0 2.2551653273694683e-06
) O 0 5.893135579526643e-08
had O 0 8.315176955875359e-07
been O 0 2.9874817641939444e-07
previously O 0 4.5910101675872284e-07
described O 0 1.3521889741241466e-06
, O 0 9.299712111499048e-09
this O 0 2.429030754313999e-09
region O 0 5.6193205644206046e-09
of O 0 1.124432325028124e-09
the O 0 4.0390560229752737e-08
ATP7B O 0 0.011620676144957542
gene O 0 1.8226614884042647e-06
may O 0 8.416579930781154e-07
be O 0 1.0278269257923967e-07
susceptible O 0 9.282574865210336e-06
to O 0 8.673545721649134e-07
gene O 0 9.140144356933888e-06
rearrangements O 0 0.004922578111290932
causing O 0 0.007888938300311565
Wilson B-Disease 0 0.003974344115704298
disease I-Disease 0 0.0008123581646941602
. O 0 3.374395873834146e-06

Disruption O 0 0.00017542747082188725
of O 0 2.1489643131644698e-07
splicing O 0 6.31848433840787e-06
regulated O 0 1.0122711273652385e-06
by O 0 5.867428853889578e-08
a O 0 2.7939657343267754e-07
CUG O 0 0.0002362589875701815
- O 0 1.2474552931962535e-05
binding O 0 3.1174486139207147e-06
protein O 0 3.1104550544114318e-06
in O 0 2.719510575843742e-06
myotonic B-Disease 1 0.9999991655349731
dystrophy I-Disease 1 0.9999997615814209
. O 0 6.50637157377787e-05

Myotonic B-Disease 1 0.9999996423721313
dystrophy I-Disease 1 1.0
( O 1 0.9985673427581787
DM B-Disease 1 0.9999998807907104
) O 0 0.0001045643221004866
is O 0 3.414852699279436e-06
caused O 0 2.291168357260176e-06
by O 0 5.186429063996911e-08
a O 0 3.9330271306425857e-07
CTG O 0 1.191431420011213e-05
expansion O 0 1.0226371927046785e-07
in O 0 1.1408904043719303e-08
the O 0 1.1656223541933741e-08
3 O 0 1.6767275212714594e-07
untranslated O 0 1.2367023373371921e-05
region O 0 8.166637144313427e-08
of O 0 1.3846755742008554e-08
the O 0 8.313884904964652e-07
DM B-Disease 1 0.9999996423721313
gene O 0 0.0001244839804712683
. O 0 4.108851499040611e-06

One O 0 1.1985734090558253e-05
model O 0 1.1959085895796306e-05
of O 0 8.625513032711751e-07
DM B-Disease 1 0.9999998807907104
pathogenesis O 1 0.8004795908927917
suggests O 0 4.761459877045127e-06
that O 0 4.934372554998845e-08
RNAs O 0 2.310044777686926e-07
from O 0 3.786192692700752e-09
the O 0 3.950821447773478e-09
expanded O 0 7.44595496371403e-08
allele O 0 6.439501589738938e-07
create O 0 3.3443974700730905e-08
a O 0 1.5124081187423144e-07
gain O 0 8.556585271435324e-07
- O 0 1.5835183830859023e-06
of O 0 1.4113477497801341e-08
- O 0 2.4871482310118154e-05
function O 0 1.4375727630522306e-07
mutation O 0 8.040025534228334e-08
by O 0 1.979471919710818e-09
the O 0 2.7621609444139494e-09
inappropriate O 0 1.3702785395253159e-07
binding O 0 6.604631863638133e-08
of O 0 3.2117069004300447e-09
proteins O 0 1.7078221503652458e-08
to O 0 3.2527793791814474e-08
the O 0 7.34608107677559e-08
CUG O 0 0.002274504629895091
repeats O 0 1.4016830391483381e-05
. O 0 1.3408028962658136e-06

Data O 0 1.528210486867465e-05
presented O 0 2.7302014586894074e-06
here O 0 1.277572607705224e-07
indicate O 0 1.4432200146075047e-07
that O 0 5.5596189874052016e-09
the O 0 6.423135356925513e-09
conserved O 0 1.3958610622921697e-07
heterogeneous O 0 4.0586837712908164e-07
nuclear O 0 4.737101448881731e-07
ribonucleoprotein O 0 4.22514585807221e-06
, O 0 3.6765225530643875e-08
CUG O 0 1.464343131374335e-05
- O 0 5.7982692851510365e-06
binding O 0 9.263853826269042e-07
protein O 0 1.7842408794876974e-07
( O 0 2.1044385789537046e-08
CUG O 0 5.1687929953914136e-05
- O 0 0.000629824586212635
BP O 0 0.013315321877598763
) O 0 5.8210130049474174e-08
, O 0 3.4519029412649616e-08
may O 0 2.2438329949636682e-07
mediate O 0 5.471832992043346e-06
the O 0 3.685214267079573e-08
trans O 0 1.5050297861307627e-06
- O 0 3.740957981790416e-05
dominant O 0 3.824703526333906e-06
effect O 0 1.9358219560672296e-07
of O 0 7.738018226177701e-09
the O 0 7.847624061696479e-08
RNA O 0 2.657202685441007e-06
. O 0 1.4165642596708494e-06

CUG O 0 0.023709354922175407
- O 0 0.01899983547627926
BP O 0 0.010661425068974495
was O 0 2.8716660835925722e-06
found O 0 3.8311245731392773e-08
to O 0 8.779100113542881e-09
bind O 0 1.226996033665273e-07
to O 0 4.209866943938323e-08
the O 0 3.7831629384754706e-08
human O 0 1.9340222934260964e-06
cardiac O 1 0.9868083596229553
troponin O 0 0.31892871856689453
T O 0 0.0007448390242643654
( O 0 5.23407024388689e-08
cTNT O 0 9.44122689361393e-07
) O 0 7.807488877631386e-09
pre O 0 1.3468617510170589e-07
- O 0 8.736456038604956e-07
messenger O 0 2.950954183233989e-07
RNA O 0 2.1628666857509415e-08
and O 0 4.46460468594978e-09
regulate O 0 6.38990087509228e-08
its O 0 5.49064935739807e-08
alternative O 0 5.324923222360667e-07
splicing O 0 6.407612545444863e-06
. O 0 1.0199299822488683e-06

Splicing O 0 0.00035809012479148805
of O 0 1.179499463432876e-06
cTNT O 0 0.00015663934755139053
was O 0 1.1290444490441587e-05
disrupted O 0 2.2032769265933894e-05
in O 0 5.000303190172417e-06
DM B-Disease 1 0.9999997615814209
striated O 1 0.9898316860198975
muscle O 1 0.6336032748222351
and O 0 8.531326329830335e-07
in O 0 1.4953212712498498e-07
normal O 0 6.910869387866114e-07
cells O 0 8.617340654382133e-07
expressing O 0 4.7088374799386656e-07
transcripts O 0 8.619090863248857e-07
that O 0 1.4460856334608252e-07
contain O 0 1.0834622798938653e-06
CUG O 0 0.000665983185172081
repeats O 0 3.2273575925501063e-05
. O 0 1.401141503265535e-06

Altered O 0 0.0002079231053357944
expression O 0 1.703425823507132e-06
of O 0 1.7196908785876985e-08
genes O 0 1.871834172106901e-07
regulated O 0 2.717937093166256e-07
posttranscriptionally O 0 5.956842869636603e-06
by O 0 1.1233893815187912e-07
CUG O 0 0.0002994726528413594
- O 0 0.000532512494828552
BP O 0 0.011315764859318733
therefore O 0 2.0539499701044406e-07
may O 0 3.578443283913657e-07
contribute O 0 1.0051115140186084e-07
to O 0 6.69129985908512e-06
DM B-Disease 1 0.9999998807907104
pathogenesis O 0 0.4965885579586029
. O 0 1.752433604451653e-06
. O 0 1.3246083199192071e-06

Identification O 0 6.924123226781376e-06
of O 0 9.759747143789355e-08
a O 0 9.624216090742266e-07
novel O 0 4.542204806057271e-06
nonsense O 0 1.8231419744552113e-05
mutation O 0 3.0722094379598275e-06
and O 0 5.445915363111453e-08
a O 0 2.8441255039979296e-07
missense O 0 3.0233625238906825e-06
substitution O 0 1.1288836532230562e-07
in O 0 2.870781479202833e-08
the O 0 2.4987921065644514e-08
vasopressin O 0 1.562820398248732e-05
- O 0 3.368527177372016e-05
neurophysin O 0 0.00012934622645843774
II O 0 2.8198017389513552e-05
gene O 0 9.696845637563456e-08
in O 0 8.772070181350955e-09
two O 0 4.5796710423928744e-08
Spanish O 0 4.081674660483259e-07
kindreds O 0 2.027727896347642e-05
with O 0 1.859345843513438e-06
familial B-Disease 0 0.2568172216415405
neurohypophyseal I-Disease 1 0.9998522996902466
diabetes I-Disease 1 0.9999346733093262
insipidus I-Disease 1 0.9257543087005615
. O 0 1.6768466593930498e-05

Familial B-Disease 1 0.9996315240859985
neurohypophyseal I-Disease 1 0.9999723434448242
diabetes I-Disease 1 0.9999995231628418
insipidus I-Disease 1 0.9999642372131348
( O 0 0.0014739078469574451
FNDI B-Disease 1 0.9999984502792358
) O 0 9.152863640338182e-07
is O 0 2.6488558546589047e-07
an O 0 1.8676844319998054e-06
autosomal B-Disease 1 0.9981045722961426
dominant I-Disease 1 0.9995062351226807
disease I-Disease 1 0.9472111463546753
caused O 0 0.02698013186454773
by O 0 0.0013425855431705713
deficiency O 1 0.5279259085655212
in O 0 1.3373569629493431e-07
the O 0 3.8879659314261517e-07
antidiuretic O 0 0.0002881494874600321
hormone O 0 3.512493640300818e-05
arginine O 0 2.7294463507132605e-06
vasopressin O 0 4.503840500547085e-06
( O 0 3.8853968931107374e-08
AVP O 0 1.4433536534852465e-06
) O 0 4.928707220130946e-09
encoded O 0 9.033727543794612e-09
by O 0 3.1260602995075715e-09
the O 0 7.443339722357223e-09
AVP O 0 2.087312714138534e-05
- O 0 0.0004700515419244766
neurophysin O 0 0.0032421103678643703
II O 0 0.0005148867494426668
( O 0 1.2113602565477777e-07
AVP O 0 1.959266228368506e-05
- O 0 0.00012377263919916004
NPII O 0 0.00030998571310192347
) O 0 6.36535304465724e-08
gene O 0 1.0314365539443315e-07
on O 0 2.544000210491504e-07
chromosome O 0 2.350067916268017e-05
20p13 O 0 3.0983883334556594e-05
. O 0 9.892462458083173e-07

In O 0 2.2373678802978247e-06
this O 0 1.449529207775413e-07
study O 0 1.4790846591949958e-07
, O 0 1.5471586678472704e-08
we O 0 9.67339897073316e-09
analyzed O 0 2.1412927253550151e-07
two O 0 2.8508431171303528e-08
families O 0 2.4377484919568815e-08
with O 0 4.348193982650628e-08
FNDI B-Disease 1 0.9997995495796204
using O 0 5.957759086072656e-08
direct O 0 2.5705359618655166e-08
automated O 0 2.182526657179551e-07
fluorescent O 0 3.376002041477477e-06
, O 0 7.3891066598719135e-09
solid O 0 1.506495976855149e-07
phase O 0 1.0721520027345832e-07
, O 0 1.5928888430494226e-08
single O 0 9.719953908415846e-08
- O 0 1.5895310525593231e-06
stranded O 0 3.9897093984109233e-07
DNA O 0 5.0829335407343024e-08
sequencing O 0 2.261849374463054e-08
of O 0 5.2243929182793636e-09
PCR O 0 1.1359351447026711e-05
- O 0 1.619510294403881e-05
amplified O 0 4.061160871060565e-05
AVP O 0 5.087745375931263e-05
- O 0 3.1968455004971474e-05
NPII O 0 0.0004146074934396893
DNA O 0 2.2565835024579428e-05
. O 0 2.650091118994169e-06

In O 0 1.225264668391901e-06
one O 0 6.789713324906188e-08
of O 0 7.1938037748964234e-09
the O 0 5.536933045391379e-08
families O 0 3.297132309398876e-07
, O 0 2.171891537727788e-07
affected O 0 2.770423179754289e-07
individuals O 0 1.1004130939795687e-08
presented O 0 1.224518939579866e-07
a O 0 2.4867330239430885e-07
novel O 0 8.818329888526932e-07
nonsense O 0 3.456819513303344e-06
mutation O 0 5.561265083997569e-07
in O 0 1.3598841164252917e-08
exon O 0 3.544131175203802e-07
3 O 0 2.129553777763249e-08
of O 0 1.5722536605977666e-09
the O 0 1.10972724343128e-08
gene O 0 8.919889182834595e-08
, O 0 1.2867684695549997e-08
consisting O 0 2.8374113725249117e-08
in O 0 1.3374942042787552e-08
a O 0 9.466652386436181e-07
G O 0 0.004780814051628113
to O 0 6.610271725548955e-07
T O 0 3.5397075407672673e-05
transition O 0 1.548784638316647e-07
at O 0 1.4431093653399785e-08
nucleotide O 0 9.808117340526223e-08
2101 O 0 1.61975992796215e-06
, O 0 2.119092101793285e-08
which O 0 1.598159649063291e-08
produces O 0 3.3538515964437465e-08
a O 0 2.572036805759126e-08
stop O 0 7.13466619117753e-08
signal O 0 5.499778126250021e-07
in O 0 2.486777184174116e-08
codon O 0 5.252517212284147e-07
82 O 0 2.3843290364311542e-06
( O 0 5.9123085094370254e-08
Glu O 0 0.00010461099009262398
) O 0 3.292804606758182e-08
of O 0 2.114368413685952e-08
NPII O 0 0.0009221577201969922
. O 0 3.4980980672116857e-06

The O 0 8.012826583581045e-06
premature O 0 0.00011920122051378712
termination O 0 8.874425475369208e-06
eliminates O 0 2.935134716608445e-06
part O 0 9.003215950542653e-08
of O 0 7.396608214804701e-09
the O 0 6.473898395142896e-08
C O 0 1.8308023754798342e-06
- O 0 3.342817581142299e-05
terminal O 0 4.797024757863255e-06
domain O 0 2.42735094246882e-08
of O 0 4.629615357742978e-09
NPII O 0 4.828496093978174e-05
, O 0 2.0032187464380513e-08
including O 0 3.1404989719874266e-09
a O 0 3.0356329006053784e-08
cysteine O 0 2.6133527342153684e-08
residue O 0 7.54157554183621e-08
in O 0 7.3832602254242374e-09
position O 0 3.636775716131524e-07
85 O 0 1.297289315971284e-07
, O 0 1.2867905851976502e-08
which O 0 4.1313239051987694e-08
could O 0 1.3061193726571219e-07
be O 0 1.4023611605296082e-08
involved O 0 4.453208468646608e-09
in O 0 5.9011182607093815e-09
the O 0 1.2396513149326438e-08
correct O 0 7.674310609218082e-07
folding O 0 9.885757208394352e-07
of O 0 1.846796671145512e-08
the O 0 9.963979152871616e-08
prohormone O 0 0.0006911056698299944
. O 0 3.570460648916196e-06

In O 0 2.731581616899348e-06
the O 0 8.931653638910575e-08
second O 0 4.838314566768531e-07
family O 0 3.7216170767351286e-07
, O 0 1.5720235779781433e-08
a O 0 3.5135062859126265e-08
G279A O 0 3.420011012167379e-07
substitution O 0 1.4145251192587693e-08
at O 0 6.603281477168821e-09
position O 0 1.473842416999105e-07
- O 0 8.601658123552625e-07
1 O 0 2.9249076050064104e-08
of O 0 9.509192322454396e-10
the O 0 6.549158548807554e-09
signal O 0 9.781566632227623e-07
peptide O 0 1.6408002068146743e-07
was O 0 2.5413888238290383e-07
observed O 0 3.010275051451572e-08
in O 0 3.506722245916194e-09
all O 0 9.788042376612793e-09
affected O 0 3.408871123156132e-07
individuals O 0 1.1320878456899663e-07
. O 0 7.25042809790466e-07

This O 0 9.539512575429399e-06
missense O 0 0.005219803657382727
mutation O 0 0.00030374995549209416
, O 0 4.78131710224261e-07
which O 0 5.35415779268078e-07
replaces O 0 4.8013596824603155e-05
Ala O 0 3.112494232482277e-05
with O 0 4.685226713263546e-07
Thr O 0 7.622522389283404e-05
, O 0 1.1350672934895556e-07
is O 0 1.1177446879173658e-07
frequent O 0 5.854762548551662e-06
among O 0 8.943942702899221e-06
FNDI B-Disease 1 1.0
patients O 1 0.9876986742019653
and O 0 1.0332954047953535e-07
is O 0 5.6393698599777053e-08
thought O 0 3.2998780596926736e-08
to O 0 1.1806227995236895e-08
reduce O 0 7.605786578324114e-08
the O 0 2.926005215897476e-09
efficiency O 0 3.255864555740118e-08
of O 0 2.3975743612680844e-09
cleavage O 0 5.79099150854745e-07
by O 0 7.797878964765914e-08
signal O 0 3.7801373764523305e-06
peptidases O 0 1.5804460417712107e-05
. O 0 2.525517288631818e-07
. O 0 5.905242232984165e-07

Genetic O 0 0.0014078859239816666
heterogeneity O 0 0.00037862907629460096
of O 0 3.414882030483568e-06
Saethre B-Disease 1 0.9713132381439209
- I-Disease 1 0.9999181032180786
Chotzen I-Disease 1 0.9999778270721436
syndrome I-Disease 1 0.9999973773956299
, O 0 2.3643477220502973e-07
due O 0 9.443049009405513e-08
to O 0 9.955562774166538e-08
TWIST O 0 0.00216412334702909
and O 0 1.499065456300741e-05
FGFR O 1 0.6195936799049377
mutations O 0 5.393151513999328e-05
. O 0 3.2621851460135076e-06

Thirty O 0 0.00012938643340021372
- O 0 0.00018159564933739603
two O 0 2.052562876997399e-06
unrelated O 0 0.0001405764778610319
patients O 0 0.00024047199985943735
with O 0 4.630032535146711e-08
features O 0 1.4136654726826237e-06
of O 0 7.252053535466985e-08
Saethre B-Disease 1 0.8669383525848389
- I-Disease 1 0.9998552799224854
Chotzen I-Disease 1 0.9999774694442749
syndrome I-Disease 1 0.9999858140945435
, O 0 4.22536068356294e-08
a O 0 8.961700928011851e-07
common O 0 1.0323205060558394e-05
autosomal B-Disease 1 0.9718182682991028
dominant I-Disease 1 0.518364429473877
condition I-Disease 0 0.007536725606769323
of O 0 1.3940810106305435e-07
craniosynostosis B-Disease 1 0.9831610321998596
and O 0 0.0008886961149983108
limb B-Disease 1 0.9779161810874939
anomalies I-Disease 0 0.044372960925102234
, O 0 3.596398130412126e-07
were O 0 3.1306598202718305e-07
screened O 0 2.3311105906032026e-05
for O 0 1.166114316220046e-07
mutations O 0 1.0665314675861737e-06
in O 0 2.3166450091594015e-08
TWIST O 0 6.492852844530717e-05
, O 0 7.91665740962344e-07
FGFR2 O 0 0.00016227604646701366
, O 0 1.4851934793114197e-07
and O 0 1.6471923913741193e-07
FGFR3 O 0 0.0009963741758838296
. O 0 2.453597971907584e-06

Nine O 0 2.2603871911996976e-05
novel O 0 8.001738933671732e-06
and O 0 1.1089785800777463e-07
three O 0 9.890399610412715e-08
recurrent O 0 0.00023795677407179028
TWIST O 0 0.2603447437286377
mutations O 0 0.00011460788664408028
were O 0 2.4613549953755864e-07
found O 0 1.397873887754031e-07
in O 0 6.975322719426913e-08
12 O 0 7.808503710293735e-07
families O 0 4.6222851324273506e-07
. O 0 9.517871149000712e-07

Seven O 0 1.3804656191496179e-05
families O 0 1.5784494280524086e-06
were O 0 1.5640925710158626e-07
found O 0 5.0342283230975227e-08
to O 0 3.1622779061990514e-08
have O 0 3.5907120832234796e-08
the O 0 2.7915307398984623e-08
FGFR3 O 0 0.006845511496067047
P250R O 0 5.816699194838293e-05
mutation O 0 9.71489157564065e-07
, O 0 1.119666759308302e-08
and O 0 9.342273621371078e-09
one O 0 3.31007115050852e-08
individual O 0 7.68390950867115e-09
was O 0 1.0929976497209282e-06
found O 0 5.2318544163654224e-08
to O 0 1.9546655849467243e-08
have O 0 6.906535077177978e-08
an O 0 1.5704988243214757e-07
FGFR2 O 0 0.0003586646053008735
VV269 O 0 1.1626486411842052e-05
- O 0 5.031861292081885e-06
270 O 0 3.7217025692370953e-06
deletion O 0 8.127761248033494e-05
. O 0 2.3130924091674387e-06

To O 0 2.7630533168121474e-06
date O 0 6.182906417961931e-07
, O 0 2.3097181056641602e-08
our O 0 4.966747901846702e-09
detection O 0 6.91647414896579e-08
rate O 0 5.6384337199233414e-08
for O 0 8.963939812645094e-09
TWIST O 0 7.136019121389836e-05
or O 0 3.7157903420848015e-07
FGFR O 0 0.02727521024644375
mutations O 0 3.6963974707759917e-06
is O 0 6.937587926358901e-08
68 O 0 1.091112608264666e-06
% O 0 1.7490455306301556e-08
in O 0 6.863091872588711e-09
our O 0 2.8629290937942642e-08
Saethre B-Disease 0 0.004775936249643564
- I-Disease 1 0.9994058609008789
Chotzen I-Disease 1 0.9999923706054688
syndrome I-Disease 1 0.9999997615814209
patients O 0 0.057107266038656235
, O 0 3.360395695040097e-08
including O 0 1.2869820764649376e-08
our O 0 1.779417324598853e-08
five O 0 4.652797542803455e-07
patients O 0 5.684065763489343e-05
elsewhere O 0 4.994665800950315e-07
reported O 0 5.024328970648639e-07
with O 0 7.964124648651705e-08
TWIST O 0 0.02930423803627491
mutations O 0 0.00019368759240023792
. O 0 1.1252158174102078e-06

More O 0 3.513343244776479e-06
than O 0 3.3090805118263233e-07
35 O 0 1.2853291764258756e-07
different O 0 7.589914474692705e-09
TWIST O 0 5.482362030306831e-05
mutations O 0 8.058261300902814e-06
are O 0 1.928892423563866e-08
now O 0 9.961774338762552e-08
known O 0 3.434971063143166e-08
in O 0 1.4289106786691264e-08
the O 0 4.306611600668475e-08
literature O 0 3.038460079096694e-07
. O 0 5.890022407584183e-07

The O 0 9.394988182975794e-07
most O 0 1.7760613957307214e-07
common O 0 8.511791804721724e-08
phenotypic O 0 2.513963590899948e-05
features O 0 9.27724704524735e-06
, O 0 7.291902903716618e-08
present O 0 1.631092239051668e-08
in O 0 6.0157172576680296e-09
more O 0 1.0369157976697352e-08
than O 0 1.1116062736959975e-08
a O 0 3.875863541225044e-08
third O 0 5.5194718129314424e-08
of O 0 5.456445517637576e-09
our O 0 5.33107673561517e-08
patients O 0 7.76864089857554e-06
with O 0 1.1623980356034735e-07
TWIST O 0 0.05046086385846138
mutations O 0 6.337933155009523e-05
, O 0 4.8529820162457327e-08
are O 0 1.7760333648197957e-08
coronal B-Disease 0 6.117179873399436e-05
synostosis I-Disease 0 0.00016442142077721655
, O 0 5.304967842789665e-08
brachycephaly B-Disease 0 7.118596840882674e-06
, O 0 1.722657572145181e-07
low B-Disease 0 2.2981179427006282e-05
frontal I-Disease 1 0.998643696308136
hairline I-Disease 1 0.9999653100967407
, O 0 4.21803051722236e-05
facial B-Disease 1 0.9935169219970703
asymmetry I-Disease 0 0.020212756469845772
, O 0 6.7162523009756114e-06
ptosis B-Disease 0 0.4698273241519928
, O 0 2.449616204103222e-06
hypertelorism B-Disease 0 0.03050757385790348
, O 0 2.8852025479864096e-07
broad B-Disease 0 4.630562386864767e-07
great I-Disease 0 1.305546788898937e-06
toes I-Disease 0 0.00018465687753632665
, O 0 2.1650507164849842e-07
and O 0 2.0561449787237507e-07
clinodactyly B-Disease 0 0.00014330932754091918
. O 0 1.2828276112486492e-06

Significant O 0 1.167064328910783e-05
intra O 0 6.255315383896232e-06
- O 0 5.902684642933309e-05
and O 0 1.0155458767258096e-06
interfamilial O 0 0.0008985798922367394
phenotypic O 0 0.0012950559612363577
variability O 0 1.6317433619406074e-05
is O 0 5.09118081026827e-08
present O 0 1.4353927824117818e-08
for O 0 1.6648177947331533e-08
either O 0 2.5787522872633417e-07
TWIST O 0 0.06682846695184708
mutations O 0 0.0004919900675304234
or O 0 1.41988743962429e-06
FGFR O 0 0.1724545955657959
mutations O 0 0.0001367486547678709
. O 0 1.7184682974402676e-06

The O 0 1.3577662230090937e-06
overlap O 0 1.5626895901732496e-06
in O 0 2.2318090486805886e-07
clinical O 0 3.113642378593795e-06
features O 0 2.284385118400678e-06
and O 0 1.2649989855617605e-07
the O 0 2.8161576182128556e-08
presence O 0 1.463924377276271e-07
, O 0 1.2685768879805437e-08
in O 0 2.2685753275908382e-09
the O 0 2.9480544672111364e-09
same O 0 1.2400414028945761e-08
genes O 0 1.4566486683520452e-08
, O 0 3.697731010277039e-09
of O 0 2.467922533000433e-09
mutations O 0 1.254571770914481e-07
for O 0 4.939812559001666e-09
more O 0 1.8490631248369027e-08
than O 0 3.947734938947178e-08
one O 0 1.1484372208769855e-07
craniosynostotic B-Disease 0 0.0025194580666720867
condition I-Disease 0 1.8021257346845232e-05
- O 0 4.872478029938065e-07
such O 0 1.0919891657579228e-08
as O 0 1.16573289687949e-07
Saethre B-Disease 0 6.3782749748497736e-06
- I-Disease 0 4.890675427304814e-06
Chotzen I-Disease 0 5.298928044794593e-06
, I-Disease 0 3.828217387535915e-08
Crouzon I-Disease 0 2.914460537795094e-06
, I-Disease 0 7.286188719035636e-08
and I-Disease 0 7.086059667926747e-07
Pfeiffer I-Disease 0 0.2853288948535919
syndromes I-Disease 0 0.10106023401021957
- O 0 2.0597613911377266e-05
support O 0 2.750109047156002e-07
the O 0 2.4737961012988308e-08
hypothesis O 0 8.477796882289113e-07
that O 0 2.7245514289120365e-08
TWIST O 0 6.435489012801554e-06
and O 0 2.99672109349558e-07
FGFRs O 0 5.161923127161572e-06
are O 0 5.28992005754958e-09
components O 0 5.884023934754623e-09
of O 0 7.182502925751066e-10
the O 0 7.652609212982497e-09
same O 0 2.6125503538310113e-08
molecular O 0 1.9818854468667269e-07
pathway O 0 5.410238657077571e-08
involved O 0 2.169377921745763e-08
in O 0 1.7548666519928702e-08
the O 0 3.064744902303573e-08
modulation O 0 8.225897909142077e-05
of O 0 4.4956775013815786e-07
craniofacial O 1 0.9992200136184692
and O 0 1.8885699319071136e-05
limb O 0 0.01796615868806839
development O 0 7.085492370606516e-08
in O 0 1.2291651785290014e-07
humans O 0 2.55379887903473e-07
. O 0 1.483499119103726e-07
. O 0 6.114260031608865e-07

Mutation O 0 0.0013891734415665269
analysis O 0 1.7008553186315112e-05
of O 0 1.9046519810217433e-06
UBE3A O 1 0.9954828023910522
in O 1 0.9955428242683411
Angelman B-Disease 1 1.0
syndrome I-Disease 1 1.0
patients O 1 0.9995006322860718
. O 0 1.0971522897307295e-05

Angelman B-Disease 1 1.0
syndrome I-Disease 1 1.0
( O 0 0.30271968245506287
AS B-Disease 1 0.9998329877853394
) O 0 7.312187904062739e-07
is O 0 1.2263110420462908e-06
caused O 0 6.993285296630347e-06
by O 0 1.898841475167501e-07
chromosome O 0 3.003851634275634e-05
15q11 O 0 7.282024853338953e-06
- O 0 5.694662831956521e-06
q13 O 0 3.780595307034673e-06
deletions O 0 1.0862473800443695e-06
of O 0 5.9396160878577575e-08
maternal O 0 2.850907367246691e-05
origin O 0 1.413370114278223e-07
, O 0 8.264605355634558e-08
by O 0 4.40114064303998e-07
paternal O 0 0.007710364181548357
uniparental B-Disease 1 0.8434054255485535
disomy I-Disease 0 0.3968133330345154
( O 0 2.250009629278793e-06
UPD B-Disease 1 0.9999780654907227
) O 0 3.775896857405314e-07
15 O 0 8.572269649675945e-08
, O 0 2.2036248381596124e-08
by O 0 8.770267356794648e-08
imprinting O 0 0.13994137942790985
defects O 1 0.9982836246490479
, O 0 5.320968909927615e-08
and O 0 4.093477912192611e-08
by O 0 8.317915245470431e-08
mutations O 0 1.0826266816366115e-06
in O 0 2.7120458767626587e-08
the O 0 2.2901080853898748e-07
UBE3A O 0 0.001552484929561615
gene O 0 1.1976982932537794e-05
. O 0 1.5604377949784975e-06

UBE3A O 0 0.01092430017888546
encodes O 0 0.00012498996511567384
a O 0 9.17322267923737e-06
ubiquitin O 0 2.323014814464841e-05
- O 0 2.0409375792951323e-05
protein O 0 1.1386617870812188e-06
ligase O 0 1.1743453569579287e-06
and O 0 1.256464798871093e-07
shows O 0 1.2631873005375382e-06
brain O 0 3.886748891090974e-05
- O 0 8.463033736916259e-06
specific O 0 2.7056552198700956e-07
imprinting O 0 8.264606003649533e-05
. O 0 4.045921741635539e-06

Here O 0 5.946382771071512e-06
we O 0 4.1024904362529924e-07
describe O 0 3.831055892078439e-06
UBE3A O 0 0.00031902987393550575
coding O 0 2.2193038603290915e-05
- O 0 7.955966430017725e-05
region O 0 1.3675203263119329e-06
mutations O 0 4.712220743385842e-06
detected O 0 8.557645969631267e-07
by O 0 4.824188337693158e-08
SSCP O 0 7.50487670302391e-05
analysis O 0 1.984493565032608e-07
in O 0 4.31856292948396e-08
13 O 0 4.121179699723143e-07
AS B-Disease 1 0.8959367871284485
individuals O 0 8.924892824779818e-08
or O 0 1.7210828673341894e-07
families O 0 6.067691629141336e-07
. O 0 1.5673612097089062e-06

Two O 0 3.2414880024589365e-06
identical O 0 5.286829036776908e-06
de O 0 4.6589292423959705e-07
novo O 0 2.2414492377720308e-06
5 O 0 2.3515123359629797e-07
- O 0 1.9964213606726844e-06
bp O 0 6.78438709655893e-06
duplications O 0 6.958936751289002e-07
in O 0 4.0138512957810235e-08
exon O 0 2.607632495710277e-06
16 O 0 3.443598188823671e-07
were O 0 2.1606098243864835e-07
found O 0 8.158975219885178e-07
. O 0 9.476389095652848e-07

Among O 0 4.3972445382678416e-06
the O 0 3.4117523028953656e-08
other O 0 1.082706191368743e-08
11 O 0 9.258372557496841e-08
unique O 0 1.9977667875537009e-07
mutations O 0 2.973808477690909e-06
, O 0 4.553167443077655e-08
8 O 0 7.552097969210081e-08
were O 0 5.1106589182836615e-08
small O 0 4.108707685190893e-08
deletions O 0 1.4240642940421822e-06
or O 0 8.155009822985448e-08
insertions O 0 8.272921149909962e-06
predicted O 0 2.522825525375083e-05
to O 0 7.346598636104318e-07
cause O 0 2.7730115107260644e-05
frameshifts O 0 0.0009574193973094225
, O 0 8.236138882011801e-08
1 O 0 3.2785411718805335e-08
was O 0 3.265454893153219e-07
a O 0 1.9271185180969042e-07
mutation O 0 3.52959347083015e-07
to O 0 2.2330008064841422e-08
a O 0 7.746969998834174e-08
stop O 0 1.552535024984536e-07
codon O 0 1.508826557028442e-07
, O 0 1.4257716784982222e-08
1 O 0 1.140207217531497e-08
was O 0 1.930125677063188e-07
a O 0 3.276960285347741e-07
missense O 0 0.00018659722991287708
mutation O 0 2.3805619093764108e-06
, O 0 1.8653471656193688e-08
and O 0 2.5055928887240952e-08
1 O 0 6.744048874907094e-08
was O 0 1.360578608000651e-05
predicted O 0 1.96002497432346e-06
to O 0 6.013838316221154e-08
cause O 0 1.988676814335122e-07
insertion O 0 2.022168104076627e-07
of O 0 5.5096767148654635e-09
an O 0 1.1494212515117397e-07
isoleucine O 0 5.444511043606326e-05
in O 0 3.5441171775119074e-08
the O 0 1.3342583926601037e-08
hect O 0 1.1108771786894067e-06
domain O 0 2.4623380667776473e-08
of O 0 1.3928704856169816e-09
the O 0 1.2827057638276074e-08
UBE3A O 0 2.7807973310700618e-05
protein O 0 1.6426101012712024e-07
, O 0 6.085456139004464e-09
which O 0 4.809779241554679e-09
functions O 0 2.4163233636187442e-09
in O 0 8.903380255276261e-09
E2 O 0 7.453737453033682e-06
binding O 0 6.12480619111011e-07
and O 0 4.767893813095725e-08
ubiquitin O 0 1.939974254128174e-06
transfer O 0 1.1492735438878299e-06
. O 0 1.128364374380908e-06

Eight O 0 4.910707048111362e-06
of O 0 4.301734790601586e-08
the O 0 5.4359325929453917e-08
cases O 0 7.639778232260142e-07
were O 0 3.676204187286203e-06
familial O 0 0.0004993720212951303
, O 0 9.494463029113831e-07
and O 0 1.2532397875020251e-07
five O 0 6.098809990362497e-08
were O 0 1.569310086324549e-07
sporadic O 0 3.883588215103373e-05
. O 0 2.290630845891428e-06

In O 0 4.42771533926134e-06
two O 0 1.3015885542699834e-06
familial O 0 0.0034999861381947994
cases O 0 1.140831045631785e-05
and O 0 2.2030201307643438e-07
one O 0 1.6521906331945502e-07
sporadic O 0 2.870112075470388e-05
case O 0 6.498001312138513e-05
, O 0 3.039112357328122e-07
mosaicism O 0 4.0124901715898886e-05
for O 0 1.5208055970106216e-07
UBE3A O 0 0.003031496424227953
mutations O 0 1.3945671526016667e-05
was O 0 1.202558678414789e-06
detected O 0 2.4460231884404493e-07
in O 0 9.50611411809632e-09
the O 0 1.49054102394075e-08
mother O 0 3.182207137797377e-06
of O 0 7.021867087786404e-09
three O 0 3.6294406413617253e-07
AS B-Disease 1 0.9987863898277283
sons O 0 6.038057108526118e-05
, O 0 1.0593616650567128e-08
in O 0 5.2651873971854e-09
the O 0 2.0885359219846578e-08
maternal O 0 5.9234994296275545e-06
grandfather O 0 7.233059022837551e-07
of O 0 3.3244829111822582e-09
two O 0 1.2570089324981382e-07
AS B-Disease 1 0.8773102164268494
first O 0 1.3107403447065735e-06
cousins O 0 2.1061146071588155e-06
, O 0 2.0039676584815425e-08
and O 0 1.145017147763383e-08
in O 0 8.938227935573195e-09
the O 0 1.2579462804751529e-08
mother O 0 2.092752083626692e-06
of O 0 3.83651954649622e-09
an O 0 5.324105813997448e-07
AS B-Disease 1 0.9997172951698303
daughter O 0 0.11827117949724197
. O 0 1.7702792547424906e-06

The O 0 2.5976098640967393e-06
frequencies O 0 4.117088337807218e-06
with O 0 6.58711982737259e-08
which O 0 4.021038435553237e-08
we O 0 1.1414911682550155e-08
detected O 0 3.638607211087219e-07
mutations O 0 3.3900579410328646e-07
were O 0 1.0595864097240337e-07
5 O 0 4.4554962386200714e-08
( O 0 9.92015181111583e-09
14 O 0 9.596604400030628e-08
% O 0 4.494603356164362e-09
) O 0 7.871917562241038e-10
of O 0 7.143183822222454e-10
35 O 0 4.902046413235439e-08
in O 0 1.7610698677117398e-08
sporadic O 0 8.427460124948993e-05
cases O 0 4.268643351679202e-06
and O 0 2.7044660555475275e-07
8 O 0 1.0459562105324949e-07
( O 0 7.464238116483557e-09
80 O 0 8.267316786714218e-08
% O 0 5.301222572029474e-09
) O 0 7.141466862314871e-10
of O 0 9.982231707894584e-10
10 O 0 2.324027015276897e-08
in O 0 4.2426265167705424e-08
familial O 0 0.0005967015167698264
cases O 0 3.7175002944422886e-05
. O 0 8.412768579546537e-07
. O 0 1.5983797538865474e-06

The O 0 7.647283200640231e-05
hemochromatosis B-Disease 1 0.9999532699584961
845 O 0 0.020191606134176254
G O 0 0.32604730129241943
- O 0 0.0021043741144239902
- O 0 0.0002485007862560451
> O 0 1.3038496717854287e-06
A O 0 3.8764704868299305e-07
and O 0 4.825945865150061e-08
187 O 0 6.474342626461294e-07
C O 0 3.0609528494096594e-06
- O 0 9.731276804814115e-05
- O 0 0.028012428432703018
> O 0 4.173859633738175e-05
G O 0 0.0737609714269638
mutations O 0 4.0834720493876375e-06
: O 0 5.2608537970399993e-08
prevalence O 0 9.676462013885612e-07
in O 0 4.0163861569908477e-08
non O 0 7.805957693562959e-07
- O 0 0.0014971500495448709
Caucasian O 0 0.0011938933748751879
populations O 0 1.615634459994908e-06
. O 0 5.879852551515796e-07

Hemochromatosis B-Disease 1 0.9986557960510254
, O 0 7.888284744694829e-05
the O 0 4.255763997207396e-05
inherited B-Disease 1 0.9999984502792358
disorder I-Disease 1 0.9999948740005493
of I-Disease 0 4.18188079720494e-07
iron I-Disease 1 0.9830237030982971
metabolism I-Disease 0 3.776332232519053e-05
, O 0 1.501215365351527e-07
leads O 0 1.3969759038445773e-06
, O 0 1.0828946273022666e-07
if O 0 3.8705596239196893e-07
untreated O 0 0.00358510110527277
, O 0 2.2001808375193832e-08
to O 0 2.289629748020161e-07
progressive O 0 0.03347063064575195
iron B-Disease 1 0.9992716908454895
overload I-Disease 0 0.10410749167203903
and O 0 6.0446282077464275e-06
premature B-Disease 0 0.007553101051598787
death I-Disease 0 0.006253467407077551
. O 0 2.514841753509245e-06

The O 0 7.425488729495555e-05
hemochromatosis B-Disease 1 0.9999788999557495
gene O 0 5.575588875217363e-05
, O 0 1.0237130254608928e-06
HFE O 0 0.0003743499983102083
, O 0 3.987103980307438e-07
recently O 0 2.989772610817454e-06
has O 0 9.913608209899394e-07
been O 0 8.062843903644534e-07
identified O 0 4.631732792859111e-07
, O 0 9.345196616550311e-09
and O 0 1.5640768680214023e-08
characterization O 0 3.609444831909059e-07
of O 0 2.1954345008623477e-09
this O 0 1.3944660537390519e-08
gene O 0 1.0840911812692866e-07
has O 0 9.683321877673734e-07
shown O 0 1.5203269754238136e-07
that O 0 6.815985553743076e-09
it O 0 7.906365340204502e-09
contains O 0 1.0590182064618148e-08
two O 0 2.6330509328431617e-08
mutations O 0 1.7454438250297244e-07
that O 0 1.2347830313785835e-08
result O 0 2.0729427063770345e-08
in O 0 5.519595447367465e-09
amino O 0 2.3700225781908557e-08
acid O 0 9.447156656960942e-08
substitutions O 0 5.4267331961455056e-08
- O 0 2.7774413524639385e-07
cDNA O 0 6.53550330298458e-07
nucleotides O 0 3.451923475950025e-07
845 O 0 2.7470316581457155e-06
G O 0 5.620982847176492e-05
- O 0 1.4610732250730507e-05
- O 0 7.274950621649623e-05
> O 0 9.214547844749177e-07
A O 0 4.914882083539851e-07
( O 0 3.124214131844383e-08
C282Y O 0 1.0367872391725541e-06
) O 0 1.0143960338382385e-08
and O 0 2.4313033364364856e-08
187 O 0 8.233183734773775e-07
C O 0 4.73598129246966e-06
- O 0 0.001554574933834374
- O 0 0.26417115330696106
> O 0 5.0965736591024324e-05
G O 0 0.00641369866207242
( O 0 1.6999678109641536e-07
H63D O 0 6.357655365718529e-05
) O 0 2.6399004582344787e-07
. O 0 5.471162012327113e-07

Although O 0 0.030170805752277374
hemochromatosis B-Disease 1 0.999988317489624
is O 0 1.8136070139007643e-06
common O 0 1.1631398422196071e-07
in O 0 1.9573505483094777e-07
Caucasians O 0 5.2099763706792146e-05
, O 0 9.805982017496717e-07
affecting O 0 4.50418752961923e-07
> O 0 1.3399452427620417e-06
= O 0 9.087942203223065e-07
1 O 0 4.525323049620056e-08
/ O 0 1.6542055902846187e-07
300 O 0 2.7254454693093066e-08
individuals O 0 3.5885059368467864e-09
of O 0 1.8115799971241131e-09
northern O 0 1.2384475667204242e-07
European O 0 5.9578727729103775e-08
origin O 0 4.6009549947712e-08
, O 0 5.6320357266770316e-09
it O 0 1.6572743177789562e-08
has O 0 2.665222496034403e-07
not O 0 1.6528833413076427e-08
been O 0 6.607832148119996e-08
recognized O 0 1.3608675075715837e-08
in O 0 7.0037833310721e-09
other O 0 1.4765147327011618e-08
populations O 0 1.9525793959473958e-07
. O 0 5.854097935298341e-07

The O 0 1.4419669014387182e-06
present O 0 2.3192296794150025e-07
study O 0 2.989242275930337e-08
used O 0 3.7362148930242256e-08
PCR O 0 5.030138709116727e-06
and O 0 5.971114092062635e-08
restriction O 0 2.018085751842591e-07
- O 0 1.5434794704560773e-06
enzyme O 0 1.4742106202447758e-07
digestion O 0 8.579712584833032e-08
to O 0 6.2185376847878615e-09
analyze O 0 1.56085544489315e-08
the O 0 1.9204993151333838e-09
frequency O 0 3.9393555084643594e-08
of O 0 1.6091732391032565e-09
the O 0 2.0657120458622558e-08
845 O 0 9.663399396231398e-06
G O 0 0.0014525162987411022
- O 0 5.115739622851834e-05
- O 0 7.140832167351618e-05
> O 0 3.727666353370296e-07
A O 0 1.5329979419220763e-07
and O 0 6.601470659006736e-08
187 O 0 8.170327987500059e-07
C O 0 1.1471394145701197e-06
- O 0 3.138667671009898e-05
- O 0 0.0028364425525069237
> O 0 1.3066357496427372e-05
G O 0 0.00341724487952888
mutations O 0 1.2883276667707833e-06
in O 0 2.7429889470909075e-08
HLA O 0 1.3297128134581726e-05
- O 0 4.113328486710088e-06
typed O 0 5.218798264650104e-07
samples O 0 5.174453221457043e-08
from O 0 2.529364717673843e-09
non O 0 2.3252287206787514e-08
- O 0 8.33576177683426e-06
Caucasian O 0 2.0716857761726715e-05
populations O 0 4.352011018227131e-08
, O 0 4.955175381127219e-09
comprising O 0 1.204556188127981e-08
Australian O 0 1.6369210698030656e-07
Aboriginal O 0 1.8938987977890065e-07
, O 0 9.654965715810704e-09
Chinese O 0 9.858359462100452e-09
, O 0 2.536506649164494e-08
and O 0 8.851014854371897e-08
Pacific O 0 2.3926492076498107e-07
Islanders O 0 8.032504410948604e-06
. O 0 7.691052132940968e-07

Results O 0 0.00031392095843330026
showed O 0 5.53561994820484e-06
that O 0 3.7588733903248794e-08
the O 0 3.7550609732761586e-08
845 O 0 4.5350490836426616e-05
G O 0 0.20733967423439026
- O 0 0.005754055920988321
- O 0 0.0052008251659572124
> O 0 1.593440970282245e-06
A O 0 1.766013156156987e-06
mutation O 0 6.986060157032625e-07
was O 0 5.681729362549959e-07
present O 0 2.6192960689286338e-08
in O 0 1.4227508060571381e-08
these O 0 1.135328897561294e-08
populations O 0 1.7108771288576463e-08
( O 0 4.728008651255777e-09
allele O 0 1.7719315792419366e-07
frequency O 0 2.8167170285087195e-07
0 O 0 5.6375416335185946e-08
. O 0 9.157473002119332e-09
32 O 0 1.0388602333932795e-07
% O 0 9.414666379825576e-09
) O 0 5.393719249013884e-09
, O 0 1.4527919312001814e-08
and O 0 9.974646530963582e-08
, O 0 9.652152499484146e-08
furthermore O 0 1.382182546194599e-07
, O 0 8.023553377256576e-09
it O 0 1.5318018853349713e-08
was O 0 1.0538566357354284e-06
always O 0 8.671497653267579e-08
seen O 0 7.222099895898282e-08
in O 0 8.155660147224353e-09
conjunction O 0 1.1698490709477483e-07
with O 0 3.2420953743894643e-07
HLA O 0 0.2763471007347107
haplotypes O 0 0.0023523776326328516
common O 0 4.3861859921889845e-07
in O 0 1.0080546530844003e-07
Caucasians O 0 4.095409622095758e-06
, O 0 3.298329787071452e-08
suggesting O 0 1.3392485698204837e-07
that O 0 3.459298270058753e-08
845 O 0 6.320960892480798e-06
G O 0 0.026468072086572647
- O 0 0.0038212037179619074
- O 0 0.006112746428698301
> O 0 2.2739106952940347e-06
A O 0 7.105574240995338e-06
may O 0 3.1736665278003784e-06
have O 0 1.4241082979538078e-08
been O 0 3.102859125192481e-08
introduced O 0 3.1769562980343835e-08
into O 0 7.731379980668862e-09
these O 0 5.004585634793557e-09
populations O 0 2.8174470756425762e-08
by O 0 7.88020244613108e-08
Caucasian O 0 4.195732617517933e-05
admixture O 0 0.00012041378795402125
. O 0 7.242588708322728e-06

187 O 0 0.0001676731917541474
C O 0 4.901299689663574e-05
- O 0 7.97649918240495e-05
- O 0 0.0010324218310415745
> O 0 1.4022727555129677e-05
G O 0 0.0002755233144853264
was O 0 9.924713140208041e-07
present O 0 1.2114107050820166e-08
at O 0 3.97039467969762e-09
an O 0 1.278631334145075e-08
allele O 0 6.200585289661831e-07
frequency O 0 1.6179212991573877e-07
of O 0 8.022420949771458e-09
2 O 0 1.1636651606750092e-06
. O 0 1.0989396059812861e-06

68 O 0 0.0075675370171666145
% O 0 4.016557340946747e-06
in O 0 5.947132208916628e-08
the O 0 2.43323317050681e-08
two O 0 2.5732984454407415e-07
populations O 0 1.005379886009905e-07
analyzed O 0 5.353401775209932e-07
( O 0 1.1983963155159927e-08
Australian O 0 1.1467135152543051e-07
Aboriginal O 0 1.289966036210899e-07
and O 0 2.5949450588313994e-08
Chinese O 0 7.540742075207163e-08
) O 0 1.6679047121215262e-07
. O 0 5.068557129561668e-07

In O 0 2.325562718397123e-06
the O 0 1.4927678648746223e-07
Australian O 0 5.745300200032943e-07
Aboriginal O 0 2.2653945563888556e-07
samples O 0 5.3725198512211136e-08
, O 0 1.1921678755300036e-08
187 O 0 3.2264387073155376e-07
C O 0 8.691398534210748e-07
- O 0 1.358326608169591e-05
- O 0 0.002561549423262477
> O 0 8.291071026178543e-06
G O 0 0.00013223211863078177
was O 0 1.4303266198112397e-06
found O 0 1.8090325681896502e-08
to O 0 2.2623067863491997e-08
be O 0 2.672183256891003e-07
associated O 0 1.8428387704716442e-07
with O 0 7.132311452551221e-07
HLA O 1 0.7626397609710693
haplotypes O 0 0.007663683965802193
common O 0 6.595013815058337e-07
in O 0 1.3217322702985257e-07
Caucasians O 0 1.646582859393675e-05
, O 0 1.0281917184329359e-07
suggesting O 0 1.812687457913853e-07
that O 0 1.652385250849875e-08
it O 0 2.3104187008016197e-08
was O 0 6.09449614330515e-07
introduced O 0 1.0528837179890616e-07
by O 0 3.60720733283415e-08
recent O 0 6.096879587857984e-07
admixture O 0 4.615507350536063e-05
. O 0 5.795101515104761e-06

In O 0 1.3682600865649874e-06
the O 0 6.326994395067231e-08
Chinese O 0 4.7379778322920174e-08
samples O 0 7.654262645928611e-08
analyzed O 0 1.4066131370782387e-07
, O 0 1.0985362841609003e-08
187 O 0 1.2969886142855103e-07
C O 0 4.057724254380446e-07
- O 0 2.471121661073994e-05
- O 0 0.007868356071412563
> O 0 5.373890417104121e-06
G O 0 0.000394829228753224
was O 0 2.596911599539453e-06
present O 0 4.000605358100984e-08
in O 0 2.789763442478943e-08
association O 0 1.407417649090803e-08
with O 0 9.962644931249542e-09
a O 0 3.116192317520472e-07
wide O 0 4.5299265138964984e-07
variety O 0 6.25829486011753e-08
of O 0 3.897577016687137e-08
HLA O 0 0.36823999881744385
haplotypes O 0 0.001437023631297052
, O 0 1.1799298960113447e-07
showing O 0 6.383590402947448e-07
this O 0 1.3995742342842732e-08
mutation O 0 1.6865776331087545e-07
to O 0 2.0290366720132624e-08
be O 0 1.1112971520788051e-07
widespread O 0 8.568294447286462e-07
and O 0 2.7036198844143655e-06
likely O 0 1.659846748225391e-05
to O 0 2.4911264517868403e-07
predate O 0 1.697822426649509e-06
the O 0 2.3979140451046987e-08
more O 0 4.400825659445218e-08
genetically O 0 5.053536824561888e-07
restricted O 0 1.7146690822755772e-07
845 O 0 1.3949409549240954e-05
G O 0 0.03761179745197296
- O 0 0.0007026985986158252
- O 0 0.0013606648426502943
> O 0 2.70998316409532e-06
A O 0 5.459526164486306e-06
mutation O 0 2.1018004190409556e-05
. O 0 1.4324629091788665e-06

Genotype O 1 0.9904853701591492
- O 1 0.8971617817878723
phenotype O 1 0.9510892629623413
correlations O 0 0.00042649012175388634
in O 0 4.511436782195233e-05
attenuated B-Disease 1 0.9995324611663818
adenomatous I-Disease 1 0.9999958276748657
polyposis I-Disease 1 0.9999634027481079
coli I-Disease 1 0.9997791647911072
. O 0 8.920767140807584e-05

Germ O 0 0.000541326473467052
- O 0 0.002634463831782341
line O 0 5.250706817605533e-05
mutations O 0 1.6667137288095546e-06
of O 0 9.0540828168173e-09
the O 0 5.3429253910053376e-08
tumor B-Disease 0 0.00010488167026778683
suppressor O 0 0.0003519208694342524
APC O 0 1.6289137420244515e-05
are O 0 1.0922916260369675e-07
implicated O 0 7.50515846448252e-06
in O 0 1.991182580241002e-05
attenuated B-Disease 1 0.9999368190765381
adenomatous I-Disease 1 0.9999996423721313
polyposis I-Disease 1 0.9999977350234985
coli I-Disease 1 0.9999970197677612
( O 0 0.0004352905962150544
AAPC B-Disease 1 0.999981164932251
) O 0 4.1931784267035255e-07
, O 0 2.8940146279410328e-08
a O 0 6.934028533578385e-07
variant O 0 0.00184362952131778
of O 0 5.485579549713293e-06
familial B-Disease 1 0.9999992847442627
adenomatous I-Disease 1 0.9999971389770508
polyposis I-Disease 1 0.9999995231628418
( O 0 8.335753227584064e-05
FAP B-Disease 0 0.08028846234083176
) O 0 5.163749847270083e-06
. O 0 3.171603111695731e-06

AAPC B-Disease 1 0.999974250793457
is O 0 8.622655877843499e-05
recognized O 0 1.8389674778518383e-06
by O 0 5.1510763654505354e-08
the O 0 1.605323873832276e-08
occurrence O 0 1.8407116897378728e-07
of O 0 2.3836321361159207e-08
< O 0 2.222623606940033e-06
100 O 0 2.4745966697992117e-07
colonic B-Disease 0 0.0011822354281321168
adenomas I-Disease 0 0.0004370822571218014
and O 0 9.792528032903647e-08
a O 0 2.9907201337664446e-07
later O 0 2.5332681161671644e-06
onset O 0 6.55603435006924e-05
of O 0 0.008286823518574238
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
( O 0 8.487666036671726e-07
age O 0 1.1434913176344708e-06
> O 0 4.5194147446636634e-07
40 O 0 1.1640631925047273e-07
years O 0 1.3280485688937915e-07
) O 0 9.052911309481715e-08
. O 0 7.013784397713607e-07

The O 0 3.4989781738659076e-07
aim O 0 3.3138744015559496e-07
of O 0 8.77990391501271e-09
this O 0 2.030593293511629e-08
study O 0 6.403040941904692e-08
was O 0 1.1556758181541227e-06
to O 0 1.5127514529922337e-07
assess O 0 3.055248089367524e-05
genotype O 0 0.15343287587165833
- O 0 0.07125402987003326
phenotype O 0 0.14115600287914276
correlations O 0 1.8839145923266187e-05
in O 0 5.753520781581756e-06
AAPC B-Disease 1 0.9999839067459106
families O 0 1.824174978537485e-05
. O 0 2.9069408356008353e-06

By O 0 3.6343665215099463e-06
protein O 0 1.7390284483553842e-06
- O 0 3.836338692053687e-06
truncation O 0 6.546465101564536e-06
test O 0 1.2915309071104275e-06
( O 0 2.60937316198806e-08
PTT O 0 1.9313313259772258e-06
) O 0 1.1581717807018777e-08
assay O 0 3.672622597150621e-07
, O 0 8.468567180841546e-09
the O 0 3.1632230168554543e-09
entire O 0 2.0278452694810767e-08
coding O 0 1.819183381712719e-07
region O 0 9.668824851871705e-09
of O 0 1.1245051556585395e-09
the O 0 9.316543092552365e-09
APC B-Disease 0 1.641394760554249e-06
gene O 0 2.255216031699092e-07
was O 0 9.000672207548632e-07
screened O 0 3.5700452372111613e-06
in O 0 1.0258449378852674e-07
affected O 0 2.533035967644537e-07
individuals O 0 1.2065567212005135e-08
from O 0 4.199713643515679e-08
11 O 0 1.7627924535190687e-05
AAPC B-Disease 1 0.9999951124191284
kindreds O 0 0.005348245147615671
, O 0 7.017384717755704e-08
and O 0 1.2852821029696315e-08
their O 0 1.2730538401228841e-08
phenotypic O 0 3.3749613066902384e-05
differences O 0 3.2020984690461773e-06
were O 0 1.0708171203077654e-06
examined O 0 7.67047968111001e-05
. O 0 2.4069377104751766e-06

Five O 0 8.556669854442589e-06
novel O 0 8.234901542891748e-06
germ O 0 1.1272069968981668e-05
- O 0 4.963414903613739e-05
line O 0 3.131883204332553e-05
APC B-Disease 0 1.731244810798671e-05
mutations O 0 4.833393631997751e-06
were O 0 7.914032806866089e-08
identified O 0 1.3573152557455614e-07
in O 0 2.2492399054385714e-08
seven O 0 6.415999678210937e-07
kindreds O 0 5.830505324411206e-05
. O 0 1.8655980511539383e-06

Mutations O 0 0.047376569360494614
were O 0 6.402628059731796e-06
located O 0 1.4810761683747842e-07
in O 0 4.375607431938988e-08
three O 0 1.7613050573572764e-08
different O 0 5.16291631669219e-09
regions O 0 5.079751730363569e-09
of O 0 1.6723820106534504e-09
the O 0 2.9022400482858757e-08
APC B-Disease 0 6.354269771691179e-06
gene O 0 1.8769806331420114e-07
( O 0 4.004993670037038e-09
1 O 0 5.3764948049206396e-09
) O 0 2.1355890389429533e-09
at O 0 1.107008040790447e-09
the O 0 2.2845241254287885e-09
5 O 0 2.2267359511829454e-08
end O 0 4.964108057947669e-08
spanning O 0 7.763330245325051e-08
exons O 0 3.9418213759745413e-07
4 O 0 4.1191594135625564e-08
and O 0 2.334142301663178e-08
5 O 0 3.7368135252791035e-08
, O 0 1.620029799198619e-08
( O 0 3.6911003142847676e-09
2 O 0 1.8291563819161638e-08
) O 0 3.903206646782564e-09
within O 0 2.955762301581899e-09
exon O 0 2.9867322837162646e-07
9 O 0 9.740164585991806e-08
, O 0 1.0589717547304645e-08
and O 0 2.73116960158859e-08
( O 0 4.483344362427033e-09
3 O 0 1.7692780573952405e-08
) O 0 4.3572576657879836e-09
at O 0 3.321542152434631e-09
the O 0 7.425317249953878e-09
3 O 0 8.11977827197552e-08
distal O 0 6.457966719608521e-06
end O 0 5.1607134565756496e-08
of O 0 8.11864353522651e-09
the O 0 4.81314081923756e-08
gene O 0 2.3746142687741667e-06
. O 0 1.202093130814319e-06

Variability O 0 0.004211330320686102
in O 0 6.874518589938816e-07
the O 0 4.553688270902967e-08
number O 0 1.757604337626617e-07
of O 0 2.3520116883446462e-05
colorectal B-Disease 1 1.0
adenomas I-Disease 1 0.9999997615814209
was O 0 0.14322319626808167
most O 0 2.6330164359933406e-07
apparent O 0 3.534303687047213e-05
in O 0 1.456404845612269e-07
individuals O 0 1.4335049591807092e-08
with O 0 1.3012817134949728e-07
mutations O 0 4.101006652490469e-06
in O 0 2.5803212011510368e-08
region O 0 1.3216640581958927e-07
1 O 0 1.4685136306979985e-07
, O 0 7.92078296285581e-08
and O 0 8.897110319594503e-07
upper O 0 0.04231643304228783
- O 1 0.9990033507347107
gastrointestinal O 1 0.9999558925628662
manifestations O 0 0.0001966741110663861
were O 0 1.5217775626297225e-06
more O 0 1.9769603909480793e-07
severe O 0 0.1072193831205368
in O 0 4.007498546343413e-07
them O 0 3.179551129051106e-07
. O 0 2.3736588445899542e-06

In O 0 7.678112524445169e-06
individuals O 0 2.5229417133232346e-07
with O 0 1.7946315722383588e-07
mutations O 0 7.948347956698854e-06
in O 0 8.982701160675788e-08
either O 0 2.906844542849285e-07
region O 0 1.8526414180541906e-07
2 O 0 3.357513378432486e-07
or O 0 4.3008324013271704e-08
region O 0 5.408051251265533e-08
3 O 0 8.363605275008013e-08
, O 0 1.5282356713441914e-08
the O 0 6.256525519887646e-09
average O 0 6.824301124197518e-08
number O 0 5.656311863333485e-09
of O 0 4.373160500392714e-09
adenomas B-Disease 0 5.019860327593051e-05
tended O 0 6.558579480042681e-05
to O 0 2.906608926878107e-07
be O 0 1.8822380809524475e-07
lower O 0 1.1093895864178194e-06
than O 0 3.064242193318023e-08
those O 0 3.3806317745188608e-09
in O 0 7.214442376834995e-09
individuals O 0 2.9579223514986097e-09
with O 0 4.4985934977148645e-08
mutations O 0 3.31678143083991e-06
in O 0 1.8062536355500924e-08
region O 0 1.057742764487557e-07
1 O 0 1.5865461477915233e-07
, O 0 7.581945737911155e-08
although O 0 2.2379602171440638e-07
age O 0 1.5350784110523819e-07
at O 0 7.60455378667757e-08
diagnosis O 0 0.0028794400859624147
was O 0 8.409178917645477e-06
similar O 0 1.3804268519379548e-06
. O 0 1.729429072838684e-06

In O 0 2.5205845304299146e-05
all O 0 1.9357273686182452e-06
AAPC B-Disease 1 0.9997127652168274
kindreds O 0 0.0013546182308346033
, O 0 3.6523780977404385e-07
a O 0 1.7565453447332402e-07
predominance O 0 4.604274181474466e-06
of O 0 1.8499578402497718e-07
right O 0 0.005294267553836107
- O 1 0.9998061060905457
sided O 1 0.9999995231628418
colorectal B-Disease 1 1.0
adenomas I-Disease 1 0.9999971389770508
and O 0 0.010920879431068897
rectal B-Disease 1 0.9997889399528503
polyp I-Disease 1 0.9515671730041504
sparing O 0 0.00012378617248032242
was O 0 4.381560574984178e-05
observed O 0 4.16237116951379e-06
. O 0 1.0425587788631674e-06

No O 0 0.0004673877265304327
desmoid B-Disease 1 0.9595524668693542
tumors I-Disease 1 0.9999890327453613
were O 0 1.5784432889631717e-06
found O 0 1.6979085160073737e-07
in O 0 3.999605979743137e-08
these O 0 8.27258546109988e-08
kindreds O 0 7.657428068341687e-05
. O 0 2.766468014669954e-06

Our O 0 2.6399916350783315e-06
data O 0 4.651045344417071e-07
suggest O 0 3.2510089909010276e-07
that O 0 3.5174689827499606e-08
, O 0 1.035534751281375e-07
in O 0 2.700924369491986e-06
AAPC B-Disease 1 0.999998927116394
families O 0 6.501568805106217e-06
, O 0 1.1446481096299976e-08
the O 0 1.959461259914974e-09
location O 0 1.4861833541601754e-08
of O 0 7.810553870335468e-10
the O 0 2.9948125757073285e-08
APC B-Disease 0 0.002252716338261962
mutation O 0 0.0001285533799091354
may O 0 2.691649569896981e-06
partially O 0 4.557321972242789e-06
predict O 0 1.263281319552334e-06
specific O 0 9.35957729097936e-08
phenotypic O 0 6.693835894111544e-05
expression O 0 1.1422834177210461e-05
. O 0 9.786250529941753e-07

This O 0 3.3999695006059483e-06
should O 0 5.642785367854231e-07
help O 0 1.2069345700638223e-07
in O 0 2.2183382242246807e-08
the O 0 1.1388379128618453e-08
design O 0 6.050985348338145e-07
of O 0 3.076657861811327e-08
tailored O 0 0.00928407907485962
clinical O 0 0.0017352773575112224
- O 0 0.01575304940342903
management O 0 2.196091628547947e-07
protocols O 0 1.3012817134949728e-07
in O 0 1.1871531313545347e-08
this O 0 4.517912710610972e-09
subset O 0 7.081668940145391e-08
of O 0 4.7101803346549787e-08
FAP B-Disease 1 0.9934456944465637
patients O 1 0.9994547963142395
. O 0 8.174544632311154e-07
. O 0 8.273696039395873e-07

Wilms B-Disease 1 0.9368690252304077
' I-Disease 0 0.0005737855681218207
tumor I-Disease 0 0.00013583904365077615
1 O 0 4.4109188479524164e-07
and O 0 9.020472901966059e-08
Dax O 0 0.0001705870672594756
- O 0 8.357410115422681e-05
1 O 0 4.4359387629810954e-07
modulate O 0 3.0990199775260407e-06
the O 0 8.294689024523905e-08
orphan O 0 7.754680154903326e-06
nuclear O 0 6.544490247506474e-07
receptor O 0 1.1302587381578633e-06
SF O 0 0.02492140419781208
- O 0 1.0504979400138836e-05
1 O 0 4.084493099298925e-08
in O 0 7.821768122084904e-09
sex O 0 1.9269292295120977e-07
- O 0 1.978417685677414e-06
specific O 0 8.187036826257099e-08
gene O 0 1.0455597703185049e-06
expression O 0 2.1671505692211213e-06
. O 0 1.242401594936382e-06

Products O 0 1.1156610526086297e-05
of O 0 3.576986671305349e-07
steroidogenic O 0 4.591962351696566e-05
factor O 0 8.875872481439728e-07
1 O 0 2.647110761699878e-07
( O 0 9.787411414663438e-08
SF O 1 0.9200642704963684
- O 0 0.0025746584869921207
1 O 0 6.61030242099514e-07
) O 0 7.949160618636597e-08
and O 0 7.983209115991485e-07
Wilms B-Disease 0 0.36553633213043213
tumor I-Disease 0 0.0004553823091555387
1 O 0 2.6373967898507544e-07
( O 0 4.0798294520527634e-08
WT1 O 0 2.7465326638775878e-05
) O 0 2.919740715867647e-08
genes O 0 3.8353654474576615e-08
are O 0 3.519695201958939e-09
essential O 0 5.817069936853159e-09
for O 0 8.798344275362524e-09
mammalian O 0 6.196010531311913e-07
gonadogenesis O 0 9.103304364543874e-06
prior O 0 3.23390558776282e-08
to O 0 3.867946674063205e-08
sexual O 0 2.806950760714244e-07
differentiation O 0 1.5649892475266824e-06
. O 0 2.0534812392725144e-06

In O 0 2.6206031179754063e-05
males O 0 2.784023672575131e-05
, O 0 7.023657531135541e-07
SF O 1 0.766345202922821
- O 0 0.0011142424773424864
1 O 0 4.951186269863683e-07
participates O 0 9.31276247229107e-08
in O 0 1.8335995832785557e-08
sexual O 0 3.1686838042332965e-08
development O 0 3.1413258660961674e-09
by O 0 7.818591107877637e-09
regulating O 0 1.5437430533893348e-07
expression O 0 6.685915110438145e-08
of O 0 2.020211997688648e-09
the O 0 2.0004925715966237e-08
polypeptide O 0 1.2685482943197712e-05
hormone O 0 7.105201348167611e-06
Mullerian O 0 9.256540579372086e-06
inhibiting O 0 5.516290002560709e-06
substance O 0 8.690422873769421e-06
( O 0 3.7746727343801467e-07
MIS O 0 4.121998426853679e-05
) O 0 8.72120551775879e-07
. O 0 9.66417019299115e-07

Here O 0 4.185470061202068e-06
, O 0 9.781775389683389e-08
we O 0 2.2877433281109916e-08
show O 0 1.6324312923643447e-07
that O 0 6.420406606366669e-08
WT1 O 0 8.583407907281071e-05
- O 0 8.006379357539117e-05
KTS O 0 0.0003793977666646242
isoforms O 0 1.3302532124725985e-06
associate O 0 2.0646315590511222e-07
and O 0 4.438964040787141e-08
synergize O 0 9.89261479844572e-06
with O 0 1.1559216090972768e-06
SF O 1 0.9979590177536011
- O 0 0.0003816745011135936
1 O 0 1.965796627700911e-07
to O 0 4.626898686410641e-08
promote O 0 6.693774707855482e-07
MIS O 0 0.0003573523135855794
expression O 0 1.0345597729610745e-05
. O 0 1.6102000017781393e-06

In O 0 1.2410904673743062e-05
contrast O 0 4.1342016629641876e-05
, O 0 9.86140662462276e-07
WT1 O 0 0.005618629511445761
missense O 0 0.023002872243523598
mutations O 0 0.00018744087719824165
, O 0 2.1561079677212547e-07
associated O 0 1.1749599337917971e-07
with O 0 6.348790293486672e-07
male B-Disease 0 0.23930293321609497
pseudohermaphroditism I-Disease 1 0.9999920129776001
in O 0 7.849893881939352e-05
Denys B-Disease 1 0.9987298846244812
- I-Disease 1 0.9999382495880127
Drash I-Disease 1 0.9999799728393555
syndrome I-Disease 1 0.999991774559021
, O 0 2.409495607480494e-07
fail O 0 1.3566738061854267e-06
to O 0 2.182776341896897e-07
synergize O 0 5.04820782225579e-05
with O 0 7.767774150124751e-06
SF O 1 0.998485267162323
- O 0 0.0026971057523041964
1 O 0 3.377460870979121e-06
. O 0 1.1627355434029596e-06

Additionally O 0 6.117500743130222e-05
, O 0 3.8948206793065765e-07
the O 0 5.794936086545022e-08
X O 0 0.000532877107616514
- O 0 0.0009686549310572445
linked O 0 1.2416077879606746e-05
, O 0 4.754943461193761e-08
candidate O 0 7.750812187623524e-07
dosage O 0 2.0580689579219325e-06
- O 0 1.0620888133416884e-06
sensitive O 0 3.818992695414636e-07
sex O 0 3.131218306862138e-07
- O 0 1.8807411379384575e-06
reversal O 0 3.3300361792498734e-06
gene O 0 1.3164198264803417e-07
, O 0 3.300620932122911e-08
Dax O 0 2.7497089831740595e-05
- O 0 1.0124813343281858e-05
1 O 0 1.501401385439749e-07
, O 0 2.199023008131462e-08
antagonizes O 0 2.631098823258071e-06
synergy O 0 5.918271313021251e-07
between O 0 1.4811185167218355e-07
SF O 1 0.8260911703109741
- O 0 0.00019457383314147592
1 O 0 3.182311729688081e-07
and O 0 1.0089202362451033e-07
WT1 O 0 7.567153807030991e-05
, O 0 3.6257834068464945e-08
most O 0 9.787557431195637e-09
likely O 0 3.823839023198161e-08
through O 0 3.203068921209251e-09
a O 0 4.083690541278884e-08
direct O 0 3.8353359599341275e-08
interaction O 0 4.0294992231793e-08
with O 0 7.387833989014325e-07
SF O 1 0.997257649898529
- O 0 0.0017095892690122128
1 O 0 1.8048679066851037e-06
. O 0 5.28500663676823e-07

We O 0 2.0007958028145367e-06
propose O 0 3.814671572399675e-06
that O 0 2.4280993216052593e-07
WT1 O 0 2.8612685127882287e-05
and O 0 4.7534834379803215e-07
Dax O 0 0.002686779946088791
- O 0 0.0001985651470022276
1 O 0 5.228079089647508e-07
functionally O 0 2.1665243821189506e-06
oppose O 0 1.7973000865367794e-07
each O 0 5.107245293345386e-09
other O 0 2.159213696728557e-09
in O 0 2.0532128885975e-08
testis O 0 1.8415265003568493e-05
development O 0 3.6982264361995476e-08
by O 0 1.7628954651627282e-07
modulating O 0 0.00017561409913469106
SF O 1 0.9754736423492432
- O 0 0.00027447458705864847
1 O 0 6.018199201207608e-07
- O 0 8.862365575623699e-06
mediated O 0 2.9138576792320237e-05
transactivation O 0 0.00010518234921619296
. O 0 3.811555586707982e-07
. O 0 4.121156109704316e-07

A O 0 2.7923249945160933e-05
mouse O 0 9.05890337890014e-05
model O 0 5.610780863207765e-05
for O 0 4.163178164162673e-05
Prader B-Disease 1 1.0
- I-Disease 1 0.9999997615814209
Willi I-Disease 1 1.0
syndrome I-Disease 1 0.9999984502792358
imprinting O 0 0.011380630545318127
- O 0 0.09362439811229706
centre O 0 0.00032747062505222857
mutations O 0 6.36554104858078e-05
. O 0 1.553041443003167e-06

Imprinting O 0 0.0006429265486076474
in O 0 2.065036596832215e-06
the O 0 1.8680606217458262e-07
15q11 O 0 8.504036486556288e-06
- O 0 1.9981865989393555e-05
q13 O 0 9.059956937562674e-06
region O 0 9.447714433008514e-08
involves O 0 3.453773089745482e-08
an O 0 2.7156898951830044e-08
imprinting O 0 9.799525287235156e-06
centre O 0 1.1403668622733676e-06
( O 0 1.6868019869775708e-08
IC O 0 3.662158178485697e-06
) O 0 2.055226744346328e-08
, O 0 6.554369491595935e-09
mapping O 0 3.557601147008427e-08
in O 0 4.8781196859692955e-09
part O 0 4.9115524980436476e-09
to O 0 8.636599879707774e-09
the O 0 9.677145307307455e-09
promoter O 0 3.592080020098365e-06
and O 0 6.322700585315033e-08
first O 0 8.801755058129856e-08
exon O 0 1.5115587075342773e-06
of O 0 5.944807313085221e-08
SNRPN O 0 0.0006453250534832478
. O 0 2.6029538275906816e-06

Deletion O 0 0.0007107048877514899
of O 0 9.174221418106754e-07
this O 0 2.7165765459358227e-07
IC O 0 5.793249874841422e-05
abolishes O 0 0.00032154045766219497
local O 0 4.3400413574090635e-07
paternally O 0 4.748064839077415e-06
derived O 0 1.643290232777872e-07
gene O 0 1.8867346796014317e-07
expression O 0 2.0485897778144135e-07
and O 0 1.8754597874703904e-07
results O 0 4.120269750274019e-06
in O 0 0.00025868008378893137
Prader B-Disease 1 1.0
- I-Disease 1 1.0
Willi I-Disease 1 1.0
syndrome I-Disease 1 1.0
( O 0 0.00011314015137031674
PWS B-Disease 1 0.9999812841415405
) O 0 1.0175382158195134e-05
. O 0 2.858046173059847e-06

We O 0 3.010918135259999e-06
have O 0 2.0789779853203072e-07
created O 0 8.85255104776661e-08
two O 0 8.898648218291783e-08
deletion O 0 0.0002055200602626428
mutations O 0 1.4532581189996563e-05
in O 0 1.388145562941645e-07
mice O 0 0.0016683642752468586
to O 0 9.300351280217001e-07
understand O 0 1.6731519281165674e-05
PWS B-Disease 1 0.9999942779541016
and O 0 4.1209284518117784e-07
the O 0 1.4511496893021558e-08
mechanism O 0 2.4924565522610465e-08
of O 0 5.008137460293938e-09
this O 0 6.113134531915421e-08
IC O 0 0.00021640287013724446
. O 0 2.7901869543711655e-06

Mice O 1 0.7782716751098633
harbouring O 0 0.0013120875228196383
an O 0 2.49712570621341e-06
intragenic O 0 0.00014351020217873156
deletion O 0 7.131420716177672e-05
in O 0 5.600491022050846e-07
Snrpn O 0 0.00012333340418990701
are O 0 1.4621329569308728e-07
phenotypically O 0 0.0001652389910304919
normal O 0 1.565611853493465e-07
, O 0 2.9045159166685153e-08
suggesting O 0 2.2004415711762704e-07
that O 0 5.053970042467881e-08
mutations O 0 1.9047432431307243e-07
of O 0 3.979105045459619e-09
SNRPN O 0 0.00037907747901044786
are O 0 1.581937425498836e-08
not O 0 2.8041032607006855e-08
sufficient O 0 2.226422282092244e-07
to O 0 1.7291388303419808e-06
induce O 0 0.003965180367231369
PWS B-Disease 1 0.9999827146530151
. O 0 2.692874477361329e-05

Mice O 0 0.09068072587251663
with O 0 1.0751732588687446e-06
a O 0 6.813589834564482e-07
larger O 0 5.453284757095389e-07
deletion O 0 4.149537744524423e-06
involving O 0 2.7017026127396093e-07
both O 0 9.977633652624718e-08
Snrpn O 0 1.0887742064369377e-05
and O 0 8.478348689777704e-08
the O 0 1.0101179270805005e-07
putative O 0 0.0011530756019055843
PWS O 1 0.9999850988388062
- O 0 0.1102757602930069
IC O 0 0.0005286814412102103
lack O 0 1.707003661977069e-06
expression O 0 1.489646308527881e-07
of O 0 4.52558879260323e-09
the O 0 2.4942874432554163e-08
imprinted O 0 2.9021684895269573e-05
genes O 0 8.688505772624922e-07
Zfp127 O 0 7.941588592075277e-06
( O 0 2.1599520394488536e-08
mouse O 0 5.958122528681997e-07
homologue O 0 3.7258362226566533e-06
of O 0 6.665249685511299e-08
ZNF127 O 0 0.00041446287650614977
) O 0 1.0288587048989939e-07
, O 0 7.27437168279721e-08
Ndn O 0 7.122066563169938e-06
and O 0 7.637914478664243e-08
Ipw O 0 7.898884177848231e-06
, O 0 6.322229495481224e-08
and O 0 1.1224041429613862e-07
manifest O 0 5.123579740029527e-06
several O 0 3.726258910319302e-07
phenotypes O 0 0.0001227202155860141
common O 0 1.3133467291481793e-06
to O 0 0.000248048163484782
PWS B-Disease 1 0.9999996423721313
infants O 1 0.9998030066490173
. O 0 1.0469403605384286e-05

These O 0 2.3263678485818673e-06
data O 0 5.145341788193036e-07
demonstrate O 0 3.793383882566559e-07
that O 0 2.781586339040132e-08
both O 0 7.325355877441098e-09
the O 0 5.697826654937899e-09
position O 0 6.931133356147257e-08
of O 0 4.012685295151641e-09
the O 0 2.3163579498941544e-08
IC O 0 7.715229912719224e-06
and O 0 5.917261347576641e-08
its O 0 1.3584427804858024e-08
role O 0 5.343129316770501e-08
in O 0 1.4836993855738001e-08
the O 0 6.010005826340148e-09
coordinate O 0 1.547808778923354e-07
expression O 0 2.601159962978272e-07
of O 0 3.1564668656614003e-09
genes O 0 4.973736977831322e-08
is O 0 9.903589948123681e-09
conserved O 0 3.298801942719365e-08
between O 0 1.2015180850255547e-08
mouse O 0 2.759756171144545e-06
and O 0 1.5012138021575083e-07
human O 0 3.22262536656126e-08
, O 0 3.013400018403445e-08
and O 0 4.9610029861923977e-08
indicate O 0 2.2463767379576893e-07
that O 0 1.151412032385224e-08
the O 0 5.185723850331669e-09
mouse O 0 1.6976961205728003e-06
is O 0 3.390280411963431e-08
a O 0 7.155871628583554e-08
suitable O 0 2.4124292963279004e-07
model O 0 1.36841015319078e-06
system O 0 3.498006151403388e-08
in O 0 6.013423092809944e-09
which O 0 3.406718818155241e-08
to O 0 2.9039343374392956e-08
investigate O 0 8.629159964357314e-08
the O 0 8.395391049020873e-09
molecular O 0 1.6255724233360525e-07
mechanisms O 0 2.7065320651331604e-08
of O 0 2.2653454667675987e-09
imprinting O 0 2.2068313683121232e-06
in O 0 4.782694418281608e-08
this O 0 1.5950595511071697e-08
region O 0 2.5242332668540257e-08
of O 0 3.7165961419560745e-09
the O 0 2.9025832404272478e-08
genome O 0 3.5199391845708305e-07
. O 0 1.2031226503950165e-07
. O 0 2.977561166517262e-07

Mutations O 0 0.0009203110239468515
of O 0 1.1765106222583199e-07
the O 0 4.52677362261511e-08
ATM O 0 4.309608812036458e-06
gene O 0 8.641691806587914e-07
detected O 0 8.938451401263592e-07
in O 0 1.4345694410167198e-07
Japanese O 0 0.01683390699326992
ataxia B-Disease 1 1.0
- I-Disease 1 0.9999998807907104
telangiectasia I-Disease 1 1.0
patients O 1 0.9999605417251587
: O 0 9.241894360911829e-08
possible O 0 7.375732735681595e-08
preponderance O 0 2.3610361949977232e-06
of O 0 5.115902812491413e-09
the O 0 1.7093309878646323e-08
two O 0 5.5674320265097776e-08
founder O 0 8.551824066671543e-06
mutations O 0 2.1882381133764284e-06
4612del165 O 0 2.4459325231873663e-06
and O 0 1.8810573010341614e-07
7883del5 O 0 2.061195846181363e-05
. O 0 8.925971428652701e-07

The O 0 1.5394808769997326e-06
ATM O 0 1.505624550190987e-05
( O 0 7.651700002497819e-07
A O 1 0.9993675351142883
- O 1 0.9999512434005737
T O 1 0.9999985694885254
, O 0 1.137149070018495e-06
mutated O 0 7.69399503042223e-06
) O 0 1.9389437611039284e-08
gene O 0 4.187579705217104e-08
on O 0 9.450526050613917e-08
human O 0 4.985709551874606e-07
chromosome O 0 0.00015092274406924844
11q22 O 0 5.4282900237012655e-05
. O 0 1.0145236046810169e-06

3 O 0 6.64013932691887e-05
has O 0 3.8095856780273607e-06
recently O 0 1.1761161431422806e-06
been O 0 1.6987037554372364e-07
identified O 0 8.980011756420936e-08
as O 0 3.498191514239579e-09
the O 0 1.6454150264522127e-09
gene O 0 3.041034091211259e-08
responsible O 0 2.6466556946047604e-08
for O 0 1.0157416241440842e-08
the O 0 1.0321726051643054e-07
human O 0 7.013572758296505e-05
recessive B-Disease 1 0.9999845027923584
disease I-Disease 1 0.9999758005142212
ataxia B-Disease 1 1.0
- I-Disease 1 0.9999995231628418
telangiectasia I-Disease 1 0.9999997615814209
( O 0 6.292213220149279e-05
A B-Disease 1 0.9999912977218628
- I-Disease 1 0.9999765157699585
T I-Disease 1 0.9999947547912598
) O 0 1.1768903505071648e-06
. O 0 6.159130521155021e-07

In O 0 3.5572256820159964e-06
order O 0 1.9520581417964422e-07
to O 0 3.8374945887653666e-08
define O 0 1.4163627781726973e-07
the O 0 2.1055107879419666e-08
types O 0 1.4184918484261289e-07
of O 0 2.1049771703474107e-07
disease O 0 0.001016965601593256
- O 0 0.016340089961886406
causing O 0 3.4588701964821666e-05
ATM O 0 4.377804998512147e-06
mutations O 0 1.012863094729255e-06
in O 0 3.4546165039728294e-08
Japanese O 0 4.126184194319649e-06
A B-Disease 1 0.9999886751174927
- I-Disease 1 0.9999980926513672
T I-Disease 1 1.0
patients O 1 0.8291184306144714
as O 0 1.0952645368433878e-07
well O 0 9.973710746180586e-09
as O 0 6.455326051479915e-09
to O 0 2.028030898770794e-08
look O 0 1.3772982754289842e-07
for O 0 1.63065365654802e-08
possible O 0 1.5579873036131175e-07
mutational O 0 9.512057295069098e-05
hotspots O 0 2.4468517949571833e-06
, O 0 1.0477912582018689e-07
reverse O 0 4.547791832010262e-06
- O 0 1.1916211406060029e-05
transcribed O 0 1.807989406188426e-06
RNA O 0 1.8764777109936404e-07
derived O 0 2.0914100673508074e-08
from O 0 3.520024272063438e-09
ten O 0 6.655937312416427e-08
patients O 0 9.465018138143932e-07
belonging O 0 1.7803612806233104e-08
to O 0 2.5591328167706706e-08
eight O 0 9.657935606810497e-08
unrelated O 0 2.9531588552345056e-07
Japanese O 0 3.36770585818158e-06
A B-Disease 1 0.9998974800109863
- I-Disease 1 0.9999346733093262
T I-Disease 1 0.9999985694885254
families O 0 7.600173148603062e-07
was O 0 5.845935788784118e-07
analyzed O 0 1.9583157495617343e-07
for O 0 1.7849343336706625e-08
mutations O 0 2.6257643526150787e-07
by O 0 6.892109105649524e-09
the O 0 1.2072841393262479e-08
restriction O 0 5.903935402784555e-07
endonuclease O 0 2.567636693129316e-05
fingerprinting O 0 9.827263966144528e-06
method O 0 3.063265694436268e-06
. O 0 8.997917007036449e-07

As O 0 5.705931926058838e-06
has O 0 1.205190301334369e-06
been O 0 2.302470107906629e-07
reported O 0 3.4131716120100464e-07
by O 0 2.8779853167293368e-08
others O 0 2.1856446608126134e-07
, O 0 6.411106312498305e-08
mutations O 0 2.597877539756155e-07
that O 0 9.146318369346318e-09
lead O 0 1.620153966541693e-07
to O 0 8.831015207988457e-08
exon O 0 1.575889541527431e-06
skipping O 0 1.012400389299728e-06
or O 0 8.300006726358333e-08
premature O 0 1.6288217921101023e-06
protein O 0 9.439843040581763e-08
truncation O 0 9.539244274492376e-07
were O 0 2.684745936676336e-07
also O 0 1.589505416177417e-07
predominant O 0 9.774740874490817e-07
in O 0 2.6352514836958107e-08
our O 0 7.07301666125204e-08
mutants O 0 8.304467883135658e-06
. O 0 8.727479325898457e-07

Six O 0 4.5394376684271265e-06
different O 0 1.4553260996308381e-07
mutations O 0 1.8952317759612924e-06
were O 0 8.329632095183115e-08
identified O 0 1.5840923595078493e-07
on O 0 6.795556117822343e-08
12 O 0 2.6792738694325635e-08
of O 0 1.8106645072180072e-09
the O 0 3.223897593329639e-08
16 O 0 1.0779463082144503e-06
alleles O 0 3.2549817206017906e-06
examined O 0 3.082476541749202e-05
. O 0 1.366289779980434e-06

Four O 0 8.072915079537779e-06
were O 0 7.463351039405097e-07
deletions O 0 3.2011366783990525e-06
involving O 0 3.4951594329868385e-07
a O 0 1.0450849003973417e-05
loss O 0 1.1890580026374664e-05
of O 0 1.1399202470840919e-08
a O 0 8.973656804300845e-07
single O 0 1.3922835933044553e-06
exon O 0 4.628461738320766e-06
exon O 0 2.671044285307289e-06
7 O 0 1.2254092496277735e-07
, O 0 1.6385008905217546e-08
exon O 0 6.61577075788955e-07
16 O 0 1.455795199944987e-07
, O 0 3.768959899730362e-08
exon O 0 1.6131311895151157e-06
33 O 0 5.752899596700445e-07
or O 0 6.089511117579605e-08
exon O 0 7.39830784368678e-06
35 O 0 2.5932163225661498e-06
. O 0 9.482463951826503e-07

The O 0 9.12388600227132e-07
others O 0 2.4974204393402033e-07
were O 0 2.0805877909424453e-08
minute O 0 1.5954572063492378e-07
deletions O 0 2.232233555332641e-06
, O 0 9.901592079586408e-08
4649delA O 0 1.4173128874972463e-06
in O 0 2.5681542226152487e-08
exon O 0 1.403695932822302e-06
33 O 0 5.5123484798969e-07
and O 0 6.388353313013795e-08
7883del5 O 0 2.4946168650785694e-06
in O 0 1.1820472423096362e-07
exon O 0 7.627892046002671e-06
55 O 0 3.6401486340764677e-06
. O 0 5.397241125137953e-07

The O 0 6.993572696956107e-06
mutations O 0 5.786613473901525e-05
4612del165 O 0 2.375178701186087e-05
and O 0 3.455154171660979e-07
7883del5 O 0 4.687721229856834e-06
were O 0 1.989528612966751e-07
found O 0 3.774794876676424e-08
in O 0 5.3181756776155e-09
more O 0 1.350568190616741e-08
than O 0 2.7710010286341458e-08
two O 0 2.714654279145634e-08
unrelated O 0 6.537323429256503e-07
families O 0 7.530422152512983e-08
; O 0 5.9285806486286674e-08
44 O 0 1.1840696743092849e-06
% O 0 2.3695887918506742e-08
( O 0 2.8000772811509478e-09
7 O 0 2.8492124215517833e-08
of O 0 3.8491263509854434e-09
16 O 0 6.014973763512899e-08
) O 0 8.210141455577968e-10
of O 0 5.433376526475797e-10
the O 0 8.736471102110954e-09
mutant O 0 7.897287105151918e-06
alleles O 0 3.612378520756465e-07
had O 0 6.974524779934654e-08
one O 0 1.7563458465374993e-09
of O 0 3.4672545390357357e-10
the O 0 9.117857580065447e-09
two O 0 4.6933121211623074e-07
mutations O 0 6.570295226993039e-06
. O 0 6.412806214939337e-07

The O 0 2.786472123261774e-06
4612del165 O 0 6.812546052969992e-05
mutations O 0 1.1749216355383396e-05
in O 0 2.7187322615418452e-08
three O 0 1.7020434839309928e-08
different O 0 9.68471525197856e-09
families O 0 2.8192639334179148e-08
were O 0 6.155313059252876e-08
all O 0 3.3733402737823326e-09
ascribed O 0 4.5585420593852177e-07
to O 0 5.4499992074852344e-08
the O 0 2.116038544386356e-08
same O 0 1.8946990110180195e-07
T O 0 3.623082739068195e-05
- O 0 2.4439123080810532e-05
- O 0 2.4670689526828937e-05
> O 0 1.0507812220339474e-07
A O 0 4.550492960220254e-08
substitution O 0 1.5348609494481025e-08
at O 0 4.398876374267502e-09
the O 0 5.37403410660886e-09
splice O 0 8.818456649350992e-07
donor O 0 1.0785473136820656e-07
site O 0 3.4142721005991916e-07
in O 0 9.496675801301535e-08
intron O 0 0.00040652367169968784
33 O 0 1.0511212167330086e-05
. O 0 1.4335972764456528e-06

Microsatellite O 0 0.008532260544598103
genotyping O 0 0.0016385074704885483
around O 0 4.69392125523882e-06
the O 0 1.2571024399221642e-07
ATM O 0 2.223198180217878e-06
locus O 0 6.638290415139636e-06
also O 0 2.787046241792268e-06
indicated O 0 4.82114819533308e-06
that O 0 6.036707844714329e-08
a O 0 2.665809688551235e-06
common O 0 4.797385827259859e-06
haplotype O 0 0.15440581738948822
was O 0 4.1577663068892434e-05
shared O 0 2.3189306475046578e-08
by O 0 4.1239842651918934e-09
the O 0 9.800782407864972e-09
mutant O 0 2.369296225879225e-06
alleles O 0 3.039828300188674e-07
in O 0 2.7037923899797534e-08
both O 0 2.0349033036382025e-07
mutations O 0 1.850014268711675e-05
. O 0 1.1447733641034574e-06

This O 0 1.3194945722716511e-06
suggests O 0 9.108810559155245e-07
that O 0 1.3198964587957107e-08
these O 0 2.8791147244078275e-09
two O 0 2.2767432383830055e-08
founder O 0 3.503110565361567e-05
mutations O 0 6.915379344718531e-06
may O 0 2.837044519310439e-07
be O 0 2.215458749788013e-08
predominant O 0 6.171642894514662e-07
among O 0 1.5058489566399658e-08
Japanese O 0 1.327835832398705e-07
ATM O 0 2.5032818484760355e-06
mutant O 0 1.301233896811027e-05
alleles O 0 3.0025478281459073e-06
. O 0 6.720152327943651e-07

W474C O 0 0.0007857112213969231
amino O 0 2.118912925652694e-05
acid O 0 3.7841157336515607e-06
substitution O 0 3.0038316367608786e-07
affects O 0 3.936757195788232e-07
early O 0 2.6382590334605993e-08
processing O 0 1.9216617630490873e-08
of O 0 2.26931118341156e-09
the O 0 1.938284865943274e-09
alpha O 0 2.587348646443388e-08
- O 0 3.230644196605681e-08
subunit O 0 1.5628154770297442e-08
of O 0 9.232865028074855e-10
beta O 0 1.441431241033797e-08
- O 0 4.7169325512186333e-07
hexosaminidase O 0 3.794555823333212e-06
A O 0 6.962123393350339e-07
and O 0 9.187129279553119e-08
is O 0 1.5168005518262362e-07
associated O 0 1.1911625108496082e-07
with O 0 1.3496869541995693e-06
subacute O 1 0.9995614886283875
G B-Disease 1 0.9875600934028625
( I-Disease 0 5.102842237647565e-07
M2 I-Disease 0 9.585529369360302e-06
) I-Disease 0 5.680104209204728e-07
gangliosidosis I-Disease 0 0.00011158773122588173
. O 0 3.4151489671785384e-06

Mutations O 0 0.013005178421735764
in O 0 1.0406446335764485e-06
the O 0 3.1477935635848553e-07
HEXA O 0 0.001357734203338623
gene O 0 1.485237817178131e-06
, O 0 2.9156224101711814e-08
encoding O 0 3.610890075833595e-08
the O 0 5.739383635017248e-09
alpha O 0 3.982812302183447e-08
- O 0 5.302267069851041e-08
subunit O 0 2.6002265229863042e-08
of O 0 2.1251300719171695e-09
beta O 0 3.151739846884993e-08
- O 0 7.096271019690903e-07
hexosaminidase O 0 8.198229807021562e-06
A O 0 1.0179467153648147e-06
( O 0 1.766782631307251e-08
Hex O 0 9.929390216711909e-07
A O 0 7.41696169370698e-07
) O 0 1.5778724105075526e-08
, O 0 5.689486215487705e-09
that O 0 7.663229162346852e-09
abolish O 0 1.6486256981806946e-07
Hex O 0 5.273250849313627e-07
A O 0 8.14701905937909e-08
enzyme O 0 1.9014382246496098e-07
activity O 0 2.271768408945718e-07
cause O 0 0.00396358035504818
Tay B-Disease 1 0.9999998807907104
- I-Disease 1 0.9999986886978149
Sachs I-Disease 1 0.9999997615814209
disease I-Disease 0 0.4760906994342804
( O 0 1.4595724451282877e-07
TSD B-Disease 0 0.00015204882947728038
) O 0 5.1305146797631096e-08
, O 0 1.6277761361038756e-08
the O 0 4.050087554219317e-08
fatal O 0 0.18398575484752655
infantile B-Disease 0 0.20722028613090515
form I-Disease 0 1.3585524811787764e-06
of I-Disease 0 1.1433839830488068e-07
G I-Disease 0 0.05920233577489853
( I-Disease 0 1.0604293976257395e-07
M2 I-Disease 0 2.204192014687578e-06
) I-Disease 0 4.375064932560235e-08
gangliosidosis I-Disease 0 1.063401850842638e-05
, I-Disease 0 1.0643057635206787e-07
Type I-Disease 0 4.0457763361700927e-07
1 I-Disease 0 4.411095062550885e-07
. O 0 9.853058600128861e-07

Less O 0 0.005128407850861549
severe O 1 0.9872252345085144
, O 0 5.641233656206168e-05
subacute O 1 0.9963435530662537
( O 0 8.309949407703243e-06
juvenile O 0 0.23981235921382904
- O 1 0.5177062153816223
onset O 0 0.009888087399303913
) O 0 1.976916337298462e-06
and O 0 0.0004795418935827911
chronic O 1 0.9998164772987366
( O 0 6.891920634188864e-07
adult O 0 0.00015212627477012575
- O 0 0.024375110864639282
onset O 0 0.000284954730886966
) O 0 1.040696702148125e-07
variants O 0 1.703809289210767e-06
are O 0 2.4665403941526165e-08
characterized O 0 5.647926855090191e-07
by O 0 3.5011435528531365e-08
a O 0 7.883063517510891e-07
broad O 0 1.040878828462155e-06
spectrum O 0 6.87657120579388e-06
of O 0 2.187489656080288e-08
clinical O 0 1.971351412066724e-05
manifestations O 0 1.3505352399079129e-05
and O 0 7.990200856511365e-07
are O 0 3.50320092934453e-08
associated O 0 4.6513378038071096e-08
with O 0 4.2445126524626176e-08
residual O 0 0.0002863300032913685
levels O 0 2.6819634513230994e-08
of O 0 2.2375317154654795e-09
Hex O 0 1.2452568398657604e-06
A O 0 2.939426906323206e-07
enzyme O 0 2.988704181916546e-07
activity O 0 8.717283606074488e-08
. O 0 2.713045148539095e-07

We O 0 4.471459760679863e-06
identified O 0 2.2253618681133958e-06
a O 0 8.877091204340104e-07
1422 O 0 0.00018321626703254879
G O 0 0.0035661787260323763
- O 0 0.0011334659066051245
- O 0 0.020258115604519844
> O 0 6.4375458350696135e-06
C O 0 6.957881737434946e-07
( O 0 7.789372702404762e-09
amino O 0 2.1246853165735047e-08
acid O 0 9.863497041351366e-08
W474C O 0 1.1976312919159682e-07
) O 0 1.271737715136112e-09
substitution O 0 4.6937929099044595e-09
in O 0 1.937345839309046e-09
the O 0 1.4496164268962275e-09
first O 0 2.9487139840966847e-08
position O 0 1.3604073956230422e-07
of O 0 8.674057028201787e-09
exon O 0 1.8295684185432037e-06
13 O 0 4.608719095244851e-08
of O 0 5.0804302986762195e-09
HEXA O 0 1.1447371434769593e-05
of O 0 1.0172325204393928e-08
a O 0 2.437233206364908e-07
non O 0 1.5265888464455202e-07
- O 0 1.0358579856983852e-05
Jewish O 0 7.717554808550631e-07
proband O 0 3.5258774005342275e-05
who O 0 2.110928789988975e-06
manifested O 0 1.1287130519122002e-06
a O 0 1.0398251788501511e-06
subacute O 0 0.1570400446653366
variant O 0 0.0017985301092267036
of O 0 3.0692964969603054e-07
G B-Disease 0 0.245942622423172
( I-Disease 0 2.08465024797988e-07
M2 I-Disease 0 1.0423756975797005e-05
) I-Disease 0 2.4827684796946414e-07
gangliosidosis I-Disease 0 5.730906195822172e-05
. O 0 1.2066358294759993e-06

On O 0 3.79106904802029e-06
the O 0 3.0152634167279757e-07
second O 0 2.837251940945862e-06
maternally O 0 0.0004268909397069365
inherited O 0 0.0002107552281813696
allele O 0 8.17226646177005e-06
, O 0 2.9333158124700276e-08
we O 0 1.6714901462933085e-08
identified O 0 1.3807544974042685e-07
the O 0 5.2072646639089726e-08
common O 0 1.432314093108289e-05
infantile O 1 0.9997250437736511
disease O 0 0.2621661126613617
- O 0 0.0035443047527223825
causing O 0 1.5858042388572358e-05
4 O 0 3.174085634327639e-07
- O 0 1.527078347862698e-05
bp O 0 3.497422585496679e-05
insertion O 0 1.83206350357068e-06
, O 0 8.682751229116548e-08
+ O 0 3.272594142345042e-07
TATC O 0 9.901410521706566e-06
1278 O 0 2.4041501092142425e-05
, O 0 3.6957093385581175e-08
in O 0 3.062168119072339e-08
exon O 0 3.6524622828437714e-06
11 O 0 7.152937087084865e-07
. O 0 6.709465196763631e-07

Pulse O 0 0.0009137748857028782
- O 0 0.00012403514119796455
chase O 0 4.522722974797944e-06
analysis O 0 9.307594694973886e-08
using O 0 8.296081688285994e-08
proband O 0 5.682922619598685e-06
fibroblasts O 0 7.842377272027079e-07
revealed O 0 3.5513514262675017e-07
that O 0 5.274384484721395e-09
the O 0 5.239141565027694e-09
W474C O 0 1.0942826520476956e-06
- O 0 3.032334916497348e-07
containing O 0 3.0953696494862015e-08
alpha O 0 2.5230493250205654e-08
- O 0 2.7404890801108195e-08
subunit O 0 3.9698736742366236e-08
precursor O 0 4.266703967914509e-08
was O 0 1.3524943653919763e-07
normally O 0 3.65920058698066e-08
synthesized O 0 3.7984557366144145e-07
, O 0 1.1791216891765544e-08
but O 0 1.4077075505269931e-08
not O 0 8.657660366395703e-09
phosphorylated O 0 1.0903475100576543e-07
or O 0 1.1731702720396697e-08
secreted O 0 1.5005926456979068e-07
, O 0 1.825998374727078e-08
and O 0 1.7486186720816477e-08
the O 0 2.0947474865806726e-08
mature O 0 3.8388932921407104e-07
lysosomal O 0 1.591973614267772e-06
alpha O 0 6.664893703600683e-08
- O 0 7.929867962275239e-08
subunit O 0 7.344218033722427e-08
was O 0 1.571913372799827e-07
not O 0 3.703160444956666e-08
detected O 0 1.5856794561841525e-06
. O 0 8.262475716946938e-07

When O 0 2.7860683076141868e-06
the O 0 9.786552368495904e-08
W474C O 0 1.1555721357581206e-06
- O 0 1.9914115512165154e-07
containing O 0 4.82661803857809e-08
alpha O 0 3.4036403917525604e-08
- O 0 8.70254766027756e-08
subunit O 0 1.17958109058236e-07
was O 0 5.047111812928051e-07
transiently O 0 5.724037691834383e-06
co O 0 1.7998833072851994e-06
- O 0 1.9120464003208326e-06
expressed O 0 7.150332237415569e-08
with O 0 5.275420544847975e-09
the O 0 6.044955647155348e-09
beta O 0 1.5483632154200677e-08
- O 0 5.225093246963297e-08
subunit O 0 2.1922721415990054e-08
to O 0 1.323047094103913e-08
produce O 0 3.627159728125662e-08
Hex O 0 6.674288215435809e-07
A O 0 6.407909722838667e-07
( O 0 3.4140629878720574e-08
alphabeta O 0 1.782665322025423e-06
) O 0 7.012672220696459e-09
in O 0 9.420791258207828e-09
COS O 0 4.33539753430523e-06
- O 0 1.1727902347047348e-05
7 O 0 3.0767347425353364e-07
cells O 0 7.617648378754893e-08
, O 0 3.0242004456226823e-09
the O 0 2.7527151669204386e-09
mature O 0 1.2087956413608936e-08
alpha O 0 9.463293260125738e-09
- O 0 5.631072141909499e-08
subunit O 0 3.543603099842585e-08
was O 0 2.2076851280417031e-07
present O 0 8.02689026357939e-09
, O 0 3.452704344653057e-09
but O 0 5.825219417943117e-09
its O 0 3.862341557692162e-09
level O 0 6.4322689397045e-09
was O 0 5.117271939525381e-07
much O 0 5.416165294036546e-08
lower O 0 3.7386388385129976e-07
than O 0 2.655651520910851e-08
that O 0 1.820003703301154e-08
from O 0 3.1083779994389715e-09
normal O 0 6.614210512623231e-09
alpha O 0 1.1182772929885232e-08
- O 0 2.923831132761734e-08
subunit O 0 3.321258290611695e-08
transfections O 0 4.741584973544377e-07
, O 0 5.383389733992772e-09
although O 0 4.4819419287023265e-09
higher O 0 7.086597975103359e-09
than O 0 1.1648311648571053e-08
in O 0 2.984183922194461e-08
those O 0 5.392703883444483e-08
cells O 0 1.8265230039560265e-07
transfected O 0 2.7570256406761473e-06
with O 0 9.459395045041674e-09
an O 0 8.206717083680815e-09
alpha O 0 8.108263216399791e-08
- O 0 3.350961890191684e-07
subunit O 0 5.06292906266026e-07
associated O 0 2.890542702971288e-07
with O 0 4.2871062078120303e-07
infantile O 0 0.310915470123291
TSD B-Disease 0 0.1077282726764679
. O 0 9.36517881200416e-06

Furthermore O 0 3.882318196701817e-05
, O 0 1.1207141170643808e-07
the O 0 1.0418403029177625e-08
precursor O 0 6.042236577741278e-08
level O 0 6.34282093514571e-09
of O 0 9.494330877046764e-10
the O 0 7.046486949491282e-09
W474C O 0 6.878964882162109e-07
alpha O 0 5.406349501413388e-08
- O 0 5.125712121412107e-08
subunit O 0 3.455618369230251e-08
was O 0 4.8019263232390585e-08
found O 0 8.706876997166546e-09
to O 0 1.7107204541844112e-08
accumulate O 0 2.8062817136742524e-07
in O 0 7.996023398959551e-09
comparison O 0 3.0015890217782726e-08
to O 0 7.040897642696109e-09
the O 0 4.41748326807101e-09
normal O 0 2.3090839462724944e-08
alpha O 0 3.237052581539501e-08
- O 0 1.1602571703406284e-07
subunit O 0 1.7916509875703923e-07
precursor O 0 1.9026661846055504e-07
levels O 0 1.1716544889850411e-07
. O 0 2.5962179961425136e-07

We O 0 3.887846560246544e-06
conclude O 0 1.935387672347133e-06
that O 0 6.782128991744685e-08
the O 0 8.121047301301587e-08
1422 O 0 0.00019302863802295178
G O 0 0.029083766043186188
- O 0 0.0006898711435496807
- O 0 0.011652885004878044
> O 0 1.400858582201181e-05
C O 0 2.6845279990084236e-06
mutation O 0 3.3779977570702613e-07
is O 0 1.562007945210553e-08
the O 0 7.979432226079552e-09
cause O 0 1.6958937010258524e-07
of O 0 2.132020782141808e-08
Hex B-Disease 0 0.005501887761056423
A I-Disease 0 0.3652471899986267
enzyme I-Disease 1 0.9999772310256958
deficiency I-Disease 1 0.9999363422393799
in O 0 1.4129940950624587e-07
the O 0 4.096817747267778e-07
proband O 0 0.0008678188896737993
. O 0 1.8793085700963275e-06

The O 0 1.5810256854820182e-06
resulting O 0 1.4906368051015306e-06
W474C O 0 2.799291678456939e-06
substitution O 0 2.5607786824366485e-07
clearly O 0 5.4382599046221e-07
interferes O 0 5.711468133995368e-07
with O 0 1.2245617853068325e-08
alpha O 0 6.150513343072816e-08
- O 0 1.002907339398007e-07
subunit O 0 2.3562888529227166e-08
processing O 0 1.985916675550925e-08
, O 0 6.430735943752097e-09
but O 0 1.3054600955797468e-08
because O 0 4.7174877337852195e-09
the O 0 1.3567252876711677e-09
base O 0 3.469778775411214e-08
substitution O 0 6.543466923858432e-08
falls O 0 2.9678758437512442e-06
at O 0 1.6084154008666474e-09
the O 0 1.336641908267211e-09
first O 0 1.4713615215100617e-08
position O 0 3.7680255360328374e-08
of O 0 5.156115978621756e-09
exon O 0 1.8580801679490833e-06
13 O 0 9.977556914009256e-08
, O 0 1.1588435100406969e-08
aberrant O 0 2.304165889199794e-07
splicing O 0 4.128789896640228e-06
may O 0 3.910731265932554e-06
also O 0 1.280795629554632e-07
contribute O 0 1.7577644229049838e-08
to O 0 1.1599496474445914e-07
Hex B-Disease 0 0.0027331546880304813
A I-Disease 0 0.11922158300876617
deficiency I-Disease 0 0.010271689854562283
in O 0 3.031223982929987e-08
this O 0 4.2879158002051554e-08
proband O 0 9.118000889429823e-05
. O 0 2.526444973227626e-07
. O 0 4.1564192088117125e-07

Two O 0 1.1892780094058253e-05
frequent O 0 9.290269372286275e-05
missense O 0 0.09640931338071823
mutations O 0 0.31303051114082336
in O 0 0.003394609782844782
Pendred B-Disease 1 0.9999997615814209
syndrome I-Disease 1 1.0
. O 0 8.203009201679379e-05

Pendred B-Disease 1 0.9999992847442627
syndrome I-Disease 1 1.0
is O 0 0.0003927290963474661
an O 0 0.33363956212997437
autosomal B-Disease 1 1.0
recessive I-Disease 1 1.0
disorder I-Disease 1 1.0
characterized O 1 0.6919348239898682
by O 0 8.550160600862e-06
early O 0 0.007280181162059307
childhood O 1 0.9956241250038147
deafness B-Disease 1 1.0
and O 1 0.9980852603912354
goiter B-Disease 1 0.9999997615814209
. O 0 0.0001375999127048999

A O 0 3.957135777454823e-05
century O 0 4.139044449402718e-06
after O 0 4.2981551473531e-07
its O 0 4.894684124678861e-08
recognition O 0 1.8624821507273737e-07
as O 0 9.30148701172584e-07
a O 0 0.15879572927951813
syndrome O 1 0.9999769926071167
by O 0 9.090768458008824e-07
Vaughan O 0 6.215508619789034e-05
Pendred O 0 5.195216363063082e-05
, O 0 1.0775335823609566e-07
the O 0 2.2455542136867734e-07
disease O 0 0.00010340064181946218
gene O 0 2.441644710415858e-06
( O 0 1.7733873391989619e-07
PDS O 0 0.005549664609134197
) O 0 1.051936280305199e-07
was O 0 1.119359126278141e-06
mapped O 0 2.439466015857761e-06
to O 0 1.6728526475162653e-07
chromosome O 0 1.4798981283092871e-05
7q22 O 0 8.478091331198812e-06
- O 0 1.5615049051120877e-05
q31 O 0 7.54628490540199e-05
. O 0 3.163881501677679e-06

1 O 0 1.5247412193275522e-05
and O 0 7.533567440987099e-07
, O 0 1.3394682696343807e-07
recently O 0 1.1796063290603342e-06
, O 0 1.7034951227401507e-08
found O 0 1.92654638908607e-08
to O 0 1.5134446584852412e-08
encode O 0 2.2380200448424148e-07
a O 0 4.450580490811262e-06
putative O 0 0.0005222290637902915
sulfate O 0 0.017141934484243393
transporter O 0 0.0006381006678566337
. O 0 3.009844476764556e-06

We O 0 8.679969141667243e-06
performed O 0 1.4584201380785089e-05
mutation O 0 2.955932814074913e-06
analysis O 0 6.748848591087153e-08
of O 0 5.461578744814233e-09
the O 0 3.6095197941676815e-08
PDS B-Disease 0 0.037992458790540695
gene O 0 2.7151882022735663e-06
in O 0 1.0188557553192368e-06
patients O 0 0.00017704656056594104
from O 0 3.2231845636943035e-08
14 O 0 2.2360849527558457e-07
Pendred B-Disease 0 1.2839565897593275e-05
families O 0 2.556771150352688e-08
originating O 0 1.1138495459306341e-08
from O 0 3.825762817655232e-09
seven O 0 1.1414606149173778e-08
countries O 0 1.1868174221163486e-09
and O 0 3.8152787595890914e-08
identified O 0 8.83645498106489e-07
all O 0 3.190309172396155e-08
mutations O 0 2.007150442295824e-06
. O 0 4.7281466208914935e-07

The O 0 6.543849849549588e-06
mutations O 0 3.0400444302358665e-05
include O 0 6.447994849168026e-08
three O 0 3.798817260758369e-08
single O 0 3.6065577546651184e-07
base O 0 3.767821112887759e-07
deletions O 0 1.3110641248204047e-06
, O 0 3.0672534734321744e-08
one O 0 9.95394522362858e-09
splice O 0 1.6430471987405326e-06
site O 0 8.552547114959452e-07
mutation O 0 1.2005122016489622e-06
and O 0 6.187683965208635e-08
10 O 0 3.2893780144149787e-07
missense O 0 0.00031598680652678013
mutations O 0 4.662986611947417e-05
. O 0 1.893206786007795e-06

One O 0 4.8063669964903966e-05
missense O 0 0.008481745608150959
mutation O 0 0.00036228392855264246
( O 0 4.4747778815690253e-07
L236P O 0 1.6863967175595462e-05
) O 0 8.317883271047322e-08
was O 0 2.06974073080346e-06
found O 0 3.6286269988750064e-08
in O 0 6.102135241548012e-09
a O 0 6.86028101881675e-07
homozygous O 0 2.7989074169454398e-06
state O 0 1.3633434825521817e-08
in O 0 8.030841769368635e-09
two O 0 4.89087668142929e-08
consanguineous O 0 4.296075348975137e-05
families O 0 1.1343616534986722e-07
and O 0 2.3576374630351893e-08
in O 0 1.7047399936132024e-08
a O 0 2.9247903512441553e-06
heterozygous O 0 1.2008410521957558e-05
state O 0 1.598062127072808e-08
in O 0 6.910696459527799e-09
five O 0 1.603876143008165e-08
additional O 0 6.490725468211167e-08
non O 0 3.324415445149498e-07
- O 0 9.461776062380522e-05
consanguineous O 0 0.0009939223527908325
families O 0 3.831750291283242e-06
. O 0 1.8757365296551143e-06

Another O 0 0.00019163821707479656
missense O 0 0.18791726231575012
mutation O 0 0.0018813296919688582
( O 0 8.510052680321678e-07
T416P O 0 1.5918574717943557e-05
) O 0 8.095283021702926e-08
was O 0 3.050118721148465e-06
found O 0 5.956100324056024e-08
in O 0 1.1568118019056328e-08
a O 0 3.032195934338233e-07
homozygous O 0 3.835011284536449e-06
state O 0 1.8340051255449907e-08
in O 0 1.0402774641704582e-08
one O 0 3.307262730345428e-08
family O 0 6.822739351264318e-08
and O 0 1.1287433210327436e-08
in O 0 1.1786743137065514e-08
a O 0 4.348223399119888e-07
heterozygous O 0 9.111442523135338e-06
state O 0 1.710054853276688e-08
in O 0 9.580707782674835e-09
four O 0 1.0986644838339998e-07
families O 0 1.6377283884594362e-07
. O 0 5.987731697132403e-07

Pendred B-Disease 1 0.9189051389694214
patients O 1 0.581504225730896
in O 0 1.9934353190365073e-07
three O 0 8.660769879043073e-08
non O 0 1.8371463283983758e-07
- O 0 5.4851960157975554e-05
consanguineous O 0 0.00045905791921541095
families O 0 1.0556633469605003e-06
were O 0 1.5013240783900983e-07
shown O 0 1.0920415860482535e-07
to O 0 3.216472066469578e-08
be O 0 8.665710282684813e-08
compound O 0 1.5571168887618114e-06
heterozygotes O 0 6.680141723336419e-06
for O 0 1.1464096161262205e-07
L236P O 0 9.102756848733407e-06
and O 0 5.183057396607182e-07
T416P O 0 4.4318410800769925e-05
. O 0 2.4264820694952505e-06

In O 0 1.275437625736231e-06
total O 0 1.4704112061281194e-07
, O 0 3.351632571479968e-08
one O 0 2.918905295246077e-08
or O 0 5.858792562207782e-09
both O 0 5.13264586388118e-09
of O 0 2.6221289584071883e-09
these O 0 1.363369328544195e-08
mutations O 0 2.5853591978375334e-07
were O 0 4.027470978940073e-08
found O 0 3.244197799290305e-08
in O 0 4.1846868192862985e-09
nine O 0 1.2769277191182482e-08
of O 0 1.66808133972296e-09
the O 0 2.9302290371902018e-08
14 O 0 4.208638699765288e-07
families O 0 1.0467305600059262e-07
analyzed O 0 3.1609079087502323e-06
. O 0 1.0477367595740361e-06

The O 0 1.810738240237697e-06
identification O 0 8.789816661192162e-07
of O 0 3.2849570175130793e-08
two O 0 2.543221455653111e-07
frequent O 0 0.0002466572041157633
PDS B-Disease 1 0.9948660135269165
mutations O 0 2.9639510103152134e-05
will O 0 3.9494668868655936e-08
facilitate O 0 3.038355700368811e-08
the O 0 5.550806392307095e-08
molecular O 0 0.00010865294461837038
diagnosis O 0 0.20977072417736053
of O 0 1.3304967978911009e-05
Pendred B-Disease 1 0.9999998807907104
syndrome I-Disease 1 1.0
. O 0 2.3443330064765178e-05

Insertional O 0 0.004747429862618446
mutation O 0 0.00029119898681528866
by O 0 9.315139664067829e-07
transposable O 0 2.6445561161381193e-05
element O 0 1.876155238278443e-06
, O 0 1.96223794546313e-07
L1 O 0 3.2583448046352714e-05
, O 0 7.263709989047129e-08
in O 0 2.9660421674293502e-08
the O 0 1.2959404784851358e-06
DMD B-Disease 1 0.9999997615814209
gene O 0 0.00011667076614685357
results O 0 2.154448338842485e-06
in O 0 3.0305798759400204e-07
X B-Disease 1 0.9930211901664734
- I-Disease 1 0.9964185953140259
linked I-Disease 1 0.9983083009719849
dilated I-Disease 1 0.999680757522583
cardiomyopathy I-Disease 1 0.9999992847442627
. O 0 0.00012031371443299577

X B-Disease 1 0.9986190795898438
- I-Disease 1 0.9996312856674194
linked I-Disease 1 0.9995054006576538
dilated I-Disease 1 0.9999783039093018
cardiomyopathy I-Disease 1 1.0
( O 0 3.714300328283571e-05
XLDCM B-Disease 0 0.1503518521785736
) O 0 8.967516862412594e-08
is O 0 4.3593217924353667e-08
a O 0 2.2706947220285656e-06
clinical O 0 0.00028647060389630497
phenotype O 0 0.007604556158185005
of O 0 2.8138918750642006e-08
dystrophinopathy B-Disease 0 0.0003664364921860397
which O 0 1.0132611123481183e-06
is O 0 1.0215065060492634e-07
characterized O 0 4.2854203456954565e-06
by O 0 1.141845814345288e-06
preferential O 0 0.000511759368237108
myocardial B-Disease 1 0.9998724460601807
involvement I-Disease 0 4.594063284457661e-06
without O 0 7.469382978797512e-08
any O 0 2.722369707441885e-08
overt O 0 6.761785698472522e-06
clinical O 0 0.00025643978733569384
signs O 0 0.0001738382561597973
of O 0 1.8172020645579323e-05
skeletal B-Disease 1 0.9999998807907104
myopathy I-Disease 1 1.0
. O 0 0.0014930376783013344

To O 0 1.053918731486192e-05
date O 0 3.1093991310626734e-06
, O 0 8.46057872649908e-08
several O 0 3.734903941676748e-08
mutations O 0 6.408282615666394e-07
in O 0 6.835660570914115e-08
the O 0 2.223834371761768e-06
Duchenne B-Disease 1 0.9999477863311768
muscular I-Disease 1 0.9999958276748657
dystrophy I-Disease 1 0.9999936819076538
gene O 0 0.006494339555501938
, O 0 4.135140261496417e-05
DMD O 1 0.9999996423721313
, O 0 8.104666449071374e-06
have O 0 2.914386527663737e-07
been O 0 7.427274226756708e-07
identified O 0 1.0159759540329105e-06
in O 0 2.4155394839908695e-07
patients O 0 8.113605144899338e-05
with O 0 2.8835384568992595e-07
XLDCM B-Disease 0 0.21551142632961273
, O 0 7.002783775078569e-08
but O 0 1.7419907294424775e-08
a O 0 7.567598458990688e-08
pathogenic O 0 3.6872992836833873e-07
correlation O 0 3.691010519446536e-08
of O 0 3.05314440396387e-09
these O 0 1.8006433677442146e-08
cardiospecific O 0 0.0024125874042510986
mutations O 0 6.336301885312423e-05
in O 0 7.564509019175603e-07
DMD O 1 0.999998927116394
with O 0 3.2729424219724024e-06
the O 0 1.9826331936201314e-06
XLDCM B-Disease 1 0.9974397420883179
phenotype O 1 0.9559853672981262
has O 0 4.284999249648536e-06
remained O 0 8.63866773670452e-07
to O 0 8.742426871322095e-08
be O 0 4.1125463212665636e-07
elucidated O 0 0.00011663516488624737
. O 0 2.1160706182854483e-06

We O 0 1.8291915466761566e-06
report O 0 1.7422907205855154e-07
here O 0 5.0911879156956275e-09
the O 0 2.3575239538331516e-09
identification O 0 4.991334900950051e-09
of O 0 2.0843522463565023e-09
a O 0 1.6377657630073372e-07
unique O 0 8.744711266217564e-08
de O 0 1.0628796331957346e-07
novo O 0 8.711746204426163e-07
L1 O 0 1.9604474346124334e-06
insertion O 0 2.507376848370768e-07
in O 0 1.4080351995460205e-08
the O 0 2.0119683696862012e-08
muscle O 0 1.897613037726842e-05
exon O 0 9.815837074711453e-06
1 O 0 1.778797127371945e-07
in O 0 4.3292479290357733e-07
DMD O 1 0.9999995231628418
in O 0 2.2116391846793704e-06
three O 0 1.8311167195861344e-06
XLDCM B-Disease 1 0.97962886095047
patients O 0 0.0008990642381832004
from O 0 5.25787147154233e-09
two O 0 2.4988921154545096e-08
unrelated O 0 9.117083550336247e-07
Japanese O 0 3.1328063414548524e-06
families O 0 7.749304131721146e-07
. O 0 1.5148966667766217e-06

The O 0 1.674603481660597e-06
insertion O 0 7.913820809335448e-06
was O 0 1.2130775530749816e-06
a O 0 1.969760177189528e-07
5 O 0 1.825311102265914e-07
- O 0 4.767421160067897e-06
truncated O 0 1.7158873788503115e-06
form O 0 5.523094870341083e-08
of O 0 8.675977269945179e-09
human O 0 4.818513943405378e-08
L1 O 0 4.496407200349495e-06
inversely O 0 1.6332984387190663e-06
integrated O 0 3.844271532216226e-07
in O 0 2.544399890780369e-08
the O 0 2.517914765576279e-08
5 O 0 1.3765603057436238e-07
- O 0 4.0287057345267385e-05
untranslated O 0 0.00018968162476085126
region O 0 1.3905955142945459e-07
in O 0 1.687645223569234e-08
the O 0 2.9910392385090745e-08
muscle O 0 1.3540339750761632e-05
exon O 0 4.9431137085775845e-06
1 O 0 1.5011436005352152e-07
, O 0 1.776074043391418e-08
which O 0 6.163243426726694e-08
affected O 0 9.708315040768412e-09
the O 0 1.8700843096297604e-09
transcription O 0 5.019692750352078e-08
or O 0 6.533911189876562e-09
the O 0 5.7608580128487574e-09
stability O 0 2.601367476984251e-08
of O 0 2.1614841028139153e-09
the O 0 1.948493988379596e-08
muscle O 0 1.5776664440636523e-05
form O 0 9.33787660528651e-08
of O 0 8.969805342928794e-09
dystrophin O 0 7.833100244170055e-05
transcripts O 0 2.4151788693416165e-06
but O 0 3.506677259679236e-08
not O 0 4.136620379568967e-09
that O 0 1.6776632305592898e-09
of O 0 9.082131713356034e-10
the O 0 4.146306409325007e-08
brain O 0 4.930523573420942e-05
or O 0 4.6743902970547424e-08
Purkinje O 0 5.463479465106502e-05
cell O 0 3.285803904873319e-05
form O 0 1.623950112161765e-07
, O 0 4.644254758545685e-08
probably O 0 6.095589242249844e-07
due O 0 8.853108823814182e-08
to O 0 3.202343634711724e-08
its O 0 3.290249850351756e-08
unique O 0 6.219857340283852e-08
site O 0 6.931860241365939e-08
of O 0 5.968424421354257e-09
integration O 0 1.710029522428158e-07
. O 0 8.447668733424507e-07

We O 0 2.851822046068264e-06
speculate O 0 3.9046344681992196e-06
that O 0 2.9473138596358694e-08
this O 0 6.2044751558687494e-09
insertion O 0 2.2736496418929164e-07
of O 0 8.41971736775804e-09
an O 0 5.808846026411629e-08
L1 O 0 2.7809484890894964e-05
sequence O 0 1.854631932474149e-07
in O 0 4.0440289694743115e-07
DMD O 1 0.9999988079071045
is O 0 1.471136442887655e-06
responsible O 0 6.31044727583685e-08
for O 0 5.988173956694709e-09
some O 0 1.637837754309146e-09
of O 0 9.47143252716387e-10
the O 0 6.131103180706532e-09
population O 0 1.0808903994075081e-08
of O 0 4.72592631695079e-09
Japanese O 0 1.8415528757032007e-05
patients O 0 0.0009993945714086294
with O 0 3.7311230016712216e-07
XLDCM B-Disease 0 0.003215770237147808
. O 0 1.9452119204288465e-07
. O 0 3.5562928246690717e-07

Severe O 1 0.977135181427002
early O 0 0.00021858024410903454
- O 1 0.9851888418197632
onset O 1 0.9967250227928162
obesity B-Disease 1 0.9999985694885254
, O 0 0.0370926670730114
adrenal B-Disease 1 0.9999977350234985
insufficiency I-Disease 1 0.9999990463256836
and O 0 0.00023181279539130628
red O 0 0.023678533732891083
hair O 1 0.9972678422927856
pigmentation O 1 0.9934728741645813
caused O 0 0.005033213645219803
by O 0 3.7834265640412923e-06
POMC O 1 0.9547986388206482
mutations O 0 0.00011798094055848196
in O 0 4.330267699970136e-07
humans O 0 1.7008059103318374e-06
. O 0 1.2150388783993549e-06

Sequential O 0 7.121607632143423e-05
cleavage O 0 5.376042099669576e-05
of O 0 1.245674354777293e-07
the O 0 4.278765430854037e-08
precursor O 0 2.76036217883302e-07
protein O 0 1.1132723898299446e-07
pre O 0 6.960722771509609e-07
- O 0 1.529124529042747e-05
pro O 0 5.128869815962389e-05
- O 0 0.0008530290215276182
opiomelanocortin O 0 0.0019994645845144987
( O 0 9.572985248951227e-08
POMC O 0 1.0232376553176437e-05
) O 0 2.8238709148808994e-08
generates O 0 1.7974956278976606e-07
the O 0 4.388956043044345e-08
melanocortin O 0 1.4998419828771148e-05
peptides O 0 5.432834768726025e-06
adrenocorticotrophin O 0 5.820405567646958e-05
( O 0 1.7905952631736e-07
ACTH O 0 1.6345000403816812e-05
) O 0 4.789258056803192e-08
, O 0 3.322246655557137e-08
melanocyte O 0 1.1747445569199044e-05
- O 0 3.30292277794797e-05
stimulating O 0 5.80084633838851e-06
hormones O 0 7.373794687737245e-06
( O 0 6.172901834133881e-08
MSH O 0 3.0426928788074292e-05
) O 0 1.3790036668126504e-08
alpha O 0 1.858273179777825e-08
, O 0 2.764732887072796e-09
beta O 0 4.393929220469772e-09
and O 0 1.5319647772571443e-09
gamma O 0 2.912721086545389e-08
as O 0 9.74489999805428e-09
well O 0 4.34254765480091e-09
as O 0 1.1620040929471998e-08
the O 0 1.2875664978651002e-08
opioid O 0 2.099142329825554e-05
- O 0 8.004410119610839e-06
receptor O 0 1.935511363626574e-06
ligand O 0 3.6458011436479865e-06
beta O 0 7.706191809120355e-07
- O 0 1.0570480299065821e-05
endorphin O 0 0.00017848474089987576
. O 0 2.0265981675038347e-06

While O 0 7.210426247183932e-06
a O 0 1.1290683232800802e-06
few O 0 3.5856274394063803e-07
cases O 0 2.455653032029659e-07
of O 0 2.0677252621226216e-07
isolated O 1 0.528451144695282
ACTH B-Disease 1 0.9999749660491943
deficiency I-Disease 1 0.9741166234016418
have O 0 7.598389970553399e-07
been O 0 1.3345047591428738e-05
reported O 0 0.00010564846161287278
( O 0 3.367261456332926e-07
OMIM O 0 0.005973723717033863
201400 O 0 1.6661364497849718e-05
) O 0 5.4992330689174196e-08
, O 0 3.7691325616151516e-08
an O 0 1.0348876458010636e-06
inherited O 0 0.13568250834941864
POMC O 1 0.9513285756111145
defect O 0 0.028849441558122635
has O 0 2.546124505897751e-06
not O 0 5.809068071016554e-08
been O 0 1.7395976215084374e-07
described O 0 9.755091241459013e-07
so O 0 1.1783499331841085e-07
far O 0 5.886147960154631e-07
. O 0 1.3194669463700848e-06

Recent O 0 3.40228398272302e-05
studies O 0 2.3940672235767124e-06
in O 0 1.3648322294557147e-07
animal O 0 2.774063432298135e-07
models O 0 1.4836932678008452e-06
elucidated O 0 6.717091309837997e-06
a O 0 1.0259486771246884e-07
central O 0 3.7226195459538758e-09
role O 0 8.097426729136714e-09
of O 0 1.4791157187943327e-09
alpha O 0 1.3454688030378747e-07
- O 0 2.2771942894905806e-05
MSH O 0 0.0002653585106600076
in O 0 1.6855478790489542e-08
the O 0 3.5372538231825956e-09
regulation O 0 3.4271572246780124e-08
of O 0 2.599466419894725e-09
food O 0 8.75495800300996e-08
intake O 0 1.9490350950945867e-06
by O 0 6.8236989392289615e-09
activation O 0 1.3751269456463433e-08
of O 0 2.0898935915170114e-09
the O 0 1.7676725860837905e-08
brain O 0 7.953435670060571e-06
melanocortin O 0 4.522749350144295e-06
- O 0 5.3559419939119834e-06
4 O 0 2.3254864345290116e-07
- O 0 5.058704573457362e-06
receptor O 0 2.6546899789536837e-06
( O 0 8.189567068939141e-08
MC4 O 0 5.8171262935502455e-05
- O 0 3.466574344201945e-05
R O 0 0.00017163633310701698
; O 0 5.440205796958253e-08
refs O 0 1.2539658200694248e-06
3 O 0 2.0103733788801037e-07
- O 0 6.8088747866568156e-06
5 O 0 9.273607304294273e-08
) O 0 5.251026280461701e-09
and O 0 3.833418027454627e-09
the O 0 5.538937308813274e-09
linkage O 0 5.14255532380048e-07
of O 0 2.8291218256981665e-08
human O 0 1.9566596165532246e-06
obesity B-Disease 1 0.9998102784156799
to O 0 1.9140074982715305e-06
chromosome O 0 3.184230445185676e-05
2 O 0 1.4751317678474152e-07
in O 0 1.0540969874739403e-08
close O 0 4.717490043049111e-08
proximity O 0 4.434792089114126e-08
to O 0 7.070817531484863e-08
the O 0 5.3777689856815414e-08
POMC O 0 0.0008380915969610214
locus O 0 5.388007593865041e-06
, O 0 3.463767583866684e-08
led O 0 2.9527662093187246e-08
to O 0 1.6395388158230162e-08
the O 0 1.3027886325289728e-08
proposal O 0 3.4910752333416895e-07
of O 0 3.2301803454259925e-09
an O 0 1.282830908166943e-07
association O 0 2.7256326973201794e-08
of O 0 1.0436759900755987e-08
POMC O 0 0.00202495651319623
with O 0 2.2790472939959727e-06
human O 0 1.794716081349179e-05
obesity B-Disease 1 0.999858021736145
. O 0 5.352883363229921e-06

The O 0 1.1993472526228288e-06
dual O 0 2.059079861282953e-06
role O 0 1.07227890566719e-07
of O 0 1.4773062773087986e-08
alpha O 0 6.388743827301369e-07
- O 0 3.2527004805160686e-05
MSH O 0 0.0002667030494194478
in O 0 3.382561786224869e-08
regulating O 0 1.945534791047976e-07
food O 0 1.368354958231066e-07
intake O 0 1.4744751979378634e-06
and O 0 5.5694076905865586e-08
influencing O 0 1.1142063840452465e-06
hair O 0 0.052847567945718765
pigmentation O 0 0.2564632296562195
predicts O 0 0.0005643473123200238
that O 0 2.864836403659865e-07
the O 0 3.932786967197899e-07
phenotype O 1 0.8553777933120728
associated O 0 3.2154940754480776e-07
with O 0 3.4922464919873164e-08
a O 0 5.5940960010048e-05
defect O 0 0.020419584587216377
in O 0 1.3540266081690788e-06
POMC O 0 0.018471451476216316
function O 0 4.4440176338866877e-07
would O 0 6.498281663880334e-07
include O 0 6.411913204829034e-07
obesity B-Disease 1 0.9999470710754395
, O 0 2.1035855297668604e-06
alteration O 0 2.5833163817878813e-05
in O 0 8.042146873776801e-06
pigmentation O 1 0.9981468915939331
and O 1 0.9193856716156006
ACTH B-Disease 1 0.9999796152114868
deficiency I-Disease 1 0.9969582557678223
. O 0 3.982960606663255e-06

The O 0 2.1179257601033896e-06
observation O 0 4.3408381316112354e-06
of O 0 6.079089587274211e-08
these O 0 1.8673944168767775e-07
symptoms O 0 0.0012217153562232852
in O 0 3.012446114780687e-08
two O 0 5.980346173828366e-08
probands O 0 4.490897117648274e-05
prompted O 0 8.093999781522143e-07
us O 0 5.459019192244341e-08
to O 0 1.0432361641221632e-08
search O 0 2.5207691933815113e-08
for O 0 3.8754272679852875e-08
mutations O 0 7.924710416773451e-07
within O 0 1.251293735293757e-08
their O 0 7.546281466375149e-08
POMC O 0 0.0019113817252218723
genes O 0 5.413105100160465e-06
. O 0 1.1908143733307952e-06

Patient O 1 0.8281913995742798
1 O 0 3.166589067404857e-06
was O 0 1.1206034287170041e-06
found O 0 2.2455706627511063e-08
to O 0 8.969754716758871e-09
be O 0 6.003521235697917e-09
a O 0 1.4537572212702798e-07
compound O 0 1.134982198891521e-06
heterozygote O 0 4.665791038860334e-06
for O 0 9.009086809896871e-09
two O 0 2.255262643302558e-08
mutations O 0 2.3616436806150887e-07
in O 0 2.120078512746204e-08
exon O 0 1.5115573432922247e-06
3 O 0 1.5061540636907012e-07
( O 0 1.3538927312595206e-08
G7013T O 0 2.4362739168282133e-06
, O 0 6.181868172916438e-08
C7133delta O 0 1.4481477137451293e-06
) O 0 4.824213473142436e-09
which O 0 1.207337074760062e-08
interfere O 0 4.381486817806035e-08
with O 0 1.7416684983118103e-08
appropriate O 0 2.5202211872965563e-08
synthesis O 0 7.32118294877182e-08
of O 0 2.876876692425867e-08
ACTH O 0 0.00014207362255547196
and O 0 2.044670566192508e-07
alpha O 0 2.544546532590175e-06
- O 0 0.00011887907749041915
MSH O 0 0.004797864239662886
. O 0 2.6345837795815896e-06

Patient O 1 0.6548333168029785
2 O 0 1.1990489838353824e-05
was O 0 2.2036010705051012e-06
homozygous O 0 2.0684719856944866e-06
for O 0 2.372618901347323e-08
a O 0 6.162009640320321e-07
mutation O 0 2.485870254531619e-06
in O 0 5.5204196769409464e-08
exon O 0 4.980818175681634e-06
2 O 0 5.263553930490161e-07
( O 0 4.43473275879569e-08
C3804A O 0 6.355093773890985e-06
) O 0 9.03231764937118e-08
which O 0 4.620584093117941e-07
abolishes O 0 0.0016318734269589186
POMC O 0 0.017781781032681465
translation O 0 1.825842264224775e-05
. O 0 3.26093459079857e-06

These O 0 5.716176929126959e-06
findings O 0 5.451207016449189e-06
represent O 0 5.744249165218207e-08
the O 0 6.019286846736804e-09
first O 0 4.134453135407057e-08
examples O 0 3.148639393657504e-08
of O 0 1.0572502873174017e-08
a O 0 0.0025643734261393547
genetic B-Disease 1 0.9999752044677734
defect I-Disease 1 0.9999556541442871
within O 0 7.070534024933295e-08
the O 0 5.259077795471967e-08
POMC O 0 0.0004406894731801003
gene O 0 2.8823643560826895e-07
and O 0 1.2439193675106708e-08
define O 0 1.39453575798143e-07
a O 0 1.2867104715041933e-06
new O 0 1.6981197404675186e-05
monogenic B-Disease 1 0.9917696714401245
endocrine I-Disease 1 0.997035026550293
disorder I-Disease 1 0.8495482802391052
resulting O 0 1.116834141612344e-06
in O 0 9.62419193228925e-08
early O 0 9.974586646421812e-06
- O 1 0.9936594367027283
onset O 1 0.9995949864387512
obesity B-Disease 1 0.9999996423721313
, O 0 0.06590109318494797
adrenal B-Disease 1 0.9999943971633911
insufficiency I-Disease 1 0.9999979734420776
and O 0 4.6707744331797585e-05
red O 0 0.0005701021291315556
hair O 1 0.7060692310333252
pigmentation O 1 0.5606940984725952
. O 0 1.7336996052108589e-06
. O 0 1.0001886039390229e-06

A O 0 6.825362652307376e-05
European O 0 1.9017597878701054e-05
multicenter O 0 0.08206900954246521
study O 0 4.758041541208513e-06
of O 0 1.6958288142632227e-06
phenylalanine B-Disease 1 0.9999994039535522
hydroxylase I-Disease 1 0.999998927116394
deficiency I-Disease 1 0.9999994039535522
: O 0 1.5839034972486843e-07
classification O 0 2.5427510763620376e-07
of O 0 7.570771565212908e-09
105 O 0 1.4133836430119118e-06
mutations O 0 2.7865944502991624e-06
and O 0 1.4554683680501057e-08
a O 0 2.783996819744061e-07
general O 0 1.0137271999610675e-07
system O 0 6.142401076658643e-08
for O 0 5.035918704265896e-08
genotype O 0 7.761119195492938e-05
- O 0 1.3933852642367128e-05
based O 0 3.62713961976624e-07
prediction O 0 1.416046984559216e-06
of O 0 8.55293293966497e-08
metabolic O 0 0.2775530517101288
phenotype O 0 0.18580643832683563
. O 0 2.512518904040917e-06

Phenylketonuria B-Disease 1 0.9988301396369934
( O 0 0.0008894529892131686
PKU B-Disease 1 0.917388916015625
) O 0 1.5165855074883439e-05
and O 0 0.00038495007902383804
mild B-Disease 1 0.9999493360519409
hyperphenylalaninemia I-Disease 1 0.9999998807907104
( O 0 0.0023182472214102745
MHP B-Disease 1 0.9999998807907104
) O 0 6.29712303634733e-06
are O 0 3.117050255241338e-06
allelic B-Disease 1 0.9893507361412048
disorders I-Disease 1 0.9998289346694946
caused O 0 0.00014715970610268414
by O 0 3.411996942759288e-07
mutations O 0 3.6746864680026192e-06
in O 0 1.397024451676998e-08
the O 0 5.1139643630904175e-08
gene O 0 2.3997865810088115e-06
encoding O 0 1.1643284778983798e-05
phenylalanine O 0 0.021895630285143852
hydroxylase O 0 0.1083107516169548
( O 0 1.8210283769803937e-06
PAH O 0 0.0005012265755794942
) O 0 6.463805561907066e-07
. O 0 1.1443803487054538e-06

Previous O 0 9.230223076883703e-05
studies O 0 1.2590800224643317e-06
have O 0 1.413398251770559e-07
suggested O 0 2.4338234538845427e-07
that O 0 9.44927958101971e-09
the O 0 1.1799766497233577e-08
highly O 0 1.2965846281076665e-06
variable O 0 0.0007948269485495985
metabolic O 0 0.44939613342285156
phenotypes O 0 0.012005936354398727
of O 0 9.888822205539327e-06
PAH B-Disease 1 0.9999903440475464
deficiency I-Disease 1 0.9993591904640198
correlate O 0 0.00011325197556288913
with O 0 0.00016519265773240477
PAH O 1 0.9980208873748779
genotypes O 0 0.04648194462060928
. O 0 8.718988283362705e-06

We O 0 7.800437742844224e-06
identified O 0 4.142515535932034e-06
both O 0 1.486081941948214e-07
causative O 0 1.015260295389453e-05
mutations O 0 1.6391612007282674e-05
in O 0 7.686813887630706e-07
686 O 1 0.5579931735992432
patients O 1 0.624915361404419
from O 0 5.253473744915027e-08
seven O 0 1.5889355609033373e-07
European O 0 2.967036323298089e-07
centers O 0 6.339297442536918e-07
. O 0 1.8840246411855333e-06

On O 0 1.3015289823670173e-06
the O 0 3.314493568495891e-08
basis O 0 7.403044399723058e-09
of O 0 1.0214490364646167e-09
the O 0 1.794783344166717e-08
phenotypic O 0 1.7778280380298384e-05
characteristics O 0 1.2487312517350801e-07
of O 0 1.7079621272841905e-08
297 O 0 8.628272553323768e-06
functionally O 0 0.002872010227292776
hemizygous O 1 0.6516593098640442
patients O 0 0.020281504839658737
, O 0 1.5892016591578795e-08
105 O 0 1.8576141513904076e-08
of O 0 1.1176903846887853e-09
the O 0 1.111214054105858e-08
mutations O 0 4.400616262500989e-07
were O 0 3.6362411748314116e-08
assigned O 0 3.039816220962166e-08
to O 0 1.3647508900760386e-08
one O 0 1.171519947718025e-08
of O 0 3.845941343172399e-09
four O 0 7.604147356232716e-08
arbitrary O 0 8.713476745469961e-06
phenotype O 0 0.1582651436328888
categories O 0 6.880979412926536e-07
. O 0 7.133828034966427e-07

We O 0 2.8878171178803314e-06
proposed O 0 4.796507369064784e-07
and O 0 1.0361827662563883e-07
tested O 0 5.997629841658636e-07
a O 0 8.946042839852453e-08
simple O 0 1.643357592229222e-07
model O 0 4.1280358686890395e-07
for O 0 9.521919253074884e-09
correlation O 0 7.468200635685207e-08
between O 0 2.8425628073591724e-08
genotype O 0 2.3070573661243543e-05
and O 0 9.766730357796405e-08
phenotypic O 0 6.394263618858531e-05
outcome O 0 6.875823601149023e-06
. O 0 1.6544798882023315e-06

The O 0 4.097577857464785e-06
observed O 0 1.1831319170596544e-05
phenotype O 0 0.00041159489774145186
matched O 0 1.6706729866200476e-06
the O 0 5.9080136338707234e-08
predicted O 0 3.30262009811122e-05
phenotype O 0 0.0013398047303780913
in O 0 1.0284663432003072e-07
79 O 0 6.856997515569674e-06
% O 0 1.6623713960939313e-08
of O 0 1.39736222593001e-09
the O 0 7.45509325383864e-08
cases O 0 3.628624426710303e-06
, O 0 1.8799920553647098e-07
and O 0 5.84430850381068e-08
in O 0 2.3487100264674154e-08
only O 0 2.1469684696739932e-08
5 O 0 1.049530951036104e-08
of O 0 2.1254826787497905e-09
184 O 0 2.1545720301219262e-05
patients O 0 0.0036882769782096148
was O 0 3.625573754106881e-06
the O 0 2.884838501415743e-08
observed O 0 3.8755042623961344e-06
phenotype O 0 3.60290941898711e-05
more O 0 1.3670200971205304e-08
than O 0 1.0071356193463998e-08
one O 0 9.247727028594e-09
category O 0 1.2634865598215583e-08
away O 0 9.937441980412132e-09
from O 0 4.539308040563128e-09
that O 0 3.5181063395839374e-08
expected O 0 1.1657845107038156e-06
. O 0 1.1953210332649178e-06

Among O 0 8.539379450667184e-06
the O 0 8.00927608679558e-08
seven O 0 1.3168077828140667e-07
contributing O 0 4.769058037368268e-08
centers O 0 1.2158017703711721e-08
, O 0 9.116779331463931e-09
the O 0 9.936759859385802e-09
proportion O 0 1.2764874668391712e-07
of O 0 2.541005095224591e-08
patients O 0 0.00032117863884195685
for O 0 6.262808227575078e-08
whom O 0 1.6441271100120503e-06
the O 0 2.6763627758441544e-08
observed O 0 1.4493857634079177e-06
phenotype O 0 7.490020652767271e-05
did O 0 7.436133842020354e-08
not O 0 7.367631393861984e-09
match O 0 2.2319660786251916e-08
the O 0 2.9188329975227134e-08
predicted O 0 3.254242619732395e-05
phenotype O 0 0.0013314029201865196
was O 0 3.662902372525423e-06
4 O 0 1.6508455757957563e-07
% O 0 3.857065422607775e-08
- O 0 1.9745571989915334e-05
23 O 0 2.6333269488532096e-05
% O 0 6.904941329821668e-08
( O 0 2.0869826755642862e-08
P O 0 8.320806955453008e-06
< O 0 2.542988681852876e-07
. O 0 2.0408009504535585e-08
0001 O 0 2.4800658593449043e-07
) O 0 9.934257860777507e-09
, O 0 9.0532532581733e-09
suggesting O 0 1.1342308425810188e-07
that O 0 1.7562195253617574e-08
differences O 0 1.000603049305937e-07
in O 0 7.306615312785425e-09
methods O 0 2.0514669074600533e-08
used O 0 5.975534378421798e-08
for O 0 3.1351859774986224e-08
mutation O 0 9.894811228150502e-07
detection O 0 6.033484964973468e-07
or O 0 1.4133782997305389e-06
phenotype O 1 0.9933446645736694
classification O 0 0.00022125009854789823
may O 0 1.616502777324058e-05
account O 0 5.407246916888653e-08
for O 0 6.083947567958603e-09
a O 0 1.0354320068017842e-07
considerable O 0 7.217121265057358e-07
proportion O 0 1.1584373282857996e-07
of O 0 2.5349201848712255e-08
genotype O 0 0.018343744799494743
- O 0 0.09372351318597794
phenotype O 0 0.34052497148513794
inconsistencies O 0 2.9306451324373484e-05
. O 0 3.1693775781604927e-06

Our O 0 1.913828782562632e-06
data O 0 3.06710774111707e-07
indicate O 0 1.2086381673270807e-07
that O 0 4.1876752732150635e-08
the O 0 1.415976527141538e-07
PAH O 0 0.34752029180526733
- O 0 0.18751980364322662
mutation O 0 0.00010441525228088722
genotype O 0 1.2412207070156e-05
is O 0 8.052345457087995e-09
the O 0 1.2426382145491743e-09
main O 0 8.297946330060313e-09
determinant O 0 1.561362239499431e-07
of O 0 1.959615403279713e-08
metabolic O 1 0.732421875
phenotype O 1 0.512401819229126
in O 0 3.792215466091875e-07
most O 0 1.3343672435439657e-05
patients O 1 0.52638179063797
with O 0 0.23271934688091278
PAH B-Disease 1 0.9999973773956299
deficiency I-Disease 1 0.9996824264526367
. O 0 7.689095582463779e-06

In O 0 4.074738626513863e-06
the O 0 2.274812231917167e-07
present O 0 1.873101922456044e-07
study O 0 1.1039768565979102e-07
, O 0 2.0186915250519633e-08
the O 0 8.60877147346173e-09
classification O 0 1.1444378600344862e-07
of O 0 1.4465843634070552e-08
105 O 0 0.00021561651374213398
PAH O 1 0.9981443881988525
mutations O 0 0.0005388144054450095
may O 0 7.096244303284038e-07
allow O 0 2.8536938145862223e-08
the O 0 1.3820475430748047e-08
prediction O 0 4.4421955180951045e-07
of O 0 2.9071247631407005e-09
the O 0 3.093121136998889e-08
biochemical O 0 7.135399937396869e-05
phenotype O 0 0.0017089806497097015
in O 0 5.8195254837301036e-08
> O 0 4.4606832716453937e-07
10 O 0 3.4062317411098775e-08
, O 0 2.8774421068078482e-08
000 O 0 1.2423264195149386e-07
genotypes O 0 6.968208253965713e-06
, O 0 6.471354652148875e-08
which O 0 5.77456205519411e-07
may O 0 1.4622266917285742e-06
be O 0 2.7061966889618816e-08
useful O 0 8.586502175944588e-09
for O 0 3.944699678015695e-09
the O 0 9.426939229228992e-09
management O 0 6.658832774064649e-08
of O 0 2.6970912614388e-08
hyperphenylalaninemia B-Disease 1 0.9999688863754272
in O 0 1.794902709661983e-05
newborns O 0 0.022925550118088722
. O 0 2.600252173579065e-06

Somatic O 0 0.0014817450428381562
instability O 0 0.00011256561265327036
of O 0 2.1221484303168836e-07
the O 0 3.0449581345237675e-07
CTG O 0 0.0002043079148279503
repeat O 0 8.661182619107421e-06
in O 0 1.6751371845202812e-07
mice O 0 6.5444801293779165e-06
transgenic O 0 7.161462463045609e-07
for O 0 6.869774438200693e-08
the O 0 9.090455932891928e-06
myotonic B-Disease 1 1.0
dystrophy I-Disease 1 1.0
region O 0 0.000312427815515548
is O 0 5.0215976443723775e-06
age O 0 4.576287437885185e-07
dependent O 0 7.335691520893306e-08
but O 0 4.2856672877178426e-08
not O 0 1.1423252566089559e-08
correlated O 0 6.543679376136424e-08
to O 0 1.3705863111113104e-08
the O 0 1.888984613174216e-08
relative O 0 6.077501666368335e-07
intertissue O 0 5.518646958080353e-06
transcription O 0 8.779579161455331e-07
levels O 0 1.5475696102384973e-07
and O 0 2.396255069925246e-07
proliferative O 0 0.08309360593557358
capacities O 0 2.9588001780211926e-05
. O 0 1.9810588582913624e-06

A O 0 0.00018514117982704192
( O 0 1.9577291823225096e-06
CTG O 0 4.509836435317993e-05
) O 0 1.2517705272330204e-07
nexpansion O 0 4.3805989662359934e-06
in O 0 5.373585665324754e-08
the O 0 1.4328296771282112e-08
3 O 0 5.814299584017135e-07
- O 0 0.005020078271627426
untranslated O 0 0.06646840274333954
region O 0 2.4313001176778926e-06
( O 0 6.370843408376459e-08
UTR O 0 7.987008757481817e-06
) O 0 6.30434549009351e-09
of O 0 2.7333988406041954e-09
the O 0 3.1508869824392605e-07
DM O 1 0.9999998807907104
protein O 0 4.8364963731728494e-05
kinase O 0 5.953935215075035e-06
gene O 0 2.3032013984902733e-07
( O 0 1.2096905699365834e-08
DMPK O 0 1.338997117272811e-05
) O 0 9.91911086600794e-09
is O 0 1.6176800343714604e-08
responsible O 0 1.6424880300291989e-07
for O 0 1.975007307919441e-06
causing O 1 0.9555264711380005
myotonic B-Disease 1 1.0
dystrophy I-Disease 1 1.0
( O 0 0.06767738610506058
DM B-Disease 1 0.9999996423721313
) O 0 2.525919262552634e-05
. O 0 5.738188065151917e-06

Major O 0 1.6538644558750093e-05
instability O 0 5.7771900173975155e-05
, O 0 2.9782142973999726e-07
with O 0 4.991518309793719e-08
very O 0 6.176540523483709e-08
large O 0 2.3044245622827475e-08
expansions O 0 2.0315215465416259e-07
between O 0 2.112659025499397e-08
generations O 0 4.94409491125225e-08
and O 0 2.3925458947360312e-08
high O 0 9.219886010214395e-08
levels O 0 1.4223113353750705e-08
of O 0 6.317996348315091e-09
somatic O 0 7.870776244089939e-06
mosaicism O 0 0.0014827668201178312
, O 0 8.388495587041689e-08
is O 0 6.177612732471971e-08
observed O 0 4.805407911590009e-07
in O 0 6.988252607698087e-07
patients O 0 0.0002836274215951562
. O 0 9.405854370925226e-07

There O 0 3.1469280656892806e-06
is O 0 9.417885138418569e-08
a O 0 8.283811325782153e-08
good O 0 1.5662001828786742e-07
correlation O 0 8.484479252501842e-08
between O 0 1.864845522447922e-08
repeat O 0 1.0850070566448267e-06
size O 0 6.17766716004553e-07
( O 0 7.453667905110706e-09
at O 0 5.6525584213318325e-09
least O 0 3.137680337772508e-08
in O 0 1.7537155727609388e-08
leucocytes O 0 5.2409661293495446e-05
) O 0 2.9716597182982696e-08
, O 0 6.288207288207559e-08
clinical O 0 1.9702572899404913e-05
severity O 0 0.0014314306899905205
and O 0 5.981658546261315e-07
age O 0 2.785486685752403e-07
of O 0 3.200243270384817e-08
onset O 0 4.212146086501889e-05
. O 0 3.203515689165215e-06

The O 0 5.328003680915572e-06
trinucleotide O 0 0.0006184943486005068
repeat O 0 4.294654354453087e-05
instability O 0 5.749554929934675e-06
mechanisms O 0 6.325275307972333e-07
involved O 0 3.9604810808668844e-07
in O 0 2.9930874916317407e-06
DM B-Disease 1 1.0
and O 0 5.219349986873567e-05
other O 0 3.919921596207132e-07
human O 0 4.63899559690617e-05
genetic B-Disease 1 0.9999945163726807
diseases I-Disease 1 0.9999672174453735
are O 0 2.5141889636870474e-07
unknown O 0 2.0137958927080035e-06
. O 0 7.451936312463658e-07

We O 0 3.930645561922574e-06
studied O 0 1.64990581197344e-06
somatic O 0 6.849286364740692e-06
instability O 0 2.414699565633782e-06
by O 0 1.0850199316791986e-07
measuring O 0 1.233377588505391e-06
the O 0 1.1454511650299537e-07
CTG O 0 5.4985244787530974e-05
repeat O 0 3.6376882235344965e-06
length O 0 1.3856341638529557e-06
at O 0 1.7475416669299193e-08
several O 0 2.415486122231414e-08
ages O 0 6.34658690046308e-08
in O 0 6.020171028353616e-09
various O 0 6.463273027890182e-09
tissues O 0 4.2792635213118047e-07
of O 0 8.529648987121163e-09
transgenic O 0 2.070516347885132e-05
mice O 0 0.00011313508730381727
carrying O 0 2.5312201046290284e-07
a O 0 3.789959635014384e-07
( O 0 7.502480059429217e-08
CTG O 0 2.6640371288522147e-05
) O 0 9.875959250393862e-08
55expansion O 0 7.052673026919365e-06
surrounded O 0 7.721257588855224e-07
by O 0 3.797375569547512e-08
45 O 0 6.027376997508327e-08
kb O 0 9.292141953665123e-07
of O 0 4.925549745848912e-09
the O 0 5.080394060996696e-08
human O 0 6.67372978568892e-06
DM B-Disease 1 0.9999998807907104
region O 0 1.0017054592026398e-05
, O 0 3.714811569466292e-08
using O 0 2.8780181793308657e-08
small O 0 3.726691844008201e-08
- O 0 6.27332065050723e-06
pool O 0 2.695594957913272e-06
PCR O 0 5.999430504743941e-05
. O 0 1.042078679347469e-06

These O 0 6.278359705902403e-06
mice O 0 0.0003078947775065899
have O 0 2.3968630102899624e-07
been O 0 1.303104681937839e-07
shown O 0 1.7279376152146142e-07
to O 0 6.469207392001408e-08
reproduce O 0 4.389233708934626e-06
the O 0 1.720589715148435e-08
intergenerational O 0 3.6100126976634783e-07
and O 0 4.438049927557586e-08
somatic O 0 8.380569624932832e-07
instability O 0 1.2182442787889158e-07
of O 0 3.7795762075631956e-09
the O 0 2.507337981683122e-08
55 O 0 9.474292710365262e-07
CTG O 0 1.6409849195042625e-05
repeat O 0 3.1130250590649666e-06
suggesting O 0 7.910401222943619e-07
that O 0 4.1262051553303536e-08
surrounding O 0 2.823326816780991e-08
sequences O 0 3.904101930629622e-08
and O 0 8.455121935924126e-09
the O 0 4.006575071713314e-09
chromatin O 0 2.6309982104066876e-07
environment O 0 1.4101736667271325e-07
are O 0 2.833116186096163e-09
involved O 0 1.2022058015759285e-08
in O 0 5.1196540340470165e-08
instability O 0 2.621015937620541e-06
mechanisms O 0 9.116831279243343e-06
. O 0 3.84787745133508e-06

As O 0 2.823337581503438e-06
observed O 0 4.508510755840689e-07
in O 0 9.875917861279504e-09
some O 0 3.5076119786481286e-09
of O 0 1.7904879801022844e-09
the O 0 3.51915332430508e-08
tissues O 0 2.938990837719757e-05
of O 0 6.789001872675726e-06
DM B-Disease 1 1.0
patients O 1 0.9999836683273315
, O 0 1.9702410725130903e-07
there O 0 2.1583995035712178e-08
is O 0 1.802801463668402e-08
a O 0 1.9337313972300763e-07
tendency O 0 8.210813007281104e-07
for O 0 6.93023451958652e-08
repeat O 0 2.080309968732763e-06
length O 0 2.653895080584334e-06
and O 0 1.0691297802623012e-07
somatic O 0 2.470039362378884e-06
mosaicism O 0 5.9130339650437236e-05
to O 0 1.1067049854318611e-07
increase O 0 2.2586965542359394e-07
with O 0 2.7957828052649347e-08
the O 0 3.776148460588047e-08
age O 0 5.7686232679543537e-08
of O 0 2.3913813151921204e-09
the O 0 7.019365710903003e-08
mouse O 0 4.338320286478847e-05
. O 0 1.5305569149859366e-06

Furthermore O 0 4.951737719238736e-05
, O 0 4.167667952970078e-07
we O 0 3.0983763110725704e-08
observed O 0 6.276309250097256e-08
no O 0 2.7551854131502296e-08
correlation O 0 6.069404179243065e-08
between O 0 4.91462603946502e-09
the O 0 1.7938971197395404e-08
somatic O 0 1.746697489579674e-05
mutation O 0 2.4445209419354796e-05
rate O 0 2.2738622362794558e-07
and O 0 8.907359472232201e-08
tissue O 0 1.717736267892178e-05
proliferation O 0 2.2394940515368944e-06
capacity O 0 1.8227502778245253e-06
. O 0 8.273428306893038e-07

The O 0 4.264932613295969e-06
somatic O 0 0.00014418009959626943
mutation O 0 0.00037061123293824494
rates O 0 1.9760038867389085e-06
in O 0 2.387991493435493e-08
different O 0 2.288079237189322e-08
tissues O 0 2.458852122799726e-06
were O 0 2.6334106451031403e-07
also O 0 2.741439004694257e-07
not O 0 2.4186302738371523e-08
correlated O 0 1.1779533082290072e-07
to O 0 1.6289160242877188e-08
the O 0 6.355512116584805e-09
relative O 0 1.5881508375059639e-07
inter O 0 2.396485854205821e-07
- O 0 0.0016825853381305933
tissue O 0 2.6082192562171258e-05
difference O 0 5.694005622558507e-08
in O 0 2.7302879956891957e-09
transcriptional O 0 2.2141897204619454e-07
levels O 0 1.431980045651926e-08
of O 0 7.64997953872637e-10
the O 0 3.5707881096413985e-09
three O 0 2.9830456327317734e-08
genes O 0 6.577904088089781e-08
( O 0 1.6672901281822305e-08
DMAHP O 0 4.447832907317206e-05
, O 0 1.039034600580635e-07
DMPK O 0 4.8456142394570634e-05
and O 0 1.512948983872775e-07
59 O 0 5.368329993871157e-07
) O 0 5.155162074998998e-09
surrounding O 0 1.461953846870756e-08
the O 0 2.869587767406756e-08
repeat O 0 5.059910563431913e-06
. O 0 3.6992713603467564e-07
. O 0 4.4846422042610357e-07

A O 0 6.202760414453223e-05
novel O 0 7.95692831161432e-05
missense O 0 0.0026318791788071394
mutation O 0 0.00020294554997235537
in O 0 4.069302121934015e-06
patients O 0 0.00025132164591923356
from O 0 3.3126166698593806e-08
a O 0 5.9560024965321645e-06
retinoblastoma B-Disease 0 0.2572116255760193
pedigree O 0 0.000310478761093691
showing O 0 1.5882033039815724e-05
only O 0 4.5949039417791937e-07
mild O 0 0.0005141534493304789
expression O 0 3.813460693891102e-07
of O 0 7.07770952956821e-09
the O 0 4.095641941148642e-07
tumor B-Disease 0 0.4465314447879791
phenotype O 0 0.016766313463449478
. O 0 1.8120113054465037e-06

We O 0 3.921730240108445e-06
have O 0 1.5255002949743357e-07
used O 0 7.080210195908876e-08
single O 0 1.9634546788438456e-07
strand O 0 2.4806954570522066e-06
conformation O 0 9.288527280659764e-07
polymorphism O 0 1.2111228897992987e-05
analysis O 0 1.0853407417243943e-07
to O 0 5.103869327172106e-08
study O 0 6.259213591874868e-08
the O 0 1.3178236279998146e-08
27 O 0 7.684776619498734e-07
exons O 0 2.0084300444977998e-07
of O 0 5.25206811374801e-09
the O 0 4.129180908307717e-08
RB1 O 0 8.780189091339707e-05
gene O 0 1.3655403563461732e-07
in O 0 1.113068126556982e-08
individuals O 0 3.41462125241776e-09
from O 0 4.095787708990883e-09
a O 0 1.0396664720246918e-06
family O 0 7.31450063540251e-06
showing O 0 0.00010675972589524463
mild O 0 0.1355806142091751
expression O 0 6.833463430666598e-07
of O 0 1.563373075441632e-08
the O 0 4.736256471460365e-07
retinoblastoma B-Disease 1 0.9259002208709717
phenotype O 1 0.8456981182098389
. O 0 6.416632459149696e-06

In O 0 2.0254735773050925e-06
this O 0 2.2493414064683748e-07
family O 0 1.999462256208062e-06
affected O 0 7.629766400896187e-07
individuals O 0 5.931137181391932e-08
developed O 0 4.522753442870453e-06
unilateral B-Disease 1 0.9406294822692871
tumors I-Disease 1 1.0
and O 0 9.216902071784716e-06
, O 0 3.267260950678974e-08
as O 0 1.0529837446426882e-08
a O 0 7.585980910107537e-08
result O 0 3.91759620299581e-08
of O 0 6.268350727367533e-09
linkage O 0 1.0384822417108808e-05
analysis O 0 4.730572982225567e-07
, O 0 1.9159274700086826e-07
unaffected O 0 1.9118924683425575e-05
mutation O 0 1.955370635187137e-06
carriers O 0 1.8762933962079842e-07
were O 0 1.4563312333848444e-07
also O 0 3.399955801342003e-07
identified O 0 1.955762627403601e-07
within O 0 5.839302819055092e-09
the O 0 7.778789523626983e-08
pedigree O 0 3.913475666195154e-05
. O 0 2.363210114708636e-06

A O 0 1.579719719302375e-05
single O 0 2.6531508865446085e-06
band O 0 7.795534884280642e-07
shift O 0 1.8749356911484938e-07
using O 0 1.2263502924270142e-07
SSCP O 0 0.00011766333045670763
was O 0 2.992351483044331e-06
identified O 0 1.117567691721888e-07
in O 0 9.605409800883535e-09
exon O 0 1.636360593693098e-06
21 O 0 2.5839588602138974e-07
which O 0 2.894544515186226e-08
resulted O 0 7.397387946639356e-08
in O 0 1.0459777044502516e-08
a O 0 8.803398827694764e-07
missense O 0 0.00010265017044730484
mutation O 0 3.8370049537661544e-07
converting O 0 6.105373984155449e-08
a O 0 4.976878358320391e-07
cys O 0 0.00034462643088772893
- O 0 6.154704897198826e-05
- O 0 5.582596349995583e-05
> O 0 2.0564402802847326e-06
arg O 0 1.2561885114337201e-06
at O 0 1.460869647473828e-08
nucleotide O 0 4.753410820512727e-08
position O 0 1.198170451743863e-07
28 O 0 1.006673144843262e-07
in O 0 1.2976278718213052e-08
the O 0 7.467830442919876e-08
exon O 0 2.9347173040150665e-05
. O 0 2.3510597202403005e-06

The O 0 7.376179382845294e-06
mutation O 0 2.8555767130455934e-05
destroyed O 0 1.761113821885374e-06
an O 0 1.4081996368986438e-07
NdeI O 0 1.8145801732316613e-05
restriction O 0 1.4095205642661313e-06
enzyme O 0 1.129085603679414e-06
site O 0 4.3439834485070605e-07
. O 0 5.387264536693692e-07

Analysis O 0 3.860105152853066e-06
of O 0 5.7239830653088575e-08
all O 0 1.5013835508170814e-08
family O 0 7.749290631409167e-08
members O 0 1.5063200464737747e-08
demonstrated O 0 1.7401470131517272e-07
that O 0 2.1894642543429654e-08
the O 0 3.565460815480037e-08
missense O 0 0.00025061098858714104
mutation O 0 9.055119335243944e-06
co O 0 7.140545221773209e-06
- O 0 2.4695807951502502e-05
segregated O 0 2.775635266516474e-06
with O 0 1.3995461813465226e-05
patients O 0 0.07491612434387207
with O 0 0.00017405787366442382
tumors B-Disease 1 0.9999996423721313
or O 0 6.686871074634837e-07
who O 0 1.0662685781426262e-05
, O 0 1.7528595464000318e-08
as O 0 9.847778592586565e-09
a O 0 1.022617652779445e-07
result O 0 3.5996333025423155e-08
of O 0 3.4510849733493387e-09
linkage O 0 5.012893780076411e-06
analysis O 0 3.329752189529245e-07
had O 0 1.6610172224318376e-06
been O 0 6.481088377086053e-08
predicted O 0 1.516091856501589e-07
to O 0 7.875000207491212e-09
carry O 0 7.394692858042617e-08
the O 0 5.7335110881240325e-08
predisposing O 0 9.590887202648446e-05
mutation O 0 1.3613924238597974e-05
. O 0 7.441851153089374e-07

These O 0 1.4343247585202334e-06
observations O 0 1.6549880683669471e-06
point O 0 1.1376063469015207e-07
to O 0 3.782347590686186e-08
another O 0 1.4394316849575262e-07
region O 0 3.108830526343809e-08
of O 0 4.17748591274858e-09
the O 0 1.4760846056560695e-07
RB1 O 0 0.0006483796169050038
gene O 0 3.623613054060115e-07
where O 0 1.1248366149629874e-07
mutations O 0 3.4173081076005474e-07
only O 0 1.3457571057529094e-08
modify O 0 2.5084960952881374e-07
the O 0 5.295452076836682e-09
function O 0 3.0274438511668222e-09
of O 0 4.710974943478163e-10
the O 0 2.6681907794312565e-09
gene O 0 3.119045999255832e-08
and O 0 2.5982682672065494e-08
raise O 0 5.7932339814215084e-08
important O 0 4.5303472084867735e-09
questions O 0 4.625230687338444e-08
for O 0 5.1034117376502763e-08
genetic O 0 1.898459004223696e-06
counseling O 0 5.105694640406e-07
in O 0 4.924011420825991e-08
families O 0 3.110443458353984e-08
with O 0 2.782202024320668e-08
these O 0 7.580499783443884e-08
distinctive O 0 8.9386579929851e-05
phenotypes O 0 0.0006588258547708392
. O 0 3.225777334137092e-07
. O 0 4.3992312726004457e-07

Maternal B-Disease 0 0.42106154561042786
disomy I-Disease 0 0.38206297159194946
and O 0 0.12075596302747726
Prader B-Disease 1 1.0
- I-Disease 1 0.9999998807907104
Willi I-Disease 1 1.0
syndrome I-Disease 1 0.9999997615814209
consistent O 0 2.993413909280207e-05
with O 0 2.477564748915029e-07
gamete O 0 6.094564469094621e-06
complementation O 0 2.4522772946511395e-05
in O 0 5.044744000315404e-08
a O 0 1.8854899508369272e-07
case O 0 5.019492164137773e-07
of O 0 2.091968376305431e-08
familial O 0 0.00022007775260135531
translocation O 0 0.0006150153931230307
( O 0 8.717931621049502e-08
3 O 0 1.3184325098336558e-07
; O 0 1.2862415132985916e-07
15 O 0 1.348617502117122e-07
) O 0 2.8302443055849835e-08
( O 0 2.4971292589270888e-08
p25 O 0 4.155001988692675e-06
; O 0 1.5140372511268652e-07
q11 O 0 2.6144305138586788e-06
. O 0 1.9686215324554723e-08
2 O 0 1.121881822996329e-07
) O 0 1.0902289915293295e-07
. O 0 5.497313395608217e-07

Maternal B-Disease 1 0.98128741979599
uniparental I-Disease 1 0.9931921362876892
disomy I-Disease 1 0.9815536737442017
( I-Disease 0 0.00022054997680243105
UPD I-Disease 1 0.9999878406524658
) I-Disease 0 8.241094064942445e-07
for I-Disease 0 1.0999077915130329e-07
chromosome I-Disease 0 3.168536568409763e-05
15 I-Disease 0 1.6416298365129478e-07
is O 0 1.5082518345366225e-08
responsible O 0 1.783440417568727e-08
for O 0 6.009478692448056e-09
an O 0 4.4124075060381074e-08
estimated O 0 2.767083060462028e-07
30 O 0 5.3288097490167274e-08
% O 0 3.313095131574073e-09
of O 0 1.195660348507488e-09
cases O 0 3.343205321471032e-07
of O 0 2.885777757910546e-05
Prader B-Disease 1 1.0
- I-Disease 1 1.0
Willi I-Disease 1 1.0
syndrome I-Disease 1 1.0
( O 0 0.00013051727728452533
PWS B-Disease 1 0.999984622001648
) O 0 3.3866663216031156e-06
. O 0 2.5351241674798075e-06

We O 0 4.4418920879252255e-06
report O 0 4.5197552367426397e-07
on O 0 4.0992205185830244e-08
an O 0 3.6897294108939604e-08
unusual O 0 3.1928783528201166e-07
case O 0 6.49158607757272e-07
of O 0 1.842110641803174e-08
maternal B-Disease 0 2.51208712143125e-05
disomy I-Disease 0 0.00016778211283963174
15 I-Disease 0 5.827155860060884e-07
in O 0 3.272978119639447e-07
PWS B-Disease 1 0.9999949932098389
that O 0 1.6857685523063992e-06
is O 0 8.579630161875684e-08
most O 0 2.113029928807464e-08
consistent O 0 2.994133296851942e-07
with O 0 3.8671132074341585e-08
adjacent O 0 2.0146320878211554e-07
- O 0 3.1673532703280216e-06
1 O 0 8.745762158923753e-08
segregation O 0 6.122142792719387e-08
of O 0 2.9106310694970716e-09
a O 0 6.981118190196867e-07
paternal O 0 0.0007117415661923587
t O 0 4.145634738961235e-05
( O 0 1.6485321552295318e-08
3 O 0 4.2660776244929366e-08
; O 0 6.472934899193206e-08
15 O 0 7.65598571206283e-08
) O 0 1.425336559890411e-08
( O 0 1.8045765770580147e-08
p25 O 0 3.5855359783454333e-06
; O 0 9.146967272499751e-08
q11 O 0 1.369068058920675e-06
. O 0 9.567650671726824e-09
2 O 0 8.085002889401949e-09
) O 0 2.4518109764670726e-09
with O 0 6.3163936303567425e-09
simultaneous O 0 1.1466472642496228e-06
maternal O 0 9.10732433112571e-06
meiotic O 0 5.5775517466827296e-06
nondisjunction O 0 3.120027395198122e-05
for O 0 1.492086170173934e-07
chromosome O 0 2.421538738417439e-05
15 O 0 7.95464927705325e-07
. O 0 8.631297987449216e-07

The O 0 7.63569369155448e-06
patient O 0 0.00014511235349345952
( O 0 2.5291279825978563e-07
J O 0 0.00039957804256118834
. O 0 1.7808407903885382e-07
B O 0 5.565764240600402e-07
. O 0 5.6702140760478414e-09
) O 0 1.6866886776156775e-09
, O 0 2.646417085472308e-09
a O 0 6.923099959976753e-08
17 O 0 8.322390243620248e-08
- O 0 1.686318341853621e-06
year O 0 1.709812664785204e-07
- O 0 9.036011761054397e-06
old O 0 0.00017293491691816598
white O 0 1.2299652553338092e-05
male O 0 4.1025276004802436e-05
with O 0 2.3826082724554e-06
PWS B-Disease 1 0.9999985694885254
, O 0 3.4373747439531144e-06
was O 0 8.164352948369924e-06
found O 0 3.024882389013328e-08
to O 0 1.0985865550594553e-08
have O 0 6.691515608281406e-08
47 O 0 3.4584246577651356e-07
chromosomes O 0 9.99058258344121e-08
with O 0 3.0097755399083326e-08
a O 0 9.288252158512478e-07
supernumerary O 0 0.0027968958020210266
, O 0 3.168415219079179e-07
paternal O 0 4.6105971705401316e-05
der O 0 0.0004055200843140483
( O 0 2.259913145508108e-08
15 O 0 3.0848312349007756e-08
) O 0 3.628541911382399e-09
consisting O 0 1.4902964196039648e-08
of O 0 2.0912414022689063e-09
the O 0 2.718623193231906e-08
short O 0 1.6965632312349044e-06
arm O 0 8.386178706132341e-06
and O 0 5.167785843696038e-08
the O 0 3.720207786273022e-08
proximal O 0 0.00037284730933606625
long O 0 6.037075308995554e-06
arm O 0 6.061252861400135e-06
of O 0 1.1535991717437355e-08
chromosome O 0 9.265955668524839e-06
15 O 0 1.2560407469663915e-07
, O 0 3.998202302568643e-08
and O 0 2.488395693944767e-07
distal O 0 0.25317052006721497
chromosome O 0 0.458407998085022
arm O 0 0.002060078317299485
3p O 0 0.00030464321025647223
. O 0 3.184860815963475e-06

The O 0 6.446090992540121e-06
t O 0 5.4901571274967864e-05
( O 0 8.780260429830378e-08
3 O 0 1.2307486940699164e-07
; O 0 6.63027961422813e-08
15 O 0 3.853668317788106e-08
) O 0 1.387668469021719e-08
was O 0 1.030759563036554e-06
present O 0 1.852024311688183e-08
in O 0 5.423088200728898e-09
the O 0 5.917404788391423e-09
balanced O 0 1.0256590599055926e-07
state O 0 1.5148453158531083e-08
in O 0 1.6763589627544206e-08
the O 0 1.8005083290972834e-07
patients O 0 0.0001058633642969653
father O 0 3.6683593407360604e-06
and O 0 8.698714282218134e-08
a O 0 1.929260406541289e-06
sister O 0 0.00011312741844449192
. O 0 1.3128195632816642e-06

Fluorescent O 0 0.0003746166476048529
in O 0 1.146519366557186e-06
situ O 0 5.488845090440009e-06
hybridization O 0 1.8981675111717777e-06
analysis O 0 4.771655426338839e-07
demonstrated O 0 6.822764362368616e-07
that O 0 6.940605601357674e-08
the O 0 1.0897425539724281e-07
PWS B-Disease 1 0.9999849796295166
critical O 0 4.643014108296484e-05
region O 0 4.200967680390022e-07
resided O 0 7.928119316602533e-07
on O 0 3.556054650744045e-08
the O 0 8.303898901829143e-09
derivative O 0 1.069767790795595e-06
chromosome O 0 4.965299922332633e-06
3 O 0 4.964647359884111e-08
and O 0 1.4443209295222914e-08
that O 0 2.3607828580907153e-08
there O 0 2.4161542100387123e-08
was O 0 9.323138669969921e-07
no O 0 2.9530422551715674e-08
deletion O 0 2.5447064899708494e-07
of O 0 5.03564701048731e-09
the O 0 2.3466867560273386e-07
PWS B-Disease 1 0.9999849796295166
region O 0 5.127814688421495e-07
on O 0 1.7710058841657883e-07
the O 0 1.9171476850488034e-08
normal O 0 8.078917090870164e-08
pair O 0 1.9035029197311815e-07
of O 0 1.113210323921976e-08
15s O 0 2.6642262582754483e-06
present O 0 2.26127625069239e-07
in O 0 2.456339132095309e-07
J O 0 0.005576296243816614
. O 0 2.71285080089001e-06

B O 0 0.004834272898733616
. O 0 6.395013770088553e-05

Methylation O 0 0.00021044134336989373
analysis O 0 8.4226312537794e-06
at O 0 1.129201265825941e-07
exon O 0 5.454282927530585e-07
alpha O 0 5.6250605950936006e-08
of O 0 1.883665889934605e-09
the O 0 6.369820226836964e-09
small O 0 3.358947608944618e-08
nuclear O 0 5.874331918676035e-07
ribonucleoprotein O 0 4.096952034160495e-05
- O 0 2.2471367628895678e-05
associated O 0 5.808081482427951e-07
polypeptide O 0 7.223818556667538e-06
N O 0 2.2142098714539316e-06
( O 0 2.518880393154177e-08
SNRPN O 0 1.0804887097037863e-05
) O 0 2.3280243510725995e-08
gene O 0 6.837551325133973e-08
showed O 0 3.755616830858344e-07
a O 0 9.650606358491132e-08
pattern O 0 1.6842097920743981e-06
characteristic O 0 2.2623828499490628e-07
of O 0 4.880102100202066e-09
only O 0 1.6081063591855127e-08
the O 0 2.5011907212046935e-08
maternal O 0 2.859847154468298e-05
chromosome O 0 1.1281006663921289e-05
15 O 0 1.67166135156549e-07
in O 0 9.671207124029024e-08
J O 0 0.0031711480114609003
. O 0 2.233760596936918e-06

B O 0 0.0023169396445155144
. O 0 2.3599426640430465e-05

Maternal B-Disease 0 0.23915104568004608
disomy I-Disease 0 0.006685709580779076
was O 0 6.199383642524481e-05
confirmed O 0 1.1200307881154004e-06
by O 0 1.557076245717326e-08
polymerase O 0 1.711922209324257e-06
chain O 0 3.68424139196577e-06
reaction O 0 3.105357961885602e-07
analysis O 0 1.9349871038798483e-08
of O 0 3.1400497757516632e-09
microsatellite O 0 1.0374397788837086e-05
repeats O 0 8.606950814282754e-07
at O 0 1.0146920637055246e-08
the O 0 9.041605686377352e-09
gamma O 0 4.784391762768792e-07
- O 0 6.396988737833453e-06
aminobutyric O 0 4.3397973058745265e-05
acid O 0 3.949395249946974e-06
receptor O 0 7.208446959339199e-07
beta3 O 0 2.514714651624672e-06
subunit O 0 8.275329719253932e-07
( O 0 5.018639726017682e-08
GABRB3 O 0 1.6071677237050608e-05
) O 0 1.3918598540385574e-07
locus O 0 6.993765509832883e-06
. O 0 1.9108160813630093e-06

A O 0 0.0002695320872589946
niece O 0 0.0025640332605689764
( O 0 7.235804559968528e-07
B O 0 1.2218458778079366e-06
. O 0 2.866622850206113e-08
B O 0 1.3639642304497102e-07
. O 0 2.48793829982219e-09
) O 0 1.8501098431045193e-09
with O 0 9.69380842263945e-09
45 O 0 4.752332216639843e-08
chromosomes O 0 7.698891124618967e-08
and O 0 7.590465145312919e-09
the O 0 4.7178114748192e-09
derivative O 0 1.5929046526252932e-07
3 O 0 3.0390626903908924e-08
but O 0 1.4650298751917035e-08
without O 0 7.187631823057927e-09
the O 0 2.0984064263984692e-08
der O 0 0.00042874491191469133
( O 0 1.4572017370539925e-08
15 O 0 1.543780570045783e-08
) O 0 6.93397339546209e-09
demonstrated O 0 5.314837494552194e-07
a O 0 5.298382347973529e-06
phenotype O 0 0.29340288043022156
consistent O 0 2.0176000816718442e-06
with O 0 3.3636016638638466e-08
that O 0 1.8224949371870025e-07
reported O 0 4.6353693505807314e-07
for O 0 9.136310374913137e-09
haploinsufficiency O 0 3.958055913244607e-06
of O 0 3.279248161902615e-08
distal O 0 0.0037408650387078524
3 O 0 2.853872865671292e-05
p O 0 2.8916014343849383e-05
. O 0 1.246643478225451e-06

Uniparental B-Disease 1 0.9999241828918457
disomy I-Disease 1 0.9998642206192017
associated O 0 9.077788854483515e-05
with O 0 5.292536684464721e-07
unbalanced O 0 9.233805758412927e-05
segregation O 0 2.1049499991931953e-06
of O 0 3.707499729443953e-08
non O 0 3.292849442004808e-07
- O 0 3.841040233965032e-05
Robertsonian O 0 0.00022118743800092489
translocations O 0 9.327640145784244e-05
has O 0 9.754694474395365e-06
been O 0 1.88061028438824e-06
reported O 0 9.902911415338167e-07
previously O 0 1.1708614522376593e-07
but O 0 4.178850687708291e-08
has O 0 2.8430625320652325e-07
not O 0 3.283704330669934e-08
, O 0 3.2530758087290224e-09
to O 0 2.9685141011981386e-09
our O 0 2.2456678738791425e-09
knowledge O 0 2.6564404009832288e-09
, O 0 7.532041657043465e-09
been O 0 2.5841726980502244e-08
observed O 0 3.4124223446951873e-08
in O 0 1.1368239682951753e-08
a O 0 2.1798744853640528e-07
case O 0 3.0056278319534613e-06
of O 0 9.411534165337798e-07
PWS B-Disease 1 0.999982476234436
. O 0 4.7414439904969186e-05

Furthermore O 0 0.00011313508730381727
, O 0 1.0741022151705693e-06
our O 0 5.020860882609668e-08
findings O 0 3.272400590503821e-07
are O 0 4.358255090153307e-09
best O 0 3.559827632670931e-08
interpreted O 0 1.8614059626997914e-07
as O 0 1.555541473408084e-08
true O 0 6.461265655843818e-08
gamete O 0 1.6712051547074225e-06
complementation O 0 1.3644807040691376e-05
resulting O 0 2.8115130135120125e-06
in O 0 1.9160677311447216e-06
maternal B-Disease 0 0.2639445662498474
UPD I-Disease 1 0.9999890327453613
15 I-Disease 0 0.00013830499665345997
and O 0 2.5720455596456304e-05
PWS B-Disease 1 0.9999202489852905

Schwartz B-Disease 1 0.9251535534858704
- I-Disease 1 0.9985308647155762
Jampel I-Disease 1 0.999523401260376
syndrome I-Disease 1 0.9999808073043823
type I-Disease 0 1.7222668247995898e-05
2 I-Disease 0 7.573698894702829e-07
and O 0 2.2828280634712428e-06
Stuve B-Disease 1 0.9177405834197998
- I-Disease 1 0.9999767541885376
Wiedemann I-Disease 1 0.9999992847442627
syndrome I-Disease 1 0.9999973773956299
: O 0 3.8663607426769886e-08
a O 0 1.9800133088665461e-07
case O 0 5.113710699333751e-07
for O 0 2.5674980363987743e-08
" O 0 1.3470827298078802e-07
lumping O 0 1.7723182281770278e-06
" O 0 6.499583378172247e-07
. O 0 3.781947555125953e-07

Recent O 0 2.2168374925968237e-05
studies O 0 7.397859462798806e-07
demonstrated O 0 5.247575245448388e-07
the O 0 1.0875410794142226e-08
existence O 0 2.3902563484057282e-08
of O 0 2.3404045368380366e-09
a O 0 2.4504757334398164e-07
genetically O 0 1.790952183000627e-06
distinct O 0 1.8948202296087402e-07
, O 0 5.5190508163605045e-08
usually O 0 1.796328490399901e-07
lethal O 0 5.603140493803949e-07
form O 0 1.4224740496615595e-08
of O 0 1.7851310429861655e-09
the O 0 1.1956159085002582e-07
Schwartz B-Disease 0 0.0905100405216217
- I-Disease 1 0.9991573095321655
Jampel I-Disease 1 0.9999673366546631
syndrome I-Disease 1 0.999991774559021
( O 0 2.874869835522986e-07
SJS B-Disease 0 0.00032803681096993387
) O 0 1.0869401023683167e-07
of O 0 8.066491830049927e-08
myotonia B-Disease 1 0.9879234433174133
and O 0 0.0002835374034475535
skeletal B-Disease 1 0.9998363256454468
dysplasia I-Disease 1 0.9999790191650391
, O 0 1.9678252556332154e-06
which O 0 2.0882774265373882e-07
we O 0 3.8069849495059316e-08
called O 0 1.6499246839885018e-06
SJS B-Disease 0 0.005194246768951416
type I-Disease 0 9.673264685261529e-06
2 I-Disease 0 7.482065029762452e-07
. O 0 7.39857227927132e-07

This O 0 0.00023362964566331357
disorder O 1 0.9265794157981873
is O 0 4.7464530439356167e-07
reminiscent O 0 3.4464967484382214e-06
of O 0 3.903215883838129e-08
another O 0 4.818174147658283e-06
rare O 0 0.0001339700975222513
condition O 0 0.0014057180378586054
, O 0 7.705737203878016e-08
the O 0 1.895423906717042e-07
Stuve B-Disease 1 0.9317893385887146
- I-Disease 1 0.999984860420227
Wiedemann I-Disease 1 0.9999995231628418
syndrome I-Disease 1 0.9999994039535522
( O 0 4.6907030082365964e-07
SWS B-Disease 0 0.11677508056163788
) O 0 4.929603036885055e-08
, O 0 3.4227348066906416e-08
which O 0 4.7083478449394534e-08
comprises O 0 3.311776453074344e-08
campomelia B-Disease 0 4.909756171400659e-06
at O 0 2.859872871852076e-08
birth O 0 7.610545367242594e-07
with O 0 1.4635729712608736e-06
skeletal B-Disease 1 0.9998553991317749
dysplasia I-Disease 1 0.9999898672103882
, O 0 3.5232118534622714e-05
contractures B-Disease 0 0.2217390537261963
, O 0 1.5392915031497978e-07
and O 0 4.930101127342823e-08
early B-Disease 0 1.5454827462235698e-06
death I-Disease 0 0.0011791458819061518
. O 0 1.1998185982520226e-06

To O 0 5.753816822107183e-06
test O 0 9.359235377814912e-07
for O 0 4.8068379499e-08
possible O 0 1.2037160956879234e-07
nosologic O 0 7.195591751951724e-05
identity O 0 4.224449980938516e-07
between O 0 8.473207202541744e-08
these O 0 5.1497795539035e-07
disorders O 0 0.008066432550549507
, O 0 3.777200063836972e-08
we O 0 1.2383232217416662e-08
reviewed O 0 6.252281536944793e-08
the O 0 4.654432839146239e-09
literature O 0 8.836520848376495e-09
and O 0 1.5506980588497754e-08
obtained O 0 3.118023172987705e-08
a O 0 3.2444205544379656e-08
follow O 0 2.896389261763943e-08
- O 0 5.919371801610396e-07
up O 0 1.8091705911160716e-08
of O 0 6.5488675593528e-10
the O 0 2.682094990547057e-09
only O 0 1.3906413798281392e-08
two O 0 1.313906352606864e-07
surviving O 0 0.012879312969744205
patients O 0 0.001106677227653563
, O 0 1.3119100472636092e-08
one O 0 1.768873225671541e-08
with O 0 6.526553164576399e-08
SJS B-Disease 0 0.0032587393652647734
type I-Disease 0 5.188954673940316e-06
2 I-Disease 0 5.043954942607343e-08
at O 0 8.574261300964281e-09
age O 0 9.072617501715285e-08
10 O 0 8.486126468199018e-09
years O 0 1.9549116103689812e-08
and O 0 1.0687400298081684e-08
another O 0 1.1171393765607718e-07
with O 0 7.544884397248097e-07
SWS B-Disease 0 0.23547306656837463
at O 0 1.798037345679404e-07
age O 0 2.0300244329973793e-07
7 O 0 2.1914846115578257e-07
years O 0 4.027072009193944e-07
. O 0 1.001168698167021e-06

Patients O 1 0.999281108379364
reported O 0 6.047438728273846e-05
as O 0 3.9018917163957667e-07
having O 0 4.687076682330371e-07
either O 0 3.878647476085462e-06
neonatal O 1 0.9999872446060181
SJS B-Disease 1 0.9991773962974548
or O 0 1.2827325917896815e-05
SWS B-Disease 1 0.9219871759414673
presented O 0 9.809471066546394e-07
a O 0 1.58957362828005e-07
combination O 0 2.0903596009702596e-07
of O 0 4.931584474121564e-09
a O 0 1.6248055544565432e-05
severe O 1 0.9446531534194946
, O 0 3.6943838495062664e-05
prenatal O 1 0.9896064400672913
- O 1 0.999799907207489
onset O 1 0.9997356534004211
neuromuscular B-Disease 1 0.9999982118606567
disorder I-Disease 1 0.9999860525131226
( O 0 9.362753417008207e-07
with O 0 5.1671329856617376e-05
congenital B-Disease 1 0.9999901056289673
joint I-Disease 1 0.9505565166473389
contractures I-Disease 1 0.9999873638153076
, O 0 0.46456098556518555
respiratory O 1 0.9998958110809326
and O 0 3.548879976733588e-05
feeding O 0 3.78540025849361e-05
difficulties O 0 1.077938486560015e-05
, O 0 8.107443250082724e-08
tendency O 0 1.7922113784152316e-06
to O 0 8.050003998505417e-06
hyperthermia B-Disease 1 0.9997863173484802
, O 0 4.235014898767986e-07
and O 0 3.2068430755316513e-07
frequent O 0 0.003172224620357156
death O 1 0.7137627601623535
in O 0 2.4032999590417603e-06
infancy O 0 6.901519373059273e-05
) O 0 1.3068302884278182e-08
with O 0 8.653780803058453e-09
a O 0 4.267457143214415e-07
distinct O 0 4.0714812143960444e-07
campomelic B-Disease 0 0.0013328480999916792
- I-Disease 0 0.04665654897689819
metaphyseal I-Disease 1 0.7852033972740173
skeletal I-Disease 1 0.9979172348976135
dysplasia I-Disease 1 0.9997192025184631
. O 0 1.3125054465490393e-05

The O 0 1.4336752656163299e-06
similarity O 0 1.2754851468343986e-06
of O 0 1.735295462879094e-08
the O 0 1.0529821281579643e-07
clinical O 0 2.6347184757469222e-05
and O 0 4.466802238312084e-06
radiographic O 1 0.9832533001899719
findings O 0 0.0002076239907182753
is O 0 8.508789051120402e-08
so O 0 3.398528747311502e-08
extensive O 0 1.192850618281227e-07
that O 0 3.011601847902057e-07
these O 0 4.923223286823486e-07
disorders O 0 0.030959881842136383
appear O 0 1.2495524970290717e-06
to O 0 3.694785988272997e-08
be O 0 4.2151377499521914e-08
a O 0 2.3444140140327363e-07
single O 0 8.523144856553699e-07
entity O 0 1.025114897856838e-06
. O 0 6.654445883214066e-07

The O 0 8.50297055876581e-07
follow O 0 4.594431004534272e-07
- O 0 2.7984349344478687e-06
up O 0 1.8129087209217687e-07
observation O 0 6.831723453615268e-07
of O 0 4.485619431449095e-09
an O 0 6.140479769101148e-08
identical O 0 5.837262051500147e-06
and O 0 7.285022007863518e-08
unique O 0 7.532864287895791e-08
pattern O 0 7.191144391072157e-07
of O 0 3.991550556747825e-08
progressive O 0 0.41728097200393677
bone B-Disease 1 0.9857367873191833
dysplasia I-Disease 1 0.9999570846557617
in O 0 6.475175950981793e-07
the O 0 2.0118653765166528e-07
two O 0 9.609526750864461e-05
patients O 0 0.02463812567293644
( O 0 1.2558749595825702e-08
one O 0 5.213963305550351e-08
with O 0 3.340076091262745e-07
SJS B-Disease 0 0.05749402567744255
type I-Disease 0 3.269996159360744e-05
2 I-Disease 0 9.67327409284735e-08
, O 0 1.7583779765573126e-08
one O 0 1.960583873028554e-08
with O 0 2.8256386030989233e-07
SWS B-Disease 1 0.6485713720321655
) O 0 6.749736769506853e-08
surviving O 0 1.0022367860074155e-06
beyond O 0 1.0158756680311853e-07
infancy O 0 2.112833954015514e-06
adds O 0 1.662281761127815e-07
to O 0 2.315536207220248e-08
the O 0 9.811368606449378e-09
evidence O 0 6.983976419405735e-08
in O 0 1.1485013828860247e-08
favor O 0 1.2124930037771264e-07
of O 0 3.0511198900740055e-08
identity O 0 1.8293328594154445e-06
. O 0 1.3421372386801522e-06

The O 0 5.548981334868586e-06
hypothesis O 0 4.051127325510606e-05
that O 0 4.3619502321234904e-07
SWS B-Disease 0 0.03937697410583496
and O 0 2.5463623387622647e-06
SJS B-Disease 0 0.012012142688035965
type I-Disease 0 1.6540554497623816e-05
2 I-Disease 0 1.422349811264212e-07
are O 0 6.835032095864335e-09
the O 0 1.6394638535643935e-08
same O 0 1.447448903491022e-05
disorder O 0 0.04255293309688568
should O 0 1.2535899429622077e-07
be O 0 3.111191304583372e-08
testable O 0 2.5942802039935486e-07
by O 0 1.5630659433440997e-08
molecular O 0 2.495939384061785e-07
methods O 0 1.8432622539421573e-07
. O 0 1.48861246884735e-07
. O 0 6.484853543042846e-07

A O 0 3.355740773258731e-05
mouse O 0 5.345155659597367e-05
model O 0 6.551343176397495e-06
of O 0 9.005394758787588e-07
severe O 1 0.9999035596847534
von B-Disease 1 1.0
Willebrand I-Disease 1 1.0
disease I-Disease 1 1.0
: O 0 0.00028307444881647825
defects O 1 0.9742981791496277
in O 0 1.4852363392492407e-06
hemostasis O 0 0.39164626598358154
and O 0 0.0004578068619593978
thrombosis B-Disease 1 0.9961851239204407
. O 0 2.5801209631026722e-05

von B-Disease 1 0.9970003962516785
Willebrand I-Disease 1 0.9955847859382629
factor I-Disease 0 0.0020419114734977484
( I-Disease 0 4.260718196746893e-05
vWf I-Disease 0 0.10295291990041733
) I-Disease 0 0.0032355524599552155
deficiency I-Disease 1 0.9982982277870178
causes O 0 0.04146748408675194
severe O 1 0.999984860420227
von B-Disease 1 1.0
Willebrand I-Disease 1 0.9999998807907104
disease I-Disease 1 0.9999996423721313
in O 0 2.2325370082398877e-05
humans O 0 9.078630682779476e-06
. O 0 3.0476819574687397e-06

We O 0 1.3900800013288972e-06
generated O 0 5.474743147715344e-07
a O 0 1.6832096605412517e-07
mouse O 0 2.348901716686669e-06
model O 0 1.332505689788377e-06
for O 0 4.433100286860281e-08
this O 0 4.1710040932230186e-07
disease O 0 3.167449904140085e-06
by O 0 2.243960750547558e-08
using O 0 3.230169909329561e-07
gene O 0 7.362969540736231e-07
targeting O 0 1.4028421446710126e-06
. O 0 9.847873343460378e-07

vWf B-Disease 0 0.4180357754230499
- I-Disease 1 0.9986995458602905
deficient I-Disease 1 0.9976268410682678
mice O 0 0.06790737807750702
appeared O 0 7.054732122924179e-05
normal O 0 1.7033693211487844e-07
at O 0 4.1135379547085904e-08
birth O 0 1.7898337318911217e-06
; O 0 5.7878221326745916e-08
they O 0 2.610059901542172e-08
were O 0 5.562570493111707e-08
viable O 0 5.977142336632824e-07
and O 0 2.0322869431765866e-07
fertile O 0 6.319556632661261e-06
. O 0 3.4581021282065194e-06

Neither O 0 0.00045664055505767465
vWf O 0 0.001866172649897635
nor O 0 0.00020874233450740576
vWf O 0 0.00040786093450151384
propolypeptide O 0 0.0011506533483043313
( O 0 3.7623453863488976e-06
von B-Disease 1 0.5059478878974915
Willebrand I-Disease 1 0.9645791053771973
antigen O 0 0.0056265718303620815
II O 0 0.0006335657672025263
) O 0 9.019647251307106e-08
were O 0 1.4537820902660314e-07
detectable O 0 7.994606789907266e-07
in O 0 2.1830466323535802e-08
plasma O 0 9.025857252709102e-06
, O 0 8.204310830706163e-08
platelets O 0 3.5171581203030655e-06
, O 0 5.6289351846317004e-08
or O 0 2.0027679070722115e-08
endothelial O 0 7.419638677674811e-06
cells O 0 2.527731908230635e-07
of O 0 3.764676126394306e-09
the O 0 6.479605474396521e-08
homozygous O 0 3.8789105019532144e-05
mutant O 0 5.645506098517217e-05
mice O 0 0.0001751460222294554
. O 0 1.7216555079357931e-06

The O 0 5.850124580319971e-06
mutant O 0 0.0010622593108564615
mice O 1 0.720824658870697
exhibited O 0 0.10815760493278503
defects O 1 0.9604935646057129
in O 0 9.722584763949271e-07
hemostasis O 0 0.007871551439166069
with O 0 2.6786131002154434e-07
a O 0 4.243478088028496e-06
highly O 0 4.346227342466591e-06
prolonged O 0 0.16263920068740845
bleeding O 1 0.9733719229698181
time O 0 8.383665317523992e-08
and O 0 3.856550279124349e-08
spontaneous O 0 3.1431366096512647e-06
bleeding O 0 0.43124112486839294
events O 0 5.5679951316278675e-08
in O 0 2.0776214526563308e-08
approximately O 0 2.481404237641982e-08
10 O 0 3.136226567335143e-08
% O 0 3.0256153138452646e-08
of O 0 4.095172556617399e-08
neonates O 1 0.6622357368469238
. O 0 9.509592018730473e-06

As O 0 1.576803470015875e-06
in O 0 3.613342869357439e-08
the O 0 4.7649209022893046e-08
human O 0 1.0452696415086393e-06
disease O 0 1.0723973900894634e-05
, O 0 2.0425183322458906e-08
the O 0 1.4505740608683482e-08
factor O 0 1.895094783321838e-07
VIII O 0 0.00463479058817029
level O 0 6.766287441450913e-08
in O 0 4.2337262584624114e-08
these O 0 2.8061045043159538e-08
mice O 0 0.00013722739822696894
was O 0 9.22633807931561e-06
reduced O 0 9.025401368489838e-07
strongly O 0 1.167461164186534e-06
as O 0 3.2521093373816257e-08
a O 0 1.6530132995740132e-07
result O 0 3.4959185768457246e-08
of O 0 7.591735018408485e-10
the O 0 8.431271680819918e-09
lack O 0 7.313771988037843e-08
of O 0 1.874702704185438e-08
protection O 0 3.636737801571144e-06
provided O 0 4.976783429810894e-07
by O 0 5.30558509126422e-07
vWf O 0 5.620570300379768e-05
. O 0 3.5481559734762413e-06

Defective O 1 0.9935324192047119
thrombosis B-Disease 1 0.9992563128471375
in O 0 9.15567397896666e-06
mutant O 0 0.0008119327831082046
mice O 0 0.010347612202167511
was O 0 5.259612407826353e-06
also O 0 2.2431910906561825e-07
evident O 0 2.1142922435046785e-07
in O 0 1.291595452812544e-08
an O 0 6.27459755264681e-08
in O 0 6.01939262878659e-08
vivo O 0 1.4591185390600003e-05
model O 0 1.003605461846746e-06
of O 0 9.054085836623926e-08
vascular B-Disease 1 0.9992377758026123
injury I-Disease 1 0.9232679009437561
. O 0 4.1587641135265585e-06

In O 0 1.3394800362220849e-06
this O 0 7.087763265190006e-08
model O 0 5.462539434120117e-07
, O 0 1.6366143995583116e-08
the O 0 1.8671375556778003e-08
exteriorized O 0 3.769326940528117e-05
mesentery O 0 7.937724876683205e-05
was O 0 1.1062993507948704e-05
superfused O 0 5.749341198679758e-06
with O 0 1.5114319751319272e-07
ferric O 0 0.00026784546207636595
chloride O 0 0.00027203396894037724
and O 0 5.4262365267732093e-08
the O 0 1.2364091972472124e-08
accumulation O 0 1.1236443953066555e-07
of O 0 2.7012974967988157e-08
fluorescently O 0 0.00017740092880558223
labeled O 0 4.0759321564109996e-05
platelets O 0 2.2335891117108986e-05
was O 0 2.4276346266560722e-06
observed O 0 2.1728115484620503e-07
by O 0 7.315375682992453e-08
intravital O 0 1.8448608898324892e-05
microscopy O 0 2.0065313947270624e-05
. O 0 1.9594810964917997e-06

We O 0 2.66155961980985e-06
conclude O 0 2.8820752504543634e-06
that O 0 1.227656127866794e-07
these O 0 2.5912601842037475e-08
mice O 0 5.7599222600401845e-06
very O 0 4.7216129672733587e-08
closely O 0 4.09841987902837e-07
mimic O 0 0.011872131377458572
severe O 1 0.9981410503387451
human O 0 0.04258042573928833
von B-Disease 1 1.0
Willebrand I-Disease 1 0.9999997615814209
disease I-Disease 1 0.9999996423721313
and O 0 7.541685590695124e-06
will O 0 1.2832252878069994e-06
be O 0 6.849220568483361e-08
very O 0 2.735564663680634e-08
useful O 0 8.333537415694536e-09
for O 0 2.282307454137822e-09
investigating O 0 1.9269691620138474e-08
the O 0 2.1676975769935325e-09
role O 0 1.4845146445452428e-08
of O 0 5.3800639499002045e-09
vWf O 0 2.0641741684812587e-06
in O 0 8.853817234921735e-08
normal O 0 2.5558065885888936e-07
physiology O 0 9.63593492997461e-07
and O 0 1.8939024926112324e-07
in O 0 2.9825475849065697e-06
disease O 0 0.0002634190896060318
models O 0 7.451797046087449e-06
. O 0 2.3069713961376692e-07
. O 0 7.285611332008557e-07

Oral O 0 0.07537950575351715
contraceptives O 0 0.11306571215391159
and O 0 6.42973247977352e-07
the O 0 1.6505575217706792e-07
risk O 0 2.3900706764834467e-06
of O 0 4.033935510960873e-06
hereditary B-Disease 1 0.9999997615814209
ovarian I-Disease 1 1.0
cancer I-Disease 1 0.9999996423721313
. O 0 2.35938023251947e-05

Hereditary B-Disease 1 0.9999914169311523
Ovarian I-Disease 1 0.9999957084655762
Cancer I-Disease 1 0.9998588562011719
Clinical O 0 0.0015505480114370584
Study O 0 3.7975353279762203e-06
Group O 0 4.551527581497794e-06
. O 0 1.7141749140137108e-06

BACKGROUND O 0 0.04181290417909622
Women O 0 2.09010140679311e-05
with O 0 3.333094298341166e-07
mutations O 0 3.5291091080580372e-06
in O 0 5.122134894008923e-08
either O 0 1.0145124917926296e-07
the O 0 6.493065285440025e-08
BRCA1 O 0 8.127395994961262e-05
or O 0 2.5560934702184568e-08
the O 0 4.778162931984298e-08
BRCA2 O 0 5.808894275105558e-05
gene O 0 1.3638980078667373e-07
have O 0 1.7184087042210194e-08
a O 0 1.5798168817582336e-07
high O 0 1.6015611663533491e-06
lifetime O 0 1.0415092219773214e-05
risk O 0 4.0008144424064085e-06
of O 0 1.3524067981052212e-05
ovarian B-Disease 1 1.0
cancer I-Disease 1 0.9999982118606567
. O 0 1.3878764548280742e-05

Oral O 0 0.029170824214816093
contraceptives O 1 0.9503493309020996
protect O 0 0.0013706509489566088
against O 1 0.9386646747589111
ovarian B-Disease 1 1.0
cancer I-Disease 1 0.9999995231628418
in O 0 2.7866744289894996e-07
general O 0 1.670920255492092e-07
, O 0 3.644364809929357e-08
but O 0 5.200961439300045e-08
it O 0 1.0648069093122103e-08
is O 0 1.862822784914897e-08
not O 0 9.13606612584772e-09
known O 0 1.6053940399274325e-08
whether O 0 1.962817464118416e-08
they O 0 2.9451166838612153e-08
also O 0 9.06511061771198e-08
protect O 0 1.3987299496420746e-07
against O 0 5.323674372448295e-07
hereditary B-Disease 0 0.18714620172977448
forms I-Disease 0 4.402166268846486e-06
of I-Disease 0 0.00016611034516245127
ovarian I-Disease 1 1.0
cancer I-Disease 1 0.9999985694885254
. O 0 8.554564374207985e-06

METHODS O 0 3.273062611697242e-05
We O 0 4.988073101230839e-07
enrolled O 0 9.703549039841164e-07
207 O 0 2.606116140668746e-06
women O 0 4.448620074981591e-06
with O 0 0.000791829836089164
hereditary B-Disease 1 0.9999998807907104
ovarian I-Disease 1 1.0
cancer I-Disease 1 0.9999992847442627
and O 0 2.6277561460119614e-07
161 O 0 3.4674900462050573e-07
of O 0 7.304580940115102e-09
their O 0 3.508336376967236e-08
sisters O 0 3.222939142233372e-07
as O 0 1.0986954457337106e-08
controls O 0 1.6692412145857816e-06
in O 0 1.87921713745709e-08
a O 0 8.109003601930453e-07
case O 0 8.309569238917902e-06
- O 0 0.00010301848669769242
control O 0 3.546928201103583e-05
study O 0 8.851704933476867e-07
. O 0 4.270950455520506e-07

All O 0 9.346239835394954e-07
the O 0 3.29908260709999e-07
patients O 0 9.629921805753838e-06
carried O 0 5.107097535983485e-07
a O 0 5.945730663370341e-07
pathogenic O 0 4.334211098466767e-06
mutation O 0 1.9923872969229706e-06
in O 0 2.528994613726354e-08
either O 0 2.3675382010424073e-07
BRCA1 O 0 0.0001415650185663253
( O 0 7.322160655576226e-08
179 O 0 6.100990049162647e-06
women O 0 2.1740186184615595e-06
) O 0 4.278863485751572e-08
or O 0 5.880379490008636e-07
BRCA2 O 0 0.0021902720909565687
( O 0 7.465666129746751e-08
28 O 0 3.1104816571314586e-06
women O 0 5.812325980514288e-07
) O 0 1.7816935837799974e-07
. O 0 7.254252523125615e-07

The O 0 3.794468966589193e-06
control O 0 9.586535270500463e-06
women O 0 9.953947710528155e-07
were O 0 1.4474075271664333e-07
enrolled O 0 9.227309760717617e-08
regardless O 0 1.7566282650705034e-08
of O 0 1.3621340722025366e-09
whether O 0 5.5914618712904485e-08
or O 0 1.5794832108895207e-08
not O 0 3.4339489474177753e-08
they O 0 6.97268873750545e-08
had O 0 3.731628794412245e-06
either O 0 3.475435619293421e-07
mutation O 0 3.6120104596193414e-06
. O 0 9.684439419288537e-07

Lifetime O 0 0.0009057899587787688
histories O 0 2.7671152565744705e-05
of O 0 6.116278541412612e-07
oral O 0 3.2551673939451575e-05
- O 0 0.0007676061359234154
contraceptive O 0 0.10546737909317017
use O 0 7.387023970295559e-07
were O 0 5.802888267680828e-07
obtained O 0 1.6530306368167658e-07
by O 0 4.0782268229122565e-08
interview O 0 1.0063129593618214e-05
or O 0 1.8134441504003007e-08
by O 0 2.2031539259614874e-08
written O 0 4.6024737798688875e-07
questionnaire O 0 1.0663835382729303e-05
and O 0 8.208427004774421e-08
were O 0 1.8632175624588854e-07
compared O 0 7.931241725600557e-07
between O 0 1.1712500480598464e-07
patients O 0 0.0020022105891257524
and O 0 4.4093792439525714e-07
control O 0 0.00016969817806966603
women O 0 8.056541105361248e-07
, O 0 1.79890964346896e-08
after O 0 5.3453309334372534e-08
adjustment O 0 9.425180280686618e-08
for O 0 7.029947735048836e-09
year O 0 3.1276123024781555e-08
of O 0 1.0424087371063706e-08
birth O 0 1.6533742837054888e-06
and O 0 2.663436191596702e-07
parity O 0 4.30158115705126e-06
. O 0 1.0472931535332464e-06

RESULTS O 0 0.00012863529263995588
The O 0 3.9138251395343104e-07
adjusted O 0 1.0404131899122149e-05
odds O 0 4.90740712848492e-05
ratio O 0 8.713603892829269e-05
for O 0 0.05306990444660187
ovarian B-Disease 1 1.0
cancer I-Disease 1 0.9999998807907104
associated O 0 4.565951599033724e-07
with O 0 9.816909951609887e-09
any O 0 5.211295395213256e-09
past O 0 2.4109844787290058e-08
use O 0 5.9221616055538107e-08
of O 0 2.5741861975348e-08
oral O 0 0.00010880939953494817
contraceptives O 1 0.8969069123268127
was O 0 4.648060348699801e-05
0 O 0 1.8987269641002058e-06
. O 0 6.840152764198137e-07

5 O 0 1.865943158918526e-05
( O 0 3.351770487824979e-07
95 O 0 3.7553698462033935e-07
percent O 0 4.2039053482767486e-07
confidence O 0 1.3778605989500647e-07
interval O 0 6.72751383490322e-08
, O 0 2.610916460810131e-08
0 O 0 6.174055755536756e-08
. O 0 6.8452732371326874e-09
3 O 0 1.955217321381042e-08
to O 0 7.741770957636618e-08
0 O 0 7.576783218610217e-07
. O 0 4.234186690155184e-08
8 O 0 1.2619720735074225e-07
) O 0 1.0715796605609285e-07
. O 0 2.715960079058277e-07

The O 0 5.587027317233151e-06
risk O 0 1.0307035154255573e-05
decreased O 0 2.118378461091197e-06
with O 0 2.8027825393905914e-08
increasing O 0 1.4635656953032594e-07
duration O 0 3.996510713477619e-07
of O 0 7.689642700370314e-09
use O 0 1.2374216851185338e-07
( O 0 2.657349007506582e-08
P O 0 5.007610184293299e-07
for O 0 6.6605201354263954e-09
trend O 0 7.958931291796034e-08
, O 0 3.322259445326381e-08
< O 0 2.5231054223695537e-07
0 O 0 1.745387265827958e-07
. O 0 2.3030448659255853e-08
001 O 0 3.548591962498904e-07
) O 0 8.02138089284199e-09
; O 0 3.607308673991838e-09
use O 0 5.999080343599417e-09
for O 0 6.351028147832949e-09
six O 0 5.956918158744884e-08
or O 0 1.4235570056086999e-08
more O 0 3.5803513043219937e-08
years O 0 5.079134552943287e-07
was O 0 6.8681497396028135e-06
associated O 0 3.5495897776627316e-08
with O 0 7.74744002285388e-09
a O 0 4.802174089491018e-07
60 O 0 3.86046622224967e-07
percent O 0 5.635487241306691e-07
reduction O 0 4.4991728032073297e-07
in O 0 5.726384415538632e-07
risk O 0 6.711072728649015e-06
. O 0 1.3291208915688912e-06

Oral O 0 0.0015877049881964922
- O 0 0.0012727318098768592
contraceptive O 0 0.013410118408501148
use O 0 3.3847416034404887e-06
protected O 0 0.0001163349297712557
against O 1 0.6570978164672852
ovarian B-Disease 1 1.0
cancer I-Disease 1 0.9999978542327881
both O 0 9.305055925779016e-08
for O 0 2.7653777934233403e-08
carriers O 0 5.9149705577965506e-08
of O 0 1.5988539381339706e-09
the O 0 5.2635634517628205e-08
BRCA1 O 0 0.0005415107007138431
mutation O 0 2.6914030968328007e-06
( O 0 1.9624955882591166e-08
odds O 0 5.302214049152099e-06
ratio O 0 1.4975189515098464e-06
, O 0 2.0559912883300058e-08
0 O 0 4.364346750662662e-08
. O 0 6.769021787533802e-09
5 O 0 8.06811861764345e-09
; O 0 5.457496676797291e-09
95 O 0 2.2153233913968506e-08
percent O 0 1.828378941581832e-07
confidence O 0 6.904282656705618e-08
interval O 0 3.924244751374317e-08
, O 0 1.0369909375640418e-08
0 O 0 1.8917608812785147e-08
. O 0 2.5898851951922097e-09
3 O 0 9.220620711403171e-09
to O 0 2.16439364209009e-08
0 O 0 2.2816017519744491e-07
. O 0 1.6653324053095275e-08
9 O 0 2.285488420739057e-08
) O 0 1.5473201608884324e-09
and O 0 3.3486085015965728e-09
for O 0 5.869642105693629e-09
carriers O 0 3.272531046150107e-08
of O 0 2.432415380226871e-09
the O 0 1.2439600993729982e-07
BRCA2 O 0 0.022061940282583237
mutation O 0 5.672808129020268e-06
( O 0 1.604515631470349e-08
odds O 0 5.6969224715430755e-06
ratio O 0 1.615589894754521e-06
, O 0 4.491169036668907e-08
0 O 0 6.072692571024163e-08
. O 0 5.657455393048849e-09
4 O 0 1.671349814102996e-08
; O 0 5.302001060414341e-09
95 O 0 5.655861556874697e-08
percent O 0 3.2037462460721144e-07
confidence O 0 1.6436851524304075e-07
interval O 0 6.894386928024687e-08
, O 0 2.0043577464434748e-08
0 O 0 3.849510221698438e-08
. O 0 2.8801694362812214e-09
2 O 0 8.06414934828581e-09
to O 0 1.9937159478899957e-08
1 O 0 4.806122788636458e-08
. O 0 2.1112210646379026e-08
1 O 0 7.530019985324543e-08
) O 0 9.522958066554565e-08
. O 0 4.5989858676875883e-07

CONCLUSIONS O 0 0.000989327090792358
Oral O 0 0.00014029686280991882
- O 0 0.0007474557496607304
contraceptive O 0 0.06285358220338821
use O 0 1.1318951465000282e-06
may O 0 8.765557595324935e-07
reduce O 0 2.3935416493259254e-07
the O 0 7.607165031231489e-08
risk O 0 3.4944732760777697e-06
of O 0 1.7231011952389963e-05
ovarian B-Disease 1 1.0
cancer I-Disease 1 0.9999995231628418
in O 0 1.4676612636321806e-06
women O 0 6.086590929044178e-07
with O 0 1.626433032697605e-07
pathogenic O 0 1.7513044440420344e-05
mutations O 0 2.9375398753472837e-06
in O 0 3.772937517965147e-08
the O 0 1.1928494814128499e-07
BRCA1 O 0 0.002217666245996952
or O 0 2.1901839772908716e-06
BRCA2 O 0 0.002451398642733693
gene O 0 0.00010983383253915235

A O 0 3.313440902275033e-05
Japanese O 0 1.027980397338979e-05
family O 0 2.9911416277172975e-06
with O 0 1.4530685348290717e-06
adrenoleukodystrophy B-Disease 1 0.999980092048645
with O 0 2.7161723892277223e-07
a O 0 9.160251011053333e-07
codon O 0 1.2655168575292919e-06
291 O 0 8.69384393809014e-07
deletion O 0 4.542520855466137e-06
: O 0 2.805692211893529e-08
a O 0 4.2368850472485065e-07
clinical O 0 1.568890547787305e-05
, O 0 2.5840944317678805e-07
biochemical O 0 9.1036772573716e-06
, O 0 1.7836606502896757e-07
pathological O 0 1.4509232642012648e-05
, O 0 6.189820567215065e-08
and O 0 2.7061869900535385e-07
genetic O 0 5.7293736972496845e-06
report O 0 1.4528343399433652e-06
. O 0 1.0001305099649471e-06

We O 0 5.962299383099889e-06
report O 0 4.927474037685897e-07
a O 0 8.43310985487733e-08
Japanese O 0 7.907557915132202e-07
family O 0 2.8722274691972416e-06
with O 0 0.00023060146486386657
adrenoleukodystrophy B-Disease 1 0.9999998807907104
( O 0 0.00894409790635109
ALD B-Disease 1 0.9999996423721313
) O 0 1.5937190767090215e-07
with O 0 4.463219127615048e-08
a O 0 7.489554150197364e-07
three O 0 6.098984073332758e-08
base O 0 2.7971489657829807e-07
pair O 0 2.505861402823939e-06
deletion O 0 1.2036122825520579e-05
( O 0 4.264604669401706e-08
delGAG O 0 3.0764256280235713e-06
291 O 0 4.808113089893595e-07
) O 0 2.2314383230082058e-08
in O 0 4.2996024518515696e-08
the O 0 1.3813171335641528e-06
ALD B-Disease 1 0.9999983310699463
gene O 0 0.00041105004493147135
. O 0 4.692185029853135e-06

A O 0 2.8921749617438763e-05
variety O 0 1.109187564907188e-06
of O 0 1.6644773381813138e-07
phenotypes O 0 0.000383076403522864
were O 0 1.0074488727696007e-06
observed O 0 1.6972430216810608e-07
within O 0 9.484073082433042e-09
this O 0 2.5184048624282696e-08
family O 0 1.1707626299539697e-06
. O 0 7.194773274932231e-07

While O 0 1.1608936802076641e-05
the O 0 4.184537658602494e-07
proband O 0 0.00021271489094942808
( O 0 6.211132017597265e-07
patient O 0 0.00013269606279209256
1 O 0 3.0287569074971543e-07
) O 0 4.322345859009147e-08
was O 0 8.448808330285829e-06
classified O 0 5.748611542344406e-08
as O 0 2.8559153264495762e-08
having O 0 1.7610698677117398e-08
a O 0 1.7915381533839536e-07
rare O 0 1.4099614418228157e-06
intermediate O 0 5.718765692108718e-07
type O 0 2.1558778939834156e-07
of O 0 1.5768794270343278e-08
adult O 0 0.00021766642748843879
cerebral O 0 0.12903043627738953
and O 0 1.5223116633933387e-06
cerebello O 0 0.07704070955514908
- O 0 0.17949892580509186
brain O 0 0.017722636461257935
stem O 0 9.503050932835322e-07
forms O 0 2.2676425714962534e-07
, O 0 9.748062979042516e-08
his O 0 2.032829115705681e-06
younger O 0 4.019476182293147e-05
brother O 0 6.442917947424576e-05
( O 0 4.7369383082696004e-08
patient O 0 2.5540073693264276e-05
2 O 0 1.529951276779684e-07
) O 0 4.2655567966676244e-08
and O 0 1.502593249824713e-06
nephew O 0 0.3184199631214142
( O 0 2.059198322967859e-07
patient O 0 0.0008369299466721714
3 O 0 2.481161232026352e-07
) O 0 4.115209506494466e-08
had O 0 2.2291105779004283e-06
a O 0 3.081594695686363e-05
childhood O 0 0.01635461300611496
ALD B-Disease 1 0.999997615814209
type O 0 0.005236623343080282
. O 0 3.2866105357243214e-06

Another O 0 0.0001774254342308268
nephew O 0 0.03784007579088211
( O 0 1.904230657601147e-06
patient O 0 8.138633711496368e-05
4 O 0 2.202146305307906e-07
) O 0 1.0397994465449756e-08
of O 0 1.6256787915835957e-08
patient O 0 0.002627403475344181
1 O 0 1.1112691709058709e-06
was O 0 2.0286968720029108e-05
classified O 0 1.6032345229177736e-07
as O 0 3.621885014126747e-08
having O 0 4.524952146311989e-08
an O 0 9.411635915057559e-08
adolescent O 0 3.543307684594765e-05
form O 0 1.969389131772914e-06
. O 0 2.7135210984852165e-06

The O 0 1.178588718175888e-06
tau O 0 1.1748539918698953e-06
level O 0 9.378913290447599e-08
in O 0 2.9036350213118567e-08
the O 0 1.5788062057708885e-07
cerebrospinal O 0 0.1888466626405716
fluid O 0 0.3315446376800537
( O 0 6.704961492687289e-07
CSF O 1 0.5817874670028687
) O 0 7.298192628013567e-08
in O 0 2.0016038604353525e-07
patient O 0 0.00028710634796880186
1 O 0 3.001555057835503e-07
was O 0 4.117728622077266e-06
as O 0 2.9234966447688748e-08
high O 0 4.372278539221952e-08
as O 0 1.56641757342868e-08
that O 0 1.1506304353758878e-08
of O 0 3.3158528367494e-08
patients O 0 0.02267652191221714
with O 0 0.007492436096072197
Alzheimers B-Disease 1 0.9999973773956299
disease I-Disease 1 0.7169731259346008
( O 0 7.047565020457114e-08
AD B-Disease 0 1.6560110452701338e-05
) O 0 4.1659035332486383e-07
. O 0 6.738956699336995e-07

His O 0 7.616782386321574e-05
brain O 0 0.00038573972415179014
magnetic O 0 0.00010677031241357327
resonance O 0 0.0010191128822043538
image O 0 0.005423963535577059
( O 0 4.6177120793799986e-07
MRI O 0 0.35196447372436523
) O 0 5.487884777721774e-07
showed O 0 0.03179028630256653
abnormalities B-Disease 0 0.051522448658943176
in I-Disease 0 2.5745544363076078e-08
the I-Disease 0 3.062056919134193e-08
bilateral I-Disease 0 2.036162413787679e-06
cerebellar I-Disease 1 0.9483141899108887
hemispheres I-Disease 1 0.6532604098320007
and O 0 8.969542250270024e-06
brain O 0 0.0004673672665376216
stem O 0 5.522830406334833e-07
, O 0 3.6889414190000025e-08
but O 0 3.6540743764135186e-08
not O 0 1.9478177293308363e-08
in O 0 1.76634120663266e-08
the O 0 1.7547938568895916e-07
cerebral O 1 0.717536449432373
white O 0 8.288753633678425e-06
matter O 0 1.1746283234970178e-07
, O 0 1.1340432592987781e-08
where O 0 9.354256036431252e-09
marked O 0 1.2155356898801983e-07
reductions O 0 2.2222751283607067e-07
of O 0 3.935440862079531e-09
the O 0 1.1778049469057805e-07
cerebral O 1 0.5162965655326843
blood O 0 5.210918970988132e-06
flow O 0 1.960524542710118e-07
and O 0 1.7592275014521874e-07
oxygen O 0 4.421942321641836e-06
metabolism O 0 2.9916500920990075e-07
were O 0 8.804290985153784e-08
clearly O 0 2.8267734819564794e-07
demonstrated O 0 1.2151843975516385e-07
by O 0 2.598689619048855e-08
positron O 0 0.00014079795801080763
emission O 0 8.17232830740977e-06
tomography O 0 0.0002664900675881654
( O 0 3.1116366017158725e-07
PET O 0 2.3552122002001852e-05
) O 0 6.942676691323868e-07
. O 0 7.579391763101739e-07

In O 0 0.00020282385230530053
patients O 0 0.028397196903824806
2 O 0 8.516596494700934e-07
and O 0 1.4124645986157702e-07
3 O 0 6.855376710745986e-08
, O 0 1.4408842119451037e-08
the O 0 1.851014452824984e-08
autopsy O 1 0.9491586089134216
findings O 0 2.191805288020987e-05
showed O 0 1.3140986993676051e-05
massive O 0 2.6602794605423696e-05
demyelination B-Disease 1 0.9999351501464844
of I-Disease 0 1.0073185308101529e-07
the I-Disease 0 1.6194633190025343e-06
cerebral I-Disease 1 0.5449870824813843
white I-Disease 0 3.7475881526916055e-06
matter I-Disease 0 1.1075369599211626e-07
with O 0 3.510933765937807e-08
sparing O 0 5.217982561589452e-07
of O 0 1.1210258499261272e-08
the O 0 6.458937207298732e-08
U O 0 0.0003092123370151967
- O 0 0.026916027069091797
fibers O 0 0.00021909667702857405
, O 0 4.0987199412256814e-08
compatible O 0 1.0839256958661281e-07
with O 0 2.2951249789571193e-08
the O 0 4.8414072750802006e-08
findings O 0 1.9410031200095546e-06
of O 0 6.20096955117333e-07
childhood O 0 0.0034032936673611403
ALD B-Disease 1 0.9999938011169434
. O 0 3.81966819986701e-05

Oleic O 0 0.49363967776298523
and O 0 7.415737491101027e-05
erucic O 0 0.3345656394958496
acids O 0 5.329599389369832e-06
( O 0 8.739709045357813e-08
Lorenzos O 0 3.7447016438818537e-06
Oil O 0 2.5704090944600466e-07
) O 0 8.026783682169025e-09
were O 0 6.710636313300711e-08
administered O 0 1.9199679002213088e-07
to O 0 8.661890547045914e-07
patients O 0 5.8799203543458134e-05
1 O 0 4.83162878595067e-08
and O 0 1.3521965058771457e-07
4 O 0 1.131998246250987e-07
, O 0 1.7734372192990122e-08
but O 0 3.621836697220715e-08
sufficient O 0 1.477681763617511e-07
effectiveness O 0 5.470259907269792e-07
was O 0 2.5917058792401804e-06
not O 0 1.0871059430428431e-07
obtained O 0 4.1484119606138847e-07
. O 0 5.631769113279006e-07

The O 0 4.033139248349471e-06
findings O 0 4.370475380710559e-06
in O 0 2.820086741905925e-08
this O 0 1.5871780334464347e-08
family O 0 1.4948165016903658e-07
suggest O 0 7.430575976741238e-08
that O 0 3.178950436222294e-08
delGAG291 O 0 3.6731414638779825e-06
is O 0 2.2747594030647633e-08
part O 0 6.223272563943283e-09
of O 0 9.198483086336751e-10
the O 0 7.956468373038206e-09
cause O 0 1.5135132969135157e-07
of O 0 1.1971488689255239e-08
Japanese O 0 0.0001630119077162817
ALD B-Disease 1 0.9999983310699463
with O 0 2.2608714971283916e-06
phenotypic O 0 0.0005693088169209659
variations O 0 2.6318206437281333e-05
. O 0 1.1540788591446471e-06

Moreover O 0 4.545773845165968e-05
, O 0 6.063815476409218e-07
although O 0 4.6160209876688896e-08
the O 0 3.213551424963157e-09
scale O 0 3.358671918363143e-08
of O 0 2.69557776100271e-09
the O 0 2.1649467996098792e-08
study O 0 1.2117219228002796e-07
is O 0 1.2555113926282502e-07
limited O 0 1.3176079960430798e-07
, O 0 8.237281967637955e-09
there O 0 4.6148129762002554e-09
is O 0 6.337113500620717e-09
a O 0 5.214579701373623e-08
possibility O 0 6.260324170170861e-08
that O 0 6.301041821643594e-08
PET O 0 9.797955499379896e-06
can O 0 4.206247083970993e-08
detect O 0 2.51808387474739e-06
an O 0 4.908432060801715e-07
insidious B-Disease 0 0.043358754366636276
lesion I-Disease 1 0.96723473072052
which O 0 2.110425612045219e-06
is O 0 1.6156764104380272e-07
undetectable O 0 4.7098302502490696e-07
by O 0 1.7450735967372566e-08
computed O 0 5.04241597809596e-07
tomogram O 0 1.71575702552218e-05
( O 0 3.800890269189949e-08
CT O 0 0.0008553503430448472
) O 0 2.4495312445083073e-08
or O 0 4.344181903093158e-08
MRI O 0 0.13194267451763153
analysis O 0 2.2268342547704378e-07
, O 0 1.5098837735649795e-08
and O 0 6.886485603985193e-09
that O 0 9.497795439017409e-09
the O 0 5.1917510290877544e-09
higher O 0 9.106663867441966e-09
level O 0 1.759410395152372e-09
of O 0 1.1180080194961306e-09
tau O 0 3.5057674097060953e-08
reflects O 0 4.546458853837976e-08
the O 0 2.5132402825533973e-09
process O 0 5.437598815660749e-09
of O 0 2.177852032048122e-08
neuronal B-Disease 0 0.00035055287298746407
degeneration I-Disease 1 0.9886879324913025
in O 0 9.579278412275016e-05
ALD B-Disease 1 0.9999982118606567
. O 0 0.000184519580216147

Lorenzos O 0 0.0005757497274316847
Oil O 0 8.115896889648866e-06
should O 0 1.5967206934419664e-07
be O 0 2.009694100024717e-08
given O 0 1.1250850917576827e-08
in O 0 6.973922772601782e-09
the O 0 7.393110124098712e-09
early O 0 2.3574041563279025e-07
stage O 0 7.403551535389852e-06
. O 0 3.869807017053972e-07
. O 0 8.86581347003812e-07

Nonsense O 0 0.0008258686866611242
mutation O 0 0.00022738522966392338
in O 0 5.545450676436303e-07
exon O 0 4.944330157741206e-06
4 O 0 3.6238273537492205e-07
of O 0 1.1979575553766608e-08
human O 0 8.824953567909688e-08
complement O 0 6.801838594583387e-07
C9 O 0 0.00025055368314497173
gene O 0 1.1009736908818013e-06
is O 0 3.072810628168554e-08
the O 0 8.971191789441946e-09
major O 0 5.0397908069044206e-08
cause O 0 2.862738881503901e-07
of O 0 2.1113418569029818e-08
Japanese O 0 2.7304924515192397e-05
complement B-Disease 0 0.0004935155739076436
C9 I-Disease 1 0.999058187007904
deficiency I-Disease 1 0.9731089472770691
. O 0 4.506031928031007e-06

Deficiency B-Disease 1 0.996681272983551
of I-Disease 0 4.024833515359205e-07
the I-Disease 0 8.884826740995777e-08
ninth I-Disease 0 8.014087029550865e-07
component I-Disease 0 1.424865558874444e-07
of I-Disease 0 1.0140768225141983e-08
human I-Disease 0 7.545173019707363e-08
complement I-Disease 0 5.244963290351734e-07
( O 0 8.009887153548334e-08
C9 O 0 0.00013014048454351723
) O 0 2.6865507152251666e-08
is O 0 9.956129254362622e-09
the O 0 4.163946520918671e-09
most O 0 1.333264236791365e-07
common O 0 1.6894920918275602e-05
complement B-Disease 1 0.9999940395355225
deficiency I-Disease 1 0.9999983310699463
in O 0 6.804725671827327e-08
Japan O 0 1.0961715446455855e-07
but O 0 1.6776439792920428e-07
is O 0 8.912304849673092e-08
rare O 0 2.0306829640048818e-07
in O 0 2.8567434640081046e-08
other O 0 1.6542962555377017e-08
countries O 0 2.591774439508754e-08
. O 0 7.528540209023049e-07

We O 0 2.177020860472112e-06
studied O 0 2.9904404641456495e-07
the O 0 1.4116358748594848e-08
molecular O 0 1.7695354870284064e-07
basis O 0 3.6425024774189296e-08
of O 0 1.56174650101093e-07
C9 B-Disease 1 0.9998465776443481
deficiency I-Disease 1 0.9810343384742737
in O 0 1.1710222480587618e-07
four O 0 1.0494592572740657e-07
Japanese O 0 7.633087079739198e-06
C9 B-Disease 1 0.8046815991401672
- I-Disease 1 0.9975851774215698
deficient I-Disease 1 0.9993948936462402
patients O 0 0.17089232802391052
who O 0 9.960831448552199e-06
had O 0 0.00020224238687660545
suffered O 1 0.9332942962646484
from O 0 3.651957740657963e-05
meningococcal B-Disease 1 0.9999980926513672
meningitis I-Disease 1 0.999998927116394
. O 0 9.173257421934977e-05

Direct O 0 1.1270823051745538e-05
sequencing O 0 2.199511300204904e-06
of O 0 1.6658700019434036e-07
amplified O 0 1.7127455066656694e-05
C9 O 0 3.0841405532555655e-05
cDNA O 0 2.780844170047203e-06
and O 0 3.027226398444327e-07
DNA O 0 1.1763606835302198e-06
revealed O 0 9.088315096050792e-07
a O 0 1.1544162958898596e-07
nonsense O 0 1.5390066891995957e-06
substitution O 0 1.28776946439757e-07
( O 0 3.038054074977481e-08
CGA O 0 2.8503377507149708e-06
- O 0 3.634727909229696e-05
- O 0 8.159537537721917e-05
> O 0 1.1550213230293593e-06
TGA O 0 1.2447293556760997e-05
) O 0 1.343018496413606e-08
at O 0 4.756228744184909e-09
codon O 0 3.434957918102555e-08
95 O 0 2.647110264319963e-08
in O 0 8.510489202251392e-09
exon O 0 3.431524078223447e-07
4 O 0 4.5219238131721795e-08
in O 0 7.954587211145281e-09
the O 0 1.9261937822534492e-08
four O 0 4.639429675989959e-07
C9 B-Disease 0 0.03843331336975098
- I-Disease 1 0.5356355309486389
deficient I-Disease 0 0.10537543892860413
individuals O 0 2.318851670679578e-07
. O 0 3.4615064237186743e-07

An O 0 7.844353604014032e-06
allele O 0 8.277754386654124e-05
- O 0 5.295583832776174e-06
specific O 0 9.976149328849715e-08
polymerase O 0 2.0150425825704588e-06
chain O 0 3.426286184549099e-06
reaction O 0 4.2869999106187606e-07
system O 0 4.453397650650004e-08
designed O 0 1.0874995268750354e-06
to O 0 1.2551726058518398e-07
detect O 0 3.3235448881896446e-06
exclusively O 0 8.496755299347569e-08
only O 0 9.164619285684239e-09
one O 0 2.0195609629070077e-09
of O 0 3.2134395144822747e-10
the O 0 3.992713715206264e-09
normal O 0 3.0429951891619567e-08
and O 0 1.9557695907224115e-08
mutant O 0 2.8896079129481222e-06
alleles O 0 2.8743653501805966e-07
indicated O 0 3.4280995464541775e-07
that O 0 4.183250634781643e-09
all O 0 7.213213915058247e-10
the O 0 3.353817890072719e-09
four O 0 4.924448262499936e-07
patients O 0 6.386419045156799e-06
were O 0 6.609597136275625e-08
homozygous O 0 3.7328814528336807e-07
for O 0 4.582315860091057e-09
the O 0 5.669510638739439e-09
mutation O 0 1.528857467292255e-07
in O 0 1.0728472332743877e-08
exon O 0 7.511528679060575e-07
4 O 0 1.063297361270088e-07
and O 0 2.404885179885241e-08
that O 0 1.5682651621773402e-08
the O 0 1.690328765846516e-08
parents O 0 7.78866251494037e-08
of O 0 6.874568914128076e-09
patient O 0 1.734010766085703e-05
2 O 0 3.604436074056139e-07
were O 0 6.335121156553214e-07
heterozygous O 0 3.083211413468234e-05
. O 0 7.947650146888918e-07

The O 0 3.556920773917227e-06
common O 0 1.5703850522186258e-06
mutation O 0 1.1092658951383783e-06
at O 0 1.1151760404004563e-08
codon O 0 9.9992952584671e-08
95 O 0 8.818643948416138e-08
in O 0 1.8131224521766853e-08
exon O 0 1.0193961088589276e-06
4 O 0 1.1377615294350107e-07
might O 0 1.1814702105539254e-07
be O 0 2.2086364737106123e-08
responsible O 0 4.8898129989538575e-08
for O 0 2.8369461446686728e-08
most O 0 2.0945822143403348e-07
Japanese O 0 0.0012646476970985532
C9 B-Disease 1 0.9995741248130798
deficiency I-Disease 1 0.8960705995559692
. O 0 3.3488086614852364e-07
. O 0 7.753125714771159e-07

BRCA1 O 0 0.3850429654121399
required O 0 8.809019163891207e-06
for O 0 1.9096577830168826e-07
transcription O 0 2.2774677290726686e-06
- O 0 0.00019026361405849457
coupled O 0 6.852015212643892e-05
repair O 0 1.891742431325838e-05
of O 0 4.900606853652789e-08
oxidative O 0 0.0029747525695711374
DNA O 0 0.0005073659704066813
damage O 0 0.00017515268700663
. O 0 3.847176230920013e-06

The O 0 4.3439878936624154e-05
breast B-Disease 1 0.9990593791007996
and I-Disease 1 0.9943254590034485
ovarian I-Disease 1 1.0
cancer I-Disease 1 0.9999998807907104
susceptibility O 1 0.9974032044410706
gene O 0 0.0001046684556058608
BRCA1 O 0 9.259172657039016e-05
encodes O 0 2.521325541238184e-06
a O 0 4.509402060648426e-06
zinc O 0 0.0012646850664168596
finger O 0 9.70303426583996e-06
protein O 0 2.1201881850174686e-07
of O 0 7.163762472117696e-09
unknown O 0 2.615240646264283e-07
function O 0 2.3227579504236928e-07
. O 0 4.3487088419169595e-07

Association O 0 1.0655468940967694e-05
of O 0 7.839306448431671e-08
the O 0 7.664957024644536e-08
BRCA1 O 0 2.1061885490780696e-05
protein O 0 1.8577334515157418e-07
with O 0 2.1338800948456083e-08
the O 0 1.7240456173794882e-08
DNA O 0 1.9438855360931484e-06
repair O 0 8.248231097240932e-06
protein O 0 2.780698764581757e-07
Rad51 O 0 3.3122298646048876e-06
and O 0 1.6434148264465875e-08
changes O 0 6.723906764705134e-09
in O 0 1.964858054037677e-09
the O 0 1.3384864328003232e-09
phosphorylation O 0 3.5703198619785326e-08
and O 0 1.4739739206959257e-08
cellular O 0 1.9921372995668207e-07
localization O 0 7.624480247159227e-08
of O 0 1.0820161433500175e-09
the O 0 2.967964984890159e-09
protein O 0 7.206908492207731e-08
after O 0 2.7502088073561026e-07
exposure O 0 5.228088753028715e-07
to O 0 4.6602178116472714e-08
DNA O 0 1.003945271804696e-06
- O 0 2.4074903194559738e-05
damaging O 0 1.8898766711572534e-06
agents O 0 9.481110652131974e-08
are O 0 5.771592093140043e-09
consistent O 0 4.919261442637435e-08
with O 0 6.037949251691543e-09
a O 0 2.637409295402904e-07
role O 0 2.1879910150346404e-07
for O 0 1.7897639281727606e-07
BRCA1 O 0 6.59576035104692e-05
in O 0 1.6027743754420953e-07
DNA O 0 1.0808422302943654e-05
repair O 0 9.199704072671011e-05
. O 0 2.2286283183348132e-06

Here O 0 8.227953912864905e-06
, O 0 2.8487565373325197e-07
it O 0 4.820876853273148e-08
is O 0 2.610259208779553e-08
shown O 0 7.276800317868037e-08
that O 0 1.4087873978496646e-08
mouse O 0 1.7466040844738018e-06
embryonic O 0 1.1866958629980218e-05
stem O 0 9.410741768078879e-06
cells O 0 1.399959819536889e-05
deficient B-Disease 0 0.00021386287698987871
in I-Disease 0 1.1814432099299665e-07
BRCA1 I-Disease 0 5.0383241614326835e-05
are O 0 5.158007354566507e-08
defective O 0 1.314078599534696e-05
in O 0 1.385106163098726e-08
the O 0 6.795592977226761e-09
ability O 0 4.207699433322887e-08
to O 0 1.3758195471780255e-08
carry O 0 6.792523521426119e-08
out O 0 3.780833068844913e-08
transcription O 0 1.9360399505785608e-07
- O 0 1.2873627383669373e-05
coupled O 0 5.866270385013195e-06
repair O 0 7.549169367848663e-06
of O 0 1.6912123257384337e-08
oxidative O 0 0.0022316838148981333
DNA O 0 0.0005922166747041047
damage O 0 0.00021897700207773596
, O 0 1.0197349809004663e-07
and O 0 8.273453744322978e-08
are O 0 6.072588121242006e-08
hypersensitive O 0 0.007794647943228483
to O 0 1.1549878763617016e-05
ionizing O 0 0.20188204944133759
radiation O 0 0.45970937609672546
and O 0 1.66138784152281e-06
hydrogen O 0 3.9885093428893015e-05
peroxide O 0 0.002600053558126092
. O 0 3.2448033380205743e-06

These O 0 3.4196104934380855e-06
results O 0 2.757557012955658e-06
suggest O 0 5.424502091955219e-07
that O 0 1.602566470637612e-07
BRCA1 O 0 1.6733658412704244e-05
participates O 0 2.0075529505447776e-07
, O 0 3.506289303345511e-08
directly O 0 3.039421869743819e-08
or O 0 1.4648707136188932e-08
indirectly O 0 8.462093887828814e-07
, O 0 1.8467826379264807e-08
in O 0 6.412069986083679e-09
transcription O 0 4.0817175772644987e-07
- O 0 6.635321187786758e-05
coupled O 0 4.505662218434736e-05
repair O 0 9.69941720541101e-06
of O 0 4.1950062978912683e-08
oxidative O 0 0.003013469045981765
DNA O 0 0.0003304266429040581
damage O 0 4.787090074387379e-05
. O 0 3.202894163223391e-07
. O 0 1.5062502143337042e-06

Truncation O 0 0.0018486951012164354
mutations O 0 0.0037687208969146013
in O 0 4.194998268758354e-07
the O 0 1.5708283740423212e-07
transactivation O 0 8.780406642472371e-05
region O 0 4.047640516091633e-07
of O 0 2.7570093763529258e-08
PAX6 O 0 0.001162316300906241
result O 0 7.304709015443223e-07
in O 0 3.666732339979717e-08
dominant O 0 3.733729045052314e-06
- O 0 0.0001822369231376797
negative O 0 9.389897968503647e-06
mutants O 0 4.4222280848771334e-05
. O 0 1.7532092897454277e-06

PAX6 O 0 0.21591965854167938
is O 0 5.7970196394308005e-06
a O 0 4.655109933082713e-07
transcription O 0 4.4203051174918073e-07
factor O 0 6.96824784540695e-08
with O 0 1.0206802514289848e-08
two O 0 4.633796280018032e-08
DNA O 0 8.824277983876527e-07
- O 0 1.3368919098866172e-05
binding O 0 4.805852768186014e-06
domains O 0 2.799516209961439e-07
( O 0 1.2148420935886861e-08
paired O 0 3.589171910789446e-07
box O 0 5.583682650467381e-06
and O 0 2.1628713398058608e-07
homeobox O 0 1.729868381517008e-05
) O 0 1.224290802070982e-08
and O 0 1.500919744046314e-08
a O 0 3.0405823281398625e-07
proline O 0 1.0008346180256922e-05
- O 0 5.3935955293127336e-06
serine O 0 2.2413851183955558e-06
- O 0 1.1567130059120245e-05
threonine O 0 6.938983460713644e-06
( O 0 4.676655152024978e-08
PST O 0 2.2898748284205794e-05
) O 0 7.542784175029738e-08
- O 0 6.451134140661452e-06
rich O 0 8.328470357810147e-07
transactivation O 0 3.708167059812695e-05
domain O 0 1.797075469767151e-06
. O 0 1.6943448599704425e-06

PAX6 O 0 0.1622360646724701
regulates O 0 0.00033520531724207103
eye O 0 0.008001291193068027
development O 0 6.587200687135919e-07
in O 0 3.018661516307475e-07
animals O 0 2.9215436825325014e-07
ranging O 0 2.721332066357718e-07
from O 0 4.9892623366076805e-08
jellyfish O 0 1.393489696965844e-06
to O 0 6.404872721077481e-08
Drosophila O 0 2.5555286242706643e-07
to O 0 2.1723928966821404e-07
humans O 0 5.65784660011559e-07
. O 0 8.554251849091088e-07

Heterozygous O 1 0.7453450560569763
mutations O 0 0.006888414733111858
in O 0 5.637928097712575e-07
the O 0 8.599322853797275e-08
human O 0 3.348943096170842e-07
PAX6 O 0 0.004574120044708252
gene O 0 3.3403864563297248e-06
result O 0 1.8851483218895737e-07
in O 0 2.204061821942105e-08
various O 0 2.0774153952629604e-08
phenotypes O 0 0.00011169844947289675
, O 0 1.3904495688166207e-07
including O 0 6.874584528304695e-07
aniridia B-Disease 1 0.999998927116394
, O 0 0.00017181366274598986
Peters B-Disease 1 0.9999722242355347
anomaly I-Disease 1 0.9999940395355225
, O 0 1.2492578207456972e-05
autosomal B-Disease 0 0.22602877020835876
dominant I-Disease 0 0.02917639911174774
keratitis I-Disease 1 0.9961724877357483
, O 0 3.483084583422169e-06
and O 0 8.538948350178543e-06
familial B-Disease 1 0.7950072288513184
foveal I-Disease 1 0.9995038509368896
dysplasia I-Disease 1 0.9999498128890991
. O 0 5.5066528148017824e-05

It O 0 3.5258092339063296e-06
is O 0 2.6763174787447497e-07
believed O 0 7.527147971586601e-08
that O 0 4.964342270596944e-09
the O 0 7.712762872813528e-09
mutated O 0 5.695369054592447e-06
allele O 0 1.8055668533634162e-06
of O 0 1.4778615664567951e-08
PAX6 O 0 0.00025391127564944327
produces O 0 1.1147164968861034e-06
an O 0 6.277590358649832e-08
inactive O 0 6.585542564607749e-07
protein O 0 1.8083122199641366e-07
and O 0 1.1765947505182339e-07
aniridia B-Disease 1 0.9999520778656006
is O 0 3.465173449512804e-06
caused O 0 5.174728357815184e-06
due O 0 6.658857500951854e-07
to O 0 8.56850761010719e-07
genetic O 0 2.512511309760157e-05
haploinsufficiency O 0 0.001116306520998478
. O 0 2.4838179797370685e-06

However O 0 3.057707363041118e-05
, O 0 2.249225730110993e-07
several O 0 2.9955323554986535e-08
truncation O 0 3.0233250072342344e-06
mutations O 0 1.490688828198472e-05
have O 0 2.4196273784582445e-07
been O 0 2.6940895736515813e-07
found O 0 6.067980251600602e-08
to O 0 8.70014105203154e-08
occur O 0 4.433396227909725e-08
in O 0 1.6334459118638733e-08
the O 0 4.637209016777888e-08
C O 0 3.41611939802533e-06
- O 0 2.0125835362705402e-05
terminal O 0 9.460783076065127e-06
half O 0 6.29180689770692e-08
of O 0 1.0741064038199966e-08
PAX6 O 0 0.00040394780808128417
in O 0 3.4290976600459544e-06
patients O 0 0.0010275552049279213
with O 0 9.413212751496758e-07
Aniridia B-Disease 1 0.9999897480010986
resulting O 0 8.758197509450838e-06
in O 0 2.5384473190115386e-08
mutant O 0 4.1804455008787045e-07
proteins O 0 4.4908925467268546e-09
that O 0 3.2667735183622426e-09
retain O 0 1.3833034984145343e-07
the O 0 9.597332706334782e-09
DNA O 0 3.870367777381034e-07
- O 0 3.481809244476608e-06
binding O 0 9.957127531379228e-07
domains O 0 9.033144721115605e-08
but O 0 6.198870750040442e-08
have O 0 3.622921340706853e-08
lost O 0 1.0731259436624896e-07
most O 0 3.5663161312982083e-09
of O 0 2.2765769269739167e-09
the O 0 6.244677308586688e-08
transactivation O 0 6.874195241834968e-05
domain O 0 2.7251546725892695e-06
. O 0 1.102183887269348e-06

It O 0 3.7127585983398603e-06
is O 0 2.2270423016834684e-07
not O 0 3.038337936800417e-08
clear O 0 1.1368938857003741e-07
whether O 0 4.004292719628211e-08
such O 0 7.262487500270254e-09
mutants O 0 6.192009095684625e-06
really O 0 8.080271527433069e-07
behave O 0 5.147756496626243e-07
as O 0 2.2508750419092394e-08
loss O 0 3.748928634195181e-07
- O 0 6.044145379746624e-07
of O 0 9.88937731705164e-09
- O 0 1.2588107892952394e-05
function O 0 1.4362174738380418e-07
mutants O 0 8.713507781976659e-07
as O 0 2.697621148683993e-08
predicted O 0 3.135913004825852e-07
by O 0 1.893299241828572e-07
haploinsufficiency O 0 0.00023578463878948241
. O 0 1.4258961300583906e-06

Contrary O 0 2.385925836279057e-05
to O 0 2.647378209985618e-07
this O 0 2.5564933281430058e-08
theory O 0 6.376496486382166e-08
, O 0 9.441911252849877e-09
our O 0 1.9570371989630075e-09
data O 0 1.396334514680575e-08
showed O 0 3.5477157211971644e-07
that O 0 4.8408685948686525e-09
these O 0 2.1642685421596752e-09
mutants O 0 3.3633460816417937e-07
are O 0 1.0925266913375253e-08
dominant O 0 3.2821770901136915e-07
- O 0 5.36035713594174e-06
negative O 0 7.565938062725763e-07
in O 0 2.6435328592810947e-08
transient O 0 5.223989774094662e-06
transfection O 0 2.081297861877829e-05
assays O 0 3.349356120452285e-06
when O 0 5.260091384684529e-08
they O 0 7.625436282410192e-09
are O 0 4.089909300120098e-09
coexpressed O 0 1.7244539094463107e-06
with O 0 5.001934866299962e-08
wild O 0 7.807029760442674e-07
- O 0 0.0002663965860847384
type O 0 0.00026414392050355673
PAX6 O 0 0.002738673472777009
. O 0 5.509612947207643e-06

We O 0 4.500199793255888e-06
found O 0 1.5549073850706918e-07
that O 0 7.799704881961134e-09
the O 0 8.052069233599468e-09
dominant O 0 3.676835376609233e-06
- O 0 0.0006268372526392341
negative O 0 1.0063705303764436e-05
effects O 0 7.966926204971969e-06
result O 0 1.5897221317118237e-07
from O 0 4.510086526465784e-09
the O 0 7.432019000219725e-09
enhanced O 0 6.901023539285234e-07
DNA O 0 9.17442321224371e-07
binding O 0 2.334797528646959e-07
ability O 0 3.5562784717058094e-08
of O 0 5.5923119468559435e-09
these O 0 4.077013571190946e-08
mutants O 0 1.1640041520877276e-05
. O 0 8.755264957471809e-07

Kinetic O 0 7.832173287170008e-05
studies O 0 2.7928226700169034e-06
of O 0 6.580125244681767e-08
binding O 0 1.1842910225823289e-06
and O 0 6.262509373300418e-07
dissociation O 0 0.00010231487976852804
revealed O 0 2.533205361032742e-06
that O 0 9.730746874936358e-09
various O 0 3.0136284578929917e-09
truncation O 0 7.681361466893577e-07
mutants O 0 7.299873686861247e-06
have O 0 7.657037315311754e-08
3 O 0 4.520716601064123e-08
- O 0 3.6539988741424168e-06
5 O 0 1.515387850758998e-07
- O 0 4.5782048800901975e-06
fold O 0 3.137458406854421e-06
higher O 0 2.8197479906566514e-08
affinity O 0 1.7272679286861603e-08
to O 0 5.773849398593711e-09
various O 0 1.6604788655172342e-09
DNA O 0 8.497289627484861e-08
- O 0 7.057437301227765e-07
binding O 0 2.0662369593082985e-07
sites O 0 1.8559141778951016e-08
when O 0 2.67602580095172e-08
compared O 0 3.366169210039516e-08
with O 0 2.896371142924181e-09
the O 0 1.065652188714239e-08
wild O 0 2.014853208720524e-07
- O 0 0.00019929121481254697
type O 0 7.983423711266369e-05
PAX6 O 0 0.0017126472666859627
. O 0 3.437499117353582e-06

These O 0 5.064526249043411e-06
results O 0 1.9539556888048537e-06
provide O 0 1.2797883641724184e-07
a O 0 1.3784691077489697e-07
new O 0 8.203716106436332e-08
insight O 0 8.682437169227342e-08
into O 0 3.3343958705245313e-09
the O 0 2.0502610720285475e-09
role O 0 1.6595013363485123e-08
of O 0 1.012573136449646e-08
mutant O 0 1.4649339391326066e-05
PAX6 O 0 0.00022768633789382875
in O 0 8.074532047430694e-07
causing O 0 2.2338681446854025e-05
aniridia B-Disease 1 0.9998175501823425
. O 0 1.9827978121611523e-06
. O 0 1.5511054698436055e-06

Reversal O 0 0.001395649160258472
of O 0 1.07762298284797e-05
severe O 1 0.9997755885124207
hypertrophic B-Disease 1 0.9999909400939941
cardiomyopathy I-Disease 1 1.0
and O 0 0.0012182635255157948
excellent O 0 4.980583253200166e-05
neuropsychologic O 0 0.0013507239054888487
outcome O 0 1.6979892052404466e-06
in O 0 8.635087311859024e-08
very B-Disease 0 2.2683045131088875e-07
- I-Disease 0 2.8971966457902454e-05
long I-Disease 0 3.48476260114694e-06
- I-Disease 0 4.67726458737161e-05
chain I-Disease 0 1.3216142178862356e-05
acyl I-Disease 0 1.1432489372964483e-05
- I-Disease 0 1.4215676856110804e-05
coenzyme I-Disease 0 1.1142575203848537e-05
A I-Disease 0 0.000314389995764941
dehydrogenase I-Disease 0 0.4944307804107666
deficiency I-Disease 0 0.08003713935613632
. O 0 1.3530146816265187e-06

Very B-Disease 0 5.5359385441988707e-05
- I-Disease 0 0.00019200878159608692
long I-Disease 0 5.2242389756429475e-06
- I-Disease 0 2.500223126844503e-05
chain I-Disease 0 1.5785000869072974e-05
acyl I-Disease 0 8.402117600780912e-06
- I-Disease 0 9.819160368351731e-06
coenzyme I-Disease 0 3.012538172697532e-06
A I-Disease 0 9.887237865768839e-06
dehydrogenase I-Disease 0 6.878799467813224e-05
( I-Disease 0 3.943927424643334e-07
VLCAD I-Disease 0 0.3607370853424072
) I-Disease 0 3.390074198250659e-05
deficiency I-Disease 0 0.07391573488712311
is O 0 2.330166353203822e-07
a O 0 8.691471884958446e-05
disorder O 0 0.013988365419209003
of O 0 1.658637316381828e-08
fatty O 0 4.8371889533882495e-06
acid O 0 2.8348283649393125e-06
beta O 0 4.8334076296896455e-08
oxidation O 0 7.533913048973773e-08
that O 0 2.3550800420935047e-08
reportedly O 0 4.975662250217283e-06
has O 0 2.534210352678201e-07
high O 0 1.2575053176533402e-07
rates O 0 6.732674506793046e-08
of O 0 2.047659286574799e-08
morbidity O 0 0.4109187722206116
and O 0 1.8676433683140203e-05
mortality O 0 0.0002915267541538924
. O 0 1.5426479649249814e-06

We O 0 1.970347511814907e-06
describe O 0 1.333306499873288e-06
the O 0 3.861526209902877e-08
outcome O 0 8.040485965921107e-08
of O 0 3.6447382889548408e-09
a O 0 2.2338703331570287e-07
5 O 0 6.714348899095057e-08
- O 0 1.6466425222461112e-05
year O 0 7.077914006003994e-07
- O 0 2.2105487005319446e-05
old O 0 7.321705197682604e-05
girl O 0 0.0004171741602476686
with O 0 2.509183104848489e-05
VLCAD B-Disease 1 1.0
deficiency I-Disease 1 0.9999992847442627
who O 0 1.069353629645775e-06
was O 0 1.6297464355830016e-07
first O 0 2.2179364123076084e-08
seen O 0 2.1790243920349894e-07
at O 0 9.403898104665132e-09
5 O 0 3.5347870408486415e-08
months O 0 1.0469801736689988e-07
of O 0 7.53303286415985e-09
age O 0 2.9141250479369774e-07
with O 0 4.088327386853052e-06
severe O 1 0.9998699426651001
hypertrophic B-Disease 1 0.9999971389770508
cardiomyopathy I-Disease 1 1.0
, O 1 0.980832040309906
hepatomegaly B-Disease 1 0.9999996423721313
, O 0 0.0335998609662056
encephalopathy B-Disease 0 0.001282964483834803
, O 0 5.709273409593152e-07
and O 0 1.4424001619772753e-06
hypotonia B-Disease 1 0.8952115774154663
. O 0 1.0764221769932192e-05

Biochemical O 0 0.12855002284049988
studies O 0 0.0021349156741052866
indicated O 1 0.9993138313293457
VLCAD B-Disease 1 1.0
deficiency I-Disease 1 0.9999998807907104
caused O 0 0.0048399125225842
by O 0 3.3371404128956783e-07
a O 0 8.634792720840778e-06
stable O 0 5.172466626390815e-05
yet O 0 2.159395535272779e-06
inactive O 0 4.978149263479281e-06
enzyme O 0 1.675362227615551e-06
. O 0 3.8521696410498407e-07

Molecular O 0 0.0005160553264431655
genetic O 0 5.115618114359677e-05
analysis O 0 4.4187751768731687e-07
of O 0 3.830050943065544e-08
her O 0 6.710861271130852e-06
VLCAD O 0 0.010803124867379665
gene O 0 2.5415683921892196e-06
revealed O 0 1.1067510286011384e-06
a O 0 4.756294913477177e-07
T1372C O 0 2.9760167308268137e-05
( O 0 6.599796620321285e-08
F458L O 0 3.6521976198855555e-06
) O 0 8.090775338587264e-08
missense O 0 1.5187188182608224e-05
mutation O 0 2.5462677513132803e-06
and O 0 9.858419502961624e-08
a O 0 1.972086465684697e-05
1668 O 1 0.7430998086929321
ACAG O 0 0.25973108410835266
1669 O 0 0.0005454078200273216
splice O 0 0.00015036480908747762
site O 0 2.1746578568127006e-05
mutation O 0 3.129476317553781e-05
. O 0 2.5560725589457434e-06

After O 0 5.202415195526555e-05
initial O 0 2.1822279450134374e-05
treatment O 0 3.6582314351107925e-05
with O 0 7.943505124785588e-07
intravenous O 0 0.00176085508428514
glucose O 0 0.0017740793991833925
and O 0 8.985321073851082e-07
carnitine O 0 3.6246034142095596e-05
, O 0 4.554756571906182e-08
the O 0 1.1189493775987103e-08
patient O 0 2.3549380784970708e-05
has O 0 1.6523243857591297e-06
thrived O 0 7.047012786642881e-07
on O 0 5.2605123812554666e-08
a O 0 2.4428226197414915e-07
low O 0 2.6155601062782807e-06
- O 0 4.8203532060142606e-05
fat O 0 0.0002489575126674026
diet O 0 1.614765778867877e-06
supplemented O 0 1.8476551133517205e-07
with O 0 7.874954910391807e-09
medium O 0 1.8045943761535455e-07
- O 0 2.4665932869538665e-06
chain O 0 2.4002101781661622e-06
triglyceride O 0 1.033706894304487e-06
oil O 0 9.565008696199584e-08
and O 0 2.0038759984686294e-08
carnitine O 0 6.756918537575984e-06
and O 0 8.324199995968229e-08
avoidance O 0 2.1376517906901427e-06
of O 0 1.8235571985769639e-07
fasting O 0 4.2418538214406e-05
. O 0 5.0236285460414365e-06

Her O 0 0.0005477029480971396
ventricular O 1 0.8579647541046143
hypertrophy O 1 0.8172245621681213
resolved O 0 0.00034014254924841225
significantly O 0 1.1889048437296879e-05
over O 0 1.267846840846687e-07
1 O 0 1.2955634076661227e-07
year O 0 1.9101112513908447e-07
, O 0 7.263017209879763e-08
and O 0 3.184528054589464e-07
cognitively O 0 0.0007658923277631402
, O 0 1.8744673013770807e-07
she O 0 3.3975896940319217e-07
is O 0 6.485587178417518e-09
in O 0 3.3548610556266567e-09
the O 0 1.3599048109824707e-08
superior O 0 7.200573577392788e-07
range O 0 1.1009804268269363e-07
for O 0 1.1937393651351158e-07
age O 0 1.9928377241740236e-06
. O 0 7.112287789823313e-07

Clinical O 0 0.007304309401661158
recognition O 0 4.70919294457417e-05
of O 0 3.223181192879565e-05
VLCAD B-Disease 1 1.0
deficiency I-Disease 1 1.0
is O 0 1.026063614517625e-06
important O 0 3.228334222171725e-08
because O 0 4.916607210248003e-08
it O 0 1.1001739075311434e-08
is O 0 7.3125550059671696e-09
one O 0 3.909860435413748e-09
of O 0 1.2531609083765716e-09
the O 0 1.4197364173185179e-08
few O 0 3.229230571832886e-07
directly O 0 8.844744115776848e-06
treatable O 1 0.8313713073730469
causes O 0 8.173357855412178e-06
of O 0 8.495343877257255e-07
cardiomyopathy B-Disease 1 0.9999998807907104
in O 0 0.0007203981513157487
children O 0 2.931234848801978e-05
. O 0 3.3771601692933473e-07
. O 0 9.676443823991576e-07

Cloning O 0 4.702336445916444e-05
of O 0 3.3319886938443233e-07
a O 0 7.952222063067893e-07
novel O 0 4.2706773228928796e-07
member O 0 1.6076096898132164e-08
of O 0 1.1059232418730858e-09
the O 0 2.0877074291547615e-08
low O 0 8.171205990947783e-06
- O 0 0.009415092878043652
density O 0 0.00041007224353961647
lipoprotein O 0 0.0018686630064621568
receptor O 0 3.268443470005877e-05
family O 0 3.1433764888788573e-06
. O 0 7.212401555989345e-07

A O 0 1.8652974176802672e-05
gene O 0 8.960385457612574e-06
encoding O 0 2.718849373195553e-06
a O 0 2.67100381279306e-06
novel O 0 6.848933480796404e-06
transmembrane O 0 8.944377441366669e-06
protein O 0 3.057283777252451e-07
was O 0 7.418616405630019e-07
identified O 0 1.1741511229956814e-07
by O 0 5.012342541022008e-09
DNA O 0 7.600348794767342e-08
sequence O 0 2.5285702420774214e-08
analysis O 0 1.0416574269811463e-08
within O 0 3.977131957100255e-09
the O 0 2.7450823836261407e-08
insulin B-Disease 1 0.8503967523574829
- I-Disease 1 0.9987910389900208
dependent I-Disease 1 0.9991564750671387
diabetes I-Disease 1 1.0
mellitus I-Disease 1 0.9999998807907104
( O 0 1.9646663531602826e-06
IDDM B-Disease 0 0.003932389430701733
) O 0 2.962351288715581e-07
locus O 0 4.406177595228655e-06
IDDM4 O 0 7.685144373681396e-05
on O 0 1.5031909015306155e-06
chromosome O 0 0.00012162176426500082
11q13 O 0 9.584012877894565e-05
. O 0 2.524330511732842e-06

Based O 0 2.5562076189089566e-05
on O 0 1.0269417316521867e-06
its O 0 2.1791450421915215e-07
chromosomal O 0 0.00012245708785485476
position O 0 1.2832441825594287e-05
, O 0 5.845490491651617e-08
this O 0 1.1322536686009244e-08
gene O 0 8.508756366154557e-08
is O 0 1.4289215144458467e-08
a O 0 6.567110943933585e-08
candidate O 0 4.611585779912275e-07
for O 0 4.3451763076518546e-08
conferring O 0 4.844782597501762e-05
susceptibility O 1 0.9537387490272522
to O 0 0.002871229313313961
diabetes B-Disease 1 0.9990536570549011
. O 0 8.754106602282263e-06

The O 0 1.4217628176993458e-06
gene O 0 2.4379962724196957e-06
, O 0 1.2178563224551908e-07
termed O 0 1.0951930562441703e-06
low O 0 4.662414994527353e-06
- O 0 5.8440768043510616e-05
density O 0 7.378669124591397e-06
lipoprotein O 0 5.391223021433689e-05
receptor O 0 2.590072426755796e-06
related O 0 9.883045493097598e-08
protein O 0 3.190787367657322e-07
5 O 0 1.2985221076178277e-07
( O 0 3.6485655385831706e-08
LRP5 O 0 0.00010901514178840443
) O 0 3.4486653532894707e-08
, O 0 1.3209164428928943e-08
encodes O 0 5.788164614273228e-08
a O 0 5.883162401687514e-08
protein O 0 3.254423930343364e-08
of O 0 3.139863924417341e-09
1615 O 0 4.270545105100609e-06
amino O 0 8.57285868960389e-08
acids O 0 3.298329787071452e-08
that O 0 5.386450840916268e-09
contains O 0 1.3843296287063822e-08
conserved O 0 6.31090486535868e-08
modules O 0 1.9780429738602834e-07
which O 0 1.8509437538227758e-08
are O 0 1.9676520413014487e-09
characteristic O 0 2.7120147905179692e-08
of O 0 1.4753316346372003e-09
the O 0 2.7789456069626794e-08
low O 0 1.3175116691854782e-05
- O 0 0.014808987267315388
density O 0 0.0010851940605789423
lipoprotein O 0 0.01255638524889946
( O 0 5.938324534326966e-07
LDL O 0 0.00018393008213024586
) O 0 4.722784012756165e-07
receptor O 0 1.0550891602179036e-05
family O 0 2.411204377494869e-06
. O 0 8.736339509596291e-07

These O 0 2.7405735636421014e-06
modules O 0 3.928794285457116e-06
include O 0 1.5819094301150471e-07
a O 0 2.477900409303402e-07
putative O 0 5.461296495923307e-06
signal O 0 1.6526048511877889e-06
peptide O 0 6.781313288684032e-08
for O 0 2.0573516223976185e-09
protein O 0 9.22456155905138e-09
export O 0 1.2782241043396425e-08
, O 0 8.653120886492616e-09
four O 0 2.8979309618648585e-08
epidermal O 0 1.62726757935161e-06
growth O 0 2.5384892410329485e-07
factor O 0 1.8432569959259126e-07
( O 0 3.351364341597218e-08
EGF O 0 3.4668328225961886e-06
) O 0 8.187521416402888e-08
repeats O 0 4.793836865246703e-07
with O 0 3.306587714746456e-08
associated O 0 5.503598288214562e-08
spacer O 0 1.1730357982742134e-06
domains O 0 9.1246803890499e-08
, O 0 9.16129838657298e-09
three O 0 2.0799806321747383e-08
LDL O 0 6.621547981922049e-06
- O 0 4.4518903450807557e-05
receptor O 0 9.375635272590443e-06
( O 0 6.125810614321381e-08
LDLR O 0 3.672468301374465e-05
) O 0 1.9511196214239135e-08
repeats O 0 1.4741094389592035e-07
, O 0 6.653028794545435e-09
a O 0 5.283690995838697e-08
single O 0 3.5578463553065376e-07
transmembrane O 0 8.492824008499156e-07
spanning O 0 9.88983401839505e-08
domain O 0 5.911000755531859e-08
, O 0 1.548549199981153e-08
and O 0 9.791870425601701e-09
a O 0 2.1039215880591655e-07
cytoplasmic O 0 5.936710294918157e-06
domain O 0 1.700345364952227e-06
. O 0 5.219187073635112e-07

The O 0 2.232069846286322e-06
encoded O 0 2.024394007094088e-06
protein O 0 8.56914482483262e-07
has O 0 7.573360250034966e-08
a O 0 6.222633430752467e-08
unique O 0 3.450027108442555e-08
organization O 0 4.794428409837792e-09
of O 0 4.032619127514181e-09
EGF O 0 9.442196642339695e-06
and O 0 1.4374799093275215e-06
LDLR O 0 0.007107947953045368
repeats O 0 4.392030859889928e-06
; O 0 4.073717718711123e-08
therefore O 0 3.5122262431741547e-08
, O 0 1.3694862133206698e-08
LRP5 O 0 6.329229654511437e-05
likely O 0 1.3569714383265818e-06
represents O 0 2.9557694958270986e-08
a O 0 4.458752300706692e-08
new O 0 3.822424332611263e-08
category O 0 2.2386299036725177e-08
of O 0 3.0403188855387953e-09
the O 0 8.401482176623176e-08
LDLR O 0 0.06391226500272751
family O 0 3.84723125534947e-06
. O 0 7.327650450861256e-07

Both O 0 4.815657121071126e-06
human O 0 5.242542897576641e-07
and O 0 1.5697172273121396e-07
mouse O 0 1.143472491094144e-05
LRP5 O 0 0.0005299472250044346
cDNAs O 0 2.0843626771238633e-05
have O 0 2.6169621492044826e-07
been O 0 3.113943307653244e-07
isolated O 0 3.719622725384397e-07
and O 0 1.2776269819880781e-08
the O 0 2.9929549949514467e-09
encoded O 0 6.97773145930114e-08
mature O 0 3.2878531897040375e-08
proteins O 0 5.10246467300135e-09
are O 0 6.257611318005729e-09
95 O 0 1.1100155461463146e-07
% O 0 5.6799908776383745e-08
identical O 0 6.079948207116104e-07
, O 0 2.6793353313792068e-08
indicating O 0 3.822592873348185e-07
a O 0 3.4422748740325915e-07
high O 0 2.8943964025529567e-07
degree O 0 6.130029817086324e-08
of O 0 4.270618081392286e-09
evolutionary O 0 2.779211456527264e-07
conservation O 0 1.9303355713873316e-07
. O 0 9.654583266183181e-08
. O 0 6.159148142614868e-07

The O 0 4.436578819877468e-06
APC B-Disease 0 4.295129110687412e-05
variants O 0 7.258347068272997e-06
I1307K O 0 1.1626951163634658e-05
and O 0 1.9776223325607134e-07
E1317Q O 0 8.25827464723261e-06
are O 0 1.2844603247685882e-07
associated O 0 6.223450782272266e-06
with O 1 0.9898275136947632
colorectal B-Disease 1 1.0
tumors I-Disease 1 1.0
, O 0 0.00013842609769199044
but O 0 6.728771495545516e-07
not O 0 3.333011378003903e-08
always O 0 5.269500036320096e-08
with O 0 1.3626310746417403e-08
a O 0 8.086754519354145e-07
family O 0 1.0952107913908549e-06
history O 0 2.9808364843120216e-07
. O 0 1.4319548427010886e-06

Classical O 0 0.3185269832611084
familial B-Disease 1 0.9999949932098389
adenomatous I-Disease 1 0.9999910593032837
polyposis I-Disease 1 0.9999996423721313
( O 0 0.0906105563044548
FAP B-Disease 1 0.9459565281867981
) O 0 2.9368984542088583e-06
is O 0 1.463966441406228e-07
a O 0 1.2864516065747011e-06
high O 0 3.1488008971791714e-05
- O 1 0.9843429327011108
penetrance O 1 0.9976663589477539
autosomal B-Disease 1 0.9988765120506287
dominant I-Disease 1 0.8089074492454529
disease I-Disease 0 0.0010940623469650745
that O 0 1.5081144510986633e-07
predisposes O 0 3.88640801247675e-05
to O 0 7.580629102221792e-08
hundreds O 0 9.471368400681968e-08
or O 0 4.0763371345065025e-08
thousands O 0 1.8272808688379882e-07
of O 0 4.1848557884804904e-05
colorectal B-Disease 1 1.0
adenomas I-Disease 1 1.0
and I-Disease 1 0.9996602535247803
carcinoma I-Disease 1 1.0
and O 0 3.820141500909813e-05
that O 0 1.1433844520070124e-06
results O 0 4.976598120265407e-07
from O 0 3.063120246338258e-08
truncating O 0 5.302244062477257e-06
mutations O 0 3.705581093527144e-06
in O 0 2.7857810280806916e-08
the O 0 6.692255283269333e-08
APC B-Disease 0 3.698342334246263e-05
gene O 0 6.2187873481889255e-06
. O 0 1.5398288724099984e-06

A O 0 8.649931260151789e-05
variant O 0 0.00024854482035152614
of O 0 5.452462801258662e-07
FAP B-Disease 0 0.12147672474384308
is O 0 0.020562075078487396
attenuated B-Disease 1 0.9997863173484802
adenomatous I-Disease 1 0.999997615814209
polyposis I-Disease 1 0.9999531507492065
coli I-Disease 1 0.999842643737793
, O 0 3.345755430927966e-06
which O 0 1.392063154526113e-06
results O 0 2.8764441140083363e-07
from O 0 1.760008672135882e-08
germ O 0 2.367069328101934e-06
- O 0 4.298997373552993e-05
line O 0 1.010155028779991e-05
mutations O 0 3.3366058005412924e-07
in O 0 5.263179225778458e-09
the O 0 9.209477624949614e-09
5 O 0 1.151651929376385e-07
and O 0 7.862831807869952e-08
3 O 0 9.57597947603972e-08
regions O 0 1.1711625447219376e-08
of O 0 4.277873610902816e-09
the O 0 8.240130000558565e-08
APC B-Disease 0 5.0694339734036475e-05
gene O 0 6.218822818482295e-06
. O 0 1.068155029315676e-06

Attenuated B-Disease 1 0.9994975328445435
adenomatous I-Disease 1 0.999985933303833
polyposis I-Disease 1 0.9999936819076538
coli I-Disease 1 0.9999982118606567
patients O 1 0.9999666213989258
have O 0 9.39507572184084e-06
" O 0 2.7835451419377932e-06
multiple O 0 2.549862620071508e-05
" O 0 0.48609182238578796
colorectal B-Disease 1 1.0
adenomas I-Disease 1 0.9999979734420776
( O 0 4.198304281999299e-07
typically O 0 5.04084368913027e-07
fewer O 0 8.662009065574239e-08
than O 0 2.4485503402615905e-08
100 O 0 1.386726555807627e-08
) O 0 1.1311096059785086e-08
without O 0 1.8907003962453928e-08
the O 0 3.5351781946246774e-08
florid O 0 0.13302069902420044
phenotype O 0 0.013309378176927567
of O 0 9.247818866242596e-08
classical O 0 9.383506039739586e-06
FAP B-Disease 0 0.009633069857954979
. O 0 1.088836415874539e-05

Another O 0 1.91645412996877e-05
group O 0 1.5695480897193193e-06
of O 0 5.760322707715204e-08
patients O 0 5.245001375442371e-05
with O 0 6.374860390678805e-07
multiple O 0 0.00046675174962729216
adenomas B-Disease 0 0.03657142072916031
has O 0 1.523280570836505e-05
no O 0 4.6268542064353824e-07
mutations O 0 2.686564357645693e-07
in O 0 7.088071463101642e-09
the O 0 2.1002124483970874e-08
APC B-Disease 0 6.621447028010152e-06
gene O 0 3.446509140303533e-07
, O 0 1.8228664799835315e-08
and O 0 3.515503621542848e-08
their O 0 1.61600610226742e-07
phenotype O 0 0.11614382266998291
probably O 0 7.4434378802834544e-06
results O 0 8.673317353213861e-08
from O 0 4.859546987034946e-09
variation O 0 2.765568751783576e-07
at O 0 1.680975891815706e-08
a O 0 3.605020424402028e-07
locus O 0 4.3196855585847516e-06
, O 0 3.632712619605627e-08
or O 0 1.2146011307834215e-08
loci O 0 1.2171213370493206e-07
, O 0 3.866773923277833e-08
elsewhere O 0 3.490601585554032e-08
in O 0 6.996692558658424e-09
the O 0 3.67563899317247e-08
genome O 0 1.36082815060945e-06
. O 0 1.2265905979802483e-06

Recently O 0 0.00012199740012874827
, O 0 6.162514978313993e-07
however O 0 1.3327161241249996e-07
, O 0 1.8108000432448534e-08
a O 0 4.924067980027758e-07
missense O 0 0.00018756317149382085
variant O 0 3.4733584470814094e-05
of O 0 7.760813502954989e-08
APC B-Disease 0 7.082820957293734e-05
( O 0 1.01998004709003e-07
I1307K O 0 6.07621950621251e-06
) O 0 5.186083029684596e-08
was O 0 1.803808004297025e-06
described O 0 8.655574106342101e-07
that O 0 3.5797093289602344e-08
confers O 0 2.5834883672359865e-06
an O 0 1.3296173051458027e-07
increased O 0 2.4393077637796523e-06
risk O 0 3.1803565434529446e-06
of O 0 0.00022223169798962772
colorectal B-Disease 1 1.0
tumors I-Disease 1 1.0
, O 0 9.868285815173294e-06
including O 0 2.355950101673443e-07
multiple O 0 5.652637810271699e-06
adenomas B-Disease 0 0.00033923640148714185
, O 0 5.862791567778913e-07
in O 0 5.002069087822747e-07
Ashkenazim O 0 6.914372352184728e-05
. O 0 3.6459889543039026e-06

We O 0 4.066233941557584e-06
have O 0 1.612669962014479e-07
studied O 0 9.160078917602732e-08
a O 0 3.7434336519481803e-08
set O 0 3.344244348113534e-08
of O 0 1.737063826112717e-08
164 O 0 7.166379509726539e-05
patients O 0 0.004753141663968563
with O 0 3.736159487743862e-05
multiple O 1 0.9995855689048767
colorectal B-Disease 1 1.0
adenomas I-Disease 1 0.9999994039535522
and I-Disease 0 0.13987021148204803
/ I-Disease 0 0.21794819831848145
or I-Disease 0 0.002239138586446643
carcinoma I-Disease 1 1.0
and O 0 3.974927312810905e-05
analyzed O 0 9.862339538813103e-06
codons O 0 2.5631975404394325e-06
1263 O 0 3.701337845996022e-05
- O 0 5.773340672021732e-05
1377 O 0 0.0001426891831215471
( O 0 1.995813079247455e-07
exon O 0 2.1733014818892116e-06
15G O 0 6.941068022570107e-06
) O 0 7.577778404765922e-09
of O 0 2.119717512627517e-09
the O 0 1.2254169234893197e-08
APC B-Disease 0 1.6651758869556943e-06
gene O 0 2.0107432874283404e-07
for O 0 3.098807610513177e-08
germ O 0 6.048566774552455e-06
- O 0 4.294859172659926e-05
line O 0 1.1254755008849315e-05
variants O 0 2.9419443308142945e-06
. O 0 8.606737651462026e-07

Three O 0 0.000234594801440835
patients O 0 0.0004967930726706982
with O 0 4.414916432438076e-08
the O 0 3.603665987839122e-08
I1307K O 0 2.005674468819052e-05
allele O 0 3.4641093407117296e-06
were O 0 1.295315001925701e-07
detected O 0 4.767930192883796e-07
, O 0 1.061019805348451e-08
each O 0 5.775171008082225e-09
of O 0 1.1783977349466568e-08
Ashkenazi O 0 3.663269308162853e-05
descent O 0 5.053785571362823e-05
. O 0 1.4762071032237145e-06

Four O 0 0.0004608213494066149
patients O 0 0.0015315141063183546
had O 0 5.002784178032016e-07
a O 0 3.079537975736457e-07
germ O 0 1.423055709892651e-05
- O 0 0.00011983580770902336
line O 0 1.9256453015259467e-05
E1317Q O 0 1.4130268027656712e-05
missense O 0 8.628947398392484e-06
variant O 0 1.1795826821980882e-06
of O 0 6.799248719602247e-09
APC O 0 2.8038068649038905e-06
that O 0 1.4207338949745463e-07
was O 0 3.919363280147081e-06
not O 0 4.1507771442184094e-08
present O 0 1.2715540620433785e-08
in O 0 2.425689338281245e-08
controls O 0 0.0010076487669721246
; O 0 8.155072350746195e-08
one O 0 4.305574563545633e-09
of O 0 5.346039166909122e-10
these O 0 3.455260744189559e-09
individuals O 0 3.273054050012547e-09
had O 0 1.9226908420932887e-07
an O 0 1.0809939254841083e-07
unusually O 0 7.512238516937941e-05
large O 0 6.281938169649948e-08
number O 0 1.6754318821199377e-08
of O 0 7.77095632287228e-09
metaplastic B-Disease 0 0.00019436654110904783
polyps I-Disease 0 1.0842957635759376e-05
of I-Disease 0 1.3161531420280426e-08
the I-Disease 0 1.0380699677625671e-07
colorectum I-Disease 0 0.00032649023341946304
. O 0 4.257329237589147e-06

There O 0 1.4152587937132921e-05
is O 0 3.262917971369461e-07
increasing O 0 7.260052825586172e-08
evidence O 0 1.5804361908067222e-07
that O 0 4.798858910248782e-08
there O 0 4.728065761128164e-08
exist O 0 2.22705445196425e-08
germ O 0 1.293203467866988e-06
- O 0 1.3273815966385882e-05
line O 0 1.3201429283071775e-06
variants O 0 5.8289682414169874e-08
of O 0 1.51665735526052e-09
the O 0 6.304261113143639e-09
APC B-Disease 0 2.1642301817337284e-06
gene O 0 1.856670763800139e-07
that O 0 2.322591363679294e-08
predispose O 0 4.982667292097176e-07
to O 0 2.6126798502446036e-08
the O 0 9.755760643770373e-09
development O 0 2.159494805198392e-08
of O 0 1.4835414674507774e-07
multiple O 1 0.9979156851768494
colorectal B-Disease 1 1.0
adenomas I-Disease 1 1.0
and I-Disease 1 0.9998953342437744
carcinoma I-Disease 1 1.0
, O 0 7.365122201008489e-06
but O 0 2.9069610718579497e-07
without O 0 6.349674208649958e-08
the O 0 1.1985430603544955e-07
florid O 0 0.1933353692293167
phenotype O 0 0.03261752426624298
of O 0 1.9896550185194428e-08
classical O 0 1.9132046418235404e-06
FAP B-Disease 0 0.008320283144712448
, O 0 6.188416250552109e-07
and O 0 4.1291496444273434e-08
possibly O 0 2.8419611552976676e-08
with O 0 9.492706176672527e-09
importance O 0 4.327906424350658e-07
for O 1 0.9767370820045471
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
risk O 0 2.0808451154152863e-05
in O 0 1.7339157665219318e-08
the O 0 1.2730756004941668e-08
general O 0 1.9211162793908443e-07
population O 0 1.5901694894182583e-07
. O 0 1.118273544875592e-07
. O 0 5.407070489127364e-07

Genomic O 0 0.00010571386519586667
structure O 0 1.0590186320769135e-05
of O 0 1.3457010084039212e-07
the O 0 1.6386514971600263e-06
human O 0 0.006104443687945604
congenital B-Disease 1 0.9999998807907104
chloride I-Disease 1 0.9999998807907104
diarrhea I-Disease 1 1.0
( O 0 0.0011658152798190713
CLD B-Disease 1 0.7537870407104492
) O 0 9.570909469402977e-07
gene O 0 2.266024239361286e-06
. O 0 6.831286896158417e-07

Congenital B-Disease 1 0.9999997615814209
chloride I-Disease 1 0.9999995231628418
diarrhea I-Disease 1 1.0
( O 0 0.13799618184566498
CLD B-Disease 1 0.9993176460266113
) O 0 2.605619101814227e-06
is O 0 1.5224424032567185e-06
caused O 0 2.2037560484022833e-05
by O 0 6.290438818723487e-07
mutations O 0 6.143020073068328e-06
in O 0 2.1243206305143758e-08
a O 0 5.352656557988666e-07
gene O 0 2.3473269550322584e-07
which O 0 4.150262711277719e-08
encodes O 0 6.587496272913995e-07
an O 0 1.247264208359411e-06
intestinal O 1 0.9841471910476685
anion O 0 0.0017156938556581736
transporter O 0 0.0006158415344543755
. O 0 2.072537654385087e-06

We O 0 7.709213605266996e-06
report O 0 1.0041243285741075e-06
here O 0 3.98314696781199e-08
the O 0 1.7021603682110253e-08
complete O 0 1.0885354839729189e-07
genomic O 0 1.8035224513823778e-07
organization O 0 4.845580381385162e-09
of O 0 1.2433257756683247e-09
the O 0 1.821250350531045e-08
human O 0 1.1618028850080009e-07
CLD B-Disease 0 0.0004890996497124434
gene O 0 7.152050329750637e-07
which O 0 1.3900266537802963e-07
spans O 0 5.535728746508539e-07
approximately O 0 6.163525512192791e-08
39kb O 0 5.9104982028657105e-06
, O 0 6.267588048558537e-08
and O 0 4.069935144457304e-08
comprises O 0 8.448419919204753e-08
21 O 0 6.133890337878256e-07
exons O 0 6.397732704499504e-06
. O 0 1.65329538504011e-06

All O 0 1.4758509223611327e-06
exon O 0 1.8118429579772055e-05
/ O 0 4.1695425352372695e-06
intron O 0 1.8745327906799503e-05
boundaries O 0 2.2593901860545884e-07
conform O 0 4.281696419639047e-07
to O 0 4.833803757264832e-08
the O 0 7.750207231538297e-08
GT O 0 0.00017434920300729573
/ O 0 0.0005027664010412991
AG O 1 0.9237509965896606
rule O 0 1.1725453077815473e-05
. O 0 1.8226684233013657e-06

An O 0 2.3283100745175034e-06
analysis O 0 2.046289608870211e-07
of O 0 7.96667354308056e-09
the O 0 2.604649296245043e-08
putative O 0 3.488496531645069e-06
promoter O 0 7.014452421572059e-06
region O 0 3.8976438077042985e-08
sequence O 0 2.3365075207948394e-08
shows O 0 4.756195082222803e-08
a O 0 1.7902264914937405e-07
putative O 0 1.4920969078957569e-05
TATA O 0 7.525732507929206e-05
box O 0 1.5910097772575682e-06
and O 0 1.2071140531588753e-07
predicts O 0 1.930885673573357e-06
multiple O 0 5.0092577197347055e-08
transcription O 0 1.5383464813112369e-07
factor O 0 8.506403759156456e-08
binding O 0 1.7518928530080302e-07
sites O 0 2.441257436203159e-07
. O 0 5.891067189622845e-07

The O 0 1.5858593087614281e-06
genomic O 0 4.419396191224223e-06
structure O 0 1.5879780903560459e-06
was O 0 1.6563221834076103e-06
determined O 0 2.375789449615695e-07
using O 0 1.0938948946659366e-07
DNA O 0 2.4711508217478695e-07
from O 0 5.268462555108044e-09
several O 0 6.655465512039882e-09
sources O 0 1.668301763402269e-08
including O 0 7.952706049252356e-09
multiple O 0 9.151591484624078e-08
large O 0 6.73212241508736e-08
- O 0 2.65086109720869e-05
insert O 0 0.00010703197767725214
libaries O 0 3.31795345118735e-05
and O 0 2.1450448528526067e-08
genomic O 0 2.1927850468728138e-07
DNA O 0 5.405595970842114e-07
from O 0 6.463078250362742e-08
Finnish O 1 0.7915152907371521
CLD B-Disease 1 0.9994687438011169
patients O 0 0.4634491801261902
and O 0 3.952994802602916e-07
controls O 0 0.00010072159057017416
. O 0 2.7289415811537765e-06

Exon O 0 0.0004203970020171255
- O 0 7.14482375769876e-05
specific O 0 7.459402127096837e-07
primers O 0 2.7721072910935618e-05
developed O 0 1.938829200298642e-06
in O 0 2.096342122115402e-08
this O 0 1.2443298835762562e-08
study O 0 1.9583113797239093e-08
will O 0 1.867654120246698e-08
facilitate O 0 9.284509161489041e-08
mutation O 0 1.5121772776183207e-06
screening O 0 3.403089579023799e-07
studies O 0 3.1161086155861994e-08
of O 0 1.588362330551263e-08
patients O 0 6.632937584072351e-05
with O 0 2.5539060288792825e-07
the O 0 1.992924626392778e-05
disease O 0 0.0010535215260460973
. O 0 1.0523573337195558e-06

Genomic O 0 3.179848863510415e-05
sequencing O 0 5.7060024118982255e-06
of O 0 1.7506285132640187e-07
a O 0 3.875881247950019e-06
BAC O 0 0.0011426808778196573
clone O 0 0.0006948336958885193
H O 1 0.9998138546943665
_ O 0 6.836298211965186e-07
RG364P16 O 0 3.3070377867261413e-06
revealed O 0 3.6123958579992177e-07
the O 0 5.125317947829444e-09
presence O 0 9.367468578602711e-09
of O 0 2.7538440416918775e-09
another O 0 1.376295131194638e-07
, O 0 3.68323220811817e-08
highly O 0 3.418448102365801e-08
homologous O 0 5.4813884986515404e-08
gene O 0 6.973886002015206e-08
3 O 0 7.853370398436255e-09
of O 0 8.91006990411114e-10
the O 0 5.383331469488439e-08
CLD B-Disease 0 0.0152959655970335
gene O 0 1.2253746035639779e-06
, O 0 1.417298634009967e-08
with O 0 1.4469320852583678e-08
a O 0 3.76256082290638e-07
similar O 0 1.4209209098225983e-07
genomic O 0 2.9389897804321663e-07
structure O 0 3.6562292393682583e-07
, O 0 1.9191967126630516e-08
recently O 0 6.554384412993386e-07
identified O 0 1.5846590883938916e-07
as O 0 4.9355019626773355e-08
the O 0 2.419521115371026e-05
Pendred B-Disease 1 1.0
syndrome I-Disease 1 1.0
gene O 0 6.128460518084466e-05
( O 0 1.755959004867691e-07
PDS B-Disease 0 0.0005813370808027685
) O 0 2.424154388336319e-07
. O 0 2.3425792505804566e-07
. O 0 9.105475555770681e-07

The O 0 7.721545443928335e-06
APCI1307K O 0 0.002138362033292651
allele O 0 0.0035151694901287556
and O 0 8.986664761323482e-05
cancer B-Disease 0 0.16460715234279633
risk O 0 7.426035040225543e-07
in O 0 2.7042204919780488e-08
a O 0 1.1193163800271577e-06
community O 0 1.205141444415858e-07
- O 0 1.2785974831786007e-05
based O 0 6.831879773017135e-07
study O 0 6.834044086190261e-08
of O 0 3.309307317067578e-08
Ashkenazi O 0 2.7262278308626264e-05
Jews O 0 3.077848532484495e-06
. O 0 1.604276121724979e-06

Mutations O 0 0.41653916239738464
in O 0 9.593595677870326e-06
APC O 0 0.0007028235122561455
are O 0 3.885174464812735e-06
classically O 1 0.9489495754241943
associated O 0 8.199724834412336e-05
with O 0 0.005710513796657324
familial B-Disease 1 0.9999997615814209
adenomatous I-Disease 1 0.9999988079071045
polyposis I-Disease 1 0.9999998807907104
( O 0 0.00011575916869333014
FAP B-Disease 0 0.20709429681301117
) O 0 5.638250399897515e-07
, O 0 1.5358719451796787e-07
a O 0 2.190856775996508e-06
highly O 0 0.000911282142624259
penetrant O 1 0.999868631362915
autosomal B-Disease 1 0.9999998807907104
dominant I-Disease 1 0.9999967813491821
disorder I-Disease 1 1.0
characterized O 0 0.054852310568094254
by O 0 1.1630410881480202e-05
multiple O 0 0.03848448395729065
intestinal O 1 0.9999644756317139
polyps B-Disease 1 0.5927135944366455
and O 0 1.4596434994018637e-06
, O 0 8.930086181635488e-08
without O 0 1.1535887267655198e-07
surgical O 0 8.438099030172452e-05
intervention O 0 7.181892556218372e-07
, O 0 2.1914862813332547e-08
the O 0 1.3853677316433277e-08
development O 0 1.1758544360418455e-07
of O 0 0.004203668795526028
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
( O 0 4.440033080754802e-06
CRC B-Disease 0 0.0002788635028991848
) O 0 8.685481702741527e-07
. O 0 9.750366416483303e-07

APC B-Disease 0 0.000614541640970856
is O 0 2.969916977235698e-06
a O 0 2.6504541892791167e-05
tumour O 1 0.9999713897705078
- O 0 0.0009467297350056469
suppressor O 0 0.0002927461464423686
gene O 0 6.864331680844771e-07
, O 0 1.7117615769279837e-08
and O 0 3.025644090826063e-08
somatic O 0 1.1869652553286869e-05
loss O 0 7.56670706323348e-05
occurs O 0 6.390821454260731e-07
in O 0 2.3527129542344483e-06
tumours B-Disease 1 0.9999977350234985
. O 0 1.9439599782344885e-05

The O 0 1.087570399249671e-05
germline O 0 0.0002844124101102352
T O 0 0.00029359248583205044
- O 0 1.2622032045328524e-05
to O 0 3.8260941437329166e-07
- O 0 5.522985702555161e-06
A O 0 4.800983333552722e-06
transversion O 0 2.0087600205442868e-05
responsible O 0 6.845341715688846e-08
for O 0 3.360060674140186e-09
the O 0 1.0020197116489271e-08
APC O 0 2.9798013656545663e-06
I1307K O 0 4.278886081010569e-06
allele O 0 3.8471617358482035e-07
converts O 0 9.236959641611975e-08
the O 0 2.6921971318927262e-09
wild O 0 1.7281379882660985e-08
- O 0 1.0651053798937937e-06
type O 0 2.2262375409809465e-07
sequence O 0 1.1982773884255948e-08
to O 0 3.26338707168361e-08
a O 0 1.4381544133357238e-05
homopolymer O 1 0.9980450868606567
tract O 1 0.9835326671600342
( O 0 1.6594134422120987e-07
A8 O 0 0.013938057236373425
) O 0 8.394898287633623e-08
that O 0 6.860294377020182e-08
is O 0 2.8903167503813165e-07
genetically O 0 4.191154403088149e-06
unstable O 0 0.00012415606761351228
and O 0 3.691715164677589e-07
prone O 0 1.4933908460079692e-05
to O 0 4.484821829464636e-07
somatic O 0 0.0001411644188920036
mutation O 0 4.122336395084858e-05
. O 0 1.958081838893122e-06

The O 0 3.234508994864882e-06
I1307K O 0 4.434618676896207e-05
allele O 0 3.0882732971804217e-05
was O 0 1.5588374253638904e-06
found O 0 9.527845890033859e-08
in O 0 5.98564113829525e-08
6 O 0 2.196073864979553e-06
. O 0 1.312844574385963e-06

1 O 0 1.2216047252877615e-05
% O 0 1.0455747769810841e-06
of O 0 5.0695721398597016e-08
unselected O 0 0.000592973839957267
Ashkenazi O 0 0.0001889375562313944
Jews O 0 7.563290296275227e-07
and O 0 1.226911905405359e-07
higher O 0 1.9748725321733218e-07
proportions O 0 8.498552119817759e-07
of O 0 2.385073649691094e-08
Ashkenazim O 0 2.3014936232357286e-05
with O 0 5.109304197503661e-07
family O 0 7.171960874075012e-07
or O 0 2.1487956303190003e-08
personal O 0 1.0357673545513535e-06
histories O 0 6.325781782834383e-07
of O 0 7.294921289258127e-08
CRC B-Disease 0 0.00044480562792159617
( O 0 1.822022284159175e-07
ref O 0 0.0001487527770223096
. O 0 8.070630741485729e-08
2 O 0 1.2299214802169445e-07
) O 0 7.762101006392186e-08
. O 0 4.669248880873056e-07

To O 0 6.606045189982979e-06
evaluate O 0 2.2118902052170597e-06
the O 0 1.821233119869703e-08
role O 0 2.9421801883700027e-08
of O 0 5.419324100586209e-09
I1307K O 0 2.51125602517277e-05
in O 0 1.1601448477449594e-06
cancer B-Disease 0 0.00015430361963808537
, O 0 2.2981607727956543e-08
we O 0 2.323446501861781e-08
genotyped O 0 3.059047458009445e-06
5 O 0 4.904431349928018e-08
, O 0 3.799230441359214e-08
081 O 0 7.679138434468769e-06
Ashkenazi O 0 3.679739847939345e-06
volunteers O 0 1.1628692675458296e-07
in O 0 9.116917887297404e-09
a O 0 2.59990713402658e-07
community O 0 1.612691420405099e-07
survey O 0 2.1056728201074293e-06
. O 0 4.766629899677355e-07

Risk O 0 7.148537406465039e-05
of O 0 3.7402148223009135e-07
developing O 0 5.1517719839466736e-05
colorectal B-Disease 1 0.9999997615814209
, I-Disease 0 0.0010365562047809362
breast I-Disease 1 0.5757590532302856
and I-Disease 0 2.431564553262433e-06
other I-Disease 0 3.738460634394869e-07
cancers I-Disease 0 0.011231928132474422
were O 0 1.3533333458326524e-06
compared O 0 5.949213459643943e-07
between O 0 2.8481364822141586e-08
genotyped O 0 8.076304948190227e-05
I1307K O 0 2.3745717044221237e-05
carriers O 0 4.27954915949158e-07
and O 0 2.668370413516641e-08
non O 0 4.5382108737612725e-08
- O 0 2.4644627956149634e-06
carriers O 0 4.727326370357332e-07
and O 0 1.3563196787913512e-08
their O 0 3.069446696812861e-09
first O 0 4.763094452187033e-08
- O 0 1.2089777555956971e-05
degree O 0 3.6563099001796218e-06
relatives O 0 4.362996151030529e-06
. O 0 9.877520597001421e-07

Sperm O 0 0.0003087660588789731
DNA O 0 4.541830639936961e-05
analysis O 0 1.9808453544101212e-06
in O 0 1.8513627253469167e-07
a O 0 1.1196761988685466e-05
Friedreich B-Disease 1 0.998833954334259
ataxia I-Disease 1 0.9997265934944153
premutation O 0 0.1853903830051422
carrier O 0 0.00012895313557237387
suggests O 0 3.373020831531903e-07
both O 0 1.3957699884770136e-08
meiotic O 0 7.437353701789107e-07
and O 0 3.8436112959061575e-08
mitotic O 0 8.928959687182214e-07
expansion O 0 1.9296177811156667e-07
in O 0 3.453180497103858e-08
the O 0 1.024546563144213e-07
FRDA B-Disease 0 0.0006684879190288484
gene O 0 8.01155147200916e-06
. O 0 1.0725340189310373e-06

Friedreich B-Disease 1 0.9998296499252319
ataxia I-Disease 1 0.9999696016311646
is O 0 0.021985646337270737
usually O 0 0.0005038472590968013
caused O 0 7.4056274570466485e-06
by O 0 3.144816318467747e-08
an O 0 3.0106196646784156e-08
expansion O 0 5.5513673657969775e-08
of O 0 5.172062778058262e-09
a O 0 9.673925660536042e-07
GAA O 0 2.91848800770822e-06
trinucleotide O 0 3.1830619263928384e-05
repeat O 0 1.9461115243757376e-06
in O 0 7.355264131092554e-08
intron O 0 1.4338475011754781e-05
1 O 0 7.718504946296889e-08
of O 0 7.252686895498073e-09
the O 0 8.810322071894916e-08
FRDA B-Disease 0 0.0014989553019404411
gene O 0 8.787068509263918e-06
. O 0 1.590562305864296e-06

Occasionally O 0 0.00015087136125657707
, O 0 7.812496392034518e-07
a O 0 4.085982254764531e-07
fully O 0 3.4067750220856396e-07
expanded O 0 1.1417386502898808e-07
allele O 0 1.079283492799732e-06
has O 0 2.0250205068350624e-07
been O 0 4.524365238012251e-08
found O 0 2.6396179464427405e-08
to O 0 6.577904088089781e-08
arise O 0 8.010559326976363e-08
from O 0 2.9246771671154193e-09
a O 0 7.529473577960744e-08
premutation O 0 1.4788166708967765e-06
of O 0 3.3570626278844884e-09
100 O 0 1.7014397002412807e-08
or O 0 1.1932370647116386e-08
less O 0 4.950336460751714e-07
triplet O 0 0.0033450520131736994
repeats O 0 1.3756768566963729e-05
. O 0 1.7079660210583825e-06

We O 0 4.849216111324495e-06
have O 0 4.0740948747952643e-07
examined O 0 4.6064917569310637e-07
the O 0 1.1951184042402474e-08
sperm O 0 1.7485994874277822e-07
DNA O 0 8.079117463921648e-08
of O 0 8.060305312085347e-09
a O 0 9.312901738667279e-07
premutation O 0 0.0008842768147587776
carrier O 0 0.00012034675455652177
. O 0 1.6194865111174295e-06

This O 0 7.726009243924636e-06
mans O 0 0.00018256023759022355
leucocyte O 0 0.0002767018449958414
DNA O 0 2.1914227545494214e-05
showed O 0 3.4848490031436086e-06
one O 0 2.9908850507354146e-08
normal O 0 5.350329246311958e-08
allele O 0 4.314562147555989e-07
and O 0 1.1751993156394747e-08
one O 0 1.3637698970114798e-08
allele O 0 2.680959028111829e-07
of O 0 3.355244970748572e-09
approximately O 0 4.834375744167119e-08
100 O 0 6.866224566692836e-08
repeats O 0 3.450617441558279e-06
. O 0 8.922890515350446e-07

His O 0 2.1238754925434478e-05
sperm O 0 2.737174327194225e-05
showed O 0 3.926786121155601e-06
an O 0 4.98573307083916e-08
expanded O 0 2.509673606709839e-07
allele O 0 1.32939339891891e-06
in O 0 1.2353932099529175e-08
a O 0 1.793861486021342e-07
tight O 0 1.029811301123118e-05
range O 0 7.778448463113818e-08
centering O 0 1.702839824702096e-07
on O 0 8.055605604795346e-08
a O 0 6.5025346884795e-08
size O 0 6.178850497917665e-08
of O 0 7.257114909009488e-09
approximately O 0 1.7659040452144836e-07
320 O 0 3.098818979196949e-06
trinucleotide O 0 0.00014626439951825887
repeats O 0 1.8759672457235865e-05
. O 0 1.6577349697399768e-06

His O 0 0.00010490268323337659
affected O 0 1.234089086210588e-05
son O 0 5.04185190948192e-05
has O 0 8.15963630884653e-07
repeat O 0 1.363703177048592e-06
sizes O 0 5.194665959606937e-07
of O 0 3.602978537742274e-08
1040 O 0 5.296255494613433e-06
and O 0 7.670176955798524e-07
540 O 0 1.3163688890927006e-05
. O 0 2.128877213181113e-06

These O 0 7.705978077865439e-07
data O 0 2.8526824280561414e-07
suggest O 0 1.858954448152872e-07
that O 0 1.498988666526202e-08
expansion O 0 9.807293821495477e-08
occurs O 0 2.090253481412674e-08
in O 0 6.667828067463688e-09
two O 0 3.0365480796490374e-08
stages O 0 2.370787370864491e-07
, O 0 9.410340062743217e-09
the O 0 2.8474942403988734e-09
first O 0 2.5339486953157575e-08
during O 0 4.7133440261859505e-08
meiosis O 0 9.899817854375215e-08
followed O 0 2.107017138541778e-08
by O 0 3.396271930355965e-09
a O 0 2.5522400193267458e-08
second O 0 1.4487304156318714e-07
mitotic O 0 6.700930043734843e-06
expansion O 0 5.86691430726205e-06
. O 0 2.539378101573675e-06

We O 0 2.123783360730158e-06
also O 0 2.3299639906326775e-07
show O 0 1.8479829577700002e-07
that O 0 1.3536138432357347e-08
in O 0 6.584805589682219e-09
all O 0 4.443332812797962e-09
informative O 0 2.814622632740793e-07
carrier O 0 7.1022404881659895e-06
father O 0 1.0667623655535863e-06
to O 0 7.259706791273857e-08
affected O 0 1.3983365931835579e-07
child O 0 2.535332214392838e-06
transmissions O 0 2.7157962904311717e-05
, O 0 1.697057783189848e-08
with O 0 7.439663551878084e-09
the O 0 7.546838709515669e-09
notable O 0 8.852652655377824e-08
exception O 0 4.981189505315342e-08
of O 0 1.2976048013868535e-09
the O 0 1.8565444293017208e-08
premutation O 0 3.766028385143727e-05
carrier O 0 2.151274429706973e-06
, O 0 4.004214293473751e-09
the O 0 2.1076753675686177e-09
expansion O 0 5.3789587894925717e-08
size O 0 2.509673606709839e-07
decreases O 0 2.6533637083048234e-06
. O 0 7.719918926341052e-08
. O 0 3.489251128030446e-07

The O 0 4.00231829189579e-06
R496H O 0 4.589138552546501e-05
mutation O 0 5.140774192113895e-06
of O 0 2.127670128970749e-08
arylsulfatase O 0 1.7923355699167587e-05
A O 0 2.393916702203569e-06
does O 0 8.602773959864862e-07
not O 0 1.2492665746322018e-06
cause O 0 0.0005111114587634802
metachromatic B-Disease 1 0.9999891519546509
leukodystrophy I-Disease 1 0.9999895095825195
. O 0 1.0661832675395999e-05

Deficiency B-Disease 1 0.9993498921394348
of I-Disease 0 2.23550591726962e-06
arylsulfatase I-Disease 0 0.0026854516472667456
A I-Disease 0 0.0001873479486675933
( O 0 2.441311835355009e-06
ARSA O 0 0.0010529948631301522
) O 0 3.424603107760049e-07
enzyme O 0 8.475145136799256e-07
activity O 0 4.6139044229676074e-07
causes O 0 3.4963686630362645e-05
metachromatic B-Disease 1 0.9999942779541016
leukodystrophy I-Disease 1 0.9999996423721313
( O 0 0.00021892981021665037
MLD B-Disease 1 0.9999406337738037
) O 0 5.441224402602529e-06
. O 0 3.1437452889804263e-06

A O 0 2.32715919992188e-05
number O 0 6.312289428933582e-07
of O 0 1.5995478008790087e-07
ARSA O 0 0.4468333423137665
gene O 0 1.4811223081778735e-05
mutations O 0 5.128615157445893e-06
responsible O 0 3.9932075424076174e-07
for O 0 1.2987180753043504e-06
MLD B-Disease 1 0.9999960660934448
have O 0 2.4995293642859906e-05
been O 0 2.833442067640135e-06
identified O 0 3.8142204630275955e-06
. O 0 1.0830118526428123e-06

Recently O 0 8.012558828340843e-05
, O 0 3.74972955796693e-07
the O 0 6.825472098626051e-08
R496H O 0 6.660885446763132e-06
mutation O 0 1.1604768133111065e-06
of O 0 2.2675470390254304e-08
ARSA O 0 0.025263482704758644
was O 0 1.5655758033972234e-05
proposed O 0 4.592161317873433e-08
to O 0 1.5817533949302742e-08
be O 0 3.3005264299390547e-08
a O 0 1.3701285297429422e-06
cause O 0 5.05936031913734e-06
of O 0 3.7915430084467516e-07
MLD B-Disease 1 0.9999969005584717
( O 0 1.0939269259324647e-06
Draghia O 0 9.715060150483623e-05
et O 0 1.6818246422189986e-06
al O 0 1.7088800632336643e-06
. O 0 2.5777238121804658e-08
, O 0 3.143323112908547e-08
1997 O 0 6.622392589861192e-08
) O 0 5.112452683420088e-08
. O 0 4.5122141045794706e-07

We O 0 5.386974407883827e-06
have O 0 4.064792449298693e-07
investigated O 0 2.535907697165385e-07
the O 0 3.3123448872629524e-08
R496H O 0 3.828263288596645e-05
mutation O 0 1.127347900364839e-06
and O 0 1.8663612877389824e-08
found O 0 3.8072315078352403e-08
this O 0 1.496734469697003e-08
mutation O 0 2.1291684504376462e-07
at O 0 5.484879217476646e-09
a O 0 1.8639676113707537e-07
relatively O 0 1.998860739149677e-07
high O 0 1.6262345070572337e-07
frequency O 0 1.4266687458075467e-06
in O 0 1.5656052454460223e-08
an O 0 2.163419487999363e-08
African O 0 1.553445194701908e-08
American O 0 5.363980548622749e-08
population O 0 3.187024688600104e-08
( O 0 7.313196714875403e-09
f O 0 8.59917292928003e-07
= O 0 3.037194176158664e-07
0 O 0 1.0371100955808288e-07
. O 0 7.64801288966055e-09
09 O 0 8.58689901406251e-08
, O 0 3.8589416107015495e-08
n O 0 6.922703619238746e-07
= O 0 7.740455885141273e-07
61 O 0 1.4928931477697915e-06
subjects O 0 3.094685325777391e-07
) O 0 1.3602010540125775e-07
. O 0 3.346382584368257e-07

The O 0 1.524928848084528e-05
ARSA O 0 0.0007546775159426033
enzyme O 0 2.9361090128077194e-06
activity O 0 1.204313093694509e-07
in O 0 3.695787142987683e-08
subjects O 0 1.6456708351597626e-07
with O 0 5.0189843392445255e-08
and O 0 1.989211568798055e-07
without O 0 4.599200309485241e-08
the O 0 1.2911372415658207e-08
R496H O 0 6.73097429171321e-06
mutation O 0 8.257497370323108e-07
was O 0 3.129414949398779e-07
determined O 0 2.011474009577796e-07
and O 0 2.2552024248057023e-08
found O 0 4.1431288622106877e-08
to O 0 3.35492025271833e-08
be O 0 1.1422451251519306e-07
normal O 0 4.779749360750429e-07
. O 0 9.419264870302868e-07

It O 0 4.49459366791416e-06
is O 0 6.205814884197025e-07
therefore O 0 2.1696060059639422e-07
concluded O 0 1.547974051163692e-07
that O 0 1.04908668419057e-08
the O 0 1.296423057794982e-08
R496H O 0 3.317382606837782e-06
mutation O 0 2.3178742480922665e-07
of O 0 1.1092553542368933e-08
ARSA O 0 0.0014016905333846807
does O 0 3.6723741914101993e-07
not O 0 9.452488569650086e-09
negatively O 0 3.625050482014558e-08
influence O 0 1.1743074956882538e-08
the O 0 2.03967931433624e-09
activity O 0 6.602059787752523e-09
of O 0 5.136572944763884e-09
ARSA O 0 0.022934505715966225
and O 0 8.910281934504383e-08
is O 0 3.1232964659011486e-08
not O 0 1.8215386532460798e-08
a O 0 6.987493179622106e-07
cause O 0 1.2153785064583644e-05
of O 0 2.6792288281285437e-06
MLD B-Disease 1 0.9999508857727051

Down O 0 5.807420893688686e-05
- O 0 1.5370604160125367e-05
regulation O 0 1.008024582915823e-06
of O 0 6.25173228741005e-08
transmembrane O 0 2.7754429538617842e-05
carbonic O 0 7.111020386219025e-05
anhydrases O 0 0.00016123386740218848
in O 0 5.1286638154124375e-06
renal B-Disease 1 0.9999803304672241
cell I-Disease 1 0.9999816417694092
carcinoma I-Disease 1 1.0
cell O 0 0.36051058769226074
lines O 0 5.0453732001187745e-06
by O 0 6.689192844078207e-08
wild O 0 4.2431284441590833e-07
- O 0 0.00012306816643103957
type O 0 0.00031689609750173986
von B-Disease 1 0.831493079662323
Hippel I-Disease 1 0.8752257227897644
- I-Disease 0 0.01085609570145607
Lindau I-Disease 0 0.02791278436779976
transgenes O 0 0.0002682656340766698
. O 0 4.279620952729601e-06

To O 0 2.8170065888843965e-06
discover O 0 1.8341979739489034e-06
genes O 0 3.419805523208197e-07
involved O 0 2.116529742579587e-07
in O 0 8.187815865312587e-07
von B-Disease 1 0.999081015586853
Hippel I-Disease 1 0.9998157620429993
- I-Disease 1 0.9994072914123535
Lindau I-Disease 1 0.9982859492301941
( O 0 1.527859012639965e-06
VHL B-Disease 0 9.189174306811765e-05
) O 0 8.327296541210671e-08
- O 0 3.6554172311298316e-06
mediated O 0 0.00011647911742329597
carcinogenesis O 0 0.0022310109343379736
, O 0 1.3831122203100676e-07
we O 0 4.6345917326107156e-08
used O 0 9.082698670681566e-05
renal B-Disease 1 0.999976396560669
cell I-Disease 1 0.9999829530715942
carcinoma I-Disease 1 1.0
cell O 1 0.8108640909194946
lines O 0 3.5258672141935676e-05
stably O 0 1.8547429135651328e-05
transfected O 0 3.878825009451248e-05
with O 0 1.3108312657550414e-07
wild O 0 3.6667887570729363e-07
- O 0 0.00016436590522062033
type O 0 0.00018024492601398379
VHL O 0 0.0013863820349797606
- O 0 0.0010128088761121035
expressing O 0 5.9754329413408414e-05
transgenes O 0 0.00030618265736848116
. O 0 7.006517080299091e-06

Large O 0 9.887653504847549e-06
- O 0 1.144972975453129e-05
scale O 0 9.676629133537062e-07
RNA O 0 5.108846039547643e-07
differential O 0 4.614234967448283e-06
display O 0 3.2800119242892833e-07
technology O 0 1.5342001802309824e-07
applied O 0 1.805696001611068e-07
to O 0 2.4988159097460994e-08
these O 0 8.869650791609729e-09
cell O 0 5.773142220277805e-06
lines O 0 2.6921320568362717e-06
identified O 0 2.6313924195164873e-07
several O 0 2.3256101044921706e-08
differentially O 0 7.67046458349796e-06
expressed O 0 5.670356699738477e-07
genes O 0 8.45267535964922e-08
, O 0 1.3240796015168144e-08
including O 0 9.73453406771796e-09
an O 0 6.270936125929438e-08
alpha O 0 1.748877480167721e-06
carbonic O 0 1.975534723896999e-05
anhydrase O 0 1.2955281817994546e-05
gene O 0 4.2587200255184143e-07
, O 0 5.315947504413998e-08
termed O 0 3.564975713743479e-06
CA12 O 0 0.000699761847499758
. O 0 2.987583684443962e-06

The O 0 2.5050753720279317e-06
deduced O 0 6.026134542480577e-06
protein O 0 4.1743103906810575e-07
sequence O 0 8.231505432831909e-08
was O 0 5.529418558580801e-07
classified O 0 4.637244188643308e-08
as O 0 1.4180205454294992e-08
a O 0 9.92702595681294e-08
one O 0 1.0869027988746893e-07
- O 0 5.430547025753185e-05
pass O 0 5.388875706557883e-06
transmembrane O 0 1.2449074347387068e-05
CA O 0 9.665284324000822e-07
possessing O 0 7.129985846177078e-08
an O 0 2.6677444253664362e-08
apparently O 0 7.734921609880985e-07
intact O 0 1.2167696183951193e-07
catalytic O 0 6.834278565293062e-08
domain O 0 2.2221113837872508e-08
in O 0 5.524197987938351e-09
the O 0 1.5679122000733514e-08
extracellular O 0 3.5956272768089548e-06
CA O 0 2.0608027625712566e-05
module O 0 0.00011004139378201216
. O 0 1.3229040405349224e-06

Reintroduced O 0 0.00023225194308906794
wild O 0 1.8971859390148893e-05
- O 0 0.00023061090905684978
type O 0 2.2867172447149642e-05
VHL B-Disease 0 0.00033577188150957227
strongly O 0 9.031720765051432e-06
inhibited O 0 1.2026619060634403e-06
the O 0 1.4789471869391946e-08
overexpression O 0 1.3288254194776528e-06
of O 0 6.743738012460199e-09
the O 0 1.9233340253776987e-08
CA12 O 0 9.399339614901692e-05
gene O 0 2.240766576733222e-07
in O 0 2.284377131900328e-08
the O 0 1.4003170178966684e-07
parental O 1 0.9690499305725098
renal B-Disease 1 0.9999985694885254
cell I-Disease 1 0.9999946355819702
carcinoma I-Disease 1 1.0
cell O 1 0.6499074697494507
lines O 0 6.791283522034064e-05
. O 0 3.277605856055743e-06

Similar O 0 9.509100345894694e-05
results O 0 1.3032235074206255e-05
were O 0 4.872441081715806e-07
obtained O 0 2.193958437146648e-07
with O 0 4.6568550260417396e-07
CA9 O 0 0.21013155579566956
, O 0 1.6693481086349493e-07
encoding O 0 1.4460663066984125e-07
another O 0 3.346650601088186e-07
transmembrane O 0 6.025266884535085e-06
CA O 0 6.623289436902269e-07
with O 0 1.6614459141806037e-08
an O 0 9.542431200770807e-08
intact O 0 2.962005510198651e-06
catalytic O 0 2.3603427052876214e-06
domain O 0 1.551860009385564e-06
. O 0 1.0167901791646727e-06

Although O 0 1.0261075658490881e-05
both O 0 1.9138127527185134e-07
domains O 0 7.073690966308277e-08
of O 0 6.0915996691335295e-09
the O 0 3.654639257888448e-08
VHL B-Disease 0 5.788345879409462e-05
protein O 0 3.9301815490944136e-07
contribute O 0 2.7705993943527574e-08
to O 0 1.85343083103362e-08
regulation O 0 8.868335754641521e-08
of O 0 2.6376753226031724e-08
CA12 O 0 0.01608017086982727
expression O 0 6.758206154700019e-07
, O 0 6.810047192828961e-09
the O 0 3.500460588057308e-09
elongin O 0 2.5613703655835707e-06
binding O 0 2.178151845555476e-07
domain O 0 8.147765129251638e-08
alone O 0 1.583519946279921e-07
could O 0 7.966311699192374e-08
effectively O 0 5.159228066986543e-07
regulate O 0 6.355233381327707e-06
CA9 O 0 0.004994404502213001
expression O 0 1.0271533028571866e-05
. O 0 2.0592997316271067e-06

We O 0 1.475597127864603e-05
mapped O 0 8.179357973858714e-05
CA12 O 0 0.0007766896160319448
and O 0 1.3829145473209792e-06
CA9 O 0 0.0004716655530501157
loci O 0 2.990502707689302e-06
to O 0 2.490216672867973e-07
chromosome O 0 8.059022547968198e-06
bands O 0 1.4317254226625664e-06
15q22 O 0 1.1965177691308782e-05
and O 0 4.811075768884621e-07
17q21 O 0 5.69587318750564e-05
. O 0 1.8464396589479293e-06

2 O 0 3.0143713956931606e-05
respectively O 0 4.817696662939852e-06
, O 0 1.9266113326921186e-07
regions O 0 1.7043002742411772e-07
prone O 0 9.926673556037713e-06
to O 0 4.835772529077076e-07
amplification O 0 1.746570887917187e-05
in O 0 1.3408831023298262e-07
some O 0 1.4538764503413404e-07
human O 0 2.6458967568032676e-06
cancers B-Disease 0 0.013130116276443005
. O 0 3.15033912556828e-06

Additional O 0 1.0924601156148128e-05
experiments O 0 6.272524842643179e-06
are O 0 4.701788114402916e-08
needed O 0 2.4498169182152196e-07
to O 0 7.789524403278847e-08
define O 0 1.1725565229880885e-07
the O 0 5.484460885440967e-09
role O 0 2.9191948414108992e-08
of O 0 1.5890531557261056e-08
CA O 0 4.8539390263613313e-05
IX O 0 0.06728868931531906
and O 0 3.1334395771409618e-06
CA O 0 3.797468889388256e-05
XII O 0 0.00019832731049973518
enzymes O 0 8.292253284025719e-08
in O 0 1.0488485635562483e-08
the O 0 5.2278616990975024e-09
regulation O 0 4.450799195865329e-08
of O 0 1.5655931662195144e-08
pH O 0 1.6514863091288134e-05
in O 0 1.0898480340415517e-08
the O 0 5.499146471521499e-09
extracellular O 0 1.4715151053223963e-07
microenvironment O 0 9.096760550164618e-06
and O 0 2.668660492588515e-08
its O 0 1.4550964877457773e-08
potential O 0 5.0348713642733856e-08
impact O 0 1.6640630917663657e-07
on O 0 2.7244344892096706e-05
cancer B-Disease 0 0.03721321001648903
cell O 0 1.7506697986391373e-05
growth O 0 5.255107566881634e-07
. O 0 7.302257358787756e-07

A O 0 3.6622706829803064e-05
gene O 0 5.226905159361195e-06
encoding O 0 1.5901558754194411e-06
a O 0 6.708972364322108e-07
transmembrane O 0 5.843266080773901e-06
protein O 0 2.9405316581687657e-07
is O 0 4.2523645049641345e-08
mutated O 0 9.114171916735359e-06
in O 0 2.079058276649448e-06
patients O 0 0.06294495612382889
with O 0 0.4126293957233429
diabetes B-Disease 1 1.0
mellitus I-Disease 1 1.0
and O 1 0.9877637028694153
optic B-Disease 1 0.9999994039535522
atrophy I-Disease 1 0.9999889135360718
( O 0 0.22341275215148926
Wolfram B-Disease 1 0.9999998807907104
syndrome I-Disease 1 1.0
) O 0 3.6648275454354007e-06
. O 0 5.820902060804656e-06

Wolfram B-Disease 1 0.9999991655349731
syndrome I-Disease 1 1.0
( O 0 0.0598747618496418
WFS B-Disease 1 0.997257649898529
; O 0 0.003273248439654708
OMIM O 1 0.7669606804847717
222300 O 0 5.8098474255530164e-05
) O 0 1.1019951529078753e-07
is O 0 1.4639817891293205e-07
an O 0 1.179732680611778e-05
autosomal B-Disease 1 0.9999562501907349
recessive I-Disease 1 0.9999985694885254
neurodegenerative I-Disease 1 0.9999996423721313
disorder I-Disease 1 0.999966025352478
defined O 0 3.063370968447998e-06
by O 0 3.47960764202071e-07
young O 0 2.1636110432154965e-06
- O 0 9.558913006912917e-05
onset O 0 3.822415237664245e-05
non O 0 3.1746110380481696e-06
- O 0 0.12315980345010757
immune O 0 0.03030373901128769
insulin B-Disease 1 0.9954984188079834
- I-Disease 1 0.9572809338569641
dependent I-Disease 1 0.9693536162376404
diabetes I-Disease 1 0.9999998807907104
mellitus I-Disease 1 0.9999991655349731
and O 0 0.00029922040994279087
progressive O 1 0.9746624827384949
optic B-Disease 1 0.9999836683273315
atrophy I-Disease 1 0.9933619499206543
. O 0 1.355866243102355e-05

Linkage O 0 0.000341609789757058
to O 0 8.01174155640183e-06
markers O 0 4.449801781447604e-05
on O 0 5.83380597163341e-06
chromosome O 0 0.0032874231692403555
4p O 0 0.02078951895236969
was O 0 1.446736860089004e-05
confirmed O 0 3.5097227168989775e-07
in O 0 1.2519358882912002e-08
five O 0 2.061086519233868e-07
families O 0 3.8563339899155835e-07
. O 0 9.93039407148899e-07

On O 0 1.94524318430922e-06
the O 0 4.8883027403689994e-08
basis O 0 1.535546267916743e-08
of O 0 1.101028246353053e-08
meiotic O 0 7.092614396242425e-05
recombinants O 0 0.37710195779800415
and O 0 0.0003708550939336419
disease O 0 0.0018929120851680636
- O 0 0.009032648988068104
associated O 0 2.827972457453143e-05
haplotypes O 0 0.00022179502411745489
, O 0 1.6844333572407777e-07
the O 0 9.85266694897291e-08
WFS B-Disease 0 9.844989108387381e-05
gene O 0 3.519851929922879e-07
was O 0 2.5286047389272426e-07
localized O 0 4.078032986853941e-07
to O 0 5.278845804923549e-08
a O 0 4.3768573050329e-06
BAC O 0 0.0040508233942091465
/ O 0 6.477173883467913e-06
P1 O 0 9.359955583931878e-06
contig O 0 2.882971330109285e-06
of O 0 7.621045128303194e-09
less O 0 8.27790458401978e-08
than O 0 5.235358457866823e-08
250 O 0 3.016062919414253e-07
kb O 0 0.0002468590682838112
. O 0 1.1778525959016406e-06

Mutations O 0 0.08333756774663925
in O 0 2.5814933906076476e-06
a O 0 3.195643330400344e-06
novel O 0 1.2109092494938523e-05
gene O 0 2.181403942813631e-06
( O 0 1.4291470051830402e-07
WFS1 O 0 6.23945306870155e-05
) O 0 2.747827387850066e-08
encoding O 0 8.049170929780303e-08
a O 0 1.2721184816655295e-07
putative O 0 2.637796796989278e-06
transmembrane O 0 9.567505685481592e-07
protein O 0 8.005824980727994e-08
were O 0 4.136661857501167e-08
found O 0 1.645095792923712e-08
in O 0 6.662578044824841e-09
all O 0 9.936494294038312e-09
affected O 0 1.3289860589793534e-07
individuals O 0 9.797194167049383e-09
in O 0 3.6161008409862916e-08
six O 0 4.222007646603743e-06
WFS B-Disease 0 0.0546884723007679
families O 0 7.539993021055125e-07
, O 0 2.5964352445839722e-08
and O 0 3.27818483469855e-08
these O 0 2.9883761243354456e-08
mutations O 0 1.653025833547872e-06
were O 0 9.347802176762343e-08
associated O 0 3.2111390879663304e-08
with O 0 8.409449492319254e-08
the O 0 2.1460149582708254e-05
disease O 0 0.4925002455711365
phenotype O 1 0.7388074398040771
. O 0 4.028057901450666e-06

WFS1 O 0 0.09336257725954056
appears O 0 0.00010330090299248695
to O 0 5.195800554247398e-07
function O 0 9.532062961170595e-08
in O 0 5.498393917946487e-08
survival O 0 1.605782244951115e-06
of O 0 1.616067102361285e-08
islet O 0 5.160868386155926e-05
beta O 0 7.711205398663878e-07
- O 0 6.4043256315926556e-06
cells O 0 5.499473445524927e-07
and O 0 1.6025849447487417e-07
neurons O 0 1.3039466466580052e-06
. O 0 7.829070369780311e-08
. O 0 4.2364570163044846e-07

Stable O 0 0.00010397649020887911
interaction O 0 4.921880645269994e-07
between O 0 6.68854198693225e-08
the O 0 9.771254028123622e-09
products O 0 2.6213552217768665e-08
of O 0 2.2514965447584245e-09
the O 0 7.261825629711893e-08
BRCA1 O 0 0.0016345574986189604
and O 0 1.1550671842996962e-05
BRCA2 O 0 0.025689663365483284
tumor B-Disease 0 4.151011671638116e-05
suppressor O 0 8.274735591839999e-06
genes O 0 1.6989872619888047e-07
in O 0 1.5388005536465243e-08
mitotic O 0 3.650818371170317e-06
and O 0 1.3740881286139484e-06
meiotic O 0 0.0002545087190810591
cells O 0 9.375885565532371e-05
. O 0 1.947017608472379e-06

BRCA1 O 1 0.9513710737228394
and O 0 0.00010705985187087208
BRCA2 O 0 0.006767631974071264
account O 0 5.722672540287022e-07
for O 0 2.8752694447575777e-08
most O 0 1.210158302455966e-07
cases O 0 1.1691620471765418e-07
of O 0 2.3653351277630463e-08
familial O 0 0.00019276987586636096
, O 0 8.575047445447126e-07
early O 0 5.966167009319179e-06
onset O 0 0.003563562175258994
breast B-Disease 1 0.9924923777580261
and I-Disease 0 0.00012139641330577433
/ I-Disease 0 0.44850367307662964
or I-Disease 1 0.8147760033607483
ovarian I-Disease 1 1.0
cancer I-Disease 1 0.9999984502792358
and O 0 9.847970261489536e-08
encode O 0 1.4279656568305654e-07
products O 0 5.7252385943229456e-08
that O 0 1.2085005884898692e-08
each O 0 3.884987442859256e-09
interact O 0 2.8941526508674542e-08
with O 0 5.12120692519602e-08
hRAD51 O 0 2.7680338462232612e-05
. O 0 1.5193297713267384e-06

Results O 0 4.760418232763186e-05
presented O 0 1.6630618802082608e-06
here O 0 5.0786887584308715e-08
show O 0 2.1408108352716226e-07
that O 0 9.167891334982414e-08
BRCA1 O 0 0.00013349700020626187
and O 0 6.124308129074052e-06
BRCA2 O 0 0.010768402367830276
coexist O 0 4.451871063793078e-06
in O 0 1.2655535286398845e-08
a O 0 3.0679328233418346e-07
biochemical O 0 3.951241069444222e-06
complex O 0 1.4381281232545007e-07
and O 0 7.452747041725161e-08
colocalize O 0 1.8805183572112583e-05
in O 0 8.105417492743072e-08
subnuclear O 0 1.9014551071450114e-05
foci O 0 4.380064183351351e-06
in O 0 4.752304505473148e-08
somatic O 0 1.44429554893577e-06
cells O 0 4.012148906440416e-07
and O 0 1.0368406577754286e-08
on O 0 3.7102374506048363e-08
the O 0 1.2405193317022167e-08
axial O 0 2.6252887437294703e-06
elements O 0 8.796921946441216e-08
of O 0 2.7873117147692028e-08
developing O 0 7.347873633989366e-07
synaptonemal O 0 0.0002647053624968976
complexes O 0 1.0261574971082155e-05
. O 0 1.1259886605330394e-06

Like O 0 5.832902024849318e-05
BRCA1 O 0 0.0031396423000842333
and O 0 7.353829005296575e-06
RAD51 O 0 0.025365522131323814
, O 0 2.6407267341710394e-06
BRCA2 O 0 5.926327867200598e-05
relocates O 0 2.2252314010984264e-05
to O 0 1.4882676850902499e-06
PCNA O 0 0.0002905589062720537
+ O 0 4.829214503843104e-07
replication O 0 5.807339675811818e-08
sites O 0 2.0431651037711163e-08
following O 0 3.4574775042983674e-08
exposure O 0 2.9845202220712963e-07
of O 0 9.808188039528432e-09
S O 0 0.00010239500988973305
phase O 0 1.324200411545462e-06
cells O 0 4.903552053292515e-07
to O 0 1.1686883283346106e-07
hydroxyurea O 0 0.0002828950237017125
or O 0 3.016477023720654e-07
UV O 0 0.015688758343458176
irradiation O 0 0.00014372657460626215
. O 0 2.2763276774639962e-06

Thus O 0 5.173191675567068e-05
, O 0 2.597124421299668e-06
BRCA1 O 0 6.128542736405507e-05
and O 0 1.2709232350971433e-06
BRCA2 O 0 6.294890044955537e-05
participate O 0 6.362549243021931e-08
, O 0 2.6290912558124546e-08
together O 0 2.1669876559826662e-08
, O 0 1.700135676685477e-08
in O 0 1.465306631587282e-08
a O 0 2.0027009668410756e-06
pathway O 0 2.175814870497561e-06
( O 0 1.1386744347419153e-07
s O 0 4.153391273575835e-05
) O 0 4.2183387449767906e-08
associated O 0 3.113708402224802e-08
with O 0 3.960675343250841e-09
the O 0 7.0433423537963336e-09
activation O 0 4.239585038590121e-08
of O 0 9.884888463318475e-09
double O 0 2.477858288330026e-06
- O 0 4.247067772666924e-05
strand O 0 9.307475011155475e-06
break O 0 1.2008740668534301e-06
repair O 0 1.1797923434642144e-05
and O 0 3.0418871688198124e-07
/ O 0 1.3648273124999832e-06
or O 0 4.387123198057452e-08
homologous O 0 1.13565886294964e-06
recombination O 0 5.5254986364161596e-06
. O 0 3.0998683087091194e-06

Dysfunction O 0 0.11984022706747055
of O 0 6.285904987635149e-07
this O 0 2.1059530297407036e-07
pathway O 0 1.4205809293343918e-06
may O 0 5.651731953548733e-06
be O 0 1.652177239463981e-08
a O 0 1.194085541555978e-07
general O 0 8.896797965007863e-08
phenomenon O 0 1.4160684713715455e-07
in O 0 5.133105940302585e-09
the O 0 8.659856831627621e-09
majority O 0 2.712077673550084e-07
of O 0 4.318174262607499e-09
cases O 0 2.1503338132333738e-07
of O 0 1.899150987583198e-07
hereditary B-Disease 1 0.9999579191207886
breast I-Disease 1 0.9998753070831299
and I-Disease 0 0.008382316678762436
/ I-Disease 1 0.8671083450317383
or I-Disease 1 0.8611202239990234
ovarian I-Disease 1 1.0
cancer I-Disease 1 0.999998927116394
. O 0 1.1489547659948585e-06
. O 0 1.2617955462701502e-06

A O 0 6.741323159076273e-05
novel O 0 2.5705765438033268e-05
Arg362Ser O 0 7.08466541254893e-05
mutation O 0 3.587013679862139e-06
in O 0 3.054322306184076e-08
the O 0 5.861187446498661e-08
sterol O 0 0.0005126366741023958
27 O 0 2.7231177227804437e-05
- O 0 9.501531894784421e-05
hydroxylase O 0 0.0002531628997530788
gene O 0 7.769705803184479e-07
( O 0 3.889631017273132e-08
CYP27 O 0 1.7330999980913475e-05
) O 0 1.5041294432194263e-08
: O 0 3.177366592055364e-09
its O 0 5.227024146847725e-09
effects O 0 2.700324444049329e-07
on O 0 9.215789731342738e-08
pre O 0 8.156789021995792e-07
- O 0 5.868379844287119e-07
mRNA O 0 9.91026425367636e-08
splicing O 0 3.915997979220265e-07
and O 0 2.8602766377616717e-08
enzyme O 0 1.6333017072156508e-07
activity O 0 1.0480270873358677e-07
. O 0 3.782084831982502e-07

A O 0 6.888606731081381e-05
novel O 0 1.326610981777776e-05
C O 0 1.1610358114921837e-06
to O 0 4.7644210354746974e-08
A O 0 1.9066219465457834e-06
mutation O 0 7.099811227817554e-07
in O 0 2.534586585056786e-08
the O 0 2.9170408311074425e-08
sterol O 0 0.0030196697916835546
27 O 0 4.228235411574133e-05
- O 0 0.0001358788285870105
hydroxylase O 0 0.0001766726782079786
gene O 0 8.661997981107561e-07
( O 0 2.9632772680088237e-08
CYP27 O 0 2.331470932404045e-05
) O 0 2.3235971369217623e-08
was O 0 7.798955152793496e-07
identified O 0 6.305237576498257e-08
by O 0 6.5180412178733604e-09
sequencing O 0 1.9895684033599537e-07
amplified O 0 2.2462798369815573e-05
CYP27 O 0 2.1687819753424264e-05
gene O 0 1.2345914512934542e-07
products O 0 1.4886261112678767e-08
from O 0 3.114300595186137e-09
a O 0 8.966591167336446e-07
patient O 0 0.0029192843940109015
with O 0 8.783974772086367e-05
cerebrotendinous B-Disease 1 0.9999969005584717
xanthomatosis I-Disease 1 0.9999911785125732
( O 0 2.693364876904525e-06
CTX B-Disease 0 0.03589955344796181
) O 0 1.3110316103848163e-06
. O 0 1.3206314406488673e-06

The O 0 3.567274916349561e-06
mutation O 0 1.0554937944107223e-05
changed O 0 2.477023599567474e-07
the O 0 2.7013900449901485e-08
adrenodoxin O 0 3.956889941036934e-06
cofactor O 0 3.0554115255654324e-06
binding O 0 8.875076673575677e-07
residue O 0 1.0957132872135844e-06
362Arg O 0 2.074926669592969e-06
to O 0 1.691561521965923e-07
362Ser O 0 4.812425231648376e-06
( O 0 3.982804841484722e-08
CGT O 0 2.218855797764263e-06
362Arg O 0 3.931890205421951e-06
to O 0 2.8914635663568333e-07
AGT O 0 0.00013168952136766165
362Ser O 0 2.740426134550944e-05
) O 0 2.4930841391324066e-08
, O 0 1.3755204086862705e-08
and O 0 2.325374914846634e-08
was O 0 3.5502578157320386e-06
responsible O 0 3.8365658383554546e-07
for O 0 3.4123784189432627e-06
deficiency O 0 0.0019493455765768886
in O 0 1.2917653613442326e-08
the O 0 2.1174033193460673e-08
sterol O 0 0.0007794496486894786
27 O 0 3.5458183447190095e-06
- O 0 2.9228888251964236e-06
hydroxylase O 0 7.048706265777582e-06
activity O 0 1.8095501985726514e-08
, O 0 4.873553560713617e-09
as O 0 1.6817649495237674e-08
confirmed O 0 1.3427462874915363e-07
by O 0 6.949557374014148e-09
expression O 0 3.003450288474596e-08
of O 0 3.731313036325901e-09
mutant O 0 2.379088357429282e-07
cDNA O 0 3.06079613210386e-07
into O 0 6.932574336815378e-08
COS O 0 4.940342478221282e-06
- O 0 5.077641617390327e-06
1 O 0 4.043319279389834e-07
cells O 0 8.447701134173258e-07
. O 0 5.537703486879764e-07

Quantitative O 0 5.7228782679885626e-05
analysis O 0 6.907924216648098e-06
showed O 0 3.5771170132647967e-06
that O 0 8.809393214903594e-09
the O 0 4.249499863107076e-09
expression O 0 2.764291551216047e-08
of O 0 4.373310602545644e-09
CYP27 O 0 1.4538209143211134e-05
gene O 0 4.345399773342251e-08
mRNA O 0 1.6303271621609383e-08
in O 0 2.6973521194406658e-09
the O 0 1.4750031418486742e-08
patient O 0 3.106986696366221e-05
represented O 0 9.448270361644973e-07
52 O 0 6.2278031691676006e-06
. O 0 1.1203235317225335e-06

5 O 0 4.6292421757243574e-05
% O 0 4.7637897182539746e-07
of O 0 1.3614984695209387e-08
the O 0 3.745833154766842e-08
normal O 0 4.3714368302971707e-07
level O 0 2.883596152969403e-07
. O 0 6.551996989401232e-07

As O 0 2.219205043729744e-06
the O 0 1.404767147050734e-07
mutation O 0 1.2933995776620577e-06
occurred O 0 8.438563980917024e-08
at O 0 7.601592244554922e-09
the O 0 2.981769942067558e-09
penultimate O 0 3.439456008891284e-07
nucleotide O 0 8.779741023090537e-08
of O 0 7.413925029453594e-09
exon O 0 7.178057330747833e-07
6 O 0 1.5400037511881237e-07
( O 0 5.944486680675709e-09
- O 0 5.545017529584584e-07
2 O 0 5.0987704725002914e-08
position O 0 5.3641439734519736e-08
of O 0 4.411496501433021e-09
exon O 0 6.580626745744667e-07
6 O 0 1.270241938300387e-07
- O 0 1.8217752995042247e-06
intron O 0 2.510661943233572e-05
6 O 0 1.970927030470193e-07
splice O 0 1.2686998616118217e-06
site O 0 1.02647128130684e-07
) O 0 1.6009503722713703e-09
of O 0 6.794798612652642e-10
the O 0 4.693945232503438e-09
gene O 0 6.228547277942198e-08
, O 0 9.688244873018448e-09
we O 0 5.664365865243326e-09
hypothesized O 0 1.3757072281350702e-07
that O 0 9.501854414395439e-09
the O 0 2.2565190604950658e-08
mutation O 0 5.856790266989265e-06
may O 0 2.8344040856609354e-06
partially O 0 3.833102255157428e-06
affect O 0 3.0046191312749215e-08
the O 0 6.922939110864945e-09
normal O 0 3.004315374255384e-08
splicing O 0 3.569745103959576e-07
efficiency O 0 1.4342411702727986e-07
in O 0 3.331441433829241e-08
exon O 0 3.3486182928754715e-06
6 O 0 3.257402454437397e-07
and O 0 5.682743520196709e-08
cause O 0 2.7542509428712947e-07
alternative O 0 1.658491015632535e-07
splicing O 0 1.8207800849268096e-06
elsewhere O 0 1.8353250652580755e-07
, O 0 1.182824860279652e-08
which O 0 4.725216484757766e-08
resulted O 0 2.751507395259978e-07
in O 0 2.426786807063763e-07
decreased O 0 1.3811083590553608e-05
transcript O 0 6.365769877447747e-06
in O 0 6.091509163752562e-08
the O 0 2.7500041710482037e-07
patient O 0 0.0002761315554380417
. O 0 2.1571499928541016e-06

Transfection O 0 0.001431610551662743
of O 0 2.656548758750432e-06
constructed O 0 4.2645067878765985e-05
minigenes O 0 0.00133081478998065
, O 0 2.2255328246956196e-07
with O 0 3.903975454022657e-08
or O 0 1.6167854610671384e-08
without O 0 1.5816508991406408e-08
the O 0 1.5230705585622673e-08
mutation O 0 2.5099845402110077e-07
, O 0 6.2183600491039215e-09
into O 0 8.653088023891087e-09
COS O 0 4.92644448968349e-06
- O 0 7.866393389122095e-06
1 O 0 1.2852409270180942e-07
cells O 0 9.44512095202299e-08
confirmed O 0 1.1235157870714829e-07
that O 0 3.3428269041735348e-09
the O 0 3.5621015026521263e-09
mutant O 0 1.2017355857096845e-06
minigene O 0 3.8970083551248536e-06
was O 0 2.9239939181024965e-07
responsible O 0 2.123988274149724e-08
for O 0 3.870070042211182e-09
a O 0 6.688988918313044e-08
mRNA O 0 1.2055954812240088e-07
species O 0 1.2504897561882444e-08
alternatively O 0 1.5493121452436753e-07
spliced O 0 7.884764272603206e-06
at O 0 2.8508756244605138e-08
an O 0 3.348450761109234e-08
activated O 0 4.177395112492377e-06
cryptic O 0 3.053261934837792e-06
5 O 0 6.022608545208641e-08
splice O 0 9.455130225433095e-07
site O 0 3.9982987232178857e-07
88 O 0 3.517476443448686e-07
bp O 0 2.3659456473978935e-06
upstream O 0 6.52650271604216e-08
from O 0 3.6575660278259647e-09
the O 0 2.5007313997349456e-09
3 O 0 1.696361984215855e-08
end O 0 2.590568470850485e-08
of O 0 2.9589678263164387e-08
exon O 0 6.4198948166449554e-06
6 O 0 1.9189387785445433e-06
. O 0 7.577347105325316e-07

Our O 0 3.096535692748148e-06
data O 0 7.954406555654714e-07
suggest O 0 2.9548010616053944e-07
that O 0 2.12674908794952e-08
the O 0 1.8197329865188294e-08
C O 0 2.6079533199663274e-07
to O 0 3.0094884806430855e-08
A O 0 6.157783445814857e-06
mutation O 0 9.535260119264422e-07
at O 0 3.313796792525636e-09
the O 0 2.2521924325502596e-09
penultimate O 0 3.569227828847943e-07
nucleotide O 0 5.1731802841459285e-08
of O 0 3.4339668886218533e-09
exon O 0 5.520050194718351e-07
6 O 0 4.1872603162573796e-08
of O 0 1.6663864732535671e-09
the O 0 1.6535265601191895e-08
CYP27 O 0 0.00013009991380386055
gene O 0 2.4897178718674695e-07
not O 0 4.3479371214516505e-08
only O 0 9.037746195872387e-08
causes O 0 2.0361760562082054e-06
the O 0 4.264863491698634e-06
deficiency B-Disease 0 0.0444570817053318
in I-Disease 0 1.518803216526976e-08
the I-Disease 0 2.1124213489542853e-08
sterol I-Disease 0 0.0005934410728514194
27 I-Disease 0 4.461429398361361e-06
- I-Disease 0 2.8599765755643602e-06
hydroxylase I-Disease 0 1.0373528311902191e-05
activity I-Disease 0 3.879154419905717e-08
, O 0 1.2750732025779143e-08
but O 0 5.1111950227777925e-08
also O 0 6.807757131355174e-07
partially O 0 6.3366478570969775e-06
leads O 0 8.961344377667047e-08
to O 0 1.6085726528558553e-08
alternative O 0 1.6305541805650137e-08
pre O 0 9.145990276238081e-08
- O 0 1.4331882880469493e-07
mRNA O 0 4.182606261338151e-08
splicing O 0 6.993066392624314e-08
of O 0 1.934458371266601e-09
the O 0 2.0101580844311684e-08
gene O 0 8.066504051384982e-07
. O 0 8.463773042421963e-07

To O 0 3.199882257831632e-06
our O 0 1.67015542729132e-07
knowledge O 0 1.8139630242330895e-08
, O 0 7.852202443814349e-09
this O 0 1.7615057190667471e-09
is O 0 6.90749368814636e-09
the O 0 4.220090943363175e-09
first O 0 2.1455078069720912e-07
report O 0 6.186421330767189e-08
regarding O 0 9.578277726518536e-09
effects O 0 1.3292573441958666e-07
on O 0 8.749565694188277e-08
pre O 0 4.063633411988121e-07
- O 0 2.409619810350705e-07
mRNA O 0 2.8027077547676527e-08
splicing O 0 7.615440011932151e-08
of O 0 1.0152626517268004e-09
a O 0 3.67460160077826e-08
mutation O 0 2.429875962661754e-07
at O 0 3.4404377124985785e-09
the O 0 7.937279278280585e-09
- O 0 4.254337909515016e-06
2 O 0 1.0925145232931754e-07
position O 0 6.304840383108967e-08
of O 0 1.3245714525211838e-09
a O 0 9.563039071736057e-08
5 O 0 1.0434415997906399e-07
splice O 0 5.097816028865054e-06
site O 0 3.4199204037577147e-06
. O 0 6.475398208749539e-07

ATM O 0 0.0015931602101773024
germline O 0 0.12745337188243866
mutations O 0 0.23732337355613708
in O 0 1.3263706023280974e-05
classical O 1 0.5806493759155273
ataxia B-Disease 1 1.0
- I-Disease 1 0.9999998807907104
telangiectasia I-Disease 1 1.0
patients O 1 0.9998617172241211
in O 0 1.631652963851593e-07
the O 0 8.941385232219545e-08
Dutch O 0 0.002537210239097476
population O 0 8.484461773150542e-07
. O 0 9.404527077094826e-07

Germline O 1 0.5378988981246948
mutations O 0 0.21375778317451477
in O 0 7.3579712989158e-07
the O 0 4.222145832954993e-08
ATM O 0 1.9660194539028453e-06
gene O 0 3.78423152369578e-07
are O 0 7.613316199694964e-09
responsible O 0 6.088976789442313e-08
for O 0 1.305850219068816e-07
the O 0 0.024248937144875526
autosomal B-Disease 1 1.0
recessive I-Disease 1 1.0
disorder I-Disease 1 1.0
ataxia B-Disease 1 1.0
- I-Disease 1 0.9999997615814209
telangiectasia I-Disease 1 0.9999998807907104
( O 0 0.00020329318067524582
A B-Disease 1 0.9999808073043823
- I-Disease 1 0.9999465942382812
T I-Disease 1 0.9999897480010986
) O 0 2.9078032639517915e-06
. O 0 1.1642168828984722e-06

In O 0 4.159744094067719e-06
our O 0 2.1123312876625278e-07
study O 0 7.125146339603816e-08
, O 0 1.0750922818658637e-08
we O 0 7.483454744772189e-09
have O 0 1.0666525440683472e-08
determined O 0 4.791048624497307e-08
the O 0 7.247653144304422e-09
ATM O 0 9.539735401631333e-07
mutation O 0 7.15207761459169e-07
spectrum O 0 2.2053156101264904e-07
in O 0 2.8616080172128022e-08
19 O 0 2.0374957898638968e-07
classical O 0 2.2064882614358794e-06
A B-Disease 1 0.9999927282333374
- I-Disease 1 0.9999990463256836
T I-Disease 1 1.0
patients O 1 0.9357841610908508
, O 0 2.2206370076105486e-08
including O 0 8.16982748119699e-09
some O 0 1.8204342921990246e-08
immigrant O 0 8.312359568662941e-06
populations O 0 7.883991059998152e-08
, O 0 7.636556276224837e-09
as O 0 1.729522836058095e-08
well O 0 2.1449713116794555e-08
as O 0 2.564214085509775e-08
12 O 0 1.6495198096322383e-08
of O 0 2.7544273528690155e-09
Dutch O 0 2.7447549655335024e-05
ethnic O 0 3.6986187978982343e-07
origin O 0 4.04194679504144e-07
. O 0 6.818523274887411e-07

Both O 0 2.3542233975604177e-06
the O 0 8.453836386479452e-08
protein O 0 1.671758695920289e-07
truncation O 0 2.046283270829008e-06
test O 0 8.705467848812987e-07
( O 0 2.3525300818505457e-08
PTT O 0 3.1392244181915885e-06
) O 0 6.488655390768372e-09
and O 0 3.2079661149708727e-09
the O 0 5.587950990815216e-09
restriction O 0 3.4149431371588435e-07
endonuclease O 0 1.959243672899902e-05
fingerprinting O 0 9.319741366198286e-06
( O 0 3.401823178705854e-08
REF O 0 8.570014870201703e-06
) O 0 5.373992806312344e-09
method O 0 3.549183702489245e-08
were O 0 3.186003638688817e-08
used O 0 1.0714938269984486e-07
and O 0 8.901720605081209e-08
compared O 0 5.238794642536959e-07
for O 0 3.1972153813342175e-09
their O 0 3.5741474224693093e-09
detection O 0 4.698103239775264e-08
efficiency O 0 8.162510312104132e-08
, O 0 1.168596330813898e-08
identifying O 0 4.848744694641027e-08
76 O 0 1.7462443793192506e-06
% O 0 1.2073232191767147e-08
and O 0 1.443288244473706e-08
60 O 0 1.0157729235515944e-07
% O 0 7.3356605234664585e-09
of O 0 7.807217095034957e-10
the O 0 8.527407402425524e-08
mutations O 0 6.8872031988576055e-06
, O 0 1.322387817026538e-07
respectively O 0 1.2520741847765748e-06
. O 0 8.061021503635857e-07

Most O 0 0.0004942537052556872
patients O 0 0.006525635719299316
were O 0 2.661041946794285e-07
found O 0 5.6430600636758754e-08
to O 0 5.2567511232837205e-08
be O 0 2.087998751676423e-07
compound O 0 4.9751402002584655e-06
heterozygote O 0 0.0002267374802613631
. O 0 1.3967268159831292e-06

Seventeen O 0 0.0003817701945081353
mutations O 0 0.00037112741847522557
were O 0 1.3576121773439809e-06
distinct O 0 3.3953028832911514e-07
, O 0 3.754316324489082e-08
of O 0 5.114507484194064e-09
which O 0 2.441208550862939e-07
10 O 0 3.474606202757968e-08
were O 0 1.4023309802269068e-07
not O 0 2.483445769030368e-07
reported O 0 2.6329512365919072e-06
previously O 0 1.443596033823269e-06
. O 0 6.441762252507033e-07

Mutations O 0 0.10403593629598618
are O 0 7.467679665751348e-07
small O 0 2.617089478462731e-07
deletions O 0 1.855185291788075e-05
or O 0 5.024946858611656e-07
point O 0 1.1135138038298464e-06
mutations O 0 8.357675142178778e-06
frequently O 0 1.0172324209634098e-06
affecting O 0 4.3310606656632444e-07
splice O 0 1.209098809340503e-05
sites O 0 1.5638853483324056e-06
. O 0 1.4250438198359916e-06

Moreover O 0 0.0001420100888935849
, O 0 8.345007813659322e-07
a O 0 1.7602204707145575e-06
16 O 0 4.497745067055803e-06
. O 0 1.8077861341225798e-06

7 O 0 7.671708590351045e-05
- O 0 8.251195686170831e-05
kb O 0 4.4837084715254605e-05
genomic O 0 2.1575840492005227e-06
deletion O 0 1.6501466006957344e-06
of O 0 5.212716924773986e-09
the O 0 5.507281297667532e-09
3 O 0 2.9564009906835054e-08
end O 0 1.2502058943653083e-08
of O 0 2.183341063499711e-09
the O 0 9.284327973091422e-09
gene O 0 7.116834410680895e-08
, O 0 9.575757076163427e-09
most O 0 9.904516318215428e-09
likely O 0 2.0447915005661343e-07
a O 0 4.510260964707413e-07
result O 0 6.92080277531204e-08
of O 0 3.3543490207676996e-09
recombination O 0 3.749964960775287e-08
between O 0 8.805814744050622e-09
two O 0 2.3003403626375984e-08
LINE O 0 2.777134113784996e-06
elements O 0 1.7187126388762408e-07
, O 0 1.0298521146978601e-07
was O 0 3.89925344279618e-06
identified O 0 2.102466396536329e-06
. O 0 7.449854138030787e-07

The O 0 1.5409776779051754e-06
most O 0 4.503452828430454e-07
frequently O 0 1.2333023278188193e-06
found O 0 2.5828774141700706e-07
mutation O 0 1.48248250297911e-06
, O 0 3.4169033824582584e-08
identified O 0 1.9157921826717939e-07
in O 0 7.315275052377501e-09
three O 0 5.294697302815621e-08
unrelated O 0 1.2714784816125757e-06
Turkish O 0 0.000521052919793874
A B-Disease 1 0.9999713897705078
- I-Disease 1 0.9999604225158691
T I-Disease 1 0.999998927116394
individuals O 0 3.6088385968469083e-07
, O 0 3.3677487465411104e-08
was O 0 2.538964054110693e-06
previously O 0 7.041960543574532e-07
described O 0 2.8465242962738557e-07
to O 0 1.49872843024923e-08
be O 0 1.1905499697206778e-08
a O 0 3.629984348663129e-07
Turkish O 0 0.001695897663012147
A B-Disease 1 0.9999809265136719
- I-Disease 1 0.9999479055404663
T I-Disease 1 0.9999935626983643
founder O 0 0.000977249350398779
mutation O 0 2.559161112003494e-05
. O 0 2.210432967331144e-06

The O 0 2.2762103526474675e-06
presence O 0 4.961614195053698e-07
of O 0 9.787202159827757e-09
a O 0 5.851223932040739e-07
founder O 0 3.71842943422962e-05
mutation O 0 3.00471924674639e-06
among O 0 1.7961772513785945e-08
relatively O 0 6.192855295239497e-08
small O 0 3.167306061868658e-08
ethnic O 0 9.914121079646065e-08
population O 0 4.650601681532862e-08
groups O 0 4.383515772587998e-09
in O 0 1.2405476645938052e-08
Western O 0 4.082514948322569e-08
Europe O 0 6.986959988353192e-08
could O 0 2.7217316755923093e-07
indicate O 0 6.550197184651552e-08
a O 0 1.1256016563265803e-07
high O 0 3.197513365194027e-07
carrier O 0 5.5572008932358585e-06
frequency O 0 3.5215609273109294e-07
in O 0 1.0153367924203849e-08
such O 0 1.6744607478358375e-08
communities O 0 1.3481815130944597e-07
. O 0 1.013966539176181e-06

In O 0 6.22984443907626e-05
patients O 0 9.846116154221818e-05
of O 0 3.828494854474229e-08
Dutch O 0 0.0003574109578039497
ethnic O 0 5.539404241972079e-07
origin O 0 3.1308897519011225e-07
, O 0 1.6741229558192572e-07
however O 0 1.791454451449681e-07
, O 0 2.042218305575716e-08
no O 0 4.3268165939025494e-08
significant O 0 2.741482596491096e-08
founder O 0 6.007384172335151e-07
effect O 0 1.2262496795756306e-07
could O 0 1.3110600605159561e-07
be O 0 7.791054912331674e-08
identified O 0 1.2611603779077996e-06
. O 0 3.8170628613443114e-07

The O 0 1.7840156942838803e-06
observed O 0 2.600430661914288e-06
genetic O 0 1.8078688981404412e-06
heterogeneity O 0 4.551818619802361e-06
including O 0 6.813051101062229e-08
the O 0 1.9834864417589415e-08
relative O 0 2.185862740589073e-06
high O 0 2.0290683266921405e-07
percentage O 0 4.1198195077640776e-08
of O 0 2.477175353732264e-09
splice O 0 7.773205652483739e-06
- O 0 0.0025407762732356787
site O 0 1.0657095117494464e-05
mutations O 0 2.2286621970124543e-06
had O 0 1.9175652710146096e-07
no O 0 3.0690149088741236e-08
reflection O 0 1.786389560720636e-07
on O 0 1.5121210594770673e-07
the O 0 7.083336868163315e-07
phenotype O 0 0.08971934020519257
. O 0 1.2811991609851248e-06

All O 0 2.7373022021492943e-05
patients O 0 0.0029144263826310635
manifested O 0 1.4775360796193127e-05
classical O 0 4.9912696340470575e-06
A B-Disease 1 0.9995622038841248
- I-Disease 1 0.9993129968643188
T I-Disease 1 0.999988317489624
and O 0 1.7844378135123407e-06
increased O 0 5.266842890705448e-07
cellular O 0 1.4656332041340647e-06
radioresistant O 0 1.0815486348292325e-05
DNA O 0 1.7261174889426911e-06
synthesis O 0 2.0082436549273552e-06
. O 0 9.462969501328189e-07

Determination O 0 3.256254058214836e-05
of O 0 1.0484489365580885e-07
the O 0 5.341641795553187e-08
genomic O 0 4.862702098762384e-07
structure O 0 7.634142207280092e-08
of O 0 2.9789675171087993e-09
the O 0 2.31345698153973e-08
COL4A4 O 0 0.00018343949341215193
gene O 0 2.5162353267660365e-07
and O 0 1.3809356325111821e-08
of O 0 2.2319575521123625e-08
novel O 0 7.578448276035488e-05
mutations O 0 0.001739062019623816
causing O 0 0.006533351261168718
autosomal B-Disease 1 0.9999697208404541
recessive I-Disease 1 0.9999983310699463
Alport I-Disease 1 0.9999998807907104
syndrome I-Disease 1 0.9999991655349731
. O 0 3.772153286263347e-05

Autosomal B-Disease 1 0.9999905824661255
recessive I-Disease 1 0.9999995231628418
Alport I-Disease 1 1.0
syndrome I-Disease 1 0.9999998807907104
is O 0 0.0001902066433103755
a O 0 6.358195241773501e-05
progressive O 1 0.9375616908073425
hematuric B-Disease 1 0.9997633099555969
glomerulonephritis I-Disease 1 0.9999994039535522
characterized O 0 0.037810277193784714
by O 0 4.992574304196751e-06
glomerular B-Disease 0 0.11705237627029419
basement I-Disease 0 0.36747679114341736
membrane I-Disease 1 0.7011460661888123
abnormalities I-Disease 1 0.999546229839325
and O 0 2.0094273622817127e-06
associated O 0 4.860796138927981e-07
with O 0 2.725523984281608e-07
mutations O 0 6.737530839018291e-06
in O 0 2.283850086826078e-08
either O 0 5.291608218271904e-08
the O 0 2.164971490969947e-08
COL4A3 O 0 0.00017442222451791167
or O 0 1.3486299188514295e-08
the O 0 2.6122114249460537e-08
COL4A4 O 0 0.0006921114400029182
gene O 0 4.436949723185535e-07
, O 0 7.43771977340657e-09
which O 0 3.4124663095269625e-09
encode O 0 1.4252849567242265e-08
the O 0 7.116614408886335e-09
alpha3 O 0 7.442309197358554e-06
and O 0 2.0457160587739054e-07
alpha4 O 0 4.604710193234496e-05
type O 0 1.8235488823847845e-05
IV O 0 0.15127438306808472
collagen O 0 0.00021158292656764388
chains O 0 1.3358188880374655e-05
, O 0 1.66565712333977e-07
respectively O 0 7.065707450237824e-07
. O 0 5.080811433799681e-07

To O 0 5.77460696149501e-06
date O 0 2.1728787942265626e-06
, O 0 1.2816215644306794e-07
mutation O 0 3.162428754421853e-07
screening O 0 9.786030119585121e-08
in O 0 1.0729495514283371e-08
the O 0 5.923107337935107e-09
two O 0 2.7282123227223565e-08
genes O 0 1.1159467305787985e-07
has O 0 1.1547746225915034e-06
been O 0 3.972832303134055e-07
hampered O 0 1.4579736671294086e-05
by O 0 1.1930315224617516e-07
the O 0 2.150665423528153e-08
lack O 0 1.1094567753389128e-07
of O 0 6.3138640982174365e-09
genomic O 0 1.324320464846096e-06
structure O 0 5.897846335756185e-07
information O 0 7.775037147439434e-08
. O 0 3.1547597245662473e-07

We O 0 5.12550514031318e-06
report O 0 6.483103334176121e-07
here O 0 1.644571945291773e-08
the O 0 8.5755695877765e-09
complete O 0 1.1277915490381929e-07
characterization O 0 6.047287683941249e-07
of O 0 4.417761267916376e-09
the O 0 2.865693460307739e-08
48 O 0 3.342940715356235e-07
exons O 0 1.9745523616165883e-07
of O 0 5.0040509513848974e-09
the O 0 2.6509804129659642e-08
COL4A4 O 0 0.00021935939730610698
gene O 0 1.3960793410205952e-07
, O 0 5.943296521593311e-09
a O 0 2.7140433900285643e-08
comprehensive O 0 1.0617328172202178e-07
gene O 0 1.531009417021778e-07
screen O 0 5.0378152991470415e-06
, O 0 1.961156037566525e-08
and O 0 5.919944978671765e-09
the O 0 7.064074658558184e-09
subsequent O 0 1.064632684233402e-07
detection O 0 7.482073272058187e-08
of O 0 4.90248330820009e-09
10 O 0 4.499838013316548e-08
novel O 0 8.553745374229038e-07
mutations O 0 1.2939917723997496e-06
in O 0 8.587439737084424e-08
eight O 0 0.00028953576111234725
patients O 1 0.9628071188926697
diagnosed O 1 0.9879228472709656
with O 0 0.0008907162118703127
autosomal B-Disease 1 0.9999903440475464
recessive I-Disease 1 0.9999988079071045
Alport I-Disease 1 0.9999997615814209
syndrome I-Disease 1 0.9999991655349731
. O 0 3.6474222724791616e-05

Furthermore O 0 0.00022789266949985176
, O 0 7.054893558233744e-07
we O 0 3.009253290997549e-08
identified O 0 3.925255143144568e-08
a O 0 2.0873011763455906e-08
glycine O 0 1.4623114452660957e-07
to O 0 2.2819296674470024e-08
alanine O 0 1.4866319020256924e-07
substitution O 0 3.774161072556126e-08
in O 0 1.0612161815970467e-08
the O 0 1.5905662564819067e-08
collagenous O 0 4.158368756179698e-05
domain O 0 1.6197786578686646e-07
that O 0 1.8995564232682227e-08
is O 0 2.314617830734278e-08
apparently O 0 4.130621164222248e-06
silent O 0 2.3849611352488864e-06
in O 0 1.369823188213104e-08
the O 0 2.2447055769703184e-08
heterozygous O 0 4.864584752795054e-06
carriers O 0 1.1647583164631214e-07
, O 0 2.1069649136506996e-08
in O 0 4.889533400387336e-08
11 O 0 3.788904336943233e-07
. O 0 7.744635581730108e-07

5 O 0 1.7129954358097166e-05
% O 0 2.0804615985525743e-07
of O 0 2.315671876473857e-09
all O 0 2.8993172307423265e-09
control O 0 2.301076847288641e-06
individuals O 0 1.496888657470663e-08
, O 0 9.391708744033167e-09
and O 0 2.3862339659785903e-08
in O 0 8.922897087870751e-09
one O 0 4.4503664753392513e-08
control O 0 4.5473092313841335e-07
individual O 0 6.460129764462863e-09
homozygous O 0 1.3419665378933132e-07
for O 0 3.261556136280319e-09
this O 0 6.615938907827967e-09
glycine O 0 4.360353216270596e-07
substitution O 0 1.094011281566054e-06
. O 0 8.073955086729256e-07

There O 0 9.842870895226952e-06
has O 0 1.7022923657350475e-06
been O 0 2.561179428539617e-07
no O 0 2.9115044597460837e-08
previous O 0 2.5343448228909438e-08
finding O 0 1.0561437058242973e-08
of O 0 1.1876372107977318e-09
a O 0 4.884015680772791e-08
glycine O 0 2.7799643476100755e-07
substitution O 0 7.14455197226016e-08
that O 0 5.8064312469241486e-08
is O 0 3.024028671916312e-08
not O 0 5.472592690125566e-08
associated O 0 1.456373688313306e-08
with O 0 5.806074288017271e-09
any O 0 4.707082013055697e-08
obvious O 0 8.151923975674435e-05
phenotype O 0 0.1721768081188202
in O 0 4.6129099473546376e-07
homozygous O 0 7.463867223123088e-05
individuals O 0 3.93626180539286e-07
. O 0 8.181454518307874e-07

Founder O 0 0.0012066276976838708
BRCA1 O 0 0.057339705526828766
and O 0 1.8696142433327623e-05
BRCA2 O 0 0.003403555369004607
mutations O 0 1.3696184396394528e-05
in O 0 4.5145901594878524e-07
French O 0 0.00021647654648404568
Canadian O 0 0.13461951911449432
breast B-Disease 1 0.9998881816864014
and I-Disease 1 0.9994310736656189
ovarian I-Disease 1 1.0
cancer I-Disease 1 0.9999984502792358
families O 0 7.272690254467307e-06
. O 0 1.6142730601131916e-06

We O 0 2.5788237962842686e-06
have O 0 1.98842641907504e-07
identified O 0 3.0659379035569145e-07
four O 0 4.536843434266302e-08
mutations O 0 1.5382950380171678e-07
in O 0 3.3284042189052343e-09
each O 0 2.096973039655836e-09
of O 0 4.168627221190491e-09
the O 0 9.048490028362721e-06
breast B-Disease 1 0.9999717473983765
cancer I-Disease 1 0.9657491445541382
- O 0 0.12588484585285187
susceptibility O 1 0.6464142203330994
genes O 0 2.1404607650765684e-06
, O 0 2.0540595357942948e-07
BRCA1 O 0 2.0964493160136044e-05
and O 0 6.045015652489383e-07
BRCA2 O 0 0.00018765027925837785
, O 0 6.006341379816149e-08
in O 0 4.2419387114023266e-08
French O 0 8.978004188975319e-05
Canadian O 0 0.08783949166536331
breast B-Disease 1 0.9999427795410156
cancer I-Disease 1 0.9977948665618896
and O 0 0.04699920490384102
breast B-Disease 1 0.9999978542327881
/ I-Disease 1 0.9999982118606567
ovarian I-Disease 1 1.0
cancer I-Disease 1 0.9999991655349731
families O 0 2.2374317723006243e-06
from O 0 4.2546361100903596e-07
Quebec O 0 0.00020709923410322517
. O 0 4.66728170067654e-06

To O 0 1.4825510334048886e-05
identify O 0 1.2014001185889356e-05
founder O 0 9.955436325981282e-06
effects O 0 9.092068466998171e-06
, O 0 8.210759716575922e-08
we O 0 3.004951665275257e-08
examined O 0 1.763273303367896e-06
independently O 0 4.724486473151046e-07
ascertained O 0 3.800955710175913e-06
French O 0 8.782587428868283e-06
Canadian O 0 0.0002761031500995159
cancer B-Disease 0 0.0021427005995064974
families O 0 2.9309443760894283e-08
for O 0 4.947733334148552e-09
the O 0 6.147790276855858e-09
distribution O 0 1.1312649483841142e-08
of O 0 1.921191872256145e-09
these O 0 1.4219532218362474e-08
eight O 0 3.392373741917254e-07
mutations O 0 5.5371301641571335e-06
. O 0 6.270882408898615e-07

Mutations O 0 0.15832191705703735
were O 0 1.2739527846861165e-05
found O 0 5.316241526998056e-07
in O 0 7.208695507188168e-08
41 O 0 4.510755502451502e-07
of O 0 2.0058569916159286e-08
97 O 0 4.045856258017011e-06
families O 0 9.137722258856229e-07
. O 0 1.5195905689324718e-06

Six O 0 3.951776307076216e-06
of O 0 4.479576887206349e-08
eight O 0 4.995818585484813e-07
mutations O 0 3.0774497190577677e-06
were O 0 2.3203203625143942e-07
observed O 0 2.522898228107806e-07
at O 0 3.4034325580023506e-08
least O 0 2.400779521849472e-07
twice O 0 3.463072289378033e-06
. O 0 1.0188692840529257e-06

The O 0 2.6677689675125293e-05
BRCA1 O 0 0.0014300273032858968
C4446T O 0 0.00026293908013030887
mutation O 0 7.774133700877428e-05
was O 0 1.1094784895249177e-06
the O 0 3.6707348272102536e-08
most O 0 1.172949097849596e-07
common O 0 4.904258048554766e-07
mutation O 0 4.177227765467251e-06
found O 0 2.1732280686137528e-07
, O 0 2.1724254395394382e-08
followed O 0 8.63633999870217e-08
by O 0 2.4973484613610708e-08
the O 0 2.157412239967016e-07
BRCA2 O 0 0.0006488918443210423
8765delAG O 0 5.727818643208593e-05
mutation O 0 8.664917004352901e-06
. O 0 1.1449513976913295e-06

Together O 0 1.0429763278807513e-05
, O 0 3.14879628149356e-07
these O 0 2.6511422390740336e-08
mutations O 0 2.740892739439005e-07
were O 0 7.88940610618738e-08
found O 0 9.742840489934679e-08
in O 0 5.902855093609105e-08
28 O 0 4.604449372891395e-07
of O 0 6.406850161511102e-09
41 O 0 5.8414502746018115e-06
families O 0 6.615146475041911e-08
identified O 0 1.0305595310455828e-07
to O 0 3.836214190755527e-08
have O 0 1.2484120759381767e-07
a O 0 4.849207016377477e-06
mutation O 0 2.3552884158561938e-05
. O 0 7.42847817036818e-07

The O 0 3.0480773602903355e-06
odds O 0 7.775927770126145e-06
of O 0 3.1727598326369844e-08
detection O 0 1.2290080064758513e-07
of O 0 2.8783240235696894e-09
any O 0 5.69388314275443e-09
of O 0 2.5809596682080382e-09
the O 0 3.636289491737443e-08
four O 0 9.624528729546e-07
BRCA1 O 0 0.0010368293151259422
mutations O 0 1.6436222722404636e-05
was O 0 1.056824294209946e-05
18 O 0 1.5147392105063773e-06
. O 0 9.367701068185852e-07

7x O 0 0.02767445705831051
greater O 0 2.357690937060397e-05
if O 0 7.661915333301295e-07
one O 0 7.989731187763027e-08
or O 0 2.691125366993674e-08
more O 0 7.400901580467689e-08
cases O 0 6.157008101581596e-06
of O 0 0.003380141220986843
ovarian B-Disease 1 1.0
cancer I-Disease 1 0.9999996423721313
were O 0 9.086079444386996e-06
also O 0 4.635294317267835e-07
present O 0 3.03040899041207e-08
in O 0 1.97002627544407e-08
the O 0 8.500175852077518e-08
family O 0 2.129530912498012e-06
. O 0 1.092019260795496e-06

The O 0 3.5423001918388763e-06
odds O 0 1.0081187610921916e-05
of O 0 1.4619454979936108e-08
detection O 0 7.143326286040974e-08
of O 0 3.4451264063761755e-09
any O 0 4.589173041580352e-09
of O 0 2.5399666814251987e-09
the O 0 3.673564563655418e-08
four O 0 4.0074592106975615e-06
BRCA2 O 0 0.01504136435687542
mutations O 0 6.410166861314792e-06
was O 0 1.7641699514570064e-06
5 O 0 6.850532372482121e-07
. O 0 8.07129083568725e-07

3x O 0 0.0035267567727714777
greater O 0 1.036790035868762e-05
if O 0 2.8501995075203013e-07
there O 0 3.947087279243533e-08
were O 0 3.15353183566458e-08
at O 0 7.574006311017456e-09
least O 0 2.376513741353392e-08
five O 0 3.496445089012923e-08
cases O 0 2.408944226317544e-07
of O 0 1.1525125955813564e-06
breast B-Disease 1 0.9999692440032959
cancer I-Disease 0 0.2976936995983124
in O 0 6.014629860828791e-08
the O 0 1.0330983002404537e-07
family O 0 2.388022494415054e-06
. O 0 7.862536790526065e-07

Interestingly O 0 0.00034373035305179656
, O 0 3.2705162311685854e-07
the O 0 9.457374439136856e-09
presence O 0 1.854873588058581e-08
of O 0 7.79071029910483e-09
a O 0 0.007664017379283905
breast B-Disease 1 0.999983549118042
cancer I-Disease 1 0.9181463122367859
case O 0 3.0441094622801756e-06
< O 0 5.25154007391393e-07
36 O 0 1.415119328385117e-07
years O 0 1.4216060328919866e-08
of O 0 2.417171574009558e-09
age O 0 1.1510490338650925e-07
was O 0 1.4952955496028153e-07
strongly O 0 1.634316220133769e-07
predictive O 0 5.752977116912916e-08
of O 0 9.32507293605056e-10
the O 0 3.3630036533338625e-09
presence O 0 6.523364515231833e-09
of O 0 3.6885436371925096e-10
any O 0 1.200472943274633e-09
of O 0 6.734299784483255e-10
the O 0 1.1785798115226953e-08
eight O 0 4.798337727152102e-07
mutations O 0 3.64152720067068e-06
screened O 0 1.4762656974198762e-05
. O 0 1.697688048807322e-06

Carriers O 0 2.2894884750712663e-05
of O 0 6.241533867523685e-08
the O 0 2.6567814614963936e-08
same O 0 1.017838471284449e-07
mutation O 0 4.5278531501935504e-07
, O 0 7.308845972886502e-09
from O 0 2.01977656821839e-09
different O 0 4.7808588199416135e-09
families O 0 2.7042357686468677e-08
, O 0 2.124879827647419e-08
shared O 0 3.965559969287824e-08
similar O 0 1.849083020033504e-07
haplotypes O 0 2.3957869416335598e-05
, O 0 2.3092555423431804e-08
indicating O 0 7.104275567826335e-08
that O 0 2.3498201162652776e-09
the O 0 2.784663832855472e-09
mutant O 0 1.8240231156596565e-06
alleles O 0 1.9037135245980608e-07
were O 0 9.744531581645788e-08
likely O 0 3.0512660487147514e-07
to O 0 1.6890999177121557e-07
be O 0 5.183858320378931e-07
identical O 0 5.832265287608607e-06
by O 0 5.065000507897821e-08
descent O 0 2.1087616914883256e-06
for O 0 1.6414787751273252e-08
a O 0 1.115492977987742e-06
mutation O 0 1.910178298203391e-06
in O 0 1.9361129588446602e-08
the O 0 6.088163218009868e-08
founder O 0 1.5386032828246243e-05
population O 0 2.850808584753395e-07
. O 0 4.772051624968299e-07

The O 0 8.819179697638901e-07
identification O 0 3.088358369041089e-07
of O 0 4.435494105337057e-08
common O 0 8.897823136067018e-07
BRCA1 O 0 0.0033606227952986956
and O 0 4.667559187510051e-05
BRCA2 O 0 0.07583124190568924
mutations O 0 5.542138296732446e-06
will O 0 5.507325795406359e-08
facilitate O 0 1.0562468588659613e-07
carrier O 0 4.366854682302801e-06
detection O 0 2.9829237746525905e-07
in O 0 9.226464925404798e-08
French O 0 6.102374754846096e-05
Canadian O 0 0.011394084431231022
breast B-Disease 1 0.9999140501022339
cancer I-Disease 1 0.9887588024139404
and O 0 0.049396321177482605
breast B-Disease 1 0.9999972581863403
/ I-Disease 1 0.9999974966049194
ovarian I-Disease 1 1.0
cancer I-Disease 1 0.9999995231628418
families O 0 8.90226147021167e-06
. O 0 2.416139523120364e-06

Are O 0 8.075378900684882e-06
Dp71 O 0 0.00012617799802683294
and O 0 3.240486421418609e-06
Dp140 O 0 0.0007227378664538264
brain O 0 0.000669953238684684
dystrophin O 0 0.00012440506543498486
isoforms O 0 3.3636006264714524e-06
related O 0 3.0867093414599367e-07
to O 0 2.8941258278791793e-07
cognitive B-Disease 0 0.004577917046844959
impairment I-Disease 0 0.04683563485741615
in O 0 5.4886710131540895e-05
Duchenne B-Disease 1 0.9999537467956543
muscular I-Disease 1 0.9999929666519165
dystrophy I-Disease 1 0.9999841451644897
? O 0 0.0005510883638635278

Molecular O 0 0.0005089229089207947
study O 0 1.0543951248109806e-05
and O 0 5.536847993425908e-07
neuropsychological O 0 4.147580693825148e-05
analysis O 0 2.682398871911573e-07
were O 0 1.0484829715551314e-07
performed O 0 1.4327181929729704e-07
concurrently O 0 2.2035517588392395e-07
on O 0 1.2016117807434057e-06
49 O 0 0.0003077674191445112
patients O 0 5.36163970537018e-05
with O 0 2.206370118074119e-05
Duchenne B-Disease 1 0.9999932050704956
muscular I-Disease 1 0.9999997615814209
dystrophy I-Disease 1 0.9999997615814209
( O 0 0.00024276530893985182
DMD B-Disease 1 0.9999997615814209
) O 0 5.824550157740305e-07
in O 0 5.6150057048398594e-08
order O 0 2.8341119673314097e-08
to O 0 6.634074622979824e-08
find O 0 1.4634052547535248e-07
a O 0 5.76520221784449e-07
molecular O 0 1.6977463701550732e-06
explanation O 0 2.3432428974956565e-07
for O 0 1.722704467965741e-08
the O 0 1.6609396880085114e-07
cognitive B-Disease 0 0.001567052211612463
impairment I-Disease 0 9.348995081381872e-05
observed O 0 1.4937576509055361e-07
in O 0 1.0451984167048067e-07
most O 0 6.658044731011614e-05
DMD B-Disease 1 1.0
patients O 1 0.9998453855514526
. O 0 8.665247150929645e-06

Complete O 0 2.9207851184764877e-05
analysis O 0 8.150715871124703e-07
of O 0 2.5321803320821346e-08
the O 0 5.689977555789483e-08
dystrophin O 0 5.258558667264879e-05
gene O 0 5.487811449711444e-07
was O 0 5.42691907412518e-07
performed O 0 7.11667098585167e-08
to O 0 1.4592600017238055e-08
define O 0 4.713694679026048e-08
the O 0 8.418609809268673e-09
localization O 0 1.2109374836200004e-07
of O 0 6.573611877058738e-09
deletions O 0 1.043149495671969e-06
and O 0 1.0155637397701867e-07
duplications O 0 4.942043574374111e-07
in O 0 3.941069337543013e-08
relation O 0 3.8157374149250245e-08
to O 0 3.3108729979858254e-08
the O 0 7.179030347970183e-08
different O 0 6.518851591863495e-07
DMD B-Disease 1 0.9999967813491821
promoters O 0 0.0006091429386287928
. O 0 3.834352810372366e-06

Qualitative O 0 9.749081073096022e-05
analysis O 0 3.3009721391863422e-06
of O 0 4.8158586452018426e-08
the O 0 3.835314288380687e-08
Dp71 O 0 2.5208177248714492e-05
transcript O 0 2.1521856979234144e-05
and O 0 5.6269922055207644e-08
testing O 0 2.9415797797582854e-08
for O 0 3.3471525551220793e-09
the O 0 1.7504198090989576e-09
specific O 0 3.5267309073105935e-09
first O 0 2.2046885206350453e-08
exon O 0 2.2298625879102474e-07
of O 0 5.663782332021583e-09
Dp140 O 0 1.8934593981612124e-06
were O 0 1.375683638116243e-07
also O 0 8.182635014009065e-08
carried O 0 3.7617283510371635e-07
out O 0 2.7217888032282644e-07
. O 0 4.865392497777066e-07

Neuropsychological O 0 0.016661912202835083
analysis O 0 3.68769615306519e-05
assessed O 0 1.7664258848526515e-05
verbal O 0 1.0209079846390523e-05
and O 0 1.254255266758264e-06
visuospatial O 0 0.00012763947597704828
intelligence O 0 1.5421685475303093e-06
, O 0 8.657367800424254e-08
verbal O 0 1.7679290067462716e-06
memory O 0 9.68466429185355e-06
, O 0 5.8425364102276944e-08
and O 0 4.164043687637786e-08
reading O 0 7.551031444563705e-07
skills O 0 4.693016535384231e-07
. O 0 4.875025183537218e-07

Comparison O 0 5.623582910629921e-05
of O 0 4.0503164200345054e-07
molecular O 0 3.502484332784661e-06
and O 0 3.7952585785205883e-07
psychometric O 0 0.00016867190424818546
findings O 0 1.5984689525794238e-05
demonstrated O 0 9.138332188740605e-07
that O 0 3.475554066767472e-08
deletions O 0 7.155625780796981e-07
and O 0 4.823617416604975e-08
duplications O 0 4.384714031857584e-07
that O 0 2.118858191124673e-07
were O 0 2.8498163828771794e-07
localized O 0 2.542841230024351e-06
in O 0 3.638946921569186e-08
the O 0 3.290525896204599e-08
distal O 0 4.8711837735027075e-05
part O 0 9.318998905882836e-08
of O 0 3.4399130210971407e-09
the O 0 6.3911294034824095e-09
gene O 0 1.084362111214432e-07
seemed O 0 6.427047196666535e-07
to O 0 4.2509046949135154e-08
be O 0 6.284634679332157e-08
preferentially O 0 6.795291028538486e-06
associated O 0 3.3685395806060114e-07
with O 0 6.758012887075893e-07
cognitive B-Disease 0 0.010428637266159058
impairment I-Disease 0 0.001782046863809228
. O 0 2.9733434985246276e-06

Two O 0 8.038911801122595e-06
altered O 0 2.2448257368523628e-05
Dp71 O 0 3.635976099758409e-05
transcripts O 0 2.5418519271624973e-06
and O 0 3.387449254432795e-08
two O 0 1.573748598104885e-08
deleted O 0 7.449335726050776e-07
Dp140 O 0 1.503119278822851e-06
DNA O 0 1.4323903485546907e-07
sequences O 0 3.510779578164147e-08
were O 0 3.083572153173009e-08
found O 0 2.963729350824451e-08
in O 0 2.139626609221068e-08
four O 0 1.1476931831566617e-06
patients O 0 6.787088932469487e-05
with O 0 1.1767549949581735e-05
severe O 1 0.999975323677063
cerebral B-Disease 1 0.9999920129776001
dysfunction I-Disease 1 0.9989721775054932
. O 0 2.99697567243129e-05

These O 0 4.30879890700453e-06
findings O 0 8.01453188614687e-06
suggest O 0 5.088530770080979e-07
that O 0 1.4496005285025149e-08
some O 0 5.864047469827938e-09
sequences O 0 2.971291124254094e-08
located O 0 3.414955429548172e-08
in O 0 8.553319830184591e-09
the O 0 1.6342747599651375e-08
distal O 0 2.7611815312411636e-05
part O 0 9.689135538337723e-08
of O 0 4.34713864905234e-09
the O 0 2.2870146665354696e-08
gene O 0 2.0755032892338932e-07
and O 0 3.0025166353198074e-08
, O 0 2.0990189142366944e-08
in O 0 2.0338413619924722e-08
particular O 0 4.546406984218265e-08
, O 0 9.080164886654529e-08
some O 0 2.026604590810166e-07
DMD B-Disease 1 0.9999988079071045
isoforms O 0 2.800982110784389e-05
expressed O 0 6.73047281907202e-07
in O 0 2.1377868364425012e-08
the O 0 1.166486853776405e-07
brain O 0 0.0032849085982888937
may O 0 1.2035568488499848e-06
be O 0 3.3310666225361274e-08
related O 0 8.847298005321136e-09
to O 0 5.62011699400955e-08
the O 0 6.451709850807674e-07
cognitive B-Disease 0 0.309461772441864
impairment I-Disease 0 0.31330406665802
associated O 0 1.6671556295477785e-06
with O 0 1.3365910490392707e-05
DMD B-Disease 1 0.9999996423721313
. O 0 1.8370272300671786e-05
. O 0 2.447218321321998e-06

I1307K O 0 0.0016984570538625121
APC O 0 0.0003121545014437288
and O 0 4.481022187974304e-06
hMLH1 O 0 6.700126687064767e-05
mutations O 0 8.629877811472397e-06
in O 0 4.75041055381098e-08
a O 0 6.111852712820109e-07
non O 0 5.214749307924649e-07
- O 0 5.347123078536242e-05
Jewish O 0 5.646784870805277e-07
family O 0 2.3191191189653182e-07
with O 0 2.185075800298364e-07
hereditary B-Disease 1 0.9079192280769348
non I-Disease 0 0.002543379319831729
- I-Disease 1 0.9999877214431763
polyposis I-Disease 1 0.9999995231628418
colorectal I-Disease 1 1.0
cancer I-Disease 1 0.9999998807907104
. O 0 2.5789326173253357e-05

We O 0 3.108557166342507e-06
describe O 0 2.4771732114459155e-06
a O 0 9.504283298156224e-07
French O 0 1.4469990674115252e-05
Canadian O 0 2.4116383428918198e-05
hereditary B-Disease 1 0.7585530877113342
non I-Disease 0 0.016480423510074615
- I-Disease 1 0.9999979734420776
polyposis I-Disease 1 0.9999998807907104
colorectal I-Disease 1 1.0
cancer I-Disease 1 1.0
( O 0 0.00012074851110810414
HNPCC B-Disease 1 0.8340936303138733
) O 0 9.806869911699323e-07
kindred O 0 2.1309884687070735e-05
which O 0 2.5729696062626317e-07
carries O 0 5.6556456229373e-07
a O 0 1.3829513534346916e-07
novel O 0 9.317263334196468e-07
truncating O 0 7.205511337815551e-06
mutation O 0 3.007325176440645e-06
in O 0 9.797609124007067e-08
hMLH1 O 0 3.7053214327897877e-05
. O 0 2.287976030856953e-06

Interestingly O 0 0.0005388092831708491
, O 0 5.666080369337578e-07
the O 0 8.876661894419158e-08
I1307K O 0 8.622103450761642e-06
APC O 0 1.5174839063547552e-05
polymorphism O 0 0.001097994390875101
, O 0 2.456868628541997e-07
associated O 0 3.3861056181194726e-08
with O 0 8.537738516167792e-09
an O 0 1.1762177365426396e-07
increased O 0 1.0846142686204985e-05
risk O 0 3.889441359206103e-06
of O 0 0.000329469155985862
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
, O 0 1.0724065759859513e-05
is O 0 4.2526608012849465e-07
also O 0 2.4262197939606267e-07
present O 0 2.140295940478154e-08
in O 0 2.1149169526779588e-08
this O 0 5.9249405381933684e-08
family O 0 2.1066368844913086e-06
. O 0 8.976044796327187e-07

The O 0 5.690797024726635e-06
I1307K O 0 6.095018034102395e-05
polymorphism O 0 0.0006923648179508746
has O 0 3.465514055278618e-06
previously O 0 4.0718225591263035e-07
only O 0 3.2093939950073036e-08
been O 0 1.2038481145282276e-07
identified O 0 1.434041365655503e-07
in O 0 8.560109954203199e-09
individuals O 0 2.0904198372306837e-09
of O 0 3.8944838465226894e-09
self O 0 6.826312892371789e-05
- O 0 0.03494507074356079
reported O 0 5.5343862186418846e-05
Ashkenazi O 0 2.519849658710882e-06
Jewish O 0 1.9063186584844516e-07
origins O 0 5.149337880538951e-07
. O 0 7.610022407789074e-07

In O 0 4.708214419224532e-06
addition O 0 5.304472097122925e-07
, O 0 4.198255965093267e-08
in O 0 1.059082865850769e-08
this O 0 2.8933907714190354e-08
family O 0 4.777160711455508e-07
, O 0 1.5564348032626185e-08
there O 0 1.3420685007758948e-08
appears O 0 7.378630471066572e-07
to O 0 3.5028936196113136e-08
be O 0 7.826502468333274e-08
no O 0 4.005484655067448e-08
relationship O 0 2.7529161172878958e-08
between O 0 4.923764951314524e-09
the O 0 1.131534776988019e-08
I1307K O 0 1.0237139576929621e-05
polymorphism O 0 1.6100166249088943e-05
and O 0 2.4916484875348033e-08
the O 0 5.857340390491572e-09
presence O 0 1.090187353725014e-07
or O 0 2.466295612180147e-08
absence O 0 5.718068223359296e-07
of O 0 4.2703192093540565e-07
cancer B-Disease 0 0.018355585634708405
. O 0 4.5159336536926276e-07
. O 0 9.72557018030784e-07

Identification O 0 1.6054933439590968e-05
of O 0 1.7605736957193585e-07
a O 0 6.966493515392358e-07
novel O 0 3.1014621981739765e-06
mutation O 0 5.707395303033991e-07
of O 0 3.1189193450131825e-09
the O 0 2.4869384773751335e-08
CPO O 0 0.00013552079326473176
gene O 0 4.823976382795081e-07
in O 0 2.755936812093296e-08
a O 0 1.0101908856086084e-06
Japanese O 0 5.6886863603722304e-05
hereditary B-Disease 1 0.8663153052330017
coproporphyria I-Disease 0 0.028240829706192017
family O 0 9.435192623641342e-06
. O 0 1.4712373967995518e-06

Hereditary B-Disease 1 0.9998995065689087
coproporphyria I-Disease 1 0.9950141310691833
( O 0 0.00021056980767752975
HCP B-Disease 1 0.7470585107803345
) O 0 6.741277616129082e-07
is O 0 3.1212098861033155e-07
an O 0 3.208885118510807e-06
autosomal B-Disease 1 0.999458372592926
dominant I-Disease 1 0.9996975660324097
disease I-Disease 1 0.9271253347396851
characterized O 0 0.00031320052221417427
by O 0 2.9828777314833133e-06
a O 0 0.02108663320541382
deficiency B-Disease 0 0.09672683477401733
of I-Disease 0 5.243963130396878e-08
coproporphyrinogen I-Disease 0 0.0019111778819933534
oxidase I-Disease 0 1.0386228495917749e-05
( O 0 1.35855728444767e-07
CPO O 0 0.00012066138151567429
) O 0 1.1667772525925102e-07
caused O 0 6.94107484378037e-07
by O 0 1.9936742035042698e-08
a O 0 1.312898461947043e-06
mutation O 0 1.4072438716539182e-06
in O 0 1.3133420573296917e-08
the O 0 3.9733279777465214e-08
CPO O 0 0.0010599251836538315
gene O 0 6.0336619753798004e-06
. O 0 1.1271329185547074e-06

Only O 0 7.96364383859327e-06
11 O 0 8.41193411815766e-07
mutations O 0 5.546974080061773e-07
of O 0 3.2975360220177663e-09
the O 0 1.1677853350988698e-08
gene O 0 1.9033394949019566e-07
have O 0 1.7858307899132342e-07
been O 0 1.9219644400436664e-06
reported O 0 1.2530545973277185e-05
in O 0 8.590729976276634e-07
HCP B-Disease 1 0.9996376037597656
patients O 1 0.8960734605789185
. O 0 2.206572617069469e-06

We O 0 3.775561708607711e-06
report O 0 4.347680260252673e-07
another O 0 1.9818457985820714e-07
mutation O 0 5.085988732389524e-07
in O 0 2.2658564802213732e-08
a O 0 6.989092753428849e-07
Japanese O 0 8.504961442667991e-06
family O 0 4.130097295274027e-06
. O 0 1.1299193829472642e-06

Polymerase O 0 0.00014269993698690087
chain O 0 6.630508869420737e-05
reaction O 0 6.070369636290707e-06
- O 0 5.217592388362391e-06
single O 0 1.0044232112704776e-06
strand O 0 4.900531166640576e-06
conformational O 0 4.523754341789754e-06
polymorphism O 0 1.876965689007193e-05
and O 0 3.384291247243709e-08
direct O 0 4.2332899852226546e-08
sequence O 0 8.056250777599416e-08
analyses O 0 2.9385327593445254e-07
demonstrated O 0 2.9025343906141643e-07
a O 0 1.27675647831893e-07
C O 0 2.640849743329454e-07
to O 0 6.381460337934186e-08
T O 0 9.315850775237777e-07
substitution O 0 1.981595687539084e-08
in O 0 1.0791642246488209e-08
exon O 0 2.143021049505478e-07
1 O 0 8.110518479043094e-09
of O 0 1.0011996787184785e-09
the O 0 8.91769058597447e-09
CPO O 0 1.847274324973114e-05
gene O 0 1.0924895121888767e-07
at O 0 3.5391298780496072e-09
nucleotide O 0 3.072441501217327e-08
position O 0 1.1888053563779977e-07
85 O 0 8.283005570319801e-08
, O 0 9.27385102045264e-09
which O 0 5.226767996191484e-08
lies O 0 9.854283433696764e-08
in O 0 7.243797561784504e-09
the O 0 8.99380658836435e-09
putative O 0 5.731618557547336e-07
presequence O 0 1.4414965789910639e-06
for O 0 1.7011508646191942e-08
targeting O 0 2.0891080509954918e-07
to O 0 4.136694258249918e-07
mitochondria O 0 2.4505705368937925e-05
. O 0 2.4210685296566226e-06

This O 0 1.8015902014667518e-06
mutation O 0 4.0218701542471536e-06
changes O 0 5.499034116951407e-08
the O 0 1.4004847948001498e-08
codon O 0 1.2199126331324806e-07
for O 0 2.2548110933939824e-08
glutamine O 0 6.875095550640253e-07
to O 0 3.706941242853645e-08
a O 0 3.1524649557468365e-07
termination O 0 1.1947192888328573e-06
codon O 0 2.403033363407303e-07
at O 0 2.347330863017305e-08
amino O 0 1.366589117424155e-07
acid O 0 1.2646422646866995e-06
position O 0 1.0659721283445833e-06
29 O 0 3.7094175695528975e-06
. O 0 7.296514468180249e-07

MaeI O 0 0.0006430957582779229
restriction O 0 3.034717337868642e-05
analysis O 0 2.48835362981481e-06
showed O 0 1.9022013475478161e-06
two O 0 2.4197468917463993e-08
other O 0 1.2397482151982331e-08
carriers O 0 9.864061922826295e-08
in O 0 2.0480461770944203e-08
the O 0 5.9111023631430726e-08
family O 0 3.496706995065324e-06
. O 0 9.76711930888996e-07

The O 0 1.0836103683686815e-05
C O 0 6.802762800361961e-05
- O 0 0.005918899551033974
T O 0 0.036063916981220245
mutation O 0 4.093574716534931e-06
is O 0 4.725387725557084e-08
located O 0 2.8530951823313444e-08
within O 0 5.229776611770376e-09
a O 0 2.0826929869599553e-07
recently O 0 1.3389679907049867e-06
proposed O 0 1.765257451324942e-07
putative O 0 9.584181270838599e-07
alternative O 0 8.749883306791162e-08
translation O 0 6.816027564582328e-08
initiation O 0 4.832375566365954e-08
codon O 0 2.5598362185519363e-07
( O 0 2.1787412762819258e-08
TIC O 0 1.314346604885941e-06
- O 0 2.5192393877659924e-06
1 O 0 6.374805394671057e-08
) O 0 1.091023182908657e-08
, O 0 1.1757149032121106e-08
supporting O 0 3.72524233682725e-08
that O 0 5.1686335211797996e-08
TIC O 0 8.89277634996688e-06
- O 0 1.130603595811408e-05
1 O 0 7.368576149247019e-08
is O 0 1.2866384402343556e-08
the O 0 5.937948355239087e-09
real O 0 9.32182544488569e-08
TIC O 0 2.1770811144961044e-06
rather O 0 6.026997567687431e-08
than O 0 2.8680666730451776e-08
TIC O 0 7.503991582780145e-06
- O 0 8.141120815707836e-06
2 O 0 6.039484219400038e-07
. O 0 9.959494207123498e-08
. O 0 3.5776926665676e-07

Human B-Disease 0 3.8931517337914556e-05
complement I-Disease 0 0.00011615048424573615
factor I-Disease 0 0.011802438646554947
H I-Disease 1 0.9999995231628418
deficiency I-Disease 1 0.999765932559967
associated O 0 0.00019724802405107766
with O 0 0.34122925996780396
hemolytic B-Disease 1 0.9999992847442627
uremic I-Disease 1 1.0
syndrome I-Disease 1 0.9999997615814209
. O 0 8.091553172562271e-05

This O 0 1.1091093483628356e-06
study O 0 4.363847665445064e-07
reports O 0 2.3788001612956577e-07
on O 0 2.0834397673752392e-07
six O 0 6.49159801469068e-07
cases O 0 1.0893440958170686e-06
of O 0 6.480606771219755e-07
deficiency B-Disease 0 0.20632842183113098
in I-Disease 0 2.2759444107123272e-08
the I-Disease 0 8.003592455452235e-09
human I-Disease 0 8.324926525915544e-09
complement I-Disease 0 2.9651259225715876e-08
regulatory I-Disease 0 2.3946009264363965e-07
protein I-Disease 0 3.8635749888271675e-07
Factor I-Disease 0 4.863193225901341e-07
H I-Disease 1 0.9999030828475952
( O 0 1.7416759590105357e-07
FH O 0 0.0017145671881735325
) O 0 1.7052245837589908e-08
in O 0 2.328769399539965e-09
the O 0 1.5235259720469685e-09
context O 0 1.2003041227615086e-08
of O 0 1.847522490550091e-08
an O 0 0.0004360356542747468
acute B-Disease 1 0.9999990463256836
renal I-Disease 1 1.0
disease I-Disease 1 0.9999998807907104
. O 0 0.00014560895215254277

Five O 0 3.6866279060632223e-06
of O 0 5.1868049411041284e-08
the O 0 5.1526484412534046e-08
cases O 0 3.413998683754471e-07
were O 0 6.003363637319126e-07
observed O 0 6.56813710975257e-07
in O 0 7.723954098537433e-08
children O 0 1.0701555765990634e-06
presenting O 0 5.01685872222879e-06
with O 0 0.07666421681642532
idiopathic O 1 0.9999998807907104
hemolytic B-Disease 1 1.0
uremic I-Disease 1 1.0
syndrome I-Disease 1 1.0
( O 0 0.0003927203069906682
HUS B-Disease 1 0.9998990297317505
) O 0 5.744736881752033e-06
. O 0 6.19805950918817e-06

Two O 0 1.117059923672059e-06
of O 0 4.036853695765785e-08
the O 0 9.633649966644953e-08
children O 0 1.5422582464452717e-06
exhibited O 0 5.120737478137016e-05
a O 0 0.015265457332134247
homozygous O 1 0.9998643398284912
deficiency O 1 0.9365392327308655
characterized O 0 4.521519713307498e-06
by O 0 4.7487709764482133e-08
the O 0 1.647853054009829e-08
absence O 0 9.802918299328667e-08
of O 0 1.9847721244303784e-09
the O 0 5.315701656627425e-09
150 O 0 2.5259719649284307e-08
- O 0 9.530859870210406e-07
kD O 0 1.9502285795169882e-06
form O 0 2.147431388266341e-08
of O 0 3.815910254445498e-09
Factor O 0 1.778861644652352e-07
H O 1 0.98687344789505
and O 0 4.946726406274138e-08
the O 0 1.050428188875685e-08
presence O 0 8.58683364413082e-08
, O 0 1.3417869482168499e-08
upon O 0 1.1977130398577174e-08
immunoblotting O 0 1.15205534712004e-06
, O 0 3.503867196386068e-09
of O 0 4.723481605850566e-10
the O 0 7.131343515709432e-09
42 O 0 1.9496117431572202e-07
- O 0 1.8583814380690455e-06
kD O 0 8.68945244292263e-06
Factor O 0 6.064109925318917e-07
H O 0 0.3081674575805664
- O 0 1.3005908385821385e-06
like O 0 5.958656856819289e-08
protein O 0 4.453125868053576e-08
1 O 0 1.750454003968116e-08
( O 0 5.759187793330511e-09
FHL O 0 3.14595558847941e-06
- O 0 1.2067649549862836e-05
1 O 0 6.304696142933608e-08
) O 0 4.641037776309531e-09
and O 0 9.555213509315763e-09
other O 0 1.210858613376331e-08
FH O 0 0.034990206360816956
- O 0 0.0010521980002522469
related O 0 1.1700393542923848e-06
protein O 0 8.44402052280202e-07
( O 0 2.4809972742900754e-08
FHR O 0 7.523740805481793e-06
) O 0 4.262539121668851e-08
bands O 0 5.008236030334956e-07
. O 0 4.565838196413097e-07

Southern O 0 3.263559483457357e-05
blot O 0 0.0005400449736043811
and O 0 5.226563644100679e-07
PCR O 0 1.476172747061355e-05
analysis O 0 1.0711995912515704e-07
of O 0 3.856004404667601e-09
DNA O 0 5.867988761565357e-08
of O 0 2.010989152978482e-09
one O 0 1.9635464809653058e-07
patient O 0 4.079560312675312e-05
with O 0 5.557979875447927e-06
homozygous O 1 0.9815981388092041
deficiency O 0 0.07385768741369247
ruled O 0 2.135927843482932e-06
out O 0 3.629312317343647e-08
the O 0 4.576358847430129e-09
presence O 0 1.537140192908737e-08
of O 0 9.34950672437651e-10
a O 0 8.957277941590291e-08
large O 0 3.432587192264691e-08
deletion O 0 1.4871100120217307e-06
of O 0 4.3751295919491895e-09
the O 0 6.749531422656219e-08
FH O 0 0.008073867298662663
gene O 0 1.9920175020615716e-07
as O 0 1.8061710349570603e-08
the O 0 1.6398640667603104e-08
underlying O 0 9.68310450844001e-06
defect O 0 3.92188158002682e-05
for O 0 2.997507237978425e-07
the O 0 3.8173086068127304e-05
deficiency O 1 0.737321138381958
. O 0 2.409710077699856e-06

The O 0 1.5938496744638542e-06
other O 0 9.620245577934838e-08
four O 0 2.1414275863662624e-07
children O 0 5.315126259120007e-07
presented O 0 1.6720086932764389e-06
with O 0 5.4512602218892425e-05
heterozygous O 1 0.9997988343238831
deficiency O 1 0.7660411596298218
and O 0 3.728380875145376e-07
exhibited O 0 1.494269963586703e-05
a O 0 1.3395592759479769e-06
normal O 0 1.8316706018595141e-07
immunoblotting O 0 1.042754502122989e-05
pattern O 0 1.176639656819134e-07
of O 0 1.7808561292298464e-09
proteins O 0 6.674024888297936e-09
of O 0 4.2171457437234494e-09
the O 0 3.420265386466781e-07
FH O 1 0.9169140458106995
family O 0 1.4744589861948043e-05
. O 0 1.8913586927737924e-06

Factor B-Disease 1 0.976436972618103
H I-Disease 1 0.9999996423721313
deficiency I-Disease 1 0.9995940327644348
is O 0 5.700464953406481e-07
the O 0 1.7152937914488575e-07
only O 0 4.37355374742765e-05
complement B-Disease 1 0.9999902248382568
deficiency I-Disease 1 0.9999995231628418
associated O 0 6.231349743757164e-06
with O 0 8.600882210885175e-06
HUS B-Disease 1 0.9998787641525269
. O 0 3.143409048789181e-05

These O 0 1.7540688759254408e-06
observations O 0 3.612303089539637e-06
suggest O 0 6.204761575645534e-07
a O 0 8.779539939496317e-08
role O 0 1.3983378721604822e-07
for O 0 2.0084645768747578e-07
FH O 0 0.46453240513801575
and O 0 1.3210673387220595e-05
/ O 0 2.777002373477444e-05
or O 0 3.5687648392013216e-07
FH O 0 0.046609118580818176
receptors O 0 5.56873374080169e-06
in O 0 5.514337075851472e-08
the O 0 5.102632982811883e-08
pathogenesis O 0 2.74274789262563e-05
of O 0 5.04471529438888e-07
idiopathic O 1 0.9998024106025696
HUS B-Disease 1 0.9999827146530151
. O 0 1.1733933206414804e-05
. O 0 2.009854824791546e-06

Further O 0 6.164117166918004e-06
evidence O 0 7.246480890898965e-07
for O 0 2.0573995840322823e-08
a O 0 1.5458790869615768e-07
major O 0 7.246578093145217e-08
ancient O 0 5.2278249995652e-07
mutation O 0 0.0012236370239406824
underlying O 0 0.13399092853069305
myotonic B-Disease 1 0.9999998807907104
dystrophy I-Disease 1 1.0
from O 0 7.026001640042523e-06
linkage O 0 0.00022021356562618166
disequilibrium O 0 0.0023731307592242956
studies O 0 5.737711035180837e-07
in O 0 1.927277892832535e-08
the O 0 1.2227086898519701e-08
Japanese O 0 1.4149441085464787e-06
population O 0 4.839855591853848e-07
. O 0 9.616445595383993e-07

The O 0 0.03437628597021103
myotonic B-Disease 1 0.9999997615814209
dystrophy I-Disease 1 1.0
( O 1 0.9708629250526428
DM B-Disease 1 1.0
) O 0 9.449459321331233e-05
mutation O 0 3.179554914822802e-05
is O 0 2.1256667537272733e-07
an O 0 7.774975756547065e-07
unstable O 0 0.0070514073595404625
( O 0 1.225537857862946e-07
CTG O 0 1.6115847756736912e-05
) O 0 4.014042787048311e-08
n O 0 1.53828494831032e-07
repeat O 0 1.6969582361525681e-07
, O 0 9.919830290527898e-09
present O 0 5.698696181610785e-09
at O 0 2.0381469845176525e-09
a O 0 2.7279210002006948e-08
copy O 0 1.281691339727331e-07
number O 0 3.9638643478667746e-09
of O 0 1.4292069749899383e-09
5 O 0 4.041522316811097e-08
- O 0 7.892875146353617e-06
37 O 0 1.1203651411051396e-06
repeats O 0 1.1194664750746597e-07
on O 0 4.9419828229702034e-08
normal O 0 4.3116664016906725e-08
chromosomes O 0 7.172830152057941e-08
but O 0 2.0464840488898517e-08
amplified O 0 3.5758205285674194e-07
to O 0 2.3524538761421354e-08
50 O 0 2.7872157914998752e-08
- O 0 1.1009221907443134e-06
3000 O 0 6.665496812274796e-07
copies O 0 3.63941950354274e-07
on O 0 3.804390189543483e-06
DM B-Disease 1 0.9999977350234985
chromosomes O 0 0.00018195166194345802
. O 0 2.921587110904511e-06

Previous O 0 0.00011647224164335057
findings O 0 2.179033799620811e-05
in O 0 5.529734607989667e-07
Caucasian O 0 2.0094994397368282e-05
populations O 0 1.9059424971601402e-07
of O 0 2.0957225288498194e-08
a O 0 0.02000957354903221
DM B-Disease 1 1.0
founder O 0 0.299930214881897
chromosome O 0 0.00019323638116475195
raise O 0 5.712072379537858e-07
a O 0 1.6784809986347682e-07
question O 0 1.0061567934371851e-07
about O 0 1.63570632594201e-08
the O 0 6.1579532584232766e-09
molecular O 0 1.1783532727349666e-07
events O 0 1.4878567711207324e-08
involved O 0 2.4896248618233585e-08
in O 0 1.3407636778595133e-08
the O 0 2.545220212368804e-08
expansion O 0 2.564659780546208e-06
mutation O 0 1.2196025636512786e-05
. O 0 1.1153993000334594e-06

To O 0 4.119810455449624e-06
investigate O 0 5.1472247832862195e-06
whether O 0 4.0751908159109007e-07
a O 0 7.757126923024771e-07
founder O 0 6.957577170396689e-06
chromosome O 0 8.076456651906483e-06
for O 0 4.831905187074881e-08
the O 0 1.2365575230433024e-06
DM B-Disease 1 1.0
mutation O 0 0.0068602971732616425
exists O 0 4.6905377359962586e-08
in O 0 2.5067199427297737e-09
the O 0 3.1719411541786258e-09
Japanese O 0 2.39759913256421e-07
population O 0 2.6997522439842214e-08
, O 0 8.458460598603779e-09
we O 0 1.0266216321497268e-08
genotyped O 0 2.164428451578715e-06
families O 0 1.2132351123739227e-08
using O 0 2.6478877757085684e-08
polymorphic O 0 7.160539098549634e-06
markers O 0 2.7703542855306296e-06
near O 0 2.042813207481231e-07
the O 0 3.4460679643188996e-08
( O 0 4.0619784869022624e-08
CTG O 0 6.707911779813003e-06
) O 0 3.2385596426820484e-08
n O 0 1.972974956743201e-07
repeat O 0 3.832068102838093e-07
region O 0 1.749637021930539e-07
and O 0 2.467359649926948e-07
constructed O 0 5.3599833336193115e-05
haplotypes O 0 0.00015233733574859798
. O 0 1.4864209560983e-06

Six O 0 1.780802631401457e-05
different O 0 3.8816713754386e-07
haplotypes O 0 1.899950802908279e-05
were O 0 5.492649393090687e-07
found O 0 6.595039394596824e-07
and O 0 2.3477427021134645e-05
DM B-Disease 1 1.0
alleles O 0 0.0008475253125652671
were O 0 3.211842567907297e-06
always O 0 1.4926213225407992e-06
haplotype O 0 0.00014817067130934447
A O 0 6.8188883233233355e-06
. O 0 1.9609149148891447e-06

To O 0 4.650087703339523e-06
find O 0 6.254201139199722e-07
an O 0 4.347538862248257e-08
origin O 0 1.3037008805838468e-08
of O 0 1.9400194783969482e-09
the O 0 2.9325102346433596e-08
( O 0 3.303549434008346e-08
CTG O 0 5.55769929633243e-06
) O 0 2.5644046885986427e-08
n O 0 1.6842133732097864e-07
repeat O 0 3.2250730441774067e-07
mutation O 0 2.878441591747105e-07
and O 0 7.147425318265732e-09
to O 0 2.0020690882915915e-08
investigate O 0 8.31117503707901e-08
the O 0 3.0497222525127654e-09
mechanism O 0 6.581917677550564e-09
of O 0 1.4760944688774202e-09
the O 0 2.7586122275380376e-09
expansion O 0 5.27538333017219e-08
mutation O 0 1.516491039410539e-07
in O 0 3.077360588576994e-09
the O 0 1.7615929825964827e-09
Japanese O 0 8.31188913252845e-08
population O 0 8.632482284554044e-09
we O 0 2.6561770560817877e-09
have O 0 6.750751513351361e-09
studied O 0 4.725604085820123e-08
90 O 0 5.18919947012364e-08
Japanese O 0 6.851389571238542e-06
DM B-Disease 1 0.9999990463256836
families O 0 8.557490787097777e-07
comprising O 0 3.721052266314473e-08
190 O 0 2.414109587789426e-07
affected O 0 1.0006755246649846e-07
and O 0 1.0472398059846455e-07
130 O 0 1.0254689186695032e-06
unaffected O 0 5.188775321585126e-05
members O 0 3.774838432946126e-07
. O 0 5.722988589695888e-07

The O 0 4.092669314559316e-06
results O 0 2.8173615191917634e-06
suggest O 0 3.4674172866289155e-07
that O 0 1.638425928263132e-08
a O 0 1.234208895084521e-07
few O 0 1.4602322551127145e-07
common O 0 1.0012081474997103e-07
ancestral O 0 1.4541165000991896e-06
mutations O 0 1.6862428537933738e-06
in O 0 3.0166088293981375e-08
both O 0 5.061630048430743e-08
Caucasian O 0 2.4810030936350813e-06
and O 0 1.3495991879608482e-07
Japanese O 0 8.417037520302983e-07
populations O 0 5.519840584611302e-08
have O 0 1.5979766843088328e-08
originated O 0 7.850045946611317e-09
by O 0 3.2217628564978895e-09
expansion O 0 9.875654072288853e-09
of O 0 2.0918398124791793e-09
an O 0 3.2175396569300574e-08
ancestral O 0 2.0380610976644675e-07
n O 0 5.228113764133013e-07
= O 0 1.467158625700904e-07
5 O 0 1.701501339823608e-08
repeat O 0 1.5717064627551736e-07
to O 0 1.3833641787641682e-07
n O 0 2.2117530988907674e-06
= O 0 8.968523843577714e-07
19 O 0 3.1586793625137943e-07
- O 0 1.7088115100705181e-06
37 O 0 9.408410619471397e-07
copies O 0 9.64351897891902e-07
. O 0 5.439696337816713e-07

These O 0 2.252689000670216e-06
data O 0 6.526129823214433e-07
support O 0 1.1509217756611179e-07
multistep O 0 4.776190507982392e-06
models O 0 1.1985995342911338e-06
of O 0 2.3643519142524383e-08
triplet O 0 2.410428896837402e-05
repeat O 0 2.333488708927689e-07
expansion O 0 4.447404933216603e-08
that O 0 2.424634715225693e-08
have O 0 2.1670290450970242e-08
been O 0 4.4776804486446053e-08
proposed O 0 6.146525777239731e-08
for O 0 4.819497689823038e-08
both O 0 4.955621079716366e-06
DM B-Disease 1 0.9999998807907104
and O 0 0.0027347304858267307
Friedreichs B-Disease 0 0.3374525010585785
ataxia I-Disease 1 0.9237393140792847
. O 0 1.9819849512714427e-06
. O 0 1.2192175518066506e-06

The O 0 1.3860782246410963e-06
molecular O 0 2.6448799417266855e-06
basis O 0 2.6014228637905035e-07
of O 0 4.291607638151618e-06
C6 B-Disease 1 1.0
deficiency I-Disease 1 0.9999997615814209
in O 0 3.8916758171581023e-07
the O 0 4.929066932390924e-08
western O 0 4.469101497761585e-07
Cape O 0 2.4468540686939377e-06
, O 0 2.266457954647194e-07
South O 0 1.790684223124117e-07
Africa O 0 4.866673180004e-07
. O 0 9.68266590462008e-07

Deficiency B-Disease 1 0.9966944456100464
of I-Disease 0 2.5734163955348777e-07
the I-Disease 0 4.793507457634405e-08
sixth I-Disease 0 4.7525270474579884e-07
component I-Disease 0 9.417202306849504e-08
of I-Disease 0 9.00310936913229e-09
human I-Disease 0 9.359791874885559e-08
complement I-Disease 0 6.10874053563748e-07
( O 0 1.5903211192380695e-07
C6 O 0 0.0009590237750671804
) O 0 5.997137719759849e-08
has O 0 1.0665569334378233e-06
been O 0 6.437929869207437e-07
reported O 0 3.196876150468597e-07
in O 0 5.59312285375313e-09
a O 0 5.682613490876065e-08
number O 0 1.0361802971203815e-08
of O 0 2.180028824128044e-09
families O 0 1.9121921823739285e-08
from O 0 5.9548250774810185e-09
the O 0 1.428864226937776e-08
western O 0 2.0149222734744399e-07
Cape O 0 8.754855684856011e-07
, O 0 9.767196473831063e-08
South O 0 1.5188632573881478e-07
Africa O 0 3.6237375411474204e-07
. O 0 1.0084102086693747e-06

Meningococcal B-Disease 1 0.9998767375946045
disease I-Disease 1 0.9986122846603394
is O 0 1.2508255167631432e-05
endemic O 0 4.308581083023455e-06
in O 0 1.2505761048942077e-07
the O 0 7.096583232168996e-08
Cape O 0 3.1487531941820635e-06
and O 0 1.1778645614413108e-07
almost O 0 3.448480967449541e-08
all O 0 3.1833538027825625e-09
pedigrees O 0 2.914689503086265e-07
of O 0 4.363672445606426e-08
total O 0 0.01230218168348074
C6 B-Disease 1 1.0
deficiency I-Disease 1 1.0
( O 0 4.794549681719218e-07
C6Q0 O 0 0.0006611878052353859
) O 0 6.651558948078673e-08
have O 0 3.965514849824103e-08
been O 0 1.917503027470957e-07
ascertained O 0 7.777304062983603e-07
because O 0 3.371348000769103e-08
of O 0 5.67474955914804e-08
recurrent O 1 0.9929797053337097
disease O 1 0.5617847442626953
. O 0 4.001607976533705e-06

We O 0 2.1201244635449257e-06
have O 0 1.65026008858149e-07
sequenced O 0 2.8777913030353375e-07
the O 0 1.9470265399945674e-08
expressed O 0 8.589438493800117e-08
exons O 0 2.7304048444420914e-07
of O 0 4.3282586403847745e-09
the O 0 5.448980644473522e-08
C6 O 0 0.001868263934738934
gene O 0 3.381227031695744e-07
from O 0 1.1187850645910657e-08
selected O 0 2.6968907107516316e-08
cases O 0 6.393729279352556e-08
and O 0 2.8129991846981284e-07
have O 0 1.0735328714872594e-06
found O 0 3.136328814434819e-07
three O 0 7.06516871673557e-08
molecular O 0 1.43558236231911e-05
defects O 0 0.04341880604624748
leading O 0 5.882606615159602e-07
to O 0 1.13678356683522e-06
total O 0 0.00029011801234446466
deficiency O 1 0.5521143078804016
879delG O 0 2.9492392059182748e-05
, O 0 3.9434905119151153e-08
which O 0 2.4674907450616956e-08
is O 0 1.1527414578438311e-08
the O 0 1.3850137037252352e-08
common O 0 3.0295743158603727e-07
defect O 0 4.83721996715758e-05
in O 0 1.0312320597449798e-07
the O 0 6.058577639578289e-08
Cape O 0 1.55437805915426e-06
and O 0 3.0936405437387293e-07
hitherto O 0 5.183871053304756e-06
unreported O 0 3.7875821590205305e-07
, O 0 1.5751298931832025e-08
and O 0 1.4026367622932412e-08
1195delC O 0 2.2110698409960605e-06
and O 0 4.9216641428984076e-08
1936delG O 0 2.5288220513175474e-06
, O 0 1.5609893821988408e-08
which O 0 1.940716209958282e-08
have O 0 4.2061987670649614e-08
been O 0 4.799609882866207e-07
previously O 0 9.622647212381708e-07
reported O 0 2.397059688519221e-07
in O 0 1.1068523875223946e-08
African O 0 2.421783129591404e-08
- O 0 3.949874735553749e-05
Americans O 0 9.524536039862141e-07
. O 0 4.94922744564974e-07

We O 0 3.7218267152638873e-06
also O 0 2.989579286349908e-07
show O 0 9.707207482279046e-08
that O 0 8.65444160780271e-09
the O 0 1.7852270772777956e-08
879delG O 0 1.7901455066748895e-05
and O 0 2.331625410079141e-06
1195delC O 0 0.0565543957054615
defects O 1 0.8344172835350037
are O 0 2.1620711265768477e-07
associated O 0 2.68899157163105e-07
with O 0 6.851166745036608e-07
characteristic O 0 0.003484737128019333
C6 O 1 0.9985044002532959
/ O 0 0.002421387005597353
C7 O 0 0.0037715844810009003
region O 0 9.491801620242768e-07
DNA O 0 1.0054054655483924e-05
marker O 0 7.751792145427316e-05
haplotypes O 0 0.00012690984294749796
, O 0 1.2553341832699516e-07
although O 0 4.9019060810451265e-08
small O 0 2.3219136835450627e-08
variations O 0 4.6925688934607024e-07
were O 0 4.5378865820566716e-07
observed O 0 1.0049060392702813e-06
. O 0 5.487759153766092e-07

The O 0 3.1192237202049e-06
1936delG O 0 8.8302324002143e-05
defect O 0 8.229673403548077e-05
was O 0 4.455871930986177e-06
observed O 0 2.1559105789492605e-07
only O 0 2.2210944194966942e-08
once O 0 3.530973202714449e-08
in O 0 9.413858137463649e-09
the O 0 2.571168522536027e-08
Cape O 0 1.7142108390544308e-06
, O 0 5.2742464617949736e-08
but O 0 2.296583367922267e-08
its O 0 4.919468210573541e-08
associated O 0 1.542787799735379e-06
haplotype O 0 0.0006873307866044343
could O 0 1.1926906609005528e-06
be O 0 2.2046090464300505e-07
deduced O 0 1.0372093129262794e-05
. O 0 9.961829618987394e-07

The O 0 9.067096016224241e-07
data O 0 1.7296241594522144e-07
from O 0 1.1046168424400093e-08
the O 0 8.388524541658171e-09
haplotypes O 0 7.319771975744516e-05
indicate O 0 1.1753166972994222e-06
that O 0 2.97194873155604e-08
these O 0 6.2143525880742345e-09
three O 0 5.938947822414775e-08
molecular O 0 5.822215825901367e-05
defects O 0 0.31695476174354553
account O 0 7.024401327271335e-08
for O 0 2.2374901931243585e-08
the O 0 2.6328808644393575e-07
defects O 1 0.5871824026107788
in O 0 1.535030769161949e-08
all O 0 3.672945947386097e-09
the O 0 1.4854691698928946e-08
38 O 0 4.888368039246416e-07
unrelated O 0 2.432315113765071e-07
C6Q0 O 0 0.0002263706992380321
individuals O 0 1.6169119376741037e-08
we O 0 8.067657653043625e-09
have O 0 1.2341896393763818e-08
studied O 0 6.115350714708256e-08
from O 0 1.2657877412891594e-08
the O 0 7.64947500897506e-08
Cape O 0 5.336312824510969e-06
. O 0 2.111290996253956e-06

We O 0 3.275937160651665e-06
have O 0 3.708412634750857e-07
also O 0 1.8000154966557602e-07
observed O 0 1.401209317464236e-07
the O 0 2.8762128678749832e-08
879delG O 0 1.7886846762849018e-05
defect O 0 1.778441946953535e-05
in O 0 8.994221900593402e-08
two O 0 1.5538963680228335e-06
Dutch O 1 0.9994658827781677
C6 B-Disease 1 0.9999996423721313
- I-Disease 1 0.9999772310256958
deficient I-Disease 1 0.9999978542327881
kindreds O 0 0.00029268587240949273
, O 0 5.410744208234064e-08
but O 0 1.511214975380426e-08
the O 0 1.0019567397989704e-08
879delG O 0 1.226921631314326e-05
defect O 0 6.899582331243437e-06
in O 0 3.366130485460417e-08
the O 0 3.0021901409327256e-08
Cape O 0 1.199315306621429e-06
probably O 0 9.912171208270593e-07
did O 0 9.530644717870018e-08
not O 0 1.169778318654835e-08
come O 0 6.7409602344525865e-09
from O 0 3.1924500820679214e-09
The O 0 1.6081463272143992e-08
Netherlands O 0 3.1566246434522327e-06
. O 0 1.2176450070455758e-07
. O 0 3.4682111049733066e-07

Complement B-Disease 1 0.9968017339706421
C7 I-Disease 1 0.9999997615814209
deficiency I-Disease 1 0.9999997615814209
: O 0 4.710253051598556e-06
seven O 0 5.973421366434195e-07
further O 0 3.705725930558401e-07
molecular O 0 0.0003431076183915138
defects O 1 0.8109370470046997
and O 0 2.664851308509242e-07
their O 0 1.4890326838212786e-07
associated O 0 1.7391909068464884e-06
marker O 0 0.0004957147757522762
haplotypes O 0 0.0013164686970412731
. O 0 3.9696733438177034e-06

Seven O 0 6.376122200890677e-06
further O 0 4.563800644064031e-07
molecular O 0 1.1150292493766756e-06
bases O 0 1.0172780093853362e-06
of O 0 1.0496226423128974e-05
C7 B-Disease 1 1.0
deficiency I-Disease 1 0.9999998807907104
are O 0 2.431680513836909e-06
described O 0 6.76183553878218e-05
. O 0 2.1649382233590586e-06

All O 0 1.2299336731302901e-06
these O 0 5.718341355986922e-08
new O 0 1.5025115374101006e-07
molecular O 0 1.991197859751992e-05
defects O 0 0.0109150605276227
involve O 0 8.31948554491646e-08
single O 0 4.5424718564390787e-07
- O 0 2.180517867600429e-06
nucleotide O 0 1.6801385527287493e-07
events O 0 1.8136136148427795e-08
, O 0 8.278469465494709e-09
deletions O 0 2.840173749518726e-07
and O 0 3.9901269843767295e-08
substitutions O 0 2.0380514342832612e-07
, O 0 2.0482609386363038e-08
some O 0 2.6119211238295748e-09
of O 0 1.2184639963663813e-09
which O 0 2.3943812266224995e-08
alter O 0 4.1392434013687307e-07
splice O 0 1.169655433841399e-06
sites O 0 4.1939660633261155e-08
, O 0 1.0637938530067004e-08
and O 0 2.555986178265357e-08
others O 0 1.505077023011836e-07
codons O 0 1.8709432652030955e-06
. O 0 8.516807383784908e-07

They O 0 4.049230028613238e-06
are O 0 9.699324010625787e-08
distributed O 0 2.8007411501107526e-08
along O 0 1.2552523465103604e-08
the O 0 2.0278722701050356e-08
C7 O 0 0.00014454778283834457
gene O 0 5.78071649215417e-07
, O 0 2.2953177136741942e-08
but O 0 2.5113727986081358e-08
predominantly O 0 6.639213268044841e-08
towards O 0 1.743632971340503e-08
the O 0 2.5802767922300518e-08
3 O 0 1.53376419120832e-07
end O 0 8.043443813221529e-07
. O 0 1.1881111277034506e-06

All O 0 1.6890529650481767e-06
were O 0 2.1299607055880188e-07
found O 0 7.175032834538797e-08
in O 0 2.2563598989222555e-08
compound O 0 1.4516608644044027e-05
heterozygous O 0 0.00012465206964407116
individuals O 0 1.872187596063668e-07
. O 0 5.274467866911436e-07

The O 0 7.21408796380274e-05
C6 O 1 0.990303099155426
/ O 0 0.0612914152443409
C7 O 1 0.6041849255561829
marker O 0 0.22618326544761658
haplotypes O 0 0.18200305104255676
associated O 0 4.762840035255067e-06
with O 0 5.210463882576732e-07
most O 0 5.065602090326138e-05
C7 B-Disease 1 0.9999028444290161
defects I-Disease 1 0.9990566372871399
are O 0 1.503840394434519e-07
tabulated O 0 1.2776150470017456e-05
. O 0 2.3773668544890825e-07
. O 0 5.978807280371257e-07

A O 0 2.631971256050747e-05
genome O 0 3.4069187222485198e-06
- O 0 6.32587625659653e-06
wide O 0 2.914594858793862e-07
search O 0 7.88375018601073e-08
for O 0 2.2437253832663373e-08
chromosomal O 0 1.5908453860902227e-05
loci O 0 1.2278827625777922e-06
linked O 0 1.934738793352153e-05
to O 0 1.8719407307798974e-05
mental O 1 0.9602777361869812
health O 0 7.197020022431388e-05
wellness O 0 5.076637171441689e-05
in O 0 2.676218002761743e-07
relatives O 0 1.2157552191638388e-06
at O 0 3.8264655444208984e-08
high O 0 2.172083441109862e-06
risk O 0 5.914016128372168e-06
for O 0 2.0344510630820878e-05
bipolar B-Disease 1 0.9999997615814209
affective I-Disease 1 0.9999945163726807
disorder I-Disease 1 0.999647855758667
among O 0 1.1509590791547453e-07
the O 0 1.325795473405833e-08
Old O 0 1.4708306252941838e-06
Order O 0 1.7766542725894396e-07
Amish O 0 1.0575371561571956e-05
. O 0 1.0921006605713046e-06

Bipolar B-Disease 1 0.9999964237213135
affective I-Disease 1 0.9999847412109375
disorder I-Disease 1 0.9999940395355225
( O 0 0.0030500947032123804
BPAD B-Disease 1 0.9999957084655762
; O 0 0.07551431655883789
manic B-Disease 1 0.9999512434005737
- I-Disease 1 0.9999971389770508
depressive I-Disease 1 0.9999997615814209
illness I-Disease 1 0.99973064661026
) O 0 1.564744565030196e-07
is O 0 1.860383775920127e-07
characterized O 0 1.2311036243772833e-06
by O 0 3.5879256898851963e-08
episodes O 0 3.5107302664982853e-07
of O 0 1.7693727372147805e-08
mania B-Disease 0 0.00016568799037486315
and O 0 2.486038511051447e-06
/ O 0 2.0719267922686413e-05
or O 0 9.637635685066925e-07
hypomania B-Disease 0 0.05018387734889984
interspersed O 0 1.1422594980103895e-05
with O 0 1.6052617013428971e-07
periods O 0 6.961970484553603e-07
of O 0 1.1272409494722524e-07
depression B-Disease 0 0.00022108644770924002
. O 0 2.3558945940749254e-06

Compelling O 0 0.00045315895113162696
evidence O 0 8.59751980897272e-06
supports O 0 1.4352661992234061e-06
a O 0 4.922654852634878e-07
significant O 0 1.5698159927524102e-07
genetic O 0 5.298011274135206e-07
component O 0 9.676890755372369e-08
in O 0 3.1355089191720253e-08
the O 0 1.5037558398489637e-07
susceptibility O 0 0.01347989309579134
to O 0 4.69787119072862e-06
develop O 0 6.593220314243808e-05
BPAD B-Disease 1 0.9999843835830688
. O 0 5.119843081047293e-06

To O 0 4.97310065838974e-06
date O 0 2.156458776880754e-06
, O 0 2.4764781869635044e-07
however O 0 1.1856046455704927e-07
, O 0 2.573567847719005e-08
linkage O 0 9.548691650707042e-07
studies O 0 6.378223815772799e-08
have O 0 3.67746224583243e-08
attempted O 0 2.382249249421875e-06
only O 0 4.3613841427259104e-08
to O 0 6.624300397106708e-08
identify O 0 8.157979323186737e-07
chromosomal O 0 4.473001536098309e-05
loci O 0 7.912898922768363e-07
that O 0 3.895024747180287e-07
cause O 0 1.0203415286014206e-06
or O 0 2.1551660012164575e-08
increase O 0 2.0871566164260003e-07
the O 0 8.138010798575124e-08
risk O 0 3.508189934109396e-07
of O 0 2.9775602428117054e-08
developing O 0 4.378017820272362e-06
BPAD B-Disease 1 0.9999818801879883
. O 0 9.003179002320394e-06

To O 0 2.314098537681275e-06
determine O 0 4.3109878333780216e-07
whether O 0 1.3373799845339818e-07
there O 0 5.188378082721101e-08
could O 0 5.470384962791286e-07
be O 0 1.0379808657035028e-07
protective O 0 5.378000787459314e-05
alleles O 0 1.0781045602925587e-06
that O 0 1.031660872286011e-07
prevent O 0 1.949107826249019e-07
or O 0 6.603598734500338e-08
reduce O 0 4.754825511099625e-07
the O 0 4.822201304932605e-08
risk O 0 1.053410016993439e-07
of O 0 4.95991248072869e-09
developing O 0 8.713025181350531e-07
BPAD B-Disease 1 0.9999982118606567
, O 0 1.7505382743365772e-07
similar O 0 3.35538103968247e-08
to O 0 2.0333215999812637e-08
what O 0 1.5166957467727116e-08
is O 0 5.768403710249004e-08
observed O 0 9.583251880940225e-08
in O 0 3.5928152897213295e-08
other O 0 1.9925848846469307e-06
genetic B-Disease 1 0.9999979734420776
disorders I-Disease 1 0.9999994039535522
, O 0 3.5306808854329574e-07
we O 0 5.46197718165331e-08
used O 0 0.00018581018957775086
mental O 1 0.9695020914077759
health O 0 4.756411362905055e-05
wellness O 0 2.627387220854871e-05
( O 0 2.8971072651984286e-08
absence O 0 8.989899669131773e-08
of O 0 2.2917262754162948e-08
any O 0 1.691363831923809e-05
psychiatric B-Disease 1 0.9999853372573853
disorder I-Disease 1 0.9948412775993347
) O 0 6.469577584766739e-08
as O 0 1.1284477352546674e-07
the O 0 1.4942307302590052e-07
phenotype O 0 0.005460284184664488
in O 0 1.793400983274296e-08
our O 0 7.071582874829119e-09
genome O 0 2.635703744147122e-08
- O 0 4.398451096676581e-07
wide O 0 3.2142645522981184e-07
linkage O 0 2.6241648356517544e-06
scan O 0 2.1411085981526412e-05
of O 0 3.306819706949682e-09
several O 0 1.9369551296222198e-08
large O 0 5.794780832957258e-08
multigeneration O 0 5.835725914948853e-06
Old O 0 6.68768677769549e-07
Order O 0 3.262416115035194e-08
Amish O 0 1.0351491255278233e-06
pedigrees O 0 1.191447040582716e-06
exhibiting O 0 3.1533457445220847e-07
an O 0 6.249526762758251e-08
extremely O 0 6.690240297757555e-06
high O 0 1.812445952964481e-05
incidence O 0 0.0006196773611009121
of O 0 5.239229494691244e-07
BPAD B-Disease 1 0.9999953508377075
. O 0 2.6600027922540903e-05

We O 0 4.257645741745364e-06
have O 0 3.7300489452718466e-07
found O 0 9.409553314299046e-08
strong O 0 1.894310628358653e-07
evidence O 0 5.8764221932960936e-08
for O 0 9.717003202069918e-09
a O 0 4.1795883021222835e-07
locus O 0 2.5480264866928337e-06
on O 0 1.5394191450468497e-06
chromosome O 0 3.2537365768803284e-05
4p O 0 4.92516192025505e-05
at O 0 4.631595729165383e-08
D4S2949 O 0 2.028330754910712e-06
( O 0 1.6087231102801525e-08
maximum O 0 3.7445764178301033e-07
GENEHUNTER O 0 2.7292817321722396e-05
- O 0 5.394994786911411e-06
PLUS O 0 6.402222538781643e-07
nonparametric O 0 2.1604212179227034e-06
linkage O 0 1.6351717704310431e-06
score O 0 7.215173809527187e-07
= O 0 3.146653000385413e-07
4 O 0 7.282937986019533e-08
. O 0 1.489546352928528e-08
05 O 0 1.2169615501989028e-06
, O 0 6.31552836694027e-08
P O 0 1.094295157599845e-06
= O 0 1.220380454469705e-07
5 O 0 1.9729895939235575e-08
. O 0 5.490175425393318e-09
22 O 0 3.792207792230329e-08
x O 0 9.147749437943276e-07
10 O 0 3.905010714788659e-08
( O 0 1.1077731620900977e-08
- O 0 1.9269564290880226e-06
4 O 0 1.767968313970414e-07
) O 0 8.70085070658888e-09
; O 0 2.325517023393786e-08
SIBPAL O 0 6.193013632582733e-06
Pempirical O 0 1.2014170351903886e-06
value O 0 7.975278215610615e-09
< O 0 3.686732696905892e-08
3 O 0 2.858836722907654e-08
x O 0 1.5619447140124976e-06
10 O 0 5.295868987786889e-08
( O 0 1.322996556751832e-08
- O 0 1.1442153663665522e-05
5 O 0 1.671519385126885e-07
) O 0 2.1583501208510825e-08
) O 0 1.5676132392172804e-08
and O 0 4.891753846436586e-08
suggestive O 0 1.076782700693002e-05
evidence O 0 1.4318030139293114e-07
for O 0 8.722551569917414e-09
a O 0 2.728405661400757e-07
locus O 0 4.300264663470443e-06
on O 0 8.005448762560263e-06
chromosome O 0 0.005507022142410278
4q O 1 0.9425418376922607
at O 0 7.795885892392107e-08
D4S397 O 0 2.7900459826923907e-06
( O 0 2.8606912394479878e-08
maximum O 0 6.667003731308796e-07
GENEHUNTER O 0 4.6903249312890694e-05
- O 0 4.382955012260936e-06
PLUS O 0 8.025162401281705e-07
nonparametric O 0 2.240964022348635e-06
linkage O 0 2.917697656812379e-06
score O 0 1.0912561947407085e-06
= O 0 4.743213253277645e-07
3 O 0 7.884983688200009e-08
. O 0 2.962062239930674e-08
29 O 0 3.06025924601272e-07
, O 0 3.5635437711789564e-08
P O 0 1.8680175344343297e-06
= O 0 9.65469411084996e-08
2 O 0 3.180915442158039e-08
. O 0 6.846565980822561e-09
57 O 0 2.0467034289595176e-07
x O 0 1.6802326854303828e-06
10 O 0 3.137524728913377e-08
( O 0 4.708848422296796e-09
- O 0 8.125855970320117e-07
3 O 0 1.5168672007348505e-07
) O 0 2.0550857016132795e-08
; O 0 3.49577859992678e-08
SIBPAL O 0 8.370653631573077e-06
Pempirical O 0 1.048943545356451e-06
value O 0 1.7442616240259667e-08
< O 0 4.525564989421582e-08
1 O 0 1.1510760344890514e-08
x O 0 1.1145624512209906e-06
10 O 0 4.41232330672392e-08
( O 0 8.636385828708626e-09
- O 0 4.0290797187481076e-06
3 O 0 7.173144211947147e-08
) O 0 3.1004436795711854e-09
) O 0 3.1930775801214395e-09
that O 0 9.469757422664316e-09
are O 0 8.473203472192381e-09
linked O 0 9.631351076677674e-07
to O 0 4.13637280871626e-06
mental O 1 0.6983305811882019
health O 0 0.00015642473590560257
wellness O 0 0.00016066190437413752
. O 0 3.2751779599493602e-06

These O 0 7.351305612246506e-06
findings O 0 6.355105597322108e-06
are O 0 3.457029151832103e-08
consistent O 0 4.656130840885453e-07
with O 0 5.62011699400955e-08
the O 0 8.757847069773561e-08
hypothesis O 0 1.5115774658625014e-06
that O 0 9.94153648292695e-09
certain O 0 4.648603724177747e-09
alleles O 0 1.3050372160705592e-07
could O 0 3.1296895031118765e-07
prevent O 0 7.850408678677923e-08
or O 0 1.617547340515557e-08
modify O 0 9.683875532573438e-07
the O 0 1.0047492082776444e-07
clinical O 0 5.8997479754907545e-06
manifestations O 0 8.471492947137449e-07
of O 0 4.72925627548193e-08
BPAD B-Disease 1 0.9999960660934448
and O 0 1.4924775086910813e-06
perhaps O 0 2.8313411348790396e-07
other O 0 9.587218841033973e-08
related O 0 8.977458492154256e-06
affective B-Disease 1 0.9995249509811401
disorders I-Disease 1 0.9987687468528748
. O 0 1.157206224888796e-05

Segregation O 0 0.0017859649378806353
distortion O 0 0.07943151891231537
in O 0 0.001150024007074535
myotonic B-Disease 1 0.9999991655349731
dystrophy I-Disease 1 0.9999998807907104
. O 0 0.001158661674708128

Myotonic B-Disease 1 0.9999995231628418
dystrophy I-Disease 1 1.0
( O 1 0.999473512172699
DM B-Disease 1 1.0
) O 0 4.3454663682496175e-05
is O 0 1.3435011396722985e-06
an O 0 2.957460992547567e-06
autosomal B-Disease 1 0.9936683773994446
dominant I-Disease 1 0.996773898601532
disease I-Disease 0 0.0714612603187561
which O 0 2.0025967728543037e-07
, O 0 2.4854967861642763e-08
in O 0 6.079805991987541e-09
the O 0 1.7101918103890057e-08
typical O 0 1.4764281104362453e-06
pedigree O 0 5.0775252020685e-06
, O 0 2.0779307163820704e-08
shows O 0 4.227770844522638e-08
a O 0 9.437557224600823e-08
three O 0 1.0659879734475908e-07
generation O 0 2.4586972813267494e-06
anticipation O 0 2.5347665086883353e-06
cascade O 0 1.657284337852616e-05
. O 0 9.87565499599441e-07

This O 0 5.33561569682206e-06
results O 0 1.1218685358471703e-05
in O 0 4.368587724457029e-06
infertility B-Disease 1 0.9943600296974182
and O 1 0.9898552894592285
congenital B-Disease 1 1.0
myotonic I-Disease 1 1.0
dystrophy I-Disease 1 1.0
( O 0 4.800439273822121e-05
CDM B-Disease 0 0.000783688563387841
) O 0 9.148484991783334e-08
with O 0 2.714980418261348e-08
the O 0 2.3126142778551184e-08
disappearance O 0 2.092175463985768e-06
of O 0 1.490422221195331e-07
DM B-Disease 1 0.9999997615814209
in O 0 6.425585070246598e-06
that O 0 8.338539601027151e-07
pedigree O 0 2.8232512704562396e-05
. O 0 7.301184723473853e-07

The O 0 6.151945513011015e-07
concept O 0 3.763827578495693e-07
of O 0 1.8119816758144225e-08
segregation O 0 1.2982487760382355e-06
distortion O 0 0.000975708244368434
, O 0 2.242763343929255e-07
where O 0 6.235904947970994e-08
there O 0 1.555998352387178e-08
is O 0 2.350363814684897e-08
preferential O 0 3.3695164347591344e-07
transmission O 0 9.893650485537364e-07
of O 0 1.0901738400903582e-09
the O 0 6.69370825434612e-09
larger O 0 4.691504074116892e-08
allele O 0 6.942352115402173e-07
at O 0 1.3509597884819868e-08
the O 0 6.545813846514648e-08
DM B-Disease 1 0.9999998807907104
locus O 0 0.000767710036598146
, O 0 1.6839514671573852e-07
has O 0 7.266814350259665e-08
been O 0 1.1988763759518406e-08
put O 0 2.0947235057633407e-08
forward O 0 2.5390379576606392e-08
to O 0 6.26775502610144e-08
explain O 0 4.2771253561113554e-07
partially O 0 2.2153333247842966e-06
the O 0 2.5103526368752682e-08
maintenance O 0 5.347911269382166e-07
of O 0 6.944339503434094e-08
DM B-Disease 1 0.9999996423721313
in O 0 1.6461336826978368e-06
the O 0 2.933120697434788e-07
population O 0 7.645718369531096e-07
. O 0 9.231232525053201e-07

In O 0 4.737273229693528e-06
a O 0 3.446736627665814e-06
survey O 0 1.6546803180972347e-06
of O 0 1.4627103439579514e-07
DM B-Disease 1 0.9999983310699463
in O 0 1.2709978364000563e-05
Northern O 0 3.303211315142107e-06
Ireland O 0 1.0196974926657276e-06
, O 0 1.4103660816999763e-07
59 O 0 1.3007571624257253e-06
pedigrees O 0 1.9066910681431182e-06
were O 0 7.36763354325376e-07
ascertained O 0 2.5385514163644984e-05
. O 0 1.7426142449039617e-06

Sibships O 0 0.0013356596464291215
where O 0 2.1535979612963274e-06
the O 0 3.985229213299135e-08
status O 0 1.3959563283094667e-08
of O 0 1.4446728258121766e-09
all O 0 3.2596778609672583e-09
the O 0 6.9880776720765425e-09
members O 0 1.6684863268778827e-08
had O 0 6.750180432391062e-07
been O 0 1.8775732257836353e-07
identified O 0 2.208493725674998e-07
were O 0 5.8863950158638545e-08
examined O 0 3.4305881513319036e-07
to O 0 2.2648583453133142e-08
determine O 0 4.808460829508476e-08
the O 0 1.8593297568259004e-08
transmission O 0 6.702090900034818e-07
of O 0 4.979961776285791e-09
the O 0 1.9355599079062813e-07
DM B-Disease 1 0.9999990463256836
expansion O 0 2.565993099779007e-06
from O 0 5.368913846837131e-08
affected O 0 1.5409850107062084e-07
parents O 0 6.545464259488654e-08
to O 0 5.1894968322585555e-08
their O 0 1.714253698992252e-07
offspring O 0 1.3384380508796312e-05
. O 0 1.7040026705217315e-06

Where O 0 1.5159810573095456e-05
the O 0 4.849886749980215e-07
transmitting O 0 4.070497652719496e-06
parent O 0 1.6652710428388673e-06
was O 0 1.051689082487428e-06
male O 0 2.9138575428078184e-06
, O 0 1.926431281162877e-07
58 O 0 7.114898380677914e-06
. O 0 1.2498290971052484e-06

3 O 0 2.382862840022426e-05
% O 0 5.112526082484692e-07
of O 0 5.358527399579316e-09
the O 0 4.128519393020724e-08
offspring O 0 5.732603767683031e-06
were O 0 1.663958187236858e-06
affected O 0 1.8124488576631848e-07
, O 0 3.856094465959359e-08
and O 0 6.764403082115678e-08
in O 0 2.9498615106149373e-08
the O 0 1.4185021157686606e-08
case O 0 2.774521306037059e-07
of O 0 2.8743629698624318e-09
a O 0 9.442811688131769e-07
female O 0 0.00014278704475145787
transmitting O 0 4.677066954172915e-06
parent O 0 9.433432524019736e-07
, O 0 6.177283040642578e-08
68 O 0 4.299932243156945e-06
. O 0 7.472559673260548e-07

7 O 0 0.00026156060630455613
% O 0 6.4864707383094355e-06
were O 0 1.4502539897875977e-06
affected O 0 2.0769100501638604e-06
. O 0 3.1059491902851732e-06

Studies O 0 1.298935148952296e-05
on O 0 9.840870234256727e-07
meiotic O 0 1.1568111403903458e-05
drive O 0 9.797422535484657e-06
in O 0 2.0196753212076146e-06
DM B-Disease 1 0.9999998807907104
have O 0 0.00030866777524352074
shown O 0 4.231403636367759e-06
increased O 0 2.2032554625184275e-07
transmission O 0 2.24452648467377e-07
of O 0 3.401601222918771e-09
the O 0 9.447603588341735e-09
larger O 0 5.904769295739243e-08
allele O 0 7.349877932938398e-07
at O 0 8.55593107473851e-09
the O 0 3.65199106511227e-08
DM B-Disease 1 0.9999996423721313
locus O 0 8.208298095269129e-05
in O 0 2.3074004218415212e-07
non O 0 1.0832204679900315e-06
- O 1 0.8753384351730347
DM O 1 0.9999998807907104
heterozygotes O 0 0.036422550678253174
for O 0 7.333396752073895e-07
CTGn O 0 8.204964979086071e-05
. O 0 2.3779184630257078e-06

This O 0 3.3147071007988416e-06
study O 0 1.3008836958761094e-06
provides O 0 1.7152741804693505e-07
further O 0 4.926021901496824e-08
evidence O 0 9.865360794947264e-08
that O 0 3.737633136324803e-08
the O 0 1.2450912834083283e-07
DM B-Disease 1 0.9999980926513672
expansion O 0 5.5307336879195645e-06
tends O 0 3.0388189315999625e-06
to O 0 9.678847590066653e-08
be O 0 2.461808037423907e-07
transmitted O 0 6.479119747382356e-06
preferentially O 0 1.0637953892000951e-05
. O 0 1.2396357078614528e-06

Diagnosis O 1 0.9964450001716614
of O 0 8.985524618765339e-05
hemochromatosis B-Disease 1 0.9999865293502808
. O 0 0.00016879625036381185

If O 0 0.0007821650942787528
untreated O 1 0.9502633810043335
, O 0 6.664518150500953e-05
hemochromatosis B-Disease 1 0.9999973773956299
can O 0 8.854769839672372e-05
cause O 0 0.0009645153768360615
serious O 1 0.8376015424728394
illness O 1 0.9972001314163208
and O 0 3.7884883568040095e-06
early B-Disease 0 8.062339475145563e-05
death I-Disease 0 0.08016453683376312
, O 0 8.211105040345501e-08
but O 0 2.853452372164611e-07
the O 0 5.959133773103531e-07
disease O 0 3.703721449710429e-05
is O 0 2.3379480751373194e-07
still O 0 6.0953839238209184e-06
substantially O 0 1.3609406778414268e-05
under O 0 8.514001820003614e-06
- O 1 0.9872779846191406
diagnosed O 1 0.9986660480499268
. O 0 4.714513124781661e-06

The O 0 8.103144182314281e-07
cornerstone O 0 1.580745220053359e-06
of O 0 2.993715852994683e-08
screening O 0 8.679247684995062e-07
and O 0 1.8661785361473449e-07
case O 0 1.0254462949887966e-06
detection O 0 9.865190975233418e-08
is O 0 1.2201181398552308e-08
the O 0 6.200547186807626e-09
measurement O 0 2.5154699301310757e-07
of O 0 1.0919808168807776e-08
serum O 0 1.2856372677561012e-06
transferrin O 0 4.437653387867613e-06
saturation O 0 8.055541798057675e-07
and O 0 2.043995195322168e-08
the O 0 2.1044305853479273e-08
serum O 0 8.313937541970517e-06
ferritin O 0 6.13082229392603e-05
level O 0 5.555646112043178e-07
. O 0 1.0482744983164594e-06

Once O 0 2.9603863367810845e-05
the O 0 1.3949417052572244e-06
diagnosis O 0 0.0010939049534499645
is O 0 2.5433089945181564e-07
suspected O 0 2.713112053243094e-06
, O 0 5.264698756946018e-07
physicians O 0 8.22650463305763e-07
must O 0 3.8591256412701114e-08
use O 0 2.0910636067128507e-07
serum O 0 1.976226303668227e-05
ferritin O 0 0.00034234332269988954
levels O 0 1.5862133295740932e-07
and O 0 1.1605692407101742e-07
hepatic O 0 0.00021036672114860266
iron O 0 0.40406301617622375
stores O 0 2.6533637083048234e-06
on O 0 1.0073000339616556e-05
liver O 0 0.010079722851514816
biopsy O 0 0.48614558577537537
specimens O 0 2.2001909201208036e-06
to O 0 3.972760396209196e-07
assess O 0 8.484064164804295e-05
patients O 0 0.00020267000945750624
for O 0 1.2148327677152793e-08
the O 0 1.4624252031580909e-08
presence O 0 6.785349881965885e-08
of O 0 3.228322142945217e-08
iron B-Disease 1 0.8620464205741882
overload I-Disease 0 0.09964483231306076
. O 0 5.631008662021486e-06

Liver O 1 0.9988846182823181
biopsy O 1 0.9871798157691956
is O 0 3.6132437344349455e-06
also O 0 2.1942409489383863e-07
used O 0 4.6266514175385964e-08
to O 0 1.821031503368431e-08
establish O 0 2.3557674921903526e-08
the O 0 1.243575287190879e-08
presence O 0 7.593379081072271e-08
or O 0 1.711177155527821e-08
absence O 0 2.7567998017730133e-07
of O 0 7.870708884638589e-08
cirrhosis B-Disease 0 0.23038432002067566
, O 0 9.221714947216242e-08
which O 0 1.4922854063570412e-07
can O 0 3.9593331280229904e-07
affect O 0 3.2912150800257223e-06
prognosis O 1 0.8771699070930481
and O 0 2.6258321668137796e-06
management O 0 1.8505467096474604e-06
. O 0 1.2264549695828464e-06

A O 0 5.141214933246374e-05
DNA O 0 3.87588152079843e-05
- O 0 4.51779123977758e-05
based O 0 7.92926812209771e-07
test O 0 1.6429203242296353e-07
for O 0 7.520256417592464e-09
the O 0 2.0277832746273816e-08
HFE O 0 0.00014074693899601698
gene O 0 2.8759393444488524e-07
is O 0 2.967734324954563e-08
commercially O 0 1.7749100322816957e-07
available O 0 1.2455599218696989e-08
, O 0 3.3285310063746465e-09
but O 0 3.791070568581745e-09
its O 0 2.9775073517868123e-09
place O 0 2.0685270385456533e-08
in O 0 1.6475576458674368e-08
the O 0 8.518678384916711e-08
diagnosis O 0 0.01705641858279705
of O 0 4.811910798707686e-07
hemochromatosis B-Disease 1 0.9999997615814209
is O 0 1.1176652151334565e-05
still O 0 5.892960643905099e-07
being O 0 7.470863465641742e-07
evaluated O 0 3.866711267619394e-06
. O 0 6.259786573536985e-07

Currently O 0 1.164201876235893e-05
, O 0 1.0529922178648121e-07
the O 0 1.3004796350912784e-08
most O 0 6.742323144237616e-09
useful O 0 8.847888643970236e-09
role O 0 1.4187916619334828e-08
for O 0 5.535114144805675e-09
this O 0 9.860446681386748e-09
test O 0 1.1405557387433873e-07
is O 0 1.2281639705236103e-08
in O 0 4.074275139487327e-09
the O 0 4.870840175641433e-09
detection O 0 1.5790772067703074e-07
of O 0 6.891888659765755e-08
hemochromatosis B-Disease 1 0.9999991655349731
in O 0 2.916997345892014e-07
the O 0 3.670594850291309e-08
family O 0 1.0804950534293312e-07
members O 0 1.257001347454434e-08
of O 0 2.511449359587914e-08
patients O 0 3.947916775359772e-05
with O 0 2.3581906205549785e-08
a O 0 4.344743501860648e-06
proven O 0 2.680775651242584e-05
case O 0 2.913521939262864e-07
of O 0 1.5640052808407745e-08
the O 0 2.0592899545590626e-06
disease O 0 0.0003238125646021217
. O 0 1.9391752630326664e-06

It O 0 1.968857759493403e-06
is O 0 1.148819563923098e-07
crucial O 0 3.789771767515049e-07
to O 0 1.5066545529407449e-05
diagnose O 1 0.999988317489624
hemochromatosis B-Disease 1 1.0
before O 0 0.04044238477945328
hepatic B-Disease 1 0.9994615912437439
cirrhosis I-Disease 1 0.9983503818511963
develops O 0 0.0016932226717472076
because O 0 2.7161102025274886e-06
phlebotomy O 0 0.002065582200884819
therapy O 0 0.0007112404564395547
can O 0 9.248133210348897e-07
avert O 0 0.0067530120722949505
serious O 1 0.9999299049377441
chronic O 1 0.9999998807907104
disease O 1 0.9973434805870056
and O 0 2.597500952106202e-06
can O 0 6.721344902871351e-07
even O 0 1.2778637881183386e-07
lead O 0 5.413468215920147e-07
to O 0 1.5596241098592145e-07
normal O 0 5.487591465680453e-07
life O 0 1.6843848698044894e-06
expectancy O 0 5.379592494136887e-06
. O 0 6.069647184858695e-08
. O 0 3.5666110420606856e-07

Prevalence O 0 0.0026649574283510447
of O 0 4.4488558614830254e-07
the O 0 1.729767689084838e-07
I1307K O 0 2.252043123007752e-05
APC B-Disease 0 1.0168173503188882e-05
gene O 0 1.1220611213502707e-06
variant O 0 5.528592737391591e-06
in O 0 4.3141422878534286e-08
Israeli O 0 6.3811098698352e-06
Jews O 0 1.1547984257731514e-07
of O 0 5.094218380463644e-09
differing O 0 2.4187460212488077e-07
ethnic O 0 1.1353422735282948e-07
origin O 0 1.7081845271604834e-07
and O 0 7.932845846880809e-07
risk O 0 1.861288728832733e-05
for O 0 0.11046428978443146
colorectal B-Disease 1 1.0
cancer I-Disease 1 0.9999998807907104
. O 0 2.7713937015505508e-05

BACKGROUND O 0 0.0008083065622486174
& O 0 1.4282329175330233e-05
AIMS O 0 3.409753162486595e-06
Israeli O 0 7.424381237797206e-06
Jews O 0 1.2996829923395126e-07
of O 0 6.4777245789571225e-09
European O 0 1.6950626502421073e-07
birth O 0 2.489160578988958e-06
, O 0 3.1677895862003425e-08
i O 0 7.556248249329656e-08
. O 0 9.462715944152933e-09
e O 0 2.1389981341712883e-08
. O 0 7.979690685999685e-09
, O 0 1.3380454078060211e-08
Ashkenazim O 0 4.47374077339191e-07
, O 0 1.4812479243175858e-08
have O 0 2.5332044018000488e-08
the O 0 3.135895099148911e-07
highest O 1 0.9743845462799072
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
incidence O 0 0.028336450457572937
of O 0 1.1061009885793283e-08
any O 0 4.647151996550747e-08
Israeli O 0 1.1532829375937581e-05
ethnic O 0 1.1520169209688902e-06
group O 0 1.8196135442849481e-06
. O 0 7.414394076477038e-07

The O 0 6.181306616781512e-06
I1307K O 0 8.485341822961345e-05
APC B-Disease 0 3.469974399195053e-05
gene O 0 6.015541202941677e-06
variant O 0 6.541384209413081e-05
was O 0 3.3229077871510526e-06
found O 0 1.6325573426456685e-07
in O 0 1.0851793774691032e-07
6 O 0 4.9431373554398306e-06
. O 0 2.1095702322782017e-06

1 O 0 7.2245629780809395e-06
% O 0 2.8083138658985263e-07
of O 0 1.7524818929359753e-08
American O 0 1.3975406432109594e-07
Jews O 0 4.776559308083961e-07
, O 0 1.2477502764340898e-07
28 O 0 5.500302222571918e-07
% O 0 5.862671681455822e-09
of O 0 3.4480978072792823e-09
their O 0 5.494574907061178e-06
familial O 1 0.9999973773956299
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
cases O 0 0.002868789480999112
, O 0 1.2482882993936073e-07
but O 0 3.0267059969446564e-08
not O 0 2.0636683473185258e-08
in O 0 1.917696401676494e-08
non O 0 1.1263951904538771e-07
- O 0 0.00010288281191606075
Jews O 0 5.618987415800802e-06
. O 0 8.73592341577023e-07

We O 0 7.186988113971893e-06
assessed O 0 8.362331755051855e-06
the O 0 1.4998957453826733e-07
I1307K O 0 5.632246029563248e-05
prevalence O 0 1.0620154171192553e-05
in O 0 5.738182551340287e-08
Israeli O 0 6.459248197643319e-06
Jews O 0 4.417123022903979e-08
of O 0 2.2935924270939267e-09
differing O 0 1.540413450129563e-07
ethnic O 0 9.566742420474839e-08
origin O 0 1.1860253579243363e-07
and O 0 5.183195526115014e-07
risk O 0 1.5205418094410561e-05
for O 0 0.06417926400899887
colorectal B-Disease 1 1.0
cancer I-Disease 1 0.9999998807907104
. O 0 2.4661563656991348e-05

METHODS O 0 2.205116288678255e-05
DNA O 0 8.829397302179132e-06
samples O 0 3.017371739133523e-07
from O 0 1.4329526898393397e-08
500 O 0 2.518827457720363e-08
unrelated O 0 2.321931873439098e-07
Jews O 0 6.798538265684329e-08
of O 0 4.896679950405769e-09
European O 0 5.3263807586745315e-08
or O 0 4.179910817470045e-08
non O 0 7.896481690750079e-08
- O 0 9.908533684210852e-06
European O 0 1.6731270591208158e-07
origin O 0 6.242129302336252e-08
, O 0 8.481158886297635e-09
with O 0 1.0283737417182692e-08
or O 0 1.4295785000228989e-08
without O 0 1.1396397603391506e-08
a O 0 9.723811444928288e-08
personal O 0 1.32683362608077e-06
and O 0 1.3860834542356315e-06
/ O 0 9.501360182184726e-06
or O 0 5.4065246501977526e-08
family O 0 5.858639084976858e-08
history O 0 7.885747166369583e-09
of O 0 1.5132426867126014e-08
neoplasia B-Disease 0 0.00016881847113836557
, O 0 3.3230998042199644e-07
were O 0 2.2662763399239338e-07
examined O 0 8.879013080331788e-07
for O 0 8.996139833072903e-09
the O 0 1.5503520245374602e-08
I1307K O 0 1.7465059499954805e-05
variant O 0 5.790991053800099e-06
by O 0 1.2746305344535358e-08
the O 0 1.1770207031247537e-08
allele O 0 1.5098313497219351e-06
- O 0 1.3880201095162192e-06
specific O 0 5.966172977878159e-08
oligonucleotide O 0 4.155027272645384e-05
( O 0 9.387468935528887e-08
ASO O 0 0.00011346427345415577
) O 0 8.211888058440309e-08
method O 0 9.042123565450311e-07
. O 0 1.200429778691614e-06

RESULTS O 0 0.00022182906104717404
In O 0 3.223929070372833e-07
persons O 0 1.1332480198689154e-07
at O 0 6.328600221650049e-08
average O 0 2.633056737977313e-06
risk O 0 1.3722856238018721e-05
for O 0 0.22914299368858337
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
, O 0 2.0393047179823043e-06
I1307K O 0 1.008445724437479e-05
was O 0 2.3128870907385135e-06
found O 0 7.962681536355376e-08
in O 0 3.267242476567844e-08
5 O 0 7.670074069210386e-07
. O 0 1.6808851341920672e-06

0 O 0 9.437202970730141e-05
% O 0 8.510328939337342e-07
of O 0 2.0451690119216437e-08
120 O 0 1.9383325877697644e-07
European O 0 1.188934675155906e-07
and O 0 1.6561233451284352e-07
1 O 0 9.772447810973972e-07
. O 0 1.1080742297053803e-06

6 O 0 4.359121521702036e-05
% O 0 3.5266526765553863e-07
of O 0 6.188365819781438e-09
188 O 0 3.1652771781409683e-07
non O 0 2.916324319812702e-07
- O 0 2.7197309464099817e-05
European O 0 1.115980239774217e-06
Jews O 0 1.0011057156589231e-06
( O 0 5.993032203832627e-08
P O 0 8.13077076600166e-06
= O 0 4.753954954139772e-07
0 O 0 2.329819608348771e-07
. O 0 2.340713933790539e-08
08 O 0 6.402527787940926e-07
) O 0 9.32164780920175e-08
. O 0 4.179879340426851e-07

It O 0 3.5201780974603025e-06
occurred O 0 1.2862847142969258e-06
in O 0 1.4142774773517885e-07
15 O 0 1.0322025900677545e-06
. O 0 1.160064130090177e-06

4 O 0 5.6765798944979906e-05
% O 0 8.113892704386672e-07
of O 0 4.141880438623957e-08
52 O 0 1.170380346593447e-05
Ashkenazi O 0 7.861700578359887e-05
Israelis O 0 0.00010920596105279401
with O 0 1.7946818843483925e-05
familial O 1 0.9988906979560852
cancer B-Disease 1 0.9983134269714355
( O 0 3.7484889503502927e-07
P O 0 7.804684719303623e-05
= O 0 1.3218221965871635e-06
0 O 0 2.53404124350709e-07
. O 0 3.662419345573653e-08
02 O 0 1.6436757732662954e-07
) O 0 5.5668665233099546e-09
and O 0 9.487185259615671e-09
was O 0 6.943848802620778e-07
not O 0 3.141519044902452e-08
detected O 0 1.9085253200046282e-07
in O 0 1.8712626115302555e-08
51 O 0 5.440168138193258e-07
non O 0 2.5912209267175967e-08
- O 0 7.546611300313089e-07
European O 0 7.65411698466778e-08
Jews O 0 1.3903873252729682e-07
at O 0 1.0966901697884168e-07
increased O 0 0.00015639429329894483
cancer B-Disease 0 0.11724729835987091
risk O 0 2.8847946396126645e-06
. O 0 1.4508309504890349e-06

Colorectal B-Disease 1 0.9994295239448547
neoplasia I-Disease 1 0.7044543623924255
occurred O 0 0.00016892894927877933
personally O 0 2.7700618375092745e-05
or O 0 9.491967034591653e-08
in O 0 1.98863823186457e-08
the O 0 2.2253432874208556e-08
families O 0 2.0562502811571903e-08
of O 0 2.6241253614500692e-09
13 O 0 4.8187438039803965e-08
of O 0 4.173113854477606e-09
20 O 0 1.0310805720337157e-07
Ashkenazi O 0 2.0748000224557472e-06
I1307K O 0 2.287173174408963e-06
carriers O 0 1.3166521739549353e-07
, O 0 3.931997394346354e-09
8 O 0 5.787223589237556e-09
of O 0 1.688909900821045e-09
whom O 0 1.6324545413226588e-06
also O 0 5.397112090577139e-07
had O 0 1.0042766689366545e-06
a O 0 3.00305515565924e-07
personal O 0 1.0122180356120225e-06
or O 0 5.339909847634772e-08
family O 0 8.459723233045224e-08
history O 0 2.5592644448124702e-08
of O 0 7.637055432496709e-08
noncolonic O 0 0.012511473149061203
neoplasia B-Disease 0 0.012652560137212276
. O 0 5.937457444815664e-06

CONCLUSIONS O 0 0.0002710915287025273
The O 0 3.057810545215034e-06
I1307K O 0 5.0018690672004595e-05
APC O 0 0.00015360221732407808
variant O 0 0.004939377307891846
may O 0 5.828283974551596e-06
represent O 0 3.9181639266416823e-08
a O 0 1.7273640651183086e-06
susceptibility O 0 0.03170865401625633
gene O 0 8.24663493403932e-06
for O 0 2.753035914793145e-05
colorectal B-Disease 1 0.9999998807907104
, I-Disease 0 2.682421836652793e-06
or I-Disease 0 3.24850724098269e-08
other I-Disease 0 9.923804000777636e-09
, I-Disease 0 1.3955298072687583e-06
cancers I-Disease 0 0.009396118111908436
in O 0 2.430490155802545e-07
Ashkenazi O 0 0.00013223919086158276
Jews O 0 9.487475267633272e-07
, O 0 1.0309900488891799e-07
and O 0 1.8196119810909295e-07
partially O 0 1.0502124496269971e-05
explains O 0 1.2836018470352428e-07
the O 0 8.685563379629002e-09
higher O 0 2.0745277140576945e-07
incidence O 0 0.0003526960499584675
of O 0 0.00023285749193746597
colorectal B-Disease 1 1.0
cancer I-Disease 1 0.9999998807907104
in O 0 1.318024487773073e-06
European O 0 1.1255420986344689e-06
Israelis O 0 4.7139743401203305e-05
. O 0 2.5553561044944217e-06

Systematic O 0 7.355660636676475e-05
analysis O 0 4.072058345627738e-06
of O 0 3.0487993285532866e-07
coproporphyrinogen O 0 0.0008535945089533925
oxidase O 0 0.00011525186710059643
gene O 0 9.412668441655114e-05
defects O 0 0.3028714060783386
in O 0 1.165942421721411e-06
hereditary B-Disease 1 0.9757006764411926
coproporphyria I-Disease 0 0.1799539029598236
and O 0 7.5838920565729495e-06
mutation O 0 3.432903395150788e-05
update O 0 1.9005796275450848e-05
. O 0 2.2390456706489203e-06

Hereditary B-Disease 1 0.9996700286865234
coproporphyria I-Disease 1 0.9747447967529297
( O 0 5.066688754595816e-05
HC B-Disease 1 0.9397004246711731
) O 0 1.9198539575882023e-06
is O 0 1.8203251102022477e-06
an O 0 9.029476495925337e-05
acute O 1 0.9999847412109375
hepatic B-Disease 1 0.9999855756759644
porphyria I-Disease 1 0.9999864101409912
with O 0 0.0169198140501976
autosomal O 1 0.9992979764938354
dominant O 0 0.13886970281600952
inheritance O 0 0.0024209367111325264
caused O 0 0.00015112923574633896
by O 0 4.547864307369309e-07
deficient B-Disease 0 6.675801705569029e-05
activity I-Disease 0 2.4183119506915318e-08
of I-Disease 0 1.5917102302864805e-08
coproporphyrinogen I-Disease 0 0.008852750062942505
III I-Disease 0 0.25103262066841125
oxidase I-Disease 0 1.8455893950886093e-05
( O 0 2.3587197972574359e-07
CPO O 0 9.124185453401878e-05
) O 0 5.334586035132816e-07
. O 0 1.3741301927439054e-06

Clinical O 0 0.011944040656089783
manifestations O 0 0.00015055433323141187
of O 0 6.077194711906486e-07
the O 0 1.8802707927534357e-05
disease O 0 0.007599303498864174
are O 0 2.98816559052284e-07
characterized O 0 7.650638144696131e-05
by O 0 1.0862393537536263e-05
acute O 1 0.9050653576850891
attacks O 0 0.007697573862969875
of O 0 7.89418481872417e-06
neurological B-Disease 1 0.9999785423278809
dysfunction I-Disease 1 0.9983762502670288
often O 0 2.1082823877804913e-05
precipitated O 0 0.0001737695129122585
by O 0 1.1096662433374149e-07
drugs O 0 1.8310802829546446e-07
, O 0 5.629579291621667e-08
fasting O 0 9.176514481623599e-07
, O 0 6.791928086613552e-08
cyclical O 0 1.0641261724231299e-05
hormonal O 0 0.0003400553250685334
changes O 0 4.384086764730455e-07
, O 0 2.1677261941022152e-07
or O 0 1.1121321676910156e-06
infectious B-Disease 0 0.04369765520095825
diseases I-Disease 0 0.009693977423012257
. O 0 5.834712737851078e-06

Skin O 1 0.999976634979248
photosensitivity O 1 0.9999058246612549
may O 0 0.024455295875668526
also O 0 1.94807239495276e-06
be O 0 1.3854911173893925e-07
present O 0 5.177820412427536e-07
. O 0 1.670822712185327e-06

The O 0 3.3882461139000952e-06
seven O 0 1.3460197578751831e-06
exons O 0 6.05743889536825e-06
, O 0 1.0348456669362349e-07
the O 0 2.6342714676275136e-08
exon O 0 2.3003419755696086e-06
/ O 0 1.543747430332587e-06
intron O 0 9.449123353988398e-06
boundaries O 0 1.3573631463259517e-07
and O 0 1.8062261020190817e-08
part O 0 1.1892154816450784e-08
of O 0 6.110870476305763e-09
3 O 0 5.4320768327897895e-08
noncoding O 0 4.193214522274502e-07
sequence O 0 1.632081847446898e-08
of O 0 1.6098241628625942e-09
the O 0 7.530820411716377e-09
CPO O 0 1.7914419004227966e-05
gene O 0 4.7058074414962903e-07
were O 0 6.316312095577814e-08
systematically O 0 3.8366169974324293e-07
analyzed O 0 2.4422121214229264e-07
by O 0 5.585190976375998e-09
an O 0 1.4051109609169998e-08
exon O 0 7.115353923836665e-07
- O 0 1.896179014693189e-06
by O 0 1.22559853821258e-07
- O 0 7.261337941599777e-06
exon O 0 1.2045067705912516e-05
denaturing O 0 0.00013286140165291727
gradient O 0 0.003415523562580347
gel O 0 0.0004309377109166235
electrophoresis O 0 1.8017268303083256e-05
( O 0 5.952795234520636e-08
DGGE O 0 4.528195859165862e-06
) O 0 2.2470187488465854e-08
strategy O 0 6.958420328828652e-08
followed O 0 2.4756747762921805e-08
by O 0 2.216155037260137e-09
direct O 0 1.0503319991528315e-08
sequencing O 0 4.4388116293703206e-08
in O 0 2.3093525314266117e-08
seven O 0 8.498197701101162e-08
unrelated O 0 4.217062269162852e-06
heterozygous O 0 0.00854164082556963
HC B-Disease 1 0.9967669248580933
patients O 1 0.6906842589378357
from O 0 7.058447692998016e-08
France O 0 4.768367034557741e-06
, O 0 2.0199978223445214e-07
Holland O 0 9.388035323354416e-06
, O 0 4.765029970599244e-08
and O 0 1.0899545088705054e-07
Czech O 0 3.442426896071993e-05
Republic O 0 1.3708723827221547e-06
. O 0 1.1581727221710025e-06

Seven O 0 4.556676867650822e-05
novel O 0 4.006957897217944e-05
mutations O 0 2.6564564905129373e-05
and O 0 6.195655544161127e-08
two O 0 3.075982846212355e-08
new O 0 1.8726393591350643e-07
polymorphisms O 0 1.0946961083391216e-05
were O 0 1.5658955589969992e-06
detected O 0 1.4617059605370741e-05
. O 0 9.554722737448174e-07

Among O 0 3.0241582862799987e-05
these O 0 5.960838507235167e-07
mutations O 0 4.205696313874796e-06
two O 0 1.253509793741614e-07
are O 0 8.939630191662218e-08
missense O 0 3.343130447319709e-05
( O 0 4.5721300523382524e-08
G197W O 0 3.4410611533530755e-06
, O 0 8.390191652551948e-08
W427R O 0 1.572358655721473e-06
) O 0 9.329489181197914e-09
, O 0 4.884422644124697e-09
two O 0 5.898226795864048e-09
are O 0 9.111563947783452e-09
nonsense O 0 1.6323081126756733e-06
( O 0 1.3392557285385465e-08
Q306X O 0 1.480898390582297e-06
, O 0 4.676182641105697e-08
Q385X O 0 1.7467041288909968e-06
) O 0 8.720522082228399e-09
, O 0 8.561742426138608e-09
two O 0 6.867741042526632e-09
are O 0 3.926002190013378e-09
small O 0 2.6973228983706576e-08
deletions O 0 2.7907378807867644e-06
( O 0 3.759683764315014e-08
662de14bp O 0 5.090398190077394e-06
; O 0 3.4003701188112245e-08
1168del3bp O 0 6.531914209517709e-07
removing O 0 3.7828165488917875e-08
a O 0 3.640599288701196e-08
glycine O 0 1.662705102489781e-07
at O 0 1.4053815888814825e-08
position O 0 1.4104428203154384e-07
390 O 0 3.4354303579675616e-07
) O 0 2.0388906563084674e-08
, O 0 1.0573309339179104e-08
and O 0 7.0795183049199295e-09
one O 0 9.139969670002301e-09
is O 0 7.005666713411074e-09
a O 0 6.976760147381356e-08
splicing O 0 5.095172127767e-06
mutation O 0 1.6752599094616016e-06
( O 0 1.1274006617156829e-08
IVS1 O 0 1.1765641829697415e-05
- O 0 3.56503005605191e-05
15c O 0 7.128986908355728e-05
- O 0 7.745126640656963e-05
- O 0 0.0018401420675218105
> O 0 5.721434717997909e-06
g O 0 7.495451882277848e-06
) O 0 5.089217047782313e-09
which O 0 6.54176757208802e-09
creates O 0 5.398971225645255e-08
a O 0 6.956668130442267e-08
new O 0 1.1014824252697508e-07
acceptor O 0 2.992917131905415e-07
splice O 0 7.28201803212869e-06
site O 0 1.9223896288167452e-06
. O 0 9.665247944212751e-07

The O 0 2.847476480383193e-06
pathological O 0 1.56662572408095e-05
significance O 0 2.533180918362632e-07
of O 0 1.2987469766301274e-08
the O 0 3.6005193493338083e-08
point O 0 3.4551874250610126e-07
mutations O 0 1.671744030318223e-06
G197W O 0 2.5247593384847278e-06
, O 0 3.399604864284811e-08
W427R O 0 6.921488306943502e-07
, O 0 1.0197656941102196e-08
and O 0 7.360046794246955e-09
the O 0 3.6395977343062214e-09
in O 0 2.5390187730067737e-08
- O 0 9.616419993108138e-05
frame O 0 0.11461714655160904
deletion O 0 4.9203030357602984e-05
390delGly O 0 1.177550893771695e-05
were O 0 2.290195340037826e-07
assessed O 0 1.394692787926033e-07
by O 0 1.0189063814891597e-08
their O 0 4.0261785017037255e-09
respective O 0 1.0742846612288304e-08
expression O 0 6.960981835391067e-08
in O 0 6.577613120839487e-09
a O 0 4.937573194752076e-08
prokaryotic O 0 8.141876861600394e-08
system O 0 2.0405167333592544e-08
using O 0 2.835301593506756e-08
site O 0 1.4233376077754656e-07
- O 0 1.567470349073119e-06
directed O 0 4.92778826810536e-06
mutagenesis O 0 0.0001245108142029494
. O 0 2.0562658846756676e-06

These O 0 7.598878255521413e-06
mutations O 0 5.678572415490635e-05
resulted O 0 9.153081350632419e-07
in O 0 2.5255141977709172e-08
the O 0 9.319458094125821e-09
absence O 0 4.852848292102863e-07
or O 0 2.2437982138967527e-08
a O 0 3.3792608178373484e-07
dramatic O 0 5.5311364121735096e-05
decrease O 0 9.12902851268882e-06
of O 0 2.6173484712899153e-08
CPO O 0 0.00022386501950677484
activity O 0 6.296404535532929e-07
. O 0 5.070172051091504e-07

The O 0 1.9477454316074727e-06
two O 0 2.9993202588229906e-07
polymorphisms O 0 5.5239547691599e-06
were O 0 5.346937541617081e-07
localized O 0 4.712845111498609e-06
in O 0 1.2784636282958672e-07
noncoding O 0 4.2220844989060424e-06
part O 0 2.1789073656464097e-08
of O 0 1.8113206490255607e-09
the O 0 8.678277652052202e-09
gene O 0 8.916435945138801e-08
1 O 0 2.075387861566469e-08
) O 0 8.419942965076643e-09
a O 0 6.017808686920034e-07
C O 0 1.1816581718449015e-05
/ O 0 7.413244929921348e-06
G O 0 0.0021198573522269726
polymorphism O 0 8.837966743158177e-05
in O 0 4.360585492690916e-08
the O 0 1.5327282554267185e-08
promotor O 0 1.7693981135380454e-05
region O 0 9.33114634449339e-08
, O 0 1.011930184091625e-08
142 O 0 8.031442888523088e-08
bp O 0 1.9320241335663013e-06
upstream O 0 1.8790307976246368e-08
from O 0 6.652783879346202e-10
the O 0 3.896725719876315e-10
transcriptional O 0 4.6376335660625045e-08
initiation O 0 2.3051674347129847e-08
site O 0 6.359758941698601e-08
( O 0 8.55815063260934e-09
- O 0 1.5654790104235872e-06
142C O 0 2.219363159383647e-05
/ O 0 1.74768047145335e-06
G O 0 4.808145604329184e-05
) O 0 1.8998534301317704e-08
, O 0 1.8270922552687807e-08
and O 0 2.5275383563894138e-08
2 O 0 5.236356770410566e-08
) O 0 5.268462555108044e-09
a O 0 2.0531625466446712e-07
6 O 0 4.6707094725206844e-07
bp O 0 4.619522951543331e-05
deletion O 0 5.077999958302826e-06
polymorphism O 0 5.137857442605309e-06
in O 0 1.8425886594286567e-08
the O 0 2.1058520260908153e-08
3 O 0 1.1865694915513814e-07
noncoding O 0 6.644445420533884e-07
part O 0 1.3588676850417869e-08
of O 0 2.457747783068953e-09
the O 0 1.601189403288572e-08
CPO O 0 2.1024277884862386e-05
gene O 0 2.0394473665419355e-07
, O 0 2.2771601493332128e-08
574 O 0 5.753524874307914e-07
bp O 0 3.1714457691123243e-06
downstream O 0 3.7958042042873785e-08
of O 0 9.553349222812813e-10
the O 0 2.3697681594825326e-09
last O 0 7.392718970322676e-08
base O 0 2.8137415952755873e-08
of O 0 1.062657739581141e-09
the O 0 6.662425722225862e-09
normal O 0 3.20436669198898e-07
termination O 0 2.3941220206324942e-06
codon O 0 1.118438262892596e-06
( O 0 1.6543616254693916e-07
+ O 0 1.1859827964144642e-06
574 O 0 3.909269707946805e-06
delATTCTT O 0 2.209547528764233e-05
) O 0 4.898503789263486e-07
. O 0 1.1302275879643275e-06

Five O 0 1.574615089339204e-05
intragenic O 0 9.461920853937045e-05
dimorphisms O 0 0.00014180036669131368
are O 0 1.7901376736517705e-07
now O 0 9.233700382083043e-08
well O 0 7.785573075125285e-08
characterized O 0 2.5600979824957903e-06
and O 0 1.0553608120744684e-07
the O 0 1.494868584472897e-08
high O 0 4.884509152702776e-08
degree O 0 2.2669329524660498e-08
of O 0 6.2816840618040715e-09
allelic O 0 1.1448659279267304e-05
heterogeneity O 0 0.00015545019414275885
in O 0 1.5044859082991024e-06
HC B-Disease 1 0.8919318914413452
is O 0 2.6029041691799648e-05
demonstrated O 0 4.857844032812864e-06
with O 0 2.0981863357860675e-08
seven O 0 3.537478221460333e-08
new O 0 2.233567464315911e-08
different O 0 3.172031748377435e-09
mutations O 0 5.652701773328772e-08
making O 0 3.884490951122643e-09
a O 0 3.8321697815035805e-08
total O 0 1.0969010588723904e-08
of O 0 9.063101380490934e-09
nineteen O 0 3.4180618513346417e-06
CPO O 0 0.008835157379508018
gene B-Disease 0 0.0001386112708132714
defects I-Disease 0 0.46756938099861145
reported O 0 2.505328893676051e-06
so O 0 1.384824059869061e-07
far O 0 2.794008366890921e-07
. O 0 1.708060750615914e-07
. O 0 1.1122106116090436e-06

Coincidence O 0 0.00012785654689650983
of O 0 4.274691036698641e-07
two O 0 1.645859128984739e-07
novel O 0 1.0983989113810821e-06
arylsulfatase O 0 8.934053767006844e-06
A O 0 1.7496581676823553e-06
alleles O 0 1.2981770396436332e-06
and O 0 3.2407970707026834e-07
mutation O 0 4.815983629669063e-06
459 O 0 8.978092409961391e-06
+ O 0 4.235173946653958e-06
1G O 0 0.0005319219781085849
> O 0 6.653245918641915e-07
A O 0 3.033361508641974e-07
within O 0 1.503831192906091e-08
a O 0 7.203396421573416e-07
family O 0 5.392212187871337e-06
with O 0 2.2915550289326347e-05
metachromatic B-Disease 1 0.9999992847442627
leukodystrophy I-Disease 1 0.9999954700469971
: O 0 1.7118244954872353e-07
molecular O 0 2.499038203040982e-07
basis O 0 2.5754140153821936e-08
of O 0 2.2579053293725337e-08
phenotypic O 0 0.00040241042734123766
heterogeneity O 0 0.0011689523234963417
. O 0 1.0847726116480771e-05

In O 0 3.337129101055325e-06
a O 0 1.49252298342617e-06
family O 0 5.295642040437087e-07
with O 0 4.4240032082143443e-08
three O 0 4.1079246670960856e-07
siblings O 0 1.5051825357659254e-05
, O 0 4.841093215190995e-08
one O 0 3.266426062964456e-08
developed O 0 2.8332968327049457e-07
classical O 0 1.4058890656087897e-06
late O 0 0.0004573165497276932
infantile O 1 0.9996576309204102
metachromatic B-Disease 1 0.9999995231628418
leukodystrophy I-Disease 1 0.9999985694885254
( O 0 1.1758014807128347e-05
MLD B-Disease 1 0.9998687505722046
) O 0 4.419533752297866e-07
, O 0 2.043945244167844e-07
fatal O 0 0.00022464542416855693
at O 0 1.3200744319874502e-07
age O 0 5.765526793766185e-07
5 O 0 1.1164300417476625e-07
years O 0 2.184467433608006e-07
, O 0 6.86563552676489e-08
with O 0 4.659475791868317e-07
deficient O 0 0.029588017612695694
arylsulfatase O 0 0.0006975771975703537
A O 0 1.4414374163607135e-05
( O 0 9.086888042020291e-08
ARSA O 0 5.5503791372757405e-05
) O 0 1.4361787314953744e-08
activity O 0 1.2259125270475124e-08
and O 0 3.231919976087738e-08
increased O 0 8.265785709227202e-07
galactosylsulfatide O 0 0.0027827478479593992
( O 0 9.255667805518897e-07
GS O 1 0.9998605251312256
) O 0 6.458542998188932e-07
excretion O 0 5.167469225852983e-06
. O 0 8.068535635175067e-07

The O 0 6.449230909311154e-07
two O 0 1.9740741663554218e-07
other O 0 4.340579096151487e-08
siblings O 0 3.071491619266453e-06
, O 0 1.1385755982473711e-07
apparently O 0 4.2071724237757735e-06
healthy O 0 1.2616423816780298e-07
at O 0 1.221841383625133e-08
12 O 0 3.1956869150917555e-08
( O 0 5.600509833669776e-09
1 O 0 4.9292172121795375e-08
/ O 0 2.2870719362799719e-07
2 O 0 9.447246185345648e-08
) O 0 7.502691801164474e-09
and O 0 2.9741093143798025e-08
15 O 0 4.108833095983755e-08
years O 0 7.387334477471086e-08
, O 0 2.1765647062466087e-08
respectively O 0 1.1517716558273605e-07
, O 0 1.2652156655690305e-08
and O 0 1.1402637944968319e-08
their O 0 1.6095178523301e-08
father O 0 6.028019470250001e-06
, O 0 2.9470271556419902e-08
apparently O 0 2.9312072911125142e-06
healthy O 0 6.14058492942604e-08
as O 0 2.8950635666546987e-08
well O 0 3.36516130516884e-08
, O 0 3.6102427714013174e-08
presented O 0 1.8040246914097224e-06
ARSA O 0 0.018411170691251755
and O 0 3.7290994896466145e-06
GS O 1 0.9993715882301331
values O 0 5.982467854437346e-08
within O 0 2.5995656738331263e-09
the O 0 5.114049184129499e-09
range O 0 1.172362047441311e-07
of O 0 2.1599855415388447e-07
MLD B-Disease 1 0.9999982118606567
patients O 1 0.9991090893745422
. O 0 4.4357198021316435e-06

Mutation O 0 0.0031216389033943415
screening O 0 4.9617490731179714e-05
and O 0 4.913921429761103e-07
sequence O 0 1.5781287743266148e-07
analysis O 0 1.1792031529012093e-07
disclosed O 0 2.535390137836657e-07
the O 0 4.42932845956534e-09
involvement O 0 6.690009968224331e-08
of O 0 3.7995837587345704e-09
three O 0 4.409530163229647e-08
different O 0 3.9192627809825353e-08
ARSA O 0 0.06551970541477203
mutations O 0 2.0010952539450955e-06
being O 0 1.2502774815459361e-08
the O 0 2.167408252873315e-09
molecular O 0 3.7840575117797925e-08
basis O 0 5.419614090840241e-09
of O 0 7.3679120582426094e-09
intrafamilial O 0 0.0006090268143452704
phenotypic O 0 0.0011166618205606937
heterogeneity O 0 0.00023903803958091885
. O 0 3.934643245884217e-06

The O 0 8.159518984030001e-06
late O 0 8.530612831236795e-05
infantile O 1 0.9963535070419312
patient O 1 0.9812164902687073
inherited O 0 0.0017289294628426433
from O 0 9.032800818431497e-08
his O 0 1.171217036244343e-06
mother O 0 1.5894940588623285e-05
the O 0 2.742507732023114e-08
frequent O 0 2.9716936751356116e-06
0 O 0 1.2243034461789648e-06
- O 0 3.322246266179718e-05
type O 0 9.368566679768264e-05
mutation O 0 2.8017886961606564e-06
459 O 0 2.089858298859326e-06
+ O 0 8.788517220637004e-07
1G O 0 9.994813444791362e-05
> O 0 9.788491297513247e-07
A O 0 1.8287329339727876e-06
, O 0 6.908326355414829e-08
and O 0 2.3173919672103693e-08
from O 0 1.691712370188725e-08
his O 0 3.711975864462147e-07
father O 0 4.508068741415627e-06
a O 0 1.927778328081331e-07
novel O 0 1.9652493676858285e-07
, O 0 8.09163580584027e-09
single O 0 4.7257302071557206e-08
basepair O 0 1.4029144494998036e-06
microdeletion O 0 3.596693147756014e-07
of O 0 1.7887198389132664e-09
guanine O 0 4.21688248763985e-08
at O 0 7.63263852121554e-09
nucleotide O 0 4.8580943712295266e-08
7 O 0 2.1503208103013094e-08
in O 0 1.0971249686519968e-08
exon O 0 1.834673867051606e-06
1 O 0 2.762089366115106e-07
( O 0 4.717004031817851e-08
7delG O 0 6.0246575230848975e-06
) O 0 2.4000331677598297e-07
. O 0 7.18148100986582e-07

The O 0 3.798154466494452e-06
two O 0 2.3357870304607786e-06
clinically O 0 0.004051719792187214
unaffected O 0 0.000309312017634511
siblings O 0 7.31537284082151e-06
carried O 0 5.984038011774828e-07
the O 0 3.927351954757796e-08
maternal O 0 2.991695873788558e-05
mutation O 0 4.727921350422548e-06
459 O 0 6.568835487996694e-06
+ O 0 1.893242711048515e-06
1G O 0 0.0002654445997904986
> O 0 8.93768458354316e-07
A O 0 8.697775228938553e-07
and O 0 9.63570840895045e-08
, O 0 1.890498424472753e-08
on O 0 1.260009554471253e-07
their O 0 3.066914189275849e-08
paternal O 0 4.827671727980487e-05
allele O 0 3.948043286072789e-06
, O 0 1.5237649364507888e-08
a O 0 5.3786102682806813e-08
novel O 0 2.0801222433419753e-07
cytosine O 0 1.763381476393988e-07
to O 0 1.5939402686626636e-08
thymidine O 0 8.311015449180559e-07
transition O 0 5.288621096610768e-08
at O 0 9.692458391441505e-09
nucleotide O 0 7.77889397340914e-08
2435 O 0 1.5985825712050428e-06
in O 0 3.953280369728418e-08
exon O 0 8.770281851866457e-07
8 O 0 8.664785156042853e-08
, O 0 1.3969578382955206e-08
resulting O 0 5.2225924918047895e-08
in O 0 5.700033334221644e-09
substitution O 0 2.5822020077725938e-08
of O 0 4.813487386456927e-09
alanine O 0 4.144668764638482e-06
464 O 0 1.2656409126066137e-05
by O 0 9.947360695150564e-07
valine O 0 0.0003627497935667634
( O 0 2.2117184528269718e-07
A464V O 0 1.4514324902847875e-05
) O 0 3.768335261611355e-07
. O 0 7.862529400881613e-07

The O 0 1.1588573215703946e-05
fathers O 0 4.391897891764529e-05
genotype O 0 0.00023784789664205164
thus O 0 2.285485379616148e-06
was O 0 5.0566209210956e-06
7delG O 0 8.68631832418032e-05
/ O 0 4.2311803554184735e-05
A464V O 0 7.51529005356133e-05
. O 0 2.903463609982282e-06

Mutation O 0 0.009340712800621986
A464V O 0 0.00032064534025266767
was O 0 8.860321031534113e-06
not O 0 1.3412527266609686e-07
found O 0 6.648870254366557e-08
in O 0 8.802275885955169e-08
18 O 0 5.015600436308887e-06
unrelated O 0 0.001787708606570959
MLD B-Disease 1 0.9999997615814209
patients O 1 0.9988693594932556
and O 0 1.011416998153436e-06
50 O 0 5.224759433986037e-07
controls O 0 2.8832610041718e-05
. O 0 2.1433531856018817e-06

A464V O 0 0.0012147490633651614
, O 0 2.981287934744614e-06
although O 0 4.904567276753369e-07
clearly O 0 7.370346111201798e-07
modifying O 0 3.21123616231489e-06
ARSA O 0 0.010997259058058262
and O 0 2.249091812700499e-05
GS O 1 0.9999825954437256
levels O 0 1.4167358131089713e-06
, O 0 9.023949587572133e-08
apparently O 0 2.3874122234701645e-06
bears O 0 7.304221867343585e-07
little O 0 1.0684652096415448e-07
significance O 0 7.431383863831797e-08
for O 0 4.066079029030334e-08
clinical O 0 3.378179144419846e-06
manifestation O 0 2.9943503250251524e-05
of O 0 1.0106091394845862e-06
MLD B-Disease 1 0.9999884366989136
, O 0 7.26842131371086e-07
mimicking O 0 3.4189747566415463e-06
the O 0 7.945673985432222e-08
frequent O 0 2.7870628400705755e-05
ARSA O 0 0.24220944941043854
pseudodeficiency O 0 0.0020814251620322466
allele O 0 8.57086997712031e-05
. O 0 1.7119938320320216e-06

Our O 0 5.018356205255259e-06
results O 0 2.5410352009203052e-06
demonstrate O 0 3.3028791790457035e-07
that O 0 4.008006371236661e-08
in O 0 4.52494361979916e-08
certain O 0 1.4557356564637303e-07
genetic O 0 3.261462552472949e-05
conditions O 0 0.01747730001807213
MLD B-Disease 1 0.9999890327453613
- O 0 0.06320177018642426
like O 0 7.132731752790278e-06
ARSA O 0 0.05824469029903412
and O 0 6.288990789471427e-06
GS O 1 0.9998762607574463
values O 0 1.4290638716829562e-07
need O 0 3.013980531818561e-08
not O 0 2.143065458426463e-08
be O 0 1.75492029796942e-08
paralleled O 0 1.2586898492372711e-06
by O 0 7.2072361945174634e-06
clinical O 1 0.664445698261261
disease O 0 0.0006196874310262501
, O 0 1.3965689049655339e-08
a O 0 6.264480845175058e-08
finding O 0 3.8946936342654226e-08
with O 0 7.753356356943186e-08
serious O 0 4.493082087719813e-05
diagnostic O 0 0.001237094751559198
and O 0 8.64746471052058e-06
prognostic O 0 0.2151658684015274
implications O 0 1.9415329006733373e-05
. O 0 4.398951659823069e-06

Moreover O 0 0.00010917992767645046
, O 0 1.1921584928131779e-06
further O 0 1.0683842219805229e-06
ARSA O 0 0.060138821601867676
alleles O 0 2.1710498913307674e-05
functionally O 0 1.2000305105175357e-05
similar O 0 1.2901506352136494e-07
to O 0 1.2236704094448214e-07
A464V O 0 2.340796527278144e-05
might O 0 2.3589925604028394e-06
exist O 0 1.9838950038320036e-08
which O 0 2.0559442148737617e-08
, O 0 8.965717945841334e-09
together O 0 9.38189792520916e-09
with O 0 3.937275039334054e-08
0 O 0 1.1343523738105432e-06
- O 0 0.0012390527408570051
type O 0 0.0020949130412191153
mutations O 0 8.732126843824517e-06
, O 0 1.5552483034753095e-07
may O 0 2.036508703895379e-05
cause O 0 1.2387113201839384e-05
pathological O 0 0.00416536582633853
ARSA O 1 0.9265509843826294
and O 0 0.0002446852158755064
GS O 1 0.9999949932098389
levels O 0 7.429697461702744e-07
, O 0 2.453065839347346e-08
but O 0 3.6063887876025547e-08
not O 0 8.301098830543197e-08
clinical O 0 2.2335475478030276e-06
outbreak O 0 3.888073649704893e-07
of O 0 2.1290421869935017e-08
the O 0 3.2132272735907463e-06
disease O 0 0.00010175530769629404
. O 0 2.9595275918836705e-07
. O 0 9.012301802613365e-07

Human O 0 0.003713552374392748
MLH1 O 1 0.9996780157089233
deficiency O 1 0.9997215867042542
predisposes O 0 0.19045035541057587
to O 0 0.00015113817062228918
hematological B-Disease 1 0.9984847903251648
malignancy I-Disease 1 0.9769147634506226
and O 0 0.0001352803665213287
neurofibromatosis B-Disease 1 0.9900673627853394
type I-Disease 0 7.245954475365579e-05
1 I-Disease 0 1.8560400576461689e-06
. O 0 2.212748995589209e-06

Heterozygous O 0 0.004180689342319965
germ O 0 0.0004674255906138569
- O 0 0.0047150966711342335
line O 0 0.00011726658703992143
mutations O 0 4.798328518518247e-06
in O 0 2.7008800529415566e-08
the O 0 2.9709285698231724e-08
DNA O 0 3.97513986172271e-06
mismatch O 0 0.0004754197143483907
repair O 0 5.239022721070796e-05
genes O 0 4.627975442872412e-07
lead O 0 1.3406533980742097e-06
to O 0 9.799992767511867e-06
hereditary B-Disease 1 0.9999786615371704
nonpolyposis I-Disease 1 0.9999992847442627
colorectal I-Disease 1 1.0
cancer I-Disease 1 0.9999998807907104
. O 0 3.90947716368828e-05

The O 0 0.00015544280176982284
disease O 0 0.035520780831575394
susceptibility O 0 0.0006013032398186624
of O 0 2.431929999602289e-07
individuals O 0 6.801727749916608e-07
who O 0 8.125218300847337e-05
constitutionally O 0 0.0006454855902120471
lack O 0 1.0678738817659905e-06
both O 0 9.358577557350145e-08
wild O 0 2.655870048329234e-07
- O 0 0.00018156554142478853
type O 0 4.283243106328882e-05
alleles O 0 1.8453411030350253e-06
is O 0 4.958099566465535e-07
unknown O 0 1.8569464828033233e-06
. O 0 9.124138387051062e-07

We O 0 5.859672455699183e-06
have O 0 4.703590832377813e-07
identified O 0 2.0489414964686148e-07
three O 0 2.0119262700291074e-08
offspring O 0 3.627637852332555e-07
in O 0 3.993393349333019e-08
a O 0 0.000238962602452375
hereditary B-Disease 1 0.9999887943267822
nonpolyposis I-Disease 1 0.9999996423721313
colorectal I-Disease 1 1.0
cancer I-Disease 1 1.0
family O 0 0.00047786044888198376
who O 0 3.825223393505439e-05
developed O 0 2.684991886781063e-05
hematological B-Disease 0 0.2595588266849518
malignancy I-Disease 0 0.0016171778552234173
at O 0 1.7463587909105627e-08
a O 0 2.0123606248034775e-07
very O 0 1.7608051905426692e-07
early O 0 1.220163198922819e-06
age O 0 2.4847250301718304e-07
, O 0 6.230279847585507e-09
and O 0 9.13023079363029e-09
at O 0 6.145082220854192e-09
least O 0 1.6187911455745052e-08
two O 0 2.5284723204066495e-09
of O 0 8.725425937328168e-10
them O 0 9.813577506179172e-09
displayed O 0 5.116891657053202e-07
signs O 0 7.819755865057232e-07
of O 0 5.790306545350177e-08
neurofibromatosis B-Disease 1 0.9169253706932068
type I-Disease 0 0.00015316288045141846
1 I-Disease 0 1.416933173459256e-06
( O 0 2.771519689304114e-07
NF1 B-Disease 0 0.00016973332094494253
) O 0 4.840501901526295e-07
. O 0 6.135562671261141e-07

DNA O 0 5.894416244700551e-05
sequence O 0 1.937326715051313e-06
analysis O 0 4.879239554611559e-07
and O 0 1.1607684768932813e-07
allele O 0 1.940277570611215e-06
- O 0 1.808632646316255e-06
specific O 0 5.8483678344600776e-08
amplification O 0 3.075384029216366e-06
in O 0 3.167402695680721e-08
two O 0 8.570684428832465e-08
siblings O 0 4.574743798002601e-06
revealed O 0 2.251769728900399e-06
a O 0 1.1382915090507595e-06
homozygous O 0 0.0003391526697669178
MLH1 O 0 0.13017110526561737
mutation O 0 1.8138431187253445e-05
( O 0 8.474354729059996e-08
C676T O 0 1.0687281246646307e-05
- O 0 8.597613486927003e-05
- O 0 0.00044246495235711336
> O 0 8.749507287575398e-06
Arg226Stop O 0 2.8013508199364878e-05
) O 0 2.371542677792604e-07
. O 0 3.7924255025245657e-07

Thus O 0 2.3743747078697197e-05
, O 0 3.1754058227306814e-07
a O 0 3.972699573751015e-07
homozygous O 0 1.2094021258235443e-05
germ O 0 1.947047348949127e-05
- O 0 0.0005256925360299647
line O 0 0.0001829793764045462
MLH1 O 0 0.1063895896077156
mutation O 0 2.9734866984654218e-05
and O 0 7.520502549596131e-07
consequent O 0 0.015302796848118305
mismatch O 1 0.9993858337402344
repair O 1 0.999969482421875
deficiency O 1 0.999841570854187
results O 0 5.797804988105781e-06
in O 0 1.2060498022492538e-07
a O 0 9.101425530388951e-05
mutator O 1 0.9998483657836914
phenotype O 1 0.9995904564857483
characterized O 0 0.00020063137344550341
by O 0 1.9716371753020212e-05
leukemia B-Disease 1 0.9978839755058289
and O 0 0.0004779333248734474
/ O 1 0.7829678654670715
or O 0 0.395121693611145
lymphoma B-Disease 1 1.0
associated O 0 0.0001409201795468107
with O 0 1.1624135368037969e-05
neurofibromatosis B-Disease 1 0.9987995624542236
type I-Disease 0 4.6392127842409536e-05
1 I-Disease 0 2.733046358116553e-07
. O 0 2.5286917093580996e-07
. O 0 7.820472092134878e-07

Missense O 1 0.8896380662918091
mutations O 0 0.12946292757987976
in O 0 8.262160804406449e-07
the O 0 2.8075444191699717e-08
most O 0 1.183061826282028e-08
ancient O 0 4.9183679351472165e-09
residues O 0 2.5676742509972428e-08
of O 0 2.3756243638928254e-09
the O 0 3.242973178885222e-08
PAX6 O 0 0.001069055637344718
paired O 0 3.954505700676236e-06
domain O 0 3.643649506557267e-07
underlie O 0 8.665857080814021e-07
a O 0 4.1260719285673986e-07
spectrum O 0 4.595579412125517e-06
of O 0 1.972083225609822e-07
human O 0 0.00025971332797780633
congenital B-Disease 1 0.9999984502792358
eye I-Disease 1 0.9999897480010986
malformations I-Disease 1 0.9999560117721558
. O 0 5.3991003369446844e-05

Mutations O 0 0.002404186176136136
of O 0 9.390339528181357e-07
the O 0 4.221035112550453e-07
human O 0 1.0556664165051188e-06
PAX6 O 0 0.16652026772499084
gene O 0 0.002394655719399452
underlie O 1 0.6009743809700012
aniridia B-Disease 1 0.9999992847442627
( O 0 0.0002694542636163533
congenital B-Disease 1 0.9999529123306274
absence I-Disease 0 2.0662520910263993e-05
of I-Disease 0 6.154702703042858e-08
the I-Disease 0 5.962374416412786e-07
iris I-Disease 0 0.2715468108654022
) O 0 3.904742840177278e-08
, O 0 1.6477713415952167e-08
a O 0 9.927762221195735e-07
rare O 0 2.424713602522388e-05
dominant O 0 0.01254277117550373
malformation B-Disease 1 0.5125956535339355
of I-Disease 0 3.873432063983273e-08
the I-Disease 0 9.311036137660267e-07
eye I-Disease 0 0.23734131455421448
. O 0 7.942543561512139e-06

The O 0 2.8451286198105663e-06
spectrum O 0 5.426388270279858e-06
of O 0 2.1570788533153973e-07
PAX6 O 0 0.11303487420082092
mutations O 0 0.002101579215377569
in O 0 1.397056348650949e-05
aniridia B-Disease 1 0.9999998807907104
patients O 1 0.9728960990905762
is O 0 4.0865589312488737e-07
highly O 0 3.3951442901525297e-07
biased O 0 9.990094440581743e-06
, O 0 7.92499932344981e-08
with O 0 4.0143490309674235e-08
92 O 0 2.0156037408014527e-06
% O 0 5.147439363639705e-09
of O 0 4.286938026787368e-10
all O 0 1.2807084281973857e-08
reported O 0 7.86951477493858e-06
mutations O 0 4.724567759240017e-07
leading O 0 1.01278025965712e-07
to O 0 3.8489014286824386e-07
premature O 0 4.3420863221399486e-05
truncation O 0 7.697149726482166e-07
of O 0 6.471586821987785e-09
the O 0 1.3948757704440595e-08
protein O 0 1.4818857607679092e-07
( O 0 7.43973460615166e-09
nonsense O 0 3.302208426703146e-07
, O 0 1.0994921417761816e-08
splicing O 0 1.4273068416059687e-07
, O 0 1.6015558657045403e-08
insertions O 0 3.3706541557876335e-07
and O 0 5.677098968703831e-08
deletions O 0 4.825158725907386e-07
) O 0 2.5257792302113558e-08
and O 0 2.995098213887104e-08
just O 0 6.757723269856797e-08
2 O 0 8.56093009815595e-08
% O 0 1.4822879812470546e-08
leading O 0 1.3323002256981908e-08
to O 0 1.49718832886947e-08
substitution O 0 2.9171799198479675e-08
of O 0 7.274410407376308e-09
one O 0 9.504304898655391e-08
amino O 0 7.925498124450314e-08
acid O 0 3.8825785964036186e-07
by O 0 3.3110499231270296e-08
another O 0 3.8149522652020096e-07
( O 0 9.981479109910651e-08
missense O 0 1.5142572010518052e-05
) O 0 1.9692642183599673e-07
. O 0 7.182399031080422e-07

The O 0 1.5200138250293094e-06
extraordinary O 0 1.1530578376550693e-06
conservation O 0 1.1028635782395213e-07
of O 0 5.2178799059277026e-09
the O 0 3.3040223001989943e-08
PAX6 O 0 0.00015675170288886875
protein O 0 1.9389148064874462e-07
at O 0 3.257415670532282e-09
the O 0 2.234929796784968e-09
amino O 0 5.1783338506083965e-08
acid O 0 6.794253408770601e-07
level O 0 2.097474194329152e-08
amongst O 0 2.6162203070612122e-08
vertebrates O 0 2.18270983509683e-07
predicts O 0 2.0431825760169886e-06
that O 0 7.871535245840278e-08
pathological O 0 4.7405035729752854e-05
missense O 0 0.0019200267270207405
mutations O 0 2.512286118871998e-05
should O 0 1.0635731939601101e-07
in O 0 4.362199490515195e-08
fact O 0 1.5407015041546401e-07
be O 0 1.1885583006687739e-07
common O 0 4.735665015687118e-08
even O 0 1.0968114594334111e-07
though O 0 8.59728928048753e-08
they O 0 1.4667774550503054e-08
are O 0 5.065509789403677e-09
hardly O 0 1.7664666529526585e-07
ever O 0 2.0144823054124572e-07
seen O 0 8.553264478905476e-07
in O 0 8.451843314105645e-07
aniridia B-Disease 1 0.999995231628418
patients O 1 0.7901608347892761
. O 0 2.2450112737715244e-06

This O 0 2.3551328922621906e-06
indicates O 0 1.3003204912820365e-06
that O 0 3.9074915747505656e-08
there O 0 1.2875025490188818e-08
is O 0 1.2798170523353747e-08
a O 0 2.0027647451570374e-07
heavy O 0 0.00027676468016579747
ascertainment O 0 0.00011454780178610235
bias O 0 3.283410842414014e-05
in O 0 1.1601395399907233e-08
the O 0 4.096099903705408e-09
selection O 0 2.160537171391752e-08
of O 0 3.055289710118814e-08
patients O 0 0.0001480709615861997
for O 0 2.5874729203678726e-07
PAX6 O 1 0.9193485975265503
mutation O 0 3.858905256493017e-05
analysis O 0 4.619976223807498e-08
and O 0 9.25948206997873e-09
that O 0 1.155656192963761e-08
the O 0 1.8697853931826103e-08
missing O 0 2.9775089842587477e-06
PAX6 O 0 0.1328076273202896
missense O 0 0.014952014200389385
mutations O 0 0.00011521647684276104
frequently O 0 2.5392002498847432e-05
may O 0 4.935501056024805e-05
underlie O 0 0.0009455091785639524
phenotypes O 0 0.0014693686971440911
distinct O 0 5.769866220362019e-07
from O 0 1.3438595658499253e-07
textbook O 0 0.0003875408146996051
aniridia B-Disease 1 0.9999657869338989
. O 0 1.2454774150683079e-05

Here O 0 6.309132913884241e-06
we O 0 2.307244244548201e-07
present O 0 1.0609777234549256e-07
four O 0 1.2556023420984275e-07
novel O 0 2.662184442669968e-06
PAX6 O 0 0.02962610311806202
missense O 0 0.003211352974176407
mutations O 0 2.0216051780153066e-05
, O 0 3.3558418266466106e-08
two O 0 1.576223951360589e-08
in O 0 3.71719330871656e-08
association O 0 6.31305994147624e-08
with O 0 1.8227869702514e-07
atypical O 1 0.7197490930557251
phenotypes O 1 0.7859287261962891
ectopia B-Disease 0 0.026372985914349556
pupillae I-Disease 0 0.0016766326734796166
( O 0 2.6517750484345015e-07
displaced B-Disease 0 3.6704066133097513e-06
pupils I-Disease 0 2.4705177565920167e-06
) O 0 4.84636814235273e-07
and O 0 0.0015901883598417044
congenital B-Disease 1 0.9999983310699463
nystagmus I-Disease 1 0.9545544981956482
( O 0 1.4449042851083505e-07
searching B-Disease 0 4.829177555620845e-07
gaze I-Disease 0 5.657842484652065e-05
) O 0 2.124239628642499e-08
, O 0 1.0358562896328749e-08
and O 0 2.019669764763421e-08
two O 0 3.636116119309918e-08
in O 0 6.031298482866987e-08
association O 0 2.7881037922838914e-08
with O 0 3.8519043954465815e-08
more O 0 3.5321693303558277e-07
recognizable O 0 0.009244653396308422
aniridia B-Disease 1 0.9999788999557495
phenotypes O 0 0.010439912788569927
. O 0 2.603142775114975e-06

Strikingly O 0 0.4276023805141449
, O 0 1.25699386899214e-06
all O 0 2.282682842746908e-08
four O 0 9.211834850475498e-08
mutations O 0 4.880197934653552e-07
are O 0 5.1291908498285466e-09
located O 0 1.711111963231815e-08
within O 0 4.894737504201885e-09
the O 0 2.1084202828092202e-08
PAX6 O 0 0.0004168908635620028
paired O 0 2.9415739390969975e-06
domain O 0 9.698584335637861e-08
and O 0 3.5705241430150636e-08
affect O 0 6.662097007392731e-08
amino O 0 4.363855410360884e-08
acids O 0 3.171519580291715e-08
which O 0 1.2121988746116585e-08
are O 0 2.172805713129833e-09
highly O 0 2.908429586057082e-08
conserved O 0 4.6568235489985454e-08
in O 0 9.599658845615977e-09
all O 0 2.2095831830881707e-09
known O 0 4.416314425270684e-08
paired O 0 3.9284765307456837e-07
domain O 0 3.522430915836594e-07
proteins O 0 2.5946289383682597e-07
. O 0 4.303967671148712e-07

Our O 0 5.1063743740087375e-06
results O 0 1.1558840924408287e-06
support O 0 7.972651161480826e-08
the O 0 4.3622161882694854e-08
hypothesis O 0 2.022387207034626e-06
that O 0 1.2776586011398194e-08
the O 0 3.6858589513855122e-09
under O 0 6.106515826331815e-08
- O 0 3.1698946258984506e-06
representation O 0 2.9538037438214815e-07
of O 0 2.660483033878336e-08
missense O 0 0.0016708290204405785
mutations O 0 8.411167982558254e-06
is O 0 1.345176343647836e-07
caused O 0 1.2673284572883858e-06
by O 0 1.8287870773292525e-07
ascertainment O 0 0.0012039743596687913
bias O 0 0.011211336590349674
and O 0 6.686105393782782e-07
suggest O 0 2.4603014026070014e-07
that O 0 1.3076132177047839e-08
a O 0 1.2249219594195893e-07
substantial O 0 1.1096022944911965e-06
burden O 0 1.191241608466953e-05
of O 0 9.850262472355098e-08
PAX6 B-Disease 1 0.6568561792373657
- I-Disease 1 0.8427819013595581
related I-Disease 0 0.0008128553163260221
disease I-Disease 0 9.740923269419e-05
remains O 0 1.3756693988398183e-06
to O 0 4.285111643298478e-08
be O 0 4.6100204542653955e-08
uncovered O 0 1.0253984328301158e-06
. O 0 1.8515551403197605e-07
. O 0 5.094172479402914e-07

The O 0 3.480647364995093e-06
chromosomal O 0 0.00010817408474395052
order O 0 4.410590292991401e-07
of O 0 2.2739007121685972e-08
genes O 0 1.1489005657949747e-07
controlling O 0 5.399943461270595e-07
the O 0 3.0212323309797284e-08
major O 0 8.451901578609977e-08
histocompatibility O 0 1.9402612451813184e-05
complex O 0 9.282859423365153e-07
, O 0 1.2230705692672927e-07
properdin O 0 6.437601314246422e-06
factor O 0 3.191709367911244e-07
B O 0 1.831895701798203e-06
, O 0 1.5452792467840482e-07
and O 0 1.1087995517300442e-05
deficiency B-Disease 0 4.87038487335667e-05
of I-Disease 0 1.6615527842489541e-09
the I-Disease 0 5.409658054844613e-09
second I-Disease 0 8.095638293070806e-08
component I-Disease 0 7.019874459501807e-08
of I-Disease 0 1.0712604137097514e-08
complement I-Disease 0 1.5895220712991431e-06
. O 0 1.239625021298707e-06

The O 0 1.1569043181225425e-06
relationship O 0 4.799197768079466e-07
of O 0 5.031048466719312e-09
the O 0 1.4738361642230302e-08
genes O 0 7.924001721448803e-08
coding O 0 2.2651418873920193e-07
for O 0 2.840324597741528e-08
HLA O 0 4.2559382563922554e-05
to O 0 2.0354953278456378e-07
those O 0 9.631368591556111e-09
coding O 0 8.017423169803806e-08
for O 0 1.1197030858056678e-08
properdin O 0 2.9862790142942686e-06
Factor O 0 8.930358319503284e-08
B O 0 2.0650666954225017e-07
allotypes O 0 2.575198777776677e-06
and O 0 1.8108335098077077e-07
for O 0 1.0131528824786074e-06
deficiency B-Disease 0 6.27117624389939e-05
of I-Disease 0 1.4742683740465168e-09
the I-Disease 0 7.477690466828335e-09
second I-Disease 0 2.008280688414743e-07
component I-Disease 0 6.21912192855234e-08
of I-Disease 0 4.415511956068485e-09
complement I-Disease 0 2.818786128955253e-07
( O 0 7.32357108290671e-08
C2 O 0 3.714566264534369e-05
) O 0 3.212903365579223e-08
was O 0 1.2279774637136143e-06
studied O 0 5.7024177380071706e-08
in O 0 1.43072416136647e-08
families O 0 9.273957601863003e-09
of O 0 1.4605770815023789e-08
patients O 0 0.0009365281439386308
with O 0 4.876524326391518e-05
connective O 1 0.9999370574951172
tissue O 1 0.9999837875366211
disorders O 1 0.9989499449729919
. O 0 7.442487003572751e-06

Patients O 1 0.9896596074104309
were O 0 1.5650341538275825e-06
selected O 0 1.1420229384384584e-07
because O 0 2.69189026624872e-08
they O 0 1.7438024357829818e-08
were O 0 1.8933859280423349e-07
heterozygous O 0 6.922795819264138e-06
or O 0 1.3613561122838291e-07
homozygous O 0 8.346459799213335e-05
for O 0 0.0011891031172126532
C2 B-Disease 1 0.9999998807907104
deficiency I-Disease 1 0.999998927116394
. O 0 1.826375228120014e-05

12 O 0 3.22521009366028e-05
families O 0 8.482277280563721e-07
with O 0 6.150513343072816e-08
15 O 0 4.788038836522901e-07
matings O 0 9.804235014598817e-05
informative O 0 7.941737567307428e-05
for O 0 0.0835733488202095
C2 B-Disease 1 1.0
deficiency I-Disease 1 0.9999991655349731
were O 0 4.109243491257075e-06
found O 0 2.3392019556922605e-06
. O 0 1.6833811287142453e-06

Of O 0 3.250830786782899e-06
57 O 0 1.4125231245998293e-05
informative O 0 3.0835542474960675e-06
meioses O 0 2.1430390916066244e-05
, O 0 2.897129469658921e-08
two O 0 7.169326021738698e-09
crossovers O 0 3.52460517660802e-07
were O 0 1.810976755223237e-07
noted O 0 1.6683088688296266e-07
between O 0 1.519248655768024e-07
the O 0 0.002907815854996443
C2 B-Disease 1 1.0
deficiency I-Disease 1 0.9999978542327881
gene O 0 8.425599276051798e-07
and O 0 4.6644505147241944e-08
the O 0 1.0527431726359282e-07
HLA O 0 0.011105307377874851
- O 0 0.007714992389082909
B O 0 9.300261808675714e-06
gene O 0 5.158647198300059e-08
, O 0 2.8676825358786573e-09
with O 0 2.820219835442117e-09
a O 0 7.681729385922154e-08
recombinant O 0 1.310503705553856e-07
fraction O 0 1.9951507113091793e-07
of O 0 2.9592669648081937e-08
0 O 0 1.218300553773588e-06
. O 0 6.5489797407281e-07

035 O 0 0.20366154611110687
. O 0 0.0005411954480223358

A O 0 9.951428364729509e-05
lod O 0 0.005051938351243734
score O 0 1.995699904000503e-06
of O 0 3.191575004279912e-08
13 O 0 2.0503743769495486e-07
was O 0 2.3098266410670476e-07
calculated O 0 1.489241441277045e-07
for O 0 4.6677083531676544e-08
linkage O 0 0.00011554622324183583
between O 0 0.026122141629457474
C2 B-Disease 1 1.0
deficiency I-Disease 1 0.9999994039535522
and O 0 1.0818868759088218e-05
HLA O 0 0.0011865675915032625
- O 0 6.778285023756325e-05
B O 0 9.560628768667812e-07
at O 0 3.894573108453869e-09
a O 0 3.200072029585499e-08
maximum O 0 1.2418952621828794e-07
likelihood O 0 4.190839675288771e-08
value O 0 2.4200133008633884e-09
of O 0 7.919824240865125e-10
the O 0 4.454567825717959e-09
recombinant O 0 1.261613533642958e-07
fraction O 0 1.820903463567447e-07
of O 0 2.2351356321337335e-08
0 O 0 1.3928214457337162e-06
. O 0 8.369986517209327e-07

04 O 0 0.0318770557641983
. O 0 0.00010773339454317465

18 O 0 6.698880315525457e-05
families O 0 9.761047294887248e-07
with O 0 6.02831988771868e-08
21 O 0 1.9850955368383438e-07
informative O 0 3.0903615311217436e-07
matings O 0 5.819552825414576e-06
for O 0 3.9196738299551726e-08
both O 0 4.5105533530431785e-08
properdin O 0 7.4023232627951074e-06
Factor O 0 1.2812721195132326e-07
B O 0 3.7629772009495355e-07
allotype O 0 4.5865081119700335e-06
and O 0 4.006359972663631e-07
HLA O 0 0.00024282133381348103
- O 0 0.0006355420919135213
B O 0 4.079848167748423e-06
were O 0 1.6785290313237056e-07
found O 0 3.65269187341255e-07
. O 0 5.435921366370167e-07

Of O 0 2.510138301659026e-06
72 O 0 1.227670600201236e-05
informative O 0 3.230248694308102e-06
meioses O 0 4.092657036380842e-05
, O 0 5.548001524857682e-08
three O 0 1.5869542124846703e-08
recombinants O 0 5.01522754348116e-06
were O 0 2.914250103458471e-07
found O 0 9.724775651420714e-08
, O 0 6.701270649500657e-09
giving O 0 7.113791777868528e-09
a O 0 3.226210765205906e-08
recombinant O 0 1.539011265094814e-07
fraction O 0 1.8768071186059387e-07
of O 0 3.392505476540464e-08
0 O 0 2.1880464373680297e-06
. O 0 1.2269742910575587e-06

042 O 0 0.010106764733791351
. O 0 0.00018665046081878245

A O 0 5.501965279108845e-05
lod O 0 0.001346187200397253
score O 0 8.396737598559412e-07
of O 0 1.4396892566992392e-08
16 O 0 1.142056689218407e-07
between O 0 5.2208097400807674e-08
HLA O 0 0.00017961136472877115
- O 0 0.0005478365928865969
B O 0 2.6400316528452095e-06
and O 0 2.8078121161456693e-08
Factor O 0 3.495505040973512e-08
B O 0 1.483755198705694e-07
allotypes O 0 1.2644057960642385e-06
was O 0 1.6089047960576863e-07
calculated O 0 3.001789394829757e-08
at O 0 1.182943742961129e-09
a O 0 1.5233755590315923e-08
maximum O 0 1.1295783508558088e-07
likelihood O 0 2.1459287680158923e-08
value O 0 1.3608330018399784e-09
of O 0 7.296751536323143e-10
the O 0 6.039170052929421e-09
recombinant O 0 2.805008136874676e-07
fraction O 0 2.6354430815445085e-07
of O 0 4.135880971034567e-08
0 O 0 1.8925009044323815e-06
. O 0 9.072813327293261e-07

04 O 0 0.019619692116975784
. O 0 9.361806587548926e-05

A O 0 1.4142185136734042e-05
crossover O 0 1.2321395843173377e-05
was O 0 9.340901669929735e-06
shown O 0 5.727417260459333e-07
to O 0 3.800796122277461e-08
have O 0 6.183200440545988e-08
occurred O 0 4.1882824319827705e-08
between O 0 4.1306598141943596e-09
genes O 0 1.0311352660608009e-08
for O 0 4.885075011173967e-09
Factor O 0 6.13305886076887e-08
B O 0 6.214846735019819e-07
and O 0 3.3206637795046845e-07
HLA O 0 0.005171185825020075
- O 0 0.03883478790521622
D O 0 0.005915805697441101
, O 0 4.2473470074355646e-08
in O 0 1.9727638189692698e-08
which O 0 8.074770789789909e-07
HLA O 0 0.0034698841627687216
- O 0 0.05407543480396271
D O 0 0.0083483150228858
segregared O 0 2.148625935660675e-05
with O 0 1.4313292240331066e-07
HLA O 0 6.73640679451637e-05
- O 0 2.5893123165587895e-05
A O 0 6.331730673991842e-06
and O 0 1.9401443296374055e-06
B O 0 1.3047257198195439e-05
. O 0 1.0731204156400054e-06

These O 0 3.2554473818890983e-06
studies O 0 4.226638168347563e-07
suggest O 0 2.687238236376288e-07
that O 0 1.4682414395394972e-08
the O 0 6.731606383425515e-09
genes O 0 2.3541190330433892e-08
for O 0 2.5759053556839717e-08
Factor O 0 2.1510516035050387e-07
B O 0 0.00013998697977513075
and O 0 0.2905062139034271
C2 B-Disease 1 1.0
deficiency I-Disease 1 0.9999997615814209
are O 0 6.004978558848961e-08
located O 0 2.050981784407213e-08
outside O 0 4.69562202454199e-08
those O 0 7.047104677582183e-09
for O 0 2.7833696236712058e-08
HLA O 0 0.0025737921241670847
, O 0 6.190682455553542e-08
that O 0 7.002286750434905e-09
the O 0 2.342061433679987e-09
order O 0 3.768109824164867e-09
of O 0 2.7882778308452316e-09
genese O 0 1.6958960259216838e-05
is O 0 2.1398351179868769e-07
HLA O 0 1.4751130038348492e-05
- O 0 5.829801466461504e-06
A O 0 4.016576440335484e-06
, O 0 1.300884520105683e-07
- O 0 4.637953225028468e-06
B O 0 7.57955888275319e-07
, O 0 2.2256575249457455e-08
- O 0 8.877354048308916e-06
D O 0 5.565060200751759e-05
, O 0 2.1106091097067292e-08
Factor O 0 3.884841248691373e-08
B O 0 7.044728249638865e-07
allotype O 0 0.0020106856245547533
, O 0 0.047281838953495026
C2 B-Disease 1 1.0
deficiency I-Disease 1 0.9999992847442627
, O 0 5.311164130716861e-08
that O 0 6.7394942959708715e-09
the O 0 1.0242803938353973e-08
genes O 0 1.3914325336372713e-07
coding O 0 3.0926901217753766e-06
for O 0 0.00017519610992167145
C2 B-Disease 1 0.9999998807907104
deficiency I-Disease 1 0.9999959468841553
and O 0 2.2162623736221576e-07
Factor O 0 1.2883616307135526e-07
B O 0 3.541860564837407e-07
allotypes O 0 2.9839873150194762e-06
are O 0 1.532812987647958e-08
approximately O 0 1.1271727551331878e-08
3 O 0 2.0657475729990438e-08
- O 0 1.7611389466765104e-06
- O 0 3.2767293305369094e-05
5 O 0 8.861403699711445e-08
centimorgans O 0 1.1279254295004648e-06
from O 0 4.6201411585400365e-09
the O 0 1.3301876933269341e-08
HLA O 0 2.1946414562989958e-05
- O 0 1.375142892356962e-05
A O 0 7.371875199169153e-06
and O 0 6.783246817576583e-07
HLA O 0 0.0006446331972256303
- O 0 0.00046030283556319773
B O 0 2.4171420136553934e-06
loci O 0 8.916028093608475e-08
, O 0 1.695731199902184e-08
and O 0 6.8032446343124775e-09
that O 0 1.1342942585201854e-08
the O 0 5.862772489706458e-09
apparent O 0 5.23056542078848e-06
lack O 0 4.9251479339318394e-08
of O 0 7.0127792461960325e-09
recombinants O 0 1.0656942322384566e-05
between O 0 7.651865807645208e-09
the O 0 1.5010515497237975e-08
Factor O 0 1.407705383371649e-07
B O 0 3.1198394481180003e-06
gene O 0 4.511019142228179e-06
and O 0 0.31169918179512024
C2 B-Disease 1 1.0
deficiency I-Disease 1 0.9999996423721313
gene O 0 2.5735193958098534e-06
suggests O 0 1.8941913992875925e-07
that O 0 6.678571029539171e-09
these O 0 1.5126331298631612e-09
two O 0 9.892187513571571e-09
genes O 0 6.06419661153268e-08
lie O 0 3.3245515851376695e-07
in O 0 5.798979962889916e-09
close O 0 3.529842018679119e-08
proximity O 0 8.711482735179743e-08
to O 0 9.982335313907242e-08
one O 0 1.9128347616970132e-07
another O 0 1.2783382317138603e-06
. O 0 2.1048376765975263e-06

Distribution O 0 6.289182692853501e-06
of O 0 3.209051726571488e-07
emerin O 0 5.394549953052774e-05
and O 0 9.282806558985612e-07
lamins O 0 6.461414159275591e-05
in O 0 5.360257659958734e-08
the O 0 3.1998037997027495e-08
heart O 0 1.9950261048506945e-05
and O 0 1.0362914792949596e-07
implications O 0 2.425851732823503e-07
for O 0 1.2447480912669562e-07
Emery B-Disease 0 0.3486618101596832
- I-Disease 1 0.9983614087104797
Dreifuss I-Disease 1 0.9999716281890869
muscular I-Disease 1 0.9999663829803467
dystrophy I-Disease 1 0.9999198913574219
. O 0 2.077644967357628e-05

Emerin O 0 0.002825555857270956
is O 0 2.6809718747244915e-06
a O 0 5.359746637623175e-07
nuclear O 0 4.4370679574967653e-07
membrane O 0 1.3060648598184343e-06
protein O 0 2.8161693421679956e-07
which O 0 3.5078077331718305e-08
is O 0 2.7679213587816776e-08
missing O 0 1.0392447080675993e-07
or O 0 1.695446627536512e-08
defective O 0 1.8041202565655112e-05
in O 0 8.650432050671952e-07
Emery B-Disease 1 0.8783872723579407
- I-Disease 1 0.9998974800109863
Dreifuss I-Disease 1 0.9999972581863403
muscular I-Disease 1 0.9999982118606567
dystrophy I-Disease 1 0.9999953508377075
( O 0 1.2961671018274501e-05
EDMD B-Disease 1 0.999976396560669
) O 0 3.1047293305164203e-06
. O 0 1.1528555887707626e-06

It O 0 1.921473312904709e-06
is O 0 8.720426336594755e-08
one O 0 1.2761485201906453e-08
member O 0 7.616482555761195e-09
of O 0 1.86793824852316e-09
a O 0 5.432391958493099e-07
family O 0 2.1498743763004313e-07
of O 0 1.8518690581004194e-08
lamina O 0 0.0013644748833030462
- O 0 0.01894480735063553
associated O 0 2.8126103757131204e-07
proteins O 0 1.2275082283963457e-08
which O 0 3.436701234704742e-08
includes O 0 4.907715833724069e-08
LAP1 O 0 0.00010221637785434723
, O 0 6.676802399852022e-08
LAP2 O 0 7.32637126930058e-05
and O 0 1.0551912055234425e-06
lamin O 0 0.07546689361333847
B O 0 0.0005350486608222127
receptor O 0 6.583934737136588e-05
( O 0 9.990104672397138e-07
LBR O 0 0.0009772019693627954
) O 0 7.170257845245942e-07
. O 0 1.198180029859941e-06

A O 0 3.162972643622197e-05
panel O 0 6.219149327080231e-06
of O 0 8.591781863742654e-08
16 O 0 9.379214702676109e-07
monoclonal O 0 2.475258406775538e-05
antibodies O 0 1.767010508046951e-05
( O 0 6.877588276665847e-08
mAbs O 0 2.892348220484564e-06
) O 0 2.0872574779673414e-08
has O 0 1.1835655300274084e-07
been O 0 5.7228366046047086e-08
mapped O 0 3.8632580867670185e-07
to O 0 9.524026900464833e-09
six O 0 6.194920576518825e-09
specific O 0 1.504306568200775e-09
sites O 0 5.90683901791067e-09
throughout O 0 4.603287528937017e-09
the O 0 1.0344978207399436e-08
emerin O 0 2.69622228188382e-06
molecule O 0 1.1201948524330874e-07
using O 0 3.192354114389673e-08
phage O 0 4.2104051090063876e-07
- O 0 9.754012353369035e-07
displayed O 0 2.7938273206018494e-07
peptide O 0 5.363775557043482e-08
libraries O 0 4.020131783022407e-09
and O 0 6.776772920602525e-09
has O 0 6.144181696754458e-08
been O 0 1.562508522567896e-08
used O 0 1.9009481988518928e-08
to O 0 4.15914627183156e-08
localize O 0 1.152291315520415e-05
emerin O 0 0.00010760783334262669
in O 0 9.762894137566036e-08
human O 0 1.3841348334153736e-07
and O 0 3.104919699126185e-07
rabbit O 0 0.002167612547054887
heart O 0 0.007886034436523914
. O 0 3.2098278097691946e-06

Several O 0 7.041147910058498e-06
mAbs O 0 6.657651101704687e-05
against O 0 8.023784516808519e-07
different O 0 9.361827579823512e-08
emerin O 0 3.9106107578845695e-05
epitopes O 0 0.00011351730063324794
did O 0 1.262568275706144e-06
not O 0 4.4835861245928754e-08
recognize O 0 1.0505287661999319e-07
intercalated O 0 1.8963816046380089e-06
discs O 0 4.3198666389798746e-05
in O 0 4.667467479180232e-08
the O 0 9.125829336653624e-08
heart O 0 0.0006548160454258323
, O 0 1.9838124387661082e-07
though O 0 1.0500599501028773e-07
they O 0 2.7126924706522004e-08
recognized O 0 3.4452330766043815e-08
cardiomyocyte O 0 2.6629409148881678e-06
nuclei O 0 5.760519456998736e-07
strongly O 0 5.228941404311627e-07
, O 0 8.74412364737509e-09
both O 0 6.319394341147699e-09
at O 0 4.288682298181357e-09
the O 0 1.3869699166946248e-08
rim O 0 3.931838250537112e-07
and O 0 7.782722377669415e-08
in O 0 3.603494036497068e-08
intranuclear O 0 2.484040851413738e-05
spots O 0 5.464018499878875e-07
or O 0 1.4847603324597003e-07
channels O 0 1.432714270777069e-06
. O 0 1.1339911907271016e-06

A O 0 0.0001361885661026463
polyclonal O 0 0.0015120056923478842
rabbit O 0 0.00037167445407249033
antiserum O 0 0.0002314020530320704
against O 0 2.912887794082053e-06
emerin O 0 0.00020604727615136653
did O 0 2.2670294583804207e-06
recognize O 0 2.519164468139934e-07
both O 0 2.416596700527407e-08
nuclear O 0 1.2503805635333265e-07
membrane O 0 5.37743972017779e-07
and O 0 9.149147928155799e-08
intercalated O 0 1.0646544978953898e-06
discs O 0 2.188576036132872e-05
but O 0 9.023174385447419e-08
, O 0 6.145363329324027e-09
after O 0 1.6868117569401875e-08
affinity O 0 3.0402915740523895e-08
purification O 0 5.931419977400765e-08
against O 0 1.6175935257933816e-08
a O 0 1.1397293775416983e-07
pure O 0 2.0789541110843857e-07
- O 0 5.125436928210547e-06
emerin O 0 9.84531197900651e-06
band O 0 2.2325265547351592e-07
on O 0 1.658909454249624e-08
a O 0 8.804727258393541e-08
western O 0 2.103712688494852e-07
blot O 0 0.008047114126384258
, O 0 8.15283272004308e-08
it O 0 7.25009030588808e-08
stained O 0 3.3370939490851015e-05
only O 0 3.89112955190285e-08
the O 0 1.4447589791188875e-08
nuclear O 0 5.865017556061503e-07
membrane O 0 4.854611233895412e-06
. O 0 5.590506475527945e-07

These O 0 2.3896582206361927e-06
results O 0 6.551160254275601e-07
would O 0 6.159059751098539e-08
not O 0 1.5938034891860298e-08
be O 0 2.6923883567064877e-08
expected O 0 3.317495043120289e-07
if O 0 3.565120820780976e-08
immunostaining O 0 2.7038649932364933e-06
at O 0 2.2430279855711888e-08
intercalated O 0 6.583276217497769e-07
discs O 0 6.673720781691372e-05
were O 0 4.6372355200219317e-07
due O 0 6.041361189090821e-08
to O 0 2.6380778450629805e-08
a O 0 1.6383907563977118e-07
product O 0 5.517177470437673e-08
of O 0 3.91486043582745e-09
the O 0 1.7383067429932453e-08
emerin O 0 1.1932359484490007e-05
gene O 0 3.547438609530218e-07
and O 0 7.255582090692769e-08
, O 0 2.9523436140266313e-08
therefore O 0 6.562014931432714e-08
, O 0 1.4792997937718155e-08
cast O 0 1.1389158771635266e-06
some O 0 2.7629631915715436e-08
doubt O 0 1.30963528022221e-07
upon O 0 1.4059178710112974e-08
the O 0 2.3700769347101414e-08
hypothesis O 0 3.052895181099302e-06
that O 0 2.1095681859151227e-06
cardiac B-Disease 1 0.9972373247146606
defects I-Disease 1 0.99919193983078
in O 0 2.1277905034366995e-05
EDMD B-Disease 1 0.9999992847442627
are O 0 8.02735212346306e-06
caused O 0 2.0935165593982674e-05
by O 0 1.2734427912164392e-07
absence O 0 4.5418221361614997e-07
of O 0 3.556631256174114e-08
emerin O 0 0.00011051207548007369
from O 0 1.739926176469453e-07
intercalated O 0 1.0313198799849488e-05
discs O 0 0.00024347694125026464
. O 0 3.703238917296403e-06

Although O 0 3.0347695428645238e-05
emerin O 0 0.0001511534646851942
was O 0 2.6909592634183355e-06
abundant O 0 7.027912829471461e-08
in O 0 9.23966947397048e-09
the O 0 1.378924796568981e-08
membranes O 0 2.2943511623907398e-07
of O 0 6.934171459249683e-09
cardiomyocyte O 0 1.8824022845365107e-05
nuclei O 0 1.0460155408509308e-06
, O 0 2.0256416988218007e-08
it O 0 1.8839578785900812e-08
was O 0 1.7589921981198131e-06
absent O 0 1.392619424223085e-07
from O 0 4.635376082973153e-09
many O 0 8.679585050686e-09
non O 0 6.522508044781716e-08
- O 0 1.980847264348995e-05
myocyte O 0 0.017688313499093056
cells O 0 1.096283995138947e-06
in O 0 5.431092731100762e-08
the O 0 1.7971321142340457e-07
heart O 0 0.00042258561006747186
. O 0 3.0108346891211113e-06

This O 0 9.989894351747353e-07
distribution O 0 1.562828089163304e-07
of O 0 8.797891304368477e-09
emerin O 0 2.048648093477823e-05
was O 0 2.588186134744319e-06
similar O 0 3.908162682364491e-08
to O 0 1.7496194715249658e-08
that O 0 1.1876241323705017e-08
of O 0 4.875785108993114e-09
lamin O 0 0.0012375107035040855
A O 0 2.1538242435781285e-05
, O 0 2.8223306358654554e-08
a O 0 1.745660398455584e-07
candidate O 0 9.326784606855654e-07
gene O 0 8.411278429321101e-08
for O 0 2.0309418147235192e-08
an O 0 4.0098422005030443e-07
autosomal O 0 0.008740915916860104
form O 0 2.297899300174322e-06
of O 0 7.439906539730146e-07
EDMD B-Disease 1 0.9999865293502808
. O 0 1.2544833225547336e-05

In O 0 1.2628364856936969e-05
contrast O 0 3.005817416124046e-05
, O 0 1.632689645703067e-06
lamin O 0 0.02383393608033657
B1 O 0 0.021345315501093864
was O 0 2.5756904506124556e-05
absent O 0 8.170327987500059e-07
from O 0 2.5043602747132354e-08
cardiomyocyte O 0 8.539427653886378e-06
nuclei O 0 1.5945840914355358e-06
, O 0 6.36270698350927e-08
showing O 0 4.1475021816950175e-07
that O 0 4.484637941004621e-07
lamin O 0 0.04076173156499863
B1 O 0 0.01863921992480755
is O 0 1.3326666703505907e-07
not O 0 1.3162009260270224e-08
essential O 0 2.849053437614657e-09
for O 0 3.158363792721275e-09
localization O 0 8.512116522751967e-08
of O 0 2.921878516914944e-09
emerin O 0 3.921535608242266e-06
to O 0 3.883307542196235e-08
the O 0 2.1905000480160197e-08
nuclear O 0 1.7795348412619205e-06
lamina O 0 0.00023224065080285072
. O 0 2.9016755433985963e-06

Lamin O 1 0.9935292601585388
B1 O 1 0.9948843121528625
is O 0 1.7968193787964992e-05
also O 0 1.513149527454516e-06
almost O 0 2.3786549263604684e-07
completely O 0 1.5786872609169222e-06
absent O 0 1.998316747631179e-06
from O 0 1.778095111149014e-07
skeletal O 0 0.01800304464995861
muscle O 0 0.0016840139869600534
nuclei O 0 6.446974293794483e-05
. O 0 1.7306666677541216e-06

In O 0 6.0266960645094514e-05
EDMD B-Disease 1 0.9998019337654114
, O 0 2.3389449665955908e-07
the O 0 1.4329772035637234e-08
additional O 0 9.964681879637283e-08
absence O 0 2.7160845661455824e-07
of O 0 7.75097603877839e-08
lamin O 1 0.9501681327819824
B1 O 0 0.309333473443985
from O 0 2.383573445285947e-07
heart O 0 4.589173477143049e-05
and O 0 6.335538387247652e-07
skeletal O 0 0.02333313785493374
muscle O 0 0.0005499827675521374
nuclei O 0 7.728617674729321e-06
which O 0 8.623596841061953e-07
already O 0 1.981206423806725e-06
lack O 0 8.321571840497199e-07
emerin O 0 0.012190171517431736
may O 0 1.0826125617313664e-05
offer O 0 1.1763737717274125e-07
an O 0 2.4124840791728275e-08
alternative O 0 1.4629057432102854e-07
explanation O 0 8.624125769074453e-08
of O 0 1.261701410015803e-09
why O 0 5.0637353865568e-08
these O 0 4.770920547514379e-09
tissues O 0 3.055814659091993e-07
are O 0 1.4385336477573674e-08
particularly O 0 1.3949188826245518e-07
affected O 0 1.4619337207477656e-07
. O 0 7.053105122167835e-08
. O 0 4.5851601271351683e-07

Genetic O 0 0.0002034279314102605
mapping O 0 3.7588770283036865e-06
of O 0 8.981741217439776e-08
the O 0 2.836914632098342e-07
copper B-Disease 0 7.741701847407967e-05
toxicosis I-Disease 0 0.0009788620518520474
locus O 0 3.70138536709419e-06
in O 0 1.5122220986540924e-07
Bedlington O 0 1.4298601854534354e-05
terriers O 0 9.059023795998655e-06
to O 0 3.611562249261624e-07
dog O 0 2.4130233214236796e-05
chromosome O 0 1.6916930690058507e-05
10 O 0 4.6259280850335927e-08
, O 0 9.309828463699432e-09
in O 0 1.078915179419937e-08
a O 0 2.0393592876644107e-06
region O 0 5.949310093456006e-07
syntenic O 0 0.0001576558715896681
to O 0 2.015471949334824e-07
human O 0 1.5886628546013526e-07
chromosome O 0 2.3156982933869585e-05
region O 0 4.064315817231545e-07
2p13 O 0 1.6069439880084246e-05
- O 0 4.60521514469292e-05
p16 O 0 3.5550521715776995e-05
. O 0 1.4912425285729114e-06

Abnormal O 1 0.9833751320838928
hepatic B-Disease 1 0.9985880255699158
copper I-Disease 0 0.05973426625132561
accumulation I-Disease 0 3.1110459531191736e-05
is O 0 4.355158296220907e-07
recognized O 0 1.2423075190781674e-07
as O 0 2.102842273643546e-07
an O 0 0.0001929648278746754
inherited B-Disease 1 1.0
disorder I-Disease 1 0.9999997615814209
in O 0 1.1650687383735203e-06
man O 0 0.0008635740960016847
, O 0 1.1180922854236996e-07
mouse O 0 2.7720086563931545e-06
, O 0 1.0074356993072797e-07
rat O 0 2.0700110326288268e-05
and O 0 2.561919529853185e-07
dog O 0 3.094304338446818e-05
. O 0 1.659778831708536e-06

The O 0 2.510056674509542e-06
major O 0 8.948139225140039e-07
cause O 0 3.6963620004826225e-06
of O 0 2.182122926797092e-07
hepatic B-Disease 1 0.7213407754898071
copper I-Disease 0 0.02032478339970112
accumulation I-Disease 0 2.28023850468162e-06
in O 0 1.6125976287639787e-07
man O 0 1.8883214579545893e-05
is O 0 9.340032391946806e-08
a O 0 2.9548348834396165e-07
dysfunctional O 0 1.2926256204082165e-05
ATP7B O 0 0.0002835857740137726
gene O 0 2.0802563085453585e-06
, O 0 4.669703059789754e-07
causing O 0 5.9675108786905184e-05
Wilson B-Disease 0 0.24312061071395874
disease I-Disease 0 0.057459261268377304
( O 0 7.549058977929235e-07
WD B-Disease 0 0.2724027633666992
) O 0 2.0255006347724702e-06
. O 0 1.5148302736633923e-06

Mutations O 0 0.01574176922440529
in O 0 2.0665652300522197e-06
the O 0 1.643023779251962e-07
ATP7B O 0 0.00020935821521561593
genes O 0 4.1344381429553323e-07
have O 0 1.4496785638584697e-07
also O 0 1.9234444437188358e-07
been O 0 2.5455412355768203e-07
demonstrated O 0 3.2335850619347184e-07
in O 0 3.0578316767559954e-08
mouse O 0 4.312416876928182e-06
and O 0 5.026820986131497e-07
rat O 0 0.001025190344080329
. O 0 1.6913531908357982e-06

The O 0 3.2318944249709602e-06
ATP7B O 0 0.00018570534302853048
gene O 0 3.6167537018627627e-06
has O 0 4.637867618839664e-07
been O 0 1.2991810649509716e-07
excluded O 0 5.079144216324494e-08
in O 0 4.997717795163226e-09
the O 0 8.565106845992432e-09
much O 0 3.069246758968802e-07
rarer O 0 0.0010262686992064118
human O 0 5.3131770982872695e-06
copper B-Disease 0 0.1785048395395279
overload I-Disease 1 0.9848811626434326
disease O 0 0.0010474289301782846
non B-Disease 0 1.1575134521990549e-06
- I-Disease 0 4.084585452801548e-05
Indian I-Disease 0 4.952526523993583e-06
childhood I-Disease 0 0.00014417954662349075
cirrhosis I-Disease 0 0.040393855422735214
, O 0 4.164060669609171e-07
indicating O 0 4.548238393908832e-06
genetic O 0 1.4539360563503578e-05
heterogeneity O 0 0.0002324511151527986
. O 0 6.527824552904349e-06

By O 0 3.4437205158610595e-06
investigating O 0 1.7873724118544487e-06
the O 0 3.771556578158197e-07
common O 0 9.100951501750387e-06
autosomal O 1 0.9948151707649231
recessive O 1 0.9994589686393738
copper B-Disease 1 0.9480685591697693
toxicosis I-Disease 1 0.8964671492576599
( O 0 4.6185002133825037e-07
CT B-Disease 0 0.006308204494416714
) O 0 4.079899440512236e-08
in O 0 3.110621449309292e-08
Bedlington O 0 6.887308700243011e-06
terriers O 0 8.112275281746406e-06
, O 0 3.4617272604009486e-08
we O 0 8.280459873333257e-09
have O 0 2.344914307172985e-08
identified O 0 4.043233658990175e-08
a O 0 2.9323535599701245e-08
new O 0 6.268664520803213e-08
locus O 0 6.59385705148452e-07
involved O 0 1.928734718603664e-07
in O 0 1.5039651088954997e-06
progressive O 1 0.9997847676277161
liver B-Disease 1 1.0
disease I-Disease 1 0.9999949932098389
. O 0 2.6032046662294306e-05

We O 0 2.5837150587904034e-06
examined O 0 6.664443844783818e-06
whether O 0 3.581540113373194e-07
the O 0 1.2399532067775e-07
WD B-Disease 0 0.0023573897778987885
gene O 0 1.929260406541289e-06
ATP7B O 0 7.71210907259956e-05
was O 0 4.942972282151459e-06
also O 0 2.3810835614312964e-07
causative O 0 9.074587410395907e-07
for O 0 7.723144079818667e-08
CT B-Disease 0 0.3675575852394104
by O 0 7.989228123506109e-08
investigating O 0 1.1381695230738842e-07
the O 0 3.1546388612468945e-08
chromosomal O 0 6.217244663275778e-05
co O 0 7.304441624000901e-06
- O 0 2.204158136009937e-06
localization O 0 5.194720529289043e-07
of O 0 1.0552416718212498e-08
ATP7B O 0 3.9027949242154136e-05
and O 0 3.849289953450352e-08
C04107 O 0 8.691696962159767e-07
, O 0 6.219570192200763e-09
using O 0 1.200409460722085e-08
fluorescence O 0 8.171270451384771e-07
in O 0 7.29522753317724e-08
situ O 0 6.672081781289307e-06
hybridization O 0 1.932119857883663e-06
( O 0 7.048559780287178e-08
FISH O 0 3.088994446898141e-07
) O 0 1.269729636987904e-07
. O 0 5.028883265367767e-07

C04107 O 0 0.0010729065397754312
is O 0 1.9886665540980175e-06
an O 0 4.0016095681494335e-07
anonymous O 0 2.0002883047709474e-06
microsatellite O 0 9.817670070333406e-05
marker O 0 4.794089181814343e-05
closely O 0 4.2070882955158595e-06
linked O 0 1.1175053259648848e-05
to O 0 2.748273800534662e-06
CT B-Disease 1 0.9633432626724243
. O 0 8.958796570368577e-06

However O 0 7.11908214725554e-05
, O 0 3.473547621979378e-06
BAC O 0 0.00011319324403302744
clones O 0 2.933990117526264e-06
containing O 0 5.683740482709254e-07
ATP7B O 0 1.599063580215443e-05
and O 0 3.5976427170680836e-08
C04107 O 0 1.4800667713643634e-06
mapped O 0 1.3917259593654308e-06
to O 0 4.075637249911779e-08
the O 0 2.3899417556094704e-08
canine O 0 1.4031382306711748e-05
chromosome O 0 4.9032256356440485e-05
regions O 0 2.048861347248021e-07
CFA22q11 O 0 7.870070476201363e-06
and O 0 7.124113210466021e-08
CFA10q26 O 0 8.916093975130934e-06
, O 0 3.7465191837782186e-08
respectively O 0 8.679340623984899e-08
, O 0 1.7625753301331315e-08
demonstrating O 0 1.1128795307513428e-07
that O 0 2.528643392452068e-07
WD B-Disease 0 0.0015448440099135041
cannot O 0 7.322844339796575e-07
be O 0 3.450526975257162e-08
homologous O 0 3.7290317322913324e-07
to O 0 1.598869175722939e-06
CT B-Disease 1 0.824110209941864
. O 0 9.580138794262893e-06

The O 0 9.088453225558624e-06
copper O 0 1.0086312613566406e-05
transport O 0 7.264859505085042e-07
genes O 0 2.927707498656673e-07
CTR1 O 0 5.2630533900810406e-05
and O 0 3.2492889090462995e-07
CTR2 O 0 0.0005306519451551139
were O 0 2.3963768853718648e-06
also O 0 9.348423759547586e-07
excluded O 0 1.3168039458832936e-07
as O 0 4.022726329822035e-08
candidate O 0 5.081693075226212e-07
genes O 0 6.21071762907377e-08
for O 0 3.5064832815123737e-08
CT B-Disease 0 0.18645605444908142
since O 0 5.618293812403863e-07
they O 0 2.0045947124458507e-08
both O 0 8.154383834835244e-09
mapped O 0 7.240968216137844e-07
to O 0 1.3993343372931122e-07
canine O 0 3.477580321487039e-05
chromosome O 0 0.00010591808677418157
region O 0 1.025668325382867e-06
CFA11q22 O 0 8.65919137140736e-05
. O 0 2.0088450582989026e-06

2 O 0 0.000173182284925133
- O 0 0.0007136640488170087
22 O 0 2.849032352969516e-05
. O 0 5.6839089666027576e-06

5 O 0 0.0003122494672425091
. O 0 4.9441499868407845e-05

A O 0 3.3471911592641845e-05
transcribed O 0 9.93297180684749e-06
sequence O 0 4.3209939804000896e-07
identified O 0 3.950232496663375e-07
from O 0 6.99202340470606e-09
the O 0 1.195223298111614e-08
C04107 O 0 3.9629403545404784e-06
- O 0 1.4600315807911102e-05
containing O 0 2.6084633191203466e-06
BAC O 0 9.869380301097408e-05
was O 0 1.8483702888261178e-06
found O 0 2.1190636800838547e-08
to O 0 7.805732060717219e-09
be O 0 7.317479955304407e-09
homologous O 0 4.299143085972901e-08
to O 0 4.6751747362350216e-08
a O 0 3.023112356004276e-07
gene O 0 5.034751779930957e-07
expressed O 0 1.204030724011318e-07
from O 0 1.0734735766959602e-08
human O 0 3.948262161657112e-08
chromosome O 0 6.800010396545986e-06
2p13 O 0 5.636666173813865e-06
- O 0 6.212948846950894e-06
p16 O 0 2.547430995036848e-06
, O 0 2.2333544791308668e-08
a O 0 5.947211789703033e-08
region O 0 6.088953341532033e-08
devoid O 0 1.19424612421426e-07
of O 0 3.0176836585127376e-09
any O 0 1.4047706109465707e-08
positional O 0 2.7705533284461126e-05
candidate O 0 1.2268899808987044e-05
genes O 0 2.2104920844867593e-06
. O 0 1.107455204873986e-06

Molecular O 0 7.249051122926176e-05
analysis O 0 1.2920988865516847e-06
of O 0 2.688693534480535e-08
the O 0 2.0004048195687574e-08
APC B-Disease 0 2.432965402476839e-06
gene O 0 2.6413209752718103e-07
in O 0 2.9099945564325935e-08
205 O 0 5.301018290992943e-07
families O 0 2.5375041445840907e-07
: O 0 6.36199146697436e-08
extended O 0 1.1552610885701142e-05
genotype O 0 0.01437519770115614
- O 0 0.011119150556623936
phenotype O 0 0.018339885398745537
correlations O 0 2.351187731619575e-06
in O 0 1.158203133400093e-07
FAP B-Disease 0 0.0007235765806399286
and O 0 4.237315351929283e-06
evidence O 0 4.391979189222184e-07
for O 0 1.1705528102368135e-08
the O 0 1.1864558224772281e-08
role O 0 5.8879560782543194e-08
of O 0 1.45014809049826e-08
APC B-Disease 0 3.819797257165192e-06
amino O 0 3.1204328365674883e-07
acid O 0 1.3452536222757772e-06
changes O 0 8.839379574965278e-07
in O 0 0.000608617439866066
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
predisposition O 1 0.9447027444839478
. O 0 1.687200892774854e-05

BACKGROUND O 0 0.002102838596329093
/ O 0 6.0316808230709285e-05
AIMS O 0 3.3440228435210884e-06
The O 0 8.318993849343315e-08
development O 0 1.3263120024475938e-07
of O 0 0.0001594858622411266
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
and O 0 2.3921686533867614e-06
a O 0 1.1811553122242913e-06
variable O 0 5.288217721499677e-07
range O 0 2.1923893811504058e-08
of O 0 8.106249893558015e-09
extracolonic O 0 0.0008166602929122746
manifestations O 0 0.00011473703489173204
in O 0 0.00016082283400464803
familial B-Disease 1 0.9999994039535522
adenomatous I-Disease 1 0.9999938011169434
polyposis I-Disease 1 0.9999997615814209
( O 0 1.3022928214923013e-05
FAP B-Disease 0 0.022109102457761765
) O 0 3.1003571621113224e-07
is O 0 5.7026785071911945e-08
the O 0 5.542699188509914e-09
result O 0 2.0763696539916054e-08
of O 0 2.9886937369383304e-09
the O 0 6.572210509148135e-08
dominant O 0 4.848271419177763e-05
inheritance O 0 9.895947005134076e-05
of O 0 8.749974767852109e-06
adenomatous B-Disease 1 0.9999982118606567
polyposis I-Disease 1 0.999993085861206
coli I-Disease 1 0.9999706745147705
( O 0 3.928681508114096e-06
APC B-Disease 0 4.339354200055823e-05
) O 0 4.286084163140913e-07
gene O 0 5.0182370614493266e-06
mutations O 0 1.0388606824562885e-05
. O 0 8.534271955795703e-07

In O 0 5.039184543420561e-06
this O 0 3.0241736226344074e-07
study O 0 1.3531935394439643e-07
, O 0 1.449606035208717e-08
direct O 0 7.6652781899611e-08
mutation O 0 6.86085684264981e-07
analysis O 0 1.5789741070193486e-08
of O 0 1.6341494823990388e-09
the O 0 1.2231518908834005e-08
APC B-Disease 0 2.7253861389908707e-06
gene O 0 2.714608342557767e-07
was O 0 3.797405270233867e-07
performed O 0 9.336184803032666e-08
to O 0 4.1470659795095344e-08
determine O 0 1.1112321089967736e-06
genotype O 0 0.010043646208941936
- O 0 0.030461978167295456
phenotype O 0 0.05259709060192108
correlations O 0 1.1208333035028772e-06
for O 0 2.3754987310553588e-08
nine O 0 2.327525550072096e-07
extracolonic O 0 6.053797187632881e-05
manifestations O 0 1.1488397149150842e-06
and O 0 3.6821997895231107e-08
to O 0 5.595248708800682e-08
investigate O 0 5.539192784453917e-07
the O 0 3.049834731427836e-07
incidence O 0 4.921195068163797e-05
of O 0 2.648170571717401e-08
APC B-Disease 0 6.262032547965646e-05
mutations O 0 5.574791430262849e-06
in O 0 1.2832371965032507e-07
non O 0 1.076122498488985e-05
- O 1 0.9997431635856628
FAP O 1 0.9999988079071045
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
. O 0 6.749061139998958e-05

METHODS O 0 1.7656711861491203e-05
The O 0 3.2007017125579296e-07
APC B-Disease 0 3.6197279769112356e-06
gene O 0 4.870545353696798e-07
was O 0 5.709654260499519e-07
analysed O 0 4.400557145345374e-07
in O 0 1.930427018237424e-08
190 O 0 3.978242659741227e-07
unrelated O 0 2.0272398160159355e-06
FAP B-Disease 0 0.0006090932874940336
and O 0 3.008730800502235e-06
15 O 0 7.208446959339199e-07
non O 0 2.5131994334515184e-06
- O 1 0.9997888207435608
FAP O 1 0.9999994039535522
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
patients O 1 0.7128932476043701
using O 0 2.1658861442119814e-06
denaturing O 0 0.0004066631954628974
gradient O 0 0.016765544191002846
gel O 0 0.00031117070466279984
electrophoresis O 0 8.102548235910945e-06
, O 0 1.8313066618702578e-08
the O 0 3.162414774493527e-09
protein O 0 3.37497674252063e-08
truncation O 0 4.993175366507785e-07
test O 0 3.462203324033908e-07
, O 0 1.4421160265953858e-08
and O 0 7.388063494317976e-09
direct O 0 9.326075911531007e-08
sequencing O 0 1.8984680991707137e-06
. O 0 9.519160357740475e-07

RESULTS O 0 0.00023185038298834115
Chain O 0 1.3733958439843263e-05
terminating O 0 3.4101140045095235e-06
signals O 0 2.275676479257527e-06
were O 0 1.6226110233219515e-07
only O 0 8.678910035087029e-08
identified O 0 1.600182486072299e-06
in O 0 4.857339490627055e-07
patients O 0 5.0081362132914364e-05
belonging O 0 6.207140756941953e-08
to O 0 4.899241901057394e-08
the O 0 1.1425228763073392e-07
FAP B-Disease 0 0.10451485961675644
group O 0 2.3867813069955446e-05
( O 0 4.9397023360597814e-08
105 O 0 8.065080692176707e-06
patients O 0 0.0014334467705339193
) O 0 2.767051228147466e-07
. O 0 5.208814286561392e-07

Amino O 0 9.101217438001186e-05
acid O 0 2.6292367692803964e-05
changes O 0 4.345073136846622e-07
were O 0 8.76969892260604e-08
identified O 0 1.9819592012026988e-07
in O 0 3.3429817136720885e-08
four O 0 7.3781347964541055e-06
patients O 0 0.00046684141852892935
, O 0 1.1748025663393946e-08
three O 0 6.89295065470219e-09
of O 0 5.835728789094219e-09
whom O 0 5.444149451250269e-07
belonged O 0 3.67460160077826e-08
to O 0 9.418528179594432e-09
the O 0 1.3906785056860826e-08
non O 0 9.057713157289982e-08
- O 0 0.0001674763479968533
FAP O 0 0.04295084998011589
group O 0 0.0009485228220000863
of O 0 0.00030018301913514733
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
patients O 1 0.9961404204368591
. O 0 7.238535545184277e-06

Genotype O 1 0.9969770908355713
- O 1 0.9919849634170532
phenotype O 1 0.996353268623352
correlations O 0 0.0004591629549395293
identified O 0 2.51446217589546e-05
significant O 0 3.3000736721078283e-07
differences O 0 7.831450830053654e-07
in O 0 4.395188568651065e-08
the O 0 2.4264943832008612e-08
nature O 0 2.498520501603707e-08
of O 0 4.105352946481844e-09
certain O 0 2.9022176661896992e-08
extracolonic O 0 0.0003068424994125962
manifestations O 0 1.3563991160481237e-05
in O 0 2.916632183769252e-06
FAP B-Disease 1 0.9993909597396851
patients O 1 0.996874213218689
belonging O 0 4.1105971604338265e-07
to O 0 1.1251885467800093e-07
three O 0 2.0545395784665743e-07
mutation O 0 2.8562478746607667e-06
subgroups O 0 1.0571966413408518e-06
. O 0 1.3946729495728505e-06

CONCLUSIONS O 0 0.0003491379029583186
Extended O 0 8.787493425188586e-05
genotype O 0 0.042177505791187286
- O 0 0.048091739416122437
phenotype O 0 0.182078018784523
correlations O 0 7.596921932417899e-06
made O 0 1.0236367415927816e-06
in O 0 3.3885736883121353e-08
this O 0 6.971571764324835e-08
study O 0 5.620812544293585e-07
may O 0 1.0646859891494387e-06
have O 0 1.0827434060445285e-08
the O 0 2.374328733623088e-09
potential O 0 1.2044022668078469e-08
to O 0 1.053594544941916e-08
determine O 0 2.1796223492742683e-08
the O 0 4.444561607641617e-09
most O 0 1.0453096166429532e-08
appropriate O 0 1.7054393453008743e-08
surveillance O 0 4.385897511838266e-07
and O 0 1.8335144602588116e-07
prophylactic O 0 0.02794881910085678
treatment O 1 0.6926037669181824
regimens O 0 0.0002543144510127604
for O 0 4.2158416135862353e-07
those O 0 7.027094284239865e-07
patients O 0 3.68787586921826e-05
with O 0 6.959222105251683e-07
mutations O 0 3.0112252716207877e-05
associated O 0 1.6329776997281442e-07
with O 0 9.496186237356596e-08
life O 0 4.646036359190475e-06
threatening O 0 0.00024698194465599954
conditions O 0 0.0001254803064512089
. O 0 4.583683221426327e-06

This O 0 6.1331220422289334e-06
study O 0 1.4942947927920613e-06
also O 0 3.4988042330041935e-07
provided O 0 1.0376581371929205e-07
evidence O 0 1.119502783808457e-07
for O 0 1.2348960964914113e-08
the O 0 4.225940841706688e-08
pathological O 0 1.1983333024545573e-05
nature O 0 3.0944132589638684e-08
of O 0 3.1230151797956296e-09
amino O 0 8.678181728782874e-08
acid O 0 9.51375966451451e-07
changes O 0 5.013941972720204e-08
in O 0 2.2632173468650763e-08
APC O 0 1.7127798855653964e-05
associated O 0 1.2173279628768796e-07
with O 0 1.1473519911930907e-08
both O 0 8.184523636600716e-08
FAP B-Disease 0 0.00037041131872683764
and O 0 5.5002210501697846e-06
non O 0 2.4393530111410655e-05
- O 1 0.9999202489852905
FAP O 1 0.9999998807907104
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
patients O 1 0.9994891881942749
. O 0 8.545576406504551e-07
. O 0 9.061459991244192e-07

Inherited B-Disease 1 0.9999129772186279
colorectal I-Disease 1 0.9999997615814209
polyposis I-Disease 1 0.9999672174453735
and O 1 0.9863759875297546
cancer B-Disease 1 0.999313473701477
risk O 0 4.845720923185581e-06
of O 0 2.637152007878285e-08
the O 0 4.2789204712789797e-07
APC O 0 0.0003914248663932085
I1307K O 0 0.0004930903087370098
polymorphism O 0 0.0003429787466302514
. O 0 3.647975063358899e-06

Germ O 0 0.0015104284975677729
- O 0 0.001323979115113616
line O 0 9.80102049652487e-06
and O 0 1.6420290194218978e-07
somatic O 0 5.4533752518182155e-06
truncating O 0 1.688173142611049e-05
mutations O 0 4.717598585557425e-06
of O 0 1.0842933662047471e-08
the O 0 7.806405477595035e-08
APC B-Disease 0 1.505920499766944e-05
gene O 0 4.775588990924007e-07
are O 0 1.1430008939328218e-08
thought O 0 4.755995419714054e-08
to O 0 1.7746171465660154e-07
initiate O 0 0.0072199213318526745
colorectal B-Disease 1 0.9999998807907104
tumor I-Disease 1 0.8286051750183105
formation O 0 2.6339357646065764e-06
in O 0 9.932186003425159e-06
familial B-Disease 1 0.9999990463256836
adenomatous I-Disease 1 0.9999991655349731
polyposis I-Disease 1 1.0
syndrome I-Disease 1 0.9999998807907104
and O 0 0.00016582186799496412
sporadic O 1 0.9942455887794495
colorectal O 1 0.9999998807907104
carcinogenesis O 1 0.9976262450218201
, O 0 1.0999096048180945e-05
respectively O 0 5.0037901928590145e-06
. O 0 1.0430271686345804e-06

Recently O 0 0.00010653121717041358
, O 0 6.467190019066038e-07
an O 0 3.078143322454707e-07
isoleucine O 0 8.978279220173135e-05
- O 0 6.388308975147083e-05
- O 0 0.00029726981301791966
> O 0 3.6639189602283295e-06
lysine O 0 3.7149720810703e-06
polymorphism O 0 3.0695500754518434e-06
at O 0 5.0360146275352236e-08
codon O 0 7.13426402398909e-07
1307 O 0 3.931575065507786e-06
( O 0 3.64168961652922e-08
I1307K O 0 8.034634220166481e-07
) O 0 6.0241913679703885e-09
of O 0 1.3673374654743498e-09
the O 0 1.3799983378248726e-08
APC B-Disease 0 3.2881152947084047e-06
gene O 0 2.36474477333104e-07
has O 0 1.143007892778769e-07
been O 0 4.451088031487416e-08
identified O 0 9.305305326279267e-08
in O 0 8.1655899819566e-09
6 O 0 1.8684882263642066e-07
% O 0 3.0020185448620396e-08
- O 0 7.938862836454064e-06
7 O 0 7.609993417645455e-07
% O 0 5.942650371792979e-09
of O 0 6.096222415763464e-10
the O 0 2.7221723541970277e-08
Ashkenazi O 0 1.0563004252617247e-05
Jewish O 0 3.1677413403485843e-07
population O 0 1.78913424520033e-07
. O 0 4.799893531526322e-07

To O 0 6.376542387442896e-06
assess O 0 8.11359041108517e-06
the O 0 1.6503356903285749e-07
risk O 0 1.7270645003009122e-07
of O 0 2.7128927992947638e-09
this O 0 3.723445018977145e-08
common O 0 1.3854237579380424e-07
APC B-Disease 0 1.666126809141133e-05
allelic O 0 4.3736868974519894e-05
variant O 0 0.0032785951625555754
in O 0 2.60290689766407e-05
colorectal O 1 0.9999998807907104
carcinogenesis O 1 0.9868675470352173
, O 0 9.100995157496072e-07
we O 0 2.3189969056147675e-08
have O 0 2.0786323773336335e-08
analyzed O 0 4.70152770049026e-08
a O 0 1.7347925762578598e-08
large O 0 2.132740739568817e-08
cohort O 0 2.941053480753908e-07
of O 0 1.2687026540447732e-08
unselected O 0 0.0001718518469715491
Ashkenazi O 0 1.4045479474589229e-05
Jewish O 0 2.213752736679453e-07
subjects O 0 4.1240855352953076e-07
with O 0 7.042967808956746e-07
adenomatous B-Disease 0 0.41360756754875183
polyps I-Disease 0 0.2777089774608612
and O 0 2.989293534483295e-06
. O 0 5.850146862940164e-06
or O 0 0.46532174944877625
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
, I-Disease 0 2.2917487285667448e-07
for O 0 1.6366799471256854e-08
the O 0 8.819770158652318e-08
APC O 0 3.66669446520973e-05
I1307K O 0 4.76738678116817e-05
polymorphism O 0 0.00011233850091230124
. O 0 1.4656834537163377e-06

The O 0 6.572739039256703e-06
APC O 0 4.019050902570598e-05
I1307K O 0 4.437779352883808e-05
allele O 0 1.2478027201723307e-05
was O 0 1.9080825950368308e-06
identified O 0 3.775011236939463e-07
in O 0 2.361701589848053e-08
48 O 0 4.249526739386056e-07
( O 0 6.5148717531826605e-09
10 O 0 7.458488937572838e-09
. O 0 5.540004455184544e-09
1 O 0 3.2128237847928176e-08
% O 0 1.3804273280015877e-08
) O 0 3.840165518909089e-09
of O 0 1.5102756378837512e-08
476 O 0 0.0029331285040825605
patients O 0 0.2102859765291214
. O 0 2.4895284695958253e-06

Compared O 0 0.00016518541087862104
with O 0 2.0865138594672317e-07
the O 0 3.123511049807348e-08
frequency O 0 8.199270951081417e-07
in O 0 2.5352200339057163e-08
two O 0 5.162623395449373e-08
separate O 0 9.897173924855451e-08
population O 0 2.7911100985988924e-08
control O 0 1.6248300482857303e-07
groups O 0 7.543039970414611e-09
, O 0 6.532192120545233e-09
the O 0 1.1450346448782511e-08
APC O 0 1.1861868188134395e-05
I1307K O 0 4.937275662086904e-05
allele O 0 4.861199158767704e-06
is O 0 3.353832411789881e-08
associated O 0 1.2797610082770916e-08
with O 0 7.836462145860423e-09
an O 0 9.795535049761384e-08
estimated O 0 2.083642556272025e-07
relative O 0 5.604476882581366e-07
risk O 0 1.3921068386935076e-07
of O 0 1.31701956007646e-08
1 O 0 9.153300197795033e-07
. O 0 1.7799507077143062e-06

5 O 0 8.347908442374319e-05
- O 0 0.00019712786888703704
1 O 0 5.674874955730047e-06
. O 0 2.5948070287995506e-06

7 O 0 0.00014001765521243215
for O 0 7.720276335021481e-05
colorectal B-Disease 1 0.999998927116394
neoplasia I-Disease 1 0.8377507925033569
( O 0 1.880339482340787e-06
both O 0 2.679734734556405e-06
P O 0 0.0008559308480471373
= O 0 7.869784894865006e-06
. O 0 1.547941508306394e-07
01 O 0 4.044671641167952e-06
) O 0 1.2489074663335487e-07
. O 0 4.6971717893029563e-07

Furthermore O 0 0.00015134872228372842
, O 0 1.242510620613757e-06
compared O 0 8.377301696782524e-07
with O 0 9.769468789500024e-08
noncarriers O 0 6.50225265417248e-05
, O 0 1.238311853057894e-07
APC O 0 1.9448573311819928e-06
I1307K O 0 5.174314082978526e-06
carriers O 0 5.75099022626091e-07
had O 0 1.691154949412521e-07
increased O 0 4.3687442996542813e-08
numbers O 0 1.2681462102648311e-08
of O 0 1.0485145196525991e-08
adenomas B-Disease 0 0.0027930932119488716
and O 0 0.3779587149620056
colorectal B-Disease 1 1.0
cancers I-Disease 1 0.9998264908790588
per O 0 4.535693005891517e-05
patient O 0 0.0018135899445042014
( O 0 1.9905476733583782e-07
P O 0 4.1008926928043365e-05
= O 0 7.559504524579097e-07
. O 0 2.8386997641405287e-08
03 O 0 2.6472673653188394e-07
) O 0 4.441807366362127e-09
, O 0 2.3112638469768854e-09
as O 0 6.297014909506515e-09
well O 0 5.885135045957668e-09
as O 0 2.070595606085135e-08
a O 0 1.1740262380044442e-06
younger O 0 8.228534716181457e-05
age O 0 4.172129877133557e-07
at O 0 1.568639760307633e-07
diagnosis O 0 0.0019344782922416925
. O 0 1.5888415418885415e-06

We O 0 3.561815674402169e-06
conclude O 0 2.4944788492575753e-06
that O 0 7.034349636114712e-08
the O 0 2.099999996119095e-08
APC O 0 5.301010787661653e-06
I1307K O 0 5.126209543959703e-06
variant O 0 7.101793926267419e-06
leads O 0 4.228895988944714e-07
to O 0 5.54665689378453e-07
increased O 0 0.000406309642130509
adenoma B-Disease 1 0.9999955892562866
formation O 0 1.5132389989958028e-06
and O 0 1.0272625416973824e-07
directly O 0 8.710020438229549e-08
contributes O 0 1.0826302343502903e-07
to O 0 4.231360861695066e-08
3 O 0 1.1440089764391814e-07
% O 0 3.778007240384795e-08
- O 0 9.667985523265088e-07
4 O 0 1.6893159227038268e-07
% O 0 3.5437501821888873e-09
of O 0 8.333152501371899e-10
all O 0 3.1622835905409374e-08
Ashkenazi O 0 0.0042191240936517715
Jewish O 0 0.2554625868797302
colorectal B-Disease 1 1.0
cancer I-Disease 1 0.9999996423721313
. O 0 8.711292139196303e-06

The O 0 3.3150897706946125e-06
estimated O 0 1.771826418917044e-06
relative O 0 1.3795188351650722e-06
risk O 0 4.923410870105727e-07
for O 0 7.665205714602052e-08
carriers O 0 3.0145554319460643e-06
may O 0 4.678096956922673e-06
justify O 0 6.894504167576088e-07
specific O 0 5.810474945633359e-08
clinical O 0 1.7744880551617825e-06
screening O 0 4.479538517898618e-07
for O 0 1.6940113312102767e-08
the O 0 1.0921057835844294e-08
360 O 0 1.0814213737830869e-06
, O 0 5.6548152826962905e-08
000 O 0 4.052421331834921e-08
Americans O 0 2.321302616792309e-08
expected O 0 5.769833677504721e-08
to O 0 4.182430757282418e-08
harbor O 0 1.1980006320300163e-06
this O 0 1.4773992695893412e-08
allele O 0 6.376715191436233e-07
, O 0 9.949124191166447e-09
and O 0 1.387123305107707e-08
genetic O 0 1.1876869621119113e-07
testing O 0 3.647174295906552e-08
in O 0 3.0386957394767933e-09
the O 0 2.3977664298513446e-09
setting O 0 1.879195643539333e-08
of O 0 4.571613310133671e-09
long O 0 7.294718784578436e-07
- O 0 0.000139899697387591
term O 0 6.561803274962585e-06
- O 0 1.6633102859486826e-05
outcome O 0 8.689558512742224e-07
studies O 0 6.702794763668862e-08
may O 0 6.972209831701548e-08
impact O 0 1.1229459317974033e-07
significantly O 0 8.213247201638296e-05
on O 1 0.9983444213867188
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
prevention O 0 1.787058135960251e-05
in O 0 3.072705112572294e-08
this O 0 1.8328233153397377e-08
population O 0 4.045950277031807e-07
. O 0 9.72574639490631e-07

Localization O 0 7.980410737218335e-05
of O 0 5.186647058508242e-07
human O 0 5.21746471804363e-07
BRCA1 O 0 5.8102799812331796e-05
and O 0 1.8472482565812243e-07
its O 0 1.7192292034451384e-07
loss O 0 1.8763554180623032e-05
in O 0 1.9633816350506095e-07
high O 0 4.241050646669464e-06
- O 0 0.0002666372456587851
grade O 0 9.305408639193047e-07
, O 0 4.5141163695916475e-08
non B-Disease 0 6.131176064627653e-07
- I-Disease 1 0.8027042746543884
inherited I-Disease 1 0.9993693232536316
breast I-Disease 1 0.9998722076416016
carcinomas I-Disease 1 0.9999967813491821
. O 0 5.1747560064541176e-05

Although O 0 1.3571276213042438e-05
the O 0 2.415318363091501e-07
link O 0 1.6502473272339557e-06
between O 0 7.865246942628801e-08
the O 0 4.1945506268348254e-07
BRCA1 O 1 0.679507315158844
tumour B-Disease 1 0.9999904632568359
- O 0 0.00031345622846856713
suppressor O 0 0.000529042852576822
gene O 0 5.45862030776334e-06
and O 0 4.968649136571912e-06
hereditary B-Disease 1 0.9997932314872742
breast I-Disease 1 0.9999909400939941
and I-Disease 1 0.9999665021896362
ovarian I-Disease 1 1.0
cancer I-Disease 1 0.9999998807907104
is O 0 3.62829524647168e-07
established O 0 5.2880665180055075e-08
, O 0 7.429241222212113e-09
the O 0 1.937567661869366e-09
role O 0 4.775247219868106e-08
, O 0 1.4709351070507637e-08
if O 0 4.754813431873117e-09
any O 0 1.3732861514625938e-09
, O 0 2.9896058961753624e-09
of O 0 2.9576854299051547e-09
BRCA1 O 0 8.570292266085744e-06
in O 0 8.023634023857085e-08
non B-Disease 0 9.068696726899361e-07
- I-Disease 0 0.4241592586040497
familial I-Disease 1 0.9962574243545532
cancers I-Disease 1 0.9981295466423035
is O 0 1.945328449437511e-06
unclear O 0 6.157072675705422e-06
. O 0 2.154247113139718e-06

BRCA1 O 1 0.9942054152488708
mutations O 0 0.08134088665246964
are O 0 1.5739608443254838e-06
rare O 0 4.701412308349973e-06
in O 0 1.1099452876806026e-06
sporadic B-Disease 1 0.918597936630249
cancers I-Disease 1 0.9977839589118958
, O 0 4.272037870123313e-07
but O 0 5.638239599647932e-07
loss O 0 2.039055743807694e-06
of O 0 2.802108944877091e-08
BRCA1 O 0 0.0009161224588751793
resulting O 0 2.389150040471577e-06
from O 0 3.925075375832421e-08
reduced O 0 1.8443347471475136e-06
expression O 0 4.894567950941564e-07
or O 0 3.90673164929467e-08
incorrect O 0 1.2592062148542027e-06
subcellular O 0 3.6039625683770282e-06
localization O 0 1.920659769893973e-06
is O 0 5.429362914810554e-08
postulated O 0 6.192206569721748e-07
to O 0 1.4805728199007717e-08
be O 0 8.24949797362251e-09
important O 0 2.2705795021948916e-09
in O 0 8.557286435006972e-09
non B-Disease 0 2.0949717338680784e-07
- I-Disease 0 0.03142401576042175
familial I-Disease 1 0.9722646474838257
breast I-Disease 1 0.9999836683273315
and I-Disease 1 0.9978265166282654
ovarian I-Disease 1 1.0
cancers I-Disease 1 0.9999969005584717
. O 0 1.084182076738216e-05

Epigenetic O 0 0.14321622252464294
loss O 0 0.4075562059879303
, O 0 3.988989192293957e-06
however O 0 6.553821663146664e-07
, O 0 6.009274500229367e-08
has O 0 3.7615956216541235e-07
not O 0 5.904814059931596e-08
received O 0 1.2317677544615435e-07
general O 0 6.882141434516598e-08
acceptance O 0 5.15606018325343e-07
due O 0 1.5746500992008805e-07
to O 0 1.0145318185550423e-07
controversy O 0 7.777927635288506e-07
regarding O 0 3.9563506248896374e-08
the O 0 1.3391688646890998e-08
subcellular O 0 1.1129342283311416e-06
localization O 0 4.5223941924632527e-07
of O 0 9.935357425661095e-09
BRCA1 O 0 6.272937298490433e-06
proteins O 0 4.226875915946948e-08
, O 0 1.9192736289141976e-08
reports O 0 1.7573420052485744e-08
of O 0 1.391303849906933e-09
which O 0 1.591732257111289e-07
have O 0 1.2761832124397188e-07
ranged O 0 7.14260295353597e-07
from O 0 8.25847212837516e-09
exclusively O 0 2.746742744363928e-08
nuclear O 0 3.985221397329042e-08
, O 0 4.283589039033586e-09
to O 0 1.1195536053776323e-08
conditionally O 0 1.795703974494245e-05
nuclear O 0 1.9562438069442578e-07
, O 0 4.93695884173917e-09
to O 0 1.7894508985705215e-08
the O 0 4.4324494297143247e-08
ER O 0 0.0004013453726656735
/ O 0 1.919736860145349e-06
golgi O 0 1.7296326404903084e-05
, O 0 9.274916124013544e-08
to O 0 2.7257158308202634e-08
cytoplasmic O 0 8.511481723871839e-07
invaginations O 0 1.9139347386953887e-06
into O 0 3.0373470849553996e-08
the O 0 4.477859860685385e-08
nucleus O 0 1.2106320355087519e-06
. O 0 8.4130897448631e-07

In O 0 1.3110641248204047e-06
an O 0 6.734266833063884e-08
attempt O 0 1.1896780733877677e-06
to O 0 2.3714476071745594e-07
resolve O 0 3.542276317602955e-06
this O 0 6.854826750668508e-08
issue O 0 4.326742555349483e-07
, O 0 1.0931687555171266e-08
we O 0 6.4724883230837804e-09
have O 0 1.5963012245379105e-08
comprehensively O 0 1.4481102880381513e-05
characterized O 0 7.073649157973705e-06
19 O 0 1.2704264236162999e-06
anti O 0 2.2316069589578547e-05
- O 0 0.05591106787323952
BRCA1 O 0 0.008752591907978058
antibodies O 0 3.9507260225946084e-05
. O 0 2.4752555418672273e-06

These O 0 2.1857415504200617e-06
reagents O 0 6.074081738915993e-06
detect O 0 5.456652615976054e-06
a O 0 6.161351393529912e-07
220 O 0 8.466065537504619e-07
- O 0 3.05282483168412e-05
kD O 0 3.544923310982995e-05
protein O 0 9.964071523427265e-07
localized O 0 7.965853683344903e-07
in O 0 1.7179729638883146e-08
discrete O 0 1.5825145283088204e-07
nuclear O 0 3.2336038202629425e-07
foci O 0 2.6424700081406627e-06
in O 0 2.983375679832534e-08
all O 0 2.059138815013739e-08
epithelial O 0 0.0007072725566104054
cell O 0 0.0060340058989822865
lines O 0 6.0733345890184864e-06
, O 0 2.003065979749863e-08
including O 0 5.995682617054854e-09
those O 0 8.780707716482539e-09
derived O 0 1.292979874278899e-07
from O 0 3.0688693186675664e-07
breast B-Disease 1 0.5942449569702148
malignancies I-Disease 0 0.013278958387672901
. O 0 3.865133749059169e-06

Immunohistochemical O 0 0.042286261916160583
staining O 0 0.0020919342059642076
of O 0 2.405886789347278e-06
human O 0 2.461759686411824e-05
breast O 1 0.9064228534698486
specimens O 0 1.785535096132662e-05
also O 0 3.629808361438336e-06
revealed O 0 1.632546445762273e-05
BRCA1 O 0 1.5927229469525628e-05
nuclear O 0 9.792609034775523e-07
foci O 0 3.612149885157123e-05
in O 0 1.773259896253876e-06
benign O 1 0.8854466080665588
breast O 1 0.9790610671043396
, O 0 6.1242380979820155e-06
invasive B-Disease 0 0.18994709849357605
lobular I-Disease 1 0.9999486207962036
cancers I-Disease 1 0.9941393136978149
and O 0 2.29936790674401e-06
low B-Disease 0 6.877323903609067e-05
- I-Disease 0 0.12022306025028229
grade I-Disease 0 0.00019273164798505604
ductal I-Disease 1 0.9977754950523376
carcinomas I-Disease 1 0.9999978542327881
. O 0 0.00010639952961355448

Conversely O 0 0.0014821175718680024
, O 0 6.8256813392508775e-06
BRCA1 O 0 0.00014684459893032908
expression O 0 6.091867817303864e-06
was O 0 9.549143214826472e-06
reduced O 0 6.88364423240273e-07
or O 0 4.9453205974714365e-08
undetectable O 0 6.224046273928252e-07
in O 0 1.589771514431959e-08
the O 0 7.336331986351752e-09
majority O 0 5.08206142058043e-07
of O 0 4.704584277703816e-09
high O 0 9.021262030728394e-07
- O 0 0.00017230486264452338
grade O 0 2.6767386316350894e-06
, O 0 8.116802518998156e-07
ductal B-Disease 1 0.9838404059410095
carcinomas I-Disease 1 0.9999995231628418
, O 0 3.0503806556225754e-06
suggesting O 0 8.825389272715256e-07
that O 0 5.792239576862812e-08
absence O 0 1.5910949002773123e-07
of O 0 1.876852984139532e-08
BRCA1 O 0 0.0009483112953603268
may O 0 7.834013558749575e-06
contribute O 0 1.9466849465743508e-08
to O 0 1.8644293220404506e-08
the O 0 2.5780090950888734e-08
pathogenesis O 0 9.630680324335117e-07
of O 0 2.9628008935134176e-09
a O 0 6.535933039231168e-08
significant O 0 6.669039009921107e-08
percentage O 0 1.7464097368247167e-07
of O 0 4.2512454001553124e-08
sporadic B-Disease 1 0.5908846855163574
breast I-Disease 1 0.9999797344207764
cancers I-Disease 1 0.9969784021377563
. O 0 2.808875933624222e-06
. O 0 2.7051030428992817e-06

